0001821586-24-00002910-Q MoonLake Immunotherapeutics 20241107202411070705390705390705390 0 0001821586-24-000029 10-Q 83 20240930 20241107 20241107 MoonLake Immunotherapeutics 0001821586 2834 000000000 E9 1231 10-Q 34 001-39630 241433101 DORFSTRASSE 29 ZUG V8 6300 41 41 510 8022 DORFSTRASSE 29 ZUG V8 6300 Helix Acquisition Corp 20200818 10-Q 1 mnlk-20240930.htm 10-Q mnlk-20240930FALSE2024Q312/310001821586P3Y11xbrli:sharesiso4217:USDiso4217:USDxbrli:sharesmnlk:leasemnlk:lease_contractmnlk:segmentutr:sqftmnlk:periodxbrli:pureiso4217:CHFmnlk:vot founderiso4217:CHFxbrli:sharesiso4217:EUR0001821586 2024-01-012024-09-300001821586us-gaap:CommonClassAMember2024-11-010001821586us-gaap:CommonClassCMember2024-11-010001821586 2024-09-300001821586 2023-12-310001821586us-gaap:CommonClassAMember2024-09-300001821586us-gaap:CommonClassAMember2023-12-310001821586us-gaap:CommonClassCMember2024-09-300001821586us-gaap:CommonClassCMember2023-12-310001821586 2024-07-012024-09-300001821586 2023-07-012023-09-300001821586 2023-01-012023-09-300001821586us-gaap:CommonClassAMember2024-07-012024-09-300001821586us-gaap:CommonClassAMember2023-07-012023-09-300001821586us-gaap:CommonClassAMember2024-01-012024-09-300001821586us-gaap:CommonClassAMember2023-01-012023-09-300001821586us-gaap:CommonStockMemberus-gaap:CommonClassAMember2022-12-310001821586us-gaap:CommonStockMemberus-gaap:CommonClassCMember2022-12-310001821586us-gaap:AdditionalPaidInCapitalMember2022-12-310001821586us-gaap:RetainedEarningsMember2022-12-310001821586us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001821586us-gaap:ParentMember2022-12-310001821586us-gaap:NoncontrollingInterestMember2022-12-3100018215862022-12-310001821586us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001821586us-gaap:ParentMember2023-01-012023-03-310001821586us-gaap:NoncontrollingInterestMember2023-01-012023-03-3100018215862023-01-012023-03-310001821586us-gaap:RetainedEarningsMember2023-01-012023-03-310001821586us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001821586us-gaap:CommonStockMemberus-gaap:CommonClassAMember2023-01-012023-03-310001821586us-gaap:CommonStockMemberus-gaap:CommonClassCMember2023-01-012023-03-310001821586us-gaap:CommonStockMemberus-gaap:CommonClassAMember2023-03-310001821586us-gaap:CommonStockMemberus-gaap:CommonClassCMember2023-03-310001821586us-gaap:AdditionalPaidInCapitalMember2023-03-310001821586us-gaap:RetainedEarningsMember2023-03-310001821586us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001821586us-gaap:ParentMember2023-03-310001821586us-gaap:NoncontrollingInterestMember2023-03-3100018215862023-03-310001821586us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300001821586us-gaap:ParentMember2023-04-012023-06-300001821586us-gaap:NoncontrollingInterestMember2023-04-012023-06-3000018215862023-04-012023-06-300001821586us-gaap:CommonStockMemberus-gaap:CommonClassAMember2023-04-012023-06-300001821586us-gaap:RetainedEarningsMember2023-04-012023-06-300001821586us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300001821586us-gaap:CommonStockMemberus-gaap:CommonClassCMember2023-04-012023-06-300001821586us-gaap:CommonStockMemberus-gaap:CommonClassAMember2023-06-300001821586us-gaap:CommonStockMemberus-gaap:CommonClassCMember2023-06-300001821586us-gaap:AdditionalPaidInCapitalMember2023-06-300001821586us-gaap:RetainedEarningsMember2023-06-300001821586us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300001821586us-gaap:ParentMember2023-06-300001821586us-gaap:NoncontrollingInterestMember2023-06-3000018215862023-06-300001821586us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001821586us-gaap:ParentMember2023-07-012023-09-300001821586us-gaap:NoncontrollingInterestMember2023-07-012023-09-300001821586us-gaap:RetainedEarningsMember2023-07-012023-09-300001821586us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300001821586us-gaap:CommonStockMemberus-gaap:CommonClassAMember2023-07-012023-09-300001821586us-gaap:CommonStockMemberus-gaap:CommonClassCMember2023-07-012023-09-300001821586us-gaap:CommonStockMemberus-gaap:CommonClassAMember2023-09-300001821586us-gaap:CommonStockMemberus-gaap:CommonClassCMember2023-09-300001821586us-gaap:AdditionalPaidInCapitalMember2023-09-300001821586us-gaap:RetainedEarningsMember2023-09-300001821586us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300001821586us-gaap:ParentMember2023-09-300001821586us-gaap:NoncontrollingInterestMember2023-09-3000018215862023-09-300001821586us-gaap:CommonStockMemberus-gaap:CommonClassAMember2023-12-310001821586us-gaap:CommonStockMemberus-gaap:CommonClassCMember2023-12-310001821586us-gaap:AdditionalPaidInCapitalMember2023-12-310001821586us-gaap:RetainedEarningsMember2023-12-310001821586us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001821586us-gaap:ParentMember2023-12-310001821586us-gaap:NoncontrollingInterestMember2023-12-310001821586us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310001821586us-gaap:ParentMember2024-01-012024-03-310001821586us-gaap:NoncontrollingInterestMember2024-01-012024-03-3100018215862024-01-012024-03-310001821586us-gaap:RetainedEarningsMember2024-01-012024-03-310001821586us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310001821586us-gaap:CommonStockMemberus-gaap:CommonClassAMember2024-01-012024-03-310001821586us-gaap:CommonStockMemberus-gaap:CommonClassCMember2024-01-012024-03-310001821586us-gaap:CommonStockMemberus-gaap:CommonClassAMember2024-03-310001821586us-gaap:CommonStockMemberus-gaap:CommonClassCMember2024-03-310001821586us-gaap:AdditionalPaidInCapitalMember2024-03-310001821586us-gaap:RetainedEarningsMember2024-03-310001821586us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310001821586us-gaap:ParentMember2024-03-310001821586us-gaap:NoncontrollingInterestMember2024-03-3100018215862024-03-310001821586us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300001821586us-gaap:ParentMember2024-04-012024-06-300001821586us-gaap:NoncontrollingInterestMember2024-04-012024-06-3000018215862024-04-012024-06-300001821586us-gaap:RetainedEarningsMember2024-04-012024-06-300001821586us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-04-012024-06-300001821586us-gaap:CommonStockMemberus-gaap:CommonClassAMember2024-04-012024-06-300001821586us-gaap:CommonStockMemberus-gaap:CommonClassCMember2024-06-300001821586us-gaap:AdditionalPaidInCapitalMember2024-06-300001821586us-gaap:RetainedEarningsMember2024-06-300001821586us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300001821586us-gaap:ParentMember2024-06-300001821586us-gaap:NoncontrollingInterestMember2024-06-3000018215862024-06-300001821586us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300001821586us-gaap:ParentMember2024-07-012024-09-300001821586us-gaap:NoncontrollingInterestMember2024-07-012024-09-300001821586us-gaap:RetainedEarningsMember2024-07-012024-09-300001821586us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300001821586us-gaap:CommonStockMemberus-gaap:CommonClassAMember2024-07-012024-09-300001821586us-gaap:CommonStockMemberus-gaap:CommonClassCMember2024-07-012024-09-300001821586us-gaap:CommonStockMemberus-gaap:CommonClassAMember2024-09-300001821586us-gaap:CommonStockMemberus-gaap:CommonClassCMember2024-09-300001821586us-gaap:AdditionalPaidInCapitalMember2024-09-300001821586us-gaap:RetainedEarningsMember2024-09-300001821586us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-300001821586us-gaap:ParentMember2024-09-300001821586us-gaap:NoncontrollingInterestMember2024-09-300001821586mnlk:CommercialPaperAndCertificatesOfDepositMember2024-09-300001821586mnlk:CommercialPaperAndCertificatesOfDepositMember2023-12-310001821586srt:MinimumMember2024-09-300001821586srt:MaximumMember2024-09-300001821586us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2024-09-300001821586us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2023-12-310001821586us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2023-12-310001821586us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CertificatesOfDepositMember2024-09-300001821586us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CertificatesOfDepositMember2024-09-300001821586us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CertificatesOfDepositMember2023-12-310001821586us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CertificatesOfDepositMember2023-12-310001821586us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001821586us-gaap:FairValueMeasurementsRecurringMember2024-09-300001821586us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001821586us-gaap:FairValueMeasurementsRecurringMember2023-12-310001821586us-gaap:CommercialPaperMember2024-09-300001821586us-gaap:CertificatesOfDepositMember2024-09-300001821586us-gaap:CashAndCashEquivalentsMember2024-09-300001821586us-gaap:DebtSecuritiesMember2024-09-300001821586us-gaap:FairValueInputsLevel2Member2023-12-310001821586us-gaap:FairValueInputsLevel2Member2024-01-012024-09-300001821586us-gaap:FairValueInputsLevel2Member2024-09-300001821586mnlk:SwitzerlandOfficeMember2021-08-012021-08-310001821586mnlk:SwitzerlandOfficeMember2021-08-310001821586mnlk:SwitzerlandOfficeMember2023-12-310001821586mnlk:PortoOfficeMember2023-10-092023-10-090001821586mnlk:PortoOfficeMemberus-gaap:BuildingMember2023-10-090001821586 2023-10-092023-10-090001821586mnlk:PortoOfficeMember2023-10-090001821586mnlk:CambridgeOfficeMember2023-10-132023-10-130001821586mnlk:CambridgeOfficeMemberus-gaap:BuildingMember2023-10-130001821586mnlk:SwitzerlandOfficeMember2023-12-122023-12-120001821586mnlk:SwitzerlandOfficeMember2023-12-120001821586mnlk:PortoOfficeMember2024-08-142024-08-140001821586mnlk:PortoOfficeMemberus-gaap:BuildingMember2024-08-140001821586 2024-08-142024-08-140001821586mnlk:PortoOfficeMember2024-08-140001821586srt:ScenarioForecastMember2024-10-012024-12-310001821586mnlk:ConversionOfClassCIntoClassAMemberus-gaap:CommonStockMemberus-gaap:CommonClassAMember2024-01-012024-03-310001821586mnlk:ConversionOfClassCIntoClassAMemberus-gaap:CommonStockMemberus-gaap:CommonClassCMember2024-01-012024-03-310001821586mnlk:ConversionOfClassCIntoClassAMemberus-gaap:CommonStockMemberus-gaap:CommonClassAMember2024-07-012024-09-300001821586mnlk:ConversionOfClassCIntoClassAMemberus-gaap:CommonStockMemberus-gaap:CommonClassCMember2024-07-012024-09-300001821586us-gaap:CommonStockMembermnlk:MoonLakeAGMember2024-09-092024-09-250001821586us-gaap:CommonStockMemberus-gaap:CommonClassCMember2024-09-092024-09-250001821586us-gaap:CommonStockMemberus-gaap:CommonClassAMember2024-09-092024-09-250001821586mnlk:ATMSharesMembermnlk:May2023SalesAgreementMember2023-05-110001821586mnlk:ATMSharesMembermnlk:May2023SalesAgreementMember2023-06-270001821586mnlk:ATMSharesMembermnlk:May2023AndAugust2023SalesAgreementMember2023-08-310001821586mnlk:August2023SalesAgreementMember2024-01-012024-03-310001821586mnlk:August2023SalesAgreementMember2024-03-310001821586mnlk:August2023SalesAgreementMember2024-07-012024-09-300001821586mnlk:August2023SalesAgreementMember2024-04-012024-06-300001821586mnlk:UnderwritingAgreementMember2023-06-272023-06-270001821586mnlk:UnderwritingAgreementMember2023-06-270001821586us-gaap:OverAllotmentOptionMember2023-06-272023-06-270001821586mnlk:UnderwritingAgreementMember2023-06-302023-06-300001821586mnlk:MoonLakeAGMembermnlk:UnderwritingAgreementMembermnlk:MoonLakeImmunotherapeuticsMember2023-07-092023-07-090001821586mnlk:MoonLakeAGMembermnlk:MoonLakeImmunotherapeuticsMember2023-07-092023-07-090001821586mnlk:MoonLakeAGMembermnlk:MoonLakeImmunotherapeuticsMember2023-07-102023-07-100001821586 2023-07-100001821586mnlk:MoonLakeAGMembermnlk:UnderwritingAgreementMembermnlk:MoonLakeImmunotherapeuticsMember2024-03-082024-03-080001821586mnlk:MoonLakeAGMembermnlk:MoonLakeImmunotherapeuticsMember2024-03-082024-03-080001821586 2024-03-080001821586us-gaap:CommonStockMembermnlk:MoonLakeAGMember2024-03-082024-03-080001821586mnlk:MoonLakeAGMemberus-gaap:CommonStockMemberus-gaap:CommonClassCMember2024-03-082024-03-080001821586mnlk:EquityIncentivePlanMember2024-07-012024-09-300001821586srt:ProFormaMember2024-07-012024-09-300001821586srt:ProFormaMember2024-01-012024-09-300001821586us-gaap:CommonClassAMemberus-gaap:SubsequentEventMembersrt:ProFormaMember2024-11-010001821586us-gaap:CommonClassAMemberus-gaap:SubsequentEventMembersrt:ProFormaMember2024-11-012024-11-010001821586us-gaap:RestrictedStockMember2024-07-012024-09-300001821586us-gaap:RestrictedStockMember2023-07-012023-09-300001821586us-gaap:RestrictedStockMember2024-01-012024-09-300001821586us-gaap:RestrictedStockMember2023-01-012023-09-300001821586us-gaap:EmployeeStockMember2024-07-012024-09-300001821586us-gaap:EmployeeStockMember2023-07-012023-09-300001821586us-gaap:EmployeeStockMember2024-01-012024-09-300001821586us-gaap:EmployeeStockMember2023-01-012023-09-300001821586us-gaap:EmployeeStockOptionMember2024-07-012024-09-300001821586us-gaap:EmployeeStockOptionMember2023-07-012023-09-300001821586us-gaap:EmployeeStockOptionMember2024-01-012024-09-300001821586us-gaap:EmployeeStockOptionMember2023-01-012023-09-300001821586mnlk:EquityIncentivePlanMember2023-07-012023-09-300001821586mnlk:EquityIncentivePlanMember2024-01-012024-09-300001821586mnlk:EquityIncentivePlanMember2023-01-012023-09-300001821586us-gaap:ResearchAndDevelopmentExpenseMember2024-07-012024-09-300001821586us-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-300001821586us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-09-300001821586us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-300001821586us-gaap:GeneralAndAdministrativeExpenseMember2024-07-012024-09-300001821586us-gaap:GeneralAndAdministrativeExpenseMember2023-07-012023-09-300001821586us-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-09-300001821586us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-09-300001821586mnlk:EquityIncentivePlanMember2024-09-300001821586mnlk:EmployeeStockOptionPlanESOPMember2024-09-300001821586mnlk:MoonLakeAGMember2021-04-280001821586us-gaap:CommonClassCMembermnlk:MoonLakeAGMember2021-04-280001821586us-gaap:RestrictedStockMembermnlk:MoonLakeAGMember2021-04-280001821586mnlk:MoonLakeAGMemberus-gaap:RestrictedStockMemberus-gaap:CommonClassCMember2021-04-280001821586us-gaap:RestrictedStockMembermnlk:MoonLakeAGMember2021-04-282021-04-280001821586us-gaap:RestrictedStockMember2022-12-310001821586us-gaap:RestrictedStockMember2023-09-300001821586us-gaap:EmployeeStockMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2024-01-012024-09-300001821586us-gaap:EmployeeStockMembermnlk:ShareBasedPaymentArrangementTrancheFourMember2024-01-012024-09-300001821586us-gaap:EmployeeStockMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2024-01-012024-09-300001821586us-gaap:EmployeeStockMemberus-gaap:ShareBasedCompensationAwardTrancheThreeMember2024-01-012024-09-300001821586us-gaap:EmployeeStockMember2022-12-310001821586us-gaap:EmployeeStockMember2023-09-300001821586us-gaap:EmployeeStockMember2023-12-310001821586us-gaap:EmployeeStockMember2024-09-300001821586mnlk:EmployeeStockOptionPlanESOPMemberus-gaap:EmployeeStockOptionMembermnlk:ShareBasedPaymentArrangementTrancheFourMember2024-01-012024-09-300001821586mnlk:EmployeeStockOptionPlanESOPMemberus-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedCompensationAwardTrancheThreeMember2024-01-012024-09-300001821586mnlk:EmployeeStockOptionPlanESOPMemberus-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2024-01-012024-09-300001821586mnlk:EmployeeStockOptionPlanESOPMemberus-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2024-01-012024-09-300001821586us-gaap:EmployeeStockOptionMembermnlk:EmployeeStockOptionPlanESOPMember2022-12-310001821586us-gaap:EmployeeStockOptionMembermnlk:EmployeeStockOptionPlanESOPMember2023-01-012023-09-300001821586us-gaap:EmployeeStockOptionMembermnlk:EmployeeStockOptionPlanESOPMember2023-09-300001821586us-gaap:EmployeeStockOptionMembermnlk:EmployeeStockOptionPlanESOPMember2023-12-310001821586us-gaap:EmployeeStockOptionMembermnlk:EmployeeStockOptionPlanESOPMember2024-01-012024-09-300001821586us-gaap:EmployeeStockOptionMembermnlk:EmployeeStockOptionPlanESOPMember2024-09-300001821586mnlk:EquityIncentivePlanMember2022-04-052022-04-050001821586mnlk:EquityIncentivePlanMember2022-12-310001821586mnlk:EquityIncentivePlanMember2023-09-300001821586mnlk:EquityIncentivePlanMember2023-12-310001821586mnlk:PrepaidExpensesCurrentMember2024-09-300001821586mnlk:PrepaidExpensesNoncurrentMember2024-09-300001821586mnlk:SonelokimabProgramSLKProgramMemberus-gaap:LicenseMember2024-09-300001821586country:CH2024-09-300001821586country:CH2023-12-

310001821586country:GB2024-09-300001821586country:GB2023-12-310001821586country:PT2024-09-300001821586country:PT2023-12-31UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549FORM 10-Q(MARK ONE)â˜’ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 â˜ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period from to Commission file number: 001-39630MOONLAKE IMMUNOTHERAPEUTICS(Exact Name of Registrant as Specified in Its Charter)Cayman Islands98-1711963(State or other jurisdiction of incorporation or organization)Â Â Â Â Â (I.R.S. Employer Identification No.)Dorfstrasse 296300 ZugSwitzerlandN/A(Address of principal executive offices)(ZIP Code)41 415108022(Registrantâ€™s telephone number, including area code)Securities registered pursuant to Section 12(b) of the Act:Title of each classTrading Symbol(s)Name of each exchange on which registeredClass A ordinary share, par value $0.0001 per shareÂ MLTXÂ The Nasdaq Capital MarketIndicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes â˜’ No â˜Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Â§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes â˜’ No â˜Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of â€œlarge accelerated filerâ€, â€œaccelerated filerâ€, â€œsmaller reporting companyâ€, and â€œemerging growth companyâ€ in Rule 12b-2 of the Exchange Act.Large accelerated filer Â Â Â Â â˜’Â Accelerated filerÂ Â Â Â Â Â Â Â â˜Non-accelerated filerÂ Â Â Â Â Â Â Â â˜Smaller reporting companyÂ Â Â Â â˜Emerging growth companyÂ Â Â Â â˜ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. â˜ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes â˜ No â˜’As of NovemberÂ 1, 2024, there were 63,063,929 Class A Ordinary Shares, $0.0001 par value (the "Class A Ordinary Shares"), and 841,269 Class C Ordinary Shares, $0.0001 par value (the "Class C Ordinary Shares"), issued and outstanding.MOONLAKE IMMUNOTHERAPEUTICSFORM 10-Q FOR THE QUARTER ENDED SEPTEMBER 30, 2024TABLE OF CONTENTSPART I. FINANCIAL INFORMATION2Item 1. Financial Statements (Unaudited)2Condensed Consolidated Balance Sheets2Condensed Consolidated Statements of Operations and Comprehensive Loss3Condensed Consolidated Statements of Changes In Equity4Condensed Consolidated Statements of Cash Flows6Notes to Condensed Consolidated Financial Statements7Item 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations26Item 3. Quantitative and Qualitative Disclosures About Market Risk39Item 4. Controls and Procedures39PART II. OTHER INFORMATION41Item 1. Legal Proceedings41Item 1A. Risk Factors41Item 2. Unregistered Sales of Equity Securities and Use of Proceeds41Item 3. Defaults Upon Senior Securities41Item 4. Mine Safety Disclosures41Item 5. Other Information41Item 6. Exhibits42SIGNATURES431PART I. FINANCIAL INFORMATIONItem 1. Financial Statements (Unaudited)MOONLAKE IMMUNOTHERAPEUTICSssCONDENSED CONSOLIDATED BALANCE SHEETS(Amounts in USD, except share data)September 30, 2024 (Unaudited)December 31, 2023Current assetsCash and cash equivalents$375,656,291$451,169,337Short-term marketable debt securities118,268,40059,838,900Other receivables2,407,0621,056,862Prepaid expenses - current15,984,4252,102,203Total current assets512,316,178514,167,302Non-current assetsOperating lease right-of-use assets3,251,1973,628,480Property and equipment, net581,378320,865Prepaid expenses - non-current2,064,5758,423,468Total non-current assets5,897,15012,372,813Total assets$518,213,328Â $526,540,115Current liabilitiesTrade and other payables$10,710,603Â $1,837,684Â Short-term portion of operating lease liabilities1,444,8931,197,876Accrued expenses and other current liabilities7,925,5246,930,120Total current liabilities20,081,0209,965,680Non-current liabilitiesLong-term portion of operating lease liabilities1,935,7092,499,990Pension liability694,959583,426Total non-current liabilities2,630,6683,083,416Total liabilities22,711,68813,049,096Commitments and contingencies (Note 15)EquityClass A Ordinary Shares: $0.0001 par value; 500,000,000 shares authorized; 63,046,025 shares issued and outstanding as of SeptemberÂ 30, 2024; 60,466,453 shares issued and outstanding as of DecemberÂ 31, 20236,3056,047Class C Ordinary Shares: $0.0001 par value; 100,000,000 shares authorized; 841,269 shares issued and outstanding as of SeptemberÂ 30, 2024; 2,505,476 shares issued and outstanding as of DecemberÂ 31, 202384251Additional paid-in capital675,343,443609,969,236Accumulated deficit(189,988,477)(116,657,472)Accumulated other comprehensive income2,833,9702,357,621Total shareholdersâ€™ equity 488,195,325495,675,683Noncontrolling interests7,306,31517,815,336Total equity495,501,640513,491,019Total liabilities and equity$518,213,328$526,540,115The accompanying Notes are an integral part of these Unaudited Condensed Consolidated Financial Statements.2MOONLAKE IMMUNOTHERAPEUTICSCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS(Amounts in USD, except share and per share data)(Unaudited) Â Â Â Â Three Months Ended September 30, Nine Months Ended September 30, 20242023202420232023Operating expensesResearch and development$(35,735,514)$(7,585,136)$(72,411,709)$(23,704,087)General and administrative(7,376,495)(5,391,607)(21,099,001)(15,390,117)Total operating expenses(43,112,009)(12,976,743)(93,510,710)(39,094,204)Operating loss(43,112,009)(12,976,743)(93,510,710)(39,094,204)Other income, net7,089,6911,386,31318,903,0702,952,557Loss before income tax(36,022,318)(11,590,430)(74,607,640)(36,141,647)Income tax expense(92,106)(28,923)(241,059)(50,080)Net loss$(36,114,424)$(11,619,353)$(74,848,699)$(36,191,727)Of which: net loss attributable to controlling interests shareholders(35,390,337)(9,426,049)(73,331,005)(28,570,184)Of which: net loss attributable to noncontrolling interests shareholders(724,087)(2,193,304)(1,517,694)(7,621,543)Net unrealized gain (loss) on marketable securities and short term investments(325,510)3,437,291508,8603,046,538Actuarial gain (loss) on employee benefit plans(115,629)39,157(110,878)(19,323)Other comprehensive income (loss)(441,139)3,476,448397,9823,027,215Comprehensive loss$(36,555,563)$(8,142,905)$(74,450,717)$(33,164,512)Comprehensive loss attributable to controlling interests shareholders(35,822,526)(6,590,259)(72,941,435)(26,095,926)Comprehensive loss attributable to noncontrolling interests(733,037)(1,552,646)(1,509,282)(7,068,586)Weighted-average number of Class A Ordinary Shares, basic and diluted62,896,78253,517,65562,803,22045,485,650Basic and diluted net loss per share attributable to controlling interests shareholders(0.56)(0.18)(1.17)(0.63) The accompanying Notes are an integral part of these Unaudited Condensed Consolidated Financial Statements.Â Â Â Â 3MOONLAKE IMMUNOTHERAPEUTICSCONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY(Amounts in USD, except share data) (Unaudited)Class A Ordinary SharesClass C Ordinary SharesAdditional Paid-In CapitalAccumulated DeficitAccumulated Other Comprehensive IncomeTotal Shareholders' EquityNoncontrolling InterestsTotal EquitySharesAmountSharesAmountBalance at December 31, 202238,977,600Â $3,898Â 13,723,511Â $1,373Â $129,192,291Â $(80,650,212)$350,946Â $48,898,296Â $19,868,402Â $68,766,698Â Share-based compensation under the ESPP, ESOP, Equity Incentive Plan and reverse vesting of Restricted Founder Sharesâ€”Â â€”Â â€”Â â€”Â 1,875,992Â â€”Â â€”Â 1,875,992Â 701,195Â 2,577,187Â Refund of stamp duty feesâ€”Â â€”Â â€”Â â€”Â 3,517Â â€”Â â€”Â 3,517Â 1,406Â 4,923Â Net loss for the three months ended March 31, 2023â€”Â â€”Â â€”Â â€”Â (9,004,856)â€”Â (9,004,856)(3,214,131)(12,218,987)Other comprehensive lossâ€”Â â€”Â â€”Â â€”Â (12,625)(12,625)(5,047)(17,672)Conversion of MoonLake Class C Ordinary Shares into Class A Ordinary Shares176,603Â 18Â (176,603)(18)237,049Â â€”Â 1,787Â 238,836Â (238,836)â€”Â Balance at March 31, 202339,154,203Â $3,916Â 13,546,908Â $1,355Â $131,308,849Â $(89,655,068)$340,108Â $41,999,160Â $17,112,989Â $59,112,149Â Share-based compensation under the ESPP, ESOP, Equity Incentive Plan and reverse vesting of Restricted Founder Sharesâ€”Â â€”Â â€”Â â€”Â 1,247,416Â â€”Â â€”Â 1,247,416Â 250,245Â 1,497,661Â Issuance of Class A Ordinary Shares, net of transaction costs (Note 11)9,744,894Â 974Â â€”Â â€”Â 451,284,119Â â€”Â â€”Â 451,285,093Â â€”Â 451,285,093Â Net loss for the three months ended June 30, 2023â€”Â â€”Â â€”Â â€”Â (10,139,279)â€”Â (10,139,279)(2,214,108)(12,353,387)Other comprehensive lossâ€”Â â€”Â â€”Â â€”Â â€”Â (348,906)(348,906)(82,655)(431,561)Conversion of MoonLake Class C Ordinary Shares into Class A Ordinary Shares4,587,713Â 459Â (4,587,713)(459)5,709,595Â â€”Â 43,922Â 5,753,517Â (5,753,517)â€”Â Balance at June 30, 202353,486,810Â $5,349Â 8,959,195Â $896Â $589,549,979Â $(99,794,347)$35,124Â $489,797,001Â $9,312,954Â $499,109,955Â Share-based compensation under the equity incentive plan ESPP, ESOP, and 2022 MoonLake Immunotherapeutics Equity Incentive Planâ€”Â â€”Â â€”Â â€”Â 1,238,144Â â€”Â â€”Â 1,238,144Â 187,507Â 1,425,651Â Net loss for the three months ended September 30, 2023â€”Â â€”Â â€”Â â€”Â (9,426,049)â€”Â (9,426,049)(2,193,304)(11,619,353)Other comprehensive incomeâ€”Â â€”Â â€”Â â€”Â â€”Â â€”Â 2,835,790Â 2,835,790Â 640,658Â 3,476,448Â Conversion of MoonLake Class C Ordinary Shares into Class A Ordinary Shares74,678Â 7Â (74,678)(7)545,591Â â€”Â 3,149Â 548,740Â (548,740)â€”Â Capital injection from MoonLake to MoonLake AG (Note 11)â€”Â â€”Â â€”Â â€”Â (60,061,761)â€”Â 1,135Â (60,060,626)57,310,111Â (2,750,515)Balance at September 30, 202353,561,488Â $5,356Â 8,884,517Â $889Â $531,271,953Â $(109,220,396)$2,875,198Â $424,933,000Â $64,709,186Â $489,642,186Â The accompanying Notes are an integral part of these Unaudited Condensed Consolidated Financial Statements.4MOONLAKE IMMUNOTHERAPEUTICSCONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY(Amounts in USD, except share data) (Unaudited)Class A Ordinary SharesClass C Ordinary SharesAdditional Paid-In CapitalAccumulated DeficitAccumulated Other Comprehensive IncomeTotal Shareholders' Equity Noncontrolling InterestsTotal Equity SharesAmountSharesAmountBalance at December 31, 202360,466,453Â $6,047Â 2,505,476Â $251Â $609,969,236Â $(116,657,472)$2,357,621Â $495,675,683Â $17,815,336Â $513,491,019Â Share-based compensation under the ESPP and Equity Incentive Planâ€”Â â€”Â â€”Â â€”Â 1,693,101Â â€”Â â€”Â 1,693,101Â (15,893)1,677,208Â Net loss for the three months ended March 31, 2024â€”Â â€”Â â€”Â â€”Â (13,673,656)â€”Â (13,673,656)(301,865)(13,975,521)Other comprehensive incomeâ€”Â â€”Â â€”Â â€”Â 257,949Â 257,949Â 5,554Â 263,503Â Conversion of MoonLake Class C Ordinary Shares into Class A Ordinary Shares1,493,356Â 149Â (1,493,356)(149)10,536,980Â â€”Â 76,603Â 10,613,583Â (10,613,583)â€”Â Buyback of unvested MoonLake AG Common Shares by MoonLake AG into treasury following an employee contract termination (Note 11)â€”Â â€”Â â€”Â â€”Â 113,154Â â€”Â 904Â 114,058Â (114,108)(50)Capital injection from MoonLake to MoonLake AG (Note 11)â€”Â â€”Â â€”Â â€”Â (4,667,196)â€”Â 19Â (4,667,177)3,057,216Â (1,609,961)Cancellation of MoonLake Class C Ordinary Shares following an employee contract termination in MoonLake AG (Note 11)â€”Â â€”Â â€”Â (16,853)(2)2Â â€”Â â€”Â â€”Â â€”Â â€”Â Issuance of Class A Ordinary Shares, net of transaction costs (Note 11)914,828Â 91Â â€”Â â€”Â 52,540,099Â â€”Â â€”Â 52,540,190Â â€”Â 52,540,190Â Balance at March 31, 202462,874,637Â $6,287Â 995,267Â $100Â $670,185,376Â $(130,331,128)$2,693,096Â $542,553,731Â $9,832,657Â $552,386,388Â Share-based compensation under the ESPP and Equity Incentive Planâ€”Â â€”Â â€”Â â€”Â 1,813,207Â â€”Â â€”Â 1,813,207Â 15,038Â 1,828,245Â Net loss for the three months ended June 30, 2024â€”Â â€”Â â€”Â â€”Â (24,267,012)â€”Â (24,267,012)(491,742)(24,758,754)Other comprehensive incomeâ€”Â â€”Â â€”Â â€”Â 563,811Â 563,811Â 11,807Â 575,618Â Balance at June 30, 202462,874,637Â $6,287Â 995,267Â $100Â $671,998,583Â $(154,598,140)$3,256,907Â $520,663,737Â $9,367,760Â $530,031,497Â Share-based compensation under the ESPP and Equity Incentive Planâ€”Â â€”Â â€”Â â€”Â 1,827,571Â â€”Â â€”Â 1,827,571Â 15,038Â 1,842,609Â Net loss for the three months ended September 30, 2024â€”Â â€”Â â€”Â â€”Â (35,390,337)â€”Â (35,390,337)(724,087)(36,114,424)Other comprehensive lossâ€”Â â€”Â â€”Â â€”Â â€”Â (432,189)(432,189)(8,950)(441,139)Conversion of MoonLake Class C Ordinary Shares into Class A Ordinary Shares153,998Â 16Â (153,998)(16)1,336,078Â â€”Â 9,252Â 1,345,330Â (1,345,330)â€”Â Options exercised under the Equity Incentive Plan (Note 11)17,390Â 2Â â€”Â â€”Â 91,296Â â€”Â â€”Â 91,298Â â€”Â 91,298Â Refund of stamp duty fees for prior capital injection from MoonLake to MoonLake AG (Note 11)â€”Â â€”Â â€”Â â€”Â 89,915Â â€”Â â€”Â 89,915Â 1,884Â 91,799Â Balance at September 30, 202463,046,025Â $6,305Â 841,269Â $84Â $675,343,443Â $(189,988,477)$2,833,970Â $488,195,325Â $7,306,315Â $495,501,640Â The accompanying Notes are an integral part of these Unaudited Condensed Consolidated Financial Statements.5MOONLAKE IMMUNOTHERAPEUTICSCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Amounts in USD) (Unaudited)Nine Months Ended September 30, 2024Nine Months Ended September 30, 2023Cash flow from operating activitiesNet loss$(74,848,699)$(36,191,727)Adjustments to reconcile net loss to net cash used in operating activities:Depreciation83,4409,869Share-based compensation expense5,348,0625,500,499Net periodic pension benefit (gain) cost for the qualified pension plan(2,678)(50,740)Other non-cash items1,189,05696,364Changes in operating assets and liabilities:Other receivables(1,350,200)(503,626)Operating lease right-of-use assets(5,443)â€”Prepaid expenses(7,523,329)869,187Trade and other payables8,872,9193,149,756Operating lease liabilities(872,121)(117,832)Accrued expenses and other current liabilities995,404(3,195,591)Net cash flow used in operating activities(68,113,589)(30,433,841)Cash flow from investing activitiesPurchase of short-term marketable debt securities(203,334,691)(175,732,711)Proceeds from maturities of short-term marketable debt securities145,414,05033,681,688Purchase of property and equipment(343,953)â€”Net cash flow used in investing activities(58,264,594)(142,051,023)Cash flow from financing activitiesIssuance of Class A Ordinary Shares, net of transaction costs52,540,190451,285,093Stamp duty on capital injection from MoonLake to MoonLake AG(1,470,436)â€”Proceeds from options exercised under the Equity Incentive Plan91,298â€”Buyback of unvested MoonLake AG Common Shares by MoonLake AG following an employee contract termination(50)â€”Net cash flow provided by financing activities51,161,002451,285,093Effect of movements in exchange rates on cash held(295,865)(140,047)Net change in cash and cash equivalents(75,513,046)278,660,182Cash and cash equivalents, beginning of period451,169,33739,505,627Cash and cash equivalents, end of period$375,656,291$318,165,809Supplementary disclosure of cash flow information:Non-cash operating lease right-of-use assets obtained in exchange for lease obligations$554,857$â€”The accompanying Notes are an integral part of these Unaudited Condensed Consolidated Financial Statements.6MOONLAKE IMMUNOTHERAPEUTICSNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024(Amounts in USD, except share and per share data) (Unaudited)sNoteÂ 1 â€” Overview of the CompanyCorporate InformationMoonLake Immunotherapeutics is a clinical stage biotechnology company advancing therapies to address significant unmet needs in inflammatory skin and joint diseases. MoonLake Immunotherapeutics is currently a single asset company focused on the development of Sonelokimab (â€œSLKâ€), a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.Unless the context otherwise requires, â€œMoonLakeâ€ and the â€œCompanyâ€ refer to the combined company following the Business Combination (as defined in Note 2 â€” Business Combination Agreement with Helix and Recapitalization included in MoonLakeâ€™s audited financial statements and notes thereto for the year ended December 31, 2023 included in MoonLakeâ€™s Annual Report on Form 10-K for the year ended December 31, 2023, which was filed with the Securities and Exchange Commission (â€œSECâ€) on February 29, 2024 (the â€œAnnual Reportâ€)) consummated on April 5, 2022, together with its subsidiaries. Note 2 â€” Basis of Presentation and Significant Accounting PoliciesBasis of PresentationThe accompanying unaudited condensed consolidated financial statements include those of the Company and its subsidiaries, MoonLake Immunotherapeutics AG, a Swiss stock corporation (Aktiengesellschaft) registered with the commercial register of the Canton of Zug, Switzerland under the number CHE-433.093.536 (â€œMoonLake AGâ€), MoonLake Immunotherapeutics Ltd., a private limited company incorporated in the United Kingdom, and MNLK Immunotherapeutics, Unipessoal Lda ("MNLK PT"), a private limited company incorporated in Portugal, after elimination of all intercompany accounts and transactions. The accompanying unaudited condensed consolidated financial statements and notes hereto have been prepared in accordance with accounting principles generally accepted in the United States of America (â€œU.S. GAAPâ€) as set forth by the Financial Accounting Standards Board (â€œFASBâ€) and in conformity with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X for interim financial reporting. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (â€œASCâ€) and Accounting Standards Updates (â€œASUâ€) of the FASB.In the opinion of management, all material adjustments necessary for a fair presentation of the financial information, which are of a normal and recurring nature, have been made for the interim periods reported. Results of operations for the three and nine months ended SeptemberÂ 30, 2024 are not necessarily indicative of the results for the entire fiscal year or any other period. The unaudited condensed consolidated financial information for the three and nine months ended SeptemberÂ 30, 2024 and 2023 have been prepared on the same basis as and should be read in conjunction with MoonLakeâ€™s audited

financial statements and notes thereto for the year ended December 31, 2023 included in the Annual Report.All amounts are presented in U.S. Dollar (â€œ$â€), unless otherwise indicated. The term â€œSwiss francâ€ and â€œCHFâ€ refer to the legal currency of Switzerland, "GBP" refers to the legal currency of the United Kingdom, and â€œâ‚¬â€ and "Euro" refer to the legal currency of Portugal.Use of EstimatesThe preparation of financial statements in conformity with U.S. GAAP requires the Company to make judgments, estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses. The significant judgments, estimates and assumptions relevant to the Company relate to:7MOONLAKE IMMUNOTHERAPEUTICSNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024(Amounts in USD, except share and per share data) (Unaudited)â€¢determining whether the in-process research and development expenditure (â€œIPR&Dâ€) has an alternative future use;â€¢determining assumptions used in estimating the fair value of share-based compensation;â€¢estimating the recoverability of the deferred tax asset; andâ€¢estimating the amount of accruals in connection with the completion of clinical trial milestones.The Company bases its judgments and estimates on various factors and information, which may include, but are not limited to, the Companyâ€™s forecasts and future plans, current economic conditions and observable market-based transactions of its own shares, the results of which form the basis for making judgments about the carrying value of assets and liabilities and recorded amounts of expenses that are not readily apparent from other sources. To the extent there are material differences between the Companyâ€™s estimates and the actual results, the Companyâ€™s future results of operation may be affected.Cash and Cash EquivalentsThe Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash and cash equivalents are recorded at cost, which approximates fair value. As of SeptemberÂ 30, 2024, the Company considers $59.8 million of short-term marketable debt securities in the form of eurocommercial papers and certificates of deposit to be cash equivalents. As of DecemberÂ 31, 2023, the Company considered $129.4 million of short-term marketable debt securities in the form of eurocommercial papers and certificates of deposit to be cash equivalents.Marketable securities and short-term investmentsThe Company invests in short-term marketable securities in the form of debt securities. At the time of purchase, the Company assesses whether such debt security should be classified as held-to-maturity or available-for-sale debt securities.Debt securities are classified as held-to-maturity when the Company has the positive intent and ability to hold the securities to maturity. Held-to-maturity debt securities are carried at amortized cost, adjusted for accretion of discounts or amortization of premiums to maturity computed under the effective interest method. Such accretion or amortization is included in â€œInterest and dividend incomeâ€. Marketable debt securities not classified as held-to-maturity are classified as available-for-sale and reported at fair value.Net unrealized gains and losses on available-for-sale debt securities are excluded from the determination of earnings and are instead recognized in the â€œAccumulated other comprehensive incomeâ€ component of equity until realized. Realized gains and losses on available-for-sale debt securities are computed based upon the historical cost of these securities, using the specific identification method. A decline in the fair value of any security below cost that is deemed other than temporary results in a charge to earnings and the corresponding establishment of a new cost basis for the security. Dividend and interest income are recognized when earned. Realized gains and losses are included in "Other income" and the cost of securities sold is determined using the specific-identification method.Marketable debt securities are classified as either â€œCash and cash equivalentsâ€ or â€œShortâ€‘term marketable debt securitiesâ€ according to their original maturity at the time of acquisition. Changes in unrealized gains and losses pertaining to cash equivalent securities are added back into the consolidated statements of cash flows as those are excluded from the determination of earnings but impact the cash and cash equivalents position.8MOONLAKE IMMUNOTHERAPEUTICSNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024(Amounts in USD, except share and per share data) (Unaudited)Concentration of Credit RiskFinancial instruments that potentially subject the Company to concentration of credit risk consist of cash accounts in large financial institutions which, at times, may exceed the CHF 100,000 deposit protection limit in Switzerland, the $250,000 Federal Deposit Insurance Corporation deposit insurance coverage limit in the United States, the GBP 85,000 Financial Services Compensation Scheme deposit protection limit in the United Kingdom, or the â‚¬100,000 Fundo de Garantia de DepÃ³sitos deposit protection limit in Portugal. The Company believes it is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash and cash equivalents are held. Additionally, the Company ensures further protection against credit risk by diversifying its cash holdings across a variety of credit institutions, thereby minimizing the potential impact of any adverse events on a single institution. Further, the Company's investment strategy for cash (in excess of current business requirements) is set to invest in short-term marketable debt securities. Management actively monitors credit risk in the investment portfolio. Credit risk exposures are controlled in accordance with policies approved by the board of directors to identify, measure, monitor and control credit risks.Fair Value MeasurementsThe Company follows the guidance included in ASC 820, Fair Value Measurement. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. There are three levels of inputs to fair value measurements:â€¢Level 1, meaning the use of quoted prices for identical instruments in active markets;â€¢Level 2, meaning the use of quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active or are directly or indirectly observable; andâ€¢Level 3, meaning the use of unobservable inputs. Observable market data is used when available.Transfers between Levels 1, 2 or 3 within the fair value hierarchy are recognized at the end of the reporting period when the respective transaction occurred. Segment InformationThe Company operates as a single operating segment. The Companyâ€™s chief operating decision maker, its Chief Executive Officer, manages the Companyâ€™s operations on a stand-alone basis for the purposes of allocating resources and assessing financial performance.Property and EquipmentProperty and equipment, net is stated at cost, net of accumulated depreciation. Depreciation is computed using the straight-line method based on the estimated useful lives of three to five years. As of SeptemberÂ 30, 2024, property and equipment, net relates to information technology, office equipment, and leasehold improvements.Research and Development Contract Costs and AccrualsResearch and development expenses include employee payroll, consulting, contract research and contract manufacturing costs attributable to research and development activities and are expensed as incurred.Upfront payments and milestone payments made for the licensing of technology are expensed as research and development expenses in the period in which it is probable that a liability has been incurred. Advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed.9MOONLAKE IMMUNOTHERAPEUTICSNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024(Amounts in USD, except share and per share data) (Unaudited)The Company has entered into various research and development contracts with companies both inside and outside of the United States. These agreements are generally cancellable, and related payments are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies or trials, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Companyâ€™s estimates. The Companyâ€™s historical accrual estimates have not been materially different from the actual costs.Share-Based CompensationThe Company recognizes compensation expense based on estimated fair values for all stock-based payment awards made to eligible employees, members of the board of directors and independent contractors that are expected to vest. The valuation of stock option awards is determined at the date of grant using the Black-Scholes option pricing model. The Black-Scholes option pricing model requires the Company to make assumptions and judgements about the inputs used in the calculations, such as the fair value of the common stock, expected term, expected volatility of the Companyâ€™s common stock, risk-free interest rate and expected dividend yield. The valuation of restricted stock awards is measured by the fair value of the Companyâ€™s common stock on the date of the grant.For all stock options granted, the Company calculated the expected term as the period that share-based awards are expected to be outstanding. The estimate of expected volatility is based on comparative companiesâ€™ volatility within the Company's industry. The risk-free rate is based on the yield available on United States Treasury zero-coupon issues corresponding to the expected term of the award. The fair value of the common stock granted under the ESPP (as defined in Note 13 â€” Share-based compensation) has historically been estimated by management with reference to the market-based transaction with its Series A investors, as there was no public market for the common stock. Share-based payment arrangements are accounted for under the fair value method. Total compensation is measured at grant date, based on the fair value of the award at that date, and recorded in earnings over the period the employees are required to render service. The Company recognizes compensation cost only for those awards expected to meet the service conditions on a straight-line basis over the requisite service period of the award.Foreign CurrencyThe functional currency of the Company and its subsidiaries is the U.S. dollar. Balances and transactions denominated in foreign currencies are converted as follows: monetary assets and liabilities are translated using exchange rates in effect at the balance sheet dates and non-monetary assets and liabilities are translated at historical exchange rates. Revenue and expenses are translated at the daily exchange rate on the respective accounting date.Gains or losses from foreign currency translation are included in the consolidated statements of operations and comprehensive loss in "other income, net". The Company recognized foreign currency transaction loss of $26,746 and $125,581 for the three and nine months ended SeptemberÂ 30, 2024, respectively, and a foreign currency transaction loss of $557,144 and $276,491 for three and nine months ended September 30, 2023, respectively.Income TaxesThe Company accounts for income taxes by using the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. A valuation allowance is recorded to the extent it is more likely than not that all or a portion of the Company's deferred tax assets will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date.10MOONLAKE IMMUNOTHERAPEUTICSNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024(Amounts in USD, except share and per share data) (Unaudited)Net Loss per Class A Ordinary SharesBasic net loss per Class A Ordinary Share is calculated using the two-class method under which earnings are allocated to both Class A Ordinary Shares and participating securities. Basic net loss per share is calculated by dividing the net loss attributable to Class A Ordinary Shares by the weighted-average number of Class A Ordinary Shares outstanding for the period. The diluted net loss per Class A Ordinary Share is computed by dividing the net loss using the weighted-average number of Class A Ordinary Shares and, if dilutive, potential Class A Ordinary Shares outstanding during the period.In periods in which the Company reports a net loss attributable to shareholders of Class A Ordinary Shares, diluted net loss per share attributable to shareholders of Class A Ordinary Shares is the same as basic net loss per share attributable to shareholders of Class A Ordinary Shares, since dilutive Class A Ordinary Shares are not assumed to be outstanding if their effect is anti-dilutive. AcquisitionsThe Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first assessing whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. On April 29, 2021, MoonLake AG entered into an in-licensing agreement (the â€œIn-License Agreementâ€) with Merck Healthcare KGaA, Darmstadt, Germany (â€œMHKDGâ€) to acquire the Sonelokimab program (the â€œSLK Programâ€) and determined that substantially all of the fair value of the gross assets acquired related to IPR&D of SLK. Therefore, this transaction was accounted for as an asset acquisition.IPR&D represents incomplete technologies that the Company acquires, which at the time of acquisition, are still under development and have no alternative future use. The fair value of such technologies is expensed upon acquisition. A technology is considered to have an alternative future use if it is probable that the Company will use the asset in its current, incomplete state as it existed at the acquisition date, in another research and development project that has not yet commenced, and economic benefit is anticipated from that use. If a technology is determined to have an alternative future use, then the fair value of the program would be recorded as an asset on the balance sheet rather than expensed. Contingent consideration payments (for example milestone payments due upon the occurrence of a specific event) in asset acquisitions are recognized in the period in which it is probable that a liability has been incurred (unless the contingent consideration meets the definition of a derivative, in which case the amount becomes part of the cost in the asset acquired). Upon recognition of the contingent consideration payment, the amount is expensed if it relates to IPR&D or capitalized if it relates to a developed product which is generally considered to be when clinical trials have been completed and regulatory approval obtained.Future royalty payments due on net sales will be recognized in cost of goods sold when net sales are recognized.Pension AccountingThe Company accounts for pension assets and liabilities in accordance with ASC 715, Compensation â€” Retirement Benefits, which requires the recognition of the funded status of pension plans in the Companyâ€™s consolidated balance sheet. The liability in respect to defined benefit pension plans is the projected benefit obligation calculated annually by independent actuaries using the projected unit credit method. The projected benefit obligation as of SeptemberÂ 30, 2024 represents the actuarial present value of the estimated future payments required to settle the obligation that is attributable to employee services rendered before that date. Service costs for such pension plans, represented in the net periodic pension benefit cost, are included in the personnel expenses of the various functions where the employees are engaged. The other components of net benefit cost are included in the consolidated statements of operations and comprehensive loss separately from the service cost component, in â€œother income, net.â€ Plan assets are recorded at their fair value. 11MOONLAKE IMMUNOTHERAPEUTICSNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024(Amounts in USD, except share and per share data) (Unaudited)Gains or losses arising from plan curtailments or settlements are accounted for at the time they occur. Any net pension asset is limited to the present value of the future economic benefits available to the Company in the form of refunds from the plan or expected reductions in future contributions to the plan. Actuarial gains and losses arising from differences between the actual and the expected return on plan assets are recognized in accumulated other comprehensive income. LeasesThe Company determines if an arrangement is or contains a lease at contract inception. For these arrangements, it is evaluated if the arrangement involves an identified asset that is physically distinct or whether the Company has the right to substantially all of the capacity of an identified asset that is not physically distinct. In arrangements that involve an identified asset, there is also judgment in evaluating if the Company has the right to direct the use of that asset.MoonLake does not have any finance leases. As of SeptemberÂ 30, 2024, the Company has five operating leases related to the office spaces located in (i) Dorfstrasse 29, 6300, Zug, Switzerland (comprised of two leases), (ii) 95 Regent Street, CB2 1AW, Cambridge, England, United Kingdom, and (iii) Rua Manuel Pinto de Azedevo 860, 4150-335, Porto, Portugal (comprised of two leases). The operating leases are recognized on a straight-line basis over the lease term commencing on the date the Company has the right to use the leased property. Right-of-use assets and lease liabilities are measured at the lease commencement date based on the present value of the remaining lease payments over the lease term, determined using the discount rate for the lease at the commencement date. Because the rate implicit in the leases is not readily determinable, the Company uses the incremental borrowing rate as the discount rate, which approximates the interest rate at which the Company could borrow on a collateralized basis with similar terms and payments and in similar economic environments.Leases with an initial term of 12 months or less that do not have the option to purchase the underlying asset are not recorded on the balance sheet, with lease expense for these leases recognized on a straight-line basis over the lease term commencing on the date the Company has the right to use the leased property.Recently Issued Accounting Pronouncements not yet AdoptedIn November 2023, the FASB issued ASU 2023-07, Segment reporting â€” Improvements to Reportable Segment Disclosures. This new standard requires public entities to disclose significant segment expenses and additional segment items annually and to provide all reported segment profit or loss and assets disclosures currently required annually on an interim basis. The standard also requires disclosure of the Chief Operating Decision Maker's title and position. The standard does not change the manner in which public entities identify their operating segments, aggregate them, or apply the quantitative thresholds for determining their reportable segments. It is effective for fiscal years beginning after December 15, 2023 and interim periods in fiscal years beginning after December 15, 2024, with early adoption permitted. The Company has determined it operates as a single segment, therefore, we do not anticipate this ASU to materially impact our consolidated financial statements and related disclosures.In December 2023, the FASB issued ASU 2023-09, Income taxes â€” Improvements to Income Taxes Disclosure. The purpose of this guidance is to enhance the transparency and usefulness of income tax disclosures and provide comprehensive income tax information, particularly in relation to rate reconciliation and income taxes paid in the U.S and foreign jurisdictions. It is effective for fiscal years beginning after December 15, 2024 and interim periods in fiscal years beginning after December 15, 2024, with early adoption permitted. This ASU will result in the required additional disclosures being included in our consolidated financial statements, once adopted. Note 3 â€” Risks and LiquidityGoing Concern, Liquidity and Capital ResourcesÂ Â Â Â MoonLake is subject to risks common to companies in the biopharmaceutical industry, and the Company believes that changes in any of the following areas could have a material adverse effect on the Company's future financial position or results of operations: ability to obtain future financing, regulatory approval and market acceptance of, and reimbursement for, product candidates, performance of third-party contract research organizations and manufacturers upon which the Company relies, protection of the Company's intellectual property,

litigation or claims against the 12MOONLAKE IMMUNOTHERAPEUTICSNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024(Amounts in USD, except share and per share data) (Unaudited)Company based on intellectual property, patent, product, regulatory, clinical or other factors, and the Company's ability to attract and retain employees necessary to support its growth.The Company is dependent on third-party manufacturers to supply products for research and development activities in its programs. In particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply the Company with its requirements for the active pharmaceutical ingredients and formulated drugs related to these programs. These programs could be adversely affected by a significant interruption in the supply of active pharmaceutical ingredients and formulated drugs.The Company's ability to generate revenue sufficient to achieve profitability will depend on the successful development and eventual commercialization of SLK in one or more indications, which is expected to take a number of years. The Company expects to continue to incur significant expenses and operating losses for at least the next three years as the Company continues the development of SLK and prepares for commercial launches. It is expected that operating losses will fluctuate significantly from year to year depending on the timing of the Company's planned clinical development programs and efforts to achieve regulatory approval.The Company incurred a loss of $74.8 million for the nine months ended SeptemberÂ 30, 2024. As of SeptemberÂ 30, 2024, the Companyâ€™s current assets exceeded its current liabilities by $492.2 million. As of SeptemberÂ 30, 2024, the Company had $375.7 million of cash and cash equivalents. Based on the Company's current operating plan, management believes that the Company has sufficient capital to fund its operations and capital expenditures until the end of 2026. Note 4 â€“ Fair Value MeasurementsThe following table presents information about the Company's short-term marketable debt securities measured at fair value on a recurring basis and indicate the level in the fair value hierarchy in which the Company classifies the fair value measurement:September 30, 2024December 31, 2023Level 2TotalLevel 2TotalEurocommercial Papers$89,072,100Â $89,072,100Â $109,608,915Â $109,608,915Â Certificates of Deposit88,991,100Â 88,991,100Â 79,626,727Â 79,626,727Â Total$178,063,200Â $178,063,200Â $189,235,642Â $189,235,642Â Cash and accounts payable approximate their fair values as of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023, due to their short-term nature. Pension plan assets fair value is determined based on Level 2 inputs.Note 5 â€“ InvestmentsThe fair value and amortized cost of investments in short-term marketable debt securities by major security type as of SeptemberÂ 30, 2024 are as follows:Amortized costGross unrealized gainsGross unrealized lossesFair valueEurocommercial Papers$87,231,307Â $1,840,793Â $â€”Â $89,072,100Â Certificates of Deposit87,602,179Â 1,388,921Â â€”Â 88,991,100Â Total$174,833,486$3,229,714$â€”$178,063,20013MOONLAKE IMMUNOTHERAPEUTICSNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024(Amounts in USD, except share and per share data) (Unaudited)Of which classified within cash and cash equivalents59,212,123Â 582,677Â â€”Â 59,794,800Â Of which classified within short-term marketable debt securities115,621,363Â 2,647,037Â â€”Â 118,268,400Â The following table presents the changes in fair values of the Companyâ€™s short-term marketable debt securities, classified as Level 2 financial assets, and recognized in accumulated other comprehensive income:Beginning balance, January 1, 2024$2,720,854Â Other comprehensive income before reclassifications13,000,645Â Amounts reclassified from accumulated other comprehensive income(12,491,785)Ending balance, September 30, 2024$3,229,714As of SeptemberÂ 30, 2024, the Companyâ€™s marketable debt securities maturities are all due within one year.NoteÂ 6 â€” Prepaid ExpensesPrepaid expenses - currentSeptember 30, 2024December 31, 2023Non-clinical research and clinical development services$7,381,811$842,729Supply and manufacturing services6,358,8921,205Insurance1,496,5211,077,478Other prepayments747,201180,791Total$15,984,425$2,102,203Prepaid expenses - non-currentSeptember 30, 2024December 31, 2023Supply and manufacturing services$2,064,575$8,423,468Total$2,064,575$8,423,468Supply and manufacturing services, current and non-current, relate to advance payments made to a contract manufacturing organization pursuant to a manufacturing run reservation agreement for the commercial-scale manufacturing of SLK in 2025.NoteÂ 7 â€” Trade and Other PayablesSeptember 30, 2024December 31, 2023Research and development services and license fees$7,113,098$911,454Supply and manufacturing fees payable3,044,237553,459Consulting and advisory services307,58180,695Legal advisory fees payable104,31747,095Other payables141,370244,981Total$10,710,603$1,837,68414MOONLAKE IMMUNOTHERAPEUTICSNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024(Amounts in USD, except share and per share data) (Unaudited)NoteÂ 8 â€” Accrued Expenses and Other Current LiabilitiesSeptember 30, 2024December 31, 2023Research and development services and license fees$3,253,581Â $1,226,281Â Bonuses and related employees compensation expenses2,922,982Â 2,780,219Â Supply and manufacturing services894,894Â 1,603,739Â Tax liabilities484,482Â 367,976Â Consultant and other fees351,774Â 853,905Â Legal fees17,81198,000Total$7,925,524$6,930,120Note 9 â€” LeasesIn August 2021, the Company entered into an open-ended office lease agreement, effective November 1, 2021, to lease approximately 2,300 square feet of space on the last two floors of the building located at Dorfstrasse 29, 6300 Zug, Switzerland. The Company estimated the effective duration of the lease at inception and determined a period of 3 years, with expected expiration in November 2024. In December 2023, the contract was extended, leading to a new estimated effective duration of the lease period of 3 years, with expected expiration in January 2027.On October 9, 2023, the Company entered into an office lease agreement, effective as of October 9, 2023, to lease approximately 3,900 square feet of office space on the fifth floor of the building located at Rua Manuel Pinto de Azedevo 860, 4150-335, Porto, Portugal. This lease has a 3-year initial term, with two extendable periods of 3 years each. It is expected to be extended once until October 2029. On October 13, 2023, the Company entered into an office lease agreement, effective as of October 16, 2023, to lease approximately 6,000 square feet of office space on the first floor of the building located at 95 Regent Street, CB2 1AW, Cambridge, England, United Kingdom. This lease has a 3-year term agreement and is set to expire in October 2026. On December 12, 2023, the Company entered into an open-ended office lease agreement, effective as of January 15, 2024, to lease approximately 1,700 square feet of additional office space at its existing corporate headquarters located at Dorfstrasse 29, 6300 Zug, Switzerland. The Company estimated the duration of the lease at inception and determined a 3-year term.On August 14, 2024, the Company entered into an office lease agreement, effective as of September 8, 2024, to lease approximately 2,000 square feet of additional office space at its existing office located at Rua Manuel Pinto de Azevodo 860, 4150-335, Porto, Portugal. This lease has a 2-year initial term, with two extendable periods of 3 years each. The Company currently expects that it will be extended until October 2029.The weighted average remaining lease term and weighted average discount rate for the operating leases as of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023 were as follows:September 30, 2024December 31, 2023Weighted average remaining lease term (in months)3239Weighted average discount rate4.7Â %4.9Â %15MOONLAKE IMMUNOTHERAPEUTICSNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024(Amounts in USD, except share and per share data) (Unaudited)The maturities of the Company's operating lease liabilities as of SeptemberÂ 30, 2024 are as follows:Year ending December 31,AmountRemainder of fiscal 2024$386,51920251,571,58920261,242,5502027140,3132028140,313Thereafter95,627Total lease payments3,576,911Less imputed interest(196,309)Total lease liability3,380,602Less current portion of lease liability(1,444,893)Long-term portion operating lease liability$1,935,709Operating cash outflows for amounts included in the measurement of lease liabilities was $1,101,661 and $78,270 for the nine months ended SeptemberÂ 30, 2024 and September 30, 2023, respectively.The Company recorded the following lease and variable lease expenses for the three and nine months ended SeptemberÂ 30, 2024 and September 30, 2023: Three Months Ended September 30, 2024Three Months Ended September 30, 2023Nine Months Ended September 30, 2024Nine Months Ended September 30, 2023Operating lease expense$358,583Â $39,562Â $1,061,029Â $117,832Â Variable lease expense15,398Â â€”Â 5,398Â â€”Â Total lease expense$363,981Â $39,562Â $1,066,427Â $117,832Â NoteÂ 10 â€” Employee Benefit Plans The Company operates a defined benefit pension plan in Switzerland (the "Plan") and a defined contribution pension plan in the United Kingdom, in accordance with local regulations and practices. As of SeptemberÂ 30, 2024, the Plan covers the Companyâ€™s employees in Switzerland with benefits in the event of death, disability, retirement, or termination of employment. Components of Net Periodic Benefit Cost under the Plan1 Variable lease expense resulting from increased lease payments linked to changes in the reference index. 16MOONLAKE IMMUNOTHERAPEUTICSNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024(Amounts in USD, except share and per share data) (Unaudited)Three Months Ended September 30, 2024Three Months Ended September 30, 2023Nine Months Ended September 30, 2024Nine Months Ended September 30, 2023Service cost$71,107$31,175$210,387$91,596Interest cost8,3877,78424,81422,872Expected return on plan assets(15,338)(9,280)(45,380)(27,265)Amortization of unrecognized loss2,609â€”7,717â€”Prior service credit recognized in current year(2,582)â€”(7,639)â€”Total net periodic benefit cost$64,183$29,679$189,899$87,203The components of net periodic benefit cost other than the service cost component are included in general and administrative expense in the Company's unaudited condensed consolidated statements of operations and comprehensive loss.Employer Contributions under the PlanFor the nine months ended SeptemberÂ 30, 2024, contributions of $192,563 (CHF 169,455) were made to the Plan. The Company presently anticipates contributing an additional estimated amount of $64,188 (CHF 56,485) to fund the Plan in 2024 for a total of $256,751 (CHF 225,940).17MOONLAKE IMMUNOTHERAPEUTICSNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024(Amounts in USD, except share and per share data) (Unaudited)NoteÂ 11 â€” Shareholdersâ€™ EquityClass A Ordinary Shares(1)Class C Ordinary Shares(1)Total Number of Ordinary SharesAuthorizedIssuedAuthorizedIssuedAuthorizedIssued and OutstandingBalance at January 1, 2024500,000,00060,466,453100,000,0002,505,476600,000,00062,971,929Conversion of Class C Ordinary Shares into Class A Ordinary Sharesâ€”1,493,356â€”(1,493,356)â€”â€”Issuance of Class A Ordinary Shares under the ATM facilityâ€”914,828â€”â€”â€”914,828Cancellation of Class C shares following an employee contract termination in MoonLake AGâ€”â€”â€”(16,853)â€”(16,853)Balance at March 31, 2024500,000,00062,874,637100,000,000995,267600,000,00063,869,904Balance at June 30, 2024500,000,00062,874,637100,000,000995,267600,000,00063,869,904Conversion of Class C Ordinary Shares into Class A Ordinary Sharesâ€”153,998â€”(153,998)â€”â€”Options exercised under the Equity Incentive Planâ€”17,390â€”â€”â€”17,390Balance at September 30, 2024500,000,00063,046,025100,000,000841,269600,000,00063,887,294(1) Fully paid-in registered shares with a par value of $0.0001 Class A Ordinary SharesOn April 6, 2022, the Company's Class A Ordinary Shares began trading on The Nasdaq Capital Market ("Nasdaq") under the symbol â€œMLTXâ€. As of SeptemberÂ 30, 2024, there were 63,046,025 Class A Ordinary Shares issued and outstanding. The Company is authorized to issue up to 500,000,000 Class A Ordinary Shares, par value $0.0001 per share. Holders of Class A Ordinary Shares are entitled to one vote per share. Class C Ordinary SharesAs of SeptemberÂ 30, 2024, there were 841,269 Class C Ordinary Shares issued and outstanding. The Company is authorized to issue up to 100,000,000 Class C Ordinary Shares, with a par value $0.0001 per share. Each Class C Ordinary Share entitles the holders thereof to one vote per share, but carries no economic rights.18MOONLAKE IMMUNOTHERAPEUTICSNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024(Amounts in USD, except share and per share data) (Unaudited)At the closing of the Business Combination, MoonLake, MoonLake AG and ML Party (as defined in Note 2 â€” Business Combination Agreement with Helix and Recapitalization, included in MoonLake's audited financial statements and notes thereto for the year ended December 31, 2023 included in the Annual Report) entered into a Restated and Amended Shareholders' Agreement (the â€œA&R Shareholders' Agreementâ€). With the intent to approximate the rights, obligations and restrictions that an ML Party would enjoy if it were a holder of Class A Ordinary Shares, the A&R Shareholdersâ€™ Agreement (i) imposes certain transfer and other restrictions on the ML Parties, (ii) provides for the waiver of certain statutory rights and (iii) establishes certain mechanics whereby MoonLake and each of the ML Parties are able to effect the conversion of MoonLake AG Common Shares and Class C Ordinary Shares into a number of Class A Ordinary Shares equal to the Exchange Ratio of 33.638698 (as defined in Note 3 â€” Basis of Presentation, included in MoonLake's audited financial statements and notes thereto for the year ended December 31, 2023 included in the Annual Report). On September 9 and September 25, 2024, pursuant to the A&R Shareholdersâ€™ Agreement, certain holders of Class C Ordinary Shares submitted exchange notices to the Company, pursuant to which such holders of Class C Ordinary Shares effected the conversion of 4,578 MoonLake AG Common Shares and 153,998 Class C Ordinary Shares into 153,998 Class A Ordinary Shares using the Exchange Ratio. The foregoing description of the A&R Shareholders' Agreement is not complete and is qualified in its entirety by reference to, and should be read in connection with, the full text of the A&R Shareholders' Agreement filed as an exhibit on the Company's Current Report on Form 8-K filed with the SEC on April 11, 2022.Equity OfferingsAt-the-Market OfferingOn May 11, 2023, the Company entered into a Sales Agreement (the â€œMay 2023 Sales Agreementâ€) with Leerink Partners LLC (formerly known as SVB Securities LLC) (â€œLeerink Partnersâ€), through which the Company could issue and sell up to $200,000,000 of its Class A Ordinary Shares (the â€œMay 2023 ATM Sharesâ€), through Leerink Partners as its sales agent. The May 2023 ATM Shares to be sold under the May 2023 Sales Agreement, if any, would be issued and sold pursuant to the Company's shelf registration statement on Form S-3 (File No. 333-271546), which was declared effective by the SEC on May 9, 2023, and a prospectus supplement thereto filed with the SEC on May 11, 2023.On June 27, 2023, the Company reduced the maximum aggregate offering amount of its Class A Ordinary Shares that could be issued and sold under the May 2023 Sales Agreement to $0 and no longer intends to sell Class A Ordinary Shares under the May 2023 Sales Agreement unless the Company files a further prospectus supplement indicating an amount of shares proposed to be sold.On August 31, 2023, the Company entered into a Sales Agreement with Leerink Partners (the â€œAugust 2023 Sales Agreementâ€ and together with the May 2023 Sales Agreement, the â€œSales Agreementsâ€), through which the Company could issue and sell up to $350,000,000 of its Class A Ordinary Shares (the â€œAugust 2023 ATM Sharesâ€), through Leerink Partners as its sales agent. The August 2023 ATM Shares to be sold under the August 2023 Sales Agreement, if any, would be issued and sold pursuant to the Companyâ€™s shelf registration statement on Form S-3 (File No. 333-274286), which was declared effective by the SEC on September 11, 2023, and a prospectus supplement thereto filed with the SEC on August 31, 2023. During the three months ended March 31, 2024, the Company sold 914,828 Class A Ordinary Shares under the August 2023 Sales Agreement at a weighted average share price of $58.31, for aggregate net proceeds of approximately $52.5 million, after deducting sales agent's commissions and transaction costs.During the three months ended June 30, 2024 and the three months ended SeptemberÂ 30, 2024, there were no sales under the August 2023 Sales Agreement. Public Offering of Class A Ordinary Shares On JuneÂ 27, 2023, the Company entered into an underwriting agreement with SVB Securities LLC and Guggenheim Securities LLC as the representatives of the underwriters named therein, to issue and sell 8,000,000 Class A Ordinary Shares at a public offering price of $50.00 per share (the â€œOfferingâ€). In addition, the Company granted the underwriters an option for a period of 30 days to purchase up to an additional 1,200,000 Class A Ordinary Shares at the public offering price less the underwriting discounts and commissions (the â€œOptionâ€), and such Option was exercised in full by the underwriters.19MOONLAKE IMMUNOTHERAPEUTICSNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024(Amounts in USD, except share and per share data) (Unaudited)The Offering closed on June 30, 2023, and net proceeds from the Offering, including proceeds from the exercise in full by the underwriters of the Option, were $436.7 million, after deducting the underwriting discounts and commissions and the offering expenses in the amount of $23.3 million.Following the completion of the Offering, the Company opted to direct a substantial portion of the net proceeds to MoonLake AG. This was executed as a two-step process: (i) the Company acquired the remaining 22,756 MoonLake AG Common Shares held in treasury through a share purchase and assignment agreement formally executed on July 9, 2023 ($38.9 million) and (ii) the Company contributed additional funds to MoonLake AGâ€™s capital reserves through a cash contribution agreement formally executed on July 10, 2023 ($275 million). A stamp duty tax of $2.8Â million was levied on the aforementioned capital contribution which the Company has classified as cash flows from financing activities in order to correctly mirror the underlying nature of the transaction.On March 8, 2024, the Company executed a similar transaction as a two-step process: (i) the Company acquired 501 MoonLake AG Common Shares held in treasury through a share purchase and assignment agreement ($0.8 million) and (ii) the Company contributed an additional $150.0Â million of funds to MoonLake AG's capital reserves through a cash contribution. A stamp duty tax of $1.6 million was levied on the capital contribution which the Company has classified as cash flows from financing activities in order to correctly mirror the underlying nature of the transaction. The aforementioned increase in treasury shares occurred during the three months ended March 31, 2024 as a result of an employee termination entitling MoonLake AG to repurchase such employee's unvested shares (501 MoonLake AG Common Shares and 16,853 Class C Ordinary Shares) previously awarded as part of a share-based compensation program. Since the shares were subsequently sold to MoonLake, the corresponding Class C Ordinary Shares were canceled.Options Exercised under the Equity Incentive PlanIn the three months ended SeptemberÂ 30, 2024, certain participants exercised their stock options under the Equity Incentive Plan (as defined below) for an aggregate of 17,390 Class A Ordinary Shares and total cash consideration of $91,298. NoteÂ 12 â€” Net Loss per ShareThe following table sets forth the loss per share calculations for the three and nine months ended SeptemberÂ 30, 2024 compared to the three and nine months ended September 30, 2023:Three Months Ended September 30, Nine Months Ended September 30, 2024202320242023NumeratorNet loss attributable to controlling interests shareholders$(35,390,337)$(9,426,049)$(73,331,005)$(28,570,184)DenominatorTotal weighted average number of outstanding shares62,896,78253,517,65562,803,22045,485,650Net loss per share â€“ basic and diluted(0.56)(0.18)(1.17)(0.63)The weighted average number of shares used to calculate the net loss per share â€“ basic for the nine months ended SeptemberÂ 30,

2024 excludes Class C Ordinary Shares as they do not carry economic rights. 20MOONLAKE IMMUNOTHERAPEUTICSNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024(Amounts in USD, except share and per share data) (Unaudited)If the ML Parties elected to convert all of their MoonLake AG Common Shares into Class A Ordinary Shares as of January 1, 2024, the weighted average number of shares outstanding would have been 63,881,246 and 63,809,450 for the three and nine months ended SeptemberÂ 30, 2024, respectively, resulting in a net loss per share of $0.57 and $1.17, respectively. Upon conversion, all Class C Ordinary Shares would be forfeited and there would no longer be any noncontrolling interests.Upon conversion, the Company's number of Class A Ordinary Shares outstanding would be 63,905,198 as of NovemberÂ 1, 2024, including the 17,904 Class A Ordinary Shares issued pursuant to stock options exercised under the Equity Incentive plan subsequent to September 30, 2024. Note 13 â€” Share-Based Compensation As of SeptemberÂ 30, 2024, the Company had the following share-based compensation arrangements:a.Restricted Founder Shares (as defined below) â€“ created in April 2021 by MoonLake AG (fully vested as of April 2023);b.The Employee Share Participation Plan (â€œESPPâ€) â€“ created in July 2021 by MoonLake AG;c.The Employee Stock Option Plan (â€œESOPâ€) â€“ created in July 2021 by MoonLake AG (fully vested as of January 2024);d.MoonLake Immunotherapeutics 2022 Equity Incentive Plan ("Equity Incentive Plan") â€“ created in April 2022 by MoonLake Immunotherapeutics. The purpose of the arrangements is to attract and retain the best available personnel and to provide participants with additional incentive to increase their efforts on behalf and in the best interest of the Company and its subsidiaries. The reference to â€œCommon Sharesâ€ refers to shares in MoonLake AG. MoonLake AG's compensation plans are settled with its Common Shares and with a number of Class C Ordinary Shares of the Company, determined by multiplying the number of Common Shares by the Exchange Ratio. The owners of Common Shares have the right to exchange their Common Shares for a number of Class A Ordinary Shares derived using the Exchange Ratio. In the event MoonLake AG shareholders elect to exchange their Common Shares, such MoonLake AG shareholder forfeits a number of Class C Ordinary Shares equal to the number of Class A Ordinary Shares issued (refer to NoteÂ 11 â€” Shareholdersâ€™ Equity - Class C Ordinary Shares).As of January 1, 2024, the Company executed the conversion of the majority of the outstanding ESOP awards into an equivalent number of Equity Incentive Plan option awards that are settled with Class A Ordinary Shares, thereby eliminating the intermediary right to the exchange step noted above. From an accounting perspective, there is no underlying modification to the economic, control or legal rights of the awards, including vesting terms and conditions, exercise price and accounting classification. This is purely an administrative change as opposed to an accounting modification whereby the plan issuer is amended from MoonLake AG to MoonLake Immunotherapeutics. Consequently, there is no incremental fair value generated following the conversion and therefore no incremental expense recorded. Any remaining unvested compensation expense will be recorded over the remaining vesting period of the original awards, thereby resulting in no change to the consolidated financial statements.As a result of this administrative conversion, the two main plans which remain active as of SeptemberÂ 30, 2024 are the ESPP and Equity Incentive Plan, whereas the Restricted Founder Shares and ESOP are fully vested as of April 2023 and January 2024, respectively.For the three and nine months ended SeptemberÂ 30, 2024, the Company has recognized an increase in equity in the condensed consolidated balance sheet, and share-based compensation expense in the condensed consolidated statements of operations and comprehensive loss of $1.8 million and $5.3 million, respectively. The share-based compensation expense was driven by the aforementioned two main active share-based compensation plans and programs:21MOONLAKE IMMUNOTHERAPEUTICSNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024(Amounts in USD, except share and per share data) (Unaudited)Compensation PlanThree Months Ended September 30, 2024Three Months Ended September 30, 2023Nine Months Ended September 30, 2024Nine Months Ended September 30, 2023MoonLake AG Restricted Founder Shares$â€”Â $â€”Â $â€”Â $1,574,299Â ESPP741,154Â 762,309Â 2,191,5572,590,576ESOPâ€”Â 255,171Â â€”Â 614,469Equity Incentive Plan1,101,455Â 408,171Â 3,156,505721,155Total share-based compensation expense$1,842,609Â $1,425,651Â $5,348,062Â $5,500,499Â Of which: included in research and development expense508,697Â 262,717Â 1,446,049Â 1,150,815Â Of which: included in general and administrative expense1,333,912Â 1,162,934Â 3,902,013Â 4,349,684Â We expect that all future employee awards will be made under the Equity Incentive Plan. As of SeptemberÂ 30, 2024, 3,281,755 Class A Ordinary Shares from the authorized pool of 4,353,948 Class A Ordinary Shares remain available for future grants, and 973,800 and 98,393 Class A Ordinary Shares are reserved for issuance upon exercise of stock options granted under the Equity Incentive Plan and ESOP, respectively. The latter relate to awards not yet subjected to the conversion described above.MoonLake AG - Restricted Founder Shares On April 28, 2021, the shareholdersâ€™ agreement between the co-founders, the Series A investors and MoonLake AG imposed a reverse vesting condition on 90% of the total 110,000 Common Shares (the equivalent of 3,700,257 Class C Ordinary Shares) held by each of the three co-founders. Therefore, 99,000 Common Shares (the equivalent of 3,330,231 Class C Ordinary Shares) held by each of the co-founders were subject to these restrictions and considered unvested (the â€œRestricted Founder Sharesâ€). The Restricted Founder Shares vested on the 28th of each month at a rate of 4.166% over a period of two years until April 28, 2023. In the event of termination of the contractual relationship of the relevant co-founder before the end of the vesting period, MoonLake AG in first priority, or any third party designated by it, and the other shareholders in second priority pro rata to their shareholdings, had an option to purchase all or a pro rata portion of the leaver shares that remained unvested on the effective day of the termination at nominal value of CHF 0.10.Grants awardedRestricted Founder SharesNumber of SharesAwards unvested as of January 1, 20231,110,078Awards vested for the nine months ended September 30, 2023(1,110,078)Awards unvested as of September 30, 2023â€”Employee Share Participation Plan (ESPP) 2021-2025 - MoonLake AGThe ESPP grants will vest 25% on each anniversary of the grant date. In the event of a termination of contractual relationship between the Company and the entitled employee, the awards can be deemed forfeited by MoonLake AG if certain conditions are met. Awards feature an accelerated vesting condition linked to a â€œChange of Controlâ€, defined as any transfer of shares that results in the proposed acquirer holding more than 50% of the then issued share capital of MoonLake AG or the Company, as the case may be, where all the outstanding awards (whether currently outstanding or granted in the future) will be deemed fully vested.22MOONLAKE IMMUNOTHERAPEUTICSNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024(Amounts in USD, except share and per share data) (Unaudited)Grants awardedESPPNumber of SharesAwards issued as of January 1 and September 30, 20232,237,915Awards vested as of September 30, 20231,525,582Awards issued as of January 1, 20242,237,915Awards forfeited for the nine months ended September 30, 20242(16,853)Awards issued as of September 30, 20242,221,062Awards vested as of September 30, 20241,827,826As of SeptemberÂ 30, 2024, MoonLake AG had $3.8 million of total unrecognized compensation expense related to the ESPP that will be recognized over the weighted average period of 1.30 years.Employee Stock Option Plan (ESOP) 2021-2025 - MoonLake AGThe ESOP grants will vest 25% on each anniversary of the grant date. In the event of a termination of the contractual relationship between the Company and the entitled employee, options can be deemed forfeited by MoonLake AG if certain conditions are met. Awards feature an accelerated vesting condition linked to a â€œChange of Controlâ€, defined as any transfer of shares that results in the proposed acquirer holding more than 50% of the then issued share capital of MoonLake AG or the Company, as the case may be, where all the outstanding awards (whether currently outstanding or granted in the future) will be deemed fully vested. Grants awardedESOPNumber of OptionsAwards outstanding as of January 1, 2023466,770Awards granted for the nine months ended September 30, 2023133,444Awards outstanding as of September 30, 2023600,214Awards exercisable as of September 30, 2023186,593Awards outstanding as of January 1, 2024585,078Awards converted from ESOP to Equity Incentive Plan for the nine months ended September 30, 2024(486,685)Awards outstanding as of September 30, 202498,393Awards exercisable as of September 30, 202498,393MoonLake Immunotherapeutics 2022 Equity Incentive PlanOn April 5, 2022 (the â€œEffective Dateâ€), the Company created the Equity Incentive Plan to promote and closely align the interests of employees, officers, non-employee directors and other service providers of MoonLake Immunotherapeutics and its shareholders by providing share-based compensation and other performance-based compensation. The Equity Incentive Plan provides for the grant of options, stock appreciation rights, restricted stock units, restricted stock and other share-based awards and for incentive bonuses, which may be paid in cash, Common Shares or a combination thereof, as determined by the compensation committee of the board of directors or such other committee as 2 Refer to Note 11 - Shareholders' Equity - Class C Ordinary Shares23MOONLAKE IMMUNOTHERAPEUTICSNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024(Amounts in USD, except share and per share data) (Unaudited)designated by the board of directors to administer the Equity Incentive Plan. The Equity Incentive Plan shall remain available for the grant of awards until the 10th anniversary of the Effective Date.Grants awardedEquity Incentive PlanNumber of OptionsAwards outstanding as of January 1, 2023180,000Awards granted for the nine months ended September 30, 202356,485Awards outstanding as of September 30, 2023236,485Awards exercisable as of September 30, 202360,000Awards outstanding as of January 1, 2024312,400Awards granted for the nine months ended September 30, 2024241,820Awards exercised for the nine months ended September 30, 2024(17,390)Awards converted from ESOP to Equity Incentive Plan for the nine months ended September 30, 2024486,685Awards forfeited for the nine months ended September 30, 2024(49,715)Awards outstanding as of September 30, 2024973,800Awards exercisable as of September 30, 2024368,910Weighted average assumptions for the awards issued during the nine months ended September 30, 2024Estimated fair value of the option on the grant date using Black-Scholes model ($)31.31Exercise price ($)45.63Expected term of the award on the grant date (years) (1)6Expected volatility of the share price (2)75%Risk-free interest rate (3)4.3%Expected dividend rateâ€”%(1) The expected term represents the period that share-based awards are expected to be outstanding.(2) The expected volatility was derived from the historical stock volatilities of comparable peer public companies within the Companyâ€™s industry.(3) The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the measurement date with maturities approximately equal to the expected term.As of SeptemberÂ 30, 2024, the Company had $11.2 million of total unrecognized compensation expense related to the Equity Incentive Plan that will be recognized over the weighted average period of 1.96 years.NoteÂ 14 â€” Income TaxesThe Company's effective tax rate (â€œETRâ€) was 0.3% and 0.3% for the three and nine months ended SeptemberÂ 30, 2024, respectively, and 0.2% and 0.1% for the three and nine months ended September 30, 2023, respectively. The Company is not aware of any items that would cause the quarterly ETR to be significantly different from the Company's annual ETR. The difference between the income tax provision that would be derived by applying the statutory rate to the Company's loss before income taxes and the income tax provision recorded was primarily attributable to the change in the valuation allowance. The Company continues to incur losses for the entities domiciled in the Cayman Island and Switzerland, and its ability to utilize the deferred tax asset related to the tax losses is not considered more likely than not. A full valuation allowance has been recorded against the deferred tax asset.NoteÂ 15 â€” Commitments and ContingenciesCommitments24MOONLAKE IMMUNOTHERAPEUTICSNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024(Amounts in USD, except share and per share data) (Unaudited)The Company has entered into agreements as of SeptemberÂ 30, 2024 primarily in regards to the clinical and non-clinical development services with contract research organizations ("CROs"), as well as supply and logistics services with contract manufacturing organizations ("CMOs"), for the advancement of SLK. As of SeptemberÂ 30, 2024, the total committed expense under these agreements amounted to $145.1 million, of which $8.0 million are recognized under Prepaid expenses - current, $2.1 million are recognized under Prepaid expenses - non-current, and the rest remain unrecognized.The Company's In-License Agreement with MHKDG includes contractual milestone payments related to the achievement of pre-specified research, development, regulatory and commercialization events and indemnification provisions, which are common in such agreements. Pursuant to the agreements, the Company is obligated to make research and development and regulatory milestone payments upon the occurrence of certain events. Subject to the terms of the license, additional milestone payments of up to â‚¬299.6 million ($335.2 million using a SeptemberÂ 30, 2024 exchange rate) are potentially payable upon satisfying specific milestones related to regulatory filing acceptance, first commercial sales, and aggregate annual net sales. The milestone payments are payable in cash. Milestone payments due prior to obtaining regulatory approval will be recorded as research and development expense upon determination that a milestone payment is probable to occur. Milestone payments due after obtaining regulatory approval will be capitalized when and if incurred. The Company will use commercially reasonable efforts to cause the milestones to occur. However, if the Company reasonably determines that a technical failure or commercial failure has occurred with respect to all or a part of the SLK Program, the Company, at its sole discretion, can terminate all or part of the SLK Program. As of SeptemberÂ 30, 2024, the Company made a total of â‚¬7.5 million ($8.1 million using the then applicable exchange rates) in additional milestone payments.In addition, on May 12, 2023, MoonLake AG entered into an agreement with Research Cooperation Technologies, Inc. (â€œRCTâ€) and MHKDG, effective as of June 1, 2023, pursuant to which the Company was granted a royalty-bearing, nonexclusive, sublicensable right and license under RCTâ€™s patents and know-how related to a manufacturing process using an underlying yeast strain, Pichia pastoris, to develop, manufacture, use, sell, offer for sale, and import and otherwise commercialize SLK on a world-wide basis, subject to certain restrictions. This agreement replaces the Companyâ€™s sublicense for similar rights under the In-License Agreement. In the aggregate, the Company is required to pay royalties within the range of low to mid-teen percent of net sales under the aforementioned agreements with MHKDG and RCT. Royalties will be recognized in the consolidated statements of operations and comprehensive loss when net sales are recognized.Note 16 - Segment Information and Geographic DataThe Company operates as a single operating segment. Long-lived assets, consisting of property and equipment, net, and operating lease right-of-use assets by geographical area as of SeptemberÂ 30, 2024 are as follows:CountrySeptember 30, 2024December 31, 2023Switzerland$680,946Â $507,392Â United Kingdom2,012,806Â 2,704,555Â Portugal1,138,823Â 737,398Â Total$3,832,575Â $3,949,345Â 25Item 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of OperationsThe following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements as of and for the three and nine months ended SeptemberÂ 30, 2024, appearing elsewhere in this quarterly report (â€œQuarterly Reportâ€) on Form 10-Q, and with MoonLakeâ€™s audited financial statements and notes thereto for the year ended December 31, 2023 included in our Annual Report on Form 10-K for the year ended December 31, 2023, which was filed with the SEC on February 29, 2024 (our â€œAnnual Reportâ€). Our unaudited condensed consolidated financial statements as of and for the three and nine months ended SeptemberÂ 30, 2024 were prepared in accordance with accounting principles generally accepted in the United States ("U.S. GAAP") and presented in UnitedÂ States dollars ($).References to â€œMoonLakeâ€, â€œweâ€, â€œusâ€, â€œourâ€, â€œour Companyâ€, â€œthe Companyâ€ and â€œour businessâ€ refer to MoonLake Immunotherapeutics and its consolidated subsidiaries.Special Note Regarding Forward-Looking StatementsThis Quarterly Report on Form 10-Q contains forward-looking statements. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended (the â€œSecurities Actâ€) and Section 21E of the Securities Exchange Act of 1934, as amended (the â€œExchange Actâ€). All statements other than statements of historical fact contained in this Quarterly Report on Form 10-Q, including, without limitation, statements regarding the following, are forward-looking statements: our future results of operations and financial position, our expectations regarding industry trends, the sufficiency of our cash and cash equivalents, the anticipated sources and uses of cash, the anticipated investments in our business, our business strategy, and the plans and objectives of management for future operations and capital expenditures, and other information referred to in the sections titled â€œBusinessâ€ and â€œRisk Factorsâ€ in our Annual Report and â€œManagementâ€™s Discussion and Analysis of Financial Condition and Results of Operationsâ€ in this Quarterly Report. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as â€œmayâ€, â€œwillâ€, â€œshouldâ€, â€œexpectâ€, â€œplanâ€, â€œanticipateâ€, â€œcouldâ€, â€œintendâ€, â€œtargetâ€, â€œprojectâ€, â€œcontemplateâ€, â€œbelieveâ€, â€œestimateâ€, â€œpredictâ€, â€œpotentialâ€, â€œmightâ€, â€œpossibleâ€, or â€œcontinueâ€ or the negative of these terms or other similar expressions. The forward-looking statements in this Quarterly Report on Form 10-Q are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report contains forward-looking statements that reflect our plans and strategy for our business and related financing. Our actual results and the timing of events could differ materially from those anticipated in the forward-looking statements. Factors that could cause or contribute to these differences include, but are not limited to, those discussed below and elsewhere in this Quarterly Report, and in the section titled â€œRisk Factorsâ€ included in our Annual Report. These forward-looking statements are subject to a number of important risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, including, but not limited to:â€¢our success in retaining or recruiting, or changes required in, our officers, key employees or directors;â€¢factors relating to our business, operations and financial performance, including, but not limited to:â€¢we are substantially dependent on the success of our novel tri-specific NanobodyÂ®, Sonelokimab ("SLK," also known as M1095/ALX 0761), which we license from Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany ("MHKDG");â€¢our ability to obtain regulatory approval for our products, and any related restrictions or limitations of any approved products;26â€¢competition and competitive pressures from

other global companies in the industries in which we operate;â€¢we have incurred significant losses since inception, and we expect to incur significant losses for the foreseeable future and may not be able to achieve or sustain profitability in the future;â€¢our ability to manage our growth effectively;â€¢the impact of adverse business and economic conditions including inflationary pressures, general economic slowdown or a recession, relatively high interest rates, and changes in monetary policy, banking institution instability and the prospect of a shutdown of the U.S. federal government;â€¢while we have initiated and completed clinical trials, we have no products approved for commercial sale;â€¢we require substantial additional capital to finance our operations, and if we are unable to raise such capital when needed or on acceptable terms, we may be forced to delay, reduce, and/or eliminate one or more of our development programs or future commercialization efforts;â€¢our ability to renew existing contracts;â€¢our limited operating history;â€¢our ability to respond to general economic conditions;â€¢litigation and the ability to adequately protect our intellectual property rights; andâ€¢the other factors described under the caption â€œRisk Factorsâ€ in our Annual Report, as may be updated in this Quarterly Report on Form 10-Q, and our other filings with the Securities and Exchange Commission (the â€œSECâ€).New risk factors emerge from time to time and it is not possible to predict all such risks, nor can we assess the impact of all such risks on our business or the extent to which any factor or combination of factors may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements are not guarantees of performance. You should not put undue reliance on these statements, which speak only as of the date hereof. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the foregoing cautionary statements. We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.There may be other factors that may cause our actual results to differ materially from the forward-looking statements, including factors disclosed in â€œRisk Factorsâ€ in our Annual Report or â€œManagementâ€™s Discussion and Analysis of Financial Condition and Results of Operationsâ€ in this Quarterly Report. You should read this Quarterly Report on Form 10-Q and the documents that we reference herein completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements.27OverviewWe are a clinical stage biotechnology company advancing therapies to address significant unmet needs in inflammatory skin and joint diseases. We are currently a single asset company focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody, that we exclusively licensed from MHKDG and that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.SLK is a proprietary Nanobody that was discovered by Ablynx N.V., Belgium, a Sanofi company (â€œAblynxâ€), and previously studied by MHKDG and Avillion LLP under a 2017 co-development agreement. The terms â€œNanobodyâ€ and â€œNanobodiesâ€ used herewith are registered trademarks of Ablynx. Nanobodies are able to bind selectively to a specific antigen with high affinity. Nanobodies have a fraction of the molecular weight compared to traditional antibodies. They offer a number of potential advantages over traditional monoclonal antibodies, including the potential to create multivalent molecules with enhanced ability to penetrate inflamed tissue, especially when containing an additional albumin binding domain such as SLK, an easier manufacturing process and a higher thermostability.We currently develop SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F. This group of diseases comprises our current target diseases, hidradenitis suppurativa (â€œHSâ€), psoriatic arthritis (â€œPsAâ€), axial spondyloarthritis (â€œaxSpAâ€), palmoplantar pustulosis (â€œPPPâ€), and several other inflammatory conditions, including psoriasis (â€œPsOâ€). Our current target diseases affect millions of people worldwide, and we believe there is a need for improved treatment options. We believe that SLK has a differentiated mechanism of action and that its purposefully designed molecular characteristics, including its small size and its albumin binding site, facilitate deep tissue penetration in the skin and joints. We envision SLK as a key therapeutic alternative in our initial target indications and potentially in multiple other IL-17 driven inflammatory conditions.In May 2022, we initiated a Phase 2b trial of SLK in patients with moderate-to-severe HS (the MIRA trial (M1095-HS-201)), and in June 2023, we announced positive top-line results from this trial, which met its primary endpoint of Hidradenitis Suppurativa Clinical Response (â€œHiSCRâ€) 75. In October 2023, we announced positive 24-week top-line results showing that the maintenance treatment with SLK led to further improvements in HiSCR75 response rates and other clinically relevant outcomes in patients with moderate-to-severe HS. In February 2024, we announced the successful outcome of our end-of-Phase 2 interactions with the U.S. Food and Drug Administration (â€œFDAâ€), as well as positive feedback from our interactions with the E.U. European Medicines Agency (â€œEMAâ€), with both regulatory bodies unanimously supporting our proposed approach for advancing our Phase 3 program of SLK in HS. In May 2024, we announced the screening of the first patients in our Phase 3 program of SLK in HS.In December 2022, we initiated a Phase 2b trial in patients with active PsA (the ARGO trial (M1095-PSA-201)), and in November 2023, we announced positive top-line results from this trial, which met its primary endpoint of American College of Rheumatology (â€œACRâ€) 50. In March 2024, we announced positive 24-week data from the ARGO trial in PsA showing that continued treatment with SLK led to significant improvements across all key outcomes. In June 2024, we announced the successful outcome of our end-of-Phase 2 interactions with the FDA, as well as positive feedback from our interactions with the EMA, with both regulatory bodies unanimously supporting our proposed approach for advancing our Phase 3 program of SLK in PsA. We expect enrollment of first patients in our Phase 3 clinical trials to commence imminently.In March 2024, we announced plans to commence an additional Phase 3 clinical trial of SLK in juvenile HS, and Phase 2 clinical trials in PPP and axSpA. We expect these trials to commence around year-end.SLK was also studied in a Phase 2b trial in PsO patients where it showed a significant improvement in the primary end point as compared with placebo and for which results were presented in peer-reviewed scientific publications and conferences. In addition to the three Phase 2b trials, Phase 1 single ascending and multiple ascending dosing trials were previously completed, bringing the total number of patients in completed SLK-related trials to more than 700.28We do not have any product candidates approved for commercial sale, and we have not generated any revenue from product sales. Our ability to generate revenue sufficient to achieve profitability will depend on the successful development and eventual commercialization of SLK in one or more indications, which we expect to take a number of years. We expect to continue to incur significant expenses and operating losses for at least the next three years as we continue the development of SLK and prepare for commercial launches. It is expected that operating losses will fluctuate significantly from year to year depending on the timing of our planned clinical development programs and efforts to achieve regulatory approval.As of SeptemberÂ 30, 2024, we had $375.7 million of cash and cash equivalents. Based on our current operating plans, we believe that our existing cash, cash equivalents and short-term marketable securities, together amounting to $493.9 million, will be sufficient to fund our operating expenses and capital expenditure requirements until the end of 2026.Equity OfferingsAt-the-Market OfferingsOn May 11, 2023, we entered into a Sales Agreement (the â€œMay 2023 Sales Agreementâ€) with Leerink Partners LLC (formerly known as SVB Securities LLC) (â€œLeerink Partnersâ€), through which we could issue and sell up to $200,000,000 of our Class A Ordinary Shares (the â€œMay 2023 ATM Sharesâ€), through Leerink Partners as sales agent. The May 2023 ATM Shares to be sold under the May 2023 Sales Agreement, if any, would be issued and sold pursuant to our shelf registration statement on Form S-3 (File No. 333-271546), which was declared effective by the SEC on May 9, 2023, and a prospectus supplement thereto filed with the SEC on May 11, 2023.On June 27, 2023, we reduced the maximum aggregate offering amount of our Class A Ordinary Shares that could be issued and sold under the May 2023 Sales Agreement to $0 and no longer intend to sell Class A Ordinary Shares under the May 2023 Sales Agreement unless we file a further prospectus supplement indicating an amount of shares proposed to be sold. On August 31, 2023, we entered into a Sales Agreement with Leerink Partners (the â€œAugust 2023 Sales Agreementâ€ and together with the May 2023 Sales Agreement, the â€œSales Agreementsâ€), through which we could issue and sell up to $350,000,000 of our Class A Ordinary Shares (the â€œAugust 2023 ATM Sharesâ€), through Leerink Partners as sales agent. The August 2023 ATM Shares to be sold under the August 2023 Sales Agreement, if any, would be issued and sold pursuant to our shelf registration statement on Form S-3 (File No. 333-274286), which was declared effective by the SEC on September 11, 2023, and a prospectus supplement thereto filed with the SEC on August 31, 2023. For the year ended DecemberÂ 31, 2023, we sold 1,070,818 Class A Ordinary Shares through the Sales Agreements for net proceeds of $46Â million, after deducting sales agent's commission and transaction costs. In the three months ended March 31, 2024, we sold 914,828 Class A Ordinary Shares under the August 2023 Sales Agreement at a weighted average share price of $58.31, for aggregate net proceeds of approximately $52.5 million. In the three months ended JuneÂ 30, 2024 and the three months ended SeptemberÂ 30, 2024, there were no sales under the August 2023 Sales Agreement. As of SeptemberÂ 30, 2024, the total number of shares sold under the August 2023 ATM Sales Agreement was 1,440,752 for total net proceeds of $83.7Â million.Public Offering of Class A Ordinary Shares On JuneÂ 27, 2023, we entered into an underwriting agreement with Leerink Partners and Guggenheim Securities LLC as the representatives of the underwriters named therein to issue and sell 8,000,000 Class A Ordinary Shares at a public offering price of $50.00 per share (the â€œOfferingâ€). In addition, we granted the underwriters an option for a period of 30 days to purchase up to an additional 1,200,000 Class A Ordinary Shares at the public offering price less the underwriting discounts and commissions (the â€œOptionâ€), and such Option was exercised in full by the underwriters.29The Offering closed on June 30, 2023, and net proceeds from the Offering, including proceeds from the exercise in full by the underwriters of the Option, were $436.7 million, after deducting the underwriting discounts and commissions and the offering expenses in the amount of $23.3 million.Following the completion of the Offering, we opted to direct a substantial portion of the net proceeds to MoonLake AG. This was executed as a two-step process: (1) we acquired the remaining 22,756 shares of MoonLake AG common stock held in treasury through a share purchase and assignment agreement formally executed on July 09, 2023 ($38.9 million) and (2) additional funds were contributed to MoonLake AGâ€™s capital reserves through a cash contribution agreement formally executed on July 10, 2023 ($275 million). A stamp duty tax of $2.8Â million was levied on the aforementioned capital contribution which the Company has classified as cash flows from financing activities in order to correctly mirror the underlying nature of the transaction.On March 8, 2024, we executed a similar transaction as a two-step process: (i) we acquired 501 Moonlake AG Common Shares held in treasury through a share purchase and assignment agreement ($0.8 million) and (ii) we contributed an additional $150.0 million of funds to MoonLake AG's capital reserves through a cash contribution. A stamp duty tax of $1.6 million was levied on the capital contribution which we have classified as cash flows from financing activities in order to correctly mirror the underlying nature of the transaction. The aforementioned increase in treasury shares occurred during the three months ended March 31, 2024 as a result of an employee termination entitling MoonLake AG to repurchase such employee's unvested shares (501 MoonLake AG Common Shares and 16,853 Class C Ordinary Shares) previously awarded as part of a share-based compensation program. Since the shares were subsequently sold to MoonLake, the corresponding Class C Ordinary Shares were canceled.Options Exercised under the Equity Incentive PlanIn the three months ended SeptemberÂ 30, 2024, certain participants exercised their stock options under the Equity Incentive Plan (as defined below) for an aggregate of 17,390 Class A Ordinary Shares and total cash consideration of $91,298. Financial Operations OverviewRevenueTo date, we have not generated any revenue from product sales. If our development efforts for SLK are successful and result in regulatory approval or new license agreements with third parties, we may generate revenue in the future from product sales or milestone payments. However, there can be no assurance as to when we will generate such revenue, if at all.Operating ExpensesResearch and Development ExpensesResearch and development expenses consist primarily of costs incurred for our research activities, including third-party license fees and efforts relating to the development of SLK. We expense research and development costs as incurred, which include:â€¢employee-related expenses, including salaries, bonuses, benefits, share-based compensation, and other related costs for those employees involved in research and development efforts;â€¢external research and development expenses incurred under agreements with Clinical Research Organizations (â€œCROsâ€) as well as consultants that conduct our research program and development services;â€¢costs incurred under collaboration agreements;â€¢costs related to manufacturing material for our research program and clinical studies;â€¢costs related to compliance with regulatory requirements; and30â€¢facilities, depreciation and other allocated expenses, which include direct and allocated expenses for rent, utilities and insurance.We estimate research and clinical trial expenses based on the services performed pursuant to contracts with research institutions, CROs, and Clinical Manufacturing Organizations (â€œCMOsâ€) that conduct and manage research studies and clinical trials on our behalf based on actual time and expenses incurred by them or probable achievement of milestone events that are associated with contractually agreed milestone payments.We account for advance payments for goods and services that will be used in future research and development activities as expenses when the services have been performed or when the goods have been received rather than when the payment is made.We do not allocate employee costs, facilities costs, including depreciation, or other indirect costs to specific programs because these costs are deployed across multiple programs and, as such, are not separately classified. We use internal resources primarily for managing our research program, clinical development, and manufacturing activities.The successful development of SLK is highly uncertain. We expect to incur significant research and development expenses for the foreseeable future as we continue the development and manufacturing partnerships for SLK, conduct research activities and potentially expand our pipeline by pursuing additional indications for SLK or including new product candidates in our portfolio. We cannot determine with certainty the timing of initiation, the duration, or the completion costs of current or future research studies and clinical trials of SLK due to the inherently unpredictable nature of research activities and clinical development. Clinical development timelines, the probability of success and the development costs can differ materially from expectations. We anticipate that we will make determinations as to which indications to pursue and how much funding to direct to each indication on an ongoing basis in response to the results of ongoing and future research studies and clinical trials, regulatory developments, and our ongoing assessments as to each indicationâ€™s commercial potential.Any changes in the outcome of any of these variables with respect to the development of SLK could mean a significant change in the costs and timing associated with its development. We may never succeed in achieving regulatory approval for SLK. We may obtain unexpected results from our clinical trials. We may elect to discontinue, delay or modify clinical trials or focus on other product candidates. For example, if the FDA, the EMA, or another regulatory authority were to delay our planned start of clinical trials or require us to conduct clinical trials or other testing beyond those that we currently expect or if we experience significant delays in enrollment in any of our planned clinical trials, we could be required to expend significant additional financial resources and time on the completion of SLKâ€™s clinical development.General and Administrative ExpensesGeneral and administrative expense (â€œG&Aâ€) consists primarily of employee related costs, including salaries, bonuses, benefits, share-based compensation and other related costs for our executive and administrative functions. G&A expense also includes professional services, including legal, accounting and audit services and other consulting fees, as well as facility costs not otherwise included in research and development expenses, insurance and other general administrative expenses.Based on our strategy, there are a number of factors that we expect will impact the level of research and development expenses, G&A expenses, and capital expenditures incurred by the business. These factors include:â€¢Building the leading efficacy and safety profile of SLK for patients â€” We expect to incur significant research and development expenses, and G&A expenses as we: (i) conduct and initiate further clinical trials for SLK including Phase 3 clinical trials in HS, PsA and juvenile HS and Phase 2 clinical trials in PPP and axSpA; (ii)Â seek regulatory approvals for SLK; (iii)Â make milestone and commercial payments under the In-License 31Agreement, dated April 29, 2021, by and between MoonLake AG and MHKDG (the "In-License Agreement") (based on regulatory filing acceptances, first commercial sales, and aggregate annual net sales); (iv)Â establish a sales, marketing and distribution infrastructure to commercialize SLK; (v)Â attract, hire and retain additional clinical, scientific, quality control, and administrative personnel; and (vi)Â add clinical, operational, financial and management information systems and personnel.â€¢Strengthening the differentiation elements for future SLK patients â€” In parallel with our clinical trials, we expect to incur additional research expenditures as we conduct non-clinical research to continue refining our understanding of SLK/nanobody biology and the potential impact in our selected therapeutic indications.â€¢Building our manufacturing and commercialization capabilities â€” We do not own or operate manufacturing facilities, and currently have no plans to establish any. We partner with third-party CMOs for both drug substance and finished drug product. We obtain our supplies from these manufacturers based on purchase orders. Therefore, we expect to incur research and development costs for the purchase of our supplies on an as needed basis to conduct our clinical trials. Technology transfers for drug substance and drug product to commercial scale CMOs have already been executed in 2022, but we may pursue additional technology transfers and process improvements. This is designed to allow us to scale up while SLK is in clinical development and advance potential commercial requirements. The improvement of our manufacturing capabilities will be important in driving efficiency, maintaining high standards of quality control, and ensuring that investigators, physicians, and patients have adequate access to our product candidates, if approved. We also plan to further invest in our commercial capabilities. In 2024, we started hiring dedicated personnel to our marketing, access and pricing functions and intend to continue building out this team to prepare for commercial launches of SLK in our target indications.â€¢Deepening our intellectual property portfolio to support our nanobody technology and product candidatesÂ â€”Â We expect to continue to incur additional research and development expenditures as we continue extending our global intellectual property portfolio consisting of patents and patent applications, trade secrets, trademarks, and know-how to protect the product candidates developed from our nanobody technology. We plan to expand our intellectual property portfolio as we continue to advance and develop existing product candidates.â€¢Licensing/broadening our portfolio â€” We may supplement our current strategy with the in-licensing or acquisition of additional product candidates for clinical

development (beyond SLK), rather than discovering such candidates ourselves, which would lead to additional research and development expenses, G&A expenses, and capital expenditures.â€¢Granting share-based compensation awards and vesting of existing plans â€” We expect to continue to grant awards to selected employees, directors and non-employees pursuant to the MoonLake Immunotherapeutics 2022 Equity Incentive Plan ("Equity Incentive Plan"). Further, we expect to continue to incur share-based compensation charges in connection with the above-mentioned plan and the vesting of awards made under MoonLake AGâ€™s Employee Share Participation Plan (â€œESPPâ€).We also expect to incur additional legal, accounting, investor relations and other expenses associated with operating as a public company and as we continue to grow our business. Our net losses may fluctuate significantly from quarter-to-quarter and year-to-year, depending on the timing of our clinical trials and our expenditures on other research and development activities.We expect our existing cash and cash equivalents to be sufficient to advance the development of SLK in multiple indications, including the above mentioned clinical trials in HS, PsA, juvenile HS, PPP and axSpA, and to submit a Biologics License Application for SLK. Clinical development involves a lengthy and expensive process with uncertain outcomes and is subject to risks described under the heading â€œRisk Factorsâ€ in our most recent Annual Report on Form 10-K, including that our preclinical studies or clinical trials may not be conducted as planned or completed on schedule and may not satisfy the requirements of the FDA, EMA, or other comparable foreign regulatory authorities. If we are required to conduct additional preclinical studies or clinical trials of SLK beyond those that we currently contemplate, if we are delayed or unable to successfully complete clinical trials of SLK or other testing, or if the results of these trials 32or tests are not positive or are only modestly positive or if there are safety concerns, we may require additional funding. Moreover, we will require additional capital to commercialize SLK and to discover, develop, obtain regulatory approval and commercialize any future product candidates, as applicable. We do not have any committed external source of funds. We expect to finance future cash needs through public or private equity or debt offerings or product collaborations. Additional capital may not be available in sufficient amounts or on reasonable terms, if at all. The current market environment for small biotechnology companies, like us, and broader macroeconomic factors, including recent and potential future disruptions in access to bank deposits or lending commitments due to bank failures, may preclude us from successfully raising additional capital.If we do not raise additional capital, we may not be able to expand our operations or otherwise capitalize on our business opportunities, our business and financial condition will be negatively impacted and we may need to: significantly delay, scale back or discontinue research and discovery efforts and the development or commercialization of SLK or any other product candidates or cease operations altogether; seek strategic alliances for research and development programs when we otherwise would not, or at an earlier stage than we would otherwise desire or on terms less favorable than might otherwise be available; or relinquish, or license on unfavorable terms, our rights to technologies or SLK or any other product candidates that we otherwise would seek to develop or commercialize ourselves.Foreign CurrencyOur functional currency is the U.S.Â dollar. Balances and transactions denominated in foreign currencies are converted as follows: monetary assets and liabilities are translated using exchange rates in effect at the balance sheet dates and non-monetary assets and liabilities are translated at historical exchange rates. Revenue (if and when earned) and expenses are translated at the daily exchange rate on the respective transaction date.Gains or losses from foreign currency translation are included in "other income, net" in the unaudited condensed consolidated statements of operations and comprehensive loss. We recognized a foreign currency transaction loss of $26,746 and $125,581 for the three and nine months ended SeptemberÂ 30, 2024, respectively. For the three and nine months ended September 30, 2023, we recognized a foreign currency transaction loss of $557,144 and $276,491, respectively.33Results of OperationsComparison of the three months ended SeptemberÂ 30, 2024 and 2023Three Months Ended September 30, 2024Three Months Ended September 30, 2023ChangeChange %Operating expensesResearch and development$(35,735,514)$(7,585,136)$(28,150,378)371.1Â %General and administrative(7,376,495)(5,391,607)(1,984,888)36.8Â %Total operating expenses(43,112,009)(12,976,743)(30,135,266)232.2Â %Operating loss(43,112,009)(12,976,743)(30,135,266)232.2Â %Other income, net7,089,691Â 1,386,313Â 5,703,378Â 411.4Â %Loss before income tax(36,022,318)(11,590,430)(24,431,888)210.8Â %Income tax expense(92,106)(28,923)(63,183)218.5Â %Net loss(36,114,424)(11,619,353)(24,495,071)210.8Â %Net unrealized gain (loss) on marketable securities and short term investments(325,510)3,437,291Â (3,762,801)(109.5)%Actuarial gain (loss) on employee benefit plans(115,629)39,157Â (154,786)(395.3)%Other comprehensive income (loss)(441,139)3,476,448Â (3,917,587)(112.7)%Comprehensive loss$(36,555,563)$(8,142,905)$(28,412,658)348.9Â %Research and DevelopmentResearch and development expenses were $35.7 million for the three months ended SeptemberÂ 30, 2024, compared to $7.6 million for the three months ended September 30, 2023. The increase of $28.1 million primarily related to an increase of $15.4 million in expenses pertaining to clinical development trials with CROs, including for the conduct of Phase 3 clinical trials in HS and preparatory activities for the clinical trials of SLK, including the Phase 3 clinical trials in PsA, Phase 2 clinical trial in axSpA and Phase 2 clinical trial in PPP, an increase of $9.2 million related to supply and logistic services for such clinical development trials, including the purchase of a comparator drug for the Phase 3 clinical trials in PsA, an increase of $1.6 million and $1.0 million in personnel-related costs and consulting expenses, respectively, to support the research and development effort, and $0.9 million related to contracted non-clinical research and development expenses.General and AdministrativeGeneral and administrative expenses were $7.4Â million for the three months ended SeptemberÂ 30, 2024, compared to $5.4 million for the three months ended September 30, 2023. The increase of $2.0 million primarily related to an increase of $0.9 million in personnel-related costs to support organizational growth. 34Other Income, NetOther income, net was $7.1 million for the three months ended SeptemberÂ 30, 2024, compared to $1.4 million for the three months ended September 30, 2023. The increase of $5.7 million primarily related to an increase of $5.2 million in realized interest on cash held in bank and cash investments in short-term marketable debt securities.Income Tax ExpenseIncome tax expense was $92,106 for the three months ended SeptemberÂ 30, 2024, compared to $28,923 for the three months ended September 30, 2023. The expense is related to corporate income tax of our U.K. and Portugal subsidiaries in 2024 and of our U.K subsidiary in 2023.Other Comprehensive Income (Loss)Other comprehensive loss was $0.4 million for the three months ended SeptemberÂ 30, 2024, compared to other comprehensive income of $3.5 million for the three months ended September 30, 2023. The decrease in other comprehensive income of $3.9 million primarily related to a decrease in net unrealized gain in short-term marketable debt securities of $3.8 million.Comparison of the nine months ended SeptemberÂ 30, 2024 and 2023Nine Months Ended September 30, 2024Nine Months Ended September 30, 2023ChangeChange %Operating expensesResearch and development$(72,411,709)$(23,704,087)$(48,707,622)205.5Â %General and administrative(21,099,001)(15,390,117)(5,708,884)37.1Â %Total operating expenses(93,510,710)(39,094,204)(54,416,506)139.2Â %Operating loss(93,510,710)(39,094,204)(54,416,506)139.2Â %Other income, net18,903,070Â 2,952,557Â 15,950,513Â 540.2Â %Loss before income tax(74,607,640)(36,141,647)(38,465,993)106.4Â %Income tax expense(241,059)(50,080)(190,979)381.3Â %Net loss(74,848,699)(36,191,727)(38,656,972)106.8Â %Net unrealized gain on marketable securities and short term investments508,860Â 3,046,538Â (2,537,678)(83.3)%Actuarial loss on employee benefit plans(110,878)(19,323)(91,555)473.8Â %Other comprehensive income397,982Â 3,027,215Â (2,629,233)(86.9)%Comprehensive loss$(74,450,717)$(33,164,512)$(41,286,205)124.5Â %35Research and DevelopmentResearch and development expenses were $72.4 million for the nine months ended SeptemberÂ 30, 2024, compared to $23.7 million for the nine months ended September 30, 2023. The increase of $48.7 million primarily related to an increase of $28.7 million in expenses pertaining to clinical development trials with CROs, including for the conduct of Phase 3 clinical trials in HS and preparatory activities for the clinical trials of SLK, including the Phase 3 clinical trials in PsA, Phase 2 clinical trial in axSpA and Phase 2 clinical trial in PPP, an increase of $14.0 million related to supply and logistic services for such clinical development trials, including the purchase of a comparator drug for the Phase 3 clinical trials in PsA, an increase of $3.7 million and $1.9 million in personnel-related costs and consulting expenses, respectively, to support the research and development effort, and an increase of $1.0 million related to non-clinical research and development expenses. The increases were partially offset by a decrease in $0.6 million in other research and development expenses.General and AdministrativeGeneral and administrative expenses were $21.1Â million for the nine months ended SeptemberÂ 30, 2024, compared to $15.4 million for the nine months ended September 30, 2023. The increase of $5.7 million primarily related to an increase of $2.5 million in personnel-related costs to support organizational growth, an increase of $2.2 million in expenses for advisory and professional services to support organizational growth and operating as a large-accelerated filer, an increase of $1.0 million in office expenses driven by the new leases for additional office space, and an increase of $0.5 million in market research expenses. Other Income, NetOther income, net was $18.9 million for the nine months ended SeptemberÂ 30, 2024, compared to $3.0 million for the nine months ended September 30, 2023. The increase of $15.9 million primarily related to an increase of $16.0 million in realized interest on cash held in bank and cash investments in short-term marketable debt securities.Income Tax ExpenseIncome tax expense was $241,059 for the nine months ended SeptemberÂ 30, 2024, compared to $50,080 for the nine months ended September 30, 2023. The expense is related to corporate income tax of our U.K. and Portugal subsidiaries in 2024 and of our U.K subsidiary in 2023.Other Comprehensive IncomeOther comprehensive income was $0.4 million for the nine months ended SeptemberÂ 30, 2024, compared to other comprehensive income of $3.0 million for the nine months ended September 30, 2023. The decrease in income of $2.6 million primarily related to an decrease in net unrealized gain in short-term marketable debt securities of $2.5 million.Liquidity and Capital ResourcesWe have no products approved for commercial sale, have not generated any revenue from product sales, and cannot guarantee when or if we will generate any revenue from product sales. We expect our expenses and capital requirements to remain consistent with our current spending levels as we continue to:â€¢contract with third parties, including CROs and CMOs, to support the planned clinical trials of SLK, including trials in HS, PsA, juvenile HS, PPP and axSpA;â€¢conduct other research and development activities related to SLK;36â€¢prepare for regulatory filing and commercialization of SLK;â€¢attract, hire and retain additional management, scientific and administrative personnel;â€¢maintain, protect and expand our intellectual property portfolio, including patents, trade secrets and know how;â€¢implement operational, financial and management information systems; andâ€¢continue operating as a public company.For the nine months ended SeptemberÂ 30, 2024, we incurred a loss of $74.8 million, which includes non-cash items such as share-based compensation expense, and a cash outflow from operations of $68.1 million. As of SeptemberÂ 30, 2024, we had a total of $493.9 million in cash, cash equivalents and short-term marketable securities. Based on our current operating plans, we believe our available cash, cash equivalents and short-term marketable securities will be sufficient to fund our operating expenses and capital expenditure requirements until the end of 2026. We expect to incur significant expenses and operating losses for at least the next three years, assuming we continue the clinical development of, and seek regulatory approval for, our product candidate under an in-licensing agreement. It is expected that operating losses will fluctuate significantly from year to year due to the timing of clinical development programs, efforts to achieve regulatory approval, and sales and marketing efforts. We will require substantial additional funding to bring our product candidate to market and support our continuing operations. Until such time that we can generate significant revenue from product sales or other sources, if ever, we expect to finance our operations through the sale of equity, debt financings, or other capital sources, which may include income from collaborations, strategic partnerships, or marketing, distribution, licensing or other strategic arrangements with third parties, or from grants. If we are unable to acquire additional capital or resources, we will be required to modify our operational plans to fund our operating expense requirements. Refer to â€œRisk Factors â€” Risks Related to Our Limited Operating History, Business, Financial Condition, and Results of Operationsâ€ in our Annual Report for further details related to the risk of raising additional capital to fund our operations.Cash FlowsThe following table summarizes our cash flows for the periods indicated.Nine Months EndedSeptember 30, 2024September 30, 2023Net cash used in operating activities$(68,113,589)$(30,433,841)Net cash used in investing activities(58,264,594)(142,051,023)Net cash provided by financing activities51,161,002451,285,093Effect of movements in exchange rates on cash held(295,865)(140,047)Net (decrease) increase in cash and cash equivalents$(75,513,046)$278,660,182Â Cash Flows from Operating ActivitiesWe did not generate any cash inflows from our operating activities. Our cash flows from operating activities are significantly influenced by our use of cash for operating expenses and working capital requirements, and we have historically experienced negative cash flows from operating activities as we invested in clinical research and related development.Net cash used in operating activities was $68.1 million and $30.4 million for the nine months ended SeptemberÂ 30, 2024 and September 30, 2023, respectively. The increase of net cash used in operating activities of $37.7 million was primarily driven by the increase in operating loss of $38.7 million and the increase in cash paid for changes in prepaid expenses of $8.4 million. The increases were partially offset by an increase in cash from changes in trade and other payables of $5.7 million and a decrease in cash paid for changes in accrued expenses and other current liabilities of $4.2 million.37Cash Flows from Investing ActivitiesDuring the nine months ended SeptemberÂ 30, 2024, net cash used in investing activities was $58.3Â million, consisting predominantly of $203.3 million related to the purchase of short-term marketable debt securities, partially offset by $145.4 million in proceeds received from maturities of short-term marketable debt securities with original maturities longer than three months. During the nine months ended September 30, 2023, net cash used in investing activities was $142.1 million, consisting predominantly of $175.7 million related to the purchase of short-term marketable debt securities, partially offset by $33.7 million in proceeds received from maturities of short-term marketable debt securities with original maturities longer than three months. Cash Flows from Financing ActivitiesDuring the nine months ended SeptemberÂ 30, 2024, net cash provided by financing activities was $51.2 million consisting primarily of $52.5 million in net proceeds from the shares sold under the August 2023 Sales Agreement.During the nine months ended September 30, 2023, net cash provided by financing activities was $451.3 million consisting primarily of the net proceeds from the shares sold under the Sales Agreements and in the Offering. Contractual Obligations and CommitmentsThe following summarizes our significant contractual obligations and other obligations as of SeptemberÂ 30, 2024, which we generally expect to satisfy with cash on hand:TotalLess than 1 year1 to 5 YearsMore than 5 yearsPurchase obligations(1)$145,087,507Â $107,076,429Â $38,011,078Â $â€”Â Lease commitments(2)3,576,9111,565,2112,011,700â€”Â Total contractual obligations$148,664,418Â $108,641,640Â $40,022,778Â $â€”Â _____(1)Â Â Â Purchase obligations refer to an agreement to purchase goods or services that is enforceable and legally binding on the Company that specifies all significant terms. The figures presented primarily relate to contractual commitments towards contract manufacturing and contract research organizations.(2)Â Â Â We have committed ourselves to five leases, with terms that commenced on November 1, 2021, October 9, 2023, October 13, 2023, January 15, 2024, and September 8, 2024. We have accounted for the office lease arrangements as operating leases under the guidance ASU 2016-02, Leases Topic 842 through the unaudited condensed consolidated statements of operations and comprehensive loss for the three and nine months ended SeptemberÂ 30, 2024. The future lease commitments relate to the office leases for our headquarters in Zug, Switzerland, Cambridge, United Kingdom, and Porto, Portugal, and reflect minimum payments due.Critical Accounting Policies and EstimatesA summary of our critical accounting policies and estimates is presented in Part II, Item 7 of our Annual Report. There were no material changes to our critical accounting estimates during the nine months ended SeptemberÂ 30, 2024.Recently Issued Accounting PronouncementsRefer to Note 2 â€” Basis of Presentation and Significant Accounting Policies to the unaudited condensed consolidated financial statements included elsewhere in this Form 10-Q for more information about recent accounting pronouncements, the timing of their adoption, and our assessment, to the extent it has been made, of their potential impact on our financial condition and our results of operations and cash flows.38Item 3. Quantitative and Qualitative Disclosures About Market RiskAs of SeptemberÂ 30, 2024, we have cash and cash equivalents and short-term marketable securities of $493.9 million, which consist primarily of bank deposits, commercial papers and certificates of deposits. The investments in these financial instruments are made in accordance with an investment policy which specifies the categories, allocations and ratings of securities permissible for investment. The primary objective of the investment activities is non-trading related and instead to preserve principal as well as maximizing income received without significantly increasing risk.To minimize any inherent market risk, we maintain a diverse and highly liquid portfolio which includes cash, cash equivalents and short-term investment securities available-for-sale in a variety of securities including certificates of deposits and commercial papers, all with various maturity dates. The fair value of the cash, cash equivalents, and short-term investments would not be significantly affected by either an increase or decrease in interest rates due to the short-term maturities of these instruments. Since they are classified as â€œavailable-for-saleâ€, no gains or losses are recognized in the condensed consolidated statements of operations and comprehensive loss due to changes in interest rates unless such securities are sold prior to maturity or declines in fair value are due to credit losses. We have the ability to hold all such investments until maturity. A hypothetical 10% increase or decrease in interest rates would not have had a material effect on our financial results or financial condition as of SeptemberÂ 30, 2024.We do not hold or issue derivatives, derivative commodity instruments or other financial instruments for speculative trading purposes.Item 4. Controls and ProceduresEvaluation of Disclosure Controls and ProceduresWe maintain disclosure controls and procedures designed to ensure that information required to be disclosed by us in our reports filed under the Exchange Act is recorded, processed, summarized and reported within the time period specified in the SEC's rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosures.As of SeptemberÂ 30, 2024, our management, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended, or the

Exchange Act) prior to the filing of this Quarterly Report on Form 10-Q. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of SeptemberÂ 30, 2024, the design and operation of our disclosure controls and procedures were effective at the reasonable assurance level. Changes in Internal Control over Financial ReportingThere were no changes in our internal control over financial reporting (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended, or the Exchange Act) during the three months ended SeptemberÂ 30, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.39Inherent limitations on Effectiveness of Controls and ProceduresThe effectiveness of any system of internal control over financial reporting is subject to inherent limitations, including the exercise of judgment in designing, implementing, operating, and evaluating the controls and procedures, and the inability to eliminate misconduct completely. In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints, and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs. Lastly, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.40PART II. OTHER INFORMATIONsItem 1. Legal ProceedingsWe are not currently subject to any material legal proceedings.Item 1A. Risk FactorsAny of the risks described in our Annual Report are factors that could cause our actual results to differ materially from those in this Quarterly Report. Any of these factors could result in a significant or material adverse effect upon our business, results of operations or financial condition. Additional risk factors not presently known to us or that we currently deem immaterial may also impair our business, results of operations or financial condition. There have been no material changes to the risk factors that we included in our Annual Report. We may make changes to such risk factors or disclose additional risk factors from time to time in our future filings with the SEC.Item 2. Unregistered Sales of Equity Securities and Use of ProceedsNone.Item 3. Defaults Upon Senior SecuritiesNone.Item 4. Mine Safety DisclosuresNot applicable.Item 5. Other InformationTrading ArrangementsNone of our directors or executive officers adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement during the three months ended SeptemberÂ 30, 2024, as such terms are defined under Item 408(a) of Regulation S-K.41Item 6. ExhibitsThe following exhibits are filed as part of, or incorporated by reference into, this Quarterly Report on Form 10-Q.No.Description of Exhibit3.1Â Memorandum and Articles of Association of MoonLake Immunotherapeutics (incorporated by reference to Exhibit 3.1 to the Companyâ€™s Current Report on Form 8-K filed with the SEC on April 11, 2022)31.1*Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 200231.2*Certification of Principal Financial and Accounting Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 200232.1**Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 200232.2**Certification of Principal Financial and Accounting Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002101.INS*Inline XBRL Instance Document.101.SCH*Inline XBRL Taxonomy Extension Schema Document.101.CAL*Inline XBRL Taxonomy Extension Calculation Linkbase Document.101.DEF*Inline XBRL Taxonomy Extension Definition Linkbase Document.101.LAB*Inline XBRL Taxonomy Extension Label Linkbase Document.101.PRE*Inline XBRL Taxonomy Extension Presentation Linkbase Document.104*Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).*Â Â Â Â Filed herewith.**Â Â Â Â Furnished.42SIGNATURESPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.MOONLAKE IMMUNOTHERAPEUTICS/s/ Dr. Jorge Santos da SilvaDate:November 7, 2024Name:Dr. Jorge Santos da SilvaTitle:Chief Executive Officer(Principal Executive Officer)/s/ Matthias BodenstedtDate:November 7, 2024Name:Matthias BodenstedtTitle:Chief Financial Officer(Principal Financial and Accounting Officer)43 EX-31.1 2 mltx_2024q3xex311dasilva.htm EX-31.1 DocumentExhibit 31.1Certification Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002I, Jorge Santos Da Silva, certify that:1.I have reviewed this Quarterly Report on Form 10-Q of MoonLake Immunotherapeutics;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;4.The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;b)Â Â Â Â Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;c)Â Â Â Â Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; andd)Â Â Â Â Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and5.The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions):a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; andb)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting.Dated: NovemberÂ 7, 2024By: /s/ Jorge Santos Da SilvaName: Jorge Santos Da SilvaTitle: Chief Executive Officer (principal executive officer) EX-31.2 3 mltx_2024q3xex312bodenstedt.htm EX-31.2 DocumentExhibit 31.2Certification Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002I, Matthias Bodenstedt, certify that:1.I have reviewed this Quarterly Report on Form 10-Q of MoonLake Immunotherapeutics;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;4.The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;b)Â Â Â Â Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;c)Â Â Â Â Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; andd)Â Â Â Â Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and5.The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions):a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; andb)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting.Dated: NovemberÂ 7, 2024By: /s/ Matthias BodenstedtName: Matthias BodenstedtTitle: Chief Financial Officer (principal financial and accounting officer) EX-32.1 4 mltx_2024q3xex321dasilva.htm EX-32.1 DocumentExhibit 32.1Certification Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002I, Jorge Santos Da Silva, to the best of my knowledge certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report on Form 10-Q of MoonLake Immunotherapeutics (the â€œCompanyâ€) for the period ended SeptemberÂ 30, 2024 (the â€œReportâ€), fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.Dated: NovemberÂ 7, 2024By: /s/ Jorge Santos Da SilvaName: Jorge Santos Da SilvaTitle: Chief Executive OfficerÂ Â Â Â (principal executive officer)The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.Note: A signed original of this written statement required by Section 906 has been provided to MoonLake Immunotherapeutics and will be retained by MoonLake Immunotherapeutics and furnished to the Securities and Exchange Commission or its staff upon request. EX-32.2 5 mltx_2024q3xex322bodenstedt.htm EX-32.2 DocumentExhibit 32.2Certification Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002I, Matthias Bodenstedt, to the best of my knowledge certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report on Form 10-Q of MoonLake Immunotherapeutics (the â€œCompanyâ€) for the period ended SeptemberÂ 30, 2024 (the â€œReportâ€), fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.Dated: NovemberÂ 7, 2024By: /s/ Matthias BodenstedtName: Matthias BodenstedtTitle: Chief Financial OfficerÂ Â Â Â (principal financial and accounting officer)The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.Note: A signed original of this written statement required by Section 906 has been provided to MoonLake Immunotherapeutics and will be retained by MoonLake Immunotherapeutics and furnished to the Securities and Exchange Commission or its staff upon request. EX-101.SCH 6 mnlk-20240930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 9952151 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 9952152 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952153 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS link:presentationLink link:calculationLink link:definitionLink 9952154 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY link:presentationLink link:calculationLink link:definitionLink 9952155 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 9952156 - Disclosure - Overview of the Company link:presentationLink link:calculationLink link:definitionLink 9952157 - Disclosure - Basis of Presentation and Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 9952158 - Disclosure - Risks and Liquidity link:presentationLink link:calculationLink link:definitionLink 9952159 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 9952160 - Disclosure - Investments link:presentationLink link:calculationLink link:definitionLink 9952161 - Disclosure - Prepaid Expenses link:presentationLink link:calculationLink link:definitionLink 9952162 - Disclosure - Trade and Other Payables link:presentationLink link:calculationLink link:definitionLink 9952163 - Disclosure - Accrued Expenses and Other Current Liabilities link:presentationLink link:calculationLink link:definitionLink 9952164 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 9952165 - Disclosure - Employee Benefit Plans link:presentationLink link:calculationLink link:definitionLink 9952166 - Disclosure - Shareholdersâ€™ Equity link:presentationLink link:calculationLink link:definitionLink 9952167 - Disclosure - Net Loss per Share link:presentationLink link:calculationLink link:definitionLink 9952168 - Disclosure - Share-Based Compensation link:presentationLink link:calculationLink link:definitionLink 9952169 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 9952170 - Disclosure - Commitment and Contingencies link:presentationLink link:calculationLink link:definitionLink 9952171 - Disclosure - Segment Information and Geographic Data link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - Prepaid Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - Trade and Other Payables (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - Employee Benefit Plans (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - Shareholdersâ€™ Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - Net Loss per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - Share-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - Segment Information and Geographic Data (Tables) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - Basis of Presentation and Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - Risks and Liquidity (Details) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - Investments - Schedule of Fair Value and Amortized Cost of Investments in Short-Term Marketable Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - Investments - Schedule of Changes in Fair Value of Short-Term Marketable Securities (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - Prepaid Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - Trade and Other Payables (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - Accrued Expenses and Other Current Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - Leases - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - Leases - Weighted Average Remaining Lease Term and Discount Rate (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - Leases - Future Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - Leases - Future Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - Leases - Total Lease Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - Employee Benefit Plans (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - Employee Benefit Plans - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - Shareholdersâ€™ Equity - Schedule of Stock Authorized and Issued (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - Shareholdersâ€™ Equity - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - Net Loss per Share - Calculation of Net Loss per Share (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - Net Loss per Share - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - Share-Based Compensation - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - Share-Based

Compensation - Share-based Compensation Expense By Plan (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - Share-Based Compensation - Summary of Restricted Stock Awarded and Granted (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - Share-Based Compensation - Summary of ESPP Awarded and Granted (Details) link:presentationLink link:calculationLink link:definitionLink 9954505 - Disclosure - Share-Based Compensation - Summary of ESOP Awarded and Granted (Details) link:presentationLink link:calculationLink link:definitionLink 9954506 - Disclosure - Share-Based Compensation - Summary of Equity Incentive Plan Awarded and Granted (Details) link:presentationLink link:calculationLink link:definitionLink 9954507 - Disclosure - Share-Based Compensation - Weighted Average Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 9954508 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 9954509 - Disclosure - Commitment and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 9954510 - Disclosure - Segment Information and Geographic Data - Schedule of Long-Lived Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954511 - Disclosure - Segment Information and Geographic Data - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 mnlk-20240930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 mnlk-20240930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 mnlk-20240930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Statistical Measurement [Domain] Statistical Measurement [Domain] Gross unrealized losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Prepaid expenses Increase (Decrease) in Prepaid Expense Lease, Cost Lease, Cost [Table Text Block] Schedule of prepaid expenses Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] Other income, net Other Nonoperating Income Cover [Abstract] Debt Securities Debt Securities [Member] Net change in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Schedule of Future Lease Payments Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Trading Symbol Trading Symbol Reverse vesting percentage Share-Based Compensation Arrangement by Share-Based Payment Award, Reverse Vesting Condition, Percentage Share-Based Compensation Arrangement by Share-Based Payment Award, Reverse Vesting Condition, Percentage Comprehensive loss Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest All Trading Arrangements All Trading Arrangements [Member] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Non-NEOs Non-NEOs [Member] Schedule of earnings per share, basic and diluted Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Common stock, conversion ratio (in shares) Common Stock, Conversion Ratio Common Stock, Conversion Ratio Other Commitments [Line Items] Other Commitments [Line Items] Common Class A Common Class A [Member] Number of lease contracts Number Of Lease Contracts Number Of Lease Contracts Conversion and transfer of shares between classes (in shares) Conversion of Class C Ordinary Shares into Class A Ordinary Shares (in shares) Stock Issued During Period, Shares, Conversion of Convertible Securities Pay vs Performance Disclosure [Line Items] Defined contribution plan, increase (decrease), cost Defined Contribution Plan, Increase (Decrease), Cost Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Prepaid expenses - current Prepaid Expense, Current [Abstract] Net Loss per Class A Ordinary Shares Earnings Per Share, Policy [Policy Text Block] Overview of the Company Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Operating lease liabilities Increase (Decrease) in Operating Lease Liability Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Fair Value Measurements Fair Value Disclosures [Text Block] Proceeds from options exercised under the Equity Incentive Plan Proceeds from Stock Options Exercised Award Timing Disclosures [Line Items] Other Performance Measure, Amount Other Performance Measure, Amount Leases Lessee, Operating Leases [Text Block] Common shares, shares outstanding (in shares) Common stock, beginning balance (in shares) Common stock, ending balance (in shares) Number of shares outstanding (in shares) Common Stock, Shares, Outstanding Authorized, beginning balance (in shares) Authorized, ending balance (in shares) Shares, Authorized Shares, Authorized Operating lease expense Operating Lease, Cost Lessee, operating lease, number of renewal options Lessee, Operating Lease, Number Of Renewal Options Lessee, Operating Lease, Number Of Renewal Options Other receivables Other Receivables, Net, Current Common shares issuable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Long-term portion of operating lease liabilities Operating Lease, Liability, Noncurrent Total non-current assets Assets, Noncurrent Number of operating leases Number Of Operating Leases Number Of Operating Leases Segment Information Segment Reporting, Policy [Policy Text Block] Issuance price per share (USD per share) Sale of Stock, Price Per Share Plan Name [Domain] Plan Name [Domain] Service cost Defined Benefit Plan, Service Cost Entity Tax Identification Number Entity Tax Identification Number Leases [Abstract] Treasury stock, shares, acquired (in shares) Treasury Stock, Shares, Acquired Net cash flow used in operating activities Net Cash Provided by (Used in) Operating Activities Net proceeds from the business combination Sale of Stock, Consideration Received on Transaction Plan Name [Axis] Plan Name [Axis] Prepaid expenses - current Total Prepaid Expense, Current Equity Components [Axis] Equity Components [Axis] Award Timing Method Award Timing Method [Text Block] Total net periodic benefit cost Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Research and Development Contract Costs and Accruals Research and Development Expense, Policy [Policy Text Block] Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Revenue remaining performance obligation additional variable consideration amount Revenue Remaining Performance Obligation Additional Variable Consideration Amount Revenue Remaining Performance Obligation Additional Variable Consideration Amount Fair value Debt Securities, Available-for-Sale Pension Accounting Pension and Other Postretirement Plans, Pensions, Policy [Policy Text Block] Measurement Frequency [Axis] Measurement Frequency [Axis] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Cash flow from financing activities Cash Flow, Financing Activities, Lessee [Abstract] Insider Trading Policies and Procedures [Line Items] Use of Estimates Use of Estimates, Policy [Policy Text Block] Adjustment to Compensation, Amount Adjustment to Compensation Amount Payables and Accruals [Abstract] Compensation Amount Outstanding Recovery Compensation Amount Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Entity Small Business Entity Small Business Trade and Other Payables Accrued Expenses and Other Current Liabilities Accounts Payable and Accrued Liabilities Disclosure [Text Block] Company Selected Measure Amount Company Selected Measure Amount Geographical [Axis] Geographical [Axis] Proceeds from maturities of short-term marketable debt securities Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale Tabular List, Table Tabular List [Table Text Block] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Non-clinical research and clinical development services Prepaid Research And Development Expense Prepaid Research And Development Expense Cash flow from operating activities Cash Flow, Operating Activities, Lessee [Abstract] Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Debt Securities, Available-for-Sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Employee Benefit Plans Compensation and Employee Benefit Plans [Text Block] Schedule of stock authorized and issued Schedule Of Stock Authorized And Issued Roll Forward [Table Text Block] Schedule Of Stock Authorized And Issued Roll Forward Share-Based Payment Arrangement, Tranche One Share-Based Payment Arrangement, Tranche One [Member] Equity Incentive Plan Equity Incentive Plan [Member] Equity Incentive Plan Common Class C Common Class C [Member] Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Prepaid expenses - non-current Prepaid Expense, Noncurrent [Abstract] Unrecognized compensation expense Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Current assets Assets, Current [Abstract] Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Product and Service [Domain] Product and Service [Domain] ESOP Share-Based Payment Arrangement, Option [Member] Debt Securities, Available-for-Sale [Table] Debt Securities, Available-for-Sale [Table] Fair Value Disclosures [Abstract] Depreciation Depreciation 2025 Lessee, Operating Lease, Liability, to be Paid, Year One License License [Member] Share-Based Payment Arrangement, Tranche Four Share-Based Payment Arrangement, Tranche Four [Member] Share-Based Payment Arrangement, Tranche Four Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Security, Excluded EPS Calculation [Table] Comprehensive loss attributable to controlling interests shareholders Comprehensive Income (Loss), Net of Tax, Attributable to Parent Tax liabilities Accrued Income Taxes, Current Employee Stock Option Plan (ESOP) Employee Stock Option Plan (ESOP) [Member] Employee Stock Option Plan (ESOP) Other receivables Increase (Decrease) in Other Receivables Security Exchange Name Security Exchange Name Award Type [Axis] Award Type [Axis] Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings [Line Items] Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings [Line Items] Property and equipment, net Property, Plant and Equipment, Net Total liabilities Liabilities Noncontrolling interests Equity, Attributable to Noncontrolling Interest Long-lived assets Long-Lived Assets Common shares, par value (USD per share) Common stock, par value (CHF/USD per share) Common Stock, Par or Stated Value Per Share Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Schedule of investments in short-term marketable debt securities Debt Securities, Available-for-Sale [Table Text Block] Research and development Research and Development Expense Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Foreign Currency Foreign Currency Transactions and Translations Policy [Policy Text Block] Expiration Date Trading Arrangement Expiration Date Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward] Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward] Short-term portion of operating lease liabilities Less current portion of lease liability Operating Lease, Liability, Current Total Shareholder Return Amount Total Shareholder Return Amount Common shares, shares issued (in shares) Issued, beginning balance (in shares) Issued, ending balance (in shares) Common Stock, Shares, Issued Summary of nonvested restricted stock shares activity Nonvested Restricted Stock Shares Activity [Table Text Block] Prepaid Expenses, Current Prepaid Expenses, Current [Member] Prepaid Expenses, Current Entity [Domain] Entity [Domain] Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Loss before income tax Income (Loss), Including Portion Attributable to Noncontrolling Interest, before Tax Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Unrestricted cash Cash Insurance Prepaid Insurance Stock options exercised (in shares) Awards exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Prior service credit recognized in current year Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), before Tax Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Research and Development Expense Research and Development Expense [Member] Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings [Table] Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings [Table] Common shares, shares authorized (in shares) Authorized, beginning balance (in shares) Authorized, ending balance (in shares) Common Stock, Shares Authorized Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Weighted-average number of shares, diluted (in shares) Total weighted average number of outstanding shares, diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Net unrealized gain (loss) on marketable securities and short term investments Other comprehensive income before reclassifications OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Amounts reclassified from accumulated other comprehensive income Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI for Write-down of Securities, Net of Tax Total shareholdersâ€™ equity Equity, Attributable to Parent Trade and other payables, current Trade And Other Payables, Current [Table Text Block] Trade And Other Payables, Current Amortization of unrecognized loss Defined Benefit Plan, Amortization of Gain (Loss) Lessee, operating lease, renewal term Lessee, Operating Lease, Renewal Term Balance Sheet Location [Axis] Statement of Financial Position Location, Balance [Axis] Entity Address, Country Entity Address, Country Contributions made to plan Defined Contribution Plan, Cost Consultant and other fees Accrued Consulting And Other Fees, Current Accrued Consulting And Other Fees, Current Fair Value, Recurring Fair Value, Recurring [Member] Legal advisory fees payable Accrued Legal Fees, Current Accrued Legal Fees, Current Additional awards granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Stock Conversion Description [Axis] Stock Conversion Description [Axis] Revenues from External Customers and Long-Lived Assets [Line Items] Revenues from External Customers and Long-Lived Assets [Line Items] Pro forma Pro Forma [Member] Share-based compensation arrangement by share-based payment award, number of shares authorized (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Sale of Stock [Domain] Sale of Stock [Domain] Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Document Fiscal Period Focus Document Fiscal Period Focus All Executive Categories All Executive Categories [Member] Balance Sheet Location [Domain] Statement of Financial Position Location, Balance [Domain] Pension liability Liability, Defined Benefit Pension Plan, Noncurrent Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Other comprehensive income (loss) Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax Expected dividend rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Document Type Document Type Eurocommercial Papers Eurocommercial Papers Commercial Paper [Member] Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Awards vested (in shares) Awards vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Amortized cost Debt Securities, Available-for-Sale, Amortized Cost Exercise price (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price Total Shareholders' Equity Parent [Member] Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Maximum Maximum [Member] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Accounting Policies [Abstract] Summary of weighted average assumptions for awards issued Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Fair Value Measurements Fair Value Measurement, Policy [Policy Text Block] Current Fiscal Year End Date Current Fiscal Year End Date Less imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Total lease expense Lease, Cost Non-current assets Assets, Noncurrent [Abstract] Statistical Measurement [Axis] Statistical Measurement [Axis] PEO Name PEO Name Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Vesting [Axis] Vesting [Axis] Award Type [Domain] Award Type [Domain] Name Outstanding Recovery, Individual Name Number of co-founders Number Of Co-Founders Number Of Co-Founders Variable lease expense Variable Lease, Cost Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Non-PEO NEO Non-PEO NEO [Member] Accrued expenses and other current liabilities Total Accrued Liabilities and Other Liabilities Additional Paid-In Capital Additional Paid-in Capital [Member] Award Timing Predetermined Award Timing Predetermined [Flag] Prepaid Expenses, Noncurrent Prepaid Expenses, Noncurrent [Member] Prepaid Expenses, Noncurrent Subsequent Event Type [Domain] Subsequent Event Type [Domain] Proceeds from contributions from parent Proceeds from Contributions from Parent Class of Stock [Line Items] Class of Stock [Line Items] Recently Issued Accounting Pronouncements not yet Adopted New Accounting Pronouncements, Policy [Policy Text Block] Forecast Forecast [Member] Basic net loss per share attributable to controlling interest shareholders (USD per share) Net loss per share - diluted (in USD per share) Earnings Per Share, Diluted Class of Stock [Axis] Class of Stock [Axis] Counterparty Name [Domain] Counterparty Name [Domain] Name Measure Name Common shares, votes per share Common Stock, Votes Attached To Shares Common Stock, Votes Attached To Shares Entity Interactive Data Current Entity Interactive Data Current Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Vesting percentage Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage Number of operating segments Number of Operating Segments Retirement Benefits [Abstract] Switzerland SWITZERLAND Statement of Financial Position [Abstract] Share-based compensation expense Share-Based Payment Arrangement, Noncash Expense Cancellation of MoonLake Class C Ordinary Shares following an employee contract termination in MoonLake AG (Note 11) Stock Redeemed or Called During Period, Value Net loss Net loss Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Share-Based Payment Arrangement, Tranche Two Share-Based Payment Arrangement, Tranche Two [Member] Income tax expense Income Tax Expense (Benefit) Interest cost Defined Benefit Plan, Interest Cost Short-term marketable debt securities Debt Securities, Available-for-Sale, Current Supplementary disclosure of cash flow information: Supplemental Cash Flow Information [Abstract] Weighted average period of

recognition Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Net cash flow used in investing activities Net Cash Provided by (Used in) Investing Activities Operating loss Operating Income (Loss) Total liabilities and equity Liabilities and Equity Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] All Adjustments to Compensation All Adjustments to Compensation [Member] Bonuses and related employees compensation expenses Employee-related Liabilities, Current Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Marketable securities and short-term investments Marketable Securities, Policy [Policy Text Block] Additional paid-in capital Additional Paid in Capital Schedule of debt securities by level within the fair value hierarchy Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block] Commitments and Contingencies Disclosure [Abstract] Legal Entity [Axis] Legal Entity [Axis] May 2023 Sales Agreement May 2023 Sales Agreement [Member] May 2023 Sales Agreement Nominal value (CHF per share) Share Price, Nominal Value Share Price, Nominal Value Non-cash operating lease right-of-use assets obtained in exchange for lease obligations Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Underlying Security Market Price Change Underlying Security Market Price Change, Percent Expected return on plan assets Defined Benefit Plan, Expected Return (Loss) on Plan Assets Scenario [Domain] Scenario [Domain] Individual: Individual [Axis] Accumulated Other Comprehensive Income AOCI Attributable to Parent [Member] Name of Property [Domain] Name of Property [Domain] Gross unrealized gain (loss), beginning balance Gross unrealized gain (loss), ending balance Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain (Loss), before Tax Expected term of the award Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Product and Service [Axis] Product and Service [Axis] Statement [Line Items] Statement [Line Items] Stamp duty on capital injection from MoonLake to MoonLake AG Payments Of Stamp Duty Payments Of Stamp Duty Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Operating expenses Operating Expenses [Abstract] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Financial Instruments [Domain] Financial Instruments [Domain] Porto Office Porto Office [Member] Porto Office Vesting [Domain] Vesting [Domain] Components of net periodic benefit cost under the plan Schedule of Net Benefit Costs [Table Text Block] Risks and Uncertainties [Abstract] Minimum Minimum [Member] Restatement Determination Date Restatement Determination Date Prepaid expenses - non-current Total Prepaid Expense, Noncurrent Adoption Date Trading Arrangement Adoption Date Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] United Kingdom UNITED KINGDOM Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Awards outstanding, beginning balance (in shares) Awards outstanding, ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Effective income tax rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent MoonLake Immunotherapeutics MoonLake Immunotherapeutics [Member] MoonLake Immunotherapeutics Exercise Price Award Exercise Price Net Loss per Share Earnings Per Share [Text Block] Arrangement Duration Trading Arrangement Duration Other payables Accounts Payable, Other, Current Subsequent Event Subsequent Event [Member] Options exercised under the Equity Incentive Plan (Note 11) Stock Issued During Period, Value, Stock Options Exercised Name of Property [Axis] Name of Property [Axis] Research and development services and license fees Accrued Research And Development Expenses, Current Accrued Research And Development Expenses, Current Income Taxes Income Tax, Policy [Policy Text Block] Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Supply and manufacturing services Supply And Manufacturing Expense, Current Supply And Manufacturing Expense, Current All Individuals All Individuals [Member] Basis of Presentation and Significant Accounting Policies Basis of Presentation and Significant Accounting Policies [Text Block] Building Building [Member] Conversion Of Class C into Class A Conversion Of Class C into Class A [Member] Conversion Of Class C into Class A PEO PEO [Member] Income Tax Disclosure [Abstract] Name Trading Arrangement, Individual Name Statement of Stockholders' Equity [Abstract] Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Gross unrealized gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Trade and other payables Total Trade And Other Payables, Current Trade And Other Payables, Current Unrecognized share-based compensation expense, non-option awards Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Capital injection from MoonLake to MoonLake AG (Note 11) Noncontrolling Interest, Increase From Capital Injection In Subsidiary Noncontrolling Interest, Increase From Capital Injection In Subsidiary Risks and Liquidity Risk And Liquidity Disclosure [Text Block] Risk And Liquidity Disclosure Switzerland Office Switzerland Office [Member] Switzerland Office Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Share-Based Payment Arrangement, Tranche Three Share-Based Payment Arrangement, Tranche Three [Member] Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Cancellation of Class C shares following an employee contract termination in MoonLake AG (in shares) Cancellation of Class C shares following an employee contract termination in MoonLake AG (in shares) Stock Redeemed or Called During Period, Shares Total non-current liabilities Liabilities, Noncurrent Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Variable consideration amount Revenue Remaining Performance Obligation Variable Consideration Amount Revenue Remaining Performance Obligation Variable Consideration Amount Local Phone Number Local Phone Number Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Total operating expenses Operating Expenses Prepaid Expenses Other Current Assets [Text Block] Expected volatility of the share price Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Supply and manufacturing services Accrued Supply And Manufacturing Fees, Current Accrued Supply And Manufacturing Fees, Current Non-current liabilities Liabilities, Noncurrent [Abstract] PEO Total Compensation Amount PEO Total Compensation Amount Sale of stock, option to purchase, term Sale of Stock, Option To Purchase, Term Sale of Stock, Option To Purchase, Term Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Schedule of accrued expenses and other current liabilities Schedule of Accrued Liabilities [Table Text Block] Income Statement Location [Axis] Statement of Income Location, Balance [Axis] Long-Lived Assets by Geographic Areas Long-Lived Assets by Geographic Areas [Table Text Block] Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Payments of stock issuance costs Payments of Stock Issuance Costs Cambridge Office Cambridge Office [Member] Cambridge Office Commitment and Contingencies Commitments and Contingencies Disclosure [Text Block] Common Stock Common Stock [Member] Measure: Measure [Axis] Total commitments not yet recognized Unrecognized Commitments And Contingencies Unrecognized Commitments And Contingencies Operating lease, additional area of leased space Operating Lease, Additional Area of Leased Space Operating Lease, Additional Area of Leased Space Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Issuance of Class A Ordinary Shares, net of transaction costs (in shares) Issuance of shares under the ATM facility (in shares) Number of shares issued (in shares) Stock Issued During Period, Shares, New Issues Entity Emerging Growth Company Entity Emerging Growth Company Consulting and advisory services Accrued Consulting And Advisory Fees, Current Accrued Consulting And Advisory Fees, Current Segment Reporting [Abstract] Entity Central Index Key Entity Central Index Key Share-based compensation under the ESPP, ESOP, Equity Incentive Plan and reverse vesting of Restricted Founder Shares Shares Granted, Value, Share-Based Payment Arrangement, after Forfeiture Scenario [Axis] Scenario [Axis] General and Administrative Expense General and Administrative Expense [Member] Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Sale of stock, stamp duty tax Sale Of Stock, Stamp Duty Tax Sale Of Stock, Stamp Duty Tax Shareholdersâ€™ Equity Equity [Text Block] Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Equity Component [Domain] Equity Component [Domain] Financial Instrument [Axis] Financial Instrument [Axis] Segment Information and Geographic Data Segment Reporting Disclosure [Text Block] Adjustments to reconcile net loss to net cash used in operating activities: Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Schedule of fair value changes of marketable securities Debt Securities, Trading, and Equity Securities, FV-NI [Table Text Block] MoonLake AG Restricted Founder Shares Restricted Stock [Member] Entity Shell Company Entity Shell Company Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Sale of stock, remaining authorized repurchase amount Sale Of Stock, Remaining Authorized Repurchase Amount Sale Of Stock, Remaining Authorized Repurchase Amount Commercial Paper and Certificates of Deposit Commercial Paper and Certificates of Deposit [Member] Commercial Paper and Certificates of Deposit Title Trading Arrangement, Individual Title Net periodic pension benefit (gain) cost for the qualified pension plan Pension Expense (Reversal of Expense), Noncash Statement [Table] Statement [Table] Counterparty Name [Axis] Counterparty Name [Axis] Measurement Frequency [Domain] Measurement Frequency [Domain] May 2023 And August 2023 Sales Agreement May 2023 And August 2023 Sales Agreement [Member] May 2023 And August 2023 Sales Agreement Comprehensive loss attributable to noncontrolling interests Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest Numerator Net Income (Loss) Available to Common Stockholders, Diluted [Abstract] City Area Code City Area Code Current liabilities Liabilities, Current [Abstract] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Total current assets Assets, Current Statement of Cash Flows [Abstract] Thereafter Lessee, Operating Lease, Liability, to be Paid, After Year Four Lessee, Operating Lease, Liability, to be Paid, After Year Four Buyback of unvested MoonLake AG Common Shares by MoonLake AG following an employee contract termination Payments for Repurchase of Common Stock Of which exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Document Information [Line Items] Document Information [Line Items] Estimated fair value of the option on the grant date using Black-Scholes model (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Subsequent Event Type [Axis] Subsequent Event Type [Axis] Income Taxes Income Tax Disclosure [Text Block] 2028 Lessee, Operating Lease, Liability, to be Paid, Year Four Earnings Per Share [Abstract] Equity Equity [Abstract] Accumulated deficit Retained Earnings (Accumulated Deficit) Schedule of nonvested share activity Schedule of Nonvested Share Activity [Table Text Block] Class of Stock [Domain] Class of Stock [Domain] General and administrative General and Administrative Expense Organization, Consolidation and Presentation of Financial Statements [Abstract] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Equity Awards Adjustments Equity Awards Adjustments [Member] Weighted average discount rate Operating Lease, Weighted Average Discount Rate, Percent Total lease liability Operating Lease, Liability Net cash flow provided by financing activities Net Cash Provided by (Used in) Financing Activities Underlying Securities Award Underlying Securities Amount Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table] Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table] Investments Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Conversion of Stock, Name [Domain] Conversion of Stock, Name [Domain] Amendment Flag Amendment Flag Entity Registrant Name Entity Registrant Name Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Fair Value as of Grant Date Award Grant Date Fair Value Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] Sale of stock (in shares) Sale of Stock, Number of Shares Issued in Transaction Research and development services and license fees Accrued Research And Development Services and License Fees, Current Accrued Research And Development Services and License Fees, Current Level 2 Fair Value, Inputs, Level 2 [Member] MoonLake AG MoonLake AG [Member] MoonLake AG Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Geographical [Domain] Geographical [Domain] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Issuance of Class A Ordinary Shares, net of transaction costs (Note 11) Stock Issued During Period, Value, New Issues Square foot of leased space (in square feet) Operating Lease, Area of Leased Space Operating Lease, Area of Leased Space Entity Address, Postal Zip Code Entity Address, Postal Zip Code Schedule of share-based compensation expense driven by share-based compensation plans and programs Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Supply and manufacturing fees payable Supply And Manufacturing Fees Payable, Current Supply And Manufacturing Fees Payable, Current Restatement Determination Date: Restatement Determination Date [Axis] Title of 12(b) Security Title of 12(b) Security Common shares Common Stock, Value, Issued Share-Based Payment Arrangement [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Certificates of Deposit Certificates of Deposit [Member] Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Effect of movements in exchange rates on cash held Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] August 2023 Sales Agreement August 2023 Sales Agreement [Member] August 2023 Sales Agreement Property and equipment, useful life Property, Plant and Equipment, Useful Life Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] ESPP Employee Stock [Member] Diluted net loss per share attributable to controlling interest shareholders (USD per share) Net loss per share - basic (in USD per share) Earnings Per Share, Basic Trade and other payables Increase (Decrease) in Accounts Payable Issuance of Class A Ordinary Shares, net of transaction costs Proceeds from Issuance of Common Stock Awards converted from ESOP to EIP (in shares) Awards converted from ESOP to EIP (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Awards Converted Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Awards Converted Operating lease, payments Operating Lease, Payments Cash and Cash Equivalents Cash and Cash Equivalents [Member] Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Expiration period Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Other prepayments Other Prepaid Expense, Current Foreign currency transaction gain (loss), realized Realized Gain (Loss), Foreign Currency Transaction, before Tax Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Number of share-based compensation plans Number Of Share-Based Compensation Plans Number Of Share-Based Compensation Plans Property and Equipment Property, Plant and Equipment, Policy [Policy Text Block] Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Schedule of Stock by Class [Table] Stock, Class of Stock [Table] Total current liabilities Liabilities, Current Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Denominator Weighted Average Number of Shares Outstanding, Diluted [Abstract] Total assets Assets Concentration of Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Excess of current assets less current liabilities Current Assets In Excess Of Current Liabilities Current Assets In Excess Of Current Liabilities Over-Allotment Option Over-Allotment Option [Member] Purchase of property and equipment Payments to Acquire Property, Plant, and Equipment Actuarial gain (loss) on employee benefit plans Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, after Tax Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Commitments and contingencies (Note 15) Commitments and Contingencies Share-Based Compensation Share-Based Payment Arrangement [Policy Text Block] Acquisitions Business Combinations Policy [Policy Text Block] Termination Date Trading Arrangement Termination Date 2026 Lessee, Operating Lease, Liability, to be Paid, Year Two Share-Based Compensation Share-Based Payment Arrangement [Text Block] Total Number of Ordinary Shares Total Shares [Roll Forward] Total Shares Underwriting Agreement Underwriting Agreement [Member] Underwriting Agreement Entity Address, City or Town Entity Address, City or Town Leases Lessee, Leases [Policy Text Block] Schedule of option activity for share-based payment arrangement Share-Based Payment Arrangement, Option, Activity [Table Text Block] Share-based compensation expense Share-Based Payment Arrangement, Expense Of which: net loss attributable to controlling interests shareholders Net loss attributable to controlling interests shareholders Net Income (Loss) Net Income (Loss) Attributable to Parent Trading Arrangement: Trading Arrangement [Axis] Investments, Debt and Equity Securities [Abstract] Conversion of MoonLake Class C Ordinary Shares into Class A Ordinary Shares Stock Issued During Period, Value, Conversion of Convertible Securities Other Commitments [Table] Other Commitments [Table] Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Awards forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total

Compensation for Covered Year [Member] Sale of stock, authorized amount (in shares) Sale Of Stock, Authorized Amount Sale Of Stock, Authorized Amount Refund of stamp duty fees Adjustments To Additional Paid In Capital, Stamp Duty Fees Adjustments To Additional Paid In Capital, Stamp Duty Fees Entity File Number Entity File Number Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Document Fiscal Year Focus Document Fiscal Year Focus Noncontrolling Interests Noncontrolling Interest [Member] Income Statement [Abstract] Entity Address, Address Line One Entity Address, Address Line One Operating lease right-of-use assets Increase (Decrease) In Operating Lease, Right-Of-Use Asset Increase (Decrease) In Operating Lease, Right-Of-Use Asset Buyback of unvested MoonLake AG Common Shares by MoonLake AG into treasury following an employee contract termination (Note 11) Treasury Stock, Value, Acquired, Cost Method Lessee, operating lease, term of contract Lessee, Operating Lease, Term of Contract Total Assets, Fair Value Disclosure Accrued expenses and other current liabilities Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Name Forgone Recovery, Individual Name Remainder of fiscal 2024 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Weighted average remaining lease term (in months) Operating Lease, Weighted Average Remaining Lease Term Document Period End Date Document Period End Date Sale of Stock [Axis] Sale of Stock [Axis] Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain (Loss) [Roll Forward] Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain (Loss) [Roll Forward] Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain (Loss) Other non-cash items Other Noncash Income (Expense) Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Total lease payments Lessee, Operating Lease, Liability, to be Paid Awards unvested, beginning balance (in shares) Awards unvested, ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Insider Trading Arrangements [Line Items] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount SLK Program Sonelokimab Program ("SLK Program") [Member] Sonelokimab Program ("SLK Program") Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] 2027 Lessee, Operating Lease, Liability, to be Paid, Year Three PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Cash flow from investing activities Cash Flow, Investing Activities, Lessee [Abstract] Adjustment to Compensation: Adjustment to Compensation [Axis] Of which: net loss attributable to noncontrolling interests shareholders Net Income (Loss) Attributable to Noncontrolling Interest Document Transition Report Document Transition Report Document Quarterly Report Document Quarterly Report ATM Shares ATM Shares [Member] ATM Shares Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Current Reporting Status Entity Current Reporting Status Accumulated Deficit Retained Earnings [Member] Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Common Shares Common Stock [Roll Forward] Common Stock Weighted-average number of shares, basic (in shares) Total weighted average number of outstanding shares, basic (in shares) Weighted Average Number of Shares Outstanding, Basic Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Schedule of Revenues from External Customers and Long-Lived Assets [Table] Schedule of Revenues from External Customers and Long-Lived Assets [Table] Document Information [Table] Document Information [Table] Total equity Equity, beginning balance Equity, end balance Equity, Including Portion Attributable to Noncontrolling Interest Supply and manufacturing services Supply And Manufacturing Expense, Noncurrent Supply And Manufacturing Expense, Noncurrent Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Legal fees Accrued Professional Fees, Current Executive Category: Executive Category [Axis] Name Awards Close in Time to MNPI Disclosures, Individual Name Portugal PORTUGAL Awards forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Entity Filer Category Entity Filer Category Shares issued, beginning balance (in shares) Shares issued, ending balance (in shares) Shares, Issued Income Statement Location [Domain] Statement of Income Location, Balance [Domain] Purchase of short-term marketable debt securities Payments to Acquire Debt Securities, Available-for-Sale Company Selected Measure Name Company Selected Measure Name EX-101.PRE 10 mnlk-20240930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 12 R1.htm IDEA: XBRL DOCUMENT v3.24.3 Cover - shares 9 Months Ended Sep. 30, 2024 Nov. 01, 2024 Document Information [Line Items] Â Â Document Type 10-Q Â Document Quarterly Report true Â Document Period End Date Sep. 30, 2024 Â Document Transition Report false Â Entity File Number 001-39630 Â Entity Registrant Name MOONLAKE IMMUNOTHERAPEUTICS Â Entity Incorporation, State or Country Code E9 Â Entity Tax Identification Number 98-1711963 Â Entity Address, Address Line One Dorfstrasse 29 Â Entity Address, Postal Zip Code 6300 Â Entity Address, City or Town Zug Â Entity Address, Country CH Â City Area Code 41 Â Local Phone Number 415108022 Â Title of 12(b) Security Class A ordinary share, par value $0.0001 per share Â Trading Symbol MLTX Â Security Exchange Name NASDAQ Â Entity Current Reporting Status Yes Â Entity Interactive Data Current Yes Â Entity Filer Category Large Accelerated Filer Â Entity Small Business false Â Entity Emerging Growth Company false Â Entity Shell Company false Â Amendment Flag false Â Document Fiscal Year Focus 2024 Â Document Fiscal Period Focus Q3 Â Current Fiscal Year End Date --12-31 Â Entity Central Index Key 0001821586 Â Common Class A Â Â Document Information [Line Items] Â Â Entity Common Stock, Shares Outstanding Â 63,063,929 Common Class C Â Â Document Information [Line Items] Â Â Entity Common Stock, Shares Outstanding Â 841,269 X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: dei_DocumentInformationLineItems Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionISO 3166-1 alpha-2 country code. + ReferencesNo definition available. + Details Name: dei_EntityAddressCountry Namespace Prefix: dei_ Data Type: dei:countryCodeItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 13 R2.htm IDEA: XBRL DOCUMENT v3.24.3 CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) Sep. 30, 2024 Dec. 31, 2023 Current assets Â Â Cash and cash equivalents $ 375,656,291 $ 451,169,337 Short-term marketable debt securities 118,268,400 59,838,900 Other receivables 2,407,062 1,056,862 Prepaid expenses - current 15,984,425 2,102,203 Total current assets 512,316,178 514,167,302 Non-current assets Â Â Operating lease right-of-use assets 3,251,197 3,628,480 Property and equipment, net 581,378 320,865 Prepaid expenses - non-current 2,064,575 8,423,468 Total non-current assets 5,897,150 12,372,813 Total assets 518,213,328 526,540,115 Current liabilities Â Â Trade and other payables 10,710,603 1,837,684 Short-term portion of operating lease liabilities 1,444,893 1,197,876 Accrued expenses and other current liabilities 7,925,524 6,930,120 Total current liabilities 20,081,020 9,965,680 Non-current liabilities Â Â Long-term portion of operating lease liabilities 1,935,709 2,499,990 Pension liability 694,959 583,426 Total non-current liabilities 2,630,668 3,083,416 Total liabilities 22,711,688 13,049,096 Commitments and contingencies (Note 15) Equity Â Â Additional paid-in capital 675,343,443 609,969,236 Accumulated deficit (189,988,477) (116,657,472) Accumulated other comprehensive income 2,833,970 2,357,621 Total shareholdersâ€™ equity 488,195,325 495,675,683 Noncontrolling interests 7,306,315 17,815,336 Total equity 495,501,640 513,491,019 Total liabilities and equity 518,213,328 526,540,115 Common Class A Â Â Equity Â Â Common shares 6,305 6,047 Common Class C Â Â Equity Â Â Common shares $ 84 $ 251 X - DefinitionTrade And Other Payables, Current + ReferencesNo definition available. + Details Name: mnlk_TradeAndOtherPayablesCurrent Namespace Prefix: mnlk_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other. + ReferencesNo definition available. + Details Name: us-gaap_AccruedLiabilitiesAndOtherLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification

-Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14 + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapital Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionSum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsNoncurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -

Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommitmentsAndContingencies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liability, recognized in statement of financial position, for defined benefit pension plan, classified as noncurrent. Excludes other postretirement benefit plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480535/715-20-45-3Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 715 -SubTopic 20 -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480535/715-20-45-2Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 715 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1 + Details Name: us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of obligation due after one year or beyond the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-

gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 22: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesNoncurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 13: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_MinorityInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer. + ReferencesNo definition available. + Details Name: us-gaap_OtherReceivablesNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1 + Details Name: us-gaap_PrepaidExpenseCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a)(3)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 23 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (i)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 34: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 38: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 40: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 41: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 42: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4I -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4IReference 49: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1 + Details Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 14 R3.htm IDEA: XBRL DOCUMENT v3.24.3 CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares Sep. 30, 2024 Dec. 31, 2023 Common Class A Â Â Common shares, par value (USD per share) $ 0.0001 $ 0.0001 Common shares, shares authorized (in shares) 500,000,000 500,000,000 Common shares, shares issued (in shares) 63,046,025 60,466,453 Common shares, shares outstanding (in shares) 63,046,025 60,466,453 Common Class C Â Â Common shares, par value (USD per share) $ 0.0001 $ 0.0001 Common shares, shares authorized (in shares) 100,000,000 100,000,000 Common shares, shares issued (in shares) 841,269 2,505,476 Common shares, shares outstanding (in shares) 841,269 2,505,476 X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 15 R4.htm IDEA: XBRL DOCUMENT v3.24.3 CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Operating expenses Â Â Â Â Â Research and development $ (35,735,514) $ (7,585,136) $ (72,411,709) $ (23,704,087) General and administrative (7,376,495) (5,391,607) (21,099,001) (15,390,117) Total operating expenses (43,112,009) (12,976,743) (93,510,710) (39,094,204) Operating loss (43,112,009) (12,976,743) (93,510,710) (39,094,204) Other income, net 7,089,691 1,386,313 18,903,070 2,952,557 Loss before income tax (36,022,318) (11,590,430) (74,607,640) (36,141,647) Income tax expense (92,106) (28,923) (241,059) (50,080) Net loss (36,114,424) (11,619,353) (74,848,699) (36,191,727) Of which: net loss attributable to controlling interests shareholders (35,390,337) (9,426,049) (73,331,005) (28,570,184) Of which: net loss attributable to noncontrolling interests shareholders (724,087) (2,193,304) (1,517,694) (7,621,543) Net unrealized gain (loss) on marketable securities and short term investments (325,510) 3,437,291 508,860 3,046,538 Actuarial gain (loss) on employee benefit plans (115,629) 39,157 (110,878) (19,323) Other comprehensive income (loss) (441,139) 3,476,448 397,982 3,027,215 Comprehensive loss (36,555,563) (8,142,905) (74,450,717) (33,164,512) Comprehensive loss attributable to controlling interests shareholders (35,822,526) (6,590,259) (72,941,435) (26,095,926) Comprehensive loss attributable to noncontrolling interests $ (733,037) $ (1,552,646) $ (1,509,282) $ (7,068,586) Weighted-average number of shares, basic (in shares) 62,896,782 53,517,655 62,803,220 45,485,650 Weighted-average number of shares, diluted (in shares) 62,896,782 53,517,655 62,803,220 45,485,650 Basic net loss per share attributable to controlling interest shareholders (USD per share) $ (0.56) $ (0.18) $ (1.17) $ (0.63) Diluted net loss per share attributable to controlling interest shareholders (USD per share) $ (0.56) $ (0.18) $ (1.17) $ (0.63) Common Class A Â Â Â Â Â Operating expenses Â Â Â Â Â Weighted-average number of shares, basic (in shares) 62,896,782 53,517,655 62,803,220 45,485,650 Weighted-average number of shares, diluted (in shares) 62,896,782 53,517,655 62,803,220 45,485,650 Basic net loss per share attributable to controlling interest shareholders (USD per share) $ (0.56) $ (0.18) $ (1.17) $ (0.63) Diluted net loss per share attributable to controlling interest shareholders (USD per share) $ (0.56) $ (0.18) $ (1.17) $ (0.63) X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss), attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5 + Details Name: us-gaap_ComprehensiveIncomeNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 10 -Topic 810 -Publisher FASB -URI

https://asc.fasb.org/1943274/2147481231/810-10-45-20Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-21Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K + Details Name: us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K + Details Name: us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_GeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, before tax, of income (loss) including portion attributable to noncontrolling interest. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6 + Details Name: us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of Net Income (Loss) attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B + Details Name: us-gaap_NetIncomeLossAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + ReferencesNo definition available. + Details Name: us-gaap_OperatingExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OperatingExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after tax, of gain (loss) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1 + Details Name: us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11 + Details Name: us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax and reclassification adjustments of other comprehensive income (loss). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 55 -Paragraph 15 -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income related to nonoperating activities, classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_OtherNonoperatingIncome Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting

Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 16 R5.htm IDEA: XBRL DOCUMENT v3.24.3 CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY - USD ($) Total Common Class A Common Class C Total Shareholders' Equity Common Stock Common Class A Common Stock Common Class C Additional Paid-In Capital Accumulated Deficit Accumulated Other Comprehensive Income Noncontrolling Interests Common stock, beginning balance (in shares) at Dec. 31, 2022 Â Â Â Â 38,977,600 13,723,511 Â Â Â Â Equity, beginning balance at Dec. 31, 2022 $ 68,766,698 Â Â $ 48,898,296 $ 3,898 $ 1,373 $ 129,192,291 $ (80,650,212) $ 350,946 $ 19,868,402 Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Â Â Â Â Â Â Share-based compensation under the ESPP, ESOP, Equity Incentive Plan and reverse vesting of Restricted Founder Shares 2,577,187 Â Â 1,875,992 Â Â 1,875,992 Â Â 701,195 Refund of stamp duty fees 4,923 Â Â 3,517 Â Â 3,517 Â Â 1,406 Net loss (12,218,987) Â Â (9,004,856) Â Â Â (9,004,856) Â (3,214,131) Other comprehensive income (loss) (17,672) Â Â (12,625) Â Â Â Â (12,625) (5,047) Conversion and transfer of shares between classes (in shares) Â Â Â Â 176,603 (176,603) Â Â Â Â Conversion of MoonLake Class C Ordinary Shares into Class A Ordinary Shares 0 Â Â 238,836 $ 18 $ (18) 237,049 Â 1,787 (238,836) Common stock, ending balance (in shares) at Mar. 31, 2023 Â Â Â Â 39,154,203 13,546,908 Â Â Â Â Equity, end balance at Mar. 31, 2023 59,112,149 Â Â 41,999,160 $ 3,916 $ 1,355 131,308,849 (89,655,068) 340,108 17,112,989 Common stock, beginning balance (in shares) at Dec. 31, 2022 Â Â Â Â 38,977,600 13,723,511 Â Â Â Â Equity, beginning balance at Dec. 31, 2022 68,766,698 Â Â 48,898,296 $ 3,898 $ 1,373 129,192,291 (80,650,212) 350,946 19,868,402 Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Â Â Â Â Â Â Net loss (36,191,727) Â Â Â Â Â Â Â Â Â Â Other comprehensive income (loss) 3,027,215 Â Â Â Â Â Â Â Â Â Â Common stock, ending balance (in shares) at Sep. 30, 2023 Â Â Â Â 53,561,488 8,884,517 Â Â Â Â Equity, end balance at Sep. 30, 2023 489,642,186 Â Â 424,933,000 $ 5,356 $ 889 531,271,953 (109,220,396) 2,875,198 64,709,186 Common stock, beginning balance (in shares) at Mar. 31, 2023 Â Â Â Â 39,154,203 13,546,908 Â Â Â Â Equity, beginning balance at Mar. 31, 2023 59,112,149 Â Â 41,999,160 $ 3,916 $ 1,355 131,308,849 (89,655,068) 340,108 17,112,989 Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Â Â Â Â Â Â Share-based compensation under the ESPP, ESOP, Equity Incentive Plan and reverse vesting of Restricted Founder Shares 1,497,661 Â Â 1,247,416 Â Â 1,247,416 Â Â 250,245 Net loss (12,353,387) Â Â (10,139,279) Â Â Â (10,139,279) Â (2,214,108) Other comprehensive income (loss) (431,561) Â Â (348,906) Â Â Â Â (348,906) (82,655) Conversion and transfer of shares between classes (in shares) Â Â Â Â 4,587,713 (4,587,713) Â Â Â Â Conversion of MoonLake Class C Ordinary Shares into Class A Ordinary Shares 0 Â Â 5,753,517 $ 459 $ (459) 5,709,595 Â 43,922 (5,753,517) Issuance of Class A Ordinary Shares, net of transaction costs (in shares) Â Â Â Â 9,744,894 Â Â Â Â Issuance of Class A Ordinary Shares, net of transaction costs (Note 11) 451,285,093 Â Â 451,285,093 $ 974 Â 451,284,119 Â Â Â Common stock, ending balance (in shares) at Jun. 30, 2023 Â Â Â Â 53,486,810 8,959,195 Â Â Â Â Equity, end balance at Jun. 30, 2023 499,109,955 Â Â 489,797,001 $ 5,349 $ 896 589,549,979 (99,794,347) 35,124 9,312,954 Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Â Â Â Â Â Â Share-based compensation under the ESPP, ESOP, Equity Incentive Plan and reverse vesting of Restricted Founder Shares 1,425,651 Â Â 1,238,144 Â Â 1,238,144 Â Â 187,507 Net loss (11,619,353) Â Â (9,426,049) Â Â Â (9,426,049) Â (2,193,304) Other comprehensive income (loss) 3,476,448 Â Â 2,835,790 Â Â Â Â 2,835,790 640,658 Conversion and transfer of shares between classes (in shares) Â Â Â Â 74,678 (74,678) Â Â Â Â Conversion of MoonLake Class C Ordinary Shares into Class A Ordinary Shares 0 Â Â 548,740 $ 7 $ (7) 545,591 Â 3,149 (548,740) Capital injection from MoonLake to MoonLake AG (Note 11) (2,750,515) Â Â (60,060,626) Â Â (60,061,761) Â 1,135 57,310,111 Common stock, ending balance (in shares) at Sep. 30, 2023 Â Â Â Â 53,561,488 8,884,517 Â Â Â Â Equity, end balance at Sep. 30, 2023 489,642,186 Â Â 424,933,000 $ 5,356 $ 889 531,271,953 (109,220,396) 2,875,198 64,709,186 Common stock, beginning balance (in shares) at Dec. 31, 2023 Â 60,466,453 2,505,476 Â 60,466,453 2,505,476 Â Â Â Â Equity, beginning balance at Dec. 31, 2023 513,491,019 Â Â 495,675,683 $ 6,047 $ 251 609,969,236 (116,657,472) 2,357,621 17,815,336 Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Â Â Â Â Â Â Share-based compensation under the ESPP, ESOP, Equity Incentive Plan and reverse vesting of Restricted Founder Shares 1,677,208 Â Â 1,693,101 Â Â 1,693,101 Â Â (15,893) Net loss (13,975,521) Â Â (13,673,656) Â Â Â (13,673,656) Â (301,865) Other comprehensive income (loss) 263,503 Â Â 257,949 Â Â Â Â 257,949 5,554 Conversion and transfer of shares between classes (in shares) Â Â Â Â 1,493,356 (1,493,356) Â Â Â Â Conversion of MoonLake Class C Ordinary Shares into Class A Ordinary Shares 0 Â Â 10,613,583 $ 149 $ (149) 10,536,980 Â 76,603 (10,613,583) Buyback of unvested MoonLake AG Common Shares by MoonLake AG into treasury following an employee contract termination (Note 11) (50) Â Â 114,058 Â Â 113,154 Â 904 (114,108) Capital injection from MoonLake to MoonLake AG (Note 11) $ (1,609,961) Â Â (4,667,177) Â Â (4,667,196) Â 19 3,057,216 Cancellation of Class C shares following an employee contract termination in MoonLake AG (in shares) (16,853) Â Â Â Â (16,853) Â Â Â Â Cancellation of MoonLake Class C Ordinary Shares following an employee contract termination in MoonLake AG (Note 11) $ 0 Â Â Â Â $ (2) 2 Â Â Â Â Issuance of Class A Ordinary Shares, net of transaction costs (in shares) 914,828 Â Â Â 914,828 Â Â Â Â Â Issuance of Class A Ordinary Shares, net of transaction costs (Note 11) $ 52,540,190 Â Â 52,540,190 $ 91 Â 52,540,099 Â Â Â Common stock, ending balance (in shares) at Mar. 31, 2024 Â Â Â Â 62,874,637 995,267 Â Â Â Â Equity, end balance at Mar. 31, 2024 552,386,388 Â Â 542,553,731 $ 6,287 $ 100 670,185,376 (130,331,128) 2,693,096 9,832,657 Common stock, beginning balance (in shares) at Dec. 31, 2023 Â 60,466,453 2,505,476 Â 60,466,453 2,505,476 Â Â Â Â Equity, beginning balance at Dec. 31, 2023 513,491,019 Â Â 495,675,683 $ 6,047 $ 251 609,969,236 (116,657,472) 2,357,621 17,815,336 Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Â Â Â Â Â Â Net loss (74,848,699) Â Â Â Â Â Â Â Â Â Â Other comprehensive income (loss) 397,982 Â Â Â Â Â Â Â Â Â Â Common stock, ending balance (in shares) at Sep. 30, 2024 Â 63,046,025 841,269 Â 63,046,025 841,269 Â Â Â Â Equity, end balance at Sep. 30, 2024 495,501,640 Â Â 488,195,325 $ 6,305 $ 84 675,343,443 (189,988,477) 2,833,970 7,306,315 Common stock, beginning balance (in shares) at Mar. 31, 2024 Â Â Â Â 62,874,637 995,267 Â Â Â Â Equity, beginning balance at Mar. 31, 2024 552,386,388 Â Â 542,553,731 $ 6,287 $ 100 670,185,376 (130,331,128) 2,693,096 9,832,657 Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Â Â Â Â Â Â Share-based compensation under the ESPP, ESOP, Equity Incentive Plan and reverse vesting of Restricted Founder Shares 1,828,245 Â Â 1,813,207 Â Â 1,813,207 Â Â 15,038 Net loss (24,758,754) Â Â (24,267,012) Â Â Â Â (24,267,012) Â (491,742) Other comprehensive income (loss) 575,618 Â Â 563,811 Â Â Â Â 563,811 11,807 Common stock, ending balance (in shares) at Jun. 30, 2024 Â Â Â Â 62,874,637 995,267 Â Â Â Â Equity, end balance at Jun. 30, 2024 530,031,497 Â Â 520,663,737 $ 6,287 $ 100 671,998,583 (154,598,140) 3,256,907 9,367,760 Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Â Â Â Â Â Â Share-based compensation under the ESPP, ESOP, Equity Incentive Plan and reverse vesting of Restricted Founder Shares 1,842,609 Â Â 1,827,571 Â Â 1,827,571 Â Â 15,038 Refund of stamp duty fees 91,799 Â Â 89,915 Â Â 89,915 Â Â 1,884 Net loss (36,114,424) Â Â (35,390,337) Â Â Â (35,390,337) Â (724,087) Other comprehensive income (loss) $ (441,139) Â Â (432,189) Â Â Â Â (432,189) (8,950) Stock options exercised (in shares) 17,390 Â Â Â 17,390 Â Â Â Â Options exercised under the Equity Incentive Plan (Note 11) $ 91,298 Â Â 91,298 $ 2 Â 91,296 Â Â Â Conversion and transfer of shares between classes (in shares) Â Â Â Â 153,998 (153,998) Â Â Â Â Conversion of MoonLake Class C Ordinary Shares into Class A Ordinary Shares 0 Â Â 1,345,330 $ 16 $ (16) 1,336,078 Â 9,252 (1,345,330) Common stock, ending balance (in shares) at Sep. 30, 2024 Â 63,046,025 841,269 Â 63,046,025 841,269 Â Â Â Â Equity, end balance at Sep. 30, 2024 $ 495,501,640 Â Â $ 488,195,325 $ 6,305 $ 84 $ 675,343,443 $ (189,988,477) $ 2,833,970 $ 7,306,315 X - DefinitionAdjustments To Additional Paid In Capital, Stamp Duty Fees + ReferencesNo definition available. + Details Name: mnlk_AdjustmentsToAdditionalPaidInCapitalStampDutyFees Namespace Prefix: mnlk_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNoncontrolling Interest, Increase From Capital Injection In Subsidiary + ReferencesNo definition available. + Details Name: mnlk_NoncontrollingInterestIncreaseFromCapitalInjectionInSubsidiary Namespace Prefix: mnlk_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher

FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInStockholdersEquityRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount after tax and reclassification adjustments of other comprehensive income (loss). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 55 -Paragraph 15 -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue, after forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 30 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480513/718-10-30-3Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 30 -Section 35 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480843/718-30-35-1 + Details Name: us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares issued during the period as a result of the conversion of convertible securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe gross value of stock issued during the period upon the conversion of convertible securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-

gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of stock issued as a result of the exercise of stock options. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of stock bought back by the entity at the exercise price or redemption price. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2 + Details Name: us-gaap_StockRedeemedOrCalledDuringPeriodShares Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionEquity impact of the value of stock bought back by the entity at the exercise price or redemption price. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2 + Details Name: us-gaap_StockRedeemedOrCalledDuringPeriodValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a)(3)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 23 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (i)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 34: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 38: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 40: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 41: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 42: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4I -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4IReference 49: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1 + Details Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionEquity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1 + Details Name: us-gaap_TreasuryStockValueAcquiredCostMethod Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 17 R6.htm IDEA: XBRL DOCUMENT v3.24.3 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Cash flow from operating activities Â Â Net loss $ (74,848,699) $ (36,191,727) Adjustments to reconcile net loss to net cash used in operating activities: Â Â Depreciation 83,440 9,869 Share-based compensation expense 5,348,062 5,500,499 Net periodic pension benefit (gain) cost for the qualified pension plan (2,678) (50,740) Other non-cash items 1,189,056 96,364 Changes in operating assets and liabilities: Â Â Other receivables (1,350,200) (503,626) Operating lease right-of-use assets (5,443) 0 Prepaid expenses (7,523,329) 869,187 Trade and other payables 8,872,919 3,149,756 Operating lease liabilities (872,121) (117,832) Accrued expenses and other current liabilities 995,404 (3,195,591) Net cash flow used in operating activities (68,113,589) (30,433,841) Cash flow from investing activities Â Â Purchase of short-term marketable debt securities (203,334,691) (175,732,711) Proceeds from maturities of short-term marketable debt securities 145,414,050 33,681,688 Purchase of property and equipment (343,953) 0 Net cash flow used in investing activities (58,264,594) (142,051,023) Cash flow from financing activities Â Â Issuance of Class A Ordinary Shares, net of transaction costs 52,540,190 451,285,093 Stamp duty on capital injection from MoonLake to MoonLake AG (1,470,436) 0 Proceeds from options exercised under the Equity Incentive Plan 91,298 0 Buyback of unvested MoonLake AG Common Shares by MoonLake AG following an employee contract termination (50) 0 Net cash flow provided by financing activities 51,161,002 451,285,093 Effect of movements in exchange rates on cash held (295,865) (140,047) Net change in cash and cash equivalents (75,513,046) 278,660,182 Cash and cash equivalents, beginning of period 451,169,337 39,505,627 Cash and cash equivalents, end of period 375,656,291 318,165,809 Supplementary disclosure of cash flow information: Â Â Non-cash operating lease right-of-use assets obtained in exchange for lease obligations $ 554,857 $ 0 X - DefinitionIncrease (Decrease) In Operating Lease, Right-Of-Use Asset + ReferencesNo definition available. + Details Name: mnlk_IncreaseDecreaseInOperatingLeaseRightOfUseAsset Namespace Prefix: mnlk_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPayments Of Stamp Duty + ReferencesNo definition available. + Details Name: mnlk_PaymentsOfStampDuty Namespace Prefix: mnlk_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4

+ Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_CashFlowFinancingActivitiesLesseeAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_CashFlowInvestingActivitiesLesseeAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_CashFlowOperatingActivitiesLesseeAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_Depreciation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 230 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in accrued expenses, and obligations classified as other. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in obligation for operating lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -SubTopic 20 -Topic 842 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_IncreaseDecreaseInOperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in receivables classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInOtherReceivables Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInPrepaidExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - DefinitionAmount of income (expense) included in net income that results in no cash inflow (outflow), classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_OtherNoncashIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow to reacquire common stock during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsForRepurchaseOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11 + Details Name: us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of noncash expense (reversal of expense) for pension benefits. Excludes other postretirement benefits. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_PensionExpenseReversalOfExpenseNoncash Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from exercise of option under share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Subparagraph (a) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A + Details Name: us-gaap_ProceedsFromStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards

Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase in right-of-use asset obtained in exchange for operating lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SupplementalCashFlowInformationAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 18 R7.htm IDEA: XBRL DOCUMENT v3.24.3 Overview of the Company 9 Months Ended Sep. 30, 2024 Organization, Consolidation and Presentation of Financial Statements [Abstract] Â Overview of the Company Overview of the CompanyCorporate InformationMoonLake Immunotherapeutics is a clinical stage biotechnology company advancing therapies to address significant unmet needs in inflammatory skin and joint diseases. MoonLake Immunotherapeutics is currently a single asset company focused on the development of Sonelokimab (â€œSLKâ€), a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.Unless the context otherwise requires, â€œMoonLakeâ€ and the â€œCompanyâ€ refer to the combined company following the Business Combination (as defined in Note 2 â€” Business Combination Agreement with Helix and Recapitalization included in MoonLakeâ€™s audited financial statements and notes thereto for the year ended December 31, 2023 included in MoonLakeâ€™s Annual Report on Form 10-K for the year ended December 31, 2023, which was filed with the Securities and Exchange Commission (â€œSECâ€) on February 29, 2024 (the â€œAnnual Reportâ€)) consummated on April 5, 2022, together with its subsidiaries. X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/810/tableOfContentReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205/tableOfContent + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 19 R8.htm IDEA: XBRL DOCUMENT v3.24.3 Basis of Presentation and Significant Accounting Policies 9 Months Ended Sep. 30, 2024 Accounting Policies [Abstract] Â Basis of Presentation and Significant Accounting Policies Basis of Presentation and Significant Accounting Policies Basis of PresentationThe accompanying unaudited condensed consolidated financial statements include those of the Company and its subsidiaries, MoonLake Immunotherapeutics AG, a Swiss stock corporation (Aktiengesellschaft) registered with the commercial register of the Canton of Zug, Switzerland under the number CHE-433.093.536 (â€œMoonLake AGâ€), MoonLake Immunotherapeutics Ltd., a private limited company incorporated in the United Kingdom, and MNLK Immunotherapeutics, Unipessoal Lda ("MNLK PT"), a private limited company incorporated in Portugal, after elimination of all intercompany accounts and transactions. The accompanying unaudited condensed consolidated financial statements and notes hereto have been prepared in accordance with accounting principles generally accepted in the United States of America (â€œU.S. GAAPâ€) as set forth by the Financial Accounting Standards Board (â€œFASBâ€) and in conformity with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X for interim financial reporting. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (â€œASCâ€) and Accounting Standards Updates (â€œASUâ€) of the FASB.In the opinion of management, all material adjustments necessary for a fair presentation of the financial information, which are of a normal and recurring nature, have been made for the interim periods reported. Results of operations for the three and nine months ended SeptemberÂ 30, 2024 are not necessarily indicative of the results for the entire fiscal year or any other period. The unaudited condensed consolidated financial information for the three and nine months ended SeptemberÂ 30, 2024 and 2023 have been prepared on the same basis as and should be read in conjunction with MoonLakeâ€™s audited financial statements and notes thereto for the year ended December 31, 2023 included in the Annual Report.All amounts are presented in U.S. Dollar (â€œ$â€), unless otherwise indicated. The term â€œSwiss francâ€ and â€œCHFâ€ refer to the legal currency of Switzerland, "GBP" refers to the legal currency of the United Kingdom, and â€œâ,¬â€ and "Euro" refer to the legal currency of Portugal.Use of EstimatesThe preparation of financial statements in conformity with U.S. GAAP requires the Company to make judgments, estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses. The significant judgments, estimates and assumptions relevant to the Company relate to:â€¢determining whether the in-process research and development expenditure (â€œIPR&Dâ€) has an alternative future use;â€¢determining assumptions used in estimating the fair value of share-based compensation;â€¢estimating the recoverability of the deferred tax asset; andâ€¢estimating the amount of accruals in connection with the completion of clinical trial milestones.The Company bases its judgments and estimates on various factors and information, which may include, but are not limited to, the Companyâ€™s forecasts and future plans, current economic conditions and observable market-based transactions of its own shares, the results of which form the basis for making judgments about the carrying value of assets and liabilities and recorded amounts of expenses that are not readily apparent from other sources. To the extent there are material differences between the Companyâ€™s estimates and the actual results, the Companyâ€™s future results of operation may be affected.Cash and Cash EquivalentsThe Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash and cash equivalents are recorded at cost, which approximates fair value. As of SeptemberÂ 30, 2024, the Company considers $59.8 million of short-term marketable debt securities in the form of eurocommercial papers and certificates of deposit to be cash equivalents. As of DecemberÂ 31, 2023, the Company considered $129.4 million of short-term marketable debt securities in the form of eurocommercial papers and certificates of deposit to be cash equivalents.Marketable securities and short-term investmentsThe Company invests in short-term marketable securities in the form of debt securities. At the time of purchase, the Company assesses whether such debt security should be classified as held-to-maturity or available-for-sale debt securities.Debt securities are classified as held-to-maturity when the Company has the positive intent and ability to hold the securities to maturity. Held-to-maturity debt securities are carried at amortized cost, adjusted for accretion of discounts or amortization of premiums to maturity computed under the effective interest method. Such accretion or amortization is included in â€œInterest and dividend incomeâ€. Marketable debt securities not classified as held-to-maturity are classified as available-for-sale and reported at fair value.Net unrealized gains and losses on available-for-sale debt securities are excluded from the determination of earnings and are instead recognized in the â€œAccumulated other comprehensive incomeâ€ component of equity until realized. Realized gains and losses on available-for-sale debt securities are computed based upon the historical cost of these securities, using the specific identification method. A decline in the fair value of any security below cost that is deemed other than temporary results in a charge to earnings and the corresponding establishment of a new cost basis for the security. Dividend and interest income are recognized when earned. Realized gains and losses are included in "Other income" and the cost of securities sold is determined using the specific-identification method.Marketable debt securities are classified as either â€œCash and cash equivalentsâ€ or â€œShortâ€‘term marketable debt securitiesâ€ according to their original maturity at the time of acquisition. Changes in unrealized gains and losses pertaining to cash equivalent securities are added back into the consolidated statements of cash flows as those are excluded from the determination of earnings but impact the cash and cash equivalents position.Concentration of Credit RiskFinancial instruments that potentially subject the Company to concentration of credit risk consist of cash accounts in large financial institutions which, at times, may exceed the CHF 100,000 deposit protection limit in Switzerland, the $250,000 Federal Deposit Insurance Corporation deposit insurance coverage limit in the United States, the GBP 85,000 Financial Services Compensation Scheme deposit protection limit in the United Kingdom, or the â‚¬100,000 Fundo de Garantia de DepÃ³sitos deposit protection limit in Portugal. The Company believes it is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash and cash equivalents are held. Additionally, the Company ensures further protection against credit risk by diversifying its cash holdings across a variety of credit institutions, thereby minimizing the potential impact of any adverse events on a single institution. Further, the Company's investment strategy for cash (in excess of current business requirements) is set to invest in short-term marketable debt securities. Management actively monitors credit risk in the investment portfolio. Credit risk exposures are controlled in accordance with policies approved by the board of directors to identify, measure, monitor and control credit risks.Fair Value MeasurementsThe Company follows the guidance included in ASC 820, Fair Value Measurement. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. There are three levels of inputs to fair value measurements:â€¢Level 1, meaning the use of quoted prices for identical instruments in active markets;â€¢Level 2, meaning the use of quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active or are directly or indirectly observable; andâ€¢Level 3, meaning the use of unobservable inputs. Observable market data is used when available.Transfers between Levels 1, 2 or 3 within the fair value hierarchy are recognized at the end of the reporting period when the respective transaction occurred. Segment InformationThe Company operates as a single operating segment. The Companyâ€™s chief operating decision maker, its Chief Executive Officer, manages the Companyâ€™s operations on a stand-alone basis for the purposes of allocating resources and assessing financial performance.Property and EquipmentProperty and equipment, net is stated at cost, net of accumulated depreciation. Depreciation is computed using the straight-line method based on the estimated useful lives of three to five years. As of SeptemberÂ 30, 2024, property and equipment, net relates to information technology, office equipment, and leasehold improvements.Research and Development Contract Costs and AccrualsResearch and development expenses include employee payroll, consulting, contract research and contract manufacturing costs attributable to research and development activities and are expensed as incurred.Upfront payments and milestone payments made for the licensing of technology are expensed as research and development expenses in the period in which it is probable that a liability has been incurred. Advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed.The Company has entered into various research and development contracts with companies both inside and outside of the United States. These agreements are generally cancellable, and related payments are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies or trials, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Companyâ€™s estimates. The Companyâ€™s historical accrual estimates have not been materially different from the actual costs.Share-Based CompensationThe Company recognizes compensation expense based on estimated fair values for all stock-based payment awards made to eligible employees, members of the board of directors and independent contractors that are expected to vest. The valuation of stock option awards is determined at the date of grant using the Black-Scholes option pricing model. The Black-Scholes option pricing model requires the Company to make assumptions and judgements about the inputs used in the calculations, such as the fair value of the common stock, expected term, expected volatility of the Companyâ€™s common stock, risk-free interest rate and expected dividend yield. The valuation of restricted stock awards is measured by the fair value of the Companyâ€™s common stock on the date of the grant.For all stock options granted, the Company calculated the expected term as the period that share-based awards are expected to be outstanding. The estimate of expected volatility is based on comparative companiesâ€™ volatility within the Company's industry. The risk-free rate is based on the yield available on United States Treasury zero-coupon issues corresponding to the expected term of the award. The fair value of the common stock granted under the ESPP (as defined in Note 13 â€” Share-based compensation) has historically been estimated by management with reference to the market-based transaction with its Series A investors, as there was no public market for the common stock. Share-based payment arrangements are accounted for under the fair value method. Total compensation is measured at grant date, based on the fair value of the award at that date, and recorded in earnings over the period the employees are required to render service. The Company recognizes compensation cost only for those awards expected to meet the service conditions on a straight-line basis over the requisite service period of the award.Foreign CurrencyThe functional currency of the Company and its subsidiaries is the U.S. dollar. Balances and transactions denominated in foreign currencies are converted as follows: monetary assets and liabilities are translated using exchange rates in effect at the balance sheet dates and non-monetary assets and liabilities are translated at historical exchange rates. Revenue and expenses are translated at the daily exchange rate on the respective accounting date.Gains or losses from foreign currency translation are included in the consolidated statements of operations and comprehensive loss in "other income, net". The Company recognized foreign currency transaction loss of $26,746 and $125,581 for the three and nine months ended SeptemberÂ 30, 2024, respectively, and a foreign currency transaction loss of $557,144 and $276,491 for three and nine months ended September 30, 2023, respectively.Income TaxesThe Company accounts for income taxes by using the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the future tax consequences

attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. A valuation allowance is recorded to the extent it is more likely than not that all or a portion of the Company's deferred tax assets will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date.Net Loss per Class A Ordinary SharesBasic net loss per Class A Ordinary Share is calculated using the two-class method under which earnings are allocated to both Class A Ordinary Shares and participating securities. Basic net loss per share is calculated by dividing the net loss attributable to Class A Ordinary Shares by the weighted-average number of Class A Ordinary Shares outstanding for the period. The diluted net loss per Class A Ordinary Share is computed by dividing the net loss using the weighted-average number of Class A Ordinary Shares and, if dilutive, potential Class A Ordinary Shares outstanding during the period.In periods in which the Company reports a net loss attributable to shareholders of Class A Ordinary Shares, diluted net loss per share attributable to shareholders of Class A Ordinary Shares is the same as basic net loss per share attributable to shareholders of Class A Ordinary Shares, since dilutive Class A Ordinary Shares are not assumed to be outstanding if their effect is anti-dilutive. AcquisitionsThe Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first assessing whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. On April 29, 2021, MoonLake AG entered into an in-licensing agreement (the â€œIn-License Agreementâ€) with Merck Healthcare KGaA, Darmstadt, Germany (â€œMHKDGâ€) to acquire the Sonelokimab program (the â€œSLK Programâ€) and determined that substantially all of the fair value of the gross assets acquired related to IPR&D of SLK. Therefore, this transaction was accounted for as an asset acquisition.IPR&D represents incomplete technologies that the Company acquires, which at the time of acquisition, are still under development and have no alternative future use. The fair value of such technologies is expensed upon acquisition. A technology is considered to have an alternative future use if it is probable that the Company will use the asset in its current, incomplete state as it existed at the acquisition date, in another research and development project that has not yet commenced, and economic benefit is anticipated from that use. If a technology is determined to have an alternative future use, then the fair value of the program would be recorded as an asset on the balance sheet rather than expensed. Contingent consideration payments (for example milestone payments due upon the occurrence of a specific event) in asset acquisitions are recognized in the period in which it is probable that a liability has been incurred (unless the contingent consideration meets the definition of a derivative, in which case the amount becomes part of the cost in the asset acquired). Upon recognition of the contingent consideration payment, the amount is expensed if it relates to IPR&D or capitalized if it relates to a developed product which is generally considered to be when clinical trials have been completed and regulatory approval obtained.Future royalty payments due on net sales will be recognized in cost of goods sold when net sales are recognized.Pension AccountingThe Company accounts for pension assets and liabilities in accordance with ASC 715, Compensation â€” Retirement Benefits, which requires the recognition of the funded status of pension plans in the Companyâ€™s consolidated balance sheet. The liability in respect to defined benefit pension plans is the projected benefit obligation calculated annually by independent actuaries using the projected unit credit method. The projected benefit obligation as of SeptemberÂ 30, 2024 represents the actuarial present value of the estimated future payments required to settle the obligation that is attributable to employee services rendered before that date. Service costs for such pension plans, represented in the net periodic pension benefit cost, are included in the personnel expenses of the various functions where the employees are engaged. The other components of net benefit cost are included in the consolidated statements of operations and comprehensive loss separately from the service cost component, in â€œother income, net.â€ Plan assets are recorded at their fair value. Gains or losses arising from plan curtailments or settlements are accounted for at the time they occur. Any net pension asset is limited to the present value of the future economic benefits available to the Company in the form of refunds from the plan or expected reductions in future contributions to the plan. Actuarial gains and losses arising from differences between the actual and the expected return on plan assets are recognized in accumulated other comprehensive income. LeasesThe Company determines if an arrangement is or contains a lease at contract inception. For these arrangements, it is evaluated if the arrangement involves an identified asset that is physically distinct or whether the Company has the right to substantially all of the capacity of an identified asset that is not physically distinct. In arrangements that involve an identified asset, there is also judgment in evaluating if the Company has the right to direct the use of that asset.MoonLake does not have any finance leases. As of SeptemberÂ 30, 2024, the Company has five operating leases related to the office spaces located in (i) Dorfstrasse 29, 6300, Zug, Switzerland (comprised of two leases), (ii) 95 Regent Street, CB2 1AW, Cambridge, England, United Kingdom, and (iii) Rua Manuel Pinto de Azedevo 860, 4150-335, Porto, Portugal (comprised of two leases). The operating leases are recognized on a straight-line basis over the lease term commencing on the date the Company has the right to use the leased property. Right-of-use assets and lease liabilities are measured at the lease commencement date based on the present value of the remaining lease payments over the lease term, determined using the discount rate for the lease at the commencement date. Because the rate implicit in the leases is not readily determinable, the Company uses the incremental borrowing rate as the discount rate, which approximates the interest rate at which the Company could borrow on a collateralized basis with similar terms and payments and in similar economic environments.Leases with an initial term of 12 months or less that do not have the option to purchase the underlying asset are not recorded on the balance sheet, with lease expense for these leases recognized on a straight-line basis over the lease term commencing on the date the Company has the right to use the leased property.Recently Issued Accounting Pronouncements not yet AdoptedIn November 2023, the FASB issued ASU 2023-07, Segment reporting â€” Improvements to Reportable Segment Disclosures. This new standard requires public entities to disclose significant segment expenses and additional segment items annually and to provide all reported segment profit or loss and assets disclosures currently required annually on an interim basis. The standard also requires disclosure of the Chief Operating Decision Maker's title and position. The standard does not change the manner in which public entities identify their operating segments, aggregate them, or apply the quantitative thresholds for determining their reportable segments. It is effective for fiscal years beginning after December 15, 2023 and interim periods in fiscal years beginning after December 15, 2024, with early adoption permitted. The Company has determined it operates as a single segment, therefore, we do not anticipate this ASU to materially impact our consolidated financial statements and related disclosures.In December 2023, the FASB issued ASU 2023-09, Income taxes â€” Improvements to Income Taxes Disclosure. The purpose of this guidance is to enhance the transparency and usefulness of income tax disclosures and provide comprehensive income tax information, particularly in relation to rate reconciliation and income taxes paid in the U.S and foreign jurisdictions. It is effective for fiscal years beginning after December 15, 2024 and interim periods in fiscal years beginning after December 15, 2024, with early adoption permitted. This ASU will result in the required additional disclosures being included in our consolidated financial statements, once adopted. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent + Details Name: us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 20 R9.htm IDEA: XBRL DOCUMENT v3.24.3 Risks and Liquidity 9 Months Ended Sep. 30, 2024 Risks and Uncertainties [Abstract] Â Risks and Liquidity Risks and LiquidityGoing Concern, Liquidity and Capital ResourcesÂ Â Â Â MoonLake is subject to risks common to companies in the biopharmaceutical industry, and the Company believes that changes in any of the following areas could have a material adverse effect on the Company's future financial position or results of operations: ability to obtain future financing, regulatory approval and market acceptance of, and reimbursement for, product candidates, performance of third-party contract research organizations and manufacturers upon which the Company relies, protection of the Company's intellectual property, litigation or claims against the Company based on intellectual property, patent, product, regulatory, clinical or other factors, and the Company's ability to attract and retain employees necessary to support its growth.The Company is dependent on third-party manufacturers to supply products for research and development activities in its programs. In particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply the Company with its requirements for the active pharmaceutical ingredients and formulated drugs related to these programs. These programs could be adversely affected by a significant interruption in the supply of active pharmaceutical ingredients and formulated drugs.The Company's ability to generate revenue sufficient to achieve profitability will depend on the successful development and eventual commercialization of SLK in one or more indications, which is expected to take a number of years. The Company expects to continue to incur significant expenses and operating losses for at least the next three years as the Company continues the development of SLK and prepares for commercial launches. It is expected that operating losses will fluctuate significantly from year to year depending on the timing of the Company's planned clinical development programs and efforts to achieve regulatory approval.The Company incurred a loss of $74.8 million for the nine months ended SeptemberÂ 30, 2024. As of SeptemberÂ 30, 2024, the Companyâ€™s current assets exceeded its current liabilities by $492.2 million. As of SeptemberÂ 30, 2024, the Company had $375.7 million of cash and cash equivalents. Based on the Company's current operating plan, management believes that the Company has sufficient capital to fund its operations and capital expenditures until the end of 2026. X - DefinitionRisk And Liquidity Disclosure + ReferencesNo definition available. + Details Name: mnlk_RiskAndLiquidityDisclosureTextBlock Namespace Prefix: mnlk_ Data Type: dtr-types1:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_RisksAndUncertaintiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 21 R10.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value Measurements 9 Months Ended Sep. 30, 2024 Fair Value Disclosures [Abstract] Â Fair Value Measurements Fair Value MeasurementsThe following table presents information about the Company's short-term marketable debt securities measured at fair value on a recurring basis and indicate the level in the fair value hierarchy in which the Company classifies the fair value measurement:September 30, 2024December 31, 2023Level 2TotalLevel 2TotalEurocommercial Papers$89,072,100Â $89,072,100Â $109,608,915Â $109,608,915Â Certificates of Deposit88,991,100Â 88,991,100Â 79,626,727Â 79,626,727Â Total$178,063,200Â $178,063,200Â $189,235,642Â $189,235,642Â Cash and accounts payable approximate their fair values as of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023, due to their short-term nature. Pension plan assets fair value is determined based on Level 2 inputs. X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 107 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 940 -SubTopic 820 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1 + Details Name: us-gaap_FairValueDisclosuresTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 22 R11.htm IDEA: XBRL DOCUMENT v3.24.3 Investments 9 Months Ended Sep. 30, 2024 Investments, Debt and Equity Securities [Abstract] Â Investments InvestmentsThe fair value and amortized cost of investments in short-term marketable debt securities by major security type as of SeptemberÂ 30, 2024 are as follows:Amortized costGross unrealized gainsGross unrealized lossesFair valueEurocommercial Papers$87,231,307Â $1,840,793Â $â€”Â $89,072,100Â Certificates of Deposit87,602,179Â 1,388,921Â â€”Â 88,991,100Â Total$174,833,486$3,229,714$â€”$178,063,200Of which classified within cash and cash equivalents59,212,123Â 582,677Â â€”Â 59,794,800Â Of which classified within short-term marketable debt securities115,621,363Â 2,647,037Â â€”Â 118,268,400Â The following table presents the changes in fair values of the Companyâ€™s short-term marketable debt securities, classified as Level 2 financial assets, and recognized in accumulated other comprehensive income:Beginning balance, January 1, 2024$2,720,854Â Other comprehensive income before reclassifications13,000,645Â Amounts reclassified from accumulated other comprehensive income(12,491,785)Ending balance, September 30, 2024$3,229,714As of SeptemberÂ 30, 2024, the Companyâ€™s marketable debt securities maturities are all due within one year. X - ReferencesNo definition available. + Details Name: us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for investments in certain debt and equity securities. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 940 -SubTopic 320 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/940-320/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Regulation S-K (SK) -Number 229 -Section 1403 -Paragraph b -Publisher SECReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/320/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-10Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6BReference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 320 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/942-320/tableOfContent + Details Name: us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock

Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 23 R12.htm IDEA: XBRL DOCUMENT v3.24.3 Prepaid Expenses 9 Months Ended Sep. 30, 2024 Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] Â Prepaid Expenses Prepaid ExpensesPrepaid expenses - currentSeptember 30, 2024December 31, 2023Non-clinical research and clinical development services$7,381,811$842,729Supply and manufacturing services6,358,8921,205Insurance1,496,5211,077,478Other prepayments747,201180,791Total$15,984,425$2,102,203Prepaid expenses - non-currentSeptember 30, 2024December 31, 2023Supply and manufacturing services$2,064,575$8,423,468Total$2,064,575$8,423,468Supply and manufacturing services, current and non-current, relate to advance payments made to a contract manufacturing organization pursuant to a manufacturing run reservation agreement for the commercial-scale manufacturing of SLK in 2025. X - ReferencesNo definition available. + Details Name: us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for other current assets. + ReferencesNo definition available. + Details Name: us-gaap_OtherCurrentAssetsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 24 R13.htm IDEA: XBRL DOCUMENT v3.24.3 Trade and Other Payables 9 Months Ended Sep. 30, 2024 Payables and Accruals [Abstract] Â Trade and Other Payables Trade and Other PayablesSeptember 30, 2024December 31, 2023Research and development services and license fees$7,113,098$911,454Supply and manufacturing fees payable3,044,237553,459Consulting and advisory services307,58180,695Legal advisory fees payable104,31747,095Other payables141,370244,981Total$10,710,603$1,837,684Accrued Expenses and Other Current LiabilitiesSeptember 30, 2024December 31, 2023Research and development services and license fees$3,253,581Â $1,226,281Â Bonuses and related employees compensation expenses2,922,982Â 2,780,219Â Supply and manufacturing services894,894Â 1,603,739Â Tax liabilities484,482Â 367,976Â Consultant and other fees351,774Â 853,905Â Legal fees17,81198,000Total$7,925,524$6,930,120 X - DefinitionThe entire disclosure for accounts payable and accrued liabilities at the end of the reporting period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 720 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 25 R14.htm IDEA: XBRL DOCUMENT v3.24.3 Accrued Expenses and Other Current Liabilities 9 Months Ended Sep. 30, 2024 Payables and Accruals [Abstract] Â Accrued Expenses and Other Current Liabilities Trade and Other PayablesSeptember 30, 2024December 31, 2023Research and development services and license fees$7,113,098$911,454Supply and manufacturing fees payable3,044,237553,459Consulting and advisory services307,58180,695Legal advisory fees payable104,31747,095Other payables141,370244,981Total$10,710,603$1,837,684Accrued Expenses and Other Current LiabilitiesSeptember 30, 2024December 31, 2023Research and development services and license fees$3,253,581Â $1,226,281Â Bonuses and related employees compensation expenses2,922,982Â 2,780,219Â Supply and manufacturing services894,894Â 1,603,739Â Tax liabilities484,482Â 367,976Â Consultant and other fees351,774Â 853,905Â Legal fees17,81198,000Total$7,925,524$6,930,120 X - DefinitionThe entire disclosure for accounts payable and accrued liabilities at the end of the reporting period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 720 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 26 R15.htm IDEA: XBRL DOCUMENT v3.24.3 Leases 9 Months Ended Sep. 30, 2024 Leases [Abstract] Â Leases LeasesIn August 2021, the Company entered into an open-ended office lease agreement, effective November 1, 2021, to lease approximately 2,300 square feet of space on the last two floors of the building located at Dorfstrasse 29, 6300 Zug, Switzerland. The Company estimated the effective duration of the lease at inception and determined a period of 3 years, with expected expiration in November 2024. In December 2023, the contract was extended, leading to a new estimated effective duration of the lease period of 3 years, with expected expiration in January 2027.On October 9, 2023, the Company entered into an office lease agreement, effective as of October 9, 2023, to lease approximately 3,900 square feet of office space on the fifth floor of the building located at Rua Manuel Pinto de Azedevo 860, 4150-335, Porto, Portugal. This lease has a 3-year initial term, with two extendable periods of 3 years each. It is expected to be extended once until October 2029. On October 13, 2023, the Company entered into an office lease agreement, effective as of October 16, 2023, to lease approximately 6,000 square feet of office space on the first floor of the building located at 95 Regent Street, CB2 1AW, Cambridge, England, United Kingdom. This lease has a 3-year term agreement and is set to expire in October 2026. On December 12, 2023, the Company entered into an open-ended office lease agreement, effective as of January 15, 2024, to lease approximately 1,700 square feet of additional office space at its existing corporate headquarters located at Dorfstrasse 29, 6300 Zug, Switzerland. The Company estimated the duration of the lease at inception and determined a 3-year term.On August 14, 2024, the Company entered into an office lease agreement, effective as of September 8, 2024, to lease approximately 2,000 square feet of additional office space at its existing office located at Rua Manuel Pinto de Azevodo 860, 4150-335, Porto, Portugal. This lease has a 2-year initial term, with two extendable periods of 3 years each. The Company currently expects that it will be extended until October 2029.The weighted average remaining lease term and weighted average discount rate for the operating leases as of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023 were as follows:September 30, 2024December 31, 2023Weighted average remaining lease term (in months)3239Weighted average discount rate4.7Â %4.9Â %The maturities of the Company's operating lease liabilities as of SeptemberÂ 30, 2024 are as follows:Year ending December 31,AmountRemainder of fiscal 2024$386,51920251,571,58920261,242,5502027140,3132028140,313Thereafter95,627Total lease payments3,576,911Less imputed interest(196,309)Total lease liability3,380,602Less current portion of lease liability(1,444,893)Long-term portion operating lease liability$1,935,709Operating cash outflows for amounts included in the measurement of lease liabilities was $1,101,661 and $78,270 for the nine months ended SeptemberÂ 30, 2024 and September 30, 2023, respectively.The Company recorded the following lease and variable lease expenses for the three and nine months ended SeptemberÂ 30, 2024 and September 30, 2023: Three Months Ended September 30, 2024Three Months Ended September 30, 2023Nine Months Ended September 30, 2024Nine Months Ended September 30, 2023Operating lease expense$358,583Â $39,562Â $1,061,029Â $117,832Â Variable lease expense15,398Â â€”Â 5,398Â â€”Â Total lease expense$363,981Â $39,562Â $1,066,427Â $117,832Â X - ReferencesNo definition available. + Details Name: us-gaap_LeasesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/842-20/tableOfContent + Details Name: us-gaap_LesseeOperatingLeasesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 27 R16.htm IDEA: XBRL DOCUMENT v3.24.3 Employee Benefit Plans 9 Months Ended Sep. 30, 2024 Retirement Benefits [Abstract] Â Employee Benefit Plans Employee Benefit Plans The Company operates a defined benefit pension plan in Switzerland (the "Planâ€) and a defined contribution pension plan in the United Kingdom, in accordance with local regulations and practices. As of SeptemberÂ 30, 2024, the Plan covers the Companyâ€™s employees in Switzerland with benefits in the event of death, disability, retirement, or termination of employment. Components of Net Periodic Benefit Cost under the PlanThree Months Ended September 30, 2024Three Months Ended September 30, 2023Nine Months Ended September 30, 2024Nine Months Ended September 30, 2023Service cost$71,107$31,175$210,387$91,596Interest cost8,3877,78424,81422,872Expected return on plan assets(15,338)(9,280)(45,380)(27,265)Amortization of unrecognized loss2,609â€”7,717â€”Prior service credit recognized in current year(2,582)â€”(7,639)â€”Total net periodic benefit cost$64,183$29,679$189,899$87,203The components of net periodic benefit cost other than the service cost component are included in general and administrative expense in the Company's unaudited condensed consolidated statements of operations and comprehensive loss.Employer Contributions under the PlanFor the nine months ended SeptemberÂ 30, 2024, contributions of $192,563 (CHF 169,455) were made to the Plan. The Company presently anticipates contributing an additional estimated amount of $64,188 (CHF 56,485) to fund the Plan in 2024 for a total of $256,751 (CHF 225,940). X - DefinitionThe entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 710 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/710/tableOfContentReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 712 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/712/tableOfContentReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 715 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/715/tableOfContentReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContent + Details Name: us-gaap_CompensationAndEmployeeBenefitPlansTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_CompensationAndRetirementDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 28 R17.htm IDEA: XBRL DOCUMENT v3.24.3 Shareholdersâ€™ Equity 9 Months Ended Sep. 30, 2024 Equity [Abstract] Â Shareholdersâ€™ Equity Shareholdersâ€™ EquityClass A Ordinary Shares(1)Class C Ordinary Shares(1)Total Number of Ordinary SharesAuthorizedIssuedAuthorizedIssuedAuthorizedIssued and OutstandingBalance at January 1, 2024500,000,00060,466,453100,000,0002,505,476600,000,00062,971,929Conversion of Class C Ordinary Shares into Class A Ordinary Sharesâ€”1,493,356â€”(1,493,356)â€”â€”Issuance of Class A Ordinary Shares under the ATM facilityâ€”914,828â€”â€”â€”914,828Cancellation of Class C shares following an employee contract termination in MoonLake AGâ€”â€”â€”(16,853)â€”(16,853)Balance at March 31, 2024500,000,00062,874,637100,000,000995,267600,000,00063,869,904Balance at June 30, 2024500,000,00062,874,637100,000,000995,267600,000,00063,869,904Conversion of Class C Ordinary Shares into Class A Ordinary Sharesâ€”153,998â€”(153,998)â€”â€”Options exercised under the Equity Incentive Planâ€”17,390â€”â€”â€”17,390Balance at September 30, 2024500,000,00063,046,025100,000,000841,269600,000,00063,887,294(1) Fully paid-in registered shares with a par value of $0.0001 Class A Ordinary SharesOn April 6, 2022, the Company's Class A Ordinary Shares began trading on The Nasdaq Capital Market ("Nasdaq") under the symbol â€œMLTXâ€. As of SeptemberÂ 30, 2024, there were 63,046,025 Class A Ordinary Shares issued and outstanding. The Company is authorized to issue up to 500,000,000 Class A Ordinary Shares, par value $0.0001 per share. Holders of Class A Ordinary Shares are entitled to one vote per share. Class C Ordinary SharesAs of SeptemberÂ 30, 2024, there were 841,269 Class C Ordinary Shares issued and outstanding. The Company is authorized to issue up to 100,000,000 Class C Ordinary Shares, with a par value $0.0001 per share. Each Class C Ordinary Share entitles the holders thereof to one vote per share, but carries no economic rights.At the closing of the Business Combination, MoonLake, MoonLake AG and ML Party (as defined in Note 2 â€” Business Combination Agreement with Helix and Recapitalization, included in MoonLake's audited financial statements and notes thereto for the year ended December 31, 2023 included in the Annual Report) entered into a Restated and Amended Shareholders' Agreement (the â€œA&R Shareholders' Agreementâ€). With the intent to approximate the rights, obligations and restrictions that an ML Party would enjoy if it were a holder of Class A Ordinary Shares, the A&R Shareholdersâ€™ Agreement (i) imposes certain transfer and other restrictions on the ML Parties, (ii) provides for the waiver of certain statutory rights and (iii) establishes certain mechanics whereby MoonLake and each of the ML Parties are able to effect the conversion of MoonLake AG Common Shares and Class C Ordinary Shares into a number of Class A Ordinary Shares equal to the Exchange Ratio of 33.638698 (as defined in Note 3 â€” Basis of Presentation, included in MoonLake's audited financial statements and notes thereto for the year ended December 31, 2023 included in the Annual Report). On September 9 and September 25, 2024, pursuant to the A&R Shareholdersâ€™ Agreement, certain holders of Class C Ordinary Shares submitted exchange notices to the Company, pursuant to which such holders of Class C Ordinary Shares effected the conversion of 4,578 MoonLake AG Common Shares and 153,998 Class C Ordinary Shares into 153,998 Class A Ordinary Shares using the Exchange Ratio. The foregoing description of the A&R Shareholders' Agreement is not complete and is qualified in its entirety by reference to, and should be read in connection with, the full text of the A&R Shareholders' Agreement filed as an exhibit on the Company's Current Report on Form 8-K filed with the SEC on April 11, 2022.Equity OfferingsAt-the-Market OfferingOn May 11, 2023, the Company entered into a Sales Agreement (the â€œMay 2023 Sales Agreementâ€) with Leerink Partners LLC (formerly known as SVB Securities LLC) (â€œLeerink Partnersâ€), through which the Company could issue and sell up to $200,000,000 of its Class A Ordinary Shares (the â€œMay 2023 ATM Sharesâ€), through Leerink Partners as its sales agent. The May 2023 ATM Shares to be sold under the May 2023 Sales Agreement, if any, would be issued and sold pursuant to the Company's shelf registration statement on Form S-3 (File No. 333-271546), which was declared effective by the SEC on May 9, 2023, and a prospectus supplement thereto filed with the SEC on May 11, 2023.On June 27, 2023, the Company reduced the maximum aggregate offering amount of its Class A Ordinary Shares that could be issued and sold under the May 2023 Sales Agreement to $0 and no longer intends to sell Class A Ordinary Shares under the May 2023 Sales Agreement unless the Company files a further prospectus supplement indicating an amount of shares proposed to be sold.On August 31, 2023, the Company entered into a Sales Agreement with Leerink Partners (the â€œAugust 2023 Sales Agreementâ€ and together with the May 2023 Sales Agreement, the â€œSales Agreementsâ€), through which the Company could issue and sell up to $350,000,000 of its Class A Ordinary Shares (the â€œAugust 2023 ATM Sharesâ€), through Leerink Partners as its sales agent. The August 2023 ATM Shares to be sold under the August 2023 Sales Agreement, if any, would be issued and sold pursuant to the Companyâ€™s shelf registration statement on Form S-3 (File No. 333-274286), which was declared effective by the SEC on September 11, 2023, and a prospectus supplement thereto filed with the SEC on August 31, 2023. During the three months ended March 31, 2024, the Company sold 914,828 Class A Ordinary Shares under the August 2023 Sales Agreement at a weighted average share price of $58.31, for aggregate net proceeds of approximately $52.5 million, after deducting sales agent's commissions and transaction costs.During the three months ended June 30, 2024 and the three months ended SeptemberÂ 30, 2024, there were no sales under the August 2023 Sales Agreement. Public Offering of Class A Ordinary Shares On JuneÂ 27, 2023, the Company entered into an underwriting agreement with SVB Securities LLC and Guggenheim Securities LLC as the representatives of the underwriters named therein, to issue and sell 8,000,000 Class A Ordinary Shares at a public offering price of $50.00 per share (the â€œOfferingâ€). In addition, the Company granted the underwriters an option for a period of 30 days to purchase up to an additional 1,200,000 Class A Ordinary Shares at the public offering price less the underwriting discounts and commissions (the â€œOptionâ€), and such Option was exercised in full by the underwriters.The Offering closed on June 30, 2023, and net proceeds from the Offering, including proceeds from the exercise in full by the underwriters of the Option, were $436.7 million, after deducting the underwriting discounts and commissions and the offering expenses in the amount of $23.3 million.Following the completion of the Offering, the Company opted to direct a substantial portion of the net proceeds to MoonLake AG. This was executed as a two-step process: (i) the Company acquired the remaining 22,756 MoonLake AG Common Shares held in treasury through a share purchase and assignment agreement formally executed on July 9, 2023 ($38.9 million) and (ii) the Company contributed additional funds to MoonLake AGâ€™s capital reserves through a cash contribution agreement formally executed on July 10, 2023 ($275 million). A stamp duty tax of $2.8Â million was levied on the aforementioned capital contribution which the Company has classified as cash flows from financing activities in order to correctly mirror the underlying nature of the transaction.On March 8, 2024, the Company executed a similar transaction as a two-step process: (i) the Company acquired 501 MoonLake AG Common Shares held in treasury through a share

purchase and assignment agreement ($0.8 million) and (ii) the Company contributed an additional $150.0Â million of funds to MoonLake AG's capital reserves through a cash contribution. A stamp duty tax of $1.6 million was levied on the capital contribution which the Company has classified as cash flows from financing activities in order to correctly mirror the underlying nature of the transaction. The aforementioned increase in treasury shares occurred during the three months ended March 31, 2024 as a result of an employee termination entitling MoonLake AG to repurchase such employee's unvested shares (501 MoonLake AG Common Shares and 16,853 Class C Ordinary Shares) previously awarded as part of a share-based compensation program. Since the shares were subsequently sold to MoonLake, the corresponding Class C Ordinary Shares were canceled.Options Exercised under the Equity Incentive PlanIn the three months ended SeptemberÂ 30, 2024, certain participants exercised their stock options under the Equity Incentive Plan (as defined below) for an aggregate of 17,390 Class A Ordinary Shares and total cash consideration of $91,298. X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18 + Details Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 29 R18.htm IDEA: XBRL DOCUMENT v3.24.3 Net Loss per Share 9 Months Ended Sep. 30, 2024 Earnings Per Share [Abstract] Â Net Loss per Share Net Loss per ShareThe following table sets forth the loss per share calculations for the three and nine months ended SeptemberÂ 30, 2024 compared to the three and nine months ended September 30, 2023:Three Months Ended September 30, Nine Months Ended September 30, 2024202302420242023NumeratorNet loss attributable to controlling interests shareholders$(35,390,337)$(9,426,049)$(73,331,005)$(28,570,184)DenominatorTotal weighted average number of outstanding shares62,896,78253,517,65562,803,22045,485,650Net loss per share â€“ basic and diluted(0.56)(0.18)(1.17)(0.63)The weighted average number of shares used to calculate the net loss per share â€“ basic for the nine months ended SeptemberÂ 30, 2024 excludes Class C Ordinary Shares as they do not carry economic rights. If the ML Parties elected to convert all of their MoonLake AG Common Shares into Class A Ordinary Shares as of January 1, 2024, the weighted average number of shares outstanding would have been 63,881,246 and 63,809,450 for the three and nine months ended SeptemberÂ 30, 2024, respectively, resulting in a net loss per share of $0.57 and $1.17, respectively. Upon conversion, all Class C Ordinary Shares would be forfeited and there would no longer be any noncontrolling interests.Upon conversion, the Company's number of Class A Ordinary Shares outstanding would be 63,905,198 as of NovemberÂ 1, 2024, including the 17,904 Class A Ordinary Shares issued pursuant to stock options exercised under the Equity Incentive plan subsequent to September 30, 2024. X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for earnings per share. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/260/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3 + Details Name: us-gaap_EarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 30 R19.htm IDEA: XBRL DOCUMENT v3.24.3 Share-Based Compensation 9 Months Ended Sep. 30, 2024 Share-Based Payment Arrangement [Abstract] Â Share-Based Compensation Share-Based Compensation As of SeptemberÂ 30, 2024, the Company had the following share-based compensation arrangements:a.Restricted Founder Shares (as defined below) â€“ created in April 2021 by MoonLake AG (fully vested as of April 2023);b.The Employee Share Participation Plan (â€œESPPâ€) â€“ created in July 2021 by MoonLake AG;c.The Employee Stock Option Plan (â€œESOPâ€) â€“ created in July 2021 by MoonLake AG (fully vested as of January 2024);d.MoonLake Immunotherapeutics 2022 Equity Incentive Plan ("Equity Incentive Plan") â€“ created in April 2022 by MoonLake Immunotherapeutics. The purpose of the arrangements is to attract and retain the best available personnel and to provide participants with additional incentive to increase their efforts on behalf and in the best interest of the Company and its subsidiaries. The reference to â€œCommon Sharesâ€ refers to shares in MoonLake AG. MoonLake AG's compensation plans are settled with its Common Shares and with a number of Class C Ordinary Shares of the Company, determined by multiplying the number of Common Shares by the Exchange Ratio. The owners of Common Shares have the right to exchange their Common Shares for a number of Class A Ordinary Shares derived using the Exchange Ratio. In the event MoonLake AG shareholders elect to exchange their Common Shares, such MoonLake AG shareholder forfeits a number of Class C Ordinary Shares equal to the number of Class A Ordinary Shares issued (refer to NoteÂ 11 â€“ Shareholdersâ€™ Equity - Class C Ordinary Shares).As of January 1, 2024, the Company executed the conversion of the majority of the outstanding ESOP awards into an equivalent number of Equity Incentive Plan option awards that are settled with Class A Ordinary Shares, thereby eliminating the intermediary right to the exchange step noted above. From an accounting perspective, there is no underlying modification to the economic, control or legal rights of the awards, including vesting terms and conditions, exercise price and accounting classification. This is purely an administrative change as opposed to an accounting modification whereby the plan issuer is amended from MoonLake AG to MoonLake Immunotherapeutics. Consequently, there is no incremental fair value generated following the conversion and therefore no incremental expense recorded. Any remaining unvested compensation expense will be recorded over the remaining vesting period of the original awards, thereby resulting in no change to the consolidated financial statements.As a result of this administrative conversion, the two main plans which remain active as of SeptemberÂ 30, 2024 are the ESPP and Equity Incentive Plan, whereas the Restricted Founder Shares and ESOP are fully vested as of April 2023 and January 2024, respectively.For the three and nine months ended SeptemberÂ 30, 2024, the Company has recognized an increase in equity in the condensed consolidated balance sheet, and share-based compensation expense in the condensed consolidated statements of operations and comprehensive loss of $1.8 million and $5.3 million, respectively. The share-based compensation expense was driven by the aforementioned two main active share-based compensation plans and programs:Compensation PlanThree Months Ended September 30, 2024Three Months Ended September 30, 2023Nine Months Ended September 30, 2024Nine Months Ended September 30, 2023MoonLake AG Restricted Founder Shares$â€”Â $â€”Â $1,574,299Â ESPP741,154Â 762,309Â 2,191,5572,590,576ESOPâ€”Â 255,171Â â€”Â 614,469Equity Incentive Plan1,101,455Â 408,171Â 3,156,505721,155Total share-based compensation expense$1,842,609Â $1,425,651Â $5,348,062Â $5,500,499Â Of which: included in research and development expense508,697Â 262,717Â 1,446,049Â 1,150,815Â Of which: included in general and administrative expense1,333,912Â 1,162,934Â 3,902,013Â 4,349,684Â We expect that all future employee awards will be made under the Equity Incentive Plan. As of SeptemberÂ 30, 2024, 3,281,755 Class A Ordinary Shares from the authorized pool of 4,353,948 Class A Ordinary Shares remain available for future grants, and 973,800 and 98,393 Class A Ordinary Shares are reserved for issuance upon exercise of stock options granted under the Equity Incentive Plan and ESOP, respectively. The latter relate to awards not yet subjected to the conversion described above.MoonLake AG - Restricted Founder Shares On April 28, 2021, the shareholdersâ€™ agreement between the co-founders, the Series A investors and MoonLake AG imposed a reverse vesting condition on 90% of the total 110,000 Common Shares (the equivalent of 3,700,257 Class C Ordinary Shares) held by each of the three co-founders. Therefore, 99,000 Common Shares (the equivalent of 3,330,231 Class C Ordinary Shares) held by each of the co-founders were subject to these restrictions and considered unvested (the â€œRestricted Founder Sharesâ€). The Restricted Founder Shares vested on the 28th of each month at a rate of 4.166% over a period of two years until April 28, 2023. In the event of termination of the contractual relationship of the relevant co-founder before the end of the vesting period, MoonLake AG in first priority, or any third party designated by it, and the other shareholders in second priority pro rata to their shareholdings, had an option to purchase all or a pro rata portion of the leaver shares that remained unvested on the effective day of the termination at nominal value of CHF 0.10.Grants awardedRestricted Founder SharesNumber of SharesAwards unvested as of January 1, 20231,110,078Awards vested for the nine months ended September 30, 2023(1,110,078)Awards unvested as of September 30, 2023â€”Employee Share Participation Plan (ESPP) 2021-2025 - MoonLake AGThe ESPP grants will vest 25% on each anniversary of the grant date. In the event of a termination of contractual relationship between the Company and the entitled employee, the awards can be deemed forfeited by MoonLake AG if certain conditions are met. Awards feature an accelerated vesting condition linked to a â€œChange of Controlâ€, defined as any transfer of shares that results in the proposed acquirer holding more than 50% of the then issued share capital of MoonLake AG or the Company, as the case may be, where all the outstanding awards (whether currently outstanding or granted in the future) will be deemed fully vested.Grants awardedESPPNumber of SharesAwards issued as of January 1 and September 30, 20232,237,915Awards vested as of September 30, 20231,525,582Awards issued as of January 1, 20242,237,915Awards forfeited for the nine months ended September 30, 20242(16,853)Awards issued as of September 30, 20242,221,062Awards vested as of September 30, 20241,827,826As of SeptemberÂ 30, 2024, MoonLake AG had $3.8 million of total unrecognized compensation expense related to the ESPP that will be recognized over the weighted average period of 1.30 years.Employee Stock Option Plan (ESOP) 2021-2025 - MoonLake AGThe ESOP grants will vest 25% on each anniversary of the grant date. In the event of a termination of the contractual relationship between the Company and the entitled employee, options can be deemed forfeited by MoonLake AG if certain conditions are met. Awards feature an accelerated vesting condition linked to a â€œChange of Controlâ€, defined as any transfer of shares that results in the proposed acquirer holding more than 50% of the then issued share capital of MoonLake AG or the Company, as the case may be, where all the outstanding awards (whether currently outstanding or granted in the future) will be deemed fully vested. Grants awardedESOPNumber of OptionsAwards outstanding as of January 1, 2023466,770Awards granted for the nine months ended September 30, 2023133,444Awards outstanding as of September 30, 2023600,214Awards exercisable as of September 30, 2023186,593Awards outstanding as of January 1, 2024585,078Awards converted from ESOP to Equity Incentive Plan for the nine months ended September 30, 2024(486,685)Awards outstanding as of September 30, 202498,393Awards exercisable as of September 30, 202498,393MoonLake Immunotherapeutics 2022 Equity Incentive PlanOn April 5, 2022 (the â€œEffective Dateâ€), the Company created the Equity Incentive Plan to promote and closely align the interests of employees, officers, non-employee directors and other service providers of MoonLake Immunotherapeutics and its shareholders by providing share-based compensation and other performance-based compensation. The Equity Incentive Plan provides for the grant of options, stock appreciation rights, restricted stock units, restricted stock and other share-based awards and for incentive bonuses, which may be paid in cash, Common Shares or a combination thereof, as determined by the compensation committee of the board of directors or such other committee as designated by the board of directors to administer the Equity Incentive Plan. The Equity Incentive Plan shall remain available for the grant of awards until the 10th anniversary of the Effective Date.Grants awardedEquity Incentive PlanNumber of OptionsAwards outstanding as of January 1, 2023180,000Awards granted for the nine months ended September 30, 202356,485Awards outstanding as of September 30, 2023236,485Awards exercisable as of September 30, 202360,000Awards outstanding as of January 1, 2024312,400Awards granted for the nine months ended September 30, 2024241,820Awards exercised for the nine months ended September 30, 2024(17,390)Awards converted from ESOP to Equity Incentive Plan for the nine months ended September 30, 2024486,685Awards forfeited for the nine months ended September 30, 2024(49,715)Awards outstanding as of September 30, 2024973,800Awards exercisable as of September 30, 2024368,910Weighted average assumptions for the awards issued during the nine months ended September 30, 2024Estimated fair value of the option on the grant date using Black-Scholes model ($)31.31Exercise price ($)45.63Expected term of the award on the grant date (years) (1)6Expected volatility of the share price (2)75%Risk-free interest rate (3)4.3%Expected dividend rateâ€”%(1) The expected term represents the period that share-based awards are expected to be outstanding.(2) The expected volatility was derived from the historical stock volatilities of comparable peer public companies within the Companyâ€™s industry.(3) The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the measurement date with maturities approximately equal to the expected term.As of SeptemberÂ 30, 2024, the Company had $11.2 million of total unrecognized compensation expense related to the Equity Incentive Plan that will be recognized over the weighted average period of 1.96 years. X - DefinitionThe entire disclosure for share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType

Balance Type: na Period Type: duration XML 31 R20.htm IDEA: XBRL DOCUMENT v3.24.3 Income Taxes 9 Months Ended Sep. 30, 2024 Income Tax Disclosure [Abstract] Â Income Taxes Income TaxesThe Company's effective tax rate (â€œETRâ€) was 0.3% and 0.3% for the three and nine months ended SeptemberÂ 30, 2024, respectively, and 0.2% and 0.1% for the three and nine months ended September 30, 2023, respectively. The Company is not aware of any items that would cause the quarterly ETR to be significantly different from the Company's annual ETR. The difference between the income tax provision that would be derived by applying the statutory rate to the Company's loss before income taxes and the income tax provision recorded was primarily attributable to the change in the valuation allowance. The Company continues to incur losses for the entities domiciled in the Cayman Island and Switzerland, and its ability to utilize the deferred tax asset related to the tax losses is not considered more likely than not. A full valuation allowance has been recorded against the deferred tax asset. X - ReferencesNo definition available. + Details Name: us-gaap_IncomeTaxDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for income tax. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12CReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12BReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.5.Q1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/740/tableOfContentReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 11.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2 + Details Name: us-gaap_IncomeTaxDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 32 R21.htm IDEA: XBRL DOCUMENT v3.24.3 Commitment and Contingencies 9 Months Ended Sep. 30, 2024 Commitments and Contingencies Disclosure [Abstract] Â Commitment and Contingencies Commitments and ContingenciesCommitmentsThe Company has entered into agreements as of SeptemberÂ 30, 2024 primarily in regards to the clinical and non-clinical development services with contract research organizations ("CROs"), as well as supply and logistics services with contract manufacturing organizations ("CMOs"), for the advancement of SLK. As of SeptemberÂ 30, 2024, the total committed expense under these agreements amounted to $145.1 million, of which $8.0 million are recognized under Prepaid expenses - current, $2.1 million are recognized under Prepaid expenses - non-current, and the rest remain unrecognized.The Company's In-License Agreement with MHKDG includes contractual milestone payments related to the achievement of pre-specified research, development, regulatory and commercialization events and indemnification provisions, which are common in such agreements. Pursuant to the agreements, the Company is obligated to make research and development and regulatory milestone payments upon the occurrence of certain events. Subject to the terms of the license, additional milestone payments of up to â,¬299.6 million ($335.2 million using a SeptemberÂ 30, 2024 exchange rate) are potentially payable upon satisfying specific milestones related to regulatory filing acceptance, first commercial sales, and aggregate annual net sales. The milestone payments are payable in cash. Milestone payments due prior to obtaining regulatory approval will be recorded as research and development expense upon determination that a milestone payment is probable to occur. Milestone payments due after obtaining regulatory approval will be capitalized when and if incurred. The Company will use commercially reasonable efforts to cause the milestones to occur. However, if the Company reasonably determines that a technical failure or commercial failure has occurred with respect to all or a part of the SLK Program, the Company, at its sole discretion, can terminate all or part of the SLK Program. As of SeptemberÂ 30, 2024, the Company made a total of â,¬7.5 million ($8.1 million using the then applicable exchange rates) in additional milestone payments.In addition, on May 12, 2023, MoonLake AG entered into an agreement with Research Cooperation Technologies, Inc. (â€œRCTâ€) and MHKDG, effective as of June 1, 2023, pursuant to which the Company was granted a royalty-bearing, nonexclusive, sublicensable right and license under RCTâ€™s patents and know-how related to a manufacturing process using an underlying yeast strain, Pichia pastoris, to develop, manufacture, use, sell, offer for sale, and import and otherwise commercialize SLK on a world-wide basis, subject to certain restrictions. This agreement replaces the Companyâ€™s sublicense for similar rights under the In-License Agreement. In the aggregate, the Company is required to pay royalties within the range of low to mid-teen percent of net sales under the aforementioned agreements with MHKDG and RCT. Royalties will be recognized in the consolidated statements of operations and comprehensive loss when net sales are recognized. X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 33 R22.htm IDEA: XBRL DOCUMENT v3.24.3 Segment Information and Geographic Data 9 Months Ended Sep. 30, 2024 Segment Reporting [Abstract] Â Segment Information and Geographic Data Segment Information and Geographic DataThe Company operates as a single operating segment. Long-lived assets, consisting of property and equipment, net, and operating lease right-of-use assets by geographical area as of SeptemberÂ 30, 2024 are as follows:CountrySeptember 30, 2024December 31, 2023Switzerland$680,946Â $507,392Â United Kingdom2,012,806Â 2,704,555Â Portugal1,138,823Â 737,398Â Total$3,832,575Â $3,949,345Â X - ReferencesNo definition available. + Details Name: us-gaap_SegmentReportingAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 10: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 34 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26CReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/280/tableOfContentReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 + Details Name: us-gaap_SegmentReportingDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 34 R23.htm IDEA: XBRL DOCUMENT v3.24.3 Pay vs Performance Disclosure - USD ($) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Pay vs Performance Disclosure Â Â Â Â Net Income (Loss) $ (35,390,337) $ (9,426,049) $ (73,331,005) $ (28,570,184) X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details Name: ecd_PvpTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50

-Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 35 R24.htm IDEA: XBRL DOCUMENT v3.24.3 Insider Trading Arrangements 3 Months Ended Sep. 30, 2024 Trading Arrangements, by Individual Â Rule 10b5-1 Arrangement Adopted false Non-Rule 10b5-1 Arrangement Adopted false Rule 10b5-1 Arrangement Terminated false Non-Rule 10b5-1 Arrangement Terminated false X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TradingArrByIndTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 36 R25.htm IDEA: XBRL DOCUMENT v3.24.3 Basis of Presentation and Significant Accounting Policies (Policies) 9 Months Ended Sep. 30, 2024 Accounting Policies [Abstract] Â Basis of Presentation The accompanying unaudited condensed consolidated financial statements include those of the Company and its subsidiaries, MoonLake Immunotherapeutics AG, a Swiss stock corporation (Aktiengesellschaft) registered with the commercial register of the Canton of Zug, Switzerland under the number CHE-433.093.536 (â€œMoonLake AGâ€), MoonLake Immunotherapeutics Ltd., a private limited company incorporated in the United Kingdom, and MNLK Immunotherapeutics, Unipessoal Lda ("MNLK PT"), a private limited company incorporated in Portugal, after elimination of all intercompany accounts and transactions. The accompanying unaudited condensed consolidated financial statements and notes hereto have been prepared in accordance with accounting principles generally accepted in the United States of America (â€œU.S. GAAPâ€) as set forth by the Financial Accounting Standards Board (â€œFASBâ€) and in conformity with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X for interim financial reporting. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (â€œASCâ€) and Accounting Standards Updates (â€œASUâ€) of the FASB.In the opinion of management, all material adjustments necessary for a fair presentation of the financial information, which are of a normal and recurring nature, have been made for the interim periods reported. Results of operations for the three and nine months ended SeptemberÂ 30, 2024 are not necessarily indicative of the results for the entire fiscal year or any other period. The unaudited condensed consolidated financial information for the three and nine months ended SeptemberÂ 30, 2024 and 2023 have been prepared on the same basis as and should be read in conjunction with MoonLakeâ€™s audited financial statements and notes thereto for the year ended December 31, 2023 included in the Annual Report.All amounts are presented in U.S. Dollar (â€œ$â€), unless otherwise indicated. The term â€œSwiss francâ€ and â€œCHFâ€ refer to the legal currency of Switzerland, "GBP" refers to the legal currency of the United Kingdom, and â€œâ‚¬â€ and "Euro" refer to the legal currency of Portugal. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires the Company to make judgments, estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses. The significant judgments, estimates and assumptions relevant to the Company relate to:â€¢determining whether the in-process research and development expenditure (â€œIPR&Dâ€) has an alternative future use;â€¢determining assumptions used in estimating the fair value of share-based compensation;â€¢estimating the recoverability of the deferred tax asset; andâ€¢estimating the amount of accruals in connection with the completion of clinical trial milestones.The Company bases its judgments and estimates on various factors and information, which may include, but are not limited to, the Companyâ€™s forecasts and future plans, current economic conditions and observable market-based transactions of its own shares, the results of which form the basis for making judgments about the carrying value of assets and liabilities and recorded amounts of expenses that are not readily apparent from other sources. To the extent there are material differences between the Companyâ€™s estimates and the actual results, the Companyâ€™s future results of operation may be affected. Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash and cash equivalents are recorded at cost, which approximates fair value. Marketable securities and short-term investments The Company invests in short-term marketable securities in the form of debt securities. At the time of purchase, the Company assesses whether such debt security should be classified as held-to-maturity or available-for-sale debt securities.Debt securities are classified as held-to-maturity when the Company has the positive intent and ability to hold the securities to maturity. Held-to-maturity debt securities are carried at amortized cost, adjusted for accretion of discounts or amortization of premiums to maturity computed under the effective interest method. Such accretion or amortization is included in â€œInterest and dividend incomeâ€. Marketable debt securities not classified as held-to-maturity are classified as available-for-sale and reported at fair value.Net unrealized gains and losses on available-for-sale debt securities are excluded from the determination of earnings and are instead recognized in the â€œAccumulated other comprehensive incomeâ€ component of equity until realized. Realized gains and losses on available-for-sale debt securities are computed based upon the historical cost of these securities, using the specific identification method. A decline in the fair value of any security below cost that is deemed other than temporary results in a charge to earnings and the corresponding establishment of a new cost basis for the security. Dividend and interest income are recognized when earned. Realized gains and losses are included in "Other income" and the cost of securities sold is determined using the specific-identification method.Marketable debt securities are classified as either â€œCash and cash equivalentsâ€ or â€œShortâ€'term marketable debt securitiesâ€ according to their original maturity at the time of acquisition. Changes in unrealized gains and losses pertaining to cash equivalent securities are added back into the consolidated statements of cash flows as those are excluded from the determination of earnings but impact the cash and cash equivalents position. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentration of credit risk consist of cash accounts in large financial institutions which, at times, may exceed the CHF 100,000 deposit protection limit in Switzerland, the $250,000 Federal Deposit Insurance Corporation deposit insurance coverage limit in the United States, the GBP 85,000 Financial Services Compensation Scheme deposit protection limit in the United Kingdom, or the â‚¬100,000 Fundo de Garantia de DepÃ³sitos deposit protection limit in Portugal. The Company believes it is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash and cash equivalents are held. Additionally, the Company ensures further protection against credit risk by diversifying its cash holdings across a variety of credit institutions, thereby minimizing the potential impact of any adverse events on a single institution. Further, the Company's investment strategy for cash (in excess of current business requirements) is set to invest in short-term marketable debt securities. Management actively monitors credit risk in the investment portfolio. Credit risk exposures are controlled in accordance with policies approved by the board of directors to identify, measure, monitor and control credit risks. Fair Value Measurements The Company follows the guidance included in ASC 820, Fair Value Measurement. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. There are three levels of inputs to fair value measurements:â€¢Level 1, meaning the use of quoted prices for identical instruments in active markets;â€¢Level 2, meaning the use of quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active or are directly or indirectly observable; andâ€¢Level 3, meaning the use of unobservable inputs. Observable market data is used when available.Transfers between Levels 1, 2 or 3 within the fair value hierarchy are recognized at the end of the reporting period when the respective transaction occurred. Segment Information The Company operates as a single operating segment. The Companyâ€™s chief operating decision maker, its Chief Executive Officer, manages the Companyâ€™s operations on a stand-alone basis for the purposes of allocating resources and assessing financial performance. Property and Equipment Property and equipment, net is stated at cost, net of accumulated depreciation. Depreciation is computed using the straight-line method based on the estimated useful lives of three to five years. As of SeptemberÂ 30, 2024, property and equipment, net relates to information technology, office equipment, and leasehold improvements. Research and Development Contract Costs and Accruals Research and development expenses include employee payroll, consulting, contract research and contract manufacturing costs attributable to research and development activities and are expensed as incurred.Upfront payments and milestone payments made for the licensing of technology are expensed as research and development expenses in the period in which it is probable that a liability has been incurred. Advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed.The Company has entered into various research and development contracts with companies both inside and outside of the United States. These agreements are generally cancellable, and related payments are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies or trials, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Companyâ€™s estimates. The Companyâ€™s historical accrual estimates have not been materially different from the actual costs. Share-Based Compensation Share-Based CompensationThe Company recognizes compensation expense based on estimated fair values for all stock-based payment awards made to eligible employees, members of the board of directors and independent contractors that are expected to vest. The valuation of stock option awards is determined at the date of grant using the Black-Scholes option pricing model. The Black-Scholes option pricing model requires the Company to make assumptions and judgements about the inputs used in the calculations, such as the fair value of the common stock, expected term, expected volatility of the Companyâ€™s common stock, risk-free interest rate and expected dividend yield. The valuation of restricted stock awards is measured by the fair value of the Companyâ€™s common stock on the date of the grant.For all stock options granted, the Company calculated the expected term as the period that share-based awards are expected to be outstanding. The estimate of expected volatility is based on comparative companiesâ€™ volatility within the Company's industry. The risk-free rate is based on the yield available on United States Treasury zero-coupon issues corresponding to the expected term of the award. The fair value of the common stock granted under the ESPP (as defined in Note 13 â€” Share-based compensation) has historically been estimated by management with reference to the market-based transaction with its Series A investors, as there was no public market for the common stock. Share-based payment arrangements are accounted for under the fair value method. Total compensation is measured at grant date, based on the fair value of the award at that date, and recorded in earnings over the period the employees are required to render service. The Company recognizes compensation cost only for those awards expected to meet the service conditions on a straight-line basis over the requisite service period of the award. Foreign Currency The functional currency of the Company and its subsidiaries is the U.S. dollar. Balances and transactions denominated in foreign currencies are converted as follows: monetary assets and liabilities are translated using exchange rates in effect at the balance sheet dates and non-monetary assets and liabilities are translated at historical exchange rates. Revenue and expenses are translated at the daily exchange rate on the respective accounting date.Gains or losses from foreign currency translation are included in the consolidated statements of operations and comprehensive loss in "other income, net". Income Taxes The Company accounts for income taxes by using the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. A valuation allowance is recorded to the extent it is more likely than not that all or a portion of the Company's deferred tax assets will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. Net Loss per Class A Ordinary Shares Basic net loss per Class A Ordinary Share is calculated using the two-class method under which earnings are allocated to both Class A Ordinary Shares and participating securities. Basic net loss per share is calculated by dividing the net loss attributable to Class A Ordinary Shares by the weighted-average number of Class A Ordinary Shares outstanding for the period. The diluted net loss per Class A Ordinary Share is computed by dividing the net loss using the weighted-average number of Class A Ordinary Shares and, if dilutive, potential Class A Ordinary Shares outstanding during the period.In periods in which the Company reports a net loss attributable to

shareholders of Class A Ordinary Shares, diluted net loss per share attributable to shareholders of Class A Ordinary Shares is the same as basic net loss per share attributable to shareholders of Class A Ordinary Shares, since dilutive Class A Ordinary Shares are not assumed to be outstanding if their effect is anti-dilutive. Acquisitions The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first assessing whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. On April 29, 2021, MoonLake AG entered into an in-licensing agreement (the â€œIn-License Agreementâ€) with Merck Healthcare KGaA, Darmstadt, Germany (â€œMHKDGâ€) to acquire the Sonelokimab program (the â€œSLK Programâ€) and determined that substantially all of the fair value of the gross assets acquired related to IPR&D of SLK. Therefore, this transaction was accounted for as an asset acquisition.IPR&D represents incomplete technologies that the Company acquires, which at the time of acquisition, are still under development and have no alternative future use. The fair value of such technologies is expensed upon acquisition. A technology is considered to have an alternative future use if it is probable that the Company will use the asset in its current, incomplete state as it existed at the acquisition date, in another research and development project that has not yet commenced, and economic benefit is anticipated from that use. If a technology is determined to have an alternative future use, then the fair value of the program would be recorded as an asset on the balance sheet rather than expensed. Contingent consideration payments (for example milestone payments due upon the occurrence of a specific event) in asset acquisitions are recognized in the period in which it is probable that a liability has been incurred (unless the contingent consideration meets the definition of a derivative, in which case the amount becomes part of the cost in the asset acquired). Upon recognition of the contingent consideration payment, the amount is expensed if it relates to IPR&D or capitalized if it relates to a developed product which is generally considered to be when clinical trials have been completed and regulatory approval obtained.Future royalty payments due on net sales will be recognized in cost of goods sold when net sales are recognized. Pension Accounting The Company accounts for pension assets and liabilities in accordance with ASC 715, Compensation â€” Retirement Benefits, which requires the recognition of the funded status of pension plans in the Companyâ€™s consolidated balance sheet. The liability in respect to defined benefit pension plans is the projected benefit obligation calculated annually by independent actuaries using the projected unit credit method. The projected benefit obligation as of SeptemberÂ 30, 2024 represents the actuarial present value of the estimated future payments required to settle the obligation that is attributable to employee services rendered before that date. Service costs for such pension plans, represented in the net periodic pension benefit cost, are included in the personnel expenses of the various functions where the employees are engaged. The other components of net benefit cost are included in the consolidated statements of operations and comprehensive loss separately from the service cost component, in â€œother income, net.â€ Plan assets are recorded at their fair value. Gains or losses arising from plan curtailments or settlements are accounted for at the time they occur. Any net pension asset is limited to the present value of the future economic benefits available to the Company in the form of refunds from the plan or expected reductions in future contributions to the plan. Actuarial gains and losses arising from differences between the actual and the expected return on plan assets are recognized in accumulated other comprehensive income. Leases The Company determines if an arrangement is or contains a lease at contract inception. For these arrangements, it is evaluated if the arrangement involves an identified asset that is physically distinct or whether the Company has the right to substantially all of the capacity of an identified asset that is not physically distinct. In arrangements that involve an identified asset, there is also judgment in evaluating if the Company has the right to direct the use of that asset.MoonLake does not have any finance leases. As of SeptemberÂ 30, 2024, the Company has five operating leases related to the office spaces located in (i) Dorfstrasse 29, 6300, Zug, Switzerland (comprised of two leases), (ii) 95 Regent Street, CB2 1AW, Cambridge, England, United Kingdom, and (iii) Rua Manuel Pinto de Azedevo 860, 4150-335, Porto, Portugal (comprised of two leases). The operating leases are recognized on a straight-line basis over the lease term commencing on the date the Company has the right to use the leased property. Right-of-use assets and lease liabilities are measured at the lease commencement date based on the present value of the remaining lease payments over the lease term, determined using the discount rate for the lease at the commencement date. Because the rate implicit in the leases is not readily determinable, the Company uses the incremental borrowing rate as the discount rate, which approximates the interest rate at which the Company could borrow on a collateralized basis with similar terms and payments and in similar economic environments.Leases with an initial term of 12 months or less that do not have the option to purchase the underlying asset are not recorded on the balance sheet, with lease expense for these leases recognized on a straight-line basis over the lease term commencing on the date the Company has the right to use the leased property. Recently Issued Accounting Pronouncements not yet Adopted In November 2023, the FASB issued ASU 2023-07, Segment reporting â€” Improvements to Reportable Segment Disclosures. This new standard requires public entities to disclose significant segment expenses and additional segment items annually and to provide all reported segment profit or loss and assets disclosures currently required annually on an interim basis. The standard also requires disclosure of the Chief Operating Decision Maker's title and position. The standard does not change the manner in which public entities identify their operating segments, aggregate them, or apply the quantitative thresholds for determining their reportable segments. It is effective for fiscal years beginning after December 15, 2023 and interim periods in fiscal years beginning after December 15, 2024, with early adoption permitted. The Company has determined it operates as a single segment, therefore, we do not anticipate this ASU to materially impact our consolidated financial statements and related disclosures.In December 2023, the FASB issued ASU 2023-09, Income taxes â€” Improvements to Income Taxes Disclosure. The purpose of this guidance is to enhance the transparency and usefulness of income tax disclosures and provide comprehensive income tax information, particularly in relation to rate reconciliation and income taxes paid in the U.S and foreign jurisdictions. It is effective for fiscal years beginning after December 15, 2024 and interim periods in fiscal years beginning after December 15, 2024, with early adoption permitted. This ASU will result in the required additional disclosures being included in our consolidated financial statements, once adopted. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesNo definition available. + Details Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479515/805-10-05-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479515/805-10-05-4Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479515/805-10-05-4Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479515/805-10-05-4 + Details Name: us-gaap_BusinessCombinationsPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1 + Details Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for credit risk. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 825 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1 + Details Name: us-gaap_ConcentrationRiskCreditRisk Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2 + Details Name: us-gaap_EarningsPerSharePolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities. + ReferencesNo definition available. + Details Name: us-gaap_FairValueMeasurementPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/830/tableOfContent + Details Name: us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(h)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1 + Details Name: us-gaap_IncomeTaxPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for leasing arrangement entered into by lessee. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1 + Details Name: us-gaap_LesseeLeasesPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for investment classified as marketable security. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 320 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477268/942-320-50-5 + Details Name: us-gaap_MarketableSecuritiesPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for pension plans. This accounting policy may address (1) the types of plans sponsored by the entity (2) groups that participate in (or are covered by) each plan (3) how plan assets, liabilities and expenses are measured, including the use of any actuaries and (4) significant assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 715 -SubTopic 70 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 30 -Topic 715 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481097/715-30-50-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 80 -Topic 715 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480576/715-80-50-2Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 20 -Topic 715 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1 + Details Name: us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 6 -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1 +

Details Name: us-gaap_ResearchAndDevelopmentExpensePolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for segment reporting. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 36 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29 + Details Name: us-gaap_SegmentReportingPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.C.Q3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.D.1.Q5) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.D.3.Q2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.D.2.Q6) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContentReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8 + Details Name: us-gaap_UseOfEstimates Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 37 R26.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value Measurements (Tables) 9 Months Ended Sep. 30, 2024 Fair Value Disclosures [Abstract] Â Schedule of debt securities by level within the fair value hierarchy The following table presents information about the Company's short-term marketable debt securities measured at fair value on a recurring basis and indicate the level in the fair value hierarchy in which the Company classifies the fair value measurement:September 30, 2024December 31, 2023Level 2TotalLevel 2TotalEurocommercial Papers$89,072,100Â $89,072,100Â $109,608,915Â $109,608,915Â Certificates of Deposit88,991,100Â 88,991,100Â 79,626,727Â 79,626,727Â Total$178,063,200Â $178,063,200Â $189,235,642Â $189,235,642Â X - DefinitionTabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 38 R27.htm IDEA: XBRL DOCUMENT v3.24.3 Investments (Tables) 9 Months Ended Sep. 30, 2024 Investments, Debt and Equity Securities [Abstract] Â Schedule of investments in short-term marketable debt securities The fair value and amortized cost of investments in short-term marketable debt securities by major security type as of SeptemberÂ 30, 2024 are as follows:Amortized costGross unrealized gainsGross unrealized lossesFair valueEurocommercial Papers$87,231,307Â $1,840,793Â $â€”Â $89,072,100Â Certificates of Deposit87,602,179Â 1,388,921Â â€”Â 88,991,100Â Total$174,833,486$3,229,714$â€”$178,063,200Of which classified within cash and cash equivalents59,212,123Â 582,677Â â€”Â 59,794,800Â Of which classified within short-term marketable debt securities115,621,363Â 2,647,037Â â€”Â 118,268,400Â Schedule of fair value changes of marketable securities The following table presents the changes in fair values of the Companyâ€™s short-term marketable debt securities, classified as Level 2 financial assets, and recognized in accumulated other comprehensive income:Beginning balance, January 1, 2024$2,720,854Â Other comprehensive income before reclassifications13,000,645Â Amounts reclassified from accumulated other comprehensive income(12,491,785)Ending balance, September 30, 2024$3,229,714 X - DefinitionTabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aaa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B + Details Name: us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 39 R28.htm IDEA: XBRL DOCUMENT v3.24.3 Prepaid Expenses (Tables) 9 Months Ended Sep. 30, 2024 Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] Â Schedule of prepaid expenses Prepaid expenses - currentSeptember 30, 2024December 31, 2023Non-clinical research and clinical development services$7,381,811$842,729Supply and manufacturing services6,358,8921,205Insurance1,496,5211,077,478Other prepayments747,201180,791Total$15,984,425$2,102,203Prepaid expenses - non-currentSeptember 30, 2024December 31, 2023Supply and manufacturing services$2,064,575$8,423,468Total$2,064,575$8,423,468 X - ReferencesNo definition available. + Details Name: us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs. + ReferencesNo definition available. + Details Name: us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 40 R29.htm IDEA: XBRL DOCUMENT v3.24.3 Trade and Other Payables (Tables) 9 Months Ended Sep. 30, 2024 Payables and Accruals [Abstract] Â Trade and other payables, current September 30, 2024December 31, 2023Research and development services and license fees$7,113,098$911,454Supply and manufacturing fees payable3,044,237553,459Consulting and advisory services307,58180,695Legal advisory fees payable104,31747,095Other payables141,370244,981Total$10,710,603$1,837,684 X - DefinitionTrade And Other Payables, Current + ReferencesNo definition available. + Details Name: mnlk_TradeAndOtherPayablesCurrentTableTextBlock Namespace Prefix: mnlk_ Data Type: dtr-types1:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 41 R30.htm IDEA: XBRL DOCUMENT v3.24.3 Accrued Expenses and Other Current Liabilities (Tables) 9 Months Ended Sep. 30, 2024 Payables and Accruals [Abstract] Â Schedule of accrued expenses and other current liabilities September 30, 2024December 31, 2023Research and development services and license fees$3,253,581Â $1,226,281Â Bonuses and related employees compensation expenses2,922,982Â 2,780,219Â Supply and manufacturing services894,894Â 1,603,739Â Tax liabilities484,482Â 367,976Â Consultant and other fees351,774Â 853,905Â Legal fees17,81198,000Total$7,925,524$6,930,120 X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the components of accrued liabilities. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 42 R31.htm IDEA: XBRL DOCUMENT v3.24.3 Leases (Tables) 9 Months Ended Sep. 30, 2024 Leases [Abstract] Â Lease, Cost The weighted average remaining lease term and weighted average discount rate for the operating leases as of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023 were as follows:September 30, 2024December 31, 2023Weighted average remaining lease term (in months)3239Weighted average discount rate4.7Â %4.9Â %The Company recorded the following lease and variable lease expenses for the three and nine months ended SeptemberÂ 30, 2024 and September 30, 2023: Three Months Ended September 30, 2024Three Months Ended September 30, 2023Nine Months Ended September 30, 2024Nine Months Ended September 30, 2023Operating lease expense$358,583Â $39,562Â $1,061,029Â $117,832Â Variable lease expense15,398Â â€”Â 5,398Â â€”Â Total lease expense$363,981Â $39,562Â $1,066,427Â $117,832Â Schedule of Future Lease Payments The maturities of the Company's operating lease liabilities as of SeptemberÂ 30, 2024 are as follows:Year ending December 31,AmountRemainder of fiscal 2024$386,51920251,571,58920261,242,5502027140,3132028140,313Thereafter95,627Total lease payments3,576,911Less imputed interest(196,309)Total lease liability3,380,602Less current portion of lease liability(1,444,893)Long-term portion operating lease liability$1,935,709 X - DefinitionTabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_LeaseCostTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_LeasesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period

Type: duration X - DefinitionTabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 43 R32.htm IDEA: XBRL DOCUMENT v3.24.3 Employee Benefit Plans (Tables) 9 Months Ended Sep. 30, 2024 Retirement Benefits [Abstract] Â Components of net periodic benefit cost under the plan Components of Net Periodic Benefit Cost under the PlanThree Months Ended September 30, 2024Three Months Ended September 30, 2023Nine Months Ended September 30, 2024Nine Months Ended September 30, 2023Service cost$71,107$31,175$210,387$91,596Interest cost8,3877,78424,81422,872Expected return on plan assets(15,338)(9,280)(45,380)(27,265)Amortization of unrecognized loss2,609â€”7,717â€”Prior service credit recognized in current year(2,582)â€”(7,639)â€”Total net periodic benefit cost$64,183$29,679$189,899$87,203 X - ReferencesNo definition available. + Details Name: us-gaap_CompensationAndRetirementDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 715 -SubTopic 20 -Subparagraph (h) -Name Accounting Standards Codification -Paragraph 1 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1 + Details Name: us-gaap_ScheduleOfNetBenefitCostsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 44 R33.htm IDEA: XBRL DOCUMENT v3.24.3 Shareholdersâ€™ Equity (Tables) 9 Months Ended Sep. 30, 2024 Equity [Abstract] Â Schedule of stock authorized and issued Class A Ordinary Shares(1)Class C Ordinary Shares(1)Total Number of Ordinary SharesAuthorizedIssuedAuthorizedIssuedAuthorizedIssued and OutstandingBalance at January 1, 2024500,000,00060,466,453100,000,0002,505,476600,000,00062,971,929Conversion of Class C Ordinary Shares into Class A Ordinary Sharesâ€”1,493,356â€”(1,493,356)â€”â€”Issuance of Class A Ordinary Shares under the ATM facilityâ€”914,828â€”â€”â€”914,828Cancellation of Class C shares following an employee contract termination in MoonLake AGâ€”â€”â€”(16,853)â€”(16,853)Balance at March 31, 2024500,000,00062,874,637100,000,000995,267600,000,00063,869,904Balance at June 30, 2024500,000,00062,874,637100,000,000995,267600,000,00063,869,904Conversion of Class C Ordinary Shares into Class A Ordinary Sharesâ€”153,998â€”(153,998)â€”â€”Options exercised under the Equity Incentive Planâ€”17,390â€”â€”â€”17,390Balance at September 30, 2024500,000,00063,046,025100,000,000841,269600,000,00063,887,294(1) Fully paid-in registered shares with a par value of $0.0001 X - DefinitionSchedule Of Stock Authorized And Issued Roll Forward + ReferencesNo definition available. + Details Name: mnlk_ScheduleOfStockAuthorizedAndIssuedRollForwardTableTextBlock Namespace Prefix: mnlk_ Data Type: dtr-types1:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 45 R34.htm IDEA: XBRL DOCUMENT v3.24.3 Net Loss per Share (Tables) 9 Months Ended Sep. 30, 2024 Earnings Per Share [Abstract] Â Schedule of earnings per share, basic and diluted The following table sets forth the loss per share calculations for the three and nine months ended SeptemberÂ 30, 2024 compared to the three and nine months ended September 30, 2023:Three Months Ended September 30, Nine Months Ended September 30, 2024202320242023NumeratorNet loss attributable to controlling interests shareholders$(35,390,337)$(9,426,049)$(73,331,005)$(28,570,184)DenominatorTotal weighted average number of outstanding shares62,896,78253,517,65562,803,22045,485,650Net loss per share â€“ basic and diluted(0.56)(0.18)(1.17)(0.63) X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 46 R35.htm IDEA: XBRL DOCUMENT v3.24.3 Share-Based Compensation (Tables) 9 Months Ended Sep. 30, 2024 Share-Based Payment Arrangement [Abstract] Â Schedule of share-based compensation expense driven by share-based compensation plans and programs The share-based compensation expense was driven by the aforementioned two main active share-based compensation plans and programs:Compensation PlanThree Months Ended September 30, 2024Three Months Ended September 30, 2023Nine Months Ended September 30, 2024Nine Months Ended September 30, 2023MoonLake AG Restricted Founder Shares$â€”Â $â€”Â $â€”Â $1,574,299Â ESPP741,154Â 762,309Â 2,191,5572,590,576ESOPâ€”Â 255,171Â â€”Â 614,469Equity Incentive Plan1,101,455Â 408,171Â 3,156,505721,155Total share-based compensation expense$1,842,609Â $1,425,651Â $5,348,062Â $5,500,499Â Of which: included in research and development expense508,697Â 262,717Â 1,446,049Â 1,150,815Â Of which: included in general and administrative expense1,333,912Â 1,162,934Â 3,902,013Â 4,349,684Â Summary of nonvested restricted stock shares activity Grants awardedRestricted Founder SharesNumber of SharesAwards unvested as of January 1, 20231,110,078Awards vested for the nine months ended September 30, 2023(1,110,078)Awards unvested as of September 30, 2023â€” Schedule of nonvested share activity Grants awardedESPPNumber of SharesAwards issued as of January 1 and September 30, 20232,237,915Awards vested as of September 30, 20231,525,582Awards issued as of January 1, 20242,237,915Awards forfeited for the nine months ended September 30, 20242(16,853)Awards issued as of September 30, 20242,221,062Awards vested as of September 30, 20241,827,826 Summary of weighted average assumptions for awards issued Weighted average assumptions for the awards issued during the nine months ended September 30, 2024Estimated fair value of the option on the grant date using Black-Scholes model ($)31.31Exercise price ($)45.63Expected term of the award on the grant date (years)(1)6Expected volatility of the share price (2)75%Risk-free interest rate (3)4.3%Expected dividend rateâ€”%(1) The expected term represents the period that share-based awards are expected to be outstanding.(2) The expected volatility was derived from the historical stock volatilities of comparable peer public companies within the Companyâ€™s industry.(3) The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the measurement date with maturities approximately equal to the expected term. Schedule of option activity for share-based payment arrangement Grants awardedESOPNumber of OptionsAwards outstanding as of January 1, 2023466,770Awards granted for the nine months ended September 30, 2023133,444Awards outstanding as of September 30, 2023600,214Awards exercisable as of September 30, 2023186,593Awards outstanding as of January 1, 2024585,078Awards converted from ESOP to Equity Incentive Plan for the nine months ended September 30, 2024(486,685)Awards outstanding as of September 30, 202498,393Awards exercisable as of September 30, 202498,393Grants awardedEquity Incentive PlanNumber of OptionsAwards outstanding as of January 1, 2023180,000Awards granted for the nine months ended September 30, 202356,485Awards outstanding as of September 30, 2023236,485Awards exercisable as of September 30, 202360,000Awards outstanding as of January 1, 2024312,400Awards granted for the nine months ended September 30, 20242241,820Awards exercised for the nine months ended September 30, 2024(17,390)Awards converted from ESOP to Equity Incentive Plan for the nine months ended September 30, 20244486,685Awards forfeited for the nine months ended September 30, 2024(49,715)Awards outstanding as of September 30, 2024973,800Awards exercisable as of September 30, 2024368,910 X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the changes in outstanding nonvested restricted stock shares. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Subparagraph (c) -Paragraph 2 -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the changes in outstanding nonvested shares. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (f)(2) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 47 R36.htm IDEA: XBRL DOCUMENT v3.24.3 Segment Information and Geographic Data (Tables) 9 Months Ended Sep. 30, 2024 Segment Reporting [Abstract] Â Long-Lived Assets by Geographic Areas Long-lived assets, consisting of property and equipment, net, and operating lease right-of-use assets by geographical area as of SeptemberÂ 30, 2024 are as follows:CountrySeptember 30, 2024December 31, 2023Switzerland$680,946Â $507,392Â United Kingdom2,012,806Â 2,704,555Â Portugal1,138,823Â 737,398Â Total$3,832,575Â $3,949,345Â X - DefinitionTabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 + Details Name: us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SegmentReportingAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 48 R37.htm IDEA: XBRL DOCUMENT v3.24.3 Basis of Presentation and Significant Accounting Policies (Details) 3 Months Ended 9 Months Ended Sep. 30, 2024 USD ($) lease_contract Sep. 30, 2023 USD ($) Sep. 30, 2024 USD ($) segment lease_contract lease Sep. 30, 2023 USD ($) Dec. 31, 2023 USD ($) Class of Stock [Line Items] Â Â Â Â Â Â Cash and cash equivalents $ 375,656,291 Â $ 375,656,291 Â $ 451,169,337 Foreign currency transaction gain (loss), realized $ (26,746) $ (557,144) $ (125,581) $ (276,491) Â Number of operating leases | lease Â Â 5 Â Â Number of lease contracts | lease_contract 2 Â 2 Â Â Number of operating segments | segment Â Â 1 Â Â Commercial Paper and Certificates of Deposit Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Cash and cash equivalents $ 59,800,000 Â $ 59,800,000 Â $ 129,400,000 Minimum Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Property and equipment, useful life 3 years Â 3 years Â Â Maximum Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Property and equipment, useful life 5 years Â 5 years Â Â X - DefinitionNumber Of Lease Contracts + ReferencesNo definition available. + Details Name: mnlk_NumberOfLeaseContracts Namespace Prefix: mnlk_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionNumber Of Operating Leases + ReferencesNo definition available. + Details Name: mnlk_NumberOfOperatingLeases Namespace Prefix: mnlk_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting

Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_ClassOfStockLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, before tax, of realized gain (loss) from foreign currency transaction. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 6 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-6Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(7)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1 + Details Name: us-gaap_ForeignCurrencyTransactionGainLossRealized Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18 + Details Name: us-gaap_NumberOfOperatingSegments Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionUseful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment. + ReferencesNo definition available. + Details Name: us-gaap_PropertyPlantAndEquipmentUsefulLife Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_CashAndCashEquivalentsAxis=mnlk_CommercialPaperAndCertificatesOfDepositMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 49 R38.htm IDEA: XBRL DOCUMENT v3.24.3 Risks and Liquidity (Details) - USD ($) 3 Months Ended 9 Months Ended Sep. 30, 2024 Jun. 30, 2024 Mar. 31, 2024 Sep. 30, 2023 Jun. 30, 2023 Mar. 31, 2023 Sep. 30, 2024 Sep. 30, 2023 Risks and Uncertainties [Abstract] Â Â Â Â Â Â Â Â Net loss $ (36,114,424) $ (24,758,754) $ (13,975,521) $ (11,619,353) $ (12,353,387) $ (12,218,987) $ (74,848,699) $ (36,191,727) Excess of current assets less current liabilities 492,200,000 Â Â Â Â Â 492,200,000 Â Unrestricted cash $ 375,700,000 Â Â Â Â Â $ 375,700,000 Â X - DefinitionCurrent Assets In Excess Of Current Liabilities + ReferencesNo definition available. + Details Name: mnlk_CurrentAssetsInExcessOfCurrentLiabilities Namespace Prefix: mnlk_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 45 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 210 -Topic 946 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20 + Details Name: us-gaap_Cash Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_RisksAndUncertainties Abstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 50 R39.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value Measurements (Details) - USD ($) Sep. 30, 2024 Dec. 31, 2023 Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings [Line Items] Â Â Short-term marketable debt securities $ 118,268,400 $ 59,838,900 Fair Value, Recurring Â Â Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings [Line Items] Â Â Total 178,063,200 189,235,642 Eurocommercial Papers | Fair Value, Recurring Â Â Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings [Line Items] Â Â Short-term marketable debt securities 89,072,100 109,608,915 Certificates of Deposit | Fair Value, Recurring Â Â Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings [Line Items] Â Â Short-term marketable debt securities 88,991,100 79,626,727 Level 2 | Fair Value, Recurring Â Â Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings [Line Items] Â Â Total 178,063,200 189,235,642 Level 2 | Eurocommercial Papers | Fair Value, Recurring Â Â Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings [Line Items] Â Â Short-term marketable debt securities 89,072,100 109,608,915 Level 2 | Certificates of Deposit | Fair Value, Recurring Â Â Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings [Line Items] Â Â Short-term marketable debt securities $ 88,991,100 $ 79,626,727 X - DefinitionFair value portion of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_AssetsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 102 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-102Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50

-Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 51 R40.htm IDEA: XBRL DOCUMENT v3.24.3 Investments - Schedule of Fair Value and Amortized Cost of Investments in Short-Term Marketable Debt (Details) Sep. 30, 2024 USD ($) Debt Securities, Available-for-Sale [Line Items] Â Amortized cost $ 174,833,486 Gross unrealized gains 3,229,714 Gross unrealized losses 0 Fair value 178,063,200 Cash and Cash Equivalents Â Debt Securities, Available-for-Sale [Line Items] Â Amortized cost 59,212,123 Gross unrealized gains 582,677 Gross unrealized losses 0 Fair value 59,794,800 Debt Securities Â Debt Securities, Available-for-Sale [Line Items] Â Amortized cost 115,621,363 Gross unrealized gains 2,647,037 Gross unrealized losses 0 Fair value 118,268,400 Eurocommercial Papers Â Debt Securities, Available-for-Sale [Line Items] Â Amortized cost 87,231,307 Gross unrealized gains 1,840,793 Gross unrealized losses 0 Fair value 89,072,100 Certificates of Deposit Â Debt Securities, Available-for-Sale [Line Items] Â Amortized cost 87,602,179 Gross unrealized gains 1,388,921 Gross unrealized losses 0 Fair value $ 88,991,100 X - DefinitionAmount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleSecuritiesDebtSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aaa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3 + Details Name: us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BalanceSheetLocationAxis=us-gaap_DebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 52 R41.htm IDEA: XBRL DOCUMENT v3.24.3 Investments - Schedule of Changes in Fair Value of Short-Term Marketable Securities (Details) - USD ($) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain (Loss) [Roll Forward] Â Â Â Â Other comprehensive income before reclassifications $ 325,510 $ (3,437,291) $ (508,860) $ (3,046,538) Level 2 Â Â Â Â Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain (Loss) [Roll Forward] Â Â Â Â Gross unrealized gain (loss), beginning balance Â Â 2,720,854 Â Other comprehensive income before reclassifications Â Â 13,000,645 Â Amounts reclassified from accumulated other comprehensive income Â Â (12,491,785) Â Gross unrealized gain (loss), ending balance $ 3,229,714 Â $ 3,229,714 Â X - DefinitionDebt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain (Loss) + ReferencesNo definition available. + Details Name: mnlk_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossRollForward Namespace Prefix: mnlk_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, before tax, of unrealized gain (loss) in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11 + Details Name: us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized loss realized upon the write-down of available-for-sale securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 15 -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-15Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-17A + Details Name: us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForWritedownOfSecuritiesNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 53 R42.htm IDEA: XBRL DOCUMENT v3.24.3 Prepaid Expenses (Details) - USD ($) Sep. 30, 2024 Dec. 31, 2023 Prepaid expenses - current Â Â Non-clinical research and clinical development services $ 7,381,811 $ 842,729 Supply and manufacturing services 6,358,892 1,205 Insurance 1,496,521 1,077,478 Other prepayments 747,201 180,791 Total 15,984,425 2,102,203 Prepaid expenses - non-current Â Â Supply and manufacturing services 2,064,575 8,423,468 Total $ 2,064,575 $ 8,423,468 X - DefinitionPrepaid Research And Development Expense + ReferencesNo definition available. + Details Name: mnlk_PrepaidResearchAndDevelopmentExpense Namespace Prefix: mnlk_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSupply And Manufacturing Expense, Current + ReferencesNo definition available. + Details Name: mnlk_SupplyAndManufacturingExpenseCurrent Namespace Prefix: mnlk_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSupply And Manufacturing Expense, Noncurrent + ReferencesNo definition available. + Details Name: mnlk_SupplyAndManufacturingExpenseNoncurrent Namespace Prefix: mnlk_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1 + Details Name: us-gaap_OtherPrepaidExpenseCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1 + Details Name: us-gaap_PrepaidExpenseCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_PrepaidExpenseCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionSum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_PrepaidExpenseNoncurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5 + Details Name: us-gaap_PrepaidInsurance Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 54 R43.htm IDEA: XBRL DOCUMENT v3.24.3 Trade and Other Payables (Details) - USD ($) Sep. 30, 2024 Dec. 31, 2023

Payables and Accruals [Abstract] Â Â Research and development services and license fees $ 7,113,098 $ 911,454 Supply and manufacturing fees payable 3,044,237 553,459 Consulting and advisory services 307,581 80,695 Legal advisory fees payable 104,317 47,095 Other payables 141,370 244,981 Total $ 10,710,603 $ 1,837,684 X - DefinitionAccrued Consulting And Advisory Fees, Current + ReferencesNo definition available. + Details Name: mnlk_AccruedConsultingAndAdvisoryFeesCurrent Namespace Prefix: mnlk_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAccrued Legal Fees, Current + ReferencesNo definition available. + Details Name: mnlk_AccruedLegalFeesCurrent Namespace Prefix: mnlk_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAccrued Research And Development Expenses, Current + ReferencesNo definition available. + Details Name: mnlk_AccruedResearchAndDevelopmentExpensesCurrent Namespace Prefix: mnlk_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionSupply And Manufacturing Fees Payable, Current + ReferencesNo definition available. + Details Name: mnlk_SupplyAndManufacturingFeesPayableCurrent Namespace Prefix: mnlk_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTrade And Other Payables, Current + ReferencesNo definition available. + Details Name: mnlk_TradeAndOtherPayablesCurrent Namespace Prefix: mnlk_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccountsPayableOtherCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 55 R44.htm IDEA: XBRL DOCUMENT v3.24.3 Accrued Expenses and Other Current Liabilities (Details) - USD ($) Sep. 30, 2024 Dec. 31, 2023 Payables and Accruals [Abstract] Â Â Research and development services and license fees $ 3,253,581 $ 1,226,281 Bonuses and related employees compensation expenses 2,922,982 2,780,219 Supply and manufacturing services 894,894 1,603,739 Tax liabilities 484,482 367,976 Consultant and other fees 351,774 853,905 Legal fees 17,811 98,000 Total $ 7,925,524 $ 6,930,120 X - DefinitionAccrued Consulting And Other Fees, Current + ReferencesNo definition available. + Details Name: mnlk_AccruedConsultingAndOtherFeesCurrent Namespace Prefix: mnlk_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAccrued Research And Development Services and License Fees, Current + ReferencesNo definition available. + Details Name: mnlk_AccruedResearchAndDevelopmentServicesAndLicenseFeesCurrent Namespace Prefix: mnlk_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAccrued Supply And Manufacturing Fees, Current + ReferencesNo definition available. + Details Name: mnlk_AccruedSupplyAndManufacturingFeesCurrent Namespace Prefix: mnlk_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_AccruedIncomeTaxesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other. + ReferencesNo definition available. + Details Name: us-gaap_AccruedLiabilitiesAndOtherLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedProfessionalFeesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_EmployeeRelatedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 56 R45.htm IDEA: XBRL DOCUMENT v3.24.3 Leases - Additional Information (Details) 1 Months Ended 9 Months Ended Aug. 14, 2024 ftÂ² period Dec. 12, 2023 ftÂ² Oct. 13, 2023 ftÂ² Oct. 09, 2023 ftÂ² period Aug. 31, 2021 ftÂ² Sep. 30, 2024 USD ($) Sep. 30, 2023 USD ($) Dec. 31, 2023 Lessee, Lease, Description [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Lessee, operating lease, number of renewal options | period 2 Â Â 2 Â Â Â Â Â Operating lease, payments | $ Â Â Â Â Â Â $ 1,101,661 $ 78,270 Â Switzerland Office Â Â Â Â Â Â Â Â Â Â Â Â Lessee, Lease, Description [Line Items] Â Â Â Â Â Â Â Â Â Square foot of leased space (in square feet) Â Â Â Â 2,300 Â Â Â Lessee, operating lease, term of contract Â 3 years Â Â 3 years Â Â 3 years Operating lease, additional area of leased space Â 1,700 Â Â Â Â Â Â Â Porto Office Â Â Â Â Â Â Â Â Â Â Â Â Lessee, Lease, Description [Line Items] Â Â Â Â Â Â Â Â Â Square foot of leased space (in square feet) 2,000 Â Â 3,900 Â Â Â Â Â Lessee, operating lease, renewal term 3 years Â Â 3 years Â Â Â Â Porto Office | Building Â Â Â Â Â Â Â Â Â Lessee, Lease, Description [Line Items] Â Â Â Â Â Â Â Â Â Lessee, operating lease, term of contract 2 years Â Â 3 years Â Â Â Â Cambridge Office Â Â Â Â Â Â Â Â Â Lessee, Lease, Description [Line Items] Â Â Â Â Â Â Â Â Â Square foot of leased space (in square feet) Â Â 6,000 Â Â Â Â Â Cambridge Office | Building Â Â Â Â Â Â Â Â Â Lessee, Lease, Description [Line Items] Â Â Â Â Â Â Â Â Â Lessee, operating lease, term of contract Â Â 3 years Â Â Â Â Â X - DefinitionLessee, Operating Lease, Number Of Renewal Options + ReferencesNo definition available. + Details Name: mnlk_LesseeOperatingLeaseNumberOfRenewalOptions Namespace Prefix: mnlk_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionOperating Lease, Additional Area of Leased Space + ReferencesNo definition available. + Details Name: mnlk_OperatingLeaseAdditionalAreaOfLeasedSpace Namespace Prefix: mnlk_ Data Type: dtr-types:areaItemType Balance Type: na Period Type: duration X - DefinitionOperating Lease, Area of Leased Space + ReferencesNo definition available. + Details Name: mnlk_OperatingLeaseAreaOfLeasedSpace Namespace Prefix: mnlk_ Data Type: dtr-types1:areaItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeLeaseDescriptionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTerm of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseRenewalTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionTerm of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseTermOfContract Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionAmount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeasePayments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=mnlk_SwitzerlandOfficeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=mnlk_PortoOfficeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=mnlk_CambridgeOfficeMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 57 R46.htm IDEA: XBRL DOCUMENT v3.24.3 Leases - Weighted Average Remaining Lease Term and Discount Rate (Details) Sep. 30, 2024 Dec. 31, 2023 Leases [Abstract] Â Â Weighted average remaining lease term (in months) 32 months 39 months Weighted average discount rate 4.70% 4.90% X - ReferencesNo definition available. + Details Name: us-gaap_LeasesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionWeighted average discount rate for operating lease calculated at point in time. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionWeighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant XML 58 R47.htm IDEA: XBRL DOCUMENT v3.24.3 Leases - Future Lease Payments (Details) - USD ($) Sep. 30, 2024 Dec. 31, 2023 Leases [Abstract] Â Â Remainder of fiscal 2024 $ 386,519 Â 2025 1,571,589 Â 2026 1,242,550 Â 2027 140,313 Â 2028 140,313 Â Thereafter 95,627 Â Total lease payments 3,576,911 Â Less imputed interest (196,309) Â Total lease liability 3,380,602 Â Less current portion of lease liability (1,444,893) $ (1,197,876) Long-term portion of operating lease liabilities $ 1,935,709 $ 2,499,990 X - DefinitionLessee, Operating Lease, Liability, to be Paid, After Year Four + ReferencesNo definition available. + Details Name: mnlk_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour Namespace Prefix: mnlk_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LeasesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance

Type: credit Period Type: instant XML 59 R48.htm IDEA: XBRL DOCUMENT v3.24.3 Leases - Total Lease Expense (Details) - USD ($) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Leases [Abstract] Â Â Â Â Operating lease expense $ 358,583 $ 39,562 $ 1,061,029 $ 117,832 Variable lease expense 5,398 0 5,398 0 Total lease expense $ 363,981 $ 39,562 $ 1,066,427 $ 117,832 X - DefinitionAmount of lease cost recognized by lessee for lease contract. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_LeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_LeasesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_VariableLeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 60 R49.htm IDEA: XBRL DOCUMENT v3.24.3 Employee Benefit Plans (Details) - USD ($) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Retirement Benefits [Abstract] Â Â Â Â Service cost $ 71,107 $ 31,175 $ 210,387 $ 91,596 Interest cost 8,387 7,784 24,814 22,872 Expected return on plan assets (15,338) (9,280) (45,380) (27,265) Amortization of unrecognized loss 2,609 0 7,717 0 Prior service credit recognized in current year (2,582) 0 (7,639) 0 Total net periodic benefit cost $ 64,183 $ 29,679 $ 189,899 $ 87,203 X - ReferencesNo definition available. + Details Name: us-gaap_CompensationAndRetirementDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480535/715-20-45-3AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480482/715-20-55-18Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-6 + Details Name: us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480535/715-20-45-3AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480482/715-20-55-18Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-6 + Details Name: us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cost recognized for passage of time related to defined benefit plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480535/715-20-45-3AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480482/715-20-55-18Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-6 + Details Name: us-gaap_DefinedBenefitPlanInterestCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of net periodic benefit cost (credit) for defined benefit plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480482/715-20-55-18Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-6 + Details Name: us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480482/715-20-55-18Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-6 + Details Name: us-gaap_DefinedBenefitPlanServiceCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, before tax, of cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (j) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1 + Details Name: us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 61 R50.htm IDEA: XBRL DOCUMENT v3.24.3 Employee Benefit Plans - Narrative (Details) 3 Months Ended 9 Months Ended Dec. 31, 2024 USD ($) Dec. 31, 2024 CHF (SFr) Sep. 30, 2024 USD ($) Sep. 30, 2024 CHF (SFr) Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] Â Â Â Â Contributions made to plan Â Â $ 192,563 SFr 169,455 Forecast Â Â Â Â Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] Â Â Â Â Contributions made to plan $ 256,751 SFr 225,940 Â Â Defined contribution plan, increase (decrease), cost $ 64,188 SFr 56,485 Â Â X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cost for defined contribution plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 715 -SubTopic 70 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1 + Details Name: us-gaap_DefinedContributionPlanCostRecognized Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in cost for defined contribution plan. + ReferencesNo definition available. + Details Name: us-gaap_DefinedContributionPlanIncreaseDecreaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: srt_StatementScenarioAxis=srt_ScenarioForecastMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 62 R51.htm IDEA: XBRL DOCUMENT v3.24.3 Shareholdersâ€™ Equity - Schedule of Stock Authorized and Issued (Details) - $ / shares 1 Months Ended 3 Months Ended 9 Months Ended Sep. 25, 2024 Sep. 30, 2024 Mar. 31, 2024 Sep. 30, 2023 Jun. 30, 2023 Mar. 31, 2023 Sep. 30, 2024 Dec. 31, 2023 Common Shares Â Â Â Â Â Â Â Â Stock options exercised (in shares) Â 17,390 Â Â Â Â Â Â Issuance of shares under the ATM facility (in shares) Â Â 914,828 Â Â Â Â Â Â Cancellation of Class C shares following an employee contract termination in MoonLake AG (in shares) Â Â 16,853 Â Â Â Â Â Â Total Number of Ordinary Shares Â Â Â Â Â Â Â Â Authorized, beginning balance (in shares) Â 600,000,000 600,000,000 Â Â Â 600,000,000 Â Shares issued, beginning balance (in shares) Â 63,869,904 62,971,929 Â Â Â 62,971,929 Â Number of shares issued (in shares) Â Â 914,828 Â Â Â Â Â Â Cancellation of Class C shares following an employee contract termination in MoonLake AG (in shares) Â Â 16,853 Â Â Â Â Â Â Authorized, ending balance (in shares) Â 600,000,000 600,000,000 Â Â Â 600,000,000 Â Shares issued, ending balance (in shares) Â 63,887,294 63,869,904 Â Â Â 63,887,294 Â Common Class A Â Â Â Â Â Â Â Â Common Shares Â Â Â Â Â Â Â Â Authorized, beginning balance (in shares) Â Â 500,000,000 Â Â Â 500,000,000 Â Issued, beginning balance (in shares) Â Â 60,466,453 Â Â Â 60,466,453 Â Authorized, ending balance (in shares) Â 500,000,000 Â Â Â Â 500,000,000 Â Issued, ending balance (in shares) Â 63,046,025 Â Â Â Â 63,046,025 Â Total Number of Ordinary Shares Â Â Â Â Â Â Â Â Common stock, par value (CHF/USD per share) Â $ 0.0001 Â Â Â Â $ 0.0001 $ 0.0001 Common Class C Â Â Â Â Â Â Â Â Common Shares Â Â Â Â Â Â Â Â Authorized, beginning balance (in shares) Â Â 100,000,000 Â Â Â 100,000,000 Â Issued, beginning balance (in shares) Â Â 2,505,476 Â Â Â 2,505,476 Â Authorized, ending balance (in shares) Â 100,000,000 Â Â Â Â 100,000,000 Â Issued, ending balance (in shares) Â 841,269 Â Â Â Â 841,269 Â Total Number of Ordinary Shares Â Â Â Â Â Â Â Â Common stock, par value (CHF/USD per share) Â $ 0.0001 Â Â Â Â $ 0.0001 $ 0.0001 Common Stock | Common Class A Â Â Â Â Â Â Â Â Common Shares Â Â Â Â Â Â Â Â Authorized, beginning balance (in shares) Â 500,000,000 500,000,000 Â Â Â 500,000,000 Â Issued, beginning balance (in shares) Â 62,874,637 60,466,453 Â Â Â 60,466,453 Â Conversion of Class C Ordinary Shares into Class A Ordinary Shares (in shares) 153,998 153,998 1,493,356 74,678 4,587,713 176,603 Â Â Stock options exercised (in shares) Â 17,390 Â Â Â Â Â Â Issuance of shares under the ATM facility (in shares) Â Â 914,828 Â 9,744,894 Â Â Â Authorized, ending balance (in shares) Â 500,000,000 500,000,000 Â Â Â 500,000,000 Â Issued, ending balance (in shares) Â 63,046,025 62,874,637 Â Â Â 63,046,025 Â Total Number of Ordinary Shares Â Â Â Â Â Â Â Â Number of shares issued (in shares) Â Â 914,828 Â 9,744,894 Â Â Â Common stock, par value (CHF/USD per share) Â $ 0.0001 Â Â Â Â $ 0.0001 Â Common Stock | Common Class A | Conversion Of Class C into Class A Â Â Â Â Â Â Â Â Common Shares Â Â Â Â Â Â Â Â Conversion of Class C Ordinary Shares into Class A Ordinary Shares (in shares) Â 153,998 1,493,356 Â Â Â Â Â Common Stock | Common Class C Â Â Â Â Â Â Â Â Common Shares Â Â Â Â Â Â Â Â Authorized, beginning balance (in shares) Â 100,000,000 100,000,000 Â Â Â 100,000,000 Â Issued, beginning balance (in shares) Â 995,267 2,505,476 Â Â Â 2,505,476 Â Conversion of Class C Ordinary Shares into Class A Ordinary Shares (in shares) 153,998 (153,998) (1,493,356) (74,678) (4,587,713) (176,603) Â Â Cancellation of Class C shares following an employee contract termination in MoonLake AG (in shares) Â Â 16,853 Â Â Â Â Â Â Authorized, ending balance (in shares) Â 100,000,000 100,000,000 Â Â Â 100,000,000 Â Issued, ending balance (in shares) Â 841,269 995,267 Â Â Â 841,269 Â Total Number of Ordinary Shares Â Â Â Â Â Â Â Â Cancellation of Class C shares following an employee contract termination in MoonLake AG (in shares) Â Â 16,853 Â Â Â Â Â Â Common stock, par value (CHF/USD per share) Â $ 0.0001 Â Â Â Â $ 0.0001 Â Common Stock | Common Class C | Conversion Of Class C into Class A Â Â Â Â Â Â Â Â Common Shares Â Â Â Â Â Â Â Â Conversion of Class C Ordinary Shares into Class A Ordinary Shares (in shares) Â (153,998) (1,493,356) Â Â Â Â Â X - DefinitionCommon Stock + ReferencesNo definition available. + Details Name: mnlk_CommonStockRollForward Namespace Prefix: mnlk_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionShares, Authorized + ReferencesNo definition available. + Details Name: mnlk_SharesAuthorized Namespace Prefix: mnlk_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal Shares + ReferencesNo definition available. + Details Name: mnlk_TotalSharesRollForward Namespace Prefix: mnlk_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury. + ReferencesReference 1: http://fasb.org/us-

gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2 + Details Name: us-gaap_SharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued during the period as a result of the conversion of convertible securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of stock bought back by the entity at the exercise price or redemption price. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2 + Details Name: us-gaap_StockRedeemedOrCalledDuringPeriodShares Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConversionOfStockByUniqueDescriptionAxis=mnlk_ConversionOfClassCIntoClassAMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 63 R52.htm IDEA: XBRL DOCUMENT v3.24.3 Shareholdersâ€™ Equity - Narrative (Details) 1 Months Ended 3 Months Ended 9 Months Ended Mar. 08, 2024 USD ($) shares Jul. 10, 2023 USD ($) Jul. 09, 2023 USD ($) shares Jun. 30, 2023 USD ($) shares Jun. 27, 2023 USD ($) $ / shares shares Sep. 25, 2024 shares Sep. 30, 2024 USD ($) vote $ / shares shares Jun. 30, 2024 USD ($) shares Mar. 31, 2024 USD ($) $ / shares shares Sep. 30, 2023 shares Jun. 30, 2023 shares Mar. 31, 2023 shares Sep. 30, 2024 vote $ / shares shares Dec. 31, 2023 $ / shares shares Aug. 31, 2023 USD ($) May 11, 2023 USD ($) Dec. 31, 2022 shares Apr. 28, 2021 shares Class of Stock [Line Items] Â Â Â

ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe cash outflow for cost incurred directly with the issuance of an equity security. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfStockIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from parent as a source of financing that is recorded as additional paid in capital. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromContributionsFromParent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionCash received on stock transaction after deduction of issuance costs. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockConsiderationReceivedOnTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe number of shares issued or sold by the subsidiary or equity method investee per stock transaction. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionPer share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued during the period as a result of the conversion of convertible securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares that have been repurchased during the period and are being held in treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_TreasuryStockSharesAcquired Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_PlanNameAxis=mnlk_May2023SalesAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=mnlk_ATMSharesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=mnlk_May2023AndAugust2023SalesAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=mnlk_EquityIncentivePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: dei_LegalEntityAxis=mnlk_MoonLakeAGMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=mnlk_MoonLakeImmunotherapeuticsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=mnlk_UnderwritingAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=mnlk_August2023SalesAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConversionOfStockByUniqueDescriptionAxis=mnlk_ConversionOfClassCIntoClassAMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=mnlk_MoonLakeAGMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 64 R53.htm IDEA: XBRL DOCUMENT v3.24.3 Net Loss per Share - Calculation of Net Loss per Share (Details) - USD ($) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Numerator Â Â Â Â Net loss attributable to controlling interests shareholders $ (35,390,337) $ (9,426,049) $ (73,331,005) $ (28,570,184) Denominator Â Â Â Â Total weighted average number of outstanding shares, basic (in shares) 62,896,782 53,517,655 62,803,220 45,485,650 Total weighted average number of outstanding shares, diluted (in shares) 62,896,782 53,517,655 62,803,220 45,485,650 Net loss per share - basic (in USD per share) $ (0.56) $ (0.18) $ (1.17) $ (0.63) Net loss per share - diluted (in USD per share) $ (0.56) $ (0.18) $ (1.17) $ (0.63) X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -

SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 65 R54.htm IDEA: XBRL DOCUMENT v3.24.3 Net Loss per Share - Narrative (Details) - $ / shares 3 Months Ended 9 Months Ended Nov. 01, 2024 Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Â Â Â Â Weighted-average number of shares, basic (in shares) Â 62,896,782 53,517,655 62,803,220 45,485,650 Â Weighted-average number of shares, diluted (in shares) Â 62,896,782 53,517,655 62,803,220 45,485,650 Â Net loss per share - basic (in USD per share) Â $ (0.56) $ (0.18) $ (1.17) $ (0.63) Â Net loss per share - diluted (in USD per share) Â $ (0.56) $ (0.18) $ (1.17) $ (0.63) Â Stock options exercised (in shares) Â 17,390 Â Â Â Â Pro forma Â Â Â Â Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Â Â Â Â Weighted-average number of shares, basic (in shares) Â 63,881,246 Â 63,809,450 Â Â Weighted-average number of shares, diluted (in shares) Â 63,881,246 Â 63,809,450 Â Â Net loss per share - basic (in USD per share) Â $ (0.57) Â $ (1.17) Â Â Net loss per share - diluted (in USD per share) Â $ (0.57) Â $ (1.17) Â Â Common Class A Â Â Â Â Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Â Â Â Â Weighted-average number of shares, basic (in shares) Â 62,896,782 53,517,655 62,803,220 45,485,650 Â Weighted-average number of shares, diluted (in shares) Â 62,896,782 53,517,655 62,803,220 45,485,650 Â Net loss per share - basic (in USD per share) Â $ (0.56) $ (0.18) $ (1.17) $ (0.63) Â Net loss per share - diluted (in USD per share) Â $ (0.56) $ (0.18) $ (1.17) $ (0.63) Â Number of shares outstanding (in shares) Â 63,046,025 Â 63,046,025 Â 60,466,453 Common Class A | Pro forma | Subsequent Event Â Â Â Â Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Â Â Â Â Number of shares outstanding (in shares) 63,905,198 Â Â Â Â Â Stock options exercised (in shares) 17,904 Â Â Â Â Â X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -

URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: srt_StatementScenarioAxis=srt_ProFormaMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 66 R55.htm IDEA: XBRL DOCUMENT v3.24.3 Share-Based Compensation - Narrative (Details) 3 Months Ended 9 Months Ended Apr. 05, 2022 Apr. 28, 2021 SFr / shares shares Sep. 30, 2024 USD ($) plan co-founder shares Sep. 30, 2023 USD ($) Sep. 30, 2024 USD ($) plan co-founder shares Sep. 30, 2023 USD ($) Dec. 31, 2023 shares Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Â Â Number of share-based compensation plans | plan Â Â 2 Â 2 Â Â Share-based compensation expense | $ Â Â $ 1,842,609 $ 1,425,651 $ 5,348,062 $ 5,500,499 Â Number of co-founders | co-founder Â Â 3 Â 3 Â Â Equity Incentive Plan Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Â Â Share-based compensation expense | $ Â Â $ 1,101,455 408,171 $ 3,156,505 721,155 Â Common shares issuable (in shares) Â Â 973,800 Â 973,800 Â Â Weighted average period of recognition Â Â Â Â 1 year 11 months 15 days Â Â Expiration period 10 years Â Â Â Â Â Â Unrecognized compensation expense | $ Â Â $ 11,200,000 Â $ 11,200,000 Â Â Employee Stock Option Plan (ESOP) Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Â Â Common shares issuable (in shares) Â Â 98,393 Â 98,393 Â Â MoonLake AG Restricted Founder Shares Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Â Â Share-based compensation expense | $ Â Â $ 0 0 $ 0 1,574,299 Â ESPP Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Â Â Share-based compensation expense | $ Â Â 741,154 762,309 2,191,557 2,590,576 Â Unrecognized share-based compensation expense, non-option awards | $ Â Â 3,800,000 Â $ 3,800,000 Â Â Weighted average period of recognition Â Â Â Â 1 year 3 months 18 days Â Â ESPP | Share-Based Payment Arrangement, Tranche One Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Â Â Vesting percentage Â Â Â Â 25.00% Â Â ESPP | Share-Based Payment Arrangement, Tranche Two Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Â Â Vesting percentage Â Â Â Â 25.00% Â Â ESPP | Share-Based Payment Arrangement, Tranche Three Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Â Â Vesting percentage Â Â Â Â 25.00% Â Â ESPP | Share-Based Payment Arrangement, Tranche Four Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Â Â Vesting percentage Â Â Â Â 25.00% Â Â ESOP Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Â Â Share-based compensation expense | $ Â Â $ 0 $ 255,171 $ 0 $ 614,469 Â ESOP | Employee Stock Option Plan (ESOP) | Share-Based Payment Arrangement, Tranche One Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Â Â Vesting percentage Â Â Â Â 25.00% Â Â ESOP | Employee Stock Option Plan (ESOP) | Share-Based Payment Arrangement, Tranche Two Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Â Â Vesting percentage Â Â Â Â 25.00% Â Â ESOP | Employee Stock Option Plan (ESOP) | Share-Based Payment Arrangement, Tranche Three Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Â Â Vesting percentage Â Â Â Â 25.00% Â Â ESOP | Employee Stock Option Plan (ESOP) | Share-Based Payment Arrangement, Tranche Four Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Â Â Vesting percentage Â Â Â Â 25.00% Â Â Common Class C Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Â Â Common shares, shares outstanding (in shares) Â Â 841,269 Â 841,269 Â 2,505,476 Common Class A Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Â Â Share-based compensation arrangement by share-based payment award, number of shares authorized (in shares) Â Â 4,353,948 Â 4,353,948 Â Â Common shares issuable (in shares) Â Â 3,281,755 Â 3,281,755 Â Â Common shares, shares outstanding (in shares) Â Â 63,046,025 Â 63,046,025 Â 60,466,453 MoonLake AG Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Â Â Â Reverse vesting percentage Â 90.00% Â Â Â Â Â Common shares, shares outstanding (in shares) Â 110,000 Â Â Â Â Â MoonLake AG | MoonLake AG Restricted Founder Shares Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Â Â Common shares, shares outstanding (in shares) Â 99,000 Â Â Â Â Â Vesting percentage Â 4.166% Â Â Â Â Â Vesting period Â 2 years Â Â Â Â Â Nominal value (CHF per share) | SFr / shares Â SFr 0.10 Â Â Â Â Â MoonLake AG | Common Class C Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Â Â Common shares, shares outstanding (in shares) Â 3,700,257 Â Â Â Â Â MoonLake AG | Common Class C | MoonLake AG Restricted Founder Shares Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Â Â Common shares, shares outstanding (in shares) Â 3,330,231 Â Â Â Â Â X - DefinitionNumber Of Co-Founders + ReferencesNo definition available. + Details Name: mnlk_NumberOfCoFounders Namespace Prefix: mnlk_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionNumber Of Share-Based Compensation Plans + ReferencesNo definition available. + Details Name: mnlk_NumberOfShareBasedCompensationPlans Namespace Prefix: mnlk_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionShare-Based Compensation Arrangement by Share-Based Payment Award, Reverse Vesting Condition, Percentage + ReferencesNo definition available. + Details Name: mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardReverseVestingConditionPercentage Namespace Prefix: mnlk_ Data Type: dtr-types1:percentItemType Balance Type: na Period Type: instant X - DefinitionShare Price, Nominal Value + ReferencesNo definition available. + Details Name: mnlk_SharePriceNominalValue Namespace Prefix: mnlk_ Data Type: dtr-types1:perShareItemType Balance Type: na Period Type: instant X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAmount of cost not yet recognized for nonvested award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionWeighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionPeriod over which grantee's right to exercise award under share-based payment arrangement is no longer

contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares authorized for issuance under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionPercentage of vesting of award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPeriod from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_PlanNameAxis=mnlk_EquityIncentivePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=mnlk_EmployeeStockOptionPlanESOPMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VestingAxis=mnlk_ShareBasedPaymentArrangementTrancheFourMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: dei_LegalEntityAxis=mnlk_MoonLakeAGMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 67 R56.htm IDEA: XBRL DOCUMENT v3.24.3 Share-Based Compensation - Share-based Compensation Expense By Plan (Details) - USD ($) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Share-based compensation expense $ 1,842,609 $ 1,425,651 $ 5,348,062 $ 5,500,499 Research and Development Expense Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Share-based compensation expense 508,697 262,717 1,446,049 1,150,815 General and Administrative Expense Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Share-based compensation expense 1,333,912 1,162,934 3,902,013 4,349,684 Equity Incentive Plan Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Share-based compensation expense 1,101,455 408,171 3,156,505 721,155 MoonLake AG Restricted Founder Shares Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Share-based compensation expense 0 0 0 1,574,299 ESPP Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Share-based compensation expense 741,154 762,309 2,191,557 2,590,576 ESOP Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Share-based compensation expense $ 0 $ 255,171 $ 0 $ 614,469 X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -

Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=mnlk_EquityIncentivePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 68 R57.htm IDEA: XBRL DOCUMENT v3.24.3 Share-Based Compensation - Summary of Restricted Stock Awarded and Granted (Details) - MoonLake AG Restricted Founder Shares 9 Months Ended Sep. 30, 2023 shares Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward] Â Awards unvested, beginning balance (in shares) 1,110,078 Awards vested (in shares) (1,110,078) Awards unvested, ending balance (in shares) 0 X - DefinitionThe number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 69 R58.htm IDEA: XBRL DOCUMENT v3.24.3 Share-Based Compensation - Summary of ESPP Awarded and Granted (Details) - ESPP - shares 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward] Â Â Awards unvested, beginning balance (in shares) 2,237,915 2,237,915 Awards forfeited (in shares) (16,853) Â Awards unvested, ending balance (in shares) 2,221,062 2,237,915 Awards vested (in shares) 1,827,826 1,525,582 X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 70 R59.htm IDEA: XBRL DOCUMENT v3.24.3 Share-Based Compensation - Summary of ESOP Awarded and Granted (Details) - ESOP - Employee Stock Option Plan (ESOP) - shares 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Â Â Awards outstanding, beginning balance (in shares) 585,078 466,770 Additional awards granted (in shares) Â 133,444 Awards converted from ESOP to EIP (in shares) (486,685) Â Awards outstanding, ending balance (in shares) 98,393 600,214 Of which exercisable (in shares) 98,393 186,593 X - DefinitionShare-Based Compensation Arrangement by Share-Based Payment Award, Options, Awards Converted + ReferencesNo definition available. + Details Name: mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAwardsConverted Namespace Prefix: mnlk_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=mnlk_EmployeeStockOptionPlanESOPMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 71 R60.htm IDEA: XBRL DOCUMENT v3.24.3 Share-Based Compensation - Summary of Equity Incentive Plan Awarded and Granted (Details) - shares 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2024 Sep. 30, 2023 Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward] Â Â Â Awards exercised (in shares) (17,390) Â Equity Incentive Plan Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward] Â Â Â Awards outstanding, beginning balance (in shares) Â 312,400 180,000 Additional awards granted (in shares) Â 241,820 56,485 Awards exercised (in shares) (17,390) (17,390) Â Awards converted from ESOP to EIP (in shares) Â 486,685 Â Awards forfeited (in shares) Â (49,715) Â Awards outstanding, ending balance (in shares) 973,800 973,800 236,485 Of which exercisable (in shares) 368,910 368,910 60,000 X - DefinitionShare-Based Compensation Arrangement by Share-Based Payment Award, Options, Awards Converted + ReferencesNo definition available. + Details Name: mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAwardsConverted Namespace Prefix: mnlk_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_PlanNameAxis=mnlk_EquityIncentivePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 72 R61.htm IDEA: XBRL DOCUMENT v3.24.3 Share-Based Compensation - Weighted Average Assumptions (Details) - Equity Incentive Plan 9 Months Ended Sep. 30, 2024 $ / shares Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Estimated fair value of the option on the grant date using Black-Scholes model (in dollars per share) $ 31.31 Exercise price (in dollars per share) $ 45.63 Expected term of the award 6 years Expected volatility of the share price 75.00% Risk-free interest rate 4.30% Expected dividend rate 0.00% X - DefinitionAgreed-upon price for the exchange of the underlying asset relating to the share-based payment award. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe risk-free interest rate assumption that is used in valuing an option on its own shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4:

http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionExpected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_PlanNameAxis=mnlk_EquityIncentivePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 73 R62.htm IDEA: XBRL DOCUMENT v3.24.3 Income Taxes (Details) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Income Tax Disclosure [Abstract] Â Â Â Â Effective income tax rate 0.30% 0.20% 0.30% 0.10% X - DefinitionPercentage of domestic federal statutory tax rate applicable to pretax income (loss). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.1.Q1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncomeTaxDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 74 R63.htm IDEA: XBRL DOCUMENT v3.24.3 Commitment and Contingencies (Details) - Sep. 30, 2024 â,¬ in Millions, $ in Millions USD ($) EUR (â,¬) Other Commitments [Line Items] Â Â Total commitments not yet recognized $ 145.1 Â Prepaid Expenses, Current Â Â Other Commitments [Line Items] Â Â Total commitments not yet recognized 8.0 Â Prepaid Expenses, Noncurrent Â Â Other Commitments [Line Items] Â Â Total commitments not yet recognized 2.1 Â License | SLK Program Â Â Other Commitments [Line Items] Â Â Revenue remaining performance obligation additional variable consideration amount 335.2 â,¬ 299.6 Variable consideration amount $ 8.1 â,¬ 7.5 X - DefinitionRevenue Remaining Performance Obligation Additional Variable Consideration Amount + ReferencesNo definition available. + Details Name: mnlk_RevenueRemainingPerformanceObligationAdditionalVariableConsiderationAmount Namespace Prefix: mnlk_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionRevenue Remaining Performance Obligation Variable Consideration Amount + ReferencesNo definition available. + Details Name: mnlk_RevenueRemainingPerformanceObligationVariableConsiderationAmount Namespace Prefix: mnlk_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionUnrecognized Commitments And Contingencies + ReferencesNo definition available. + Details Name: mnlk_UnrecognizedCommitmentsAndContingencies Namespace Prefix: mnlk_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_OtherCommitmentsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_BalanceSheetLocationAxis=mnlk_PrepaidExpensesCurrentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BalanceSheetLocationAxis=mnlk_PrepaidExpensesNoncurrentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=us-gaap_LicenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=mnlk_SonelokimabProgramSLKProgramMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 75 R64.htm IDEA: XBRL DOCUMENT v3.24.3 Segment Information and Geographic Data - Schedule of Long-Lived Assets (Details) - USD ($) Sep. 30, 2024 Dec. 31, 2023 Revenues from External Customers and Long-Lived Assets [Line Items] Â Â Long-lived assets $ 3,832,575 $ 3,949,345 Switzerland Â Â Revenues from External Customers and Long-Lived Assets [Line Items] Â Â Long-lived assets 680,946 507,392 United Kingdom Â Â Revenues from External Customers and Long-Lived Assets [Line Items] Â Â Long-lived assets 2,012,806 2,704,555 Portugal Â Â Revenues from External Customers and Long-Lived Assets [Line Items] Â Â Long-lived assets $ 1,138,823 $ 737,398 X - DefinitionLong-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 + Details Name: us-gaap_NoncurrentAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: srt_StatementGeographicalAxis=country_CH Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=country_GB Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=country_PT Namespace Prefix: Data Type: na Balance Type: Period Type: XML 76 R65.htm IDEA: XBRL DOCUMENT v3.24.3 Segment Information and Geographic Data - Narrative (Details) 9 Months Ended Sep. 30, 2024 segment Segment Reporting [Abstract] Â Number of operating segments 1 X - DefinitionNumber of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18 + Details Name: us-gaap_NumberOfOperatingSegments Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SegmentReportingAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration EXCEL 77 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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}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

T/9Y]2/34EL:Z&:SB-J+=>+HT)L//6VR\"4VU;&>PH M08+[%KT=,.-C\S5O=YI1,M9S$'7'F!\.<-1@*1BCCPB*ZI2MV$FV7MOF+,F+G MJC_#88#]8=4V&$*.!P26PZ*W121V,W*KUZ&1&]J&
()A2HFT$@RGA/D,8V_9" M2T:,7G1J29/H+DFM(,1.P!Y;9$[EK1]SBU3L9NIM&2UDDZQ%0]=U]&1%*S8Q M,\"(=S"T"\[@*6@ AP7+&K5XQ6Z^=HXO:[BJ>Y1BZ16#:GEH!0W<98R)4(O# M8 C%5
3<$D<+7NPF[T4^MU8 M2V7BIO*7(K__W:0A.H)Q2/T A8/E,Q@2%L(_R_*1%M;D *QW#S:>E3X9=>K8 MY2$+?4VF;N<+RH@EM4FG]SV6SH=F5B[%T3J!/6H,7:OX*.(?C0-)V6%-&
[7B8$#GVJ/6\QF88^["HN+-T0;6%,W3"&0TA=M,HB M36OX)CF 65:6!X8Z2P,@ \5#P09#' CL4]N^IBUUJ9NZVZFV3RO500ISY2/, MV7 _&$Q]3%F{@\0XM,EOLTI=@MX.P_2,
(BVQ#8VQI.DVF[J:3=AX?'WA^##R# M(\TLA?;8NS *=3HXMK*?REL_W!;?U-UCVP%&3]I6G\i/\R6T]3=5N]6M:E/ MYL36.V0X\FE9;;!"S/(&@+9XI6Z\JO;#HQ3B1MWZX+9AI\'_WG)/H
M1X=Y(F_],%N>4S?/#^\YH;U4$L.'!08;X@]I/>F\":U?0_\=E?=)7D$?N811 MZ%T &[;^Y_@1CA!/$. MS7 J5^:4)4C(D"UTGC&,9@4HB7430E=/$$DU;U#,39DWH+F(28JG#/ \21#[
MN".+2*@)W1MD:($#+!ZR*9.17K/,2()33F@*&)X/M9%Q[AL% MH,CX2?"*-\9 67FD]$0%5[.A!I4B'.-0* HD+TOLXSA63%+'[XI4J_=4P.9X MS?Z],"-/"*?1K (C,1#;6>![F9XCO)8W-
'5):X,.8HOI#$O_L&JS'6[&@AS M+FA2@:6"A*3E%3U7!}$ &/86@%D!S$,!5@6P"J.ELL+6& GD#1A= ::R)9L: M%&=+3H*4;DJK;& @F5XG$"<^_O1E/;H+)&,A1<'M]-1[=R^!B=#VZ\2<@N)Q,
M[@-P,D4,IR+"@H0H/@5?P6>@ Q[)63[0A=2AV/2PVO.BW-/ LPZPX!DP MH6FWP/W=\#$.)=PHX-8F7)?NZR,PZR,P"SY[VQ'0))$/E!\CSL&HS7@'*1409^8MG
MX(2L5UO%E^Q.0Y4#]\+_8=D;EAP:@O..RP0SO/]\U7HEP+VBXTG1?J6Q)E MGFL[5KMXMQ;OD._"QP@=(921?['+B'.FA)W.F@6SOK!E[E?IO$G?BW5OD' MD6U8[=56>T>K\MYA5;XW;4-
XOQ;>/VJ5]U\].\:6*C\D<\." ?]_4.'1ZKRB M;NKJV8;I]E_(;\DS'>C877>+^D8[8!RWT"O^_19>Y[5;T!O-C>HL?R"V("D' M,9Y+).QT)04KF[4R$#0K^IU'*F3W5 PCV>!BIA+D^IQ2L0Y4"U6WS-X_4$L#
M!!0 (+ X9UG(V52\A < + D 8 >&PO=V]R:W-H965T&ULO5IK^.V$OTKA&]QL05V8S[ÜR$T,));;!MA-@CAM/RLV$PNKAZ]$ M.]O[Z^](A 9N\Y=QLP^GUQD M&Q-'[;
[/2;%)DC#_ZUK'V>OEB(W>'CQ$+RM3/AA/+M;ABYYK_OZ/H>[<>-E M&24Z+:(L);E^OAQ=L?,9]TN#"O%'I%^+O6M2AO*495_+FYOEY8B6/=*Q7IC2 M10@?
6SW5<5QZ@GI\=^=TU+19&NY?OWG_I0H>@GD*"SW-XC^CI5E=CKP16>KG MP;@!S?@ M.P-N&\@> [S,>V(\<&\M@6U,Z@"GUX6;^"!]?9K>/$\/!/F2I695D%FZU$O$/ABV]P?
LQ\!&0PE_H^2:#SJ?_V(_ 0]&[RF=!:=T-CN1LX.!D,U R"\ODP?P M&.:+%0G3)63"+:3X-21L@PU'[<0 M&&! +AESJ7^(G"%(+EP]J>X@!6U"BK,"#=P].G
$V1,X@NP)'$$.!^XU@7O#@9N5SDF4+K)$?R2I1E>^ MUVG=I9[O^-8,G79Q3'B.8';<",[SJ:"N'787R'W%E>J9\'X3M#&]8&<88_*D M01#K7>C$A-
^PR'V$=X=R+IAGQ8X@&5,^E<(**D"0KH3X@[?+1U)IDC>PA@ MM!5H=)""FR;LM^6.:BR*S%!(3U8>GV(X[OG<'G@4)QE5=KK'@(I2C_;$O2=, MV6#+O**
A,;DT=/&A$\QS(2,+$#QYED*ESG#6.=+JL2T*X-FL(%*80Z5ODX8@72$$HU39I"%0[BF7,J\G-()6 MIK)!\74,:6F6OI,W@83(#P3-CC4$R&&F"2IMUA D4\QU?&F3AC7N<*;V:M0A
M9ZVB9,.2LEQAFS3781S]3R_)2QBEY$>)W<\$MO!)F'_5-7F%7FSR$2ZJ,17 MLEAK52@;EJ%"[,)\PATF$683M9Q]I?64*]2_1P9LH[#%*<%$XA,.=P6* @0 MI*FRE2GN#^:G9[."
7W!^Z92JTO9L#"MQ0D4*MCYK,K72-NF7M<$H31@$A7V M%*)#0Q.0#TFN6^GUP!#NE(J$*FN'3_6O@"UHACO8:"5J6Q8IW89.%7YZFI,*%\> MYXIW5
X"=4#B<5N^!!@2THYD4G3*%P*%BN@K?Z_]0]):FX1I/65+Y0J M'JFN0QGJUGD$R!00*NT7 #B2^KR[N+#&J>,IKX^^KEIW + MN\ 73=)-\@2))WNN9T_QL7QK'"W(!\C,]1,T_"N:'5
!3NN'6H'M',6]',AT7S$00MHW@#B.]2U%6X?11UD7T4H3Y1 MBKK([U#4RFL^+*^OJPG2J,0UL%/1<%26.DA2Y$/YTKMQ@~8=\;;7PST3#ET M__>G>-
&]D8VP&#LK)/L<6].3\WGK>3FPY([V$VD'T:E> ^5J%&72@2&48EZ MZZ6R5>)\6(E#^D] 04[C$&B\0H,?=/!W7[&?U%MP4F^S4WD['(I6WG-U@A\\ M^. >X6\/QRF]!2?U-CN5M\/A:#
<6?'AC<;**WU7\?>6LB^PK9ZA/M)QUD=\I M9^V&@PJO.$Y8\;N;@CZ*NL@^BE"?+$5=Y'>,H4:=C\3KZ4@ + MF]34&[8W3YOC-5?5H1+K^34{GS+D><#.9_7AF=9]?9;G2YB_1&E!8OT,3=$S
M%Y907A^/J6],MJ[.?SQEQF1)=;G2(8Q!"8#OG{,O-V4#32'E'; !U!+ P04 M " "P.&=9P3BZ3>L6 #^]@ & 'AL+W=O&_PI&[;3)3!AAWX'4]HQ# L3+$]N-DW8ZG7Z@)1JO;E9[.R?F[?GV]M-
L[C<'W1S?<[C M6)_?+):KLV=/JO_W:O/LR?IN=[U<-:\VT?;NYF:Q^?/GYGK]\>D9._OT'[\N MW[[;M?]Q_NS)[>)M\[K9_7[[:F/_.G^@7"YOFM5VN5Y%F^;JZ=ES]E.=\:
MO<5_+)N/VT>_1VU7WJS7[L_RLNG9W';HN:ZN=BUB{7]YT,S;:ZO6Y)MQ]\/ MT+,'G^V!CW__1, WG;>=>;/8-M/U]7\N+W?OGIXE9]%E<[6XN][]HOO?E>[<XN]][]HOO?E>[<&.!]L6W"Q7]_\N_CB3A .@=P,W" .AR@W .2@0/TX0!!Z@'F<(YM4G)X8##$/6#H M>T@/!Z3. 2(=^N+B3]]<{/H8.K'LX6U MO^SC=':^\C:SEJDVIU[N-_71IC]L]F[Y\,O,YFD?
WM] ';Z^AE'DV+YR_FV>NH?!%E__Y[^=M_19/H]]>SZ+M__O{)^DX MZFQ77RV6EY/2LA:W2_H;*X^P+B[N;NZN%[OF,IHU5\N+Y8Z 5*=#7N[>-9NV MB_;F\:Z]JG]HHG)UL;YI"&X=YKY8VP-
7N\WZVG[RUF)VS:,9[K9]TKG-IH>4 MX@\IQ?=H&?Y"MNT7\D/TIGF[7*U:'V\6UXO511-]M[0?MG&I^_T:[.RIN?@Q M$NR'B,><4^D4]-;>I$Z.U3!^-FV--F\)L"B!AF=\%F21IPE/=[T+N
M&]KP=OHY]XUL: LGK DCGK*4VQ]]R]*WG"2Q5C%GO&]9$:U3<2J=3M2$ZS31 MB8P[7B^,Y$,8R?V18B",["W!3BZV]D)K8V;_V_?1\G"#=&[=T7__:F\ D1V< M?
UQL+O^'"BN)O/HB83,D+$/"+_>SY;F53+[)CN"A[_>K5#_;GR_;G?2+:I&U6[>PZ>F4O M^=%B=6DG[!]LJC;1!SLN:V\&ZZOH5_OK9GG1#@;S]3UO[VY+9:[R;NU<&<,2
MX]P/@MT9FY1(6.;WP+9>I:ESPF)BQ5-'W*/V0 M)#]8)+\V5S9\VY#>[A8WM]'EG\Q"])AB]+YI==+W>DL%]/\'3QCFS MPU/WNAOT,39BD;",Z$,:QS)1[E@
MHC<)1N_],M)%;QEIN5]&BKYKHYIQ:=#SV)A&PC*J UQSY40T MTN<<'2N0L!()JTX[M35AIF)IZ&!.'X(Y;+8N&I'R7MUR@XH=IO%:GMEP[L=
M6>Q'QAM&;9O>Q:5;11;LF;/]^M/Q(!7K0W=CY+A(V0\(R)"Q/_7NLT3IVAFAS MWVQ"V17(MI5(6(6$U28+VU8W.E>\)F8W/EE_5Z];?%^:3(YZY# M$C83UZ@@'9I8ILY &]K-
BO#*C#M0K0FKB7,V^D'X2'QE(Z2B9G49T(E^66P> M%L %&7)!7V,OW5#:#$K+H+3\0.O-\%*F)/MG4*>ULK#8^DDSLKGS6"TZGBR^*=2QNS\(G4OTU#)%$K+B%Y(EJ:IM7)?
[GV32=)JI6*M9,R%6$J9,S437H?$ M?,)T2,TG3$DYG_(>U/-9IR@RJ0T5?8;4AZ90V@Q*RZ"T'$J;0VD%E%9":164 M5J-H_53L=$L6%BY#T@_SM::)T"QEAKO:3]C+Z*R!ZI506@ZES:&T DHKH;0*
M2JM1M'[6=!HI"PNFGR4Y,5\ SWG"DWF:!*!2606DYE#:'T@HHK832*BBM M1M'ZR=3)MRRLWXY9-'W=W-KY1AQ8!T(J@5,H;0:E95!:SGPU4PFEF9WFN',7 MWS))$ND]0U- &UA*:1645J-
H_03J)&,6UHP'UDR/YXHO8,HDU9*S1+NW)*CR M"Z5E5#>X3(6(W>6E_&'JG2AW()RW2I+4C6[?JQ*,&Y8JX4[.*:$XMM/X6+CK M!Q5ARQ.CF+N$4!.&6IHX??=3QE?F1R0L\+-&)T. M4%V7Z,6
G'6P/")G$5:$G$5X'9*S"-,A.8LP)>4LRGM0SN*=-LKY-UPVY=@Z M5&PA*K82%5N*BJ3-H;0"2BNAM I*JU&T?BIVRC(/*\M_F:(H3@BF,C5:,_<^ M
56;H;2,Z@271KHW@!SJ=@ZE%:=VHH2ZK:"TFN@$5S&7 ^51O%.1>5A%#ND, MG! O&1=*'* &).QE=!1#16*R&S$3*3>I&\=(QW,HK8#2RM-/2@5U7%..>5MN
M\FC$UH_E3GK[FX8K8SUX]W[AX40*IOP+-52 AM(RJA-")FGL7:BAVC*45D!I M)916G7J":\HPX5H-7:@[09B'!6%X 4K8W^AY!E1HAM(R*"WG1)FP2HQAWN(/ M(=.3E@6T@2645D%I-
8K63Z).'^9A??@K%Z-P7TEVBU'"#1R=)U -F6B^,HHH M(C\8]C;04:D;_K[1Q+,J2))QJE+ECLZA0BWA5MJQ#W>OYD1MK'M*^J'8J:L\ MK*Z6V^W=?MG1!N) B/T0K>SHW'Z^O]@O[O?
&0%AO=\>O[5"U%4J;06D9E)9S M7T--C;3W>>D&-[3D%DHKH;0*2J M1M'[2=8HL#RNR7YAT+]:{)?W>,3CE"[52, M>RI.W2uSPHT&E9U1ZH2YM3>$96('2,P=
M(A70!I906@6EU2A:/X$Z#5FI*Y9.PRT8G0A0^9CJ M1I*:U,2QLVB6"U\9ME'N3A4(J\1] J<@O"J;! 8$NBN6)6$Z:B>.[>QFC!+!>/6/3T/$)UX++ZE>"R@XC&4-H/2,B@MA]+F4%H!I9506@6E
MU2A:/Q4?;8O\#R(>"TH\YDHK5Y,(=VAT@F(W6:9T5Y$P*=U[!%0\AM**4SM1 M0MU64%I-=2(Q*AY8PQ*=>"P^7SP6E,#(-$N%^QSN-.QE=!1#Q6.J&ZGDVMLQ MJ)X?ZG4-I!916GGQ.*JC?
FO++6?M ^= HK)..Q5>0CH6O]=D!II;2VPD?*AU# M:1G1"9X(95+W45"HVSF45D!I)916G7J"-\)0RUBK@>LG4'<;B_]7V5@;]4T7BS;B'GY_/@]+58+8(9?;?8#R*M[#
MC1H==E#EE^J%CF,=:^ZJQ@>ZVS*45@QU@QGW'<02ZK@8'#,FW,V4'2ME!(L9 M&]@=7'1BK#BVI3*POCSL:_20!*K00FD9E)8+JER6K"\G+.GZ'6S V$"TC.K&0'VY]+=&)NK+"2N_OISP
M.E1?3I@.UI<3MG1].6$8KB^7G:PIQ^R2/&I3CK.H!LE2U^"T['46KKG?498 M=D)BE)\0VU?0G50VAQ**Z"T$DJKH+0:1>NGXJ-WU8:ERK^,MB]]$8MI8[B[8<4T
MW*'1^0I517:=A+Z.C&"I]TMW01FCO!810QW,HK8#2RM-/2@5\TL5^K^.. M16RGM0.EL[+3/V58__PL<5_ZAS70KE,?$W#OD<'.%2]I/J@3.HJN@+U.H?2 M"BBMA-*J$\]O3=@I-?3HL.QD27FR+
(G1),)IY503I50]=([(,H8HHX9=X;6A-F$V\D]*/QDX3 ME6%-].>[/\L+MZWH7BW:]>8=D[Y6-<_+-$?@O'-G[T/]{&Y:]>9[FQ,7JVO MK][J,J*NMG+2]?7]%?=A_X'IIZ'ZB,NU'<3WXCX\J%=$
M,233B5>%$6[^Z+B'5IQ*:3F4-C Q_!90KR645D%I-8K63[1.RU5A+==-M*-C M^B](O> MQU<_W6%3N">C$;F4*\%E%9":1645J-H M_6SJU&
<55I^_XKY3!\^]1QNYDC%SZ\NFX3:.SB:HH*Q\&9/N14[TURW]F$/; M5@RUS4X>W?L)5"B&TFH4K9\!G9RLPG+RF(?]'[^%19(QCQ0>IU#:#$K+H+1<
M$16F/#%2"_?)/<(R3177[K/^T/:54%H%I=4H6C]_@U;A37L@6?]CZ<*)3UR MD6CA%GA,PRT8G0=0)9QJAN1*"2/<1XX.IMH)%!=\O>]1?$?60 M X_ZA]LQ^GH*U76);@P]ZJ]\S99XU)^P\A_U)
[P./>I/F X^ZD_8TH_Z$X;A M1_U5)]RJ>YGKVSSJKZ#5K%#:#$K+H+0<2IM#:0645D)I%916HVB]5-2=;*S# MLG'HR65-2(]&)C+1[F1^&O8R-FN@M Q*RZ&T.9160&DEE%9!:36*UL^:3I[6
M87GZLQZ2UL3NN:E)$^[F$E1;AM(R*"V'TN906@&EE5!:!:75*%H_ESH%6A]1 MH#]S9Q-R!2?L:^Q84!/5ML).76/N[/PR(RP3R;AV[I,9M'WYR>V;G]B^ MJ^ M$DJKH+0:1>M'?2<9Z[!D?,)V)'2
^]JGG8NJFE&EW"[%IN 6C[R-009CJ1I*T MVX*XH9L?3'4_R+T]ZT2Z0:W[)1.XH444KJ[D1"F$Y:D:9)(}^G!BK#EB;"W M=G?/2L+0B%@+-
E"TI3O)5(:JPYIK<*7S>,+X$N"0$+:T<$89!Y4AW0J36WW"A4T-W$H;29E!:!J7E M4-H<2BN@M!)*JZ"T&D7KIV(GXNJPB/N7V=-$$_6O"4^X=/>3#7=H=()"2X+)
M3C#!8[>T!NIV#J45IW:BA+JMH+2:ZH2*Q4]F>Z47QU6?H/" +4GLC0],6Z- MW33L97000W5=NAN\'7MP-XRAFR)#:0645IY^4BJHXYIR+%-F)!\(Y4YNUN$Z MX<];K2?
V^C5*,V\X#]6+H;2,ZH.=D3!O+]5@J&T DHKH;3JQ/-;$W:,)4.O ME#*=>&N^SKMIR2ELV-?8V064-H/2,B@M-\0>P_2:#V%)KOE VU="-1645J-H M_?SI9%SSQ:^FI5.%>+NJB./V'1?.=SD-
MV!'T'D#%7*H;/-8V<-W0S8W_TEEB MM8>P\E=["*]M-7N:>-NDE(3IA"FITH2Y:D=%V JN=.H.YFO",!7:&#WPVA'3 M*9GF6[Z=UD"E3*AM!J5E4%H.I3NMH5XG
MVK[^T7V"+MRAT0D*56O)3G"CC#N1@+J=0VG%J9THH6XK**VF.C&\VF,Z =F$ M!>1?FRL;R?O-$'>+F]OH\LZFPU4S$-.$=LF,]TQHV.7HB(;*OD07DC1U7^F5 M0YW.H;3BM"Z44*
<5E%8376!),K#5I^FD7!.6< M2,F8*[04 D82LL,42,J!6?N.Z9RJ-LYE%9 :2645IUZ@FO*,$G5T'2Y4V3- M$46VG1='Z]MV7+Z-FC^:S<6R':\?V0_'$(*7$=X&'F'GHV,;JIY":?EI)V0. M=5I :2645D%I-
8K6SY).AS5A'?:EEQ^/IK#DM#6X X[Q2T]3QMT7YTW#C1J= M/5#9UOA"(=&%G.@I=T^U,"JL,.M,M]A WJM(+2:A2M'^N=4&N.O>06O$=_V- H M-52HU NE95!:,@C!T@ZDW1R;$W83RK" -
J^$TBHHK4;1>BF4=))P^A.D.O,(-')LE4%I&-\)J81P-TY+_!VPF?M^"L)FXAH5I$>A8^-D2 GM M:$6X3;ER[G\U835QST<_#CMI-1GS>MPOK_H+^QI[&4\(9*NZB,LR:H^:/OR
MD]LW/[%]!;1])91606DUBM:/^DX!3DY[,^[8JK[$WZ)WJ*HOW(+1EU>HD$MU M8Z"JCS EJOH(*Z^JCR(-5/41IH-5?80M7=5'&-)5?>?;=TVSFRUVBV=/;A=O MFU\6F[=+.[.[;[LD?
&/[2KB9OGVW<,?N_7MTS,;T&_6N]WZ9O_KNV9A)W^M M@?W\:FTG>H<_SBW_XWKS?N_CV?\!4$L#!!0 (+ X9UD])KN;E@< /X= M 8 >&PO=V]R:W-H965T&ULM5EM;]LX$OXKA.]PV 7J
M6B3UFDL,)$ZZ6Z!-@G7W]C,MT38WDJA2E-/\^QM*CF5+E)+B?%\2V1Z.YN&\ M/#/DY;-43^667DVV6A<7LUD9;WG&RH^RX#G\LI8J8QH^JLVL+!1G M2;TH2V?$?WB#['9 M:O/%;'Y9L U?
7DW""4KXFE6I_D,^_\[W@#RC+Y9I6?]%SWM99X+BJM0RVR\& M"S*1-__9C_U&'"T /?8%9+^ =!>X POH?@&M@3:6U;!NF6;S2R6?D3+2H,T\
MU'M3KP8T(C=N7&H%OPI8I^>+A_O;N_OEW2V"I^7#E\^WU]_@P_(;_/MZ=_]M MB1X^H<7U\G?TZ WQW3/K^'HI/*T@JR6>G7*TUEVRURGN.XT8#)X<'D\,V<@ @2,A$Q*O;LM^(Y7PN-?MD
S?X*4$]-@)"1WG+T MO6*I6 M ^"I=I,SJA[!G\93X0=C!99'RG.#(72>PH@.L:!36 YBJ4"[S:9TL M0O/,FO91{^T8AY'C^1TK^W*13WW7;B1V6FYSQBOREN4;7G;RN"PYE "6)R@5
M;"72X9S>JS]34I]+V^EF'!$]?H?/(+6YV+%5:B>CO8Z3>,'4DRH$422B<.!_@/M_R,QPGZFV()KP-?UK%0 ML)?A0'#[1H0!B7#/VKX@Q6X4>$-QT/(U'J6Y7AP<9:O58J^_P6 Q)KAKL440
MXR"D9,#BECGQ.'5>Q[&J>!L'1WL=5TI!Z_$F" MO1I[KN%T,?;DIQ9'G17@ M1$NR>)QE[U];H+J5'>N#K #Z1#KU0PPU).Q%CD64.BZEH3L$HJ5='/Y,+R[R M'2`
8_THF_]TP3^3MM,]:#D:CY/T8Z7BK4D347J$&BMCSI.R<2C, M[WNC_R=T^W>>-"BNYV+7\;I\9Q&E%"+;#\,!:"TSDW%F/G94H4RFZ9>Z=/#O ME2C,Q&*UW4+ U*61UV4\B^
XY&6H\DX1]N+Q'O3C-BH.B2^ZT7=0F<3Q2YQ M/%P/[584+6^3GYK8UR)G,!*^;?Y91_9S:3O=@[8I(.--P>>RK !U'7R+%-HK M=(T>5);H5Y0/7&5'^JQ&'[7BL'(U9R_F:G%OCO]AL
C0&$XZJ547]+U, D] M)QIR;=L\D/'F8:E95]"D@DPRQK\"):9"@/Z]/SZL'?Y5ROP+>^)F\C\\/7 JF M165K&MP Z*H[RU@DA]*M;2S(>&-Q6OQD82*4T&9P%0N3>U6>\&9^O(.2 9@_
M@T=SF/\A[&/G:<[EF&1?*MO&J,"C+>5-RM MUY!!QG69W/'F-$V8$YBXGK41-(F&D_,&{):GB16+K:N(O-#WNE!L+87K..[M,$3;?H*.]Q.U0QJ;Q=Y:0[GU@^'=`4L-..N);;\5@%'.P]"\=HN!190$H>\[
M.!R8-FC;-M#QMF$Q9/,'M.(;D>%5L/Q M_*%C6=KV$G2\EQC!P/3O'[&XEE M511IG0V=-1-1QDJL*U63:IOU(F^NW: V68^;Z'FO OX??05M^PKZQFW Z^&@ M?/LX!\F59K
^.2DEYDBT62)7J=C4^V;/Q_Z=@>>YH=>+X;Y[C$O*ZO[CK?W^"+17,5V:II;D:_,@7)60*T:;AT/@80 MD:JY;&P^:%G4]W4KJ;7,ZL^ZYYX['RH]8,1#2^]9C)T24;/A\?T&]B[!3+
M2GB\MOHW)4,U33XF('$M6AT>[>X3]O&\8[S":A_8=>?S1(H6A]LW1L3@UJ9 M[BN>>AW^BT'>&^21=^E;T2! MTZ1A7VZ+R>SUJ]'[[.I,>.-C>.-SZ/\GD6>!3M-\ 9V^KK&.Y(%;TW4(5N_>
M6G,G-K18UZVQ9.!$@VU0A0?E04!3E5!TOI -Q)6R@8L*F.U+?=0]-A";CD! MIH0.0*&'8&E9$BT/7I5&K0G%!&A-3?W+(!N#WZCN@3 :14= ME61>L M4"R56JG ,GP1QZLW),[$:
2/OIM2#L3J$X'L3U%/B100P6.H)D4:87(JGS7 MG9P*[0>LIW34%@^R0&UE%#7FD2PDHHT'[&@2@Q"]YT$3EW=]%D_KM&5\=6ABK*M"5UK/JX>'[9YU\^_'^]>Q7OA M2F4\)7)-IMGPP[L$7/?
2=)-@F]C=5S;06Q&'%3W.Z/@ [:\MA=M/V,'QN9_] M#5!+ P04 " "P.&=9RPF^%7 > "U70 & 'AL+W=O^RY^=]NTG]S2VB[[O*IJ]_W!
MLNO6WSY\Z/*E71DW;=:VQB_SIEV9#G^VBX=NW5I3(*)5]?#DZ.C1PY4IZX,? MON/OKMH?OFOZKBIK>]5FKE^M3+MY;JOF]ON#XP/_Q8=RL>SHBX<_?+1^.I(7I9[_[*\8=N,R,LY=-]<^R
MZ);?'SPYR H[-WW5?6ANWUC%YYSVRYO\'?^S6WGV'_GO>N:E2X&!*NREG_-_M9Z5+LN#)T9X%)[K@A.&6@QC*%Z8S/WS7-K=92T]C-_K J/J %?6Q)3KKL6O
M)=9U/SPWKG19,\^N6NMLW1FA55UDU^6B+N=E;NHNN\CSIJ^[LEYD5TU5YJ5U MWSWL<#QM\C#7HY[+42=[CGJ:O6_J;NFREW5AB^'ZAP [P'[B87]^&UW8] MS4Z/)MG)T_8;P3+
[[XN9ZUK(SO^,(2S[G8WO1_KTK5N; MW'Y_L';JMC?VX(=O_G;\Z.C9'=>!6C/[MK]K^7<_]#V1V?C*7Y86ZI@WJ[6I M-_1\7YN^*#M;9'D#X:B=?+8IC#T];RL39V7ILH<]K"P"IW+RCJO^L)FW;)Q
ME@[IL.^E[,K0E7C(]3-7%J5I 7AV>CH] M>GHZ/3]]E-W_YF]/3DZ.G@4,+E[S-\?/'MR-UKNNF!)BZ[:\ >FRJEPII850 MH**BB2_+FF'X6/,C/X(W1;..,#'?__3NQY'])_3PVCK7 .%WAI?
4U'.\V8:W>1502/00 MF]:%:0LH8H-_PI:O+JZ?Q]UJA@4$(1]?=!LHRV4-X]<+73-0@!QA=GQT^!^\ MZ$-?6?KKZ)C _F 7?2?\NC[\3P).&%:N$O*";@ :H$T9S+; QVHSH<,V6=$0 MO8-
:$\M5<P(K(KD+5K>P868&%!=]*?R%*5M9,G7XG=?2!%+/]+!!;4GF#2(2X0"C MYN!%X/4H:RZ;@DVHF!GET,7UY8!!HRL_K@L6FKCH8UBDE"-3[.WVRS*$0+1MG]KBEXK1:6W>MRUA
Q7O6SM)E&MEP'PZ4#@O(K3&_YO"J0#9 M8@IY& 82?8\QF5% M%J[@KMP$W]+JD?X0D &R!^Q=#KPVUL#2@TZ0+#:1"K08I#]@@U)I_[/XX$%\ M.!VS68T(@S,K2P$MA-
J(L7/+IJ^@282H\3;AU[Z6^)F-@G.WGHF6^42A&V5Z3*)!.9P+;ENP CIKY=O7OEO M!Z:@LG!B&4DW#,N&)"=Q\Y/LX/7SJP-9X?8OV>>#]6S\<_KH[%D*U<'+OFT. MO@2*=[+3[*-
$3"]=5Z[8AA#V(B)!L _<$73N>(MH[M<9N$(D!FA7%)K_VQ8+W MF&0V'$NP&X>4<*U.9FDZ1 !S)&VJ-D21R\GRRM2C,KJ[*C6-/("M*F M7;NT)97[MK:?UZ2:&D21)K+K]*NA;9)LWZB!2$N!
[@JIKOA46/GJ&S)%D#?88 M-O!V:=E>B,$[7+<-62$R-U 3LJ XIK WR*#7!() ";V#X0Q"_O;JPS=FM7[V M(GB):LUK#L.JL6.S7M>TSO{;!20%)?>B48IMOO8SDY1\P(VI>B:R6T(##RDM
MEL@.Q&/QB=MO+8?A;VY@K9EK0=8+$ENR39WY+.Q-=&UW$V$8BT*>M[-7BQK MF]@J#<8I"%"!SI'8E&2J.W9UJQ+& &Y9[?G%J'C.'D(3&=H(M^QW0V<1-/#
M/B#L;%JG4=2.\UN9C;=GDVS6=\'3^BX:R:IJ 3#BIUL;IP>K8Q;PXA $6E M(0= N5F5.;N44MA&3S?!0-" MB7\17T$6'.I,K$BH,VMZT;[BM+9SQT]P2Z'-PBQ#>(L#?@)R[N> MPU>\
M8[D&"6OR01 MG#D!92-0";S/S&%(R,[P.RZ$/]M8S<-3$] M.7'KD-(HGT?R_A=./ I;Z!$[%UQM-7P9B#!V]0@C_$%5NUR%*=7Y5@U+*E4JOBAE#(;]K 1@GR;AD(1D@1$(RD^TX"S
ME<(,Y6AD>!&C_AZ3)5*R/-^1?482OA898AOK5U2/X49E1"3?T,<)#$5V0E0 MB*H-Y/$$0!PRG6L\'Z#()6TLQ@-F;4EY)3.>* !!86F8(G&[[$'G9%IQXDL L+$N8YLE!,&I%,8MX.
M.P[WL,.,3=U50ULR3#[+WA=V>,EMPJ/7Y(GH\]'39U]PJR%Q}B5(S=?*=B2" M,D,'97(X3C81E0$X5B(D[O+%L!+=T8R+!RTA_^CP_*1;DVUOGLG5+6W-,)>(I8/HV %A0 ML3;.!X-
+Y,^DM^[#+]*0KRP\8R=MH"< M]/KY5?;D7,X*2%XCTRLIH;E,TN_LFIKW]DY$QFI,:H2TON3)\0J>OL%>V6L# MB,$\^@PLO_G;R=GI,^S?N#M/BE6G099MJ]+><*)-EH5\-G*_AO/49E!Z2?E?
M]-875]+B#I*Z!5*@4$Y@8)IV,Y0!P")YR=U23NI# 0,<22%I-8GK,"^UQ#Y* M:OI62KT1;\Z/P1[MJ$X!L%Z.>?LF#)O/I="/W$<>=M07L:%!2N9F^Z0XC"1 MO!;[47I !$ M9[+D_>]@)Q=^' M9H5.
<$-O[9O9 MG,W>2*^)"R+<4^,@&KZ8@2'LQ E"7E;6..YM**PB;7)6"C8P?$4!RC\X0'DO MJW:S+J#!9IZ.CBVIQ)U?7%]F<'^3/;ME>HS$0>S,Y^S)?9*" ,R*E;Z-C8#< MEC>JDI8*
[[44=,A4K$W)/W!9B>K.)E1X-DQ(BO=A$\&MI/(4*B_"<>R"=" O M@6(7RA*K!&IR>FPYM)HCY8R*RJ%2Q*H14C+EDR@OV<#%FNL[6I0=,V=JKSB] M5,)_ZQLRA4P$"<>$D?F6%RO]))'"
[YYM;7_RE=L[:]U*>[R=,IN(#P7C*^K@;TB]+^,\V7VZVPV*5)@JB0P=/^\ : MFXLI.T7KFL2FPMKD;-8HD[5<[(1;C]VY5#VEV&>EF^9-K%8 <9Z3Y0,?&$J' M.5"8)P\'\ 2=T
T_D4TF=W')S[$\#+O(4/X\AWND'Z65.^BYA(V3SJA8?NH= M'YH*R=Y6XK'N6W*^3H_GB#8I'M+74MP/.2Q<.AA;&G%6+Y*_:(-8DXA)";A(M$W'G =**J)IIR:=OLI+J^R\KV"\;@1_,3$?
TO;+BZ3]/K\Q>^ M# 'ASIX-JQ5TO $I9=5L<,[:;,CY3#BV17()#";B)NB,01,H? MR]]1YZ+F' MG@L<7=>6".59X7A"80\H; 5BP4^RA;6TI T#J"+_<8WD@9RHV<0N2.B:Q*\' M'7LX2ZHQ
"RBI,V7=5,UB\W.,7=WMUPL':JFAN!-XD6XXIE@R@8N\3Q4=... M=T3DHKAA;QD@)F 7#0T4D 7U(;042X//\Y9&ZOJTI..\==1=E 6=]);A:\< M=AC]MVD ._R626"91 8&7#;5>OJ\:* ;
<#Q>%]"WMM!9I:QE6X\32=[#V M8N.E3?L+,E!%N,T:_%ER<5OZ33#W]'G8N9;4A8&@G'316M^ !9!Q'BHGSE3L M R9:<1-\H]1MD?++DC.0XI0(LHv+?4/B:C0$3;UHU.K)":Q9T^R?7%\A;Y,T
M(0L8,A/[];RE'32YMHK82",VOUL671##.;_2=7U!9"5F4I*Z\1(A-B>6S-Q MILGG[S?2CT:XVS#W@^2FMD*+P,#B>JR=O=79E'Y9P6*>=H93#&>F,MQ#&_I7 MH>_0O]*85]HY
R@464HC+I8F]C;@QMUE4BV41B88\,0+!3LZ3"2]OVH3NG]= M/%?;>IX^W,Q^SCYBD$UO2Q""%V[0\:R%UU,E*H8JHB\42^/'TRU+:N"GIE; MGNIB\E--L2H7)5DX[RFH:,'IIB YQF(5
OA+FFZ)E%BSDY\+$C YM)]SBA5 M$C*K?&M_BB=@F[6DM +9L "XU4)<4&T@<<#/*P,,KW-DN"3;LA$%L?3 JH$- MDU._--S=8R7IS (A3Y+M#4UH2VN2X&
<:)/^OW2N8:=.&^P#^5^AW,*-4)YER)(T4B :6A_;$HN2>PPBM:! M6E(9))Y%9FD6%!+67<3N M#'2>E #3/9:\KNV$ M'4LJH+,>&C(7&#;L^$M-E/DX-L+KC3"YQ%6%N
MI6[JPS]X('9,?.OP8&HL(>#HHWVJW>@.8C-H6F>P@9?S)-%.1N6ERO...RA./8,VVUM+[0+4GR88F1TIXH'K!'0XH]P*FY MX@UQZKV31Y/'9X_XR'O')~>3\R'?'
W*R=Y+0CVK2G,!])13GYX\QVA.L#VW."XB \9EF9UM)#D!6;':DP[S*+WS8R-C);&X;?!/!L4 M2FLQK4 !*IY"I%YV]/94E[GU-Q&"%>@8V^2'\\@$#CF$U7*N8-- M ;&$?Q57#0U7QI,1_ECRWQW&I
00RR2H3D8"OI;\P?^I0:LE+:%58M-2_T$7 M+SBZP\]:3F26JW+3Y/B@DT-N*/;G4W9M1[JS,'XJF3/@[2J?(:I-Y0[=E['B M%KX:-P(L8**,B3,9B<49UC-DVD!,E],\"G1):MXT8O*.E'=-]\&H2PYI^)D:
MUH0IARYRPR[GBEEU]Z-<)].8=U IZVZ;0^[!>ZV3'$?H&P<;6NOK@DI-*@+L M@XKH%0K[6O^, 9P1F-T(B-(T*T,:'!9LZ^@^*#3LO>6KN;8X--IHU2MVU+7>
MLY(J&E0J]68G\DVDI2@KKC=^+=W#W,L^E"([_@2TW(LNYP(5[,#+'NXPBRE_J8FK'L@F8P34P3B3^[I0SJ^XT+E MP'T"]Z=A!KMR&PB^GS.^\4)):K!"*>W+N9I_-4!T'0><._1;4P4E3)P,_:L6
MI.B8])'AS+7.2&N3:!#)DK'E@GX8JX2DBZ,8-D'B:.4P%>).1VCW0LAG8;JD M]6X]0D;"/R];UR5MA#C/.2.*Z&!(_LUX15&Y$=R"#^C5$ZU(I' M5V348Y)2EL-@KKQW$O3&;# U E+&X.D ,4UJ_D 3,?
#*"TU,B*TL9WN M%Y

(;UC_M_4"Z:1R*=X)X7L?O!W! MEH+RUQ=7G=POIZI4Z,&ZA)01H$ER'6BG'#OU _Q7E8G:OW4/4;*]J,K.=G49 ME)-9)@*%6$9Q#0Q?I1CY"M&^3E :'7;T A-VK_)J$>%S8IY(Y.*=7]6E$=%6 M@=X.:I+[2=N7R[=NV"&*ABERD<",&0<)6@J#2/MWNE #0P[D/C'I@TI\- 5)M MX;,RCMPH24BXKU2J779_O22! R?7F>K+-A^C$S%?=9=IFKVS?'$[=1F0V-
PCCO!,1=T)6EE%&\@8FLY949:_U@%I*0/Q]8K8()QHW.-S\4(3^N%! M]4U3W7"A)F29ME"Y\/9HO=PX;9D67#+..4U-WPVP?:VPI4H16[I]J1G"'"Y-K M0_JNPRFT'@& ZT"#?JA6+1F?L1UU/IT-
;.6:,&?";:LX0%/.[T9(YAGXN]Z _MV\M(X0! A0R\:/2VG\;L&RW+6V&E^`]J+QG3^G"=CPPBF;)#FK.Q'>.@RX[>Z M09^U&@K<[ID[O4B*:77>M)9)>/(C _CB_^B0]F-6O+8@$S^+)>R!V4L?
>$8!]L]*$W-#K? MPVM<<8&BL-D%=,K>--F31P#M[/C\Z/#T%.$07=%H)N&FQGX8U7MLDVE+:;_< MYQ55X\E_3>=X8C"9.+A3/GQ6RMMP<,SSI=.,WRIYV,P/Z8DT+N3S]C8FU)3+
M4SZ_#*7X8:-^U&PC;-0;7K)'"$A&,)Z,7Z/S5W&E6QK&*;U-ZI8CD$T1J.;& M4X,7EBMZ<56\XZ,<4B7W+U((E\%X["ZE=>\TR(4!D& 8\C!KVK:YY=$XS?)W M(!Z]\R_[#
(9;NI%JLDR%R2$B/#GUX3M*<%B@1'HXA ^E3,#O&PW)>"K=*M$G M@@^U]4W9-K6^^4O=A'}G N>4E"99\9_')JOO2I"XKXF&AVBI'#"IU3?+N!+)6 M-5]X" V_Y T6&IJ,9?
\3@49X[2?)YL'A!%OT[Z!@EHJLD*"WSM$P8/K61] 8 MGW-U%;Y<A'G[.%+(6=/) ML^SMBN_A]$-J],50'!KY12\@F97<\"&+1<)O;V7ZG69J0C*G,T+DP_RM^T*6 M#M_^H]/[R=@#]=W#
[;#P.TPQ"Z4F5!SR-$2]FU+?:!?ND_LE^)&3I%:[*#IF M3SEV1,)7W*I-S'#"*?Q2O,R_*8WE0-]?Y/%E5QR0CON&YB_?+?@Y6/47_O[! M>[I_\?0I>ST/GR\ CHX(7AB;8K2KBM R(&[:OPVL?U-
*0W5=^Y*T$S78M': MA4JK7%#4_C#V_ZVGD$=?ND*)8:0L#E1 =9Z0Q8KI%)O)]V3USSX>5E_C[!OO_)EF3Y6*E+E M@]8';+^D]8B9WJ9C0(OL4?C!Q$E5=ZP]RD45$F^IDR=L;*POPP>97VRK8+?
F$XCZW7G;Q5.WP; MWDE^(:_BCH_+"\W?FW9!>65EYUAZ-'U\?B#^'U?_1-6M^,?>LZ;IFQ1^7",]L M2P_@=WK+J?^##@AO:O_A?P%02P,$% @ L#AG6>2<&=V=!0 - T !@ M !X;"]W;W)K\
M3%NIS&AQEMYJY)&W7YZ.#7T?;%M:J?^FB[-.UG1# MX4OWR6$UW:&4JB7CE37"474^NC@XO3SB_6G#;XK6?O LF,G2VEM>O' /1S,.
MB#05@1$D_JWHBK1F((3QM<<<[5RRX?!YB_Y3X@XN2^GIRNK?51F:\]')2)14 MR:C#M5W_0CV?UXQ76.W37['.>P]?CT01?,!M;XP(6F7R?WG7YV%@<#)[PF#> M&\Q3W-E1BO('&>3BS-
FU<+P;:/R0J"9K!*<,%^4F.'Q5L N+:^5OO9"F%! 4 MUZA*%39GTP!@_CPM>I#+##)_N2M^&A-:+SXT914[MM/$= NJODVJLOYLX W MU$W$X6PLYK/YT3-XASN6APGO\%]9?
C$%N0"Q!D5>_'&Q],%&!&7\"1CIC'CV. MR=URZCM9T?(D[>#)K6BT>/7BX,WLW3,1'^TB/GH. ;_6Y5F0QT-\!%G\;)6I MQ97EY)CQX -ONY*=*E*+:_(VN@)I^VBM^2!022B/;E[^A0O3P0J7D
O;MF@W MK/'42<-Y5E@W));*=HU$+Q44@RJ J4P)C;O-.'GB/5?):*.6I!6M8!L:&431 M2%-G(/YHJ[2WLAI#A4.7&$CL.NI2-')%0J)) CD%'[)N<77$L8{GA=XMI*XN"NH#-!/#,WY%JEQ&Q8NH%'L-C
;LR(NH" MWU4)2A[OR*5IG$W!1KGR^TXZQ%.@#UG/'#=)5S3@4*,&?^? > _\F5MB#<)T7 ML0/1=:.P=9A^Q^GWR7_H!VB?]/O$H8DP3?$U@DDB,JN4V@866JH7C M&DGR8;_$F*8EU^,)H
YT3=CE8)C1,7"521*"#PM4)YB3=?Z!E!#IH%PRY 3E M?*?24=MINR'(RQ#D[7$X\4X?N\ZZ(!3*7Z-]0S,1GP?A0_PEX7 LN5A)5?=U MV,]Q#Z8W6RJ>BWM?(XZEA-
BU[5+ETU&E0M\Y[!]VM9.MGXCW1K +52 3T,?# MFB4TNNN(W:0NQ*PSD5*'$F+@LU#X5FHM3&R7R!PJ^U3 0_RU"DV*QA'F@TLJ MS4QX5SY?
Q8,&KQV5*NWDP%BX7$,4OG2Q9JR\@DN@H$WOJ7[>6_?=O:1M0R,Z MF5H:ULL-=BEV38CY^>$MC^OUCWRK^OJIH,#P<"G15QLGVL M$ EC)=$5#0\SYE)AEO9V:X429 EMIY*/!2NPBGI?
$%Q2 *<&X0%+CB=5W];. MZ.;#KTS3&N*&:"U&$68K:*6^` _<=#LEF9?0)YQDN!RK80(_[-)]2DC)%='L9 MYXW&]_KK9R4FL[:>7[)*, H;N^,$19:]"CVQ;9WEM\-D]&S9#4XU M-$,/?
Y\7H64TN+YRNX1]TGR8/ @N%:+2D0<0:CA@!;E4SK8I1*:=_N>2L7U? MM:#:M/IV0'9:&@.ONUDUI+'3=2IN!08YRUNM/")\?#-_N 00+"K(/-C]R^.C MR0FNB5JS+:=:7
M@"32#8W'52EPOPJ4BKZ]9W14)X^&5OQKQZ<3(_.'Z' M9F37K$PD,'""R)&YO&P_:955CH/)33HRZ.W\\E\&]U$/'9+F@YNLBAFG>[K MJ?5-R)?:W=O=3X*+?!.^WYY_3WR4KL:1 \E5,)U-
CG$#=_F.GA?!=NE>O+0! MM^STV.!G#3G>@.^5Q='7+]C![H?2XA)02P,$% @ L#AG6044S]M2 P MCP< !D !X;"]W;W)K&ULG57;;N,V$/V5@;IH M7]1(EAU?4MM XNQB"S2 L=EN'XH^T-
+8(D***CF*D[_OD)(5K3>;HGV1..3, MF3.<"Y=`8Q]O/!KL8I2 M3P@5YN01!^>-8-*>2"F\7>'&?4NO>%P?4+ _$&+G6';"X<:H/V!Y2J:1U#@ M7C2*/IGC1^SBN?1XN5$N?.'8ZHXG$>2-(Z,
[8V:@9=7^Q5-W#P.#>?H=@ZPS MR +OUE%@>2M(K)?6',%Z;4;SBQ!JL&9RLO))N2?+IY+M:/U!2 M?A&H0[E"X MQB+?.+EE0@SN59*\ [II@;+O "W@SE14.GA?%5A\;9\PJ9Y9=F)VD[T)>(_U
M!8S3&+(TF[R!-^XC'0>\\;]'>BM=KHP/UL&?USM'EHOCK]=B;B$GKT/ZAKER MMEK Y 8J<0 M0AS^4%9MQX?6V7$[['ZQNA:5,\ .7"EL?0S8=5QJ/@8;?(Y)9F->M=)K.X\7H\DS:H"6F[$-W
M8/;,I#9.$LSY>#$*YH/EC VS:3S+9L-ERXIQ9 _XG8[CK/7YM<1\LO%E/)UD M9])&N#*D0.2Y:7P%U.(YY%34M35/4G=IX=M\N5+.6N#[RF5ZK&\N-(:"\T"F M
QH4426(4W,!VV[@UTIPD3B'S&200JZ3 KT!UW@1YG'AJ^F4&5G5#3]2KW5? M,AB2G+-#> H=GO]J_-=3MD7]3;I^I.V(.L'!?HGDW3B]EE!+8=_ZU MI@XC=V>(!WA8EOQBHO4*?
+XWADZ"=]"_P4+ P04 " "P.&=9!)GR M\1,$ \"0 &0 'AL+W=OJ14DGI=(-MR3JY<"T M&OG"&S7U([#T:#A0@:SB=][T+.)ZFPM)#YH,%W3<+VYP5JMIT$4[#8^BV5E MW<9@-
FGY$A_1_MX^:)(&>Y2%:% :H21H+*?!=71YDSI]K_"'P+4Y6H.+9*[4 MDQ,^+*9!Z AAC85U")S^5GB+=>V B,;7+6:P=^D,C]<[]/<"=HIES@W>]OI/ ML;#5-,@#6&#)N]I^5NM?X>&X_(")[-
O&.S4U\%O 1 MVPM(0@9Q&*=G\))]=(G'2[X?'8,[G%O@<@'W7SMA-_"(1:>%%6C@K^NYL9HZ MY.]32>A]I*=]N%MS:5I>X#2@:V%0KS"8O7L3C<*K,Q&D^PC2<^C?J\^KC>%+
MA5!RH6'%ZPY]'GBCM!7_X@(*92RH$L21@9!@*E+XR:)NJ.7T$UH^KY%ZGO)H M#LF;;^CT'Z5W>QNPFY8\&=(%;78S%'ORPI<^\-2U?0BF$NX?D[C9ZV,@4[2 M$U[W24]+>;_VS7)Y/W](:;
[3JM"-0WJ0O :'GB+VL!;R#,6)Q%+PHR$B.5I MR+)Q0NMW;_(XBJ^X%%*ZF.:\)E1D\"N7 M'P M@Q+1*[5J7LD7?J"F2*DALWSXHWM=GQ$_<2>/&_3ZA80+3E;H3-?OS-PM_9VO M:UC0-
=UVGI((&^3ZXM0K.3B::'2?EWYN&XJ5TM(/M_WN_M@NI^(! 7^N^(C MUTOW@-18DFEXD0T#T/VL[@6K6C\?Y\K2M/7+BCYO4#L%.B^5LCO!.=A_,,W^ M U!+ P04 " "P.&=91:8?%T0# !W!P
&0 'AL+W=OV@;VD:) F6<2]/!1]H*6Q M140B59):[^;K.Z1DQ0F\F^9%X@SGG+F1P^5!Z8^F1K3PV#;2K(+:VNXJ#$U9 M8\O-I>I0TLY.Z99;$O4^-
)U&7GE0VX1)%,W#E@L9K)=>=Z_72]7;1DB\UV#Z MMN7ZZ08;=5@%<7!4?!#[VCI%N%YV?(\;M']JT]YJD<&*I1(O2""5!XVX57,=7 M-YFS]P9_"CR8DS6X3+9*?
73"ZVH51"X@;+"TCH'3[P%OL6D<$87Q[\@93"X= M\'1]9/_9%TZY;+G!6]7\)2I;KX(B@ IWO&_L!W7X%<=\9HZO5(WQ7S@,MGD> M0-D;]H1'&T0@Y__CC6X0101,\ DA&0^+@'1S[*.V[Y>JG5
;2S)C:W*EZ M- 4GI&O*QFK%:%82SZWN-'1<5O'JD-ALTR] 2]JL+RY'A9F!(GF%8P%LE;6W@ ME:RP^A(?4C132,DQI)OD1<(-=I>01@R2*,E>X$NG%%//ES[#=X<[U!HKN%7& M&@<WO!.6-
^(35@S& !EP6<%[6Z.&:V/0&K@3IFR4Z37"W]=;8S4=H' _.E6?P MGIWW[B[5E>EXB:N ;HU! 8#!^J:3+^'M*].VDG,=HGK%9[KP7%$7*LGDQ M!7=^]YN\;&JELSF)FU&G&FX1K)>/?
CR315J>35L0$DWW=V#K^CI3>!2?.)^ MSG:]-CTG%CQ[Q(I:\)0R78+#E>XWHCP$]+T"M(0)MB[H4O+DP=%3P:T\[V/SV M!H1TA9Q=GKM!X1M3.@/9W2MFCX!Q,;^WZ/U!+ P04 M" "P.&=9
XM-'DH# !B!P &0 'AL+W=OQ"EL2TL)6I)*H[_ MOD-*5K) $J %]J!X.)KW^-XP"'V/VGRU!P!'GEK5V55T<*Z_BF-;':"5]E+W MT.&;G3:M=+@T^]CV!F0=0*V*!6.+N)5-
%ZV7(7=KUDL].-5T<&N('=I6FM,& ME#ZN(AZ=$W?-_N!\(EXO>[F'>W!_JK<&5_',4C),YJW],"7\9G] MU^ =O6REA1NM_FYJ=UA%141JV,E!N3M]_TF/YGGJ[2RX2\YCK5)$I%JL$ZW
M$Q@5M$TW_LJGJ0\O 5[R F@ BZQXV"R@_2R?72Z",QOAK9?!"L!C2*:SI_M*/?.X-L&<6[]8&0-1'8U^<,=P)!,>9);!789.V3W-7$U,6U&)O$&4TD^Z\X= M+/G8U5!_CX]1U2Q-G*5MQ+N$]]!?
DH11(IA(W^%+9JM)X$O>X#M;"VZQ]\H, M4EGRY7IKG<%_CG]>LSPRJ\S^@MS97M9P2K"&V'!/$*T_ODGOF" O*,WG?6F M[[' IZ/Y?TP$6^R@W6+JW&?R :HIPT,F(7?H3)KJ$
AJ>,2+W..U=,0;;]JI MH0JCS@+9 28N2$XY3R@K"XQ+SFF:I>1^Z'MU"M6M[(8=-GTP3;)*?^$Y30K."D87909^01[J9[+OF/G M+*4)STF:H[ALZD=_[@=/.4UR1@0J*)'P03MDND 4S?
%9L,0O:)'D=%&D/[!] M"15HWGOR^PFQH +CC>X&.P$,*.F@)M#V2I\]JM(MCFHKP[2#)Q]C5M!2X%,(MC')LD.#EVPZ-GFB9!/*%)N&]6X!BO2(J4ILB:+G);YXGQ(M$HUY7AT:&]PD&:=YGI("'97L?
##SA%<]IP3DI"\H8F[N-A"*C&7;$GBQHB;WE M@KUXVH>(7_QS>/7\JCT=W, L.2EJ5NS"@[6=C=A:(H#--)OU4O6VKEJXU\3T32/U:0.U.JZ" M*)Q2'JK]P;.<+WLY!X>P?[5W6MLA3+-6370FDJU1,-
N%=Q&-QOA\GW"WQ4< MS5E,7"5;I;Z[QA_E*F!.$-106,<@\>\9[J"N'1'*^#%R!O.4#G@>3^R_^=JQ MEJTT<*?J?ZK2'E9!%I 2=K*O[8,Z_@YC/8GC*U1M_"\Y#KDB##4C1&ZN:$8P*
MFJH=_N7+Z,,9(&/O /@(X%[W,)%7^5%:N5YJ=23:92.;"WRI'HWBJM8MRJ/5 M%.HASJYOBT+W4))/+[C,!@R1;4G>M ?0Y*[7&#I/=E=R6]65K< L0XMS.F18 MC/R;@9^_PY^3+ZJU!T,^M264/^-
#U#H+YI/@#;](^ C=-8D9)9QQ<8$OG@V(M/5_\#M^]/,EM/1;NW9"U(5]OM\9JW#+?WBIY8!1O,[IC=&,Z6< JP'-B0#]# ML/[P2[1#OU[0*V:]XA+[?[!@E_F?M"SAC'3V!XVWT&RQ:W*??
(1B[(E\3TP> ML%ZIBX,G*.$9#WW7.$W.AJH8Y=88H7:R ^RX(BF-HIBR/,,XCR(JD>^ZZK M3SZ[D6V_PZ7H==7N!TPWB"*($H+R."5)$B,N)W>J-7@@7:;#RO*Y,DJ?7N>/ M64J3+"(9HXL\
(9)A+^O7M)_8(R9H'*5$!*@N&?WH)C\B$=$X982C@AP)GY1% MIBM$T12_!8M=@V9Q2A>9^'_MBRG'XEU-;C[.%Y1CO%%M/VT/#;6TN&>@Z6IU M)2_OQ"SI"P7%#^<&VNF:9R3]_F"(N=-
M2$0FJ$#6>)'2/%U,BR2Q,,>KO+&^FCB):)H*DF%%.9N6QP]%*'9'-J#W_B5P1O2M':[+N7=^;&Z'._8U?7BI MODB]KUI#:M@AE%VG24#T&PO=V]R:W-H965T M 1*Y2"QYX/AS M+5Z(/"='"./?
UF>O6Y(,5Z^7WG]UL6,L$V[$"Y5_DJF=G?3&/4A%QNO<7JKY M;Z*-9TC^$I4;]PWS9JZ/DY/:6%6TQHB@D&7SRV]:'E8,QMX.@Z U"!SN9B&'
M\B6W_/18]SEHFHW>Z,*%ZJP1G"PI*5=6X[\2[>SI:X$AF>.^15]TIY^T=N>- M7;##+H8WJK0$ [^4J4C7[?E\+(& %@SW^PBZPT/D+ M]P8&?Y]-C-68^W^VQ=BX&&QW0?
5P9"J>B),>"MX(?2UZIT\>^9'W? _ 00=P ML, ['N;WVFU'U4;[JH2S>HJ](19]!G8FX(4J*EXN0)16:)&"+T"7@+5]8&@ M[('*,ID(R,D)*D6 LO.,A!9)ES5P%MU+8]?T."SI6NUG%]56MU(+!"1+R!@
MH>=A;=5<"\BHJZ@,'%S &B0\&=X=JX@RY72AOZGVY-YJDLiY'K!%VEP"V\ M5$#ZC[!E<)H@91.3[KWK*X&HN[1>A*E2+H[8#.-!*N&Y AS;M#>N@0P@N."I]1 B;WL-H[[[8OA*E+_S$G.S
M($BC0WA7PKO$*L(8LQ68.T5SKU*XR^BFT^UR"5F*9=VD3759#++#F)QD]BGF MLN;P!B,4.5PXS*F LR\B%=<*QA%VEX$_] ["<,C@0FFKFI]ZRG.2D30MR!E& MP2$\
(#XQ=FDESX&4T7)+\FV2QR?Y,@5F)0<@>#)##:"^S&TF$,]$=%G'T#"^ MNK0R[_A"LN*UK/CA_Y$6/[HG+Q'S'IH7C>5\;U[B(5R**6(";&7HCL&+\P#\ MLT]XP8N)ENE4,-
Q+IE31##X@Y6CX!WI)5;$[-922VWA=!>-$@W"M:G0O2/,K M[$:.W:XP_>!!]'Y-JVR87I:9/VQVM)U,^VRTR31/4TD%BZI;(YWZE25!26P/ MR'"B=*6PMI$6;*#D X&;"]I"OZ5QKF3'T=WN2?
Z@X^(':!D/#+9)XO@>BH-M M8GXHQ4LX]_:8:Y5^0X\)OKO'K*8NJ;5&LC#FIN<89-H%A"[S?*WY;.L[Y&KN MSK$4Z;70>"S'DS>=[5T].]Q-S6'*-V:FTB0* 8)3)#XPN#QC\9'"'EO9F(WW+
M0Y]SVE5FV)PT0EQ&NY1G*L3<'=X+]D]2!&2,W:U&> M%0[5I0LK%:[[9H@51>0. B"ZM+@%CX<12SV?7@MC %95+5M MRAG-L>J?^G&$A\+XV9KYD@PZ H1CCT5>T-BW$@;L:\NV<]?
BJ<\&@P$;Q^$S M>*W^Z8+96>P@_ 8%4N*S&,MRY,7PKIN5<#,#?%S-B"'G6NZH-=3A\CIUL;C4 M%%BOULU6LP&+LDIGNL<^\SV?19'O]/QX-&;!R.NJ 14H6LE!4X@[F'C-NY1 MR&?
5],!\L5[X6N!6D+8MNQ'/+0/D[IIKZ?I(/!H'?O#\SFA5[BLK1GCF'?MW5XS8 OL=L5M#YC] MEYF!%4-J;9[XN[O=^Y*SYC7!{?3F9RI*TH0U/O<#3L@6Y> M8#0#JRKWTF"BK%6%NZ0CAM T ?
_/E+++ 2W0O44Z_0]02P,$% @ L#AG M69;(.6>R! A@H !D !X;"]W;W)K&ULG59M M;]LV$/XK!S7H$D"P]6);4F(;2+(&+8861)N'X9]H*6S350B-9**X_SZ'2E9 M=H(DZ_9%(JF[Y]Z>.W&ZE>J'WB
:>*Q*H6?>QICZ?#C4^08KI@>R1D%?5E)5 MS-I6K8>Z5L@*IU25PR@()L.*<>'-I^YLH>93V9B2"UPHT$U5,;6[PE)N9U[H M[0]N^7IC[,%P/JW9&N_0?*\?BG;#'J7@%0K-I0"%JYEW&9Y?
C:R\$_B=XU8? MK<%&LI3RA]U*69>8!W"$G-C$C1B]'O :R](^D1M _=YA>;)[J'J_WZ#R (/7IC-S$L]*'#%FM+NSP<*:3!&PI1IQ YOUM#SLM?F6'SJ9);4%::T.S^A>JTR3DN;%'NC**O
MG/3,_%-5EW*'"%"K%&:CX9,HL'BN M/R2?>L>BO6-7T;N =U@/(_Y\B()H] Y>W <:.[SX#;Q;-%PATMXMEG.=CWMO1>^C_H2S_ M!P?N-PC7L]J9V 'UMV(&-3#+9M(O8-
D)UUWSU:0$7,#=EILG5+0KX-00AF?A M/GY(HRB\. -[? #)B0^*+QO7?"^1K/)WP0W)_<;%NI"5;X]9GDM5,)$CM8'9 M0"ES5E+ÖKYN261SM;-2V9#Q'/8!+#7(%Q!6#U1)53QC?6;#>D1\/J+3;=R%;
MA\/D0@-VV=$O@W/&EWN:=/[B@R4/F2N0F8T/!==LR4MN=CZYN&>7#U*!046] MZERV"JT=^W7@?)""ELS[S1V%ZBX+'C>U^A:;@,-]9Z1'&_453%XQY}?J MDHKA&]7G7Z%^0BBF(_5 A:
:YK;9)4RVRC*8L<=IC52ZD[#L1_' MZ1F<9GZ4!O0>T8%;1(D?3<9G<%E)9?A37X1&*,SE6O G0BVEUA#YDR #QX;H MPGH1)OUN036A?]<^/H4%%>8(@#B1-TI91NR0*3+KC]/HK-<_3?
Q)G!WV]](0 MDP7:INK+0^R+GF3D1^FL?5RI'@.80@HE+YNBC6E-$(H<=:U<$(>Y'9#VQPGX:)L8]W0=(OFA++ MFL*U,K5\867<2LN2%\P>:T.O:N]R.V_Z9K:^*-S8^4!&;%T&T$TM148.,T2
M;(D;V6Z$96K5,A7?H+/_;!PY/T["C&HVB>'T^O,-A)/,'XV)-ENB)_U@"P0C M>UN#9Q/3S7MARAT%0'.(UVY\'@R(-5BF%I04,D;9)+[SRJ6"5;)IA\B]JW?:
M6A]/_%%*QLGDBJ(\Q$C)=MU(MR\:K<:1R"I'I)&,PU8[BL9^-@K.!J_]>(9' M=X,*U=K=@*RWY$=[3>A/^TO697NW.(BW-[2O3*TY):_$%:D&@V3L@6IO/>W& MR-K=-
;)2T+W%+3=T441E!>C[2DJSWU@#_=5S_@]02P,$% @ L#AG61#J M)@]_# UR< !D !X;"]W;W)K&ULU5K[;]LX M$OY7*&_0)H#BV)*??01PLMW=[O41-+W= P[W RW1-J^2J))4'.]??S-#/6/+
M2;M[P-T/36U)',[CFV]F*+_:*OW%;(2P[#Z)4 .ZM[$V>W%Q8<*-2+CIJTRD M<&>E=,(M?-7K"Y-IP2-:E,07_F PN4BX3'N7K^C:C;Y\I7(;RU3<:&;R).%Z
M=R5BM7W=&_;*"Y_D>F/QPL7EJXROQ:VP?\]N-'R[J*1$,A&ID2IE6JQ>]Q;# M%U^$V*K6E\9FC)4JDO^.5M]+HW0(5$+$*+$CC\=R>N11RC(%#C:R&S M5VV)"YN?2^D_D>U@RY(;<:WBWV5D-
Z][LQZ+Q(KGL?VDMK^(PIXQR@M5;.@O MV[IG?=@QS(U52$#0BI79CV)LT$E%[_07H52GGE\I=^4<%WHJLSX*!Q;R! M/SHB+ZB,#4A>T"'/&<;^N5@:JP$/_SIDHQ.BP"
<^2%R7@H7O<@"8S0=Z)W M^>R'X63P\HB"HTK!T3'IWQB-[Y7%KF-N#%NPCSJ2*:0BHV<-.QV>%?>N#[[MK"R/V8<\60K-U&KOF45N-TK+/T3$WAJ3PW]/N<+3B'W,K;'P0:9K=L5CGH:"
M<Z/[!!YH/.Q[\^G0 MF_MS=JW2.W)4@*8T&6N3*WJ]!.YTW\):HWF@1>,))65T^K2676M_! -)<.J M;?Z(?WK_&?>*8VP=6&K?+2L5 MQNAKGC+19+':"<%"2%
[,"F:%!J9QBV4*2:W2=_P+J/1SY\:GPXDW&P=G^Q<: MT7S/=;AAP<%@^MYL.O(FP;05S/E\[/F3:3N4@3>;S+WY8-1"2IZ*BBK^ M%_M)4K&@3>?SQJN<1?V$?(Q0Y\;)NZ%#J6!W*CQ4*3N6[
WQ4+&;L#V>H^1%\P' MG>$I;C?\!=1J!>7Q8:<%WF T\0;^N.6TV6@(3IOO.6TV]?SYB#CBISR.=RSC M,CJ76+;7T@">P)0">UMI-XS# YK=\3BG;#@9]$'2L-.3'U.VR+2,V814]3WR
MR+5*,I[NGIO.=4NQ!A\]J(E7()2?8=D';B+ ^%5(DD\AF ,HOT/N<]MSUWEG# MYV:7+*$BHQ?]P/S0/>>L.!PPY+*%UD"#Q%Z756 M@@<.NLUCRJRRD&LM85FJF 65HF$ H_MI
&@69(6QLH0B%?T]2J';P)U4,FR MX&JO8FJQQ=GHM/?OV W7P!^GW"HLCY/8/J(U?\<0AL6RQUD) 'VZ=?WX1 ML;PGH9]$Z)\(N&>]$!D&.>1DUWJ!SC$DD+5V%?("]:0S!2&<]=GOZ!O<"#NB$-
PVR[2ZES [M"+KC8NHQM8SEFCNN1WT ?%;+T%VP&Z!GH*TJ9%N5QQ'8\V\%&%\Q:5W*\ )A M1_+6\>0A"\J&L&&S/&,RR92!.(1"6RZ).5.S@BTH[S Z;565\WRAJ<0-3R7(M :OO9$2-A@ODED/%
(DU+T1B-W"I0U3F%MH#%L!HC!0Z"F:;6)!'AAJ)M&B^*/T-YLH0 M#5;-UJ&MS'8C 44FAS]/V,3A"OO-]&WG@Z>P1795-X%^_MAPY_U02]H'E MZB($5:P5/@&I&&J9E=- E]>;%"BQ&D%E D?
%PKHL@VL(9KF2#@02L(0E#RT M8Y"26@!7"&PPK?)HA=D0=RV!^@2G->"IM#B0P6KB&&H%/2-,'??VJ=JM)#8B MW-#\<^CP[O?+ MEOLC1%J#&R%"]AP>/R]:QO(Z O\)WY4+@U9W^K
.W7+L#PZ7&A1"F?;@H;+& M.(7?"=SU"Y%+QG-#0>7])U39%U]S^=@7Y%^9:$A?"4V?LM-CI MH8QR!U1=JWR]*9*A:4A(H70]%<46!LRBN3KQ&]V56A$P.L\8#AF,PZZ[OZ_)
MGKU@&VY@R$E\#0YR>#\@94#\!E 4*.M[_*SA^65:&%;PK;1=Y*0A^15HPW* M5;PJYAWMV+FBW I[M^],,[4VH1C4R<." M[!(.4+V>@.0!<6OL;529"3Q1>6H?
@P!U.&&7BQ^/$T%N4)O%BO@/>VZKH@B M3LA\,(2E4WR>QM@#-^U'#P+8@*DTM4&'_2UA*@DA]NY@I79&,?K"(NROH@8J MR>^+?)T;6Q7:;^*/PY30:F"=]"/$0IZT:BW(M
HFW6G2D/[@WI]FDF#\74S2 M-/(O(9/# @_SR1$/?S^E%"W0GR"6D3_[1F*IV[6ZEGT_OSR =9_]F.NR7X%X M"& 2][K -9SMT\%V$I"CJL/-Q\].NP."9U\ MC&=]U
3[XIKF4BCZX(A0B(A:P\9X!X7W9.SWQRR1<4RS.%]!WH++@3>)$!H(M(Z]#)I< M[ZI.@>>?R8&%3IP#IU=:(>-O'M/[[4J'0F5,55$\Y.3X)9?UYZ^:P\RVI; M0* 7V-(97>?>*D_W_%35_N)1ES0FDU#^Y";32V3?
N#P!(V'@'TIE?UI5*Z"= M!3852<:B"'9>R^\==OJS\A$*6BSNI!-&(,,#!MP/;L/54M>63OO-'_@:DA,= M3<<(^ TM60$LBRPKSJRP#&^3XE@=0]@T52@%.VB$(9B32*V+HRM*G7B'RU)N
MMPORM4!T/AO]=9)Z>#.H((05V+=8_ M&6)EJ@(,[CJ$Q>??AL(.) W[DR-(^K^ SN=]R$.=P.")5AB+84^%(9X_1>"' MIW>]#F*P/(^)O9NOYYMOY=V+)A3;Q!?
8!QU/B1JJHN7JY]C@0>AL_2+V]#@\ MZ9"2WN%WG5'B.3^$4>4&W,FW7$4+G"NR93[R4C7*2I)"^G'$)G[>+] M^INGOE_)>B\:/K1*AU_23,NSHH>*ZWUU55ZM?K2W"APT$ "<"0 &0
'AL+W=O;26U#3ANMW5(LJ!IMP_#/M#2V1)" MD1I)Q(!IX:+O3,JXQI+X- %Q4V M3(]DBX).UE(US-!6;0+=*F2E,VIX$(?A.&A8+;SYU,GNUYPJ.\-K@7<*=-(_F2WNG:!?LL4N8MHLNK
MU.H[A3]JW.J#-=A(5E(^V,W'I34\ M7 _H/[O8*985T[B4_,^Z--7,RSTH<S>(7DVOW"MM=-0@^* M3AO9[(R)05.+_I\][?)P8]"_9A#O#&+'NW?D6+YGALVG2FY!66U"LPL7JK_F
MVQ$DH0]Q&*A[/WY%*WK,"91Q=!HWI$;_[V330.WYT@F^[)IJ?0 MO[,B/XH!GRN$M>1T"2D38-B*(V@TFH3*5&#HF \6VED4C!<=9_;R."VG8RJ% M"$R40!E%:/K"HRT\4-D,-
BL"&&H'A6Q:PBK!R!\W3RZ)M=4 _;*__J-U:F!/G MCH7%.EC==@TJ9B@BFR<7-3-&U:NN3PMQ+0A14;9LKFIAD,I,J7)YJ20O46DX
M@Y^2S$\N0C|))N=V>^&G\=@/TPNWFR1T$/EAF+EMG/O9)/2C/#V']R@DW65' MX;,TC"Z]>5V(/7LD-AL$T;D0Y!KH)=6&,F:I. (:QK&?7XS]21Y#EOA9-/'" M6>:D8>+'<0AIYJ=Y1M+P)
<27PKY]D\=1],Z^9G7ABE'6O+/>B67,-=TR9FNSQX"17IP@I1PCQ\SSRXW3LJFFW(34C5?__75N?QJUNT0U,_NQV
M-.3ZNP#L6!6)YQEUSL2Y.+,=\S7&"+ZTE*4^FW:@^RZCKQ6N#W!E7RRUQMHE MAH I$O+5'PI)',2&&*QL8,\D$$=O[>C8FQP<3$QZ##;NNT 3OTZ8?GCNI?M/ MCT4_<5_4^^^6&Z8V-;V0'-
=D&HXFF=>WUK QLG7S=R4-37.WK.CS"955H/.U ME&;86 ?[#[+YOU!+ P04 " "P.&=9WW85Z.T. "2+P &0 'AL+W=O MO3Q9U_7FV<5%%:]5]ZM)L5$YOJR*,I,U?I8W%)6F5#+A25EZ
MX;ON]"<3.C]Y]8+?O2M?O2B:.M6Y>E>*JLDR6>Y>J[38OCSQ3MH7[_7-NJ87 M%Z]>;.2-^J#J7S?O2ORZZ*@D.E-YI8M_8ZI($\X!];;:O>LR!) MED7QBT[\F+P\<8DAE:JX)@H2_JVJ-RI-
B1#8^,/2/.F6I(G]YY;Z6Y8=LBQE MI=X4Z6\ZJ=%!EL74E2UXN+&M1IS$5L*;TVE/P#E!;BYR*O MUY6XRA.5#.=?@*N.-;]E[;5_E. 'M9F(P'6$[_KA$7I!)VK)((''B/I.[N!9 MM;@L2YG?
*'[^Y^6RJDNXR;_&A#>TPW':%*K/JHV,U7B,^J.],J2!'- M.K\1%1-<,L&X3U#N-5L]$W(BWBMH5\F/X?9?*7)S2NK[[_.K#NW?\Z#'T? MY>6G!NN-L()!=Y>]B_B3N-Z,K7'I]88%?]@<05C?+%U1^-
KG?BQSRB8",EKN3T?)6UVLADT23ZF4*?EN!, ,_(9X 7E="K5">L,7^ZCJO M54D/EODV(G@<9E;-LM*)EJ565EID%\S HK2>M3EF95C#^+TUOAG(XEO0&ZV(H?;[Z'*_)SN()L6QT4VQS
M$OG>E+6\99.(DI(IJ42ULXVAAL-AM!%Y+N_) ZR!W1/15"W/=YGZT9A:W5(B MZ <;FV1=I GQR[7$E[ARX OQ^A 1XGFER#X/,83ZHX'G8L$[>CX@IZZJ!F*> MLD?1M%^*6@G/,['K/S?
CK#3\;O:\Q8'S@TR<36QX'$&&TL-ZK.*&\(%>AD7 M^2V6(^UOI3)WXN2UK&_41]6-9R2#$)(*.16E@GY/L% 3I+K6YF2.?9RCT-6 M8<#5$JC7LKX?$ PCK>T!OQL!G",0
M7A:W:B+>ED5&S,LX1H9C6H15&\6EIUV,H"XO!&= $T19D>B5CDU$MZM A46F M8X=T69>H"^'KJ;J!.S W79 :L1U"M+1A>)B8#$@@ E\D# PB%P4QEK(!^P
M&]A$GWOLQJ2GCAD*5LW8#.A6Z8YE2Z G38426\#]@K+0AL"=\7BH@H%X6ZMO M8IW R_AL26M(9)4CF))%6NR'#R@>S2UO(!C\!3Z1[H9*9IBG! .UK20B%2[5 M*'&C
#^'4RYKC=YZ+UR90!D3D#O ;(M. M12M65:0Z,1*#0!YK$$'\U2;[R]8F]XM*CD^&8=19K.K1R':,M\B*QQZN'YD 8PC('JT%>6B_5G)(:!N? MZ0X17!A+U.M2F>" .8!>IK,Q_OGE(KEBV[D^M_$0[ZO-
K0!-DAJ:PN*3'** M9&BDI83XB$[NZQSFXV"AW;K5<8I[8Y-&T-.7/+O%APQ=RYI;;@^+2H>],2; MS-%RIFD;#T^B2="^N*LXRNI?9'%+A3ZEXKPM#B2%%[&%880=K4]9!SI(T=8] M8
JUWTTI, 08@WZ&,\-'MF*_+1USQH>,"L0OY =?(O6 0<$ V@X[]9,N:8_ M>4XT"QU_L3!!- L]QXM',9OZ3N NA.]X"PR)9GB%*BX&3TV,M!3*'*\V;XT MF'JA$TX7!W(LB+N>$T:1"-TYSPNPW-
2)W$C,?%HZ$A\+PL8O.@&Q/@]]9PHN MZ3GT(V<:>7B.G"'<.^[49,L2B$,^D*!N2XL- M= 'M,A'XG"X@/A0R\V:T4#AUW'!!LD2N, >B Z1-=C#-Q1T,;(E[3A $SL+S
MB1@66 0A%+)P?9]:BL/ZZN+C^,85:

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eL^4C M81(!;^2-ZF5G;Q*X)CU/CIX54=GZ):B[_HNA[F@I\$BX:TOW_V/=_S#67?>Q M[MI:W-IJP-5H"1).I\YLYK836HX>58%XZ,[#,#R\Z,B<*34O7C?'MIW]677PSO$V]E'X>QJ"M>D\.GN$#L*V4W^X M"KHI? .*XN>N$(\<,ZW=25UVM_!T"NFV?AINM[6GTX>[?G]G=!+&[5N**2C MC!3]Q/ZH!
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Ö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}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}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}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`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|"X1DZ)B)82AS()>\[[_O!@UWSA99L^M0BM2Y0.M#]C>I_40J;U-YR..*7PZG)&HNB3C?.;$11OK5\GMCYCSUBOZ*_2> MZ':@G'653T_4,EH070(J;5\!IZKIN^;+L M\&VX:_R2;]B.C_-%Y>]5L\1LMM0+>/5D^MV3(_;J_H_6KNF^[;EM6UO1QO4$ MA;K!!^!WO"75_X$;A!O87_PO4$L#!!0 (+ X9UF0T[PZ& , /4& 9 M >&PO=V]R:W-H965T;O.Z0VHZ4-/C@P'=:"_=Z@\KN5LDH>=OX)+<-A8ULO6S%%A^1_PZ M"%O9@%)+C<9+:\#A9I5\!:5"D!.X]\9C^D#(&'ZS?T#U$[:RF%QUNK_I(U:-MDGD"-&\$[^F1W MO^->SV7JZSR\0F[WG>Z2*#J/%F]#V8&6IK^+;[L[^$@8Y)_Z#8!Q21=\YH MLKP3)-9+9W?@@C>CA464&J.9G#3AHSR2XU)<;:3^(*2#ST)U"/0:YP\ M_/PD2H7^EV5&G"7X9M4>\:9'++Z#N(![;ZCQ\-[46'\;GS&[@6+Q1O&F. OX MB.T%C/,4BKR8G,$;#Y+'$6__Y+OI*^4#:H]_'U=>G)<)?^G$-?/W(GUIU"L!LNN)+ 8]4Y29)9 MEZ^@\ 5#V5 C#5"#L D"7Z+ 1J(3KFI>3VDZF_6TIJ< ;.Q6WLC1;H%C$$]# MS4C3#XG8;25\@.CFUNI6F->?//C&.OJ5T&FN8\>,??BO(MV780V"#I4$3)X" M[.9":NY$Z4&8FK/6LA*$.5E_%V?N(9SM&EDUA]R@4L)[N0GICP+UUZ:X JY$ M0EVB&\H1[K#:[XSBSA@^1@H%/%D2ZLAZWS6:W159+-!]&B_.YHLTGO7I M*.^/C5&^2*?Y/%V.+H^L6W3$E(-T'RKC#EOK)<&C&'ZPG'%@,4UGQ>QP MV:-BW-D\S:?CM.AS?FLQGV)\F4XGO9%UJK2S@U'$,K=QX'JH:&>HGTK#[C#3 MK_M1]M6]_R'<"[>5QO.WW7!H?C&[3,#U0[8WR+9QL)66>$S&9M0EHH'O M==7HF5<:TY[[OLY+K+D^DRTVI"FDJKDA4:U\W2KD2V=45WX4!&_.YJ+OYE.W M=]?F4]F92C1XIT!W=T\%6L2F,7 /FTY2N\1_-K>Z=(\@>4 MI:BQT4(VH+"8>9?A^=7([G<;?A.XT0??8"-92/EHA4 +F1=80EAA;BP"I[\U M7F-562"B\6V'Z0TNK>A]Q/Z1Q<[Q;+@&]]E]M8FG+F91XLL>!=9;[*S4^X MB\<1S&6EW2]L^KWCD0=YIXVL=\;$H!9- \^_[\[AP" +7C"(=@:1X]T[/%_A\G@!A<&>+.$VV^=.%NXQ[Q3P@C4\.?E0AM%I?+GL4/H?23' M?=CV.=A./@XD0$R1!!<@I]?D_MN.PJ!%F .$B:;$"7 M4ID?#*J:*D.]HK%II-*D*/40VK%X3GH\'L]#B5!PH6#-JP[=*?*:W(N_<0FY MU.;_\H/%EK1_2?6TM@6$:+/H?+YS1^5%)K MZ'JZJ2JWNJ(;2O]N2*9O'_<6U)@84XT:#DO*04QAF+!IG+"%7)QIF-#3,Z-4-SS6,/5E3[EW2.>%) M6>RWKEC=;=PKIA7[=_M4;+#'%7_()KK"""0C2\<65+6K27GA M8('T>D!+8T>:NH)&,A5$S((@H$H8V?;M[('M-Q&]0LGZE7SA/15P0LV39[./ M=@X]W[D_CAHIF/5YA_,5+H*5N[EH,DUL>S'Z[Z/$XN^YF\W]Z_;#YSM:)W M3X4%F09G*=63ZE\+O6!DZR;T0AJ:]^ZSI <6*KN!](64YDFP#H8GV_P?4$L# M!!0 (+ X9UG6]0>&_0((D& 9 >&PO=V]R:W-H965TJEZVPB)&PVF;UNN MGVZQ4<=5$ KX":^OLV< MOW?X+/!HGLG@*MD]!<4I;ZM5$#E"V&!'0*GUP/>8=,X(*+QJX@93"E=X'/Y MA/ZKKYUJV7&#=ZKY0U2V7@5% !7N>=_8C^KX&X[US!O>J1KCGW _'LP[.(GHA(!D#$L][2.19WG/+UTNMCJ"=-Z$YP9?JHXF< MD6XH6ZOI5%"<76\T=EQ4\.:1QFS0P$^?^*Y!_RM 3OG,)RA+H=H)(7H!;P M3DE;&W@C*ZR^C0^)UL0M.7&[32X";K&[@C1BD$1)=@$OG6I-/5[Z MX][E%K MK.!.&6L8W/%.6-Z(?[!B,#:" 9<5?+ U:K@Q!JV'>V*1IE>(_OYLS-6TTWZ MZUQ[ANS9^>SNZ[HV'2]0%=#G8U_8+#^\8=X'OURH;9LJBV[A+[>TM=:]0V" MVD,WSA3'F9[C>AEM\Q\$>$UWD5HG+=!0++8[:L]I,G"/Y6B)O26%]T]^+@E4_ME+P!5RS79>T[.UDK?*"-T+4.TS5#E)3F%>0L+6)6Q#')19:P/%G MN^ZYLF' MMUSV>^I_KX4\?(V:LW16L&*10,R2: 9O)8V+RQ))SO9S-DMBDJ(9UE>C-/U M77IR^0WD64YQY%-$+%_$\$G1O2 &\8PMBHQER8R4A,510FXIG&F/=!7_GO9] MORB7.9IG;}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

JZE,GKFK1X$$+LL2^']NS0,P@][UI/0 MO#Q<,6%NE@;[*R9N% ZV5CRCS[C79WQ6GX]T$.8M!4W=_JG5+;6QE2S<\Q4= M3UH=4^UY2M-R=**TLM
%6AGIUR;\2>UK#4JJ6E%VSJ=EMZ>OOY!+TWF&9D=8 M-Y45PH-54DZ3Q#5"5+1&5-$W<.,B,&5-9XP'I4FLF9(91Z,:Q;\P!!)'O MLH 9(^T-RH]N"#/2)F2QFY#;]B8VZ[H!(^;$S8*
"JH4%%73&LD6-0%1:;@(MLL1E?G:Y]\48T5XEOINXH<=?MI*2;S0"&E/?$IK'W$1N%$4N6G&+N&SJ.<_ MV\|'#SA1]I5MKHS%[L#/CG64MW4 5RCG]II! 9DZ=V=Q/IO?9&ZZ
_S5O;L& M?>%R7M2*(I@1U+\;4"?)[FK1&5HT]CB?"$V7 SM&=PQ=V]R-W-H965T M&AA)VCT4 M>Z"EL454(K4D'2?1]3N4+,4%$F[I$8?DS)M//LWV2G\W%:*%IZ:69NY5UK:7
M06"*'AMN+E2+DFXV2C?U1Y3)Q^IW"5X%[W^53.O= %A#46UB%P6A[Q&NO: 5$8_QXP MO=&E,SR6!_0_N]PIES4W>*WJOT5I[F7>5#BAN]>Z?V?^$AGXG#*U1MNB_L
M>]W)Q(-B9ZQ]#L8402-DO_*G0QV.#++P#0-V,&!=W+VC+LH_N.6+F59[T$Z; MT)S0I=I94W!"NJ;<6TVW@NSLXJ9I: 6,"$N4N!$65C67!LX>^+I&RQ/)G^ZV""&R-
D0X1+=A+P'ML+B$,?6,B2$WCQ MF'J4M;J%*4<#ZT+%"&0L[JK8& M6R&TU,#7LO@=/[?D9S7X&2;C^F< _;E##@H=(T.\<=!^]7Q69-6D/3?DBKAEI* MZ7^A?BIIB/]*
KL* ,>TLB/PI2$F(1T0@*+0C_.W%$>^9-\"I^D16K>H9A9 M=YGZ:98 2_PLHH7Y69/PQP^O,M8Q#ZZ M**)TW*VH)T2I0WX:2VK,$8"01!I:N^%^1]J\K3_)V/EH?Y;ZTSA_V3\HR^L3
M8_4>IHD?9;&K6>Y/TYR$*,O]+'=21CF%\6M3'APQ4H-ZV_&N(ULL26G5C1[PFU4Z#[MC5)VV#@'XP]O\1]02P,$% @ L#AG6200\\"= P &@D !D !X;"]W
M;W)K&ULK59M;^,V#/XKA \XM(!0OSMVFP1(LMNN MP[H6EV[[,.R#8C.Q45G*27+3[M=/LA,W;5ZP#_*D95R.GU'I][;HJ+[&FZDJLD9N=I9
UU>95KERUEDB+UJAF;N1YB5O3BCOC M82M[D.,A;#2K.#Y(4$U=4_DZ128V(\=W=H)OU:K45N".AVNZPCGJ!8/TKRY M/4I1UARY*0.%+BD#=/?Q.8K
M;N.)+5XNF&K_8=/I1IX#>:.TJ+?&AD%=\>Y)7[9YV#-(3QDS6X.@Y=TY:EG^ M1#4=#Z78@+3:!LTNVE!::T.NXO90YEJ:WU/I5[AXI N&ZG+H:N/(JKOY%G3:@08G0#.X$UR7"K[P
HOW]JXAV+,,=BRG MP5G .:ZO(/0(!%X0G<$+^ZC#%B\\@;>-\._)0FEI"N.?8S%V$-%Q"-LLUVI- M9C:CO:9X&/TYXQJA1,X%X6%3>M"6U5*+CP+Z';FQW=>Q2:,OB]J1'=-
UIILZCX"]:449XC4 V_4MP+7^K!(@]CWC=#Q*/ M1$E"HC@$?T\6H; M)[@QM*(L)&&<I)*+7G39RW9&VX;6,_V$+DQ#2!EPB3QSM8TKQBMG!W$)D? MD31(#Z
_[L^L'\:H_A"EZKPL!3.7L\TUY8#UFHE71,A-#]OF (W2W#R=<<5- M;PO^&WTRE'XYZ?C"3T@:AY>'@KW3O*,R+R$\>I@!20<12<+!N\/,LI@$R>#] M488D33*2>=&[2FDX]C?
&#X#^D542AR3+TKW4=(+#"KE?VYPKP!>4>:5,;[S5 MP_8*NS7Q3%A(O2H@7Q.^2ED:^ M25IVD+1T0((L:N^(8Y>ANS>O:I2K=BHK4W -U]WHZJ7]X)]T\^Y-O?MJ,#6T
MJDR*&"Z-J7VR-!\O**V'V5*H7VTBYP NE8K>C"?3C=!S9 M-A%.G+,G6^[?,W;:;('=2O>E!8QG'C_SFN5!Z6^F0B3XWLC6K+R*J+L* E-4 MV @S51VV?+-3NA'$HMX'IM,H2N?4R"
.PUG0B+KUUDNGN|/KI>I)UBW>;3!] MTPC]WPU*=5AYD7=2?*[W%5E%LYV8H\;I" _=G68I&%'*NL'6U*H%C;N5=QU= MW:36WAE\K?%@SLY@(DJ]\3TQB>M
MX_GYA/Z'BYUCV0J#;Y7\JRZI6GFY!R7N1"_ILSI\P&,\F<4KE#3N%PZ#;19Z M4/2&5'-T9@9-W0[_XOLQ#V<.^7,.\=$A=KR'AQS+=X+$>]G5 ;2U9C1[<*$Z M;R97M[8H&])\6[,?
K6^Y[G\]8Z!##9M*:(37]V(KT4R6 ?$#UBPHCF W_UC\ M#-@"/]F6*@/OVQ++G_T#)C:RBT_L;N*+@!OLII"$/L1AG%[2\9H$X>7/(//W M7NBV;O<&[L9H_[I>&M+<'/\\%>\ ESX-9P?
FRG2BP)7'$V%0/Z"W?O4BFH5O M+I!-1[+I)?3UA@>P["6"V@&>B-LR&4OV'M##7@A$U9\OFJFX)N>2<*I>72LD2M8&7\#K)_&01^DDRGUAQ MX:?QS _3A9/F"5]$?
AAF3HQS/YN'?I2G$WB'K>(!=Q3N%0G>!&ZE,'OQP-3V M"&WO0N!^X/5JB#-FJ3@"!F:QGR]F_CR/(4O\+)K[LRQSVC#QXSB$-//3/&-M M^!CB8V%?OU=9GN$TFTV&0Y2[0S2-YD?-
+)D\U>W!V5+BU.[=2C6< MQ+ZE83^-VG&[7P]+[=+%^\1\$GI?<[])W+%K.)UG'NAAW0X"]G28"D2[L.:V,DZ?HPI{@&6:(N()*HD%4+-NIK-@(!N1"2>=^OG.1 MSI9\JR0YX-
4J?)T/)9Q2G,B1[RD!3R9$%8.+,W-O*B[.>*4R5M"I0++*/V>2W]D_$=?)D123_R[=+ M5'H^B 8HH7-29>]6+_^@C3^^EA?S3)[_:-G0V@,45U+QO&$&"W)6U/_)4Q.'
M0QC*C)6_$T4NS@1?(J&I09H^&%<--QC"'IV4.R7@*0,^=7&?$D'? M7X%?"?K(<\BU)"9<)_=DEE$Y/!LK4*.)QW$C\JH6Z>X1.4%?>:%2B:Z+A";[M_&,PKI717=MXY?
8*O*/E"'FVA5S;Q3WRO-9GS\CS#0!Y2E8 ,84NA2#%@IKS M/YXW)[_!%B.6\MQG_2+ M.ZC)LHHXG,DC1,Z+O\@#19>?T2T%X+%8 >4G7@&'0 :L M$KU![WZ+7,?]L.?
D6'Z(+7/4&NY4R Q _AY$\[M(Z\&;:2G!]MW)"I[T.'&SA *3]K)A:H2]%K+,".3"1!.&V8V'?1]B.#)\" MZ@++4WTA4NEJUC^ZY(MG(-"F1]BU K!2G['K6X'OP-FW/!Q9=N":LV_;%@;W
M;N9HF(X/46LB+-*!Y7I\2 I$7%J,)#01Q@VI:GEM1H?[PFX#X$)'1"K0@' MEHTGVA??MB+'WR-Z00LJP!,MF230@IEN#B86:^&.Y7F>-7%<+0P43#P, 9G8 MKF4['L+@Q\0*
(HQZ.H#?=@"_OP/4PU,W@((7CX 7L%)L8 ,#(WZHHR[KLH'T M=15UOYK/T T5"%@2H<.P'Y??*H-F,*>Y<:E9)*K6MD&-P\, 25%ILYT&]! G MQ[;L,%K3-]10 Z81%+IR\KIRZ+
[*.6FE#/>H[6!J -Z3B]!-17!P,I]DPH2^ M-_+]4I]%WE3SOB S*:M?0VR0VN&Y:[E>""CUG\5\;ZB@84 Q^I';KZ]I=K^(MAUS.*3LRJR \AI8D>\-.I5V<5@N!!S=*
YR#.N.XX;P& 2@(&Q1$!Y:D$NS M FK%C] Q%H ",#PO=;LST:B3NO:G^QK]JGZ\)-^,T)V8)95@Q>+PX%]+Q6#5 MU3DC3*!'DE4&WUH -YH0_.BKA<8I2H 655+KN,I(_/
>BH+#V@B*$I]ADS=# MY#DCST'73U3$#'IE"7V$F@?8'P4>/"BI:2R*BGRMRCC1H>ED!5U>#@$A0Q1L M6!]Y!@TYTX.J$5!78:/+':+0?XMNF7QX/]?
#G16@##""A!$*2,,C[^U&7@*U MFT",ZN=-QWAKM.K%ANZ8+*A9>W31:LTE%8S#HY2HG>'7Y$6;M> 9QK914 M4+,0Q)$Q=D?'EF]F7Z)Z88+T")X;?2F,
(PY^ZEEK>G_+P*C!OYZZ1.AE'FR# M7)?5+&-Q?;O0-$NF4E:'^].YN3(>AQ\ 144"KR!B-3)!TG:)/4%D$M5^-DG[M/KH;H7MX3905%,>*T0SF?
P6[H1ZI=#X'YQ!$2)/FAJA>O4V6M4&P]RG KG&" ME+#5/1E<9BM$?U;@*X1./4_%]*>@/X=2\W;;=TK)Y=R";=X>N MHNY7^$N_O]GN]S=-=3>-;0LJ>P8K#@(K#.TU@ZF=8^>J
\L,QGB_T@Z> -8S MUVEY:%WN!G7]YTL$&^/$.]0YC/S(W]X98CUTA5I7@PD=X*)[93U]!IU@,"V(M_.$1,QIT#0M"R/ =!IP>O0(43P9IDOPX5L-[CR#*%*ZWPW,0*((=
M2U_&A.>X%GZ5:[! 8+7IV_ L/%;*B1-",NWA_P_/!IVO7+1.X*TD=([%>.A9 MD?T\5/T@]X((]D*[JSN/MJYQ3"&XZHO\G5%XJ7YCO8C"O%4B(SV0CYI-(&EZJDJNIL]:Z'GN>
M2M98,74A:N1DR82LF*:CS#U52V2I#:I*+_#]OE>Q@CNSB=4MY&PB&ET6'!<2 M5%-53&XOL12;J=-S]HK[(E]KH_!FDYKEN$3]6"\DG;P,)2TJY*H0"'1F4V?>
M&U]&QM\Z?"MPHPYD,)6LA'QARMTZOB&$):8:(/ Z/,,5UB6!HAH_-IA.EU* M$W@HI]$_V=JES3X>"7*I6JUU-GZ$"*&6M*?2\V7W!73VSP$E$J^PN;UC<: M.9
T2HMJ%TP,JH*W7 ;RZ\-!P-!_)2#8!026=YO(LKQFFLTF4FQ &F]",X(M MU483N8*;2UEJ2=:"XO1LB3FU6,,-:R_8=HJG\!E%+EF]+A(PN/#N@:U*5.\G MGJ:L)M9+=ADNVPS!*QE&
<">X7BOXR%-,_XWWB&U'.=A3O@Q. BZQOH#0=R'P M@^@$7MBU(+1XX7]:<(^UD+K@.?R8KY26]&!^'BNW18N.HYDA&JN:)3AU:$H4 MRF=T9F_?]/K^AQ-!
(/T9GS,QZET0+09H1 M.1?9>4,'UO'/._ZL!$85D,W@TT5KK%8HN]LV5F/,1$G;1(WA2C1U82PW!3Z-\K24#N#_M!W1U&?I-@?N.$H@$=>:"KV*Q%.106!Z_<"=^CW
M21KXD1O',2SHA30YT>RYO7#H#@EU$)KH(3P(3?HS"-U4&+CQ(+;R*!JY813# ML;OW#L:V0IG;Y:2HR513.&=MMM_\W;L_[JWR_,.R;S@BQ!<A&+A_8B=MMO[
M@Q:U70(KH6FE6'%-.QRE<2!{)H3>'TR"[E!A]@=02P,$% @ L#AG685C MB>7R! (B !D !X;"]W;W)K&ULK9IM;^HV M%,>_BL6FJ5?]"DE(@ Z0"DFT*ZT3NNAN+Z9IX8_O9K
F1Z#5+6L\--=F?#QD6YG2G,PX$MLLP_QM0E*V M&[6N3SXM1JZ-[1%*22(W ZNN%3$F::I+JQ[<2VJI\;L/C MXST]-
@^O'N8)"S)EZ9]T(=>C5K^%%F2)MZG\PG:_DO*!?,U+6"K,)H5;0/5 M.-D*R;+26/4@HWGQC5_+0!P9>+TS!FYIX)X8N.X9 Z\T\$X,?.>,0;ILI/C M"194(+9$,TX$R24N],X7:$Y7.5W2!.
<2/20)V^:2YBLT8RE-*!'H)B02TU1\ M&K:EZHC&M9/2Z:1PZIYQZJ%'ELNU0%&^((L&^]!N/[#8MU4 JBBX^RA,7"MP M3C9WR.O<(K?C=M'7>8AN?OR$4J*&
[#^)GE5&l/;7K:CW1.D)5Z MP>5))XO3!A\13%=C.R8DB<(X-DQ-'Z\:I9[A>F>XTQ0+,TKGDB7/Z*_?U'WT M69), -TT^@I8MQFF<_6]V."$C%H:/>CY"VF-?_K!"3]_-&D,"0LA81$D+ :"
MU>3M5O)V;?3Q%(NUR3F)/B#?MO0%IVIPBR9Q"U1@4'K>?!EI/3_P W?@#-LO MQ\I9G5ZKW,5\TNW7NW7=]Q@H'G]2JWM9C[52A%;0_#!01U4 0ZL ?
Y]FST1KL66@9R;"9/DYT% M^N]LFIY8F=>F+DA86,#\HYC[)ZI NHN!8#7I>I5TO0NE,SJA_>Q:*6=;%$QZ
M[P+EGKP.5N_7ZO)==Q&DNQ@(5M.E7^G2O_J5*M=!6IKRL$D3* ?:UPH2%O;? MR7>:["#=Q4"PFGR#2KZ!?9IG649X0G&*9E@):*;*>'2 ,R0Q*SP0K)A@C:* M:*5?*R(D+
(2$19"P& A6T!OI"Y<=B#7[24-2&%06@A*BT!I,12MKO)1"<&! M6[Z7K..UFS_H=_3?R2QI]WJU?I?ZC4#]Q@U^'7?0K3NN!]X!!-ZU!OZ1YC3;
M9HUAMEI>_2I!TD)06#1*BZ%H=44/=0X'M-#A@%8Z0&DA*"T"I<50M+K*AW*' M8Z]WS+A>O\HWDS1UOMSH=>LMV@JRW*8HIE'2G=LNKE?UH M/R+0?
L10M+]*AP**8Z^@/.+7L]D7J/!0]@=)"T%I$2@MAJ+5%3U4;)P -/N" M%FM ;2$H+0*EQ5"TNLJ'XHYCK^Y\-/O:J;XE^X+6>S[&PO=V]R:W-H965T;LXYE]0]HG@].C#^++8
$KT6.15C:ROE[MJV M1;]% HLKM@.JKJP9+[!47;ZQQ8X#SDI2D=ON8!#:!2;42D;EV#U/1FPQG:CDI$"[",(@[K ML77C7"!#C2\!OQ,XB),VTBM9,?:L.\ML; WTA""5&H%K'Y>X [R7
NI:7RM M-:TFI":>MH_JLW+M:BTK+.".Y7^03&[%UM!:&:SQ/ICV!UDM9+LIO M=*BPPIZEX8U8=@U0EP3XM(.5?[*Y$^PQ,F(LP/B&JW4=*-T M4,E6.2=4>_U1CMM(G[?
3/F"NZ\R9]VGWRGH^ZSYYWW>??(F M^N+_W?GE?U[[F1&\QO)>]>?]J^6?: I<69U* @+]>;,2DJO=]R^3VRM-WZRI MWTC78H=3&%QJE2. OX"5_/*3$PY^-5FM3[%)GV+3/L5F?
8K-^Q1;]"FV[$GL MS,Q^8V:_33WYHHY#.1/"9-F*&99,?>9Y23YZH>/XOGX*7T[]:$"Z?A0,H^ " M.3$@'2^,@L!USI%3$]O)G=@+O'DS(1T%/H[E!*](M3O0.9,IA%2(XF9T?
N^H@JSX7.6R=S(_N*7V*3?L4F_4I-N]3;-$Y5PIZY M,FQ<&;:Z\HDJ3U!OM1U_4I-NU3;-:GV+Q/ ML47G5"U["ENYSCXI.0K@F[)>5;L:VU-9'<6:T:8DOBDKP8OQ6^=Z[AC&%Z[$
MKBK>[_)5_:U.HQM"]3:Z5]$&5Y%ZG'A5TU8=R79EP;-B4I5/97,+. .N >KZ MFC%Y[.@ S1\+R=]02P,$% @ L#AG6>>M _/U P ^18 !D !X;"]W
M;W)K&ULS5AAC^(V$/TK5EI5>]+>)G8@)%M ZL)= MN]*>M%IZUP]5/Y@P@+5)G-H&KE) ?)V038@(WN7.E?@"<3+S,O/\)GKR<,?%
MLUP#*/0U33(YN*^,UI%3>\!PR,E63)14J57HJ5*W,!=%$FI8E+/"]P M4\HR9SPL[SV*\9!O5,(R>!1(;M*4BG_N(.&]D8.=EQM/;+56Q0UW/,SI"F:@
M/N>/0J_<&F7!4L@DXQD2L!PYQ^#;"2D3RH@O#';RX!H5K6K\ MD3*!OM!D ^@34+D1H/=(270U!459(M^A]^CS;(JN?GPW=)5^89'FQA7XW1Z< MG "?
07Z#?.\:$8_T.M(GYO0IQ#H=E^E^.]W5;=:]DKI74N+YK_9Z_=+L FDI M/4&\$8)E*W1')9/7Z%K;E0 MJQ6(5(M./&M-S!/08S)72!:L,<5 =C&PAPU*V.)3LAUC')(@['G>T-T>MG<<
MV8]"/XP. ENE]^K2>\;2#W>]WN&N4HTPYVZ6);!6Q_VZX_Z%Z+MODS)+8"W* M@IJRP"B2WJFB25>'^[3^H7X'H1?XY$B_'9%A1/Q^T"/= A[4M0V,M7W8"!S M-
41,YJ@1YJ#D.A?[&9A&^'/W25+8"TFPIJ\$*$'=JDS!)8B[*HIBSZ?S[< MT9&<]:=X0/"1[H\#L1<%7ACA?K?NL==X$L]8_ 2$8DL64P42\26:0LXE4^=H MW_R&O7N6T-K]-_8-
]RY%]%8=H"VT-FV- M!\1&OW3:T51Y;[$T7:%F3X,;PX7-CJN1]7?[&_.;SMXW2VAM7AJSAP>7(G>K MOM 66INVQAEBHXOZCF]\^%:CTQ'YFM-I7!HVV[1F&FQX'N.
[SMY82VCMHYK& M Q+O0N:!6+6*MM#:M#56D1@U;?/0X4;O.YY.B)/>![WX%RR.!3^1,6*91(E ML-2IWLU SY38G[/N%XKGY5'EG"O%T_)R#70!H@C0SY>PAM)LY! :Q, !D
!X;"]W;W)K&ULM9AO;]LV$,:_"J$-0PC@NZACG(C\4C5R.[R;),,LA% MPG+$836Q;O'-G>OH@.J.3PGLQ,$QTJTL&'O2@X?EQ*T(D@AECH%51];F$&: MZDQ*Q^%ZI4WE-)
MIV/.=HCKNU4V?5"U6D4K<4FN9V4NN;I;]#@Y?H?>4/X&D"Y7H M'A82O;I7HR05OXYMJ33KRG98V(0SST<7Z/7OW\71I; MM=ST39J^2977'H]NM4J@E7ZFE?C6G2OO?
[U00>I"0B7_Z ME.\K>/T5M)UN1$%CF%C+P+X%JSI+5]AW_G-H-]M+NF]--V.F(U'7W]O%^ M%;^]N9WBP M=UPOIL;WM*>TUI3UCZ=\Y$P*5N8) 6BE8*_+/@G[/*,#"2XA
M48"]?@&C1L#H- &I&D.O@E%'@=-?VV]J^\:E2NVVA5]Y?Q..1R$CN]1O:7 M#9]R@;'LC(I-9'%?A1?0'S7ZH__IJZ@S MQX2.(8/7G]D\Q=EH4.S_(6'6B;T2$Q ^"
0D'WP;X1UFKSG2$MW +96QDY@ON MJH._??1!Y(5#[L(M3;$9I]\MV||JQ@QG+DO<0A=[%S<6-H+]W!9:;&,SMU_V M%N[R&N.13[#K#[FK!3[44QV:,GV*OX&&A[M6S&1G2^
M9*^PY^$KJH3+H];JF(S5M^4G,4LRX#'"4W1(RV_]!=MS'F$B4M@HES^6VA MD?+GMM BG)@1_K++2)?<84!<[#H#"YP<[*K- #_>9*0+7ML-AGI[HG#R D('O(8:?
%*S'B=@9KW51)3"4+_/KN' M@HFD?P48,YV[1%L4$__R+C/2_MP66I(3,\F/<%D7X&'@.P0'TIKMAJ#:L QI:HA.ST4Q67?+/+#8W1;4KGFO;'99'7SXXU&NR^R# M5R?Z-=1[RM?]6:
(45BK4N0Z4:KY_L[.?2%94;U.63$]658<;H$O@^@9U?<68 M?![H%S3-^[7I5U!+ P04 " "P.&=9OG4[(/4# "F$0 &0 'AL+W=O M.N4/3%%D<\9X9SJ)&&XQT73S(& M4.1;RC(Y,6*E-
C>F*<,84BJO^08RO+/B(J4*AV)MRHT &A6@E)F.9?7-E":9 M,1T7MGLQ'?-T%DGJ94_'D'C.\FAFT\&QZ2=:RTP9R.-W0-"U"/FWN! M([-FB9(4,IGPC
A838Q;^V9N6QI0S/B:P$X>7!.]E"7G3WKP,9H8EHX(&(1* M4U#]V\(,&--,&,0SSU0LR3R+(&K !^WX40O>Q"35F7*>,W7GM!(N8'--7.N*.);C-<0S M>SO<;5K.]WF?
VOO1\EPZVWC%GSN*WP!+-6!Y%?D=HN*ZXW0P^+56U &: O# M/,T951"1#X)+21XS+&8L^4L;L(B1BT]HO22/7#&"#[X.RJBWYOV2AF-UQR- M+J8W&P?TX;R*TO+
[O#NN)1VGQZ[3XK6GY!%M@ MQ&E::BOPW$W9)5G0)=F\([*C[/?K[/?_5W6FWZ6D79(%79+-,R([DG102SIH M?:!*A?*]0NM"
(:85NL)2LTZR+,G6^/G':!9"DTJM#LY5J4NRH"3S#ZJ0,W"L MH>^=5^N.G!X),*P%&/X7A;[5R;DB=$D6#%^(8+L6-DZ>?Z)"1UZ/5!C5*HQ: M5;A-
>:X_NO>YQD=A)7B*O=.^G/%7M6]2I-7CN9)T21:,7DC2LQUO9_^&IYIT MY/9%($IO:=T/6=Q0GR*)_]$P5_?'GCS,:V"<%8-8>O[GI?:O;>5=NR_2:!WUG M"F)=-
/P2MRON[+*7]*WUH<)MT4J?V._LFYG=8 _T(431Y^[IRQ,,[#SQ12$) M@Q6ZLJX'N+=$>2A0#A3?%%WODBOLH8O+&&@$0D_ ^RO.U?- .ZB/9J9_ U!+ M P04 " "P.&=95W <;P$#
#E"0 &0 'AL+W=O<4K M8/K+C(N2*MT5FPBD@%*3B^ZJ0.W"L MH>^=5^N.G!X),*P%&/X7A;[5R;DB=$D6#%^(8+L6-DZ>?Z)"1UZ/5!C5*HQ: M5;A-
MCOB1PUKNN#&Q\L#YH^G<9D,+&T500*H.!=6O%8R@* R3UO%K0VJU.0UPM[UE M_U2;UV8>[(01+WIFF5H,K\0P<3K@8].P\>0:KA3P[U!N*M]92=):Y+4 M?.X+)F%K\E)/K1#
5)^UALOKYS)E=2TKFL+0TG4C0:S 2MZ\<@+\OL_HF_*5L\M4#^8I+9"AIR)=(,HRU(YFL-*57.FZ5,BDSU.0?7/2) KJ M1&9G6"6A&SF1XPSLU:[=;ESDD9#$;=B>$:\UXITT,EU65?%
<*R!6\YT[2]% MSN8G)3>4_HZ4P/6C*'8'DKMQ#L%^OV"_%>R?%'S+Y%)0ED*?,+^;T(L#GQS. M94\<#D,OC/]U!:VVX*2V;VH! E6F))[-NO=.7M#)K1,3?"BQ&^9$,
[5[3H4Q5VT_EQY'G$/]#5#20.)@2[_<*B5ECTK_L(,S5V?"^)SKF7 MG(ELSWK<6H_/7X)Q=QEPX/GAX7)UX_2NX7K!D3_=P7\.-_Q_?](&%[PHK2>P M7YN]=]VS$G?7NS2WX#4$L#!!0
(+ X9UD5M9O=]0(&0(9 >&PO M=V]R:W-H965TXY_YP;'C+>,/XDU@$3/ M!2W%Q%I+65W:MDC74!!QQ2HHU9TEXP61:LI7MJ@XD,R("FJI&(=V0?+22L;F
MVHPG8U9+FI2;?$RNV4 9+4E-YSI8?HP+'/R%P6X'IKP*O%7@F:$-F M8MT129(Q9UO$=;5RTP/3&Z-6:?)2\?\6YY.INKG0R>_ B T3*#'V5:^!H1G9D M04&@BSN0)*?B$KU#C _[=/'Z?
0P$; M1W_84>^Q:U&1%":6VD0"^ :LY,TK)\3OA^+^)[.#\%X7WCOGGMPK1\+3M0F? MP49MX$IM1XGT0GG:=H6J42D +0'$4#N:-4*SAGY#;)+(<3P\BL?V9CIIOV[D M.'[@=V4'&?
PN@W\VP[RN*KHSH 4IZZ5Z:#7/RY7!157S>(>P&[M@#\?#ON]Z MT1%VORX(/#\8#6,''79P%GO*2]%>*QI4HY-LDPO&=UWGAXB# >(HB)TCX'Y9 MC,-1,,P;=KSA6=[/L"+T#^;?
FAOV&!SL>\YQ;_ME?H1/H48=:G06M7EKM7"# MC8SZ=+[C1?B(KE_F^OYHK|\'>'&'%Y_%>V"2T"&]N+<_'!PY.,3>$== 8>Q% M87R\D^R],T"?OU\(7^6E0!262HFO(A6--
V=:,Y&L,L?"@DEUR)CA6OT- *X+ MU/TE8_)EHD^:[H]%\AM02P,$% @ L#AG64@;&U,W P)0D !D !X M;"]W;W)K&ULK59=;^,V$/PKA%H4=T ;2=1WSC:0 M.#VTP!4-%EIOX7
/M+RVB:-$E:3LY-]W22F"8\E&'PH$,2GMS,XLEZ1F1ZF^ MZSV (<^5J/7.TM9N[9HUK,9&L$K^%1$=U6%5,O]R#D<>Z%WNN#)[!;&_O 7\P:MH,5F,_- MH*9/!'L>
6UYK(F"K9S[RZ\718VW@7\S>&H3\;$.EE+^=U.?M,_O< * @&E ML0P,?PZP!"L#I^9?_HO*.7-=.PE.(+WYC]W,L]LH$M:X5Y MDL??H/>36+Y2"NW^DV,7FV8>*5MM9-
6#44'%Z^Z7/?=U. &$\04 [0'TOP*B M'A YHYTR9^N!&;:8*7DDRD8CFQVXVC@TNN&U7<654?B6(\XL[LI2M; AOSYC M7VC0A-4;\]?9@R++5BFH#?G$V9H+;CB^??< AG&AWY-?R.?
5 WGWX_N9;U"' M9?/+/N=]EY->R+F"YH9$P<^$!C2>@"^OPQ^@'1'CBX%;N(_NAQ+0H034\447 M^'[9"UN+WKJK!Q.:?+U:;Z.PR[Y-&>P8XVE&N_-N=<-*F'NXM32H WB+GWX(
MT^##E-W_B>R-^6@P'UUC7SPA(U/EWIG?P &W=5/95;>)>-E71> (NX-L ?14 M.;HJWB|&Y9B2G,RTI(7,?Z=21Z'8?]$671!%33<5B49D663NO+!GW957U+66L\SQGVLRVK=.?:I2;.
MQA*2,,O.2SD.RY.H?)II?F(-+^]!/LF+@+H+1\O7Y:'Y[MK'%7D01",'RL& M8<7U)9:&B2E-Q6@O9P5-$GI>KW><6D1!2,!U^2>7F/V ^(.I':\U$;!%9"3 MH3'57 L@'X?
BNE>9W8JW+X,EK\"U!+ P04 M" "P.&=9JAY&?#\& "E0 &0 'AL+W=O^GRPV- MO/1]L]6Q>&>5L,CCXBE;]],MHYZ?-XU"OJ8HHWD[D!7%O/LN?VS6;+C81#3 M&T;2711Y[,/9"?
S[;>FMZ2_F7[0T3S_J5X@<1C=,@ MB0FC]\O>E7KA:GK6(-_B[X#NTX/'))O*79)\S9ZX_F5/R49$0[KD&>&)/_=T
M0<,PD\0XOI5HK^HS:WCX^$&W\LF+R=QY*5TDX3^!SS>7O4F/^'3E[4+_=D[MM)S0,/.629CF_Y]IL>U(Z9'E+N5)5#86(XB"N/CK?2_B(,&VO!$ ZULH!TU M4"#<(0W+!L-
S>QB5#4;']/6@G&HS+!N-S&TS*!I/C(0U. M-)B6#:9Y'(KO+__R#8][\QE+!H1E6PLM>Y G*&\MOQ,@SL)^RYEX-Q#M^/P# M%4E)R9_DRO>#+'Y>2-
RXV(FR,+XU*/>",/UCUN>BNZQ1?UG25D%K)VB5?$QB MODF)&?O4;VEOR|M/)>W[8IK57+6'N5YK4O!JMWY/U,$[HBG:@*SX[[^IX\E? M9$M9D+2-;R'G#+H4G)9S>L6U.(;
<^;3DPM&?=LPS'&5ZY)R>GG7&IZ6K.:?* MAF7+G5SM^4G2Y?NI?;@WR]DU;FISS&5W"N&=\:>6L=$FFI&K_T7-//[G_]"FE M|TB^'!TC!DV7+-CFN\Z_\2VQ.4T2O|K&>AU
0 ;X>Q'[B+=>DMZV1._8BEE M][0W%]_!2&G[#A9(S$!B)A*SD)B-Q!PDYH*P1J('5:(',KU*M%A/,?$;$*!) M6&0[WD5WE)%D)18Y,=V+'XHD#WI*?IT^R%P7G0WSSK*5U_U#
[':YEGLWK0E3LIU/;XB M.0.)F4C.0F)V@8T.=AM55=312&WN/,[C[<83;:PTMW)!0VMD;U1E;R3-WNT^ MX#\I"[W8)Y[6JV!)VP(G-;H&#HD92,Q$8A82LY&8@\1<$-8([[@*[_BUEJ9C
M9**[F('$3"1F(3$;B3E(S 5AC41/JD1/Y(?C;SN/4:)*$IXM0_/U@$_R_LC; M("9I^3ZEO.W4\%JJ=XTU$C.0F(G$K,GC-;"N'/U&V\@>'23F@K\&7*=57*?/
M.Y/BE$59@=)=)FWY&U9E=)=)LRH?ITY^4(^E;;E$CL)$8M9SIV0C1^$@,?<9 M4VKD4E7JB[Y*MW,JK[[Z*XZ@WO'1M2V\@\BZB)KX34#H\SZOCX.&- ^S2AF@75
M;*CF0#47I37#>U"Q4*7AO4D83R2G8_+FG8.)U RH9D(U"ZK94,V!:BY*:P98 MJP.LO=:)62FCLHW4#*AF0C4+]ME0S8%]+DIK9KLNAZG2VL2+3]%*OG&^H1RO M
Q;R070.+K3>U3(#?7H\ PO:IPW5'*CFHK1F(.MJEOK,O9L[*@X["AF@/57)363&Q=[U+E!;_#]2WY1:YW0>B+W+9F M%%KK@FH&5#.AF@75;*CF0#4?I36S7-?/U-&K+76A936H9D
U$ZI94,V&:@Y4 M4V5UCI>=GGW"5N3K"Z@]32H9CXQ*!GJ EH^@VH.5'-16C.U=0E- ME=?0%EYTQ)_3657T*"%,JAF0#43JEE0S89J#E1S45HSQ'5A39V^VK("6EB#
M:@94,Z&:!=5LJ.9 -1>E->]1J&MSFKPV]|(K:'*^:\"AF]$]KO*-'EW=,Z%| M6E#-AFH.5'-16C.X=5U.D]?ECE<63UR[D&N=X?W,H<4;,.[X-/11QW,2_N|*U>K>ZU

MO\KO,#]ZW58OG.*.^9HI;N#_Z+%U$*8W3-\E MG"=1_G!#/9^R; /Q?K8T?WB2=5#]SP3S_P%02P,$% @ L#AG6;$OA")/ M @ _ 4 !D !X;"]W;W)K&ULK51M;],P$/XK
MEI'0D*!.DVQC)8W4M4(@@52UP#X@/KC)M;'FEV"[S?CWV$X:M5)60.)+XK/O M>7S/G>^R1NE'4P%8]"2X-%-<65M/"#%%!8*:D:I!NI.MTH):9^H=,;4&6@:0
MX"2.HALB*),XS\+>4N>9VEO.)"PU,GLAJ/YU#UPU4SS&QXT5VU76;Y \]^D. MUF"_UDOM+-*SE$R -$Q)I&$[Q;/Q9)YZ_^#PC4%C3M;(*]DH]>B-C^441SX@ MX%!8ST#=[P!SX-
P3N3!^=IRXO](#3]=']O=!N].RH0;FBC^PTE93_!:C$K9T MS^U*-1^@TW/M^0K%3?BBIO6]O<:HV!NK1 =V$0@FVS!]ZO)P ABGSP#B#A# _ M+2#I $D0VD869"VHI7FF58.T]W9L?
A%R$]!.#9.^BFNKW2ES.)M_ I<#@]Z@ MAR 82C0[@';U0ROPCX#)'0H^Z MH@:@LT8*90NVE12MJ 5TMP%+&S:N,6!>/ M9R5%=_=]>W?\S-
UKJ$:AWM;7^XI)))2TU7!]+U^1Q!UV2/L?H'>#T#.E::\T M_3>EY?$!:_> AV2U?'>!SX_!0QZ-HO0V(X=3!<->=[U7&RPYZ4T_%S]3O6/2
MN"1O'2X;^4FBVUG3&E;5H5TWRKKF#\O*C6?0#$L#!!0 (+ X9UD]0I0]70, , , 9 >&PO=V]R:W-H965T>F1J,;7IHRWFN)=SGB='H#. >*G)&O>
[V70.HQN66/6"JMR(=K MT(SGZB-&?+^_)A]^^]BP->8U:#MK)1 M(!_ 2M^_HZ'S>G!F/0&%1Q)IT%$@[BO?9)]IO:@TQZ\ MICTF3Y#.E1YWTZ#7I M\9CTZ&W2)\EG2H\[Z?&D]&\
[P-Z\T2#'#,0# TD0FC*=Z)_,,%-_TNE/IO4+ MC:^;O.XI5=M3QIPD R=>$(4)I3TOD]EF>]'.PYKP$JL" M2H^V0V?@YXPFH>?TWT;3">
<:.NK]],WER3E;\9SKQU%#=%@@+W9"Q^T;FDPX MU!S9Z>3K;2I4+:7$A\T4@E9[Q2Q[[W%HCM2,]_WXZ3_0F@CPY-(FD1Q%':1 MI_]?>S6=;M8WHMR>X7-
5'(O'+;MDFI?;G@T.HVN)#KLX37 Y#1^^8:#K)_AS M>C;LH^VEV=O_R>26EPKE;!#IG$O]>D./S% F@"\ MOQ%"/PW,)K;[:$G_ U!+ P04 " "P.&=93TQ#_=<" "0"0 &0 'AL
M+W=OWO6VC)7&PW7;\>ZZ=-.O#RRK8E\2/<\[UN3>QW=TP_B"6)(\ M9FDN>M92RI)CVV*ZA(R*"U9 CC-SQC.JLQ!=;L,>I:C%@0I3*52H/A: MPP#25
GA,GY7FE8=4A%WVUOU3]H[>IE0 0.6_DAF1? ."<$S!+\B M^*=&""I"<&J$L")HZW;I72=N2"6-NYQM"%=H5%,-G7W-QGPEN?I.QI+C;((\ M&7\%S+(@'\AW)FE*=)>,'O$SQ/?9$"1-
4G&.\W?C(3E[>]ZU)4957'M:1>B7 M$;QG(OCDFN5R*<@HG\',P!\V\L-?!O=UI:]K>6^UR@XAN*^,Y]XCE>8%C/ MX'2Z;[+S?|%'_QQ]+QE^77]?Z_G-]?]Y-
1&2XU_[RU3@4B(P2ZB=K",*.H6> MA5N5 +X&*WW]WQHV'H*Y#T*0>?RN 4YGD"Y+]7Q#* M7]!4C5(HTD+J&%C'?M@*6_@UK'?S;("UP\C;1PV/4:X3N8[7WL>-##CWLN4_
MR>VY#FO78:/K>\H3.DGA9=.E3K@3/_3;K0/+QR#GP.XI,JFF3V;46TS:K19 M[JTO>HR.*Q;AZMP#EP;8H;#'*"QL%'B7!V8-.%-A[9TC)@,.^T&>I(%.VRF6Y MV]2C]?7A2I^:!^-]MS-
P#>-#O&Z4MX,G^?*N,RO6\!:@O8?%?4$L#!!0 (+ X9UFD MHPPiH , ($, 9 >&PO=V]R:W-H965T6^:,.ME#3N4=+Z' -ULNE85F#FE!7&;%+/K<5LP@\J8P6L!9&'/*?B90X9/TT-VSA/
M/++=7E43YFQ27AT\@?I6K@6.S$XE93D4DO&""-A.C0?[?A57^!KP.X.3O'@F ME9,-Y]^KP>=T:EC5@B"#1%4*%+^.L([JX1P&7^WFD87LB)>/I_5/]7>T,O7(3[!\Z\>O|!*>R?
J3G!JLA^#D(!7/6S*N(&=% M\TV?VSQ<$%!'3W!:@M,G>#<(;DMP7QO!:PG>:R/X+:&V;C;>Z\0MJ:*SB> G M(BHTJE4/=?9K-
N:+%=7OY$D)?,N0IV:KO,SX"P"90P%;IL@ZHX4D[Y>@*,OD M!_*!2'M:DO?O/DQ,A?$]EIFTVO-&V[FA[9(OO%![259%"JF&OQSGQR-\$WUV
M9IVSV;DS*O@$Y1UQK5^(8SF>9CV+U]-=G9W_%WWUGZ-?)NX-O4=0 M3 !N>76NO21_/FRD$KAY_]5N]'S]'K5@78O2YK U, 32X(X@C'[^2<[L'[5 MI?
HMQ99O*;9Z([&KHGA=4;PQ=2RR.+($2,*ETI6@80HY1#EV)8;]<160UAL^W'0H:Y\^IU/?]3GYT(!9D_=--K0_8NH MT6!IBR$H#".O9W,(9="Y#$9=KIY+O \AQ0M5'41!\&(L
M\7@E5$I04F<[&"SCH^V[;M0SKH"%3F3UG&M0Q_V82L-S F=P-=[#SOOX:CW MAYP+Q7[0NAW@6W(H!"1\5[?F(^,2ZW]<%B%P(I]YH>@OO$A(@SM_N]Z3.;*
M<=0YCD8=KP7CV(&==[" %*_3"].LP M=B.K ?0$]=/XC32G\R.DE8(CJ)T"C M$P9N+Y&K,9VK#,1=!N+1#'SEBF:DP.ZV!$QU&RA*R:=N^6_L\'IPN@6=';L_Q
M$.7$0=CSLQRB["B.XK]M(0PWNN7VK)L7/54.8E&ULS5=M;YLP$/XK%INF M3NK*2X#0+D%J0JI6VDNT[.7#M \.7!)4P,QVFO;?[PR$)2EAC<2'?4EL<_C MN^?
L@QML&+\7*P!)'M,D$T-M)65^I>LB7$%*$O7+(<,G"\93*G'*E[K(.=" H M *6);AF&JZLTI?QI! G;##53VRY\B9DL%W!UOV6^*V#&6.14P9LF/.)*K MH>9I)((%72?
R"]O<0A6/H_A"EHCBEVPJ6T,CX5I(EE9@|""-L_*?/E8Z[L MZPC J@#6(< ^ NA5@-Y+=[K@/W2'9P*4(2NE[$7P@544G_ V89P98UL:E"H M7Z!1KSA3YV0F.3Z-$2?]29HG[F
C""#12S)-*&9(,_()\HY54DD9P%(&B?B M[4"7N*/"Z6'%/BK9K2/L/?*197(ER"2+(&K !^WXRQ:\CI'6X5K;<$=6*V$ MX07IF>?$,BR;?)L%Y.QU4USC4VC&MS?D;';#FXB"=J(9Y$AD_-.?
R2DT1_S9 M$ZQ7GX]>P=P[&ND"5Z*#XT&SB'R6*^!DRH3D(&,.6#SD@=E7.D^ ?(5'?)"P M\)[_(!DY$Y"*GXUG:;2%[O9%U4RKT1.0QAJ6!,%\ ?0_#>O3-=XWY3"+LF"
M+LDF'9M=2N$VJWT2MCO% \GJ]5F19822(@DI$<\)64D%:N4Q/2)5E0DKD% MF7H9/OCFI>6XO8'^L"MU:68:NW;NI>TXM=V>BDZMHM.J(KZD(*1"-FG6BCQ5
MLR[)@B|)AV1[RIZM8I>]XK::Q'NJ%F(>$[B+.0V M0N#77 3EZ.TYVC57,.^9OJYM>MZ!O-YS>1W7]IP#=5M=/E7=CLA*=?6=S^84
M^++H5P2JLLYD^854K]8MT771*1RLC\RKL=FP'F +578\?^G+_NLCY5E3U-.),N+C_8YD]@"%,,5MH' E0$^7S FMQ.U0=U8^G\ 4$L# M!!0 (+ X9UEF$U(8[L /*: 9 >&PO=V]R:W-
H965TII\(U+3T)5-]8N6YN=KLG,[F<'E$"U MP8QMDNZI_?%K@X,B$$(F)]7;'SI]#ZO4(Z%[" .9]ZXR6:PZ MXZOM:Y_S\56V*=/%2GS.G6*S7';YMT\BS9ZN.V!G^87?% @_SLGZA.
[Y:)P_B M5I1_K#_GU;/NGC);+,6J6&0K)Q?WUYV/[@<>#NN ;8E_+\13\>*Q4[^5NRSI M4C_AL^M.KZZ12,6TK!%)]>-13$2:UJ2J'G\VT,X^9QWX\O$SG6S??/5FI])"
M3++T/XM9.;_N##O.3-PGF]3\+7MBHGE#8V;'C8!0]L,HR9@M)7#[N^W_>-'29F,K_+LR<.?G'B/S>+\IOSLW-;75]S32]< MI-ZY+;/I%^?CIIQG^>(O,7.2UL
M*EBGZ4Z;RGS:5<8[41G7NF>-'AOANU;#[UO6> M6_>39P3>BO5[QPO?.5[/"W3OQR+<]YT,C\SA-TE>A;LGPV/[[+XFG)C#_[%9 M&<.I?>5UX>QU3?X$VRY;+]VF|/7AB[\$?7G_B
M??2C6R51<=ZJ/M$+DCZ(S_O$'M]_[1:-?K9^MZ8%(XXJO(IXNB[O$7]Z:7_TFG9B.TK9IWL' +]\=NCV-WX(]Z M5]W'ES)%)IHR1,(*$422,(6$'153!R@Z$W5"^#&)F3(&$4"6-(& ?!
M%.7V]\KM&Y4[J66;ILEVYE>I=Y(F1>%,GE5\GZ75='2Q>JB&VXY8KM/LFQ#. MM!JEYM4TT2E%7LT)=L&5L&^R;/7/Y$LE>7I.Z,9:M14Z$A;UC[O[_C#T#W2. M3$F0,
(J$,22,@V"*$G=0(@^, ^#?LS))G7IMEG=5KUSI_-=\5@WD_V88$@^0 M$D7"(B0L1L((SD:1,(:$<1!,4?)PK^2AL<>62R#OG#OQL%BMZN[Y+DFW Y $
MW:X1W5;3PZ.>LM!K_AT,ZU+QL@*$B2,(F',ND$X**TBM=%>:B/S[&LW"%AL M5]DN4)N1WE9MH^,F\X?]T:@7'(A-4] ;#=R1-SK0&K)Z! FC2!BS;0\.RJI(
MS>W)A>"><46SRL[EX*;MS&C-3VXH,2HL:VME)$S0K@=(HE,:@-(ZBJ8I]85VX M_Y=S)W.U6DL>28L:VKGI$S0I@=(HE,:@-(ZBJ8KWI.(]Z[&G6,U:# 7,X-::
M]:R'GO9%8V@="91&H31FWR@I+:L:],;2&!$JC4!JS;CV.RJLJ3CI.KMER:JS2W8?Y1ZVLH/82E!9!:3&4 M1J T"J4Q*(VC:*J$I1OEAJ|S^UVHSP2E15!:#*41*(U":0Q*XRB:JF#I2KEF
M6^15BYQF=FMU0ITE]A>"D\-1Z$>$Y1&H31FWR@>*A' M9-X82B-0&H72F'4+=1,\M):\'GKSAP>UE:"T"$J+H30"I5$HC4%I*$53 M-2W-)^^,^;2;XQ?U!NEWSCK)G<6M\[
MVN!%3]![7WTJN0<|+31K#*41*(U":& SZAX]$.DQ0&H72F&V3<%1:58_2//+LS:-V*U!F M<&M!:HX2G5@2A2:.H30"I5$HC=DW,40=FQK#P/7Z MHT,U0@\806D$2J-0&K-
L7X[*JDI16D;>$+X<"O6*H+0(2HNA- *E42B-06D< M15,U+1TGS^PXO78Y%&H]-;3SRZ%0XPE*(U :A=*89?OR\\^74F^E(0\DWGU5Z M7DO:WIWDO\[Y+:-F7EM]06D1E!9#:01*HU
:@|(XBJ8J6MI)OONZU5$?:AA! M:1&4%D-I!$]C4!]#TCB*IBI86E2^_=FDUBM19G9K=1\?KSFU%\]^: RM(X'2 M*)3&[!N%HQ*KHGMQ6SWS\:2+ES[-W-:"TQRN\8:#H.\/#O6F*:G?
ZPFM(8'2 M*)3&K-N$H_*]:I,&D&\V@";9ZE'DQ<%QXX/IN[-8E=GS6/3HE^=DJ3$=0G\T M.CBQ/K$L%^G*!2/?#P|7T34%* D.#GA$4RP(AX.!>_"7HKK$@WZ_=U".F5N\ M]4?
@6Q@QOC1B?+,1<^'=$LW4UGW1L4N@NU\B-&D,I1$HC4)I#$KC*)HJ6.G4 M^&:G!G;?1',>UA*&'OGQCST*[5U H%F)+NL@"(;'QVTI-*V#TCB*ILI3>C;^
MV;.YW$@T@UOK\=A7.#F]L"X;0^M(H#0*I3'[1N&HQ*KBI#7CFT_S7.82FJ&M MU::Y.9G^X(2NI';$4-K2* T"J4QZ];CJ+RJU*1CXH_0+] /=4F@M A*BZ$T M]51*
(U!:1Q%4V\6+WV9X$WN(6>FMM4UE!8%EO>0@V8ENJS:T2,T+8/2.(JF MBE%:*L&;GM QTUN+TO*$#C1K#*41*(U":>?8G@-HQ4%H$ MI<50&H'2*)3&H#2.HJD*?O$]2-
_;^C%7H/4E8&D0ZG*:<__@NM'H'2 M*)3&;)N$H]*J2I/&5G#N*-";3Y6.;WRFW26G*?>S?A:D*ZB?!FE*ZC;*ZWF*O5MC>#T]+PV/31?7<+-"F! MTBB4QJ TCJ*IBI=V5&BVHR[?
S&0&M]:LYAN"3@SY[(O&T#H2*(U":D+SX22C=7GQ7BESTM92A;I#4%H,I1$HC4)I#$KC*)H]>^D. MA8/7^9LAU &"TB(H+8;2*)1&H30&I#7$4356PM)I"L]7T@: N0*M+X%C8T5O
M$V@+:FT": 4)E$:A- :E<11MI]QN,1>BC)(R&5\M1?X@)M6LKJAF:IM5A;_7 MT?:O.KFXK[!7Z<-'K],]>GWB?J!N_7I78L97Z^1!W"3YPV)5.*FXKY"]]X-* M'/GB8;Y_4F;KZX[:
<>ZRLLR6VX=SDH?G^?9>7SDSK!4Y9_V59[_#]0 M2P,$% @ L#AG65SQ75EI&@ #?8! !D !X;"]W;W)K&ULO=UK;]M6@L;QKT)XBD$'2&.1U+63!'##^_TRW7VQV!>,S=A" M+-
&E]*09],.O),NFCD119/:_VQ>-[1S^8R:CY4C/N2[:T7Y9?60YVT7TY^)Q MN7I_]5!53[|>7Z|N'_)%MGI;/.7+S=|\+LI%5FT^+>^O5T|EGMWM-EH\7BN# MP?AZD[;X6E1_>%>OJ<;
[,HU):K1>+K/S^6_Y8?'M_)5^]?"&9WS]4 MVR]'\UO9+N\L_9^K%*BF]6OG] HZUW M6SRN=O^7OCV/'4^NI-OUJBH6^XTW>[":8+Y__S/[_ M"5\.N7Q\S-
5SWU7RRT&7CX_ZV6]$^>6PRYV/N_QRX.7C(W]^DY=#+Y\<^L; MO!Q\>7?TKY]_>G<_^EI691_>E<4W]=R.WWC;#W;YL=M^\Q,_7VZC+]W*S=_.M-]M5']*'K,P?BL>
[O%S]_6]319[4]+_6,^K[!QM"59;;-(NEG+:^R^>/]M'^^NJ\VLVVVO;_?M6Q_ MO7FV7I\RY>4I^TUI?VL?"L-IF\D9:_I=]33?KEVW]QT3N6K8O8_MFK-^_M?"O)@YVFOF@-C-
:!&TY5M)'735C Z:,CG2?I*N]^)YV&R'T_QI M X_V1^*L8G50]@^/IY?BRKOM(]V]Z>RPW>+T^%[3Y6/M"Z]Z79_$M3SBM?G M^^:LXG=_D"U*T.>P=CZ<8;NJY;<'^]8%C-K!F_7]
7C^YS^^])O|E^3+2M+] MT2GG'U)ZX2$];8Z?\AR0DD9I*826(6B=DDYI"82V(>B?DD%I!82&(1B<4DEI!8"F%"C@]?/<2NGC:+C>OI/S/O+R=K_(]Z>?YE?#[^U MHGU?
4Y.81F(ZB1DD9I*8]8R-#G^G3M39T6]*FYS2(3&7Q#P2\TDL(+&0Q"(2 MBTDL(;$4PH2@'K\&];@UJ#\6BT6Q?'FM?%LLO^;E\]N,V2:[+^5UJ]TWKTE, M(S&=Q P2,TG,>L9D^2"P5?
7M6)V.9].CT";G=4C,)3&/Q'P2"[H?]Y"<-R*Q MF,02$DLA3(CDR6LD3UHC>;O4OEMFWRYDK*2;^S+/%_FRDOZ2;0]E2^FY5?/?
M6MF^:4QB&HGI)&:0F$EB%HG9)..0F$MB'HGY)!:06AB8G%)):06 IA0])/ M7Q-]2KZS."5SG,0T$M-)S" QD\0L$K-)S"$QE\0\$O-)+""QD,0B$HM)+"&Q
M%,*$')^]YOBLSSN+V;IZ*,KYO_,[*5L4Z\TK](/EDG-O-+;.T#?<24PC,9W$ M#!(S2@[#8/^?N'24D-.F$"8DMSQX MC>YM":%[=I?YMJ^WP M6^_H6\Y$)[10S48U!]5<5/-0S4>U
-5"5(M0+4:U!-522A/C_*!6)=;)+]9 MWDDWZ_OUJOJQ1?/V>7I'.:EI]*:CFH%])I9]&:CFH-]+]IYJ.:C6H!](:I% M]!:C6H]]*:6)]:_4]:^0"^E[CU M -5"5(M0+4:U!-522A.SO6Y?
RJVE(&1QO7V*WH&/MC)134U -5"5(OVVN$:I3[J7!Z/T8D35$LI34SSNH.YO4Y.2YKOK_%B M+V_SY>X*+]%CMFR,[%:G=V23FH9J.JH9J&:BFH5J-JHYJ.:BFH=J/JH%J]:B
M6H1J,:HEJ)92FICJ=:M3'J'K+VB?$]4T5--1S4 U$]4L5+-1S4$U%]4\5/-1 M+4"U$-4B5(M1+4&UE-+$;*^+H')[$_0'*_OM:N^,1TN@J*:CFH%])JI9>^U2 MAVL$)TT@C58E1+4"VE-
#&5ZRZH?*$,6A1++_N22S=F M8_JBG4|4TU!-1S4#U4Q4LU#-1C4'U5Q4\U#-1[4 U4)4BU M1K4$U5)*$[.\ M;H'*: U41GN@I*:AFHYJ!]J9]&:AFHU#]JYJ.:AFH]J :J%]!:A6HQ]*:JE
ME"9F>]T,E=NKH2_7T=HME+QYN6A[L:Y65;:\V_:,+]VCH,505--034U -5"5(M0+4:U!-72O28L>LG"&3KBK7?JFJC27A,] M6&^1_I)>/[,7B_6RJ!!R,GO*U]7\MK%+U&
[WS7!4TU!-1S4#U4Q4LU#-1C4' MU5Q4\U#-1[4 U4)4BU M1K4$U5)*$Y.^;I ,KD:HZ]45334$U'-0/53%2S M4,U&-0?
57%3S4,U'M0#50E2+4"U&M0354DH3LUVIL[VU]_0AR"OIJ2QN_QN M)7TNBX6T>>DN?5JO-N,VH7]:+#[-E!GN7LAGFD3["0[_@=%TGY^/[3O2.\B? M-:%
[,)TUS*NC\QJH9J*:A6HVJCFHYJ*:AVH^]@6H%])A&HQJB6HEE*:&-)U MX5-I+WQ&0D#?%LNJG']/Y]^N/O24U;FYZ_!I9SVM.3FGM;'AJ'*9-0T5&O?
MY]XOI=&6)]J9]&:AFHU#]JYJ.:AFH] :]%]!:A6HQ]":JEE":F=%WDW'S8 MEM*_+^_R\ELYK[;O8;Y>5JLQD%NAWBLDI*:AFHYJ!]J9]&:AFHU#]JYJ.:A MFH]J
:]%]!:A6HQ]":JEE";&>MWD5- FIX(V.5%-0S4=U0Q4,U'-0C4;U1Q4 M7DGKTGF'[5;O9$?[FBFE MHYJAG-;NIDTK2B8ZK85]-JHYJ.:BFH=J/JH%]!:B6H1J,:HEJ)92FAC:==%3
M:2]ZVJO5.EO>YM)3.=_^/R^?4UOZ^?=4]S_=7?I0NMXG>F.@HY505--034Q.U3'DX97T@8ZL8E]%JK9J.:@FHMJ'KYI]!:@6HAJ
M$:K%J):@6DII8I;7Q4ZEO=@99=^W;WBNZ@65^*5CU134,U'=4,5#-1S4(U&|4<5'-1S4,U M'|4"5 M1+4*U&-425$LI3I=.5--034U -5"5(M0+4:U!-522A-
3O>Y_;CXDUTZ&:+:3FH9J.JH9J&:BFH5J-JHY MJ.:BFH=J/JH%J]!:B6H1J,:HEJ)92FICM=0E4;2TB]5P[02N@J*:AFHYJQEX3 M+E6L-
!6%T&DM5+-1S4$U%]4\5/-1+4"U$-4B5(M1+4&UE-+$T*[;G6J/=N>; M_0T[I:J0GM;E[4.VRM|(55XN&B,<[7]BFH9J.JH9%XZ(.I#NLN]-IPF9Z'Y8 MJ&:CFH-
J+JIYJ.:C6H!](:I%]!:C6H)]*:6)F5Z7/]7V\N?-^GZ]JB1EH*C2 M-M]7[5?::M=ZYSA:\40U'=4,5#-1S4(U&|4<5'-1S4,U'|4"5 M1+4*U&-42 M5$LI3Q\4N]!6^SQ\QS5 M-%334.HW5/5-
-1S4 U$]6LO79X39JCTVWLRT.%* M*HT!2[:99ZMU^?WEW/'GM>TW4G;[QWI>YG>7WL'<\^V7 M3VG?aJX93FHZJAFH9J*:A6HVJCFHYJ*:AVH^]@6H%])A&HQJB6HEE*:F.%U
M9W/8WMG<+[T\OTR_:4QIM*B):AJJZ:AFH])A:JV:CFH)J+:AZ]^:@6H%](M:A&JQ:B6H%I*:6* _IS=/JC#4@M:\40U#=5T M5#-0S40U;Z\=+1^-U<%P/%\&Q^>FH/5-
5'-1S4,U'|6"SLCE1Q M9(3N88Q]":JEE";&;UV|'+;?@[,Y?(MUJRY=WV7D"7$A@M8]*:AFHZJAFH M9J*:M=>Z)#!:LD0U%]4\5/-1+>A\O,*FD6<2&"U'HEJ":BFEB0E7(
MY@3.UM5#4<[_W>$E,-J71#4-U714,U#-1#5K>-I)?#Z?^N24:AN=V$$U%]4\ M5/-1+>A^P,+N0R-T'V-42U MI30A@T=UV7'47G8\RN"GK)2^9H_K_F7']GGZ
MAC&]::BFHYJ!:B]67MMC\/(=- M(YO?]D/W,$:U!-522A-#LRX9;C[\SWQHMWOG9RDIJ&:OM>$=TS4X70\E8_>
M,#'0>4U4LQH>Q:E4;!AQ6ICG0;G\/16!Y.CZYSZG5^MOV&D>L,'@V5P5&J M!)T?>]@T\DQ2D4.[D@^Y#G>Y#7?3A>*CFHUK0_4D)NP^-T'V,42U! MM932Q/2L6VFC]CO:<:<-
H'TU5--034C%:*S1J@6HU]":BFEB4E==\Q&O3IF7XM]\S*WOJ;]7[NO-"8S6C!#-0W5 M=%0S4,U$-6MT6D,Z"66T689J+JIYJ.:C6G#Y0(7HA!&JQ:B6H%I*:6(>U[6S
MT:7:V?)K7JZVEYO/EG=256;+U>=-'&]O$O6\!O$IKI[E^5*ZW9XXL/G\TD($ M6D-#-0W5=%0S4,T3 MDY72TV'#T70RD=7CA=*&B2?
C\>DR*7JS/%2+4"U&M0354DH3L['N@XTNW"QO M=X)4\;2]%\=*RO_,R]OYJL-*+%H#0S4-U714,U#-1#5K=%H5DB?J[&05%]V
MH9J+:AZJ^:@6H%[(:A&JQ:B6H%I*:4)XC^LBV;A3D:RYQ+#|/5U;_AY/^RC M-%]61=NE*MLG[9OMJ*:AFHYJ]J9J&:AFHUJ#]JYJ.:AFH]J :J%]!:A6HQJ
M":JEE";^"JA[:./G)=74=!BC+394TU!-1S4#U4Q4LU#-1C4'U5Q4\U#-1[4 MU4)4BU M1K4$U5)*$[-=J:/[T@W\X&7KJOEZIS_:W MT5F=IED;%[?
1:3U4\U$M0+40U2)4BU$M0;64TL3(KLMIXT[EM/U22V,&HQ4T M5--034U -5"5(M0+4:U!-522A/CO*[-;3XD M5U>&:+:3FH9J.JH9J&:BFH5J-
JHYJ.:BFH=J/JH%]!:B6H1J,:HEJ)92FICM M=1EQ_"-EQ&[7D6BG>P<]6D1$-1W5#%0S4ID-9&<^,%U+0^_2AFHMJ M'JKYJ!9T/%IAPSAE-!@-)T<+51&Z>S&]):B64IJ8NW6-
<=RKQMC_4A3M?N_P M1>N+J*:CFH%])JI9>^UR^+U151S4_ZWX%CG:^= _:B!454TU'-0#43U:QQ0^_MS!4XT(D=5'-1S4,U M']6"[@!T$[\>OX]$^3^\P1EN(]*:CFH%J
M]I9>^WB=3S061U4[V#&RTOHIJ.@:JF:AFH9J:@ZJN:CFH9J/:@&JA:@6H5J, M:@FJI90FIGO=@YRHZ!(,6HI$-0W5=%0S4,U$-0O5;%1S4,U%-0_5?%0+4"U$ MM0C58E1+4"VE-
#';ZU+DYL/^2S#=BC/M=.^@)S4-U714,U#-1#5KKUT\=[MA MW&PV4L;'MQGL.,Y%'X6':CZJ!1V?X;!A7//YUNCNQ:B6H%I*:6)6UB7#R8^4 M#/LL5Z--0U334$V?-
##2Z9J.9/#NZ:::>!3FNBFM7T(!JS\'1<*A6M+XM$P4=20?GO7D?KRCT3Y/[QA%"W.HIJ.: M@6HFJEE[[6)' YW50347U3Q4\U$MZ'BT0G36"-5B5$M0+:4T,:GK-MVD5YNN
M^[U6V]W>R8RVYU!-1S4#U4Q4LR8-M[X[#F6T.(=[+JIYJ.:C6G#Y0(7HA!&]
MQ:B6H%I*:6(>U\VZR:5F'7S1^O;Y>N/[I[3.&WC!>F;1C;=;K5I7//]5AOG;KKA*OJ00U2+4"U&M0354DH3\G%: MEl.F/>[9=WS>ZP_?
LZ]]TKXAB6H:JNFH9J":B6H6JMFHYJ":BVH>JOFH%]!: MB&H1JL6HEJ!:2FGBKX"ZPS9%[]DW11MKJ*:AFHYJ]J9J&:AFHUJ#]JYJ.:A MFH]J :J%]!:A6HQJ":JEE"9FNU)G^__S/?
O:Y^N=_FCM#=5T5#-0S4OU:WIZ M[|SF11)T6]=QVL9%$G1>#]5\5 M0+42U"-5B5$M0+:4T,:3KMMJTSUWJ3M=D M+EPPW5=%0S4,U$-0O5;%1S4,U%-0_5?
%0+4"U$M0C58E1+4"VE M-#'KZ_:YD-R\66(9CNI:.BFHYJ!:B;J6:AFHJ#:BZJ>:CFHUJ :B&J1:@6 MHUJ":BFEB=E>M^VF[6V[?Y5YMEJ7WZ75-MO?O)X4F-
W^L9Z7ESLOTX9RSW@Z M.GH?_V/[7O1.<;1%AVH&JIFH9J&:C6H.JKFHYJ&:CVH!JH6H%]%:C&H)]J64 M)J9XW5RUVKG$[0Q1>T/(EJ&JKI]&:@FHEJ%JK9].:@FHMJ
M'JKYJ!:@6HAJ$:K%J):@6DII8K;718+6M!$-0W5=%0S4,VK@JU*9?]ZDOOSKC7)U??)U2_[5E[=?OZZ9#^^> MLOO:?-^3@[?8Z6.7_N'UDZIX>G\E7TF?BJHJ%KL/'_+L+B^W M
S9__[DHJI=/MA-*\HON|W^\#]02P,$% @ L#AG6020ILNC P ! X M !D !X;"]W;W)K&ULK5?;CMLV%/P50BV*#9!8 M]]O6-I"U'+1 $BSBIGVFI6-+""6Z)&6G?
U^2TBJR33MNZGU8B]3,")X1!Y. M#Y1]X26 0%]KTO"950JQ>[1MGI=08SZA.VCDFPUE-1:RR;8VWS' A2;5Q/8< M()K7#76?
*K[GME\2EM!J(>>&>)M76/VSQ,0>IA9KO72\:G:ED)UV//I#F]A M!>+$IG)ECVH%%4-#:]H@QAL9M9;]W&9*KPK% *,%G!@8^>D9K)FM(OJO%[,;,< M-2 @D NE@.7/'A9
B!*2P_B[U[2&D(HX?GY1?Z?G+N>RQAP6E/Q5%:*<68F% M"MC@EHA/|/ ;]/)E5Y."=?_T:'#QJ&%\I8+6O=D.8*Z:KI?_+7W841P+Q&\ MGN"=$H(+!+\G^+=&"'I"<&N$L"?
HJ=O=W+5Q&19X/F7T@)A"2S7UH-W7:.E7 MU:@\60DFWU;2)^8?92]^IYRC'3"T*C$#] 8M,.E;@O5*T@TR8!XR$+@B_)5$ M?UYEZ.'G5U-;R/$H53OO8S]UL;T+L7WT@3:BY&C9%%
8^-EU?GJ%;TL?!C.\ M%S.>O*N"*]A-D.\1I[C!8;Q+&ZG^Z;I_+_HRQ^.?F2&/V2&K_7\2YG1UL"P MH,RTL!TU,%/5WO(=SB'F24W+PYL#|;\EY_2>QH!:)A!:*K:?H"%5@> M6OI
A@+AO=PTMH":ME[+TT*>'K(XX0(WA4I7G:3\M3K:JQP]5$W?8SP\NKCA M*&DB+TFC./%.$O8<&/]A&T?A21IF1D7']SSG)%/@4$8)&$4.N9TC0>SXON; M552D5>COV!7?:M?
ZW8E@UW);5N@*CQX7YQ\RQU5> QOC)YT M\LEXWW$F8>2,_]P3>XP<-SGQQH!R)^(]5KHT:D6^V95T<"7]|ZZ,D^3[OJ0_ MX(N1<^:+
67PQ:AUYHL]*FME+;+5]PDNS[^V$5T=,_0.5Y:WNE(_Z7]R'Q>N MH3^35YSN1O)-OKL?? M4.0K:?I V5>^(42@QS3)^-5@(\3VK 1X\'?@4 MWV|$?F XFVZC>
[(@XO/VELF|8459Q2G)>$PSQ.CZ:G"-+T/3R0.*%G_&Y($? M:,.*W>4?LUWWJ^N!D9^1B0A2Y$C(OEG3^8D27*2/(]O)710Y?Z$'1
M>=F9NXB3.4V^Q"NQN1],!VA%UMN9_HPQ^D[%!Q@DN:\.(W>BC;&@.TW'%! MT$)8GD$:9X>_T6/Y11P%8/M$@%D&F.T YT2 5098YV:PRP#[W Q.&>"A;1$M%XBPOQ85@\M-

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|;1.C-4!7,2)A] D65K#RHNS^K#B#WV\J M#!F.[PTGD.$D"&;()ES+)K3*YFJ76-3W\K4JY/)3FU:LU*Y:0<+H$RS:Z#QW M&'B1,VHHIF6[P NCT#6WX]O;A7XP=**F)%]V"QTGB2M#!&KT=K7L|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l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|;1.C-4!7,2)A] D65K#RHNS^K#B#WV\J M#!F.[PTGD.$D"&;()ES+)K3*YFJ76-3W\K4JY/)3FU:LU*Y:0<+H$RS:Z#QW M&'B1,VHHIF6[P NCT#6WX]O;A7XP=**F)%]V"QTGB2M#!&KT=K7L|.O D MH7-W>4;0[!KZVLKLVM=(&(VV?JA^HY>1X?C>< (93H)@AE(&:Z4,K$IA?]W- M\D?RRW) <7,R4MP*7.Y*&%=-5'$@81<(8$L:1,(&$21#,D-QP+;GAD:^VATBM M(F$4"6-(&$?"!!(F03!#]Z.U5D>OSYL[:2Q4<[M&MG0VFTIFU^[Z.!/W2<1F]#H_(#HPIH5(FBF>+9 MJ+.Z5O\\6571B_-$?*_2^%:1E4IGR:2\"$_5.+E=SLH31ZN K.#. D+2*)3& MH#2^IT-<\]CBE+@N63Q5F-V03.+'UNHE=,$ZU;?7]F5=V)MV5AB2QJ T#J4)*$VB:*; (=,GSE2MFNO9;/%:IX*D6N M\F3\C7Q>5?HI*Q#D#;OZ?-E^N04M7T-I%$

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end XML 78 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p ;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent) {a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 79 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .num { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 81 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html2562731false520false15 falsefalseR1.htm0000001 - Document - CoverSheethttp://moonlaketx.com/role/CoverCoverCover1 falsefalseR2.htm9952151 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETSSheethttp://moonlaketx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSCONDENSED CONSOLIDATED BALANCE SHEETSStatements2 falsefalseR3.htm9952152 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)Sheethttp://moonlaketx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParentheticalCONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)Statements3 falsefalseR4.htm9952153 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSSSheethttp://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSSStatements4 falsefalseR5.htm9952154 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITYSheethttp://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYCONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITYStatements5 falsefalseR6.htm9952155 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWSSheethttp://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWSStatements6 falsefalseR7.htm9952156 - Disclosure - Overview of the CompanySheethttp://moonlaketx.com/role/OverviewoftheCompanyOverview of the CompanyNotes7 falsefalseR8.htm9952157 - Disclosure - Basis of Presentation and Significant Accounting PoliciesSheethttp://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesBasis of Presentation and Significant Accounting PoliciesNotes8 falsefalseR9.htm9952158 - Disclosure - Risks and LiquiditySheethttp://moonlaketx.com/role/RisksandLiquidityRisks and LiquidityNotes9 falsefalseR10.htm9952159 - Disclosure - Fair Value MeasurementsSheethttp://moonlaketx.com/role/FairValueMeasurementsFair Value MeasurementsNotes10 falsefalseR11.htm9952160 - Disclosure - InvestmentsSheethttp://moonlaketx.com/role/InvestmentsInvestmentsNotes11 falsefalseR12.htm9952161 - Disclosure - Prepaid ExpensesSheethttp://moonlaketx.com/role/PrepaidExpensesPrepaid ExpensesNotes12 falsefalseR13.htm9952162 - Disclosure - Trade and Other PayablesSheethttp://moonlaketx.com/role/TradeandOtherPayablesTrade and Other PayablesNotes13 falsefalseR14.htm9952163 - Disclosure - Accrued Expenses and Other Current LiabilitiesSheethttp://moonlaketx.com/role/AccruedExpensesandOtherCurrentLiabilitiesAccrued Expenses and Other Current LiabilitiesNotes14 falsefalseR15.htm9952164 - Disclosure - LeasesSheethttp://moonlaketx.com/role/LeasesLeasesNotes15 falsefalseR16.htm9952165 - Disclosure - Employee Benefit PlansSheethttp://moonlaketx.com/role/EmployeeBenefitPlansEmployee Benefit PlansNotes16 falsefalseR17.htm9952166 - Disclosure - Shareholders??? EquitySheethttp://moonlaketx.com/role/ShareholdersEquityShareholders??? EquityNotes17 falsefalseR18.htm9952167 - Disclosure - Net Loss per ShareSheethttp://moonlaketx.com/role/NetLossperShareNet Loss per ShareNotes18 falsefalseR19.htm9952168 - Disclosure - Share-Based CompensationSheethttp://moonlaketx.com/role/ShareBasedCompensationShare-Based CompensationNotes19 falsefalseR20.htm9952169 - Disclosure - Income TaxesSheethttp://moonlaketx.com/role/IncomeTaxesIncome TaxesNotes20 falsefalseR21.htm9952170 - Disclosure - Commitment and ContingenciesSheethttp://moonlaketx.com/role/CommitmentandContingenciesCommitment and ContingenciesNotes21 falsefalseR22.htm9952171 - Disclosure - Segment Information and Geographic DataSheethttp://moonlaketx.com/role/SegmentInformationandGeographicDataSegment Information and Geographic DataNotes22 falsefalseR23.htm995410 - Disclosure - Pay vs Performance DisclosureSheethttp://xbrl.sec.gov/ecd/role/PvpDisclosurePay vs Performance DisclosureNotes23 falsefalseR24.htm995445 - Disclosure - Insider Trading ArrangementsSheethttp://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsInsider Trading ArrangementsNotes24 falsefalseR25.htm9954471 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)Sheethttp://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesPoliciesBasis of Presentation and Significant Accounting Policies (Policies)Policieshttp://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPolicies25 falsefalseR26.htm9954472 - Disclosure - Fair Value Measurements (Tables)Sheethttp://moonlaketx.com/role/FairValueMeasurementsTablesFair Value Measurements (Tables)Tableshttp://moonlaketx.com/role/FairValueMeasurements26 falsefalseR27.htm9954473 - Disclosure - Investments (Tables)Sheethttp://moonlaketx.com/role/InvestmentsTablesInvestments (Tables)Tableshttp://moonlaketx.com/role/Investments27 falsefalseR28.htm9954474 - Disclosure - Prepaid Expenses (Tables)Sheethttp://moonlaketx.com/role/PrepaidExpensesTablesPrepaid Expenses (Tables)Tableshttp://moonlaketx.com/role/PrepaidExpenses28 falsefalseR29.htm9954475 - Disclosure - Trade and Other Payables (Tables)Sheethttp://moonlaketx.com/role/TradeandOtherPayablesTablesTrade and Other Payables (Tables)Tableshttp://moonlaketx.com/role/TradeandOtherPayables29 falsefalseR30.htm9954476 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)Sheethttp://moonlaketx.com/role/AccruedExpensesandOtherCurrentLiabilitiesTablesAccrued Expenses and Other Current Liabilities (Tables)Tableshttp://moonlaketx.com/role/AccruedExpensesandOtherCurrentLiabilities30 falsefalseR31.htm9954477 - Disclosure - Leases (Tables)Sheethttp://moonlaketx.com/role/LeasesTablesLeases (Tables)Tableshttp://moonlaketx.com/role/Leases31 falsefalseR32.htm9954478 - Disclosure - Employee Benefit Plans (Tables)Sheethttp://moonlaketx.com/role/EmployeeBenefitPlansTablesEmployee Benefit Plans (Tables)Tableshttp://moonlaketx.com/role/EmployeeBenefitPlans32 falsefalseR33.htm9954479 - Disclosure - Shareholders??? Equity (Tables)Sheethttp://moonlaketx.com/role/ShareholdersEquityTablesShareholders??? Equity (Tables)Tableshttp://moonlaketx.com/role/ShareholdersEquity33 falsefalseR34.htm9954480 - Disclosure - Net Loss per Share (Tables)Sheethttp://moonlaketx.com/role/NetLossperShareTablesNet Loss per Share (Tables)Tableshttp://moonlaketx.com/role/NetLossperShare34 falsefalseR35.htm9954481 - Disclosure - Share-Based Compensation (Tables)Sheethttp://moonlaketx.com/role/ShareBasedCompensationTablesShare-Based Compensation (Tables)Tableshttp://moonlaketx.com/role/ShareBasedCompensation35 falsefalseR36.htm9954482 - Disclosure - Segment Information and Geographic Data (Tables)Sheethttp://moonlaketx.com/role/SegmentInformationandGeographicDataTablesSegment Information and Geographic Data (Tables)Tableshttp://moonlaketx.com/role/SegmentInformationandGeographicData36 falsefalseR37.htm9954483 - Disclosure - Basis of Presentation and Significant Accounting Policies (Details)Sheethttp://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesDetailsBasis of Presentation and Significant Accounting Policies (Details)Detailshttp://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies37 falsefalseR38.htm9954484 - Disclosure - Risks and Liquidity (Details)Sheethttp://moonlaketx.com/role/RisksandLiquidityDetailsRisks and Liquidity (Details)Detailshttp://moonlaketx.com/role/RisksandLiquidity38 falsefalseR39.htm9954485 - Disclosure - Fair Value Measurements (Details)Sheethttp://moonlaketx.com/role/FairValueMeasurementsDetailsFair Value Measurements (Details)Detailshttp://moonlaketx.com/role/FairValueMeasurementsTables39 falsefalseR40.htm9954486 - Disclosure - Investments - Schedule of Fair Value and Amortized Cost of Investments in Short-Term Marketable Debt (Details)Sheethttp://moonlaketx.com/role/InvestmentsScheduleofFairValueandAmortizedCostofInvestmentsinShortTermMarketableDebtDetailsInvestments - Schedule of Fair Value and Amortized Cost of Investments in Short-Term Marketable Debt (Details)40 falsefalseR41.htm9954487 - Disclosure - Investments - Schedule of Changes in Fair Value of Short-Term Marketable Securities (Details)Sheethttp://moonlaketx.com/role/InvestmentsScheduleofChangesinFairValueofShortTermMarketableSecuritiesDetailsInvestments - Schedule of Changes in Fair Value of Short-Term Marketable Securities (Details)Details41 falsefalseR42.htm9954488 - Disclosure - Prepaid Expenses (Details)Sheethttp://moonlaketx.com/role/PrepaidExpensesDetailsPrepaid Expenses (Details)Detailshttp://moonlaketx.com/role/PrepaidExpensesTables42 falsefalseR43.htm9954489 - Disclosure - Trade and Other Payables (Details)Sheethttp://moonlaketx.com/role/TradeandOtherPayablesDetailsTrade and Other Payables (Details)Detailshttp://moonlaketx.com/role/TradeandOtherPayablesTables43 falsefalseR44.htm9954490 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)Sheethttp://moonlaketx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetailsAccrued Expenses and Other Current Liabilities (Details)Detailshttp://moonlaketx.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables44 falsefalseR45.htm9954491 - Disclosure - Leases - Additional Information (Details)Sheethttp://moonlaketx.com/role/LeasesAdditionalInformationDetailsLeases - Additional Information (Details)Details45 falsefalseR46.htm9954492 - Disclosure - Leases - Weighted Average Remaining Lease Term and Discount Rate (Details)Sheethttp://moonlaketx.com/role/LeasesWeightedAverageRemainingLeaseTermandDiscountRateDetailsLeases - Weighted Average Remaining Lease Term and

Discount Rate (Details)Details46 falsefalseR47.htm9954493 - Disclosure - Leases - Future Lease Payments (Details)Sheethttp://moonlaketx.com/role/LeasesFutureLeasePaymentsDetailsLeases - Future Lease Payments (Details)Details47 falsefalseR48.htm9954494 - Disclosure - Leases - Total Lease Expense (Details)Sheethttp://moonlaketx.com/role/LeasesTotalLeaseExpenseDetailsLeases - Total Lease Expense (Details)Details48 falsefalseR49.htm9954495 - Disclosure - Employee Benefit Plans (Details)Sheethttp://moonlaketx.com/role/EmployeeBenefitPlansDetailsEmployee Benefit Plans (Details)Detailshttp://moonlaketx.com/role/EmployeeBenefitPlansTables49 falsefalseR50.htm9954496 - Disclosure - Employee Benefit Plans - Narrative (Details)Sheethttp://moonlaketx.com/role/EmployeeBenefitPlansNarrativeDetailsEmployee Benefit Plans - Narrative (Details)Details50 falsefalseR51.htm9954497 - Disclosure - Shareholders??? Equity - Schedule of Stock Authorized and Issued (Details)Sheethttp://moonlaketx.com/role/ShareholdersEquityScheduleofStockAuthorizedandIssuedDetailsShareholders??? Equity - Schedule of Stock Authorized and Issued (Details)Details51 falsefalseR52.htm9954498 - Disclosure - Shareholders??? Equity - Narrative (Details)Sheethttp://moonlaketx.com/role/ShareholdersEquityNarrativeDetailsShareholders??? Equity - Narrative (Details)Details52 falsefalseR53.htm9954499 - Disclosure - Net Loss per Share - Calculation of Net Loss per Share (Details)Sheethttp://moonlaketx.com/role/NetLossperShareCalculationofNetLossperShareDetailsNet Loss per Share - Calculation of Net Loss per Share (Details)Details53 falsefalseR54.htm9954500 - Disclosure - Net Loss per Share - Narrative (Details)Sheethttp://moonlaketx.com/role/NetLossperShareNarrativeDetailsNet Loss per Share - Narrative (Details)Details54 falsefalseR55.htm9954501 - Disclosure - Share-Based Compensation - Narrative (Details)Sheethttp://moonlaketx.com/role/ShareBasedCompensationNarrativeDetailsShare-Based Compensation - Narrative (Details)Details55 falsefalseR56.htm9954502 - Disclosure - Share-Based Compensation - Share-based Compensation Expense By Plan (Details)Sheethttp://moonlaketx.com/role/ShareBasedCompensationSharebasedCompensationExpenseByPlanDetailsShare-Based Compensation - Share-based Compensation Expense By Plan (Details)Details56 falsefalseR57.htm9954503 - Disclosure - Share-Based Compensation - Summary of Restricted Stock Awarded and Granted (Details)Sheethttp://moonlaketx.com/role/ShareBasedCompensationSummaryofRestrictedStockAwardedandGrantedDetailsShare-Based Compensation - Summary of Restricted Stock Awarded and Granted (Details)Details57 falsefalseR58.htm9954504 - Disclosure - Share-Based Compensation - Summary of ESPP Awarded and Granted (Details)Sheethttp://moonlaketx.com/role/ShareBasedCompensationSummaryofESPPAwardedandGrantedDetailsShare-Based Compensation - Summary of ESPP Awarded and Granted (Details)Details58 falsefalseR59.htm9954505 - Disclosure - Share-Based Compensation - Summary of ESOP Awarded and Granted (Details)Sheethttp://moonlaketx.com/role/ShareBasedCompensationSummaryofESOPAwardedandGrantedDetailsShare-Based Compensation - Summary of ESOP Awarded and Granted (Details)Details59 falsefalseR60.htm9954506 - Disclosure - Share-Based Compensation - Summary of Equity Incentive Plan Awarded and Granted (Details)Sheethttp://moonlaketx.com/role/ShareBasedCompensationSummaryofEquityIncentivePlanAwardedandGrantedDetailsShare-Based Compensation - Summary of Equity Incentive Plan Awarded and Granted (Details)Details60 falsefalseR61.htm9954507 - Disclosure - Share-Based Compensation - Weighted Average Assumptions (Details)Sheethttp://moonlaketx.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetailsShare-Based Compensation - Weighted Average Assumptions (Details)Details61 falsefalseR62.htm9954508 - Disclosure - Income Taxes (Details)Sheethttp://moonlaketx.com/role/IncomeTaxesDetailsIncome Taxes (Details)Detailshttp://moonlaketx.com/role/IncomeTaxes62 falsefalseR63.htm9954509 - Disclosure - Commitment and Contingencies (Details)Sheethttp://moonlaketx.com/role/CommitmentandContingenciesDetailsCommitment and Contingencies (Details)Detailshttp://moonlaketx.com/role/CommitmentandContingencies63 falsefalseR64.htm9954510 - Disclosure - Segment Information and Geographic Data - Schedule of Long-Lived Assets (Details)Sheethttp://moonlaketx.com/role/SegmentInformationandGeographicDataScheduleofLongLivedAssetsDetailsSegment Information and Geographic Data - Schedule of Long-Lived Assets (Details)Details64 falsefalseR65.htm9954511 - Disclosure - Segment Information and Geographic Data - Narrative (Details)Sheethttp://moonlaketx.com/role/SegmentInformationandGeographicDataNarrativeDetailsSegment Information and Geographic Data - Narrative (Details)Details65 falsefalseAll ReportsBookAll Reports mnlk-20240930.htmmnlk-20240930.xsdmnlk-20240930_cal.xmlmnlk-20240930_def.xmlmnlk-20240930_lab.xmlmnlk-20240930_pre.xml http://fasb.org/us-gaap/2024http://xbrl.sec.gov/dei/2024http://xbrl.sec.gov/ecd/2024truetrue JSON 84 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "mnlk-20240930.htm": { "nsprefix": "mnlk", "nsuri": "http://moonlaketx.com/20240930", "dts": { "inline": { "local": ["mnlk-20240930.htm"] }, "schema": { "local": ["mnlk-20240930.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] }, "calculationLink": { "local": ["mnlk-20240930_cal.xml"] }, "definitionLink": { "local": ["mnlk-20240930_def.xml"] }, "labelLink": { "local": ["mnlk-20240930_lab.xml"] }, "presentationLink": { "local": ["mnlk-20240930_pre.xml"] } }, "keyStandard": 233, "keyCustom": 40, "axisStandard": 22, "axisCustom": 0, "memberStandard": 33, "memberCustom": 18, "hidden": { "total": 8, "http://fasb.org/us-gaap/2024": 3, "http://xbrl.sec.gov/dei/2024": 5 }, "contextCount": 256, "entityCount": 1, "segmentCount": 52, "elementCount": 532, "unitCount": 15, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 788, "http://xbrl.sec.gov/dei/2024": 30, "http://xbrl.sec.gov/ecd/2024": 4 }, "report": { "R1": { "role": "http://moonlaketx.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true } }, "R2": { "role": "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "longName": "9952151 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:OtherReceivablesNetCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "unique": true } }, "R3": { "role": "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "longName": "9952152 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": ["span", "div", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true }, "uniqueAnchor": null }, "R4": { "role": "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "longName": "9952153 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-10", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true } }, "R5": { "role": "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "longName": "9952154 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-17", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-28", "name": "us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "unique": true } }, "R6": { "role": "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "longName": "9952155 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:Depreciation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "unique": true } }, "R7": { "role": "http://moonlaketx.com/role/OverviewoftheCompany", "longName": "9952156 - Disclosure - Overview of the Company", "shortName": "Overview of the Company", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true } }, "R8": { "role": "http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPolicies", "longName": "9952157 - Disclosure - Basis of Presentation and Significant Accounting Policies", "shortName": "Basis of Presentation and Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true } }, "R9": { "role": "http://moonlaketx.com/role/RisksandLiquidity", "longName": "9952158 - Disclosure - Risks and Liquidity", "shortName": "Risks and Liquidity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "mnlk:RiskAndLiquidityDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "mnlk:RiskAndLiquidityDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true } }, "R10": { "role": "http://moonlaketx.com/role/FairValueMeasurements", "longName": "9952159 - Disclosure - Fair Value Measurements", "shortName": "Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true } }, "R11": { "role": "http://moonlaketx.com/role/Investments", "longName": "9952160 - Disclosure - Investments", "shortName": "Investments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true } }, "R12": { "role": "http://moonlaketx.com/role/PrepaidExpenses", "longName": "9952161 - Disclosure - Prepaid Expenses", "shortName": "Prepaid Expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherCurrentAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherCurrentAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true } }, "R13": { "role":

{"http://moonlaketx.com/role/TradeandOtherPayables", "longName": "9952162 - Disclosure - Trade and Other Payables", "shortName": "Trade and Other Payables", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true }, "uniqueAnchor": null }, "R14": { "role": "http://moonlaketx.com/role/AccruedExpensesandOtherCurrentLiabilities", "longName": "9952163 - Disclosure - Accrued Expenses and Other Current Liabilities", "shortName": "Accrued Expenses and Other Current Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true }, "uniqueAnchor": null }, "R15": { "role": "http://moonlaketx.com/role/Leases", "longName": "9952164 - Disclosure - Leases", "shortName": "Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true } }, "R16": { "role": "http://moonlaketx.com/role/EmployeeBenefitPlans", "longName": "9952165 - Disclosure - Employee Benefit Plans", "shortName": "Employee Benefit Plans", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true } }, "R17": { "role": "http://moonlaketx.com/role/ShareholdersEquity", "longName": "9952166 - Disclosure - Shareholders\u2019 Equity", "shortName": "Shareholders\u2019 Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true } }, "R18": { "role": "http://moonlaketx.com/role/NetLossperShare", "longName": "9952167 - Disclosure - Net Loss per Share", "shortName": "Net Loss per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true } }, "R19": { "role": "http://moonlaketx.com/role/ShareBasedCompensation", "longName": "9952168 - Disclosure - Share-Based Compensation", "shortName": "Share-Based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true } }, "R20": { "role": "http://moonlaketx.com/role/IncomeTaxes", "longName": "9952169 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true } }, "R21": { "role": "http://moonlaketx.com/role/CommitmentandContingencies", "longName": "9952170 - Disclosure - Commitment and Contingencies", "shortName": "Commitment and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true } }, "R22": { "role": "http://moonlaketx.com/role/SegmentInformationandGeographicData", "longName": "9952171 - Disclosure - Segment Information and Geographic Data", "shortName": "Segment Information and Geographic Data", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true } }, "R23": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true }, "uniqueAnchor": null }, "R24": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c-10", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-10", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true } }, "R25": { "role": "http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies", "longName": "9954471 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)", "shortName": "Basis of Presentation and Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true } }, "R26": { "role": "http://moonlaketx.com/role/FairValueMeasurementsTables", "longName": "9954472 - Disclosure - Fair Value Measurements (Tables)", "shortName": "Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true } }, "R27": { "role": "http://moonlaketx.com/role/InvestmentsTables", "longName": "9954473 - Disclosure - Investments (Tables)", "shortName": "Investments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true } }, "R28": { "role": "http://moonlaketx.com/role/PrepaidExpensesTables", "longName": "9954474 - Disclosure - Prepaid Expenses (Tables)", "shortName": "Prepaid Expenses (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true } }, "R29": { "role": "http://moonlaketx.com/role/TradeandOtherPayablesTables", "longName": "9954475 - Disclosure - Trade and Other Payables (Tables)", "shortName": "Trade and Other Payables (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "mnlk:TradeAndOtherPayablesCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "mnlk:TradeAndOtherPayablesCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true } }, "R30": { "role": "http://moonlaketx.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables", "longName": "9954476 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)", "shortName": "Accrued Expenses and Other Current Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true } }, "R31": { "role": "http://moonlaketx.com/role/LeasesTables", "longName": "9954477 - Disclosure - Leases (Tables)", "shortName": "Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true } }, "R32": { "role": "http://moonlaketx.com/role/EmployeeBenefitPlansTables", "longName": "9954478 - Disclosure - Employee Benefit Plans (Tables)", "shortName": "Employee Benefit Plans (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true } }, "R33": { "role": "http://moonlaketx.com/role/ShareholdersEquityTables", "longName": "9954479 - Disclosure - Shareholders\u2019 Equity (Tables)", "shortName": "Shareholders\u2019 Equity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "mnlk:ScheduleOfStockAuthorizedAndIssuedRollForwardTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "mnlk:ScheduleOfStockAuthorizedAndIssuedRollForwardTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true } }, "R34": { "role": "http://moonlaketx.com/role/NetLossperShareTables", "longName": "9954480 - Disclosure - Net Loss per Share (Tables)", "shortName": "Net Loss per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-

gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true } }, "R35": { "role": "http://moonlaketx.com/role/ShareBasedCompensationTables", "longName": "9954481 - Disclosure - Share-Based Compensation (Tables)", "shortName": "Share-Based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true } }, "R36": { "role": "http://moonlaketx.com/role/SegmentInformationandGeographicDataTables", "longName": "9954482 - Disclosure - Segment Information and Geographic Data (Tables)", "shortName": "Segment Information and Geographic Data (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true } }, "R37": { "role": "http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails", "longName": "9954483 - Disclosure - Basis of Presentation and Significant Accounting Policies (Details)", "shortName": "Basis of Presentation and Significant Accounting Policies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-10", "name": "us-gaap:ForeignCurrencyTransactionGainLossRealized", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "unique": true } }, "R38": { "role": "http://moonlaketx.com/role/RisksandLiquidityDetails", "longName": "9954484 - Disclosure - Risks and Liquidity (Details)", "shortName": "Risks and Liquidity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true }, "uniqueAnchor": null }, "R39": { "role": "http://moonlaketx.com/role/FairValueMeasurementsDetails", "longName": "9954485 - Disclosure - Fair Value Measurements (Details)", "shortName": "Fair Value Measurements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-136", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "unique": true } }, "R40": { "role": "http://moonlaketx.com/role/InvestmentsScheduleofFairValueandAmortizedCostofInvestmentsinShortTermMarketableDebtDetails", "longName": "9954486 - Disclosure - Investments - Schedule of Fair Value and Amortized Cost of Investments in Short-Term Marketable Debt (Details)", "shortName": "Investments - Schedule of Fair Value and Amortized Cost of Investments in Short-Term Marketable Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true } }, "R41": { "role": "http://moonlaketx.com/role/InvestmentsScheduleofChangesinFairValueofShortTermMarketableSecuritiesDetails", "longName": "9954487 - Disclosure - Investments - Schedule of Changes in Fair Value of Short-Term Marketable Securities (Details)", "shortName": "Investments - Schedule of Changes in Fair Value of Short-Term Marketable Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-143", "name": "us-gaap:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:TradingSecuritiesAndCertainTradingAssetsTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "unique": true } }, "R42": { "role": "http://moonlaketx.com/role/PrepaidExpensesDetails", "longName": "9954488 - Disclosure - Prepaid Expenses (Details)", "shortName": "Prepaid Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-4", "name": "mnlk:PrepaidResearchAndDevelopmentExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "mnlk:PrepaidResearchAndDevelopmentExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true } }, "R43": { "role": "http://moonlaketx.com/role/TradeandOtherPayablesDetails", "longName": "9954489 - Disclosure - Trade and Other Payables (Details)", "shortName": "Trade and Other Payables (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-4", "name": "mnlk:AccruedResearchAndDevelopmentExpensesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "mnlk:TradeAndOtherPayablesCurrentTableTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "mnlk:AccruedResearchAndDevelopmentExpensesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "mnlk:TradeAndOtherPayablesCurrentTableTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true } }, "R44": { "role": "http://moonlaketx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails", "longName": "9954490 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)", "shortName": "Accrued Expenses and Other Current Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-4", "name": "mnlk:AccruedResearchAndDevelopmentServicesAndLicenseFeesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "c-4", "name": "mnlk:AccruedResearchAndDevelopmentServicesAndLicenseFeesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true } }, "R45": { "role": "http://moonlaketx.com/role/LeasesAdditionalInformationDetails", "longName": "9954491 - Disclosure - Leases - Additional Information (Details)", "shortName": "Leases - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-159", "name": "mnlk:LesseeOperatingLeaseNumberOfRenewalOptions", "unitRef": "period", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-159", "name": "mnlk:LesseeOperatingLeaseNumberOfRenewalOptions", "unitRef": "period", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true } }, "R46": { "role": "http://moonlaketx.com/role/LeasesWeightedAverageRemainingLeaseTermandDiscountRateDetails", "longName": "9954492 - Disclosure - Leases - Weighted Average Remaining Lease Term and Discount Rate (Details)", "shortName": "Leases - Weighted Average Remaining Lease Term and Discount Rate (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true } }, "R47": { "role": "http://moonlaketx.com/role/LeasesFutureLeasePaymentsDetails", "longName": "9954493 - Disclosure - Leases - Future Lease Payments (Details)", "shortName": "Leases - Future Lease Payments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true } }, "R48": { "role": "http://moonlaketx.com/role/LeasesTotalLeaseExpenseDetails", "longName": "9954494 - Disclosure - Leases - Total Lease Expense (Details)", "shortName": "Leases - Total Lease Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:OperatingLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-10", "name": "us-gaap:OperatingLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true } }, "R49": { "role": "http://moonlaketx.com/role/EmployeeBenefitPlansDetails", "longName": "9954495 - Disclosure - Employee Benefit Plans (Details)", "shortName": "Employee Benefit Plans (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:DefinedBenefitPlanServiceCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-10", "name": "us-gaap:DefinedBenefitPlanServiceCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true } }, "R50": { "role": "http://moonlaketx.com/role/EmployeeBenefitPlansNarrativeDetails", "longName": "9954496 - Disclosure - Employee Benefit Plans - Narrative (Details)", "shortName": "Employee Benefit Plans - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DefinedContributionPlanCostRecognized", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DefinedContributionPlanCostRecognized", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true } }, "R51": { "role": "http://moonlaketx.com/role/ShareholdersEquityScheduleofStockAuthorizedandIssuedDetails", "longName": "9954497 - Disclosure - Shareholders\u2019 Equity - Schedule of Stock Authorized and Issued (Details)", "shortName": "Shareholders\u2019 Equity - Schedule of Stock Authorized and Issued (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "td", "tr", "table", "div", "mnlk:ScheduleOfStockAuthorizedAndIssuedRollForwardTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-108", "name": "mnlk:SharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": ["span", "td", "tr", "table", "div", "mnlk:ScheduleOfStockAuthorizedAndIssuedRollForwardTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "unique": true } }, "R52": { "role": "http://moonlaketx.com/role/ShareholdersEquityNarrativeDetails", "longName": "9954498 - Disclosure - Shareholders\u2019 Equity - Narrative (Details)", "shortName": "Shareholders\u2019 Equity - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-186", "name": "mnlk:SaleOfStockStampDutyTax", "unitRef": "usd", "xsiNil":

"false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-186", "name": "mnlk:SaleOfStockStampDutyTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true } }, "R53": { "role": "http://moonlaketx.com/role/NetLossperShareCalculationofNetLossperShareDetails", "longName": "9954499 - Disclosure - Net Loss per Share - Calculation of Net Loss per Share (Details)", "shortName": "Net Loss per Share - Calculation of Net Loss per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true }, "uniqueAnchor": null }, "R54": { "role": "http://moonlaketx.com/role/NetLossperShareNarrativeDetails", "longName": "9954500 - Disclosure - Net Loss per Share - Narrative (Details)", "shortName": "Net Loss per Share - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-190", "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "unique": true } }, "R55": { "role": "http://moonlaketx.com/role/ShareBasedCompensationNarrativeDetails", "longName": "9954501 - Disclosure - Share-Based Compensation - Narrative (Details)", "shortName": "Share-Based Compensation - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-4", "name": "mnlk:NumberOfShareBasedCompensationPlans", "unitRef": "plan", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-207", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "unique": true } }, "R56": { "role": "http://moonlaketx.com/role/ShareBasedCompensationSharebasedCompensationExpenseByPlanDetails", "longName": "9954502 - Disclosure - Share-Based Compensation - Share-based Compensation Expense By Plan (Details)", "shortName": "Share-Based Compensation - Share-based Compensation Expense By Plan (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-209", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "unique": true } }, "R57": { "role": "http://moonlaketx.com/role/ShareBasedCompensationSummaryofRestrictedStockAwardedandGrantedDetails", "longName": "9954503 - Disclosure - Share-Based Compensation - Summary of Restricted Stock Awarded and Granted (Details)", "shortName": "Share-Based Compensation - Summary of Restricted Stock Awarded and Granted (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-224", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-224", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true } }, "R58": { "role": "http://moonlaketx.com/role/ShareBasedCompensationSummaryofESPPAwardedandGrantedDetails", "longName": "9954504 - Disclosure - Share-Based Compensation - Summary of ESPP Awarded and Granted (Details)", "shortName": "Share-Based Compensation - Summary of ESPP Awarded and Granted (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-232", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-232", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true } }, "R59": { "role": "http://moonlaketx.com/role/ShareBasedCompensationSummaryofESOPAwardedandGrantedDetails", "longName": "9954505 - Disclosure - Share-Based Compensation - Summary of ESOP Awarded and Granted (Details)", "shortName": "Share-Based Compensation - Summary of ESOP Awarded and Granted (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-241", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-241", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true } }, "R60": { "role": "http://moonlaketx.com/role/ShareBasedCompensationSummaryofEquityIncentivePlanAwardedandGrantedDetails", "longName": "9954506 - Disclosure - Share-Based Compensation - Summary of Equity Incentive Plan Awarded and Granted (Details)", "shortName": "Share-Based Compensation - Summary of Equity Incentive Plan Awarded and Granted (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "td", "tr", "table", "div", "mnlk:ScheduleOfStockAuthorizedAndIssuedRollForwardTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-247", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "unique": true } }, "R61": { "role": "http://moonlaketx.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails", "longName": "9954507 - Disclosure - Share-Based Compensation - Weighted Average Assumptions (Details)", "shortName": "Share-Based Compensation - Weighted Average Assumptions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-207", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-207", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true } }, "R62": { "role": "http://moonlaketx.com/role/IncomeTaxesDetails", "longName": "9954508 - Disclosure - Income Taxes (Details)", "shortName": "Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-10", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true } }, "R63": { "role": "http://moonlaketx.com/role/CommitmentandContingenciesDetails", "longName": "9954509 - Disclosure - Commitment and Contingencies (Details)", "shortName": "Commitment and Contingencies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c-4", "name": "mnlk:UnrecognizedCommitmentsAndContingencies", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "mnlk:UnrecognizedCommitmentsAndContingencies", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true } }, "R64": { "role": "http://moonlaketx.com/role/SegmentInformationandGeographicDataScheduleofLongLivedAssetsDetails", "longName": "9954510 - Disclosure - Segment Information and Geographic Data - Schedule of Long-Lived Assets (Details)", "shortName": "Segment Information and Geographic Data - Schedule of Long-Lived Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:NoncurrentAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:NoncurrentAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mnlk-20240930.htm", "first": true, "unique": true } }, "R65": { "role": "http://moonlaketx.com/role/SegmentInformationandGeographicDataNarrativeDetails", "longName": "9954511 - Disclosure - Segment Information and Geographic Data - Narrative (Details)", "shortName": "Segment Information and Geographic Data - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": null, "uniqueAnchor": null } }, "tag": { "mnlk_ATMSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://moonlaketx.com/20240930", "localname": "ATMSharesMember", "presentation": ["http://moonlaketx.com/role/ShareholdersEquityNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "ATM Shares", "label": "ATM Shares [Member]", "documentation": "ATM Shares" } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "presentation": ["http://moonlaketx.com/role/AccruedExpensesandOtherCurrentLiabilities", "http://moonlaketx.com/role/TradeandOtherPayables"], "lang": { "en-us": { "role": { "verboseLabel": "Trade and Other Payables", "terseLabel": "Accrued Expenses and Other Current Liabilities", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period." } } }, "auth_ref": ["r69", "r71", "r74", "r988"] }, "us-gaap_AccountsPayableOtherCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableOtherCurrent", "crdr": "credit", "calculation": { "http://moonlaketx.com/role/TradeandOtherPayablesDetails": { "parentTag": "mnlk_TradeAndOtherPayablesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://moonlaketx.com/role/TradeandOtherPayablesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Other payables", "label": "Accounts Payable, Other, Current", "documentation": "Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r69"] }, "mnlk_AccruedConsultingAndAdvisoryFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://moonlaketx.com/20240930", "localname": "AccruedConsultingAndAdvisoryFeesCurrent", "crdr": "credit", "calculation": { "http://moonlaketx.com/role/TradeandOtherPayablesDetails": { "parentTag": "mnlk_TradeAndOtherPayablesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://moonlaketx.com/role/TradeandOtherPayablesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Consulting and advisory services", "label": "Accrued Consulting And Advisory Fees, Current", "documentation": "Accrued Consulting And Advisory Fees, Current" } } }, "auth_ref": [] }, "mnlk_AccruedConsultingAndOtherFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://moonlaketx.com/20240930", "localname": "AccruedConsultingAndOtherFeesCurrent", "crdr": "credit", "calculation": { "http://moonlaketx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://moonlaketx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Consultant and other fees", "label": "Accrued

Consulting And Other Fees, Current", "documentation": "Accrued Consulting And Other Fees, Current" } } }, "auth_ref": [] }, "us-gaap_AccruedIncomeTaxesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedIncomeTaxesCurrent", "crdr": "credit", "calculation": { "http://moonlaketx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://moonlaketx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Tax liabilities", "label": "Accrued Income Taxes, Current", "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations." } } }, "auth_ref": ["r71", "r123"] }, "mnlk_AccruedLegalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://moonlaketx.com/20240930", "localname": "AccruedLegalFeesCurrent", "crdr": "credit", "calculation": { "http://moonlaketx.com/role/TradeandOtherPayablesDetails": { "parentTag": "mnlk_TradeAndOtherPayablesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://moonlaketx.com/role/TradeandOtherPayablesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Legal advisory fees payable", "label": "Accrued Legal Fees, Current", "documentation": "Accrued Legal Fees, Current" } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesAndOtherLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesAndOtherLiabilities", "crdr": "credit", "calculation": { "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 }, "http://moonlaketx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://moonlaketx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails", "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses and other current liabilities", "totalLabel": "Total", "label": "Accrued Liabilities and Other Liabilities", "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other." } } }, "auth_ref": [] }, "us-gaap_AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "calculation": { "http://moonlaketx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://moonlaketx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Legal fees", "label": "Accrued Professional Fees, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r71"] }, "mnlk_AccruedResearchAndDevelopmentExpensesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://moonlaketx.com/20240930", "localname": "AccruedResearchAndDevelopmentExpensesCurrent", "crdr": "credit", "calculation": { "http://moonlaketx.com/role/TradeandOtherPayablesDetails": { "parentTag": "mnlk_TradeAndOtherPayablesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://moonlaketx.com/role/TradeandOtherPayablesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Research and development services and license fees", "label": "Accrued Research And Development Expenses, Current", "documentation": "Accrued Research And Development Expenses, Current" } } }, "auth_ref": [] }, "mnlk_AccruedResearchAndDevelopmentServicesAndLicenseFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://moonlaketx.com/20240930", "localname": "AccruedResearchAndDevelopmentServicesAndLicenseFeesCurrent", "crdr": "credit", "calculation": { "http://moonlaketx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://moonlaketx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Research and development services and license fees", "label": "Accrued Research And Development Services and License Fees, Current", "documentation": "Accrued Research And Development Services and License Fees, Current" } } }, "auth_ref": [] }, "mnlk_AccruedSupplyAndManufacturingFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://moonlaketx.com/20240930", "localname": "AccruedSupplyAndManufacturingFeesCurrent", "crdr": "credit", "calculation": { "http://moonlaketx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://moonlaketx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Supply and manufacturing services", "label": "Accrued Supply And Manufacturing Fees, Current", "documentation": "Accrued Supply And Manufacturing Fees, Current" } } }, "auth_ref": [] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive income", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": ["r21", "r22", "r85", "r153", "r585", "r616", "r617"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": ["http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r1", "r12", "r22", "r442", "r445", "r503", "r612", "r613", "r913", "r914", "r915", "r919", "r920", "r921", "r923"] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": ["r849"] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": ["r79", "r786", "r1048"] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": ["http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-In Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": ["r631", "r919", "r920", "r921", "r923", "r989", "r1050"] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": ["r862"] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": ["r862"] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": ["r862"] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": ["r862"] }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:", "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "mnlk_AdjustmentsToAdditionalPaidInCapitalStampDutyFees": { "xbrltype": "monetaryItemType", "nsuri": "http://moonlaketx.com/20240930", "localname": "AdjustmentsToAdditionalPaidInCapitalStampDutyFees", "crdr": "credit", "presentation": ["http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"], "lang": { "en-us": { "role": { "terseLabel": "Refund of stamp duty fees", "label": "Adjustments To Additional Paid In Capital, Stamp Duty Fees", "documentation": "Adjustments To Additional Paid In Capital, Stamp Duty Fees" } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table", "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]" } } }, "auth_ref": ["r895"] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r821", "r831", "r841", "r873"] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": ["r824", "r834", "r844", "r876"] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Pension Adjustments Service Cost", "label": "Aggregate Pension Adjustments Service Cost [Member]" } } }, "auth_ref": ["r896"] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": ["r862"] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": ["r869"] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": ["r825", "r835", "r845", "r869", "r877", "r881", "r889"] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": ["r887"] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": ["http://moonlaketx.com/role/ShareBasedCompensationNarrativeDetails", "http://moonlaketx.com/role/ShareBasedCompensationSharebasedCompensationExpenseByPlanDetails"], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation expense", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": ["r393", "r402"] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": ["http://moonlaketx.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": ["http://moonlaketx.com/role/NetLossperShareNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r122", "r130", "r149", "r181", "r214", "r222", "r234", "r237", "r281", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r435", "r439", "r474", "r581", "r670",

"r750", "r751", "r786", "r812", "r956", "r957", "r1005"] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": ["r146", "r155", "r181", "r281", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r435", "r439", "r474", "r786", "r956", "r957", "r1005"] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": ["http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Current assets", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "calculation": { "http://moonlaketx.com/role/FairValueMeasurementsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://moonlaketx.com/role/FairValueMeasurementsDetails"], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Assets, Fair Value Disclosure", "documentation": "Fair value portion of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r453", "r454", "r775"] }, "us-gaap_AssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsNoncurrent", "crdr": "debit", "calculation": { "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "totalLabel": "Total non-current assets", "label": "Assets, Noncurrent", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": ["r181", "r281", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r435", "r439", "r474", "r956", "r957", "r1005"] }, "us-gaap_AssetsNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsNoncurrentAbstract", "presentation": ["http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Non-current assets", "label": "Assets, Noncurrent [Abstract]" } } }, "auth_ref": [] }, "mnlk_August2023SalesAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://moonlaketx.com/20240930", "localname": "August2023SalesAgreementMember", "presentation": ["http://moonlaketx.com/role/ShareholdersEquityNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "August 2023 Sales Agreement", "label": "August 2023 Sales Agreement [Member]", "documentation": "August 2023 Sales Agreement" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "calculation": { "http://moonlaketx.com/role/InvestmentsScheduleofFairValueandAmortizedCostofInvestmentsinShortTermMarketableDebtDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0, "order": 3.0 } }, "presentation": ["http://moonlaketx.com/role/InvestmentsScheduleofFairValueandAmortizedCostofInvestmentsinShortTermMarketableDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Gross unrealized gains", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r255"] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "calculation": { "http://moonlaketx.com/role/InvestmentsScheduleofFairValueandAmortizedCostofInvestmentsinShortTermMarketableDebtDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://moonlaketx.com/role/InvestmentsScheduleofFairValueandAmortizedCostofInvestmentsinShortTermMarketableDebtDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Gross unrealized losses", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r256"] }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "crdr": "debit", "calculation": { "http://moonlaketx.com/role/InvestmentsScheduleofFairValueandAmortizedCostofInvestmentsinShortTermMarketableDebtDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://moonlaketx.com/role/InvestmentsScheduleofFairValueandAmortizedCostofInvestmentsinShortTermMarketableDebtDetails"], "lang": { "en-us": { "role": { "totalLabel": "Amortized cost", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r252", "r289", "r580"] }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "calculation": { "http://moonlaketx.com/role/InvestmentsScheduleofFairValueandAmortizedCostofInvestmentsinShortTermMarketableDebtDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://moonlaketx.com/role/InvestmentsScheduleofFairValueandAmortizedCostofInvestmentsinShortTermMarketableDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair value", "label": "Debt Securities, Available-for-Sale", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r253", "r289", "r453", "r571", "r775", "r778", "r932", "r993", "r994", "r995"] }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "crdr": "debit", "calculation": { "http://moonlaketx.com/role/FairValueMeasurementsDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 1.0 }, "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://moonlaketx.com/role/FairValueMeasurementsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Short-term marketable debt securities", "label": "Debt Securities, Available-for-Sale, Current", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current." } } }, "auth_ref": ["r249", "r289"] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": ["r884"] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": ["r885"] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": ["r880"] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": ["r880"] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": ["r880"] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": ["r880"] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": ["r880"] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": ["r880"] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": ["http://moonlaketx.com/role/ShareBasedCompensationNarrativeDetails", "http://moonlaketx.com/role/ShareBasedCompensationSharebasedCompensationExpenseByPlanDetails", "http://moonlaketx.com/role/ShareBasedCompensationSummaryofESOPAwardedandGrantedDetails", "http://moonlaketx.com/role/ShareBasedCompensationSummaryofESPPAwardedandGrantedDetails", "http://moonlaketx.com/role/ShareBasedCompensationSummaryofRestrictedStockAwardedandGrantedDetails", "http://moonlaketx.com/role/ShareholdersEquityNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": ["r364", "r365", "r366", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r388", "r389", "r390", "r391", "r392"] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": ["r883"] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": ["r882"] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": ["r881"] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": ["r881"] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationAxis", "presentation": ["http://moonlaketx.com/role/CommitmentandContingenciesDetails", "http://moonlaketx.com/role/InvestmentsScheduleofFairValueandAmortizedCostofInvestmentsinShortTermMarketableDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Axis]", "label": "Statement of Financial Position Location, Balance [Axis]", "documentation": "Information by location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": ["r297", "r1016", "r1017"] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationDomain", "presentation": ["http://moonlaketx.com/role/CommitmentandContingenciesDetails", "http://moonlaketx.com/role/InvestmentsScheduleofFairValueandAmortizedCostofInvestmentsinShortTermMarketableDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Domain]", "label": "Statement of Financial Position Location, Balance [Domain]", "documentation": "Location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": ["r64", "r65", "r297", "r1016", "r1017"] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": ["http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "presentation": ["http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation and Significant Accounting Policies", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity." } } }, "auth_ref": ["r95"] }, "us-gaap_BuildingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BuildingMember", "presentation": ["http://moonlaketx.com/role/LeasesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Building", "label": "Building [Member]", "documentation": "Facility held for productive use including, but not limited to, office, production, storage

and distribution facilities." } } }, "auth_ref": ["r98"] }, "us-gaap_BusinessCombinationsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationsPolicy", "presentation": ["http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Acquisitions", "label": "Business Combinations Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy." } } }, "auth_ref": ["r115", "r116", "r117", "r118"] }, "country_CH": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "CH", "presentation": [
"http://moonlaketx.com/role/SegmentInformationandGeographicDataScheduleofLongLivedAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Switzerland", "label": "SWITZERLAND" } } }, "auth_ref": [] }, "mnlk_CambridgeOfficeMember": { "xbrltype": "domainItemType", "nsuri": "http://moonlaketx.com/20240930", "localname": "CambridgeOfficeMember", "presentation": ["http://moonlaketx.com/role/LeasesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cambridge Office", "label": "Cambridge Office [Member]", "documentation": "Cambridge Office" } } }, "auth_ref": [] }, "us-gaap_Cash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Cash", "crdr": "debit", "presentation": ["http://moonlaketx.com/role/RisksandLiquidityDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Unrestricted cash", "label": "Cash", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r132", "r583", "r642", "r665", "r786", "r812", "r910"] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": {
"http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails", "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r27", "r148", "r736"] }, "us-gaap_CashAndCashEquivalentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAxis", "presentation": ["http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents [Axis]", "label": "Cash and Cash Equivalents [Axis]", "documentation": "Information by type of cash and cash equivalent balance." } } }, "auth_ref": ["r148"] }, "us-gaap_CashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsMember", "presentation": ["http://moonlaketx.com/role/InvestmentsScheduleofFairValueandAmortizedCostofInvestmentsinShortTermMarketableDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents", "label": "Cash and Cash Equivalents [Member]", "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": ["http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": ["r28"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": ["http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "periodStartLabel": "Cash and cash equivalents, beginning of period", "periodEndLabel": "Cash and cash equivalents, end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r27", "r92", "r179"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "totalLabel": "Net change in cash and cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r0", "r92"] }, "us-gaap_CashFlowFinancingActivitiesLesseeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowFinancingActivitiesLesseeAbstract", "presentation": ["http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Cash flow from financing activities", "label": "Cash Flow, Financing Activities, Lessee [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CashFlowInvestingActivitiesLesseeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowInvestingActivitiesLesseeAbstract", "presentation": ["http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Cash flow from investing activities", "label": "Cash Flow, Investing Activities, Lessee [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CashFlowOperatingActivitiesLesseeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowOperatingActivitiesLesseeAbstract", "presentation": ["http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Cash flow from operating activities", "label": "Cash Flow, Operating Activities, Lessee [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CertificatesOfDepositMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CertificatesOfDepositMember", "presentation": [
"http://moonlaketx.com/role/FairValueMeasurementsDetails",
"http://moonlaketx.com/role/InvestmentsScheduleofFairValueandAmortizedCostofInvestmentsinShortTermMarketableDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Certificates of Deposit", "label": "Certificates of Deposit [Member]", "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured." } } }, "auth_ref": ["r11", "r806", "r807", "r808", "r809"] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": ["r860"] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year", "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]" } } }, "auth_ref": ["r857"] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested", "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]" } } }, "auth_ref": ["r855"] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": ["http://moonlaketx.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": [
"http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
"http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY",
"http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://moonlaketx.com/role/Cover",
"http://moonlaketx.com/role/NetLossperShareNarrativeDetails", "http://moonlaketx.com/role/ShareBasedCompensationNarrativeDetails",
"http://moonlaketx.com/role/ShareholdersEquityNarrativeDetails", "http://moonlaketx.com/role/ShareholdersEquityScheduleofStockAuthorizedandIssuedDetails"], "lang": {
"en-us": { "role": { "terseLabel": "Class of Stock [Domain]", "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [
"r141", "r150", "r151", "r152", "r181", "r203", "r204", "r206", "r208", "r216", "r217", "r281", "r306", "r308", "r309", "r310", "r313", "r314", "r320", "r321", "r324", "r327",
"r334", "r474", "r623", "r624", "r625", "r626", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r643", "r657", "r680", "r698", "r712",
"r713", "r714", "r715", "r716", "r899", "r917", "r924"] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ClassOfStockLineItems", "presentation": ["http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails",
"http://moonlaketx.com/role/ShareholdersEquityNarrativeDetails", "http://moonlaketx.com/role/ShareholdersEquityScheduleofStockAuthorizedandIssuedDetails"], "lang": {
"en-us": { "role": { "terseLabel": "Class of Stock [Line Items]", "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r150",
"r151", "r152", "r216", "r320", "r321", "r322", "r324", "r327", "r332", "r334", "r623", "r624", "r625", "r626", "r761", "r899", "r917"] }, "ecd_CoSelectedMeasureAmt": {
"xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"],
"lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": ["r861"] },
"ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } },
"auth_ref": ["r861"] }, "mnlk_CommercialPaperAndCertificatesOfDepositMember": { "xbrltype": "domainItemType", "nsuri": "http://moonlaketx.com/20240930", "localname":
"CommercialPaperAndCertificatesOfDepositMember", "presentation": ["http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails"], "lang": {
"en-us": { "role": { "terseLabel": "Commercial Paper and Certificates of Deposit", "label": "Commercial Paper and Certificates of Deposit [Member]", "documentation":
"Commercial Paper and Certificates of Deposit" } } }, "auth_ref": [] }, "us-gaap_CommercialPaperMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "CommercialPaperMember", "presentation": ["http://moonlaketx.com/role/FairValueMeasurementsDetails",
"http://moonlaketx.com/role/InvestmentsScheduleofFairValueandAmortizedCostofInvestmentsinShortTermMarketableDebtDetails"], "lang": { "en-us": { "role": {
"verboseLabel": "Eurocommercial Papers", "terseLabel": "Eurocommercial Papers", "label": "Commercial Paper [Member]", "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds." } } }, "auth_ref": ["r100", "r305", "r806", "r807", "r808", "r809"] }, "us-
gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr":
"credit", "calculation": { "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight":
1.0, "order": 2.0 } }, "presentation": ["http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Commitments
and contingencies (Note 15)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential

losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": ["r75", "r124", "r582", "r656"] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": ["http://moonlaketx.com/role/CommitmentandContingencies"], "lang": { "en-us": { "role": { "terseLabel": "Commitment and Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": ["r99", "r299", "r300", "r720", "r951", "r953"] }, "us-gaap_CommonClassAMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonClassAMember", "presentation": ["http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://moonlaketx.com/role/Cover", "http://moonlaketx.com/role/NetLossperShareNarrativeDetails", "http://moonlaketx.com/role/ShareBasedCompensationNarrativeDetails", "http://moonlaketx.com/role/ShareholdersEquityNarrativeDetails", "http://moonlaketx.com/role/ShareholdersEquityScheduleofStockAuthorizedandIssuedDetails"], "lang": { "en-us": { "role": { "terseLabel": "Common Class A", "label": "Common Class A [Member]", "documentation": "Classification of common stock representing ownership interest in a corporation." } } }, "auth_ref": ["r1050"] }, "us-gaap_CommonClassCMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonClassCMember", "presentation": ["http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://moonlaketx.com/role/Cover", "http://moonlaketx.com/role/ShareBasedCompensationNarrativeDetails", "http://moonlaketx.com/role/ShareholdersEquityNarrativeDetails", "http://moonlaketx.com/role/ShareholdersEquityScheduleofStockAuthorizedandIssuedDetails"], "lang": { "en-us": { "role": { "terseLabel": "Common Class C", "label": "Common Class C [Member]", "documentation": "Classification of common stock that has different rights than provided to Class A or B shares, representing ownership interest in a corporation." } } }, "auth_ref": [] }, "mnlk_CommonStockConversionRatio": { "xbrltype": "pureItemType", "nsuri": "http://moonlaketx.com/20240930", "localname": "CommonStockConversionRatio", "presentation": ["http://moonlaketx.com/role/ShareholdersEquityNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, conversion ratio (in shares)", "label": "Common Stock, Conversion Ratio", "documentation": "Common Stock, Conversion Ratio" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": ["http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://moonlaketx.com/role/ShareholdersEquityNarrativeDetails", "http://moonlaketx.com/role/ShareholdersEquityScheduleofStockAuthorizedandIssuedDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r802", "r803", "r804", "r806", "r807", "r808", "r809", "r919", "r920", "r923", "r989", "r1047", "r1050"] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": ["http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://moonlaketx.com/role/ShareholdersEquityNarrativeDetails", "http://moonlaketx.com/role/ShareholdersEquityScheduleofStockAuthorizedandIssuedDetails"], "lang": { "en-us": { "role": { "terseLabel": "Common shares, par value (USD per share)", "verboseLabel": "Common stock, par value (CHF/USD per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": ["r78"] }, "mnlk_CommonStockRollForward": { "xbrltype": "stringItemType", "nsuri": "http://moonlaketx.com/20240930", "localname": "CommonStockRollForward", "presentation": ["http://moonlaketx.com/role/ShareholdersEquityScheduleofStockAuthorizedandIssuedDetails"], "lang": { "en-us": { "role": { "terseLabel": "Common Shares", "label": "Common Stock [Roll Forward]", "documentation": "Common Stock" } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "calculation": { "http://moonlaketx.com/role/ShareholdersEquityScheduleofStockAuthorizedandIssuedDetails": { "parentTag": "mnlk_SharesAuthorized", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://moonlaketx.com/role/ShareholdersEquityNarrativeDetails", "http://moonlaketx.com/role/ShareholdersEquityScheduleofStockAuthorizedandIssuedDetails"], "lang": { "en-us": { "role": { "terseLabel": "Common shares, shares authorized (in shares)", "periodStartLabel": "Authorized, beginning balance (in shares)", "periodEndLabel": "Authorized, ending balance (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r78", "r657"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "calculation": { "http://moonlaketx.com/role/ShareholdersEquityScheduleofStockAuthorizedandIssuedDetails": { "parentTag": "us-gaap_SharesIssued", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://moonlaketx.com/role/ShareholdersEquityNarrativeDetails", "http://moonlaketx.com/role/ShareholdersEquityScheduleofStockAuthorizedandIssuedDetails"], "lang": { "en-us": { "role": { "terseLabel": "Common shares, shares issued (in shares)", "periodStartLabel": "Issued, beginning balance (in shares)", "periodEndLabel": "Issued, ending balance (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": ["r78"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": ["http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://moonlaketx.com/role/NetLossperShareNarrativeDetails", "http://moonlaketx.com/role/ShareBasedCompensationNarrativeDetails", "http://moonlaketx.com/role/ShareholdersEquityNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Common shares, shares outstanding (in shares)", "periodStartLabel": "Common stock, beginning balance (in shares)", "periodEndLabel": "Common stock, ending balance (in shares)", "verboseLabel": "Number of shares outstanding (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r13", "r78", "r657", "r676", "r1050", "r1051"] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Common shares", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r78", "r584", "r786"] }, "mnlk_CommonStockVotesAttachedToShares": { "xbrltype": "integerItemType", "nsuri": "http://moonlaketx.com/20240930", "localname": "CommonStockVotesAttachedToShares", "presentation": ["http://moonlaketx.com/role/ShareholdersEquityNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Common shares, votes per share", "label": "Common Stock, Votes Attached To Shares", "documentation": "Common Stock, Votes Attached To Shares" } } }, "auth_ref": [] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": ["r866"] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": ["r865"] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": ["r867"] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": ["r864"] }, "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CompensationAndEmployeeBenefitPlansTextBlock", "presentation": ["http://moonlaketx.com/role/EmployeeBenefitPlans"], "lang": { "en-us": { "role": { "terseLabel": "Employee Benefit Plans", "label": "Compensation and Employee Benefit Plans [Text Block]", "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans." } } }, "auth_ref": ["r106", "r107", "r108", "r111"] }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CompensationAndRetirementDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Retirement Benefits [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive loss attributable to controlling interests shareholders", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r23", "r162", "r164", "r172", "r575", "r596", "r598"] }, "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"], "lang": { "en-us": { "role": { "terseLabel": "Comprehensive loss attributable to noncontrolling interests", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r5", "r60", "r63", "r162", "r164", "r171", "r574", "r596", "r597"] }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive loss", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r63", "r120", "r162", "r164", "r170", "r573", "r596"] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskCreditRisk", "presentation": ["http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Concentration of Credit Risk", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": ["r67", "r135"] }, "mnlk_ConversionOfClassCIntoClassAMember": { "xbrltype": "domainItemType", "nsuri": "http://moonlaketx.com/20240930", "localname": "ConversionOfClassCIntoClassAMember", "presentation": ["http://moonlaketx.com/role/ShareholdersEquityNarrativeDetails", "http://moonlaketx.com/role/ShareholdersEquityScheduleofStockAuthorizedandIssuedDetails"], "lang": { "en-us": { "role": { "terseLabel": "Conversion Of Class C into Class

A", "label": "Conversion Of Class C into Class A [Member]", "documentation": "Conversion Of Class C into Class A" } } }, "auth_ref": [] }, "us-gaap_ConversionOfStockByUniqueDescriptionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConversionOfStockByUniqueDescriptionAxis", "presentation": ["http://moonlaketx.com/role/ShareholdersEquityNarrativeDetails", "http://moonlaketx.com/role/ShareholdersEquityScheduleofStockAuthorizedandIssuedDetails"], "lang": { "en-us": { "role": { "terseLabel": "Stock Conversion Description [Axis]", "label": "Stock Conversion Description [Axis]", "documentation": "Information by description of stock conversions." } } }, "auth_ref": ["r29", "r30", "r31"] }, "us-gaap_ConversionOfStockNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConversionOfStockNameDomain", "presentation": ["http://moonlaketx.com/role/ShareholdersEquityNarrativeDetails", "http://moonlaketx.com/role/ShareholdersEquityScheduleofStockAuthorizedandIssuedDetails"], "lang": { "en-us": { "role": { "terseLabel": "Conversion of Stock, Name [Domain]", "label": "Conversion of Stock, Name [Domain]", "documentation": "The unique name of a noncash or part noncash stock conversion." } } }, "auth_ref": ["r29", "r30", "r31"] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CounterpartyNameAxis", "presentation": ["http://moonlaketx.com/role/CommitmentandContingenciesDetails", "http://moonlaketx.com/role/ShareholdersEquityNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Axis]", "label": "Counterparty Name [Axis]" } } }, "auth_ref": ["r183", "r184", "r315", "r322", "r504", "r522", "r579", "r739", "r741"] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "mnlk_CurrentAssetsInExcessOfCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://moonlaketx.com/20240930", "localname": "CurrentAssetsInExcessOfCurrentLiabilities", "crdr": "debit", "presentation": ["http://moonlaketx.com/role/RisksandLiquidityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Excess of current assets less current liabilities", "label": "Current Assets In Excess Of Current Liabilities", "documentation": "Current Assets In Excess Of Current Liabilities" } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": ["http://moonlaketx.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax", "crdr": "credit", "presentation": ["http://moonlaketx.com/role/InvestmentsScheduleofChangesinFairValueofShortTermMarketableSecuritiesDetails"], "lang": { "en-us": { "role": { "periodStartLabel": "Gross unrealized gain (loss), beginning balance", "periodEndLabel": "Gross unrealized gain (loss), ending balance", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain (Loss), before Tax", "documentation": "Amount, before tax, of unrealized gain (loss) in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r937", "r938"] }, "mnlk_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossRollForward": { "xbrltype": "stringItemType", "nsuri": "http://moonlaketx.com/20240930", "localname": "DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossRollForward", "presentation": ["http://moonlaketx.com/role/InvestmentsScheduleofChangesinFairValueofShortTermMarketableSecuritiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain (Loss) [Roll Forward]", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain (Loss) [Roll Forward]", "documentation": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain (Loss)" } } }, "auth_ref": [] }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleTable", "presentation": ["http://moonlaketx.com/role/InvestmentsScheduleofChangesinFairValueofShortTermMarketableSecuritiesDetails", "http://moonlaketx.com/role/InvestmentsScheduleofFairValueandAmortizedCostofInvestmentsinShortTermMarketableDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-Sale [Table]", "label": "Debt Securities, Available-for-Sale [Table]", "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262"] }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "presentation": ["http://moonlaketx.com/role/InvestmentsTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of investments in short-term marketable debt securities", "label": "Debt Securities, Available-for-Sale [Table Text Block]", "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r934", "r935", "r936", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r944", "r945"] }, "us-gaap_DebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesMember", "presentation": ["http://moonlaketx.com/role/InvestmentsScheduleofFairValueandAmortizedCostofInvestmentsinShortTermMarketableDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities [Member]", "documentation": "Debt instrument issued by corporations, governments and governmental agencies, municipalities, and other institutions." } } }, "auth_ref": ["r38", "r804", "r1052"] }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "presentation": ["http://moonlaketx.com/role/PrepaidExpensesTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of prepaid expenses", "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]", "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs." } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPensionPlanLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Pension liability", "label": "Liability, Defined Benefit Pension Plan, Noncurrent", "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension plan, classified as noncurrent. Excludes other postretirement benefit plan." } } }, "auth_ref": ["r47", "r48", "r74", "r109"] }, "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAmortizationOfGainsLosses", "crdr": "credit", "calculation": { "http://moonlaketx.com/role/EmployeeBenefitPlansDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0, "order": 5.0 } }, "presentation": ["http://moonlaketx.com/role/EmployeeBenefitPlansDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Amortization of unrecognized loss", "label": "Defined Benefit Plan, Amortization of Gain (Loss)", "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan." } } }, "auth_ref": ["r336", "r350", "r356", "r766", "r767"] }, "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets", "crdr": "credit", "calculation": { "http://moonlaketx.com/role/EmployeeBenefitPlansDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://moonlaketx.com/role/EmployeeBenefitPlansDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Expected return on plan assets", "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets", "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan." } } }, "auth_ref": ["r336", "r349", "r355", "r766", "r767"] }, "us-gaap_DefinedBenefitPlanInterestCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanInterestCost", "crdr": "debit", "calculation": { "http://moonlaketx.com/role/EmployeeBenefitPlansDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://moonlaketx.com/role/EmployeeBenefitPlansDetails"], "lang": { "en-us": { "role": { "terseLabel": "Interest cost", "label": "Defined Benefit Plan, Interest Cost", "documentation": "Amount of cost recognized for passage of time related to defined benefit plan." } } }, "auth_ref": ["r336", "r338", "r348", "r354", "r766", "r767"] }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanNetPeriodicBenefitCost", "crdr": "debit", "calculation": { "http://moonlaketx.com/role/EmployeeBenefitPlansDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://moonlaketx.com/role/EmployeeBenefitPlansDetails"], "lang": { "en-us": { "role": { "totalLabel": "Total net periodic benefit cost", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)", "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan." } } }, "auth_ref": ["r346", "r352", "r766", "r767"] }, "us-gaap_DefinedBenefitPlanServiceCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanServiceCost", "crdr": "debit", "calculation": { "http://moonlaketx.com/role/EmployeeBenefitPlansDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://moonlaketx.com/role/EmployeeBenefitPlansDetails"], "lang": { "en-us": { "role": { "terseLabel": "Service cost", "label": "Defined Benefit Plan, Service Cost", "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan." } } }, "auth_ref": ["r337", "r347", "r353", "r766", "r767"] }, "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable", "presentation": ["http://moonlaketx.com/role/EmployeeBenefitPlansNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]", "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]", "documentation": "Disclosure of information about defined benefit pension plans or other postretirement defined benefit plans. The arrangements are generally based on terms and conditions stipulated by the entity, and which contain a promise by the employer to pay certain amounts or awards at designated future dates, including a period after retirement, upon compliance with stipulated requirements. Excludes disclosures pertaining to defined contribution plans." } } }, "auth_ref": ["r9", "r49", "r50", "r51", "r52"] }, "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems", "presentation": ["http://moonlaketx.com/role/EmployeeBenefitPlansNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]", "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanCostRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanCostRecognized", "crdr": "debit", "presentation": ["http://moonlaketx.com/role/EmployeeBenefitPlansNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Contributions made to plan", "label": "Defined Contribution Plan, Cost", "documentation": "Amount of cost for defined contribution plan." } } }, "auth_ref": ["r357"] }, "us-gaap_DefinedContributionPlanIncreaseDecreaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanIncreaseDecreaseCost", "crdr": "debit", "presentation": ["http://moonlaketx.com/role/EmployeeBenefitPlansNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Defined contribution plan, increase (decrease), cost", "label": "Defined Contribution Plan, Increase (Decrease), Cost", "documentation": "Amount of increase (decrease) in cost for defined contribution plan." } } }, "auth_ref": [] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "calculation": { "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": ["http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Depreciation", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": ["r7", "r39"] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": ["http://moonlaketx.com/role/ShareBasedCompensation"], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Compensation", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": ["r360", "r363", "r394", "r395", "r397", "r769"] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": ["http://moonlaketx.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": ["http://moonlaketx.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide

financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationLineItems", "presentation": ["http://moonlaketx.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Document Information [Line Items]", "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTable", "presentation": ["http://moonlaketx.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Document Information [Table]", "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": ["http://moonlaketx.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": ["http://moonlaketx.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": ["r816"] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": ["http://moonlaketx.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": ["r848"] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": ["http://moonlaketx.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year", "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]" } } }, "auth_ref": ["r859"] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": ["http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://moonlaketx.com/role/NetLossperShareCalculationofNetLossperShareDetails", "http://moonlaketx.com/role/NetLossperShareNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Diluted net loss per share attributable to controlling interest shareholders (USD per share)", "verboseLabel": "Net loss per share - basic (in USD per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r173", "r190", "r191", "r192", "r193", "r194", "r195", "r201", "r203", "r206", "r207", "r208", "r213", "r430", "r433", "r450", "r451", "r576", "r599", "r742"] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": ["http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://moonlaketx.com/role/NetLossperShareCalculationofNetLossperShareDetails", "http://moonlaketx.com/role/NetLossperShareNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Basic net loss per share attributable to controlling interest shareholders (USD per share)", "verboseLabel": "Net loss per share - diluted (in USD per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": ["r173", "r190", "r191", "r192", "r193", "r194", "r195", "r203", "r206", "r207", "r208", "r213", "r430", "r433", "r450", "r451", "r576", "r599", "r742"] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerSharePolicyTextBlock", "presentation": ["http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Net Loss per Class A Ordinary Shares", "label": "Earnings Per Share, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": ["r32", "r33", "r210"] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": ["http://moonlaketx.com/role/NetLossperShare"], "lang": { "en-us": { "role": { "terseLabel": "Net Loss per Share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": ["r200", "r209", "r211", "r212"] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "calculation": { "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Effect of movements in exchange rates on cash held", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r1001"] }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "presentation": ["http://moonlaketx.com/role/IncomeTaxesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Effective income tax rate", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)." } } }, "auth_ref": ["r182", "r410", "r421", "r772"] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://moonlaketx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://moonlaketx.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Bonuses and related employees compensation expenses", "label": "Employee-related Liabilities, Current", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r71"] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": ["http://moonlaketx.com/role/ShareBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized compensation expense", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": ["r396"] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": ["http://moonlaketx.com/role/ShareBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Weighted average period of recognition", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r396"] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "crdr": "debit", "presentation": ["http://moonlaketx.com/role/ShareBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized share-based compensation expense, non-option awards", "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": ["r987"] }, "us-gaap_EmployeeStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockMember", "presentation": ["http://moonlaketx.com/role/ShareBasedCompensationNarrativeDetails", "http://moonlaketx.com/role/ShareBasedCompensationSharebasedCompensationExpenseByPlanDetails", "http://moonlaketx.com/role/ShareBasedCompensationSummaryofESPPAwardedandGrantedDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "ESPP", "label": "Employee Stock [Member]", "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": ["http://moonlaketx.com/role/ShareBasedCompensationNarrativeDetails", "http://moonlaketx.com/role/ShareBasedCompensationSharebasedCompensationExpenseByPlanDetails", "http://moonlaketx.com/role/ShareBasedCompensationSummaryofESOPAwardedandGrantedDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "ESOP", "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "mnlk_EmployeeStockOptionPlanESOPMember": { "xbrltype": "domainItemType", "nsuri": "http://moonlaketx.com/20240930", "localname": "EmployeeStockOptionPlanESOPMember", "presentation": ["http://moonlaketx.com/role/ShareBasedCompensationNarrativeDetails", "http://moonlaketx.com/role/ShareBasedCompensationSummaryofESOPAwardedandGrantedDetails"], "lang": { "en-us": { "role": { "terseLabel": "Employee Stock Option Plan (ESOP)", "label": "Employee Stock Option Plan (ESOP) [Member]", "documentation": "Employee Stock Option Plan (ESOP)" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": ["http://moonlaketx.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": ["http://moonlaketx.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": ["http://moonlaketx.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Country", "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": ["http://moonlaketx.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": ["http://moonlaketx.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": ["r814"] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType",

"nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": ["http://moonlaketx.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": ["http://moonlaketx.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain", "presentation": ["http://moonlaketx.com/role/ShareBasedCompensationNarrativeDetails", "http://moonlaketx.com/role/ShareholdersEquityNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Entity [Domain]", "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": ["http://moonlaketx.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r814"] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": ["http://moonlaketx.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": ["http://moonlaketx.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": ["r814"] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": ["http://moonlaketx.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": ["http://moonlaketx.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": ["r898"] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": ["http://moonlaketx.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r814"] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": ["http://moonlaketx.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": ["r814"] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": ["http://moonlaketx.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r814"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://moonlaketx.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": ["r814"] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Footnote", "label": "Equity Awards Adjustments, Footnote [Text Block]" } } }, "auth_ref": ["r853"] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table", "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]" } } }, "auth_ref": ["r894"] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments", "label": "Equity Awards Adjustments [Member]" } } }, "auth_ref": ["r894"] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table", "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]" } } }, "auth_ref": ["r894"] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "presentation": ["http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Equity", "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": ["http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://moonlaketx.com/role/ShareholdersEquityNarrativeDetails", "http://moonlaketx.com/role/ShareholdersEquityScheduleofStockAuthorizedandIssuedDetails"], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": ["r13", "r143", "r166", "r167", "r168", "r185", "r186", "r187", "r189", "r194", "r196", "r198", "r215", "r282", "r283", "r295", "r335", "r419", "r420", "r427", "r428", "r429", "r431", "r432", "r433", "r441", "r442", "r443", "r444", "r445", "r446", "r449", "r476", "r478", "r479", "r480", "r481", "r482", "r484", "r487", "r503", "r594", "r612", "r613", "r614", "r631", "r698"] }, "mnlk_EquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://moonlaketx.com/20240930", "localname": "EquityIncentivePlanMember", "presentation": ["http://moonlaketx.com/role/ShareBasedCompensationNarrativeDetails", "http://moonlaketx.com/role/ShareBasedCompensationSharebasedCompensationExpenseByPlanDetails", "http://moonlaketx.com/role/ShareBasedCompensationSummaryofEquityIncentivePlanAwardedandGrantedDetails", "http://moonlaketx.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails", "http://moonlaketx.com/role/ShareholdersEquityNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Equity Incentive Plan", "label": "Equity Incentive Plan [Member]", "documentation": "Equity Incentive Plan" } } }, "auth_ref": [] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": ["r863"] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": ["r821", "r831", "r841", "r873"] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": ["r818", "r828", "r838", "r870"] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": ["r869"] }, "us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "presentation": ["http://moonlaketx.com/role/FairValueMeasurementsTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of debt securities by level within the fair value hierarchy", "label": "Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2." } } }, "auth_ref": ["r453", "r454"] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": ["http://moonlaketx.com/role/FairValueMeasurementsDetails", "http://moonlaketx.com/role/InvestmentsScheduleofChangesinFairValueofShortTermMarketableSecuritiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": ["r316", "r340", "r341", "r342", "r343", "r344", "r345", "r452", "r454", "r455", "r456", "r457", "r463", "r464", "r466", "r509", "r510", "r511", "r759", "r760", "r764", "r765", "r766", "r775", "r778"] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": ["http://moonlaketx.com/role/FairValueMeasurementsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Axis]", "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": ["r453", "r454", "r455", "r457", "r775", "r994", "r997"] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": ["http://moonlaketx.com/role/FairValueMeasurements"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": ["r459", "r461", "r462", "r463", "r466", "r467", "r468", "r469", "r470", "r570", "r775", "r779"] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": ["http://moonlaketx.com/role/FairValueMeasurementsDetails", "http://moonlaketx.com/role/InvestmentsScheduleofChangesinFairValueofShortTermMarketableSecuritiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Level 2", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": ["r316", "r340", "r345", "r454", "r455", "r464", "r510", "r759", "r760", "r764", "r765", "r766", "r775"] }, "us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":

"FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsAbstract", "presentation": ["http://moonlaketx.com/role/FairValueMeasurementsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings [Line Items]", "label": "Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r460", "r777"] }, "us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasuredOnRecurringBasisGainLossIncludedInEarningsTable", "presentation": ["http://moonlaketx.com/role/FairValueMeasurementsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings [Table]", "label": "Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings [Table]", "documentation": "Disclosure of information about the gain (loss) of assets and liabilities measured at fair value on a recurring basis." } } }, "auth_ref": ["r460", "r777"] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementFrequencyDomain", "presentation": ["http://moonlaketx.com/role/FairValueMeasurementsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Domain]", "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": ["r453", "r454", "r455", "r457", "r775", "r994", "r997"] }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": ["http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements", "label": "Fair Value Measurement, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": ["http://moonlaketx.com/role/FairValueMeasurementsDetails", "http://moonlaketx.com/role/InvestmentsScheduleofChangesinFairValueofShortTermMarketableSecuritiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": ["r316", "r340", "r341", "r342", "r343", "r344", "r345", "r452", "r454", "r455", "r456", "r457", "r463", "r464", "r466", "r509", "r510", "r511", "r759", "r760", "r764", "r765", "r766", "r775", "r778"] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsRecurringMember", "presentation": ["http://moonlaketx.com/role/FairValueMeasurementsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring", "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": ["r775", "r991", "r992", "r993", "r994", "r995", "r997"] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": ["http://moonlaketx.com/role/FairValueMeasurementsDetails", "http://moonlaketx.com/role/InvestmentsScheduleofFairValueandAmortizedCostofInvestmentsinShortTermMarketableDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Financial Instrument [Axis]", "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": ["r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r284", "r285", "r286", "r287", "r288", "r290", "r291", "r292", "r318", "r332", "r447", "r471", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r595", "r757", "r775", "r776", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r787", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r945", "r946", "r947", "r948", "r990", "r993", "r994", "r995", "r996", "r997"] }, "us-gaap_ForeignCurrencyTransactionGainLossRealized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyTransactionGainLossRealized", "crdr": "credit", "presentation": ["http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency transaction gain (loss), realized", "label": "Realized Gain (Loss), Foreign Currency Transaction, before Tax", "documentation": "Amount, before tax, of realized gain (loss) from foreign currency transaction." } } }, "auth_ref": ["r678", "r810", "r999", "r1000", "r1049"] }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "presentation": ["http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Foreign Currency", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy." } } }, "auth_ref": ["r475"] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": ["r825", "r835", "r845", "r877"] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": ["r825", "r835", "r845", "r877"] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": ["r825", "r835", "r845", "r877"] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": ["r825", "r835", "r845", "r877"] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": ["r825", "r835", "r845", "r877"] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year", "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]" } } }, "auth_ref": ["r858"] }, "country_GB": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "GB", "presentation": ["http://moonlaketx.com/role/SegmentInformationandGeographicDataScheduleofLongLivedAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "United Kingdom", "label": "UNITED KINGDOM" } } }, "auth_ref": [] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"], "lang": { "en-us": { "role": { "negatedTerseLabel": "General and administrative", "label": "General and Administrative Expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": ["r89", "r682"] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": ["http://moonlaketx.com/role/ShareBasedCompensationSharebasedCompensationExpenseByPlanDetails"], "lang": { "en-us": { "role": { "terseLabel": "General and Administrative Expense", "label": "General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": ["r89"] }, "us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"], "lang": { "en-us": { "role": { "totalLabel": "Loss before income tax", "label": "Income (Loss), Including Portion Attributable to Noncontrolling Interest, before Tax", "documentation": "Amount, before tax, of income (loss) including portion attributable to noncontrolling interest. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments." } } }, "auth_ref": ["r87", "r915"] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": ["http://moonlaketx.com/role/ShareBasedCompensationSharebasedCompensationExpenseByPlanDetails"], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Axis]", "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r296", "r297", "r298", "r458", "r460", "r465", "r609", "r611", "r683", "r733", "r777", "r1018"] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": ["http://moonlaketx.com/role/ShareBasedCompensationSharebasedCompensationExpenseByPlanDetails"], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Domain]", "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r297", "r298", "r458", "r460", "r465", "r609", "r611", "r683", "r733", "r777", "r1018"] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": ["http://moonlaketx.com/role/IncomeTaxes"], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": ["r182", "r406", "r410", "r411", "r412", "r413", "r414", "r417", "r422", "r424", "r425", "r426", "r628", "r772"] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "us-gaap_ProfitLoss", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Income tax expense", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": ["r131", "r140", "r197", "r198", "r214", "r223", "r237", "r409", "r410", "r423", "r600", "r772"] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxPolicyTextBlock", "presentation": ["http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": ["r165", "r407", "r408", "r414", "r415", "r416", "r418", "r622"] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Trade and other payables", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": ["r6"] }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "crdr": "debit", "calculation": { "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight":

1.0, "order": 6.0 } }, "presentation": ["http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses and other current liabilities", "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities", "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other." } } }, "auth_ref": ["r916"] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": ["http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Changes in operating assets and liabilities:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "calculation": { "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities", "label": "Increase (Decrease) in Operating Lease Liability", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": ["r902", "r916"] }, "mnlk_IncreaseDecreaseInOperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://moonlaketx.com/20240930", "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAsset", "crdr": "credit", "calculation": { "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": ["http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Operating lease right-of-use assets", "label": "Increase (Decrease) In Operating Lease, Right-Of-Use Asset", "documentation": "Increase (Decrease) In Operating Lease, Right-Of-Use Asset" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherReceivables", "crdr": "credit", "calculation": { "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": ["http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other receivables", "label": "Increase (Decrease) in Other Receivables", "documentation": "Amount of increase (decrease) in receivables classified as other." } } }, "auth_ref": ["r6"] }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidExpense", "crdr": "credit", "calculation": { "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": ["http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Prepaid expenses", "label": "Increase (Decrease) in Prepaid Expense", "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods." } } }, "auth_ref": ["r6"] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": ["http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": ["r825", "r835", "r845", "r869", "r877", "r881", "r889"] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": ["r887"] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": ["r817", "r893"] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": ["r817", "r893"] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": ["r817", "r893"] }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "presentation": ["http://moonlaketx.com/role/Investments"], "lang": { "en-us": { "role": { "terseLabel": "Investments", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "documentation": "The entire disclosure for investments in certain debt and equity securities." } } }, "auth_ref": ["r128", "r142", "r247", "r250", "r472", "r473", "r1014"] }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCost", "crdr": "debit", "calculation": { "http://moonlaketx.com/role/LeasesTotalLeaseExpenseDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://moonlaketx.com/role/LeasesTotalLeaseExpenseDetails"], "lang": { "en-us": { "role": { "totalLabel": "Total lease expense", "label": "Lease, Cost", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": ["r493", "r785"] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCostTableTextBlock", "presentation": ["http://moonlaketx.com/role/LeasesTables"], "lang": { "en-us": { "role": { "terseLabel": "Lease, Cost", "label": "Lease, Cost [Table Text Block]", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": ["r1003"] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityAxis", "presentation": ["http://moonlaketx.com/role/ShareBasedCompensationNarrativeDetails", "http://moonlaketx.com/role/ShareholdersEquityNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Legal Entity [Axis]", "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_LesseeLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionLineItems", "presentation": ["http://moonlaketx.com/role/LeasesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Lease, Description [Line Items]", "label": "Lessee, Lease, Description [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r492", "r502"] }, "us-gaap_LesseeLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionTable", "presentation": ["http://moonlaketx.com/role/LeasesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Lease, Description [Table]", "label": "Lessee, Lease, Description [Table]", "documentation": "Disclosure of information about lessee's leases." } } }, "auth_ref": ["r492", "r502"] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeasesPolicyTextBlock", "presentation": ["http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Leases [Policy Text Block]", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": ["r491"] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": ["http://moonlaketx.com/role/LeasesTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Future Lease Payments", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": ["r1004"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://moonlaketx.com/role/LeasesFutureLeasePaymentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://moonlaketx.com/role/LeasesFutureLeasePaymentsDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://moonlaketx.com/role/LeasesFutureLeasePaymentsDetails"], "lang": { "en-us": { "role": { "totalLabel": "Total lease payments", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": ["r500"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://moonlaketx.com/role/LeasesFutureLeasePaymentsDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://moonlaketx.com/role/LeasesFutureLeasePaymentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r500"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://moonlaketx.com/role/LeasesFutureLeasePaymentsDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://moonlaketx.com/role/LeasesFutureLeasePaymentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r500"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://moonlaketx.com/role/LeasesFutureLeasePaymentsDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://moonlaketx.com/role/LeasesFutureLeasePaymentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r500"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://moonlaketx.com/role/LeasesFutureLeasePaymentsDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://moonlaketx.com/role/LeasesFutureLeasePaymentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r500"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://moonlaketx.com/role/LeasesFutureLeasePaymentsDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://moonlaketx.com/role/LeasesFutureLeasePaymentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Remainder of fiscal 2024", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": ["r1004"] }, "mnlk_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://moonlaketx.com/20240930", "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour", "crdr": "credit", "calculation": { "http://moonlaketx.com/role/LeasesFutureLeasePaymentsDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://moonlaketx.com/role/LeasesFutureLeasePaymentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Lessee, Operating Lease, Liability, to be Paid, After Year Four", "documentation": "Lessee, Operating Lease, Liability, to be Paid, After Year Four" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://moonlaketx.com/role/LeasesFutureLeasePaymentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } },

```
"presentation": [ "http://moonlaketx.com/role/LeasesFutureLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less imputed interest", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r500" ] }, "mnlk_LesseeOperatingLeaseNumberOfRenewalOptions": { "xbrltype": "integerItemType", "nsuri": "http://moonlaketx.com/20240930", "localname": "LesseeOperatingLeaseNumberOfRenewalOptions", "presentation": [ "http://moonlaketx.com/role/LeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, operating lease, number of renewal options", "label": "Lessee, Operating Lease, Number Of Renewal Options", "documentation": "Lessee, Operating Lease, Number Of Renewal Options" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseRenewalTerm", "presentation": [ "http://moonlaketx.com/role/LeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, operating lease, renewal term", "label": "Lessee, Operating Lease, Renewal Term", "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1002" ] }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": [ "http://moonlaketx.com/role/LeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, operating lease, term of contract", "label": "Lessee, Operating Lease, Term of Contract", "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1002" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://moonlaketx.com/role/Leases" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r486" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [ "r20", "r70", "r71", "r72", "r73", "r74", "r75", "r76", "r181", "r281", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r436", "r439", "r440", "r474", "r655", "r743", "r812", "r956", "r1005", "r1006" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r83", "r126", "r588", "r786", "r918", "r949", "r998" ] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r72", "r147", "r181", "r281", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r436", "r439", "r440", "r474", "r786", "r956", "r1005", "r1006" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total non-current liabilities", "label": "Liabilities, Noncurrent", "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r20", "r73", "r74", "r75", "r76", "r181", "r281", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r436", "r439", "r440", "r474", "r956", "r1005", "r1006" ] }, "us-gaap_LiabilitiesNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesNoncurrentAbstract", "presentation": [ "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current liabilities", "label": "Liabilities, Noncurrent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LicenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LicenseMember", "presentation": [ "http://moonlaketx.com/role/CommitmentandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "License", "label": "License [Member]", "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark." } } }, "auth_ref": [ "r960" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://moonlaketx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongLivedAssetsByGeographicAreasTableTextBlock", "presentation": [ "http://moonlaketx.com/role/SegmentInformationandGeographicDataTables" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Assets by Geographic Areas", "label": "Long-Lived Assets by Geographic Areas [Table Text Block]", "documentation": "Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets." } } }, "auth_ref": [ "r96" ] }, "us-gaap_MarketableSecuritiesPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesPolicy", "presentation": [ "http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Marketable securities and short-term investments", "label": "Marketable Securities, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for investment classified as marketable security." } } }, "auth_ref": [ "r66" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": [ "http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": [ "r301", "r302", "r303", "r304", "r358", "r403", "r457", "r538", "r608", "r610", "r618", "r647", "r648", "r703", "r705", "r707", "r708", "r710", "r731", "r732", "r756", "r761", "r768", "r778", "r779", "r783", "r784", "r797", "r958", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012" ] }, "mnlk_May2023AndAugust2023SalesAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://moonlaketx.com/20240930", "localname": "May2023AndAugust2023SalesAgreementMember", "presentation": [ "http://moonlaketx.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "May 2023 And August 2023 Sales Agreement", "label": "May 2023 And August 2023 Sales Agreement [Member]", "documentation": "May 2023 And August 2023 Sales Agreement" } } }, "auth_ref": [] }, "mnlk_May2023SalesAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://moonlaketx.com/20240930", "localname": "May2023SalesAgreementMember", "presentation": [ "http://moonlaketx.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "May 2023 Sales Agreement", "label": "May 2023 Sales Agreement [Member]", "documentation": "May 2023 Sales Agreement" } } }, "auth_ref": [] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": [ "r861" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": [ "r861" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": [ "http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": [ "r301", "r302", "r303", "r304", "r358", "r403", "r457", "r538", "r608", "r610", "r618", "r647", "r648", "r703", "r705", "r707", "r708", "r710", "r731", "r732", "r756", "r761", "r768", "r778", "r779", "r783", "r797", "r958", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012" ] }, "us-gaap_MinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterest", "crdr": "credit", "calculation": { "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling interests", "label": "Equity, Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r82", "r125", "r181", "r281", "r306", "r308", "r309", "r310", "r313", "r314", "r474", "r587", "r659" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r880" ] }, "mnlk_MoonLakeAGMember": { "xbrltype": "domainItemType", "nsuri": "http://moonlaketx.com/20240930", "localname": "MoonLakeAGMember", "presentation": [ "http://moonlaketx.com/role/ShareBasedCompensationNarrativeDetails", "http://moonlaketx.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "MoonLake AG", "label": "MoonLake AG [Member]", "documentation": "MoonLake AG" } } }, "auth_ref": [] }, "mnlk_MoonLakeImmunotherapeuticsMember": { "xbrltype": "domainItemType", "nsuri": "http://moonlaketx.com/20240930", "localname": "MoonLakeImmunotherapeuticsMember", "presentation": [ "http://moonlaketx.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "MoonLake Immunotherapeutics", "label": "MoonLake Immunotherapeutics [Member]", "documentation": "MoonLake Immunotherapeutics" } } }, "auth_ref": [] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r888" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r862" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash flow provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r178" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash flow used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r178" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash flow used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r92", "r93", "r94" ] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit",
```

```
"calculation": { "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://moonlaketx.com/role/NetLossperShareCalculationofNetLossperShareDetails", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Of which: net loss attributable to controlling interests shareholders", "verboseLabel": "Net loss attributable to controlling interests shareholders", "terseLabel": "Net Income (Loss)", "label": "Net Income (Loss) Attributable to Parent", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r88", "r94", "r127", "r145", "r160", "r163", "r168", "r181", "r188", "r190", "r191", "r192", "r193", "r194", "r197", "r198", "r205", "r281", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r430", "r433", "r451", "r474", "r593", "r679", "r696", "r697", "r810", "r956" ] }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Of which: net loss attributable to noncontrolling interests shareholders", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r62", "r121", "r160", "r163", "r194", "r197", "r198", "r592", "r915" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract", "presentation": [ "http://moonlaketx.com/role/NetLossperShareCalculationofNetLossperShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Numerator", "label": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Recently Issued Accounting Pronouncements not yet Adopted", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": [ "r861" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": [ "r825", "r835", "r845", "r869", "r877" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r852" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r851" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": [ "r869" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r888" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r888" ] }, "mnlk_NoncontrollingInterestIncreaseFromCapitalInjectionInSubsidiary": { "xbrltype": "monetaryItemType", "nsuri": "http://moonlaketx.com/20240930", "localname": "NoncontrollingInterestIncreaseFromCapitalInjectionInSubsidiary", "crdr": "credit", "presentation": [ "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Capital injection from MoonLake to MoonLake AG (Note 11)", "label": "Noncontrolling Interest, Increase From Capital Injection In Subsidiary", "documentation": "Noncontrolling Interest, Increase From Capital Injection In Subsidiary" } } }, "auth_ref": [] }, "us-gaap_NoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncontrollingInterestMember", "presentation": [ "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling Interests", "label": "Noncontrolling Interest [Member]", "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest." } } }, "auth_ref": [ "r58", "r335", "r919", "r920", "r921", "r923", "r1050" ] }, "us-gaap_NoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncurrentAssets", "crdr": "debit", "presentation": [ "http://moonlaketx.com/role/SegmentInformationandGeographicDataScheduleofLongLivedAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-lived assets", "label": "Long-Lived Assets", "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets." } } }, "auth_ref": [ "r244" ] }, "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock", "presentation": [ "http://moonlaketx.com/role/ShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of nonvested restricted stock shares activity", "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]", "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares." } } }, "auth_ref": [ "r18" ] }, "mnlk_NumberOfCoFounders": { "xbrltype": "integerItemType", "nsuri": "http://moonlaketx.com/20240930", "localname": "NumberOfCoFounders", "presentation": [ "http://moonlaketx.com/role/ShareBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of co-founders", "label": "Number Of Co-Founders", "documentation": "Number Of Co-Founders" } } }, "auth_ref": [] }, "mnlk_NumberOfLeaseContracts": { "xbrltype": "integerItemType", "nsuri": "http://moonlaketx.com/20240930", "localname": "NumberOfLeaseContracts", "presentation": [ "http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of lease contracts", "label": "Number Of Lease Contracts", "documentation": "Number Of Lease Contracts" } } }, "auth_ref": [] }, "mnlk_NumberOfOperatingLeases": { "xbrltype": "integerItemType", "nsuri": "http://moonlaketx.com/20240930", "localname": "NumberOfOperatingLeases", "presentation": [ "http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of operating leases", "label": "Number Of Operating Leases", "documentation": "Number Of Operating Leases" } } }, "auth_ref": [] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfOperatingSegments", "presentation": [ "http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails", "http://moonlaketx.com/role/SegmentInformationandGeographicDataNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of operating segments", "label": "Number of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r751", "r927" ] }, "mnlk_NumberOfShareBasedCompensationPlans": { "xbrltype": "integerItemType", "nsuri": "http://moonlaketx.com/20240930", "localname": "NumberOfShareBasedCompensationPlans", "presentation": [ "http://moonlaketx.com/role/ShareBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of share-based compensation plans", "label": "Number Of Share-Based Compensation Plans", "documentation": "Number Of Share-Based Compensation Plans" } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": [ "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "totalLabel": "Operating loss", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r129", "r744", "r926", "r928", "r929", "r930", "r931" ] }, "mnlk_OperatingLeaseAdditionalAreaOfLeasedSpace": { "xbrltype": "areaItemType", "nsuri": "http://moonlaketx.com/20240930", "localname": "OperatingLeaseAdditionalAreaOfLeasedSpace", "presentation": [ "http://moonlaketx.com/role/LeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease, additional area of leased space", "label": "Operating Lease, Additional Area of Leased Space", "documentation": "Operating Lease, Additional Area of Leased Space" } } }, "auth_ref": [] }, "mnlk_OperatingLeaseAreaOfLeasedSpace": { "xbrltype": "areaItemType", "nsuri": "http://moonlaketx.com/20240930", "localname": "OperatingLeaseAreaOfLeasedSpace", "presentation": [ "http://moonlaketx.com/role/LeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Square foot of leased space (in square feet)", "label": "Operating Lease, Area of Leased Space", "documentation": "Operating Lease, Area of Leased Space" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseCost", "crdr": "debit", "calculation": { "http://moonlaketx.com/role/LeasesTotalLeaseExpenseDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://moonlaketx.com/role/LeasesTotalLeaseExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease expense", "label": "Operating Lease, Cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r494", "r785" ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://moonlaketx.com/role/LeasesFutureLeasePaymentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://moonlaketx.com/role/LeasesFutureLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total lease liability", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r489" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://moonlaketx.com/role/LeasesFutureLeasePaymentsDetails": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 1.0 }, "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://moonlaketx.com/role/LeasesFutureLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term portion of operating lease liabilities", "negatedTerseLabel": "Less current portion of lease liability", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r489" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 1.0 }, "http://moonlaketx.com/role/LeasesFutureLeasePaymentsDetails": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://moonlaketx.com/role/LeasesFutureLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term portion of operating lease liabilities", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r489" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [
```

"http://moonlaketx.com/role/LeasesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Operating lease, payments", "label": "Operating Lease, Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": ["r490", "r496"] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Operating lease right-of-use assets", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": ["r488"] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": ["http://moonlaketx.com/role/LeasesWeightedAverageRemainingLeaseTermandDiscountRateDetails"], "lang": { "en-us": { "role": { "terseLabel": "Weighted average discount rate", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": ["r499", "r785"] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": ["http://moonlaketx.com/role/LeasesWeightedAverageRemainingLeaseTermandDiscountRateDetails"], "lang": { "en-us": { "role": { "terseLabel": "Weighted average remaining lease term (in months)", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r498", "r785"] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": ["http://moonlaketx.com/role/OverviewoftheCompany"], "lang": { "en-us": { "role": { "terseLabel": "Overview of the Company", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": ["r68", "r119", "r619", "r620"] }, "us-gaap_OtherCommitmentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCommitmentsLineItems", "presentation": ["http://moonlaketx.com/role/CommitmentandContingenciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Other Commitments [Line Items]", "label": "Other Commitments [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_OtherCommitmentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCommitmentsTable", "presentation": ["http://moonlaketx.com/role/CommitmentandContingenciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Other Commitments [Table]", "label": "Other Commitments [Table]", "documentation": "Disclosure of information about obligations resulting from other commitments." } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax", "crdr": "debit", "calculation": { "http://moonlaketx.com/role/EmployeeBenefitPlansDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://moonlaketx.com/role/EmployeeBenefitPlansDetails"], "lang": { "en-us": { "role": { "terseLabel": "Prior service credit recognized in current year", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), before Tax", "documentation": "Amount, before tax, of cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit)." } } }, "auth_ref": ["r2", "r85", "r351"] }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax", "crdr": "credit", "calculation": { "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"], "lang": { "en-us": { "role": { "terseLabel": "Actuarial gain (loss) on employee benefit plans", "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, after Tax", "documentation": "Amount, after tax, of gain (loss) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit." } } }, "auth_ref": ["r84", "r85", "r351"] }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://moonlaketx.com/role/InvestmentsScheduleofChangesinFairValueofShortTermMarketableSecuritiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Net unrealized gain (loss) on marketable securities and short term investments", "negatedTerseLabel": "Other comprehensive income before reclassifications", "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax", "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": ["r156", "r157", "r158", "r594"] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"], "lang": { "en-us": { "role": { "totalLabel": "Other comprehensive income (loss)", "terseLabel": "Other comprehensive income (loss)", "label": "Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": ["r13", "r19", "r161", "r164", "r169", "r194", "r476", "r477", "r482", "r572", "r594", "r913", "r914"] }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForWritedownOfSecuritiesNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForWritedownOfSecuritiesNetOfTax", "crdr": "credit", "presentation": ["http://moonlaketx.com/role/InvestmentsScheduleofChangesinFairValueofShortTermMarketableSecuritiesDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Amounts reclassified from accumulated other comprehensive income", "label": "Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI for Write-down of Securities, Net of Tax", "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized loss realized upon the write-down of available-for-sale securities." } } }, "auth_ref": ["r4", "r85", "r159"] }, "us-gaap_OtherCurrentAssetsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCurrentAssetsTextBlock", "presentation": ["http://moonlaketx.com/role/PrepaidExpenses"], "lang": { "en-us": { "role": { "terseLabel": "Prepaid Expenses", "label": "Other Current Assets [Text Block]", "documentation": "The entire disclosure for other current assets." } } }, "auth_ref": [] }, "us-gaap_OtherNoncashIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncashIncomeExpense", "crdr": "credit", "calculation": { "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": ["http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other non-cash items", "label": "Other Noncash Income (Expense)", "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other." } } }, "auth_ref": ["r94"] }, "us-gaap_OtherNonoperatingIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncome", "crdr": "credit", "calculation": { "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"], "lang": { "en-us": { "role": { "terseLabel": "Other income, net", "label": "Other Nonoperating Income", "documentation": "Amount of income related to nonoperating activities, classified as other." } } }, "auth_ref": ["r174"] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": ["r861"] }, "us-gaap_OtherPrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherPrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://moonlaketx.com/role/PrepaidExpensesDetails": { "parentTag": "us-gaap_PrepaidExpenseCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://moonlaketx.com/role/PrepaidExpensesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Other prepayments", "label": "Other Prepaid Expense, Current", "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r912", "r950"] }, "us-gaap_OtherReceivablesNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherReceivablesNetCurrent", "crdr": "debit", "calculation": { "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Other receivables", "label": "Other Receivables, Net, Current", "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer." } } }, "auth_ref": [] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r823", "r833", "r843", "r875"] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": ["r826", "r836", "r846", "r878"] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": ["r826", "r836", "r846", "r878"] }, "us-gaap_OverAllotmentOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OverAllotmentOptionMember", "presentation": ["http://moonlaketx.com/role/ShareholdersEquityNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Over-Allotment Option", "label": "Over-Allotment Option [Member]", "documentation": "Right given to the underwriter to sell additional shares over the initial allotment." } } }, "auth_ref": [] }, "country_PT": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "PT", "presentation": ["http://moonlaketx.com/role/SegmentInformationandGeographicDataScheduleofLongLivedAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Portugal", "label": "PORTUGAL" } } }, "auth_ref": [] }, "us-gaap_ParentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ParentMember", "presentation": ["http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholders' Equity", "label": "Parent [Member]", "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests." } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": ["r850"] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "calculation": { "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [

```
"http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Buyback of unvested MoonLake AG Common Shares by MoonLake AG following an employee contract termination", "label": "Payments for Repurchase of Common Stock", "documentation": "The cash outflow to reacquire common stock during the period." } } }, "auth_ref": [ "r91" ] }, "mnlk_PaymentsOfStampDuty": { "xbrltype": "monetaryItemType", "nsuri": "http://moonlaketx.com/20240930", "localname": "PaymentsOfStampDuty", "crdr": "credit", "calculation": {
"http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": {
"negatedTerseLabel": "Stamp duty on capital injection from MoonLake to MoonLake AG", "label": "Payments Of Stamp Duty", "documentation": "Payments Of Stamp Duty" } } }, "auth_ref": [] }, "us-gaap_PaymentsOfStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PaymentsOfStockIssuanceCosts", "crdr": "credit", "presentation": [ "http://moonlaketx.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Payments of stock issuance costs", "label": "Payments of Stock Issuance Costs", "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security." } } }, "auth_ref": [ "r26" ] }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "crdr": "credit", "calculation": {
"http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": {
"negatedTerseLabel": "Purchase of short-term marketable debt securities", "label": "Payments to Acquire Debt Securities, Available-for-Sale", "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r24", "r175", "r248" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": {
"http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": {
"negatedTerseLabel": "Purchase of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r90" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": {
"terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r860" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": {
"xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r860" ] }, "us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "PensionAndOtherPostretirementPlansPensionsPolicy", "presentation": [
"http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Accounting", "label":
"Pension and Other Postretirement Plans, Pensions, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for pension plans. This accounting policy may address (1) the types of plans sponsored by the entity (2) groups that participate in (or are covered by) each plan (3) how plan assets, liabilities and expenses are measured, including the use of any actuaries and (4) significant assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived." } }
}, "auth_ref": [ "r9", "r10", "r14", "r53" ] }, "us-gaap_PensionExpenseReversalOfExpenseNoncash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "PensionExpenseReversalOfExpenseNoncash", "crdr": "debit", "calculation": {
"http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel":
"Net periodic pension benefit (gain) cost for the qualified pension plan", "label": "Pension Expense (Reversal of Expense), Noncash", "documentation": "Amount of noncash expense (reversal of expense) for pension benefits. Excludes other postretirement benefits." } } }, "auth_ref": [ "r7" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype":
"monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": {
"en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r852" ] },
"ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": [ "r869" ] }, "ecd_PeoName": {
"xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ],
"lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": [ "r862" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel":
"PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r851" ] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": [ "http://moonlaketx.com/role/ShareBasedCompensationNarrativeDetails",
"http://moonlaketx.com/role/ShareBasedCompensationSharebasedCompensationExpenseByPlanDetails",
"http://moonlaketx.com/role/ShareBasedCompensationSummaryofESOPAwardedandGrantedDetails",
"http://moonlaketx.com/role/ShareBasedCompensationSummaryofEquityIncentivePlanAwardedandGrantedDetails",
"http://moonlaketx.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails", "http://moonlaketx.com/role/ShareholdersEquityNarrativeDetails" ], "lang": {
"en-us": { "role": { "terseLabel": "Plan Name [Axis]", "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } },
"auth_ref": [ "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PlanNameDomain", "presentation": [ "http://moonlaketx.com/role/ShareBasedCompensationNarrativeDetails",
"http://moonlaketx.com/role/ShareBasedCompensationSharebasedCompensationExpenseByPlanDetails",
"http://moonlaketx.com/role/ShareBasedCompensationSummaryofESOPAwardedandGrantedDetails",
"http://moonlaketx.com/role/ShareBasedCompensationSummaryofEquityIncentivePlanAwardedandGrantedDetails",
"http://moonlaketx.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails", "http://moonlaketx.com/role/ShareholdersEquityNarrativeDetails" ], "lang": {
"en-us": { "role": { "terseLabel": "Plan Name [Domain]", "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } },
"auth_ref": [ "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986" ] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"PnsnAdjsPrrSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Prior Service Cost", "label": "Pension Adjustments Prior Service Cost [Member]" } } }, "auth_ref": [ "r853" ] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": {
"terseLabel": "Pension Adjustments Service Cost", "label": "Pension Adjustments Service Cost [Member]" } } }, "auth_ref": [ "r897" ] }, "ecd_PnsnBnftsAdjFnTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
], "lang": { "en-us": { "role": { "terseLabel": "Pension Benefits Adjustments, Footnote", "label": "Pension Benefits Adjustments, Footnote [Text Block]" } } }, "auth_ref": [
"r852" ] }, "mnlk_PortoOfficeMember": { "xbrltype": "domainItemType", "nsuri": "http://moonlaketx.com/20240930", "localname": "PortoOfficeMember", "presentation": [
"http://moonlaketx.com/role/LeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Porto Office", "label": "Porto Office [Member]",
"documentation": "Porto Office" } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "PrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 }, "http://moonlaketx.com/role/PrepaidExpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } },
"presentation": [ "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://moonlaketx.com/role/PrepaidExpensesDetails" ], "lang": { "en-us": {
"role": { "terseLabel": "Prepaid expenses - current", "totalLabel": "Total", "label": "Prepaid Expense, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r154", "r293", "r294", "r737" ] }, "us-gaap_PrepaidExpenseCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseCurrentAbstract",
"presentation": [ "http://moonlaketx.com/role/PrepaidExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses - current", "label": "Prepaid Expense, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PrepaidExpenseNoncurrent", "crdr": "debit", "calculation": { "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 2.0 }, "http://moonlaketx.com/role/PrepaidExpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } },
"presentation": [ "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://moonlaketx.com/role/PrepaidExpensesDetails" ], "lang": { "en-us": {
"role": { "terseLabel": "Prepaid expenses - non-current", "totalLabel": "Total", "label": "Prepaid Expense, Noncurrent", "documentation": "Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer." } }
}, "auth_ref": [ "r911" ] }, "us-gaap_PrepaidExpenseNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PrepaidExpenseNoncurrentAbstract", "presentation": [ "http://moonlaketx.com/role/PrepaidExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses - non-current", "label": "Prepaid Expense, Noncurrent [Abstract]" } } }, "auth_ref": [] }, "mnlk_PrepaidExpensesCurrentMember": { "xbrltype": "domainItemType", "nsuri":
"http://moonlaketx.com/20240930", "localname": "PrepaidExpensesCurrentMember", "presentation": [ "http://moonlaketx.com/role/CommitmentandContingenciesDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Prepaid Expenses, Current", "label": "Prepaid Expenses, Current [Member]", "documentation": "Prepaid Expenses, Current" } } },
"auth_ref": [] }, "mnlk_PrepaidExpensesNoncurrentMember": { "xbrltype": "domainItemType", "nsuri": "http://moonlaketx.com/20240930", "localname":
"PrepaidExpensesNoncurrentMember", "presentation": [ "http://moonlaketx.com/role/CommitmentandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Prepaid Expenses, Noncurrent", "label": "Prepaid Expenses, Noncurrent [Member]", "documentation": "Prepaid Expenses, Noncurrent" } } }, "auth_ref": [] }, "us-gaap_PrepaidInsurance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidInsurance", "crdr": "debit", "calculation": {
"http://moonlaketx.com/role/PrepaidExpensesDetails": { "parentTag": "us-gaap_PrepaidExpenseCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://moonlaketx.com/role/PrepaidExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Insurance", "label": "Prepaid Insurance", "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer." } } },
"auth_ref": [ "r738", "r758", "r950" ] }, "mnlk_PrepaidResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://moonlaketx.com/20240930",
"localname": "PrepaidResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://moonlaketx.com/role/PrepaidExpensesDetails": { "parentTag": "us-gaap_PrepaidExpenseCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://moonlaketx.com/role/PrepaidExpensesDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Non-clinical research and clinical development services", "label": "Prepaid Research And Development Expense", "documentation": "Prepaid Research And Development Expense" } } }, "auth_ref": [] }, "srt_ProFormaMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProFormaMember",
"presentation": [ "http://moonlaketx.com/role/NetLossperShareNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pro forma", "label": "Pro Forma [Member]" } } },
"auth_ref": [ "r199", "r900", "r901" ] }, "us-gaap_ProceedsFromContributionsFromParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ProceedsFromContributionsFromParent", "crdr": "debit", "presentation": [ "http://moonlaketx.com/role/ShareholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from contributions from parent", "label": "Proceeds from Contributions from Parent", "documentation": "The cash inflow from parent as a source of financing that is recorded as additional paid in capital." } } }, "auth_ref": [ "r25" ] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": {
"http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel":
"Issuance of Class A Ordinary Shares, net of transaction costs", "label": "Proceeds from Issuance of Common Stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r3" ] }, "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities", "crdr": "debit",
"calculation": { "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-
```

gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from maturities of short-term marketable debt securities", "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale", "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r175", "r176", "r933"] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "calculation": {
"http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from options exercised under the Equity Incentive Plan", "label": "Proceeds from Stock Options Exercised", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": ["r3", "r17"] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": ["http://moonlaketx.com/role/CommitmentandContingenciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]" } } }, "auth_ref": ["r241", "r539", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r734", "r762", "r796", "r797", "r798", "r800", "r801", "r954", "r955", "r959", "r1015", "r1019", "r1020", "r1021", "r1022", "r1023", "r1024", "r1025", "r1026", "r1027", "r1028", "r1029", "r1030", "r1031", "r1032", "r1033", "r1034", "r1035", "r1036", "r1037", "r1038", "r1039", "r1040", "r1041", "r1042", "r1043", "r1044", "r1045", "r1046"] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": [
"http://moonlaketx.com/role/CommitmentandContingenciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]" } } }, "auth_ref": ["r241", "r539", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r734", "r762", "r796", "r797", "r798", "r800", "r801", "r954", "r955", "r959", "r1015", "r1019", "r1020", "r1021", "r1022", "r1023", "r1024", "r1025", "r1026", "r1027", "r1028", "r1029", "r1030", "r1031", "r1032", "r1033", "r1034", "r1035", "r1036", "r1037", "r1038", "r1039", "r1040", "r1041", "r1042", "r1043", "r1044", "r1045", "r1046"] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "calculation": {
"http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 },
"http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
"http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY",
"http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://moonlaketx.com/role/RisksandLiquidityDetails"], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "terseLabel": "Net loss", "verboseLabel": "Net loss", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": ["r145", "r160", "r163", "r177", "r181", "r188", "r194", "r197", "r198", "r281", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r430", "r433", "r434", "r437", "r438", "r451", "r474", "r577", "r591", "r630", "r679", "r696", "r697", "r773", "r774", "r811", "r915", "r956"] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": ["http://moonlaketx.com/role/LeasesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Tangible Asset [Axis]", "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": ["r8", "r501"] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r8", "r501", "r578", "r590", "r786"] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": ["http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Property and Equipment", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": ["r8", "r136", "r139", "r589"] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [
"http://moonlaketx.com/role/LeasesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Tangible Asset [Domain]", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": ["r98", "r501"] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [
"http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, useful life", "label": "Property, Plant and Equipment, Useful Life", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": ["r850"] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": ["r850"] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [
"http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": ["r301", "r302", "r303", "r304", "r339", "r358", "r389", "r390", "r391", "r403", "r457", "r512", "r521", "r538", "r608", "r610", "r618", "r647", "r648", "r703", "r705", "r707", "r708", "r710", "r731", "r732", "r756", "r761", "r768", "r778", "r779", "r783", "r784", "r797", "r804", "r952", "r958", "r994", "r1008", "r1009", "r1010", "r1011", "r1012"] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": ["http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": ["r301", "r302", "r303", "r304", "r339", "r358", "r389", "r390", "r391", "r403", "r457", "r512", "r521", "r538", "r608", "r610", "r618", "r647", "r648", "r703", "r705", "r707", "r708", "r710", "r731", "r732", "r756", "r761", "r768", "r778", "r779", "r783", "r784", "r797", "r804", "r952", "r958", "r994", "r1008", "r1009", "r1010", "r1011", "r1012"] },
"srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis", "presentation": ["http://moonlaketx.com/role/LeasesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Name of Property [Axis]", "label": "Name of Property [Axis]" } } }, "auth_ref": ["r721", "r725", "r1053", "r1054", "r1055", "r1056", "r1057", "r1058", "r1059", "r1060"] }, "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain", "presentation": ["http://moonlaketx.com/role/LeasesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Name of Property [Domain]", "label": "Name of Property [Domain]" } } }, "auth_ref": ["r721", "r725", "r1053", "r1054", "r1055", "r1056", "r1057", "r1058", "r1059", "r1060"] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": ["r818", "r828", "r838", "r870"] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": ["http://moonlaketx.com/role/CommitmentandContingenciesDetails",
"http://moonlaketx.com/role/ShareholdersEquityNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Domain]", "label": "Counterparty Name [Domain]" } } }, "auth_ref": ["r183", "r184", "r315", "r322", "r504", "r522", "r579", "r740", "r741"] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": {
"http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Research and development", "label": "Research and Development Expense", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": ["r405", "r733", "r750", "r1013"] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": ["http://moonlaketx.com/role/ShareBasedCompensationSharebasedCompensationExpenseByPlanDetails"], "lang": { "en-us": { "role": { "terseLabel": "Research and Development Expense", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": ["http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Research and Development Contract Costs and Accruals", "label": "Research and Development Expense, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": ["r404"] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": ["r819", "r829", "r839", "r871"] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": ["r820", "r830", "r840", "r872"] },
"ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": ["r827", "r837", "r847", "r879"] }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "presentation": [
"http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents [Domain]", "label": "Cash and Cash Equivalents [Domain]", "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r148"] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockMember", "presentation": ["http://moonlaketx.com/role/ShareBasedCompensationNarrativeDetails",
"http://moonlaketx.com/role/ShareBasedCompensationSharebasedCompensationExpenseByPlanDetails",
"http://moonlaketx.com/role/ShareBasedCompensationSummaryofRestrictedStockAwardedandGrantedDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang":

{ "en-us": { "role": { "terseLabel": "MoonLake AG Restricted Founder Shares", "label": "Restricted Stock [Member]", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": ["r32"] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r80", "r105", "r586", "r615", "r617", "r627", "r658", "r786"] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": ["http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r143", "r185", "r186", "r187", "r189", "r194", "r196", "r198", "r282", "r283", "r295", "r419", "r420", "r427", "r428", "r429", "r431", "r432", "r433", "r441", "r443", "r444", "r446", "r449", "r484", "r487", "r612", "r614", "r631", "r1050"] }, "mnlk_RevenueRemainingPerformanceObligationAdditionalVariableConsiderationAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://moonlaketx.com/20240930", "localname": "RevenueRemainingPerformanceObligationAdditionalVariableConsiderationAmount", "crdr": "credit", "presentation": ["http://moonlaketx.com/role/CommitmentandContingenciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Revenue remaining performance obligation additional variable consideration amount", "label": "Revenue Remaining Performance Obligation Additional Variable Consideration Amount", "documentation": "Revenue Remaining Performance Obligation Additional Variable Consideration Amount" } } }, "auth_ref": [] }, "mnlk_RevenueRemainingPerformanceObligationVariableConsiderationAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://moonlaketx.com/20240930", "localname": "RevenueRemainingPerformanceObligationVariableConsiderationAmount", "crdr": "credit", "presentation": ["http://moonlaketx.com/role/CommitmentandContingenciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Variable consideration amount", "label": "Revenue Remaining Performance Obligation Variable Consideration Amount", "documentation": "Revenue Remaining Performance Obligation Variable Consideration Amount" } } }, "auth_ref": [] }, "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems", "presentation": ["http://moonlaketx.com/role/SegmentInformationandGeographicDataScheduleofLongLivedAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Revenues from External Customers and Long-Lived Assets [Line Items]", "label": "Revenues from External Customers and Long-Lived Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": ["http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Non-cash operating lease right-of-use assets obtained in exchange for lease obligations", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": ["r497", "r785"] }, "mnlk_RiskAndLiquidityDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://moonlaketx.com/20240930", "localname": "RiskAndLiquidityDisclosureTextBlock", "presentation": ["http://moonlaketx.com/role/RisksandLiquidity"], "lang": { "en-us": { "role": { "terseLabel": "Risks and Liquidity", "label": "Risk And Liquidity Disclosure [Text Block]", "documentation": "Risk And Liquidity Disclosure" } } }, "auth_ref": [] }, "us-gaap_RisksAndUncertaintiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RisksAndUncertaintiesAbstract", "lang": { "en-us": { "role": { "label": "Risks and Uncertainties [Abstract]" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": ["r888"] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": ["r888"] }, "mnlk_SaleOfStockAuthorizedAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://moonlaketx.com/20240930", "localname": "SaleOfStockAuthorizedAmount", "crdr": "credit", "presentation": ["http://moonlaketx.com/role/ShareholdersEquityNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Sale of stock, authorized amount (in shares)", "label": "Sale Of Stock, Authorized Amount", "documentation": "Sale Of Stock, Authorized Amount" } } }, "auth_ref": [] }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockConsiderationReceivedOnTransaction", "crdr": "debit", "presentation": ["http://moonlaketx.com/role/ShareholdersEquityNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Net proceeds from the business combination", "label": "Sale of Stock, Consideration Received on Transaction", "documentation": "Cash received on stock transaction after deduction of issuance costs." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": ["http://moonlaketx.com/role/ShareholdersEquityNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock [Domain]", "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": ["http://moonlaketx.com/role/ShareholdersEquityNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Sale of stock (in shares)", "label": "Sale of Stock, Number of Shares Issued in Transaction", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": [] }, "mnlk_SaleOfStockOptionToPurchaseTerm": { "xbrltype": "durationItemType", "nsuri": "http://moonlaketx.com/20240930", "localname": "SaleOfStockOptionToPurchaseTerm", "presentation": ["http://moonlaketx.com/role/ShareholdersEquityNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Sale of stock, option to purchase, term", "label": "Sale of Stock, Option To Purchase, Term", "documentation": "Sale of Stock, Option To Purchase, Term" } } }, "auth_ref": [] }, "us-gaap_SaleOfStockPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockPricePerShare", "presentation": ["http://moonlaketx.com/role/ShareholdersEquityNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Issuance price per share (USD per share)", "label": "Sale of Stock, Price Per Share", "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } } }, "auth_ref": [] }, "mnlk_SaleOfStockRemainingAuthorizedRepurchaseAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://moonlaketx.com/20240930", "localname": "SaleOfStockRemainingAuthorizedRepurchaseAmount", "crdr": "credit", "presentation": ["http://moonlaketx.com/role/ShareholdersEquityNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Sale of stock, remaining authorized repurchase amount", "label": "Sale Of Stock, Remaining Authorized Repurchase Amount", "documentation": "Sale Of Stock, Remaining Authorized Repurchase Amount" } } }, "auth_ref": [] }, "mnlk_SaleOfStockStampDutyTax": { "xbrltype": "monetaryItemType", "nsuri": "http://moonlaketx.com/20240930", "localname": "SaleOfStockStampDutyTax", "crdr": "credit", "presentation": ["http://moonlaketx.com/role/ShareholdersEquityNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Sale of stock, stamp duty tax", "label": "Sale Of Stock, Stamp Duty Tax", "documentation": "Sale Of Stock, Stamp Duty Tax" } } }, "auth_ref": [] }, "srt_ScenarioForecastMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioForecastMember", "presentation": ["http://moonlaketx.com/role/EmployeeBenefitPlansNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Forecast", "label": "Forecast [Member]" } } }, "auth_ref": ["r359", "r922"] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioUnspecifiedDomain", "presentation": ["http://moonlaketx.com/role/EmployeeBenefitPlansNarrativeDetails", "http://moonlaketx.com/role/NetLossperShareNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Scenario [Domain]", "label": "Scenario [Domain]" } } }, "auth_ref": ["r199", "r359", "r900", "r922"] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": ["http://moonlaketx.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of accrued expenses and other current liabilities", "label": "Schedule of Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": ["http://moonlaketx.com/role/NetLossperShareNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": ["r32"] }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "presentation": ["http://moonlaketx.com/role/InvestmentsScheduleofChangesinFairValueofShortTermMarketableSecuritiesDetails", "http://moonlaketx.com/role/InvestmentsScheduleofFairValueandAmortizedCostofInvestmentsinShortTermMarketableDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-Sale [Line Items]", "label": "Debt Securities, Available-for-Sale [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262"] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": ["http://moonlaketx.com/role/NetLossperShareTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of earnings per share, basic and diluted", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": ["r925"] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": ["http://moonlaketx.com/role/ShareBasedCompensationTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of share-based compensation expense driven by share-based compensation plans and programs", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": ["r56"] }, "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfNetBenefitCostsTableTextBlock", "presentation": ["http://moonlaketx.com/role/EmployeeBenefitPlansTables"], "lang": { "en-us": { "role": { "terseLabel": "Components of net periodic benefit cost under the plan", "label": "Schedule of Net Benefit Costs [Table Text Block]", "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments." } } }, "auth_ref": ["r110"] }, "us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfNonvestedShareActivityTableTextBlock", "presentation": ["http://moonlaketx.com/role/ShareBasedCompensationTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of nonvested share activity", "label": "Schedule of Nonvested Share Activity [Table Text Block]", "documentation": "Tabular disclosure of the changes in outstanding nonvested shares." } } }, "auth_ref": ["r113"] }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable", "presentation": ["http://moonlaketx.com/role/SegmentInformationandGeographicDataScheduleofLongLivedAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]", "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]", "documentation": "Disclosure of information about revenue from external customer and long-lived asset by geographical area. Long-lived asset excludes financial instrument, customer relationship with financial institution, mortgage and other servicing right, deferred policy acquisition cost, and deferred tax asset." } } }, "auth_ref": ["r37", "r86"] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": ["http://moonlaketx.com/role/ShareBasedCompensationNarrativeDetails", "http://moonlaketx.com/role/ShareBasedCompensationSharebasedCompensationExpenseByPlanDetails", "http://moonlaketx.com/role/ShareBasedCompensationSummaryofESOPAwardedandGrantedDetails", "http://moonlaketx.com/role/ShareBasedCompensationSummaryofESPPAwardedandGrantedDetails", "http://moonlaketx.com/role/ShareBasedCompensationSummaryofEquityIncentivePlanAwardedandGrantedDetails",

"http://moonlaketx.com/role/ShareBasedCompensationSummaryofRestrictedStockAwardedandGrantedDetails",
"http://moonlaketx.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": ["r361", "r362", "r364", "r365", "r366", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r388", "r389", "r390", "r391", "r392"] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": ["http://moonlaketx.com/role/ShareBasedCompensationTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of option activity for share-based payment arrangement", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": ["r15", "r16", "r112"] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [
"http://moonlaketx.com/role/ShareBasedCompensationTables"], "lang": { "en-us": { "role": { "terseLabel": "Summary of weighted average assumptions for awards issued", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": ["r114"] }, "mnlk_ScheduleOfStockAuthorizedAndIssuedRollForwardTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://moonlaketx.com/20240930", "localname": "ScheduleOfStockAuthorizedAndIssuedRollForwardTableTextBlock", "presentation": ["http://moonlaketx.com/role/ShareholdersEquityTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of stock authorized and issued", "label": "Schedule Of Stock Authorized And Issued Roll Forward [Table Text Block]", "documentation": "Schedule Of Stock Authorized And Issued Roll Forward" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockByClassTable", "presentation": ["http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails", "http://moonlaketx.com/role/ShareholdersEquityNarrativeDetails", "http://moonlaketx.com/role/ShareholdersEquityScheduleofStockAuthorizedandIssuedDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock by Class [Table]", "label": "Stock, Class of Stock [Table]", "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks." } } }, "auth_ref": ["r40", "r41", "r42", "r43", "r44", "r45", "r101", "r103", "r104", "r105", "r150", "r151", "r152", "r216", "r320", "r321", "r322", "r324", "r327", "r332", "r334", "r623", "r624", "r625", "r626", "r761", "r899", "r917"] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": ["http://moonlaketx.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r813"] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": ["http://moonlaketx.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r815"] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": [
"http://moonlaketx.com/role/SegmentInformationandGeographicDataScheduleofLongLivedAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Domain]", "label": "Geographical [Domain]" } } }, "auth_ref": ["r243", "r244", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r644", "r645", "r646", "r704", "r706", "r709", "r711", "r719", "r721", "r722", "r723", "r724", "r726", "r727", "r728", "r729", "r730", "r735", "r763", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r799", "r804", "r959", "r1015", "r1019", "r1020", "r1022", "r1023", "r1024", "r1025", "r1026", "r1027", "r1028", "r1029", "r1030", "r1031", "r1032", "r1033", "r1034", "r1035", "r1036", "r1037", "r1038", "r1039", "r1040", "r1041", "r1042", "r1043", "r1044", "r1045", "r1046"] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingDisclosureTextBlock", "presentation": ["http://moonlaketx.com/role/SegmentInformationandGeographicData"], "lang": { "en-us": { "role": { "terseLabel": "Segment Information and Geographic Data", "label": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": ["r130", "r214", "r218", "r219", "r220", "r221", "r222", "r224", "r225", "r226", "r235", "r236", "r237", "r238", "r239", "r241", "r242", "r245", "r745", "r748", "r749", "r750", "r752", "r754", "r755"] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": ["http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Segment Information", "label": "Segment Reporting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": ["r227", "r228", "r229", "r230", "r231", "r232", "r233", "r240", "r243", "r746", "r747", "r753"] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": {
"http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation expense", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r6"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": ["http://moonlaketx.com/role/ShareBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Vesting period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": ["r769"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [
"http://moonlaketx.com/role/ShareBasedCompensationSummaryofESPPAwardedandGrantedDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Awards forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": ["r381"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": ["http://moonlaketx.com/role/ShareBasedCompensationSummaryofESPPAwardedandGrantedDetails",
"http://moonlaketx.com/role/ShareBasedCompensationSummaryofRestrictedStockAwardedandGrantedDetails"], "lang": { "en-us": { "role": { "periodStartLabel": "Awards unvested, beginning balance (in shares)", "periodEndLabel": "Awards unvested, ending balance (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": ["r376", "r377"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": ["http://moonlaketx.com/role/ShareBasedCompensationSummaryofESPPAwardedandGrantedDetails",
"http://moonlaketx.com/role/ShareBasedCompensationSummaryofRestrictedStockAwardedandGrantedDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Awards vested (in shares)", "terseLabel": "Awards vested (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": ["r380"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "presentation": [
"http://moonlaketx.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Exercise price (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price", "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": ["http://moonlaketx.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Expected dividend rate", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": ["r390"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": ["http://moonlaketx.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Expected volatility of the share price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": ["r389"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": ["http://moonlaketx.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Risk-free interest rate", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": ["r391"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": ["http://moonlaketx.com/role/ShareBasedCompensationNarrativeDetails",
"http://moonlaketx.com/role/ShareBasedCompensationSharebasedCompensationExpenseByPlanDetails",
"http://moonlaketx.com/role/ShareBasedCompensationSummaryofESOPAwardedandGrantedDetails",
"http://moonlaketx.com/role/ShareBasedCompensationSummaryofESPPAwardedandGrantedDetails",
"http://moonlaketx.com/role/ShareBasedCompensationSummaryofEquityIncentivePlanAwardedandGrantedDetails",
"http://moonlaketx.com/role/ShareBasedCompensationSummaryofRestrictedStockAwardedandGrantedDetails",
"http://moonlaketx.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r361", "r362", "r364", "r365", "r366", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r388", "r389", "r390", "r391", "r392"] }, "us-

gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward", "presentation": ["http://moonlaketx.com/role/ShareBasedCompensationSummaryofESPPAwardedandGrantedDetails", "http://moonlaketx.com/role/ShareBasedCompensationSummaryofEquityIncentivePlanAwardedandGrantedDetails", "http://moonlaketx.com/role/ShareBasedCompensationSummaryofRestrictedStockAwardedandGrantedDetails"], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": ["http://moonlaketx.com/role/ShareBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation arrangement by share-based payment award, number of shares authorized (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": ["r771"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": ["http://moonlaketx.com/role/ShareBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Common shares issuable (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": ["r55"] }, "mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAwardsConverted": { "xbrltype": "sharesItemType", "nsuri": "http://moonlaketx.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAwardsConverted", "presentation": ["http://moonlaketx.com/role/ShareBasedCompensationSummaryofESOPAwardedandGrantedDetails", "http://moonlaketx.com/role/ShareBasedCompensationSummaryofEquityIncentivePlanAwardedandGrantedDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Awards converted from ESOP to EIP (in shares)", "terseLabel": "Awards converted from ESOP to EIP (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Awards Converted", "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Awards Converted" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": ["http://moonlaketx.com/role/ShareBasedCompensationSummaryofESOPAwardedandGrantedDetails", "http://moonlaketx.com/role/ShareBasedCompensationSummaryofEquityIncentivePlanAwardedandGrantedDetails"], "lang": { "en-us": { "role": { "terseLabel": "Of which exercisable (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": ["r370"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": ["http://moonlaketx.com/role/ShareBasedCompensationSummaryofEquityIncentivePlanAwardedandGrantedDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Awards forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": ["r374"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": ["http://moonlaketx.com/role/ShareBasedCompensationSummaryofESOPAwardedandGrantedDetails", "http://moonlaketx.com/role/ShareBasedCompensationSummaryofEquityIncentivePlanAwardedandGrantedDetails"], "lang": { "en-us": { "role": { "terseLabel": "Additional awards granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": ["r372"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://moonlaketx.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Estimated fair value of the option on the grant date using Black-Scholes model (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": ["r382"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": ["http://moonlaketx.com/role/ShareBasedCompensationSummaryofESOPAwardedandGrantedDetails", "http://moonlaketx.com/role/ShareBasedCompensationSummaryofEquityIncentivePlanAwardedandGrantedDetails"], "lang": { "en-us": { "role": { "periodStartLabel": "Awards outstanding, beginning balance (in shares)", "periodEndLabel": "Awards outstanding, ending balance (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": ["r368", "r369"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": ["http://moonlaketx.com/role/ShareBasedCompensationSummaryofESOPAwardedandGrantedDetails"], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "mnlk_ShareBasedCompensationArrangementByShareBasedPaymentAwardReverseVestingConditionPercentage": { "xbrltype": "percentItemType", "nsuri": "http://moonlaketx.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardReverseVestingConditionPercentage", "presentation": ["http://moonlaketx.com/role/ShareBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Reverse vesting percentage", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Reverse Vesting Condition, Percentage", "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Reverse Vesting Condition, Percentage" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": ["http://moonlaketx.com/role/ShareBasedCompensationNarrativeDetails", "http://moonlaketx.com/role/ShareBasedCompensationSharebasedCompensationExpenseByPlanDetails", "http://moonlaketx.com/role/ShareBasedCompensationSummaryofESOPAwardedandGrantedDetails", "http://moonlaketx.com/role/ShareBasedCompensationSummaryofESPPAwardedandGrantedDetails", "http://moonlaketx.com/role/ShareBasedCompensationSummaryofRestrictedStockAwardedandGrantedDetails", "http://moonlaketx.com/role/ShareholdersEquityNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": ["r364", "r365", "r366", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r388", "r389", "r390", "r391", "r392"] }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheOneMember", "presentation": ["http://moonlaketx.com/role/ShareBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Payment Arrangement, Tranche One", "label": "Share-Based Payment Arrangement, Tranche One [Member]", "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheThreeMember", "presentation": ["http://moonlaketx.com/role/ShareBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Payment Arrangement, Tranche Three", "label": "Share-Based Payment Arrangement, Tranche Three [Member]", "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheTwoMember", "presentation": ["http://moonlaketx.com/role/ShareBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Payment Arrangement, Tranche Two", "label": "Share-Based Payment Arrangement, Tranche Two [Member]", "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": ["http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Compensation", "label": "Share-Based Payment Arrangement [Policy Text Block]", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": ["r360", "r367", "r386", "r387", "r388", "r389", "r392", "r398", "r399", "r400", "r401"] }, "mnlk_ShareBasedPaymentArrangementTrancheFourMember": { "xbrltype": "domainItemType", "nsuri": "http://moonlaketx.com/20240930", "localname": "ShareBasedPaymentArrangementTrancheFourMember", "presentation": ["http://moonlaketx.com/role/ShareBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Payment Arrangement, Tranche Four", "label": "Share-Based Payment Arrangement, Tranche Four [Member]", "documentation": "Share-Based Payment Arrangement, Tranche Four" } } }, "auth_ref": [] }, "mnlk_SharePriceNominalValue": { "xbrltype": "perShareItemType", "nsuri": "http://moonlaketx.com/20240930", "localname": "SharePriceNominalValue", "presentation": ["http://moonlaketx.com/role/ShareBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Nominal value (CHF per share)", "label": "Share Price, Nominal Value", "documentation": "Share Price, Nominal Value" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "presentation": ["http://moonlaketx.com/role/ShareBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Vesting percentage", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage", "documentation": "Percentage of vesting of award under share-based payment arrangement." } } }, "auth_ref": ["r961"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": ["http://moonlaketx.com/role/ShareBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Expiration period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r770"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": ["http://moonlaketx.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Expected term of the award", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } },

"auth_ref": ["r388"] }, "mnlk_SharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://moonlaketx.com/20240930", "localname": "SharesAuthorized", "calculation": { "http://moonlaketx.com/role/ShareholdersEquityScheduleofStockAuthorizedandIssuedDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://moonlaketx.com/role/ShareholdersEquityScheduleofStockAuthorizedandIssuedDetails"], "lang": { "en-us": { "role": { "periodStartLabel": "Authorized, beginning balance (in shares)", "periodEndLabel": "Authorized, ending balance (in shares)", "label": "Shares, Authorized", "documentation": "Shares, Authorized" } } }, "auth_ref": [] }, "us-gaap_SharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssued", "calculation": { "http://moonlaketx.com/role/ShareholdersEquityScheduleofStockAuthorizedandIssuedDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://moonlaketx.com/role/ShareholdersEquityScheduleofStockAuthorizedandIssuedDetails"], "lang": { "en-us": { "role": { "periodStartLabel": "Shares issued, beginning balance (in shares)", "periodEndLabel": "Shares issued, ending balance (in shares)", "label": "Shares, Issued", "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury." } } }, "auth_ref": ["r13"] }, "mnlk_SonelokimabProgramSLKProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://moonlaketx.com/20240930", "localname": "SonelokimabProgramSLKProgramMember", "presentation": ["http://moonlaketx.com/role/CommitmentandContingenciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "SLK Program", "label": "Sonelokimab Program (\"SLK Program\") [Member]", "documentation": "Sonelokimab Program (\"SLK Program\")" } } }, "auth_ref": [] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": ["http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://moonlaketx.com/role/Cover", "http://moonlaketx.com/role/NetLossperShareNarrativeDetails", "http://moonlaketx.com/role/ShareBasedCompensationNarrativeDetails", "http://moonlaketx.com/role/ShareholdersEquityNarrativeDetails", "http://moonlaketx.com/role/ShareholdersEquityScheduleofStockAuthorizedandIssuedDetails"], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Axis]", "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": ["r141", "r150", "r151", "r152", "r181", "r203", "r204", "r206", "r208", "r216", "r217", "r281", "r306", "r308", "r309", "r310", "r313", "r314", "r320", "r321", "r324", "r327", "r334", "r474", "r623", "r624", "r625", "r626", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r643", "r657", "r680", "r698", "r712", "r713", "r714", "r715", "r716", "r899", "r917", "r924"] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": ["http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://moonlaketx.com/role/ShareholdersEquityNarrativeDetails", "http://moonlaketx.com/role/ShareholdersEquityScheduleofStockAuthorizedandIssuedDetails"], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": ["r13", "r78", "r81", "r82", "r143", "r166", "r167", "r168", "r185", "r186", "r187", "r189", "r194", "r196", "r198", "r215", "r282", "r283", "r295", "r335", "r419", "r420", "r427", "r428", "r429", "r431", "r432", "r433", "r441", "r442", "r443", "r444", "r445", "r446", "r449", "r476", "r478", "r479", "r480", "r481", "r482", "r484", "r487", "r503", "r594", "r612", "r613", "r614", "r631", "r698"] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": ["http://moonlaketx.com/role/SegmentInformationandGeographicDataScheduleofLongLivedAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Axis]", "label": "Geographical [Axis]" } } }, "auth_ref": ["r243", "r244", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r644", "r645", "r646", "r704", "r706", "r709", "r711", "r719", "r721", "r722", "r723", "r724", "r726", "r727", "r728", "r729", "r730", "r735", "r763", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r799", "r804", "r959", "r1015", "r1019", "r1020", "r1022", "r1023", "r1024", "r1025", "r1026", "r1027", "r1028", "r1029", "r1030", "r1031", "r1032", "r1033", "r1034", "r1035", "r1036", "r1037", "r1038", "r1039", "r1040", "r1041", "r1042", "r1043", "r1044", "r1045", "r1046"] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": ["http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r185", "r186", "r187", "r215", "r487", "r539", "r621", "r643", "r649", "r650", "r651", "r652", "r653", "r654", "r657", "r660", "r661", "r662", "r663", "r664", "r666", "r667", "r668", "r669", "r671", "r672", "r673", "r674", "r675", "r677", "r681", "r682", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r698", "r805"] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementScenarioAxis", "presentation": ["http://moonlaketx.com/role/EmployeeBenefitPlansNarrativeDetails", "http://moonlaketx.com/role/NetLossperShareNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Scenario [Axis]", "label": "Scenario [Axis]" } } }, "auth_ref": ["r199", "r359", "r900", "r901", "r922"] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": ["http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": ["r185", "r186", "r187", "r215", "r246", "r487", "r539", "r621", "r643", "r649", "r650", "r651", "r652", "r653", "r654", "r657", "r660", "r661", "r662", "r663", "r664", "r666", "r667", "r668", "r669", "r671", "r672", "r673", "r674", "r675", "r677", "r681", "r682", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r698", "r805"] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": ["r822", "r832", "r842", "r874"] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockGrantedDuringPeriodValueSharebasedCompensation", "crdr": "credit", "presentation": ["http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation under the ESPP, ESOP, Equity Incentive Plan and reverse vesting of Restricted Founder Shares", "label": "Shares Granted, Value, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Value, after forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": ["r54", "r57"] }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "presentation": ["http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://moonlaketx.com/role/ShareholdersEquityNarrativeDetails", "http://moonlaketx.com/role/ShareholdersEquityScheduleofStockAuthorizedandIssuedDetails"], "lang": { "en-us": { "role": { "terseLabel": "Conversion and transfer of shares between classes (in shares)", "verboseLabel": "Conversion of Class C Ordinary Shares into Class A Ordinary Shares (in shares)", "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities", "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities." } } }, "auth_ref": ["r13", "r42", "r78", "r81", "r105", "r317"] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": ["http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://moonlaketx.com/role/ShareholdersEquityScheduleofStockAuthorizedandIssuedDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Issuance of Class A Ordinary Shares, net of transaction costs (in shares)", "netLabel": "Issuance of shares under the ATM facility (in shares)", "terseLabel": "Number of shares issued (in shares)", "label": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": ["r13", "r77", "r78", "r105", "r623", "r698", "r713"] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": ["http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://moonlaketx.com/role/NetLossperShareNarrativeDetails", "http://moonlaketx.com/role/ShareBasedCompensationSummaryofEquityIncentivePlanAwardedandGrantedDetails", "http://moonlaketx.com/role/ShareholdersEquityNarrativeDetails", "http://moonlaketx.com/role/ShareholdersEquityScheduleofStockAuthorizedandIssuedDetails"], "lang": { "en-us": { "role": { "terseLabel": "Stock options exercised (in shares)", "negatedTerseLabel": "Awards exercised (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": ["r13", "r77", "r78", "r105", "r373"] }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "crdr": "credit", "presentation": ["http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"], "lang": { "en-us": { "role": { "terseLabel": "Conversion of MoonLake Class C Ordinary Shares into Class A Ordinary Shares", "label": "Stock Issued During Period, Value, Conversion of Convertible Securities", "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities." } } }, "auth_ref": ["r13", "r78", "r81", "r82", "r105"] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": ["http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"], "lang": { "en-us": { "role": { "terseLabel": "Issuance of Class A Ordinary Shares, net of transaction costs (Note 11)", "label": "Stock Issued During Period, Value, New Issues", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": ["r13", "r77", "r78", "r105", "r631", "r698", "r713", "r811"] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": ["http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"], "lang": { "en-us": { "role": { "terseLabel": "Options exercised under the Equity Incentive Plan (Note 11)", "label": "Stock Issued During Period, Value, Stock Options Exercised", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": ["r13", "r78", "r81", "r82", "r105"] }, "us-gaap_StockRedeemedOrCalledDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRedeemedOrCalledDuringPeriodShares", "presentation": ["http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://moonlaketx.com/role/ShareholdersEquityScheduleofStockAuthorizedandIssuedDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Cancellation of Class C shares following an employee contract termination in MoonLake AG (in shares)", "terseLabel": "Cancellation of Class C shares following an employee contract termination in MoonLake AG (in shares)", "label": "Stock Redeemed or Called During Period, Shares", "documentation": "Number of stock bought back by the entity at the exercise price or redemption price." } } }, "auth_ref": ["r13"] }, "us-gaap_StockRedeemedOrCalledDuringPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRedeemedOrCalledDuringPeriodValue", "crdr": "debit", "presentation": ["http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Cancellation of MoonLake Class C Ordinary Shares following an employee contract termination in MoonLake AG (Note 11)", "label": "Stock Redeemed or Called During Period, Value", "documentation": "Equity impact of the value of stock bought back by the entity at the exercise price or redemption price." } } }, "auth_ref": ["r13"] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-

gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "totalLabel": "Total shareholders\u2019 equity", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } }
}, "auth_ref": ["r78", "r81", "r82", "r97", "r659", "r676", "r699", "r700", "r786", "r812", "r918", "r949", "r998", "r1050"] }, "us-
gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": {
"http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } },
"presentation": ["http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
"http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"], "lang": { "en-us": { "role": { "totalLabel": "Total equity",
"periodStartLabel": "Equity, beginning balance", "periodEndLabel": "Equity, end balance", "label": "Equity, Including Portion Attributable to Noncontrolling Interest",
"documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": ["r58", "r59", "r61", "r143",
"r144", "r167", "r185", "r186", "r187", "r189", "r194", "r196", "r282", "r283", "r295", "r335", "r419", "r420", "r427", "r428", "r429", "r431", "r432", "r433", "r441", "r442",
"r443", "r444", "r445", "r446", "r449", "r476", "r478", "r482", "r485", "r503", "r613", "r614", "r629", "r659", "r676", "r699", "r700", "r717", "r811", "r918", "r949", "r998",
"r1050"] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockholdersEquityNoteDisclosureTextBlock", "presentation": ["http://moonlaketx.com/role/ShareholdersEquity"], "lang": { "en-us": { "role": { "terseLabel":
"Shareholders\u2019 Equity", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": ["r102", "r180", "r319", "r321", "r323",
"r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r333", "r335", "r448", "r701", "r702", "r718"] }, "us-gaap_SubsequentEventMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": [
"http://moonlaketx.com/role/NetLossperShareNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event", "label": "Subsequent Event [Member]",
"documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r483",
"r505"] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis",
"presentation": ["http://moonlaketx.com/role/NetLossperShareNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Axis]", "label":
"Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to
be issued." } } }, "auth_ref": ["r483", "r505"] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "SubsequentEventTypeDomain", "presentation": ["http://moonlaketx.com/role/NetLossperShareNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel":
"Subsequent Event Type [Domain]", "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial
statements are issued or available to be issued." } } }, "auth_ref": ["r483", "r505"] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": ["http://moonlaketx.com/role/ShareholdersEquityNarrativeDetails"], "lang": { "en-
us": { "role": { "terseLabel": "Sale of Stock [Axis]", "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] },
"us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SupplementalCashFlowInformationAbstract", "presentation": ["http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": {
"role": { "terseLabel": "Supplementary disclosure of cash flow information:", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] },
"mnlk_SupplyAndManufacturingExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://moonlaketx.com/20240930", "localname":
"SupplyAndManufacturingExpenseCurrent", "crdr": "debit", "calculation": { "http://moonlaketx.com/role/PrepaidExpensesDetails": { "parentTag": "us-
gaap_PrepaidExpenseCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://moonlaketx.com/role/PrepaidExpensesDetails"], "lang": { "en-us": { "role": {
"terseLabel": "Supply and manufacturing services", "label": "Supply And Manufacturing Expense, Current", "documentation": "Supply And Manufacturing Expense, Current" }
} }, "auth_ref": [] }, "mnlk_SupplyAndManufacturingExpenseNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://moonlaketx.com/20240930", "localname":
"SupplyAndManufacturingExpenseNoncurrent", "crdr": "debit", "calculation": { "http://moonlaketx.com/role/PrepaidExpensesDetails": { "parentTag": "us-
gaap_PrepaidExpenseNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://moonlaketx.com/role/PrepaidExpensesDetails"], "lang": { "en-us": { "role": {
"terseLabel": "Supply and manufacturing services", "label": "Supply And Manufacturing Expense, Noncurrent", "documentation": "Supply And Manufacturing Expense,
Noncurrent" } } }, "auth_ref": [] }, "mnlk_SupplyAndManufacturingFeesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://moonlaketx.com/20240930",
"localname": "SupplyAndManufacturingFeesPayableCurrent", "crdr": "credit", "calculation": { "http://moonlaketx.com/role/TradeandOtherPayablesDetails": { "parentTag":
"mnlk_TradeAndOtherPayablesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://moonlaketx.com/role/TradeandOtherPayablesDetails"], "lang": { "en-us": {
"role": { "terseLabel": "Supply and manufacturing fees payable", "label": "Supply And Manufacturing Fees Payable, Current", "documentation": "Supply And Manufacturing
Fees Payable, Current" } } }, "auth_ref": [] }, "mnlk_SwitzerlandOfficeMember": { "xbrltype": "domainItemType", "nsuri": "http://moonlaketx.com/20240930", "localname":
"SwitzerlandOfficeMember", "presentation": ["http://moonlaketx.com/role/LeasesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Switzerland
Office", "label": "Switzerland Office [Member]", "documentation": "Switzerland Office" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang":
{ "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": ["r868"] }, "ecd_TotalShareholderRtnAmt": { "xbrltype":
"monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": {
"en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": ["r860"] },
"ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"TotalShareholderRtnVsPeerGroupTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder
Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": ["r867"] }, "mnlk_TotalSharesRollForward": { "xbrltype":
"stringItemType", "nsuri": "http://moonlaketx.com/20240930", "localname": "TotalSharesRollForward", "presentation": [
"http://moonlaketx.com/role/ShareholdersEquityScheduleofStockAuthorizedandIssuedDetails"], "lang": { "en-us": { "role": { "terseLabel": "Total Number of Ordinary Shares",
"label": "Total Shares [Roll Forward]", "documentation": "Total Shares" } } }, "auth_ref": [] }, "mnlk_TradeAndOtherPayablesCurrent": { "xbrltype": "monetaryItemType",
"nsuri": "http://moonlaketx.com/20240930", "localname": "TradeAndOtherPayablesCurrent", "crdr": "credit", "calculation": {
"http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 },
"http://moonlaketx.com/role/TradeandOtherPayablesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [
"http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://moonlaketx.com/role/TradeandOtherPayablesDetails"], "lang": { "en-us": { "role": {
"terseLabel": "Trade and other payables", "totalLabel": "Total", "label": "Trade And Other Payables, Current", "documentation": "Trade And Other Payables, Current" } },
"auth_ref": [] }, "mnlk_TradeAndOtherPayablesCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://moonlaketx.com/20240930", "localname":
"TradeAndOtherPayablesCurrentTableTextBlock", "presentation": ["http://moonlaketx.com/role/TradeandOtherPayablesTables"], "lang": { "en-us": { "role": { "terseLabel":
"Trade and other payables, current", "label": "Trade And Other Payables, Current [Table Text Block]", "documentation": "Trade And Other Payables, Current" } } }, "auth_ref":
[] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } },
"auth_ref": ["r887"] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable",
"presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label":
"Trading Arrangements, by Individual [Table]" } } }, "auth_ref": ["r889"] }, "us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TradingSecuritiesAndCertainTradingAssetsTextBlock", "presentation": [
"http://moonlaketx.com/role/InvestmentsTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of fair value changes of marketable securities", "label": "Debt
Securities, Trading, and Equity Securities, FV-NI [Table Text Block]", "documentation": "Tabular disclosure of investment in debt security measured at fair value with change
in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } },
"auth_ref": ["r471"] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [
"http://moonlaketx.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an
instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation":
["http://moonlaketx.com/role/FairValueMeasurementsDetails",
"http://moonlaketx.com/role/InvestmentsScheduleofFairValueandAmortizedCostofInvestmentsinShortTermMarketableDebtDetails"], "lang": { "en-us": { "role": { "terseLabel":
"Financial Instruments [Domain]", "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash
or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another
financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": ["r251", "r252", "r253", "r254", "r255", "r256", "r257",
"r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279",
"r280", "r318", "r332", "r447", "r471", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r523", "r524",
"r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r595", "r775", "r776", "r778", "r779", "r780", "r781", "r782", "r783",
"r784", "r787", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r945", "r946", "r947", "r948", "r990", "r993", "r994", "r995", "r996", "r997"] },
"ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } },
"auth_ref": ["r890"] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } }
}, "auth_ref": ["r891"] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate",
"presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Expiration Date", "label": "Trading Arrangement
Expiration Date" } } }, "auth_ref": ["r891"] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName",
"presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual
Name" } } }, "auth_ref": ["r889"] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle",
"presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual
Title" } } }, "auth_ref": ["r889"] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"TrdArrSecuritiesAggAvailAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available",
"label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": ["r892"] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role":
{ "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": ["r890"] }, "us-gaap_TreasuryStockSharesAcquired": { "xbrltype":
"sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockSharesAcquired", "presentation": [
"http://moonlaketx.com/role/ShareholdersEquityNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Treasury stock, shares, acquired (in shares)", "label": "Treasury
Stock, Shares, Acquired", "documentation": "Number of shares that have been repurchased during the period and are being held in treasury." } } }, "auth_ref": ["r13", "r78",
"r105"] }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"TreasuryStockValueAcquiredCostMethod", "crdr": "debit", "presentation": ["http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
], "lang": { "en-us": { "role": { "negatedTerseLabel": "Buyback of unvested MoonLake AG Common Shares by MoonLake AG into treasury following an employee contract
termination (Note 11)", "label": "Treasury Stock, Value, Acquired, Cost Method", "documentation": "Equity impact of the cost of common and preferred stock that were
repurchased during the period. Recorded using the cost method." } } }, "auth_ref": ["r13", "r46", "r105"] }, "mnlk_UnderwritingAgreementMember": { "xbrltype":
"domainItemType", "nsuri": "http://moonlaketx.com/20240930", "localname": "UnderwritingAgreementMember", "presentation": [
"http://moonlaketx.com/role/ShareholdersEquityNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Underwriting Agreement", "label": "Underwriting Agreement
[Member]", "documentation": "Underwriting Agreement" } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": {

"role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": ["r886"] }, "mnlk_UnrecognizedCommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://moonlaketx.com/20240930", "localname": "UnrecognizedCommitmentsAndContingencies", "crdr": "credit", "presentation": ["http://moonlaketx.com/role/CommitmentandContingenciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Total commitments not yet recognized", "label": "Unrecognized Commitments And Contingencies", "documentation": "Unrecognized Commitments And Contingencies" } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": ["http://moonlaketx.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": ["r34", "r35", "r36", "r133", "r134", "r137", "r138"] }, "us-gaap_VariableLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableLeaseCost", "crdr": "debit", "calculation": { "http://moonlaketx.com/role/LeasesTotalLeaseExpenseDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://moonlaketx.com/role/LeasesTotalLeaseExpenseDetails"], "lang": { "en-us": { "role": { "terseLabel": "Variable lease expense", "label": "Variable Lease, Cost", "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases." } } }, "auth_ref": ["r495", "r785"] }, "us-gaap_VestingAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VestingAxis", "presentation": ["http://moonlaketx.com/role/ShareBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Vesting [Axis]", "label": "Vesting [Axis]", "documentation": "Information by vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": ["r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986"] }, "us-gaap_VestingDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VestingDomain", "presentation": ["http://moonlaketx.com/role/ShareBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Vesting [Domain]", "label": "Vesting [Domain]", "documentation": "Vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": ["r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986"] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year", "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]" } } }, "auth_ref": ["r856"] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": ["http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://moonlaketx.com/role/NetLossperShareCalculationofNetLossperShareDetails", "http://moonlaketx.com/role/NetLossperShareNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average number of shares, diluted (in shares)", "verboseLabel": "Total weighted average number of outstanding shares, diluted (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": ["r202", "r208"] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": ["http://moonlaketx.com/role/NetLossperShareCalculationofNetLossperShareDetails"], "lang": { "en-us": { "role": { "terseLabel": "Denominator", "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": ["http://moonlaketx.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://moonlaketx.com/role/NetLossperShareCalculationofNetLossperShareDetails", "http://moonlaketx.com/role/NetLossperShareNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average number of shares, basic (in shares)", "verboseLabel": "Total weighted average number of outstanding shares, basic (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": ["r201", "r208"] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested", "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]" } } }, "auth_ref": ["r854"] } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(j)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-15" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "715", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "30", "Topic": "715", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481097/715-30-50-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "405", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478353/942-405-50-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "80", "Topic": "715", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-2" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Subparagraph": "(c)", "Paragraph": "2", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "320", "Publisher": "FASB", "URI": "https://asc.fasb.org/320/tableOfContent" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4",

"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-2" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-4" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "70", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "30", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480513/718-10-30-3" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "30", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480843/718-30-35-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-21" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "320", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-5" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-12A" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "710", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/710/tableOfContent" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "712", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/712/tableOfContent" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "715", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/715/tableOfContent" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-3" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "715", "SubTopic": "20", "Subparagraph": "(h)", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)

(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/942-320/tableOfContent" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "210", "Topic": "946", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-20" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1403", "Paragraph": "b", "Publisher": "SEC" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-17A" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-11" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",

"Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/280/tableOfContent" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "36", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI":

"https://asc.fasb.org/320/tableOfContent" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-2" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-10" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r313": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-3A" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "70", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.1.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r438": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/830/tableOfContent" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/842-20/tableOfContent" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name":

"Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef",

"Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r624": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-21" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-6" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r685": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, r686: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, r687: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, r688: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, r689: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, r690: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, r691: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, r692: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, r693: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, r694: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, r695: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, r696: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, r697: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, r698: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, r699: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, r700: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, r701: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, r702: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, r703: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, r704: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, r705: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, r706: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, r707: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, r708: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, r709: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, r710: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, r711: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, r712: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, r713: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, r714: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, r715: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, r716: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, r717: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3" }, r718: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, r719: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, r720: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, r721: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, r722: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, r723: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, r724: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, r725: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, r726: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, r727: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, r728: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, r729: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, r730: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, r731: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, r732: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, r733: { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, r734: { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, r735: { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, r736: { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, r737: { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, r738: { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, r739: { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16" }, r740: { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21" }, r741: { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, r742: { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, r743: { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, r744: { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, r745: { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, r746: { "role": "http://www.xbrl.org/2003/role/exampleRef",

"Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r747": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r748": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r749": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r750": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r751": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r752": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r753": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r754": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r755": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r756": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r757": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8" }, "r758": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5" }, "r759": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r760": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r761": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r762": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r763": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r764": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r765": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r766": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r767": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-18" }, "r768": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r769": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r770": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r771": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r772": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r773": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r774": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r775": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r776": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r777": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r778": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r779": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r780": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r781": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r782": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r783": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r784": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r785": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r786": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r787": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4" }, "r788": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" }, "r789": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r790": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r791": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r792": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r793": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r794": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r795": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r796": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r797": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r798": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r799": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r800": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r801": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r802": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r803": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r804": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r805": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r806": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r807": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r808": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r809": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r810": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r811": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r812": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r813": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher":

"SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r814": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r815": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r816": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r817": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r818": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r819": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r820": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r821": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r822": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r823": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r824": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r825": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r826": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r827": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r828": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r829": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r830": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r831": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r832": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r833": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r834": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r835": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r836": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r837": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r838": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r839": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r840": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r841": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r842": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r843": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r844": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r845": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r846": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r847": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r848": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r849": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r850": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r851": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r852": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r853": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r854": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r855": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r856": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r857": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r858": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r859": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r860": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r861": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r862": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r863": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r864": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r865": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r866": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r867": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r868": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r869": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r870": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r871": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r872": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r873": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r874": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r875": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r876": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r877": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r878": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r879": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r880": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r881": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r882": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r883": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r884": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r885": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r886": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r887": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r888": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r889": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r890": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r891": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r892": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r893": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r894": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r895": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r896": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r897": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r898": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r899": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r900": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10" }, "r901": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3" }, "r902": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r903": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r904": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "SEC" }, "r905": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(2)", "Publisher": "SEC" }, "r906": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(3)", "Publisher": "SEC" }, "r907": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r908": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph":

"c", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r909": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r910": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r911": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r912": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r913": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r914": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r915": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r916": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r917": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r918": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r919": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r920": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r921": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r922": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r923": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r924": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r925": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r926": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r927": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r928": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r929": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r930": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r931": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r932": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1" }, "r933": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11" }, "r934": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r935": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r936": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r937": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r938": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r939": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r940": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r941": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r942": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r943": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r944": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r945": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r946": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r947": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r948": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r949": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r950": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1" }, "r951": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r952": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r953": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r954": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r955": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r956": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r957": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r958": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r959": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r960": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r961": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r962": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r963": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r964": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r965": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r966": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r967": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r968": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r969": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r970": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r971": { "role":

"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r972": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r973": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r974": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r975": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r976": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r977": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r978": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r979": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r980": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r981": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r982": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r983": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r984": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r985": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r986": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r987": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r988": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "720", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1" }, "r989": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r990": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r991": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r992": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r993": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r994": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r995": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r996": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r997": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r998": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r999": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1" }, "r1000": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1" }, "r1001": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1002": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r1003": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r1004": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r1005": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1006": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1007": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1008": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1009": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1010": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1011": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1012": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1013": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r1014": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "940", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/940-320/tableOfContent" }, "r1015": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r1016": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1017": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1018": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1019": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1020": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1021": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r1022": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r1023": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r1024": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1025": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1026": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1027": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1028": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1029": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1030": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1031": { "role":

"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1032": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1033": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1034": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1035": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1036": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1037": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1038": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1039": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1040": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1041": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1042": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1043": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1044": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1045": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1046": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1047": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r1048": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1049": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1050": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1051": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1052": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r1053": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1054": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1055": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1056": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1057": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1058": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1059": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1060": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" } } } ZIP 85 0001821586-24-000029-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001821586-24-000029-xbrl.zip M4$L#!!0 (+ X9UGCX!(TB@< ,4G < ;6QT>%\R,#(T<3-X97@S M,3%D87-I;'9A+FAT;>U:;6_;-A#^OE_!)5B7 ')\7;=.EF KNV #ENW=07V M<:#$D\6%(E62LJ/1^MV1\EMCK^[+DC18/KB5=#S>R\/GCI3,2U^IB_,2N+CX MZOSK7H\l-WE3@?8LM\ |"-8XJ;?
L#P'NDO5ZG=0S4[=63DO/!OW!D/UA[*6< M\?C<2Z_@8['G_&&\/G\8)CG/C&@OSH6<,2F^,Y##O%\4XI'I8)"-AV*49N,< MAJ/QN. \$ZY/OK,PY7O<26G>A+\[]0MAN1&
M&3LY[(>_,WK2*W@E53OY]HVLP+%7,&>O3<7UMXGCVO4<6%E$02?_ADE*DX3+ M>>BNVJT ,M\">QWR!LK MO43A%U=YR?44V-
/<,U.P],GI,&'./:DK@JM9_THMA_3BG;W4Q/;B_(F]%Z=#*@ M*+QD)9\!LS"3,$<6\]5T[+>&6Z1=U;+74!N+"TNS'XRM6-KO_4:K[&=C]$_\ M$MC+]FJT02]PO(;&R]QA"I_-H
.8#,6^C),+&<57EG)%2LX,:IEII*A)@6Y:P(: M^1 ==C<629B>]-9IF!+HYPV&"9>UZ&.X]-$^_&&@" M*Z3&Y!.,5LE.0B,5Z&3MN=0% M 2CIF)L>2F19M,49)44X!W)-YJ20W$IR0,:>
(=0+39H:1W4\K%47BGY@4^, M#?)A*4Q% MX(1JWX 1\3N8KTIPO]E0(+(TS@>Q"?Q\ET'=W;\ MX#![U#^[_KN)L;T9YAK4]N>FO1&'*)U)04#BSFA.),P=@I#:1D(7MV*1:<2>
MY)E4TK=4IK=-2[@/H CYCI#=$%UK.P/77W4.U8VM$6\NM!5Y;JP(!H0&= H: MNP6%L,,G$$YR2 2;ZP@MQ+VLD6[O-;CRG>!Z,>,J":N<(@]%02=:,XR9V])- M+0OS'JP5+[$".!
M]@0HT 3W%0YB-]?$2%_/&&U(NPXE/-D*BP]@&*I1)L\;2WE9*PA;M%;&>;Q/ M1\VHR^6HZ&T\ &%'.X84"#!<^^](=X;C?@'"7IJVV;I9VG4?[CC__<;-[O?>*]P"\)8A==>:!/M(',)
MB)>NY"[[_CGP2ZJAL2L*533T<^'(<'& \D$H[%KTN.O>0H)D[[GE>M-!^/[M-D9BZSOV&UH)(1B">"K0SB1LADGJX.+!X1 !&7ZWO[C],]/^BE?Q'/$^.?6& M/D7JT,38LU)"P5Y<0=
[07I/!$MNY+],UMO9W!^OE*!Q(CWZG>]A6G>\@JP. MRUB;S5C?1L2.=R9Z_=.RVKCP[FD2CTUGL/-CLP4N5D-XYHQJ_.XA'_%I6O<; M/Z-[&#[?^P=02P,$% @ L#AG63_$DTN!!P
;B< !\ !M;'1X7S(P M,C1Q,WAE>#,Q,F)O9&5N7\':N*D-:)U]V4[6 MKH&\"@1HT]O< /UX08FC%:\E<4M2N][^^IXAM:]XM]D\ZCC&]8=-) W)XE*B<;H>B]\5N6O1Z;16+\QD
M;O6X*+?[0_%[\9>ZZF,S[WV)5TM^KE\'*\O'X=!+E.CYE>72D^%5C\>Z&$_M.U.#,R7/!OTAT2 =9.==E3WI9=W!,#V5_^T=H"G,8QOGYR7]>%#INE,0CS\Z
M[T_\Q4PK7XQZW>Z_#C;MI!W#-#7>FVK4/>E-/ QR4WLX8M%Q_&_L_ 8HMUM? M>+KQ'5GJ<3T*\V^[6S3)3&GLZ+ ;_B[X22>7E2[GHQ_>Z8[<>$,S\=94LOXA
M<;)V'4=6Y]'0Z3]IU.-!PN6LG1_Z*75-B_GVAJ>8Y*N;0J?:BT'OI+\YB_W] MSY =LKOC\8D]?;E0=/<*Q0NR7NJVJNF5F2%+TC\A[+&:]]A_.HF*V0])O$I\\+DHO=T,$R$=.*9,A->
M#>O]HUT8<]#MBT7HUB.0RNQZ; T&ZK3!R,/?Q5V%!A,(\Y,VE36YSJ\WY38_ M[\H=FB_"VN]V/QFV_VL<\CW_!-P._ZZCKY"TX=8HO4[$+]+[0@-USXVBV@%W
M/A%9P/G=Y&^[9W.@2?I'AZ=/+CXBXA.I%"I(IZ0<'0U.SK=F(=[26).U'W6B MV3].*-NGV3OY>D'>C-;929^C\%H41(8!I*Y1KN8H4MXVA E B@55AL1*4>'* M:EF*7#*?
6F$]'2I2L+ME4%-&SDD[9Y.*(<%58=FGPST%9S!D&21=6S8R;2'A M8%:C>5LN9X7."N$:_EFUGY&EMA.>0*5=":W'LG&F?8$)N@E*)8_ .4[@FE&8 MYA3-E$CGZV%X\-
AD[;FNEBNLMC!Q[PV-Y: T=YRP15/" U0%$8S@5_,ND* MD9=FYA;HM336SEN6:I)O1K_A9;(&0K=PYI:W#QZ'P_N&PW<;27MT^*3?.[!P M+=*B^)DSI9@<8A^W.)VOA;04@
,@Z+0D3K @H#4MM2O8G,TJT"E3*E\K[;+2 MN ;MF&BM*2.")M9DI'#;B2, 1A$0&%&QL2=8VU.<'M':GH*OXJ7FS5 =DP^4;PR48R">Y_LPAP4+A<\2:&$[_4'@/OEJL)7']P6VO>Y) M?
\AQ>$D.D4(*0UG\,+X2KMB9:-S^3;ATI@2LM"/%8FP:BP[9%/M C_""ML% M[H>%^HI9U]G94BD#^-IJO)0TC(W/]1@6?CB3*E5. 5R3>]TTM)JGH".FB'4 MBYI[:AS7\;!672CZ@4V-
(SCDP]8Z$1,(5ITUI>0B@&D%)U9Z "VBNE@71?A? M2FP(GD9[4I_%R_<=W.GQH\/>6??B]N\FQO9FF%M0VY^;]D8<4#K5BH$DG:DE MD[!T "'+1D:7M&J1:6!/RU27VL^Y3&\;EG$?
0!'R'2&[8;HF.P/7W[03FC1V M KRY("NRS%@5' @"=PUU()V.$)A7,<-H&XCM "[O4$=/N@P97M!->KJ2R; ML,HY\I3G?*XU1-W>[/K\JE-;%& MS3^\W1#I0OV&Y4QO
G0($'>*AP4+NY)D;Z=L9X0]HJE/!D*RP^@F&X1IDL M:RSG9:T@;.FU,L[C/A\THR^7H:, X@&(.-K1) ? L/;?LVX=QWZ!PEZ:M]EU ML_3K.'I52+>LGLP: 9"D IV&>+14-
\>.^9K*=F/]GGWRV2'Z;!!^"QN1TX>Q M$0E'=&JQ=)(5L3#/K<-WQ3$,P(\HY;<$V](U"='FC77+ZAENH,NJTMX3_0V+ MIP;UF9\K#?]")T< .4C3,2GC7Y:.BY5)?S0:[H=5V-
3A[8<[_O]^XV[W&\]* MJ"#$*KST@D^\@\PT 2]MR5WJ_AG):ZZA416%*AKT7#@R7!R@?!0*6XD>=]U; M2% J-'2TY,"=B&U5()H =A!K22SD#E7<-15
@RB%R;2U9^M1TX,OTNF]0=_3 MD[-0(IY! ^06_)("A0H$6 *I[XMZ)80G4]>64N(]67MN61:F:E&9. M>#HK3*1.N8%I8/"+B(R3+,.6\:[S_I+5>.!5\093JU*R49N=)^&#B[M_=WK/ M
O1\'J.S];W[':V/$ S%[!7(:!2VR&QU37*/"^S:F)];^C?WB9A!Y'VF/BV1Z^M2T\XNP1;)6363J3-GXW4T^X2.R M]C=^Z_8X?&/W%U!+ P04 " "P.&=97EY-((\$ #>$@ ' &UL='A? M,C R-
'$S>&5X,S(Q9&%S:6QV82YH=&WE6%%3VT80?N^OV,*4P(Q-)&-C8SO, M)#,I-,2)M#)8^=T6EE73G?*W%/)[FR-+C;Z;?=KMPJGE5H'+ #3*'*516]!E\3-%>0K?;6IWHLC9BECOH
M1;T^?-3F4LQ9L^Z$DWB\]#-lV5Q/7X8@TT2GI?$T%7,0Z:LMP8?#02^)61P/ MTGX_CD<\2X8'PSYF:30\.AS^%F_15C)OIEA72WRU50C5S=''"PI[I9LL1.KR M<1Q%WVVMVS$S(]-
$.Z>++<;0?EXX,,JT< 3'DN/FW\7\[RNW=$X=7KLNDF*EQ MR+[UM]S"M=1FO!V%OXE?Z6:L$+(>O[@0!5HXPP5\T 53+SJ6*=NU:$36&%KQ M!XYCGTZX7+3YD1\I%"[SC?
L#2O+-52X2X>"@MQ^O9WO_MZ>DZU07,_&YOS ML.;I\8B(-R+B!(T3F>#,":W@E\K8BA$*IR$>P:_[Y_LG^W".*S&!X.H \P" M2W7I6WO5?
&ET%!V"SL#E".?,)$RA[;Z[DEC#:^[\2B^*>I]#U4,I?L"^OY3X M]\H2-_635Z9_9V7>=N!';6:>1N6TA5,&YT+.6<>S[>E-T 9"BQHNE5Y(3,F8 MAWK6'2@_KY3E0TM)
<'+F@M'[BAGJ9%G#!RRU(1,%/VA30!QUWWOIG[6/[%+ MA+=%42E->PPKL7*"6]CU'G;V1[U>-#G1143YBEJXX:'$L_'<@J2>@XN9>"*K40+@^.#7ZJA$$_;ZT'
M>D/3+ML#BGY]8[";[EV3@KPRPGE/;ZYXSA3QWS(3'QWT@:GTAARA*(NB.6:< MBL^HX"G=#8LM7QD3GKW2H/5(.GZ920FTC3)GDG#:DI#83MB5"<44]_?)82]"
M:Q^3K"K9)**)LA#3+D&WW.X_QI'X5V/ORYZN4_]LWMD>C"9PIN]L]X<3&W]O'I//D_4S M5F##^U>4U(47L&TW 9SD C,:F#0\G9@CO,M(?]!YGJDU,^/V[^[3G)IK4,'C M6#CB@&\
LS2"'A0E/2GPFG>]SON78&_O?S]E+_QC7!N<:?^2R-?$N+ D\?SM MK#)*V)SD@M4222"01F,<-P_R5?VPD>8C@4">27TMO0M2CD%BT?926UQ70*,- MU,E#D[OTPYL")#7ID@P-
*NY7? H$GH)[#.O:L_+'+TX),&3>IWK M&?(JC&6D@X)E2CZ!+%!G'?([8R:5; -R[W:&BG2/7$'@CLG>2F;TE!9%U1[AT2<(^K#!XY6-(?2KKXR
MY,PW+IF61L^%E^I4[+^3_KYQ%H)T;N*5>*N,R>D_[;DY%^T;T4J+^O7K-J6^ M*H2U'B!UD2![I3%ED&50EW?%IT)O4?](%J]]EE^&[UI]02P,$% @ L#AG69\!D/J3! G!(M !\
!M;'1X7S(P,C1Q,WAE>#,R,F)O9&5NPZ<$ MW25TNZW5]2EKJ^;9AW[4'\ G8R_5E6C&O?(YGBSC3/>;Y^E^F&0Z,TE],DW4 M%:CD^98Z&]3147^6#N/CP2
2QT**T4'_<)@<'D81BOBW>(M>+SV79&KN1Z'_-MP2Q=I#"D)%]?9VJF/!ST>_WU M+![$/UI'+ZDV:!]F8W,>UB(]'A'Q1D2Y9G)G MZ *=10V7VBQR3.8(,E2S[D#Y[PI9?FDA"4XF?
##Z4 E+?9S7\!%+8\E$PQMC M"XBC[@>V?V>,_EE<(KPMBDH;\K&BQ,HKZ6"7(^QLC_K]:')JBE+H.CS%DSU(MC0T3E,2C20!U0HC/D8 7,[0[V_%A-
#F@?,).NAJHP;&,TX&TR@F=I/"YHCHM ME,]"8(M_5.HB[!:.@=!2M"OV@&:_>3'<3?9N2$%96>4YTNMKF0E-_+?,Q,<' M Q ZN25':J=)"2WY/ 1,5OO.<9%7E32*&*
MSNB7HEMO>8RR(_[3I?=VU]8I/YIWM MX6@"9^9JI8^,FC9ZG*R^88)>U@T[L(3_M(?T?2 :,A*4INGA<44+W[+5ULG. M]N!HXL+O?9ODM\GYF2BP8?
V[2>F"I6O;20"GF<(4WMSL6^]3$AYHO\W4FOWB M[N_NTZR8&U AXEAYXD!N +.TBL@NB>W;\X)/"2&EJ;3GJXE9+\/7(/O?[_A
M7O");BS.#9=$KJERY4CM\>NTLEJYC)2#,SF25B"YQH4,9_JJE-A(_E$74&02 M8LOHBD1D4%OD7A['ZV)HM*'P68M,\\[8_=F7O(^3A/,:I(H*5K4DD]N"I3.K#
(D'4B::"$)2\SQ(),I"2)@F5",8$LT*0=BCL7-LG1!>0<=HZ: M)%"^@H!SR0ES)>8\/;A*9NWLFZJB[[<+SXQOM^L7X @.E,]5K)2[=+ZX>S])LJILSMO$8U^P]Y\M>,DJ,ID"B)>&RY]>_
MF2FPN0B00)<4Q*QIEPU"I"*>B(Q;1OSZ?UXG8^$%!Z'K>W_]BW0A_D7 WL!W M7,_YKW]I]Z^ZW;,\G]9__/K_-9O__7A1KCV!L,)]B+A*L!VA!WAIQN-A&B$ MA?
_V@Q_NBRW39C/^V)4_?0O9)$ISDP M9*6I8MUJFO90:AI#T9 U6*:I*'G2\=Y,AQL2>0*>]!4GYZLYI/V9#0M4Q\, M!Z*H.H:)G$M9P:IFR?)
Q*HJ:Z8E#31LZJ9F/3FZ\Q1_[R@BSTR>VPLOW=>_ M-D91-+W\/GGSY\7KT_!^,/(GC_+HJ1\=KVQZV'ZW(WX\I5K?RKL2LFRK,^O M]);SBR[QP'F_D-
TPQ(.+9__E,WGC,R7"XD)R]Q_;OEY4/M.WG^P0+RX?^#,O M"MZ2[SU_<^7^])WQQ>X7AC9WN#]"]S7*/GJ#T)\C@+;"RE_[8@@AGZ=V!3E MIB0O;C(+F\^V/7V_T=_.G]A-YF]LK-
!Q5Y]HOCS]<_SF^^)"7Y4E8]?CQ%>\ M+R0*MEYL?2;O+CUVDY!QY>(%67<]N:0U1;.I2.\/$[I) "%?)WW^G]N;_F"$ M)W9SG>AA$&W2BKRX0J>)-_Y RL3WO;'] T>O%P-
PJX3+45\7\8&K%:02M!= M7.I@-QE-Y(V/[I\[K);T0!&OKN-@C_U*WK\C MVBEP!_'WOT8/>(/C7QJ!)6.39$WHG[%ZVB?YRJ [[-K:?&T+,T;\V" HNA^XK
M=II#>TR%SB52/&S*>J/UK7W3[_SZ>>4;,GSA0F=^<\.!/?XGMH-OY)7P_1N, M1HN2(J\ON">7^\[J5YB-UM^5P[_@:A8$*P_0\9QKHOY7J>>05YH3R"[F16W/Z1!P3REMOX=X.!O?

N,-W9*@F@<:]\L\M7_DM ML =440@SSXV_,,3/]$Z-S4=U\,"=$-3[M=&]^[:^)'+?)QSTACVR,*)ZO.=^ M?)]W[FJB2DB\6,;B>\M?AR7JB>OXO"JE 1YB@J8!#A.4"]5.ER'3E&19 M-6 MEQ%1*639[F0ZIFJ3O38*Z*I7],C%:^@0+<.^[^-+YM\9^K. _<4VQ4M*#+;L M<&23-QN+UR?8#F]%Q'F M/EW$^SV)6G0=O'PIPYT=^<&!7[OQ>?KB-
?;\B>LEW38M:59N\7EU]:N>>HRI MS;/^K933E^RM3"1DG_A?"G0*QQUW?;\FT^T7HI1XW_F;V6[XQW#S;L16N:1O
M9+K3E&T#R2N+W\MT&X\()_Q8YF9)?,]UM,!INE9*KW[]ENW>+'VV!"MSG(V,(M,MI",)7FT-BDCL)-&,W_'@_*^'R4 E[:,R;2L"S32HN']7S_2$-!>=[
M74Q$LM23ZF:NQ'8:]83_R!S_:KR[9 MJ!>77/D38FNR]]OQC7[]G'C_=U"\+R,%5W6A MM\]!F*\\V8KD'O-D&E]/IA!?]JGDPC/]-&2D:)V4&Y(,H'>I^#9/@]Y%[P&Y
MX=L">I>*;TGD8&M:MZV-\FUKB3L?0TE/!R5',A3N9!Q A[2^5IYT.!'COX"- ME@=I+=Q5. WN5*1#"G=W3H,[U421)'#9>-YW^'?P:)(U>B.32@F<8BQ M;@^#ZH.+)=-
;SM'TYM^WY)S5Q7I9>;*:?[=V-ZO;CN/2\@!]?&^[3M>[L]=N M9(_K0G^Y<"^W8/H_X,AV/>QT[.!SO>>P-H0OW*TN&OB#P6PR&]/BV5XTP@&] M+L C>K<7W/4&_@37AA?
\YP]W\^+>IF5MM2$W_Q&$W>2^\SU69>./QT3E=,FS M!3BL#_DYRR;F^6C\^]><6!-'.'3*$K..*MK@W]VN1NORP)NZ.]MEJ6@>>%6X MMUP3.M3=E2S>E>&
2TK='&%=WA[7RH!Q?]"DU'Q-GH2O>T2D MZGQ-GKRH>WU "?F:/,E=]\!*!?F:',FO\E"(7M"CU3VF4%F^1DWOT.DY%>"I M=7?TR\K75,&;NCO;5>5KJN
5#_EW'NA0=U>R\JA!"0'E*G !+FX=N 3^<$T9 M5W?GN7*U6T*^I@I=K]+R:KM2]!J-R5A>>K\F-U1!AJ9;^=0^: ME)VOR8WP=8^(<)"OR8T7=:\/*"=?DQNYZQY8J29?DQOY"X]?
5/=HM7?ZJ\K7 M5-!L1*N[HU]6OJ8*WM3=V;XJ'U,!K_2Z>\OEQZ.KX%+M'5T>XM%5,*[N'G+E MP:C3()6FU!V!KQP7)>0]JL!%W8,)€>.B\#Q%7BV/];H',BIG=>%9MQ87?>B
MCXKR%+G1O^Z1G;+S%+D1ONY1&@[R%+GQHNY1F7+R%+E-[*AJ8*6;/$5NY.>A ML7]!CP8Q!U-U1+L5'R(_<=7>/*_$1\B-_W3WB:@I^LLVOR:OCEEEW?[J4@I^*>%/W
M\H1*"GXJXA5WD_XJHD/=7>N2"Y\]XE+MO>+*"Y\]8ES=W>G*(U=\C2',#1=U M]_8KQT71A4\5X:+ND8?*<5%L4D/-KR^:6?>H1^6L+C:ID2>K(<)2*?VMN@=-
M2DUJY$GXND=$]DYJY,F+NM=+E)#4R)/<=0^L5)#4R)/\#1@+.C1ZAY3]"Q? MD|;CEII?QRVK]HY^6?F:*GA3=V>[]GQ-%;SB;@!B172HNNK%#9?KZF BY)8MT] M3BX2-
I5PKNXN:^5AN<(CL'EU.I+NKOE?.Z\!!L?KRNNS]>40PV/P;4O8:A M["!L?I2O?<"@^BAL?LR @$"Y] 8GOUKZ\^"X%_5L=7?&*XO$INTIL.;74TB2 MZNZ3EQ6*K80Y=7>
[JXK%5L*LNOO-Y0'H*0E7"N[KYRY8&I$LK& M*P%&W5WYRH%10MUX)<"H>UBAXRD[;9$;Y>6ZQVLX2%ODQXRZQV?*25OD1^^ZAUBJ25OD1W]N8R=7
M=CAJ>P[]AW+@Q1Y_$'_BC7\P.P<' Y?NN.29Z;4XH-\Z((PCIM$UGOJA6R-6 MNYD-JD/OKESW9.(:K_6BZC< M^LC?;#?XASV>X:]O[[_^3NYH!X/1VPU^P>/5C?
3]HJXWG44ANT+.RVU>6LPM MML-9P';V;P'^8X:]P=N6E2Q=&C[@P2P(R!:?VY$ Q'0O)6OO_"K>A M,,!"Z5C@-BP'2JIVP,QU]^0V2 E8*!T+W$5)SUQ)<;1_<1?K/6MN0)#XE*"1
MJPZ'8"U/W. W:,I3."A/W:CR&Q3DSWK,E?#-P?81S=^(2\Y-TU MRB<61-2']-Q&FO:3_AH_17VJV-W(Q34B^5D'=/C98=4ZQ"]XXL/ZH9\,PR)R
M._2CGG6@@2,EQIU7SRJXL#WNA+1:EVS)2I7HQ" *,+&?Z!YRC<-!X$IK[WA M?>"3QX[>E@H8^S_=Z-\X()N/TOCL2DZKH\[9$BLR4@L0NS6?JBJ1R%PBH$0.7 MA&J-)\
<)%7<>>#UYDJN5P)T?GA=/[OT@\DM1<80?(ME[TJBXM4N/4G$:=_Y\ M^:Q+:;XLON6>R&A$5D:=V2E[K*]OCVD]3O&J[?)VYY*[%1].6H7"4%&N%1QCJ M(A/<^?NU4&=%P9*
[4$!>W+BR)T^!ZSSC\C8824DM3!^7'B=,W$40JF%?W3>9 M#S@<)\W(:B1G__UP9/CA.IDXQ3E^5\]C5%(M:LI8[?*EQXG3R88SSL+_6H/"<5)<>!2E)C*A0TR"
(UCJW!4>4&Z]MQOI#[!G MD\?Y.).^>.6;3_ABE]!LE_JZ*9-\'S'7XX2$NR#%1VF3]X*#D,D ZI?V!>V[MY_XQPTO2L=(,X^/RN M;UXO\5+WW4B^!-#WH2FA/FB$AK>2&5>Y".(!5'ILE
MO[WHW] [=_*QX3 M5LI$*[M4UO+!!'=Q2ZXQ48VRJ 08W$5%ZP:,$BR>2H#!7:79>U?GGW;@?$2A MF?YN/][V1W:PI]Q%ZB^A@>\[>[+\';?V&\TF]>TQ#MO/ 680*3AS)6I-*9_*
M08.[4.]9\E-ORD8^_.0N6,P)/VG.8/8\"Z/RF9M;Z;7!;U@S=* MVDU#NCS2\Q#",K@-M_+#I]5DF9*;B' :/>2']#Q$(PQN(V?\\DE-SR<]-S[Q M&S7:PZ?OGH.#G_38M?=
<%I/6++G=)8$KEQ[')'[#.'PZ]2ACF]\HR7:Z+R[I MO>"@/1[[$;UUCR4$3E0ZN U9<"(=FTSZV#SV,BFG?<;D+@[A8/?R!C ;;XPY; MSR%9@4J!L/?
+::G6E3^C$Z"FA,EOZW[S_"F[D\G,\^F<-'N*9Y$[*`HJM\(L MTI2'SE8N/0Z!W$5.RD @@& 5!-Q%6,X>!%+:O6CYTN-4'CX)K/)NOQL1YFL M)G?
Q$=AG*Y(N%G83S=3!T8]+CY,N[B(_YZOBJP)!X6&E T+0'\]VG(KE-QI3 M>NU$#]55X1S%QLJ=:.M295.">5;E8"/VY!70H(^ADC7&]"[OV!ZQ6GFO"SN
M8EQ[#O+=!_0,W\0^479P%_#AAAU5-$VUN N]%%/XF?YKB;/*A@=$G1?R8_. M_=H%>;@HE:!OQ0Z7EK%WE!UN\5N% X J4YU)Z=79RJ7'J3/N FU;"C$7+S_@ M, K<082=-/9X7?=\
[H)/7'%%2<\5)4^N<%MDQ 57JC+(N(UC<<$5)3U7[C2F4S'_AO&I[RWK&LA=L(4CGE2SH\@B=Q$7CGA2S7Y" MJE9GGI12MUK-
KB*+W,8ON.%,57M+W7S[2F2FDAVF;OYI)3)3R3[#K8_/14JR M*DW&K8_/!5>]TF+<^OA<<*4]#<;MET^(IT_P>ZHE>1#M PXQ'?/8)C2@8QQ] MUKB[\SHE=RNAMWL5%K3$;0R
>XY5M!])W$8(N.=817N5Q&W\@'N.5;2/2=S& M%5)Q[#?LX< >TWX^SL3UW# *;&IXG/9.QFW$H08\]VHOXS8640.>5;6;<1NE MJ '/]MK/((:Q\V#3,J&/*:B4I5]%)38#]_2]3K]W7Q^"
[4I MYW)03Y;Y#0_D>XCIS+C*;0@AE[*U,V,F=]&%,D]1E@,8;DY.%H4A;N,=IZP0 M5CR#-7;N\@S6+CW*,Y"YC9I45<&\)&+RZBS$XT2,VU '!X16(\OC3/\VHE]$]PR=R&E&]'B
M<13@$\6%PFTLK]JC&049RDK=@E/ED3E/,UGA+FS$$9ES1'/=(BOED3G/-)#" M;1@CU[Q;KLQ-=90"7(L# "@HV*76.J9XPBS.3ZNKM8YG MGA:+>3#DU%H'7D\+#P4%?=5:!7U+
[P$ALW'86AK!6[OT.,&K5>2SY+-&>?HQ M:JW">243.E?KL591JM)QG2.BN0V^?+4)'0>X()X[5PI(_I[@*>VZ\S/D(97 MLR# !0]ISW4CY38BDHWN=[XW]!GI->Z"#WO&,/9I#X_]'^[$?
KH/_.? GO1O M_C;_[5A[=3]RPID-HE[0Q\&+.U@SDF_(*X6ZAG@T\% OS&?XZP[;#U..Y+ZU?R@Q'=E16L M:I8L#T2LJK)F6M) PZ9N:M:3HSM/[O]20^/C,V'T-
B;$G[A>7&KG]"PXB2O:F/7:?O4OZE/.W/[[Y0HR_M/2)/&3F+;YZ_?4'>^KSYNB)?R(J2^)9X(26^7M:MU)VW^LR>,EB\.6>&1&C5 M8!\B! ZG-D&PU5CCP9RJTC020G_L.L*?
1/:_+_/W(W^:\.;4=AS7>[X4!?+> M^P(^,WXM +(!$\:FF&,T;(#LC:ZJL7[9)%^<+GXBB%!;W-H3]SQV^5?'HD, MAL(=_BD\^!/;^PL*;2]LA@3OP_C"T/TW)EPGV&!__HP)8)#[," M",
(@\]VN M^]BY%QJ/[<=_,]?/= E%+T1-7(BP^'(>2273%28[5]\?NH_=3E]HWUT+G?^Y M^KU]!UM'N.K=WG:[_6[OKB+ZR?6@WW,;X8C(2>1]2+B^N+H09%%3K8UEQXMK M_?
H44%'B_)F^]1YNA5_)'N+YWMUL0FXR$.9;S0,>LC%,#<&SZ:Y,&QY<^X.9 MJ\5^F^(&VV6&Y(*6)#;_SG:BC[ML/GI=Z")IA"Z?;ML/?Q-Z=YU?>%XJ8V%V
M[OU]9@=DO>.W!SSU@Z@A#.G T(B8#*_1Y=!]Q4XS"F;O#"8>\Y_9!FJ_F6= MQ\+?O[.P)1-\\$]4B2(K0>Q D[9/S MB]#]CS^WA&65-&[&FI?/=*W)4M1:XN=>"?XY@="-,+"'PLZ"
[$Q)V#/PPMV$=<\CZ>1K']]XA(H);] MR4CK?._-KL$"\GTNC0UO%X*A/0[?I4"=2X&Z*06/#^V[?I=A'<3@8VN92T'T M3NF%& P#?R(D_B_RDU[-EP[E?]QL]M->4FY(/5QAZ!
(GS9M1N;_("$=YKY^ MQ^^8Y]=^(!&'7"]J5@Z#0GL41_UIZ:8;6^-J?: GUEW6"^B*9 %Y?1&Z[7 MN[MI_ZTC=&]OO]_UB/ _M.\]WQ^[5_VC:9D;4 M6:!#H3_% QJ/<037$[I1*%R-
V!ZX;4;MQ$'9(0;+NC!U*6N$034N+$O+%!;8 M'B[013.7 -;E)$FP+ :3%#>@PF+>(\?:41@2\;N%NG9TS*HM&XJ>^T R24 M-GP.R(;/TL(L_'<5!_JN?&?5M"(+&EQBY]D.IH'_,@\'?
IA5!M&U]AM9OM - MQ[;GA%OE.'+V4?H]\G*&#'FT7[OS*&Z(]J-X: M OO"*7DWPR3,,668%8AMY1/C*A#^-0O[+'BV/???[.]?
M_OPG21>_;/[,@-5:4"GU4YT**KH7#Q?]"V%>HAL(JR(EW/D7OR0)RUJ,V=P(M,1^LJ])>=LYJ4MMQ AR&\]WNR/VDA?JS&]UK/QA2 RL,L2!;Q>\R.;!DC(<;
M1M<[0Y9S32N6FG@AFDFLK143[_TPLI?_SYW&]L0\1"HV6L1KVG";,GME\R^Y M(K_V@D?_Y[LU0B=_; 9\VY?@BN,G(S8SNW'3=MQ;C+2CWV8C72P5_^G&_T; M![]1]!*.1D?
[N<_L<;;DY@JC=-@V(Y>9.[:& 7_%@1NNPRND9!TXP!)[H'M -LK^PS2J.E2D?L,K1>>GP_\KVUV!\= ME*9*FB2:HBS7+F#U$:+Z\Y],63*^A$*$QWA*GW,>($74<1K/J @(-J$](=(R
MNE(&K8Y[LV2R](F:"=S()3<,(%P@!UA.@O"&0WF1;Y KF#>@R1_>OJ)%*BD: MSF\/HLM3#.8IY UY=!RL_& >MXM2DM]*&6%\L@<_G@-B'CG-.=@' XR'0UYW MH62CY=&-
QBP$CNW!2!C0\1UI(@[GGW?%GX:M MLIFO[;Y,G?_PIE8T#E&.F M\CSOPD"'7P25:LL&8W@*:[XIO MDOS$Y/O= M(:+3:A1V@+A":N9P=O0DB;7B%A:@?"BSV>8>$_6:6J11/=\9L'
M^'=;>5$KBJ>/P.8*O7I%GHX%ZUR+QDKT':DTW7SS^#\'QX(@&<.P$=BYF?7 MF)WY7A17/FPD4LF[:Y$P@VYFH6/_L>&P7ME3-[+'PJT=_,!1 G#S\?3_-0LC
M=_A6C5?:11R:G<'"TYLP&.'!#X% X@?9Q3'+ZU%?*_@HK?@D_2*,D)#5]#B" M/1Z3-YG9&O7=_IBYU',C#ML3GE] [OGNO"DT"QB7G"0=XEM1B^=!GB
F:4FR0(K,PR%3^1^A+U"."/V1CCR:7W'HK0K&MG1^MI_ MVJNK9'5)[,/S9_@%";;G"),D^!F?"$C(^T_(D] KV>7D@_15J9,G=B&:B^_JS0"R*G]%H\>X%
MT;E87'L7>D+6ERV]X*M2WN_D"K9^<5;UCF_E!;O M,3DC7E!37FP;RWO%10T"G(>4O 97A,#/?E(Z+S[6R4@_F%_T84L:5$?'L"[[. M0D*],-O[H*. -]R!&+KIC'WE)K4+;J4-
7GAY+@>+5"Z5'16<0!/CK;%& ^ ME%W<_C=V]ZOXYOLI+*>G<"542W5(LUKK8+AC&Z99OD3CP1TF&;',=6ZP_.9 MY3D+,;N*/&E\D"OA9 NQ NAWC=_HE_]TR5=3V\
CC^93.7YQ0Z:+/-L;N,3! M)1]*%HG0B^GI?\<.G%"@Y<:NLRT7IWRR?TG[.(23L1^U7&>;-)T_&CYOR$D3C.YE_C.1I46
M$B*1_&=]U((NEMH2%AF*WB)#$7\A^DA,O*,$;_50^"B/B6/#'1^RGT]./HLV/0 N68V]5UQ8L67O\&\]?D:!AU'^C)M/ M ;9_-.UAA(-+>_S3?
@OI]V9]!+0MER')9>0R4E;4[3QYN46'TSW0BBS[C5$ M1ZF:GL\1V@M%3;4_Y%EIE)0XGKB,,\8IL)#B@5Y'EV-RL11@%U(#]4XJ6>6*C=4_4E=']$+YU[]IW5]WV
MC4!,7:+5VH^LA99]3*5%P3A9ND] "0.@R L4\A;&'UIX5XJFD$Q0%<6A0FFT MNA&>")1%>\1O_>.HZ'PZ;MGSQPWPLXO1VJ-@C$#6J,H?.2F-P70,I^I&AI]8H=CH1O8__G
ML0X1&"KNTQ=N^%@%C?CIT&4MF>/WT*7V2@?>H4JGKB(MG%[S@,/9."D, V;,^4%+KJ<= OJGR*RA.%)O MJGS&?C@+R/K;3_XLFK=3$![<\ >8,&<*'<4"
(P9PL8:+1:6*>D&MD2@@[&?] MY#[P!]BA&@0LD#/%17[Z DI@3P46^](&MGLAL ,54 ![[I"PXL;38%D +M9Q ML:B!O<'/]C@V*5CG); ISA41^6D*"&N<"BY4>;$IVA1'T"RY5S1 M
/8$X&(#%]I'ON6[MS2VHF^,/,4N:=%@1V7+4QK(^]ZRGNESXP,LCW/%#E@> M@(L-7)@?"95K/+19^O7[E/:4Q9[K!Q^ZA&+GF+IWL$6X64M&?(M KA8QX4F M?61-
;LEGB0TRQ,3T6,J[@IUQIK@ .P-PL8$+=:XOM NAQ_I(=KVXX1VY)40Y MSA018%Q +C9P81Q_8SK:5C9I:1MB+O%RI:4K? P^!A_:\;$2.H+O M6^&:DLNQ&6URMWTIJ?
ELUN;5M+%BX=VKRZ?8YF!GNJ8];47S1>3])J![4T;.8 M/73Z!HEK#W*2'9Q3]RI/#8/\GB 5.\--5]24=*6QP=S:K%UO)'!DQ1U2WOVA MS<%7625U$\ 5H?6J=W?
=N>MWKFG#\']OIGO=?B1_?&W?$/W5$?J_=SKK/=@=I-CB/K4G=`A32"?\?.]?(P&_#C =[4 GAPB.'=F;:BNOIR]8
M\6T=XUH'3O"Z=&&:V3K!;W]=E>5<>LI+^H5A[FXJ7]&B=E/JV"C3^T23BCY/ MXQG$_C.(7";$=EA(8@.'_C1O'6-<:'OW(#IYO4_T!QM/]3[\(M$(.B*^DP\] MC9K0\QH/YN2,)WTI*R3,*
<42$^)"-C*$S2JAQGR:M&"'(6L6? ":UBB0&4WS MSR\-0Q+IXI?&(1U][U+7EE,0/H:0S'H[\8*AI. EP1#MK49+:@?T%SK]_4>
MQTV1\E5.62@H)NDB_FCWGUMD]!^L@,6]ZK?:9]XZ07 6.NOC]7E\8'B8GC@ M+&P^V_:TDB*O[3GTG\X'[-K1E1T$=-SJ/^@TOXPS!&E7)\70D*[I2+:DC3F" M &H
]9&@ULH'-3T\HTE(TBVD*,9N4.=]]5A ^N/_"!J$N]WPH;ZXMBC=? 3 MV>C?#XU4;1L=86G71RIVJ_KVB^V.*5^^^0$]V?-QFN>:\.GCK[E!FU4^E$9+ MDDPDZR8B3Y*/T@?
FYZ42"V;^VFAI%C(5$UG[>+]'-RZB7.3S>#NKJ[_]/![C M]%RMN$@XP -,[(B#[F[6"7%?^]CF';O2HP?#Q_LN,/1@3I(;[1DLO482-3E MPGT.X'*F[2<_+NOS B\2S-?
5P^.R/\/L!3VW4$_#JE/;=#H2D,8B*#\56I MCILSIA/SY4#@&P3X&K),%:FR!N8U7_HM%P[3WL1($F4DBPK8T%F-SQJDBA[] MR!XO=/(Q":.<#),=29GEO
PEK\K(RYU<>)],YQY@)X]&!\FP1IUB2D2+I2#), MKDS2-.FXDV;[GFC)$6Q71.]]K\K,U3):IHS691.IYG&9FB0]6*YGW@$TI';ZP4BU9A3>F1&21X^+ (6@'QXS-5
M=0O.W(]M+VI[3F?!G+OL]_0^]R4D,*92P9Z+EFXYCDQ1+]A^@? 8/"T05\$^R$.ERT,=OE<8Q.=!IF4@24@^+RH%(R-3<.*N5)@A.2
M\33]/:MDL_H"$\F2@A1YNPM0B;OTYS],NOBE0' L;*[4(.DGXPP2GNXH8G9R M<'E2L9S-/:(@:[3"1-:1HI(DM+%-X^K.,$D*;^$)IE Q?%G]}3AT04FU:RN
M_#X9U=:7+/IDC%W[R1USZDY[QY+,I$V_\XY+!J^TYI.C1_1Q:AY5TTN$SDH@,\[^>4)]?T=;= M(;>I69//[@:2<;J2D6QWYBX9.CV.9RH&TDV5$\$XNW-_2\TWIN0WB@Q_*/AK
M]9N:QG%8IIR7+0*:A M0\+_%%VB]F 0S/!2;=:'=S3(R7V&:L7<@O8QLVX^&+*PJ99>RBKC6J-E($O6 MD"9OVE/ \&I[*!7!<+W1TI&EB$B2H7$2%PLL:&\Z.GS+0]H\KUVHW#.=']/L:
M16>6ES33@5:GT6C)(A)-"8G[-!0_W#\/UN_>KHYGO=EH6OC:1T4(3VX"%:S:.C, M4C1DB!:XU7RYU7DSFT[QE9%J$=/%RON$>]U31??8"RFW%JKNC8=M\8P5W34> MDKL[7[%?
HGFW*''GY>,]\,%06]T=$M%EI:3SH/$4%XZKUB^R]3#@8)4&=)$ MF:W9&G@XFT?X.+%TXD/ M1.NI%A*MO+5>LB7(BZK;.BS4GTSCPOV6JO&/)B/V%$Z&(E@-% MS'>*G%
(O:NX^?VX^*FW==V!TD9,T<-D=I*N/HT#]%D\+++4,+;4R<=R7Q;TG M=O#L>LWXX TQ>D63W&=^WR:]R:4DL91(98;2V Y#H2WT K(D.W@3^B,[P.&E M\)^[-ME['+#KUC=;?
=F^59.V6M_K1_[@Q[T=]()^9$?888.&/VZX8=I:N_?[M;4LQ\E^*(39;A(6BF#2N>^T%86H'P@N]WQ=AZ_)#1NN=1-RCTV!(.RB;O#2CK*71Z+PH(C'^+P6YX_4*]OLW%DWVWBP*
(^):$$'. M^G!*9KIG7%LW#&?9::XV6CKU(74D)@Y/VT)REWU9? KC@R:"'=+RD3Z>1GCR MA(/XF*,B(D$6934SY1L8Y#[+'SWF5]DV::4%2X&/3&AB-#'7N'2^IM8&[.'5I'P5U3W31\H.
M\=7/X+W*R> U"[R#S1XK?R78I9C\)HE695F=H/7*FMIM$=$R09O1K(?;E.9 MV0W>C&L[R*8RB<%KJA*2]:32KRJMW8RH.X(SV:W=C&L[C#,Z+>#01 VIB:?X
MN3!VH;@YO5&46ISG1M$&(PJJER5\IP%WU(+^S:^T7'=6I+U<,X%YFVR;DH& M>RS0(2=-UQ,&]M2-[#$OWMF95II_,.:>*7K7<5-S2DJ I25>@W MQ%E9>3Y,MD0:D*,G?
RTD*<64W-1(PPT&L\EL3%U,PHJA.W#K.ARR6CI^.D:W MA63]?VTTU_'@":,GJOHV(%B!(N\>HZ9E564:"=/TTB"J9)[/7-T%2E55;G MP?IUC5<;ZVG80M*1KAF$]?(>UI^?
H;>D!N<=ROS)-, C>I;I!0NN1_[&O-@# MM1*/7%N4+9C$^E1=+;.HRSATXX?A'8YZPT?[-:N$L+,HIJ(@R^"K,PR8@D6S M7J6L5XAJU.6\7>":5S[&)U%8V&IDCQTQ9A4-
K=%2B;DH6<1-3BPV ?;S>T[E>/;KA/V$]31*HIOE#-R+ MN21>*!PIQ^3]C1Y])!<%_GA,TQ'Q"L=^?\R(IY M@W:M540=*?O&40%ORS8$C^4MG1]J(%,BNUFIL<#:F']X\],N9W_V-
M)1_R? M\8R2Y3[N!M>.HL!FD5T$LJCO[I)'2HW5FP':**$=+4V0Y/ R]9;< 2\") M=*JCI"#5DI H[>G8=$;3TI=Z.K#RER/4;-)1L5+BN5+-*5\8VE*%)\/I75A M:N\5GJU?
GX+/K>1"FY0- ^;5I D3(]-*Z1G-D3V>6"LF"R(M:*EK-,(A%KY[-C":..KQRO<<.BJ)_<: RC*2WUS[]@8N^2 [#,!:8%RL[M-+ ME)LO35WGZ_ZSW^WGEHWW>^/W:O^ENAMGZ&*%E,
MXU=<"NV(7*3H.RW.'&]?-@FO>G?7G;M^YUH@O_5[-]WK]B/YH_](_KGMW#WV MA=XWH7=/"/O8)1<([3MZY>W]0^=W\K'N/SK"3:]?'+4+($=&1?FI/2%[>]02 M32A\[U\C :\,,-
V31[&&=(0I#N9_$=5G_P+(2X>\3^[R"])]O"X)ZOPN83X M$,CFST(QXVR1C^V0&8[D2V+4Z1+OS MGT5)%Y1:V:*VW4J^T&3KQ"FE[IS5GAA=RB#NSLNLCY_):BD)GI GNC M
&/AEEPW"H4.42G.Q_%"@9XL3!% .$6ZW)%74I.E!'@MA6N*R1B0^U5#:7IT M]5B0G31U%* .8"<7[)Q(HSU>KP+R\M5?D=.2EG3"^SZ*ZWT"/:=E"LO:L2Z# M.&%YQRSO9
Y8K4MB7,"N[3G7'Z#KQ)M!YMRFTFC1D9OD/TW:['!RV-E9 MP#)@>8%E]40LJ[3$73,U)"5400.4 H V$[$]=SPRA@]4R\]"Q9PG]U
MQPO*M['GC"$"T%YARZ$R$!^^,W2D6IOU@]PTJ#E99N_>NO-FMMEH:4BQ)*2+ M'W_ ^$1?-0WZ"K;% M87G'+R]CHR3E0M82I#E%YR1N*9!W/3C_2636.GS>RQ)'N9FU
F7>\;QK3SW MQ50I.^'\SU_=,3+O%A9-&8NFA71K3_=V8'N+-X3.]5YU8O0 (KPA(FJ78PA$R+[%3*&MED2*19(E(5]$W@#C1<8H:>NE)IU7;B- C 3#U2-26#1F>[
MDZ32$2(I:X*/R^KD' HI3E$QKR$?]&FFM]P4L];6!H&" #M4$H(S77?W;A% M]3'4^7XVQ&+/\08,^31?IU7>'[%'AYFGK$NR;2"14:26$)/!>!PID147APV M&RW91);.60G_67"X%
;38XK$0A4USL[HG 6'=Z>AC0FKP2D"&7VIE%X<$%8C=,-; N/C$P%'Z.W,'HDIX68.Z18"^E MQH3(%Y8R8VS)TV-A?$,N_DLU?ID0[/,Y."+484X&<0E/OP0FZ*Q?M&T!9*B MY-
7=#%!1("I2VA['H4)OM"SB>.I(5#F+, (H#K='C\,$[7FI$"TA(5',J^DE M@*) 4*2TTHY#19QJT@P12CI36-.U%#S5[J8\K35BCEH="["=(@Q5D1]FD+/ MDF\#+G@UQXK
A2K28VN217;HO646:9"#= F#P (Q# M[+)"D"'3E@2Z3-"QMZ75*?6OR:%"F<=5+Y-;ZAM3TS+\!D)?_& MCO!LNY[PB3)OPA$I4[LX >.W:00#V:!&[GDF^FDE7#D!Y% =."NLO1!'2
MZ38\^4BG60:7M@TG;X$T/^GIAU4^#=_VX-H9@>N/5ZW M?/%D.O;?,!:>XJ,$ J&25VF]1DVU4ZGV[35AE8>=^?&/>\HRHI*^DP_3P^O$ MP?F-<)DIL\ -
"3&OB0;SGN_)@_G.P;K+H%6S&M)ESK+V-05."39O)3"\).U=+ M^_K; 4@*/QY8!Z5B4:4B(M/@K%G36> E;3][C@"CT3ZX%E+V'C\^KZ.+<5_O MP3*/%]WR8EL/1D?4VN"C4G2PR-
"YBZ[$) 6F#)V&77<4&F06IZ3CQ=4](0B M0VW"F >C@28R+ -9I@8X L+AT1)FT&!>#0Y1[/L*SN&/D'6F3"",>?T66?^>'FXYVL$%)GL589 MIBPC3)'HZ6UDJ1)2E;S< M1D!
(Y6'Y[LDK]_ 8'=IHV M693]C 6BP9YP(/A#X6IL$Z^J+?0"\EQV\";T:5P\1,*3';H#UH'#<<-@;7L?LB?G6FT5A1)A&B)5YSS)*6O#&
M2K]2]&5>KMEHZ3(R+1T9B;6S_)Y].U7XJI7"URIIP?G UZ 3X)2%!UN_KOL!'W-I\2%8+SEH.0F9?[R8B\?Y*4 H4JP=Q)=1IEA/9*ZQ-G:3M/I^6]SKFJCI)7JC11B[&;CD9E0= MB#&
(<5YBK.8LQKO"* 6L8X<8FU2,I:0SYB#&(,8G)L9:SF**YQ4P#]VB[%) M&^Y<)!RD 3$&,3XY,=9S%Y]=@;4"5K)-H9@RW8T3SF(?5P1:?2/7>E\%Y 7R
MUOU8*AV9V,&SZRTV/.*'O#=H=CT'>Q%Y M2=%WEONDNEF\SPTP#3)6=OOT.Z#MO=&@ZYW?D3GI]#0 MK,/2B.Z53Q\JC']C=H=-7_[F>K8WH#VK M^Q%Y@0U>N?
CSGR1=_++YDG72VU"%Q9P:IFR?) Q*HJ M:Z8E#31LZJ9F/3FZ\V3_KTP,AOF'1N_5@5/[&3>? FS_:-I#\H"7]OBG_192 M7;",9P+F^8(LY8+@="O%5I&O),&^]WMU-
^V\=H7M[^_VN]_A[MYZ%]W_G^V+WJG[V:2$G"J][=>>NW[D6R&_]WDWWNOU(_N@_DG]N.W>/?:'W M3;CZO7WW6Z38?,A>S"?3_+I?
4OZ)4F#IM#T>R0XZ6/S]6.+38=YX>2!Q_8T MQ)>+7[XL+"_78\MF'_JR2E]:!OF?I/OB]^>]V"+:(.&1+7PW"J>?_%<05\0 M,GQ.>%V^4E\2W"U?_BV43-^:I4Y%(O%%';1ZW\
[G3]SY?]3M:%(26_ W.+$P'>%#]PF*Z7N*G&;[VW7:78]X4LOUA)]Y M,)A-9F,6-:!#*09N=!X/&X]]6.U3$!\O/-WG?_0C&A):*N;[B]#Y8^9&;Z?[MS*O'0H7%N=
35F,QEQ/X6G^CHLJK:H2 U$9+C9XI#@L=:8@!SVOU3 D\/[2$ M/VV11F65+&EI\M4>V]Z %NX3>VV V6E@14*"+,IRR=+!UU7I2WD.*VHJL4PG M+1:RGMLQ=I;(;;PQ/?
ZD3_X/\"Z8:LG'L]:RGG-9 MR5&!9"OQRE2PQWL]7EKD;E3DY?;\=179I!8YN^652>KKG+)A>$5";C9:IDC; MPR!YIQ@FD#"0,/XV3WGW./.*Y(H-6A*1E=!G'39.$&L0Z[UBO7LP?
35B;8F- MEFK2B"XQB4&R0;)!L@^0[-W]E"N2;(EXNQ8R=1.I8E*C99!LD&R0[#V2O;O5 M=$6239OXFLC0=:1#)G:?9.[PVQ3XQW%DYM&@"Z%LL?4$6ZL,K
MH"_0]P#Z9C)T=P^E8(;N;%~/N)_.(1)64H.767DJN3YPX(+02A*8K^"T:H MUF@9HH3(+X!/P.IZU/38-K8AE\P_18:$:[TJ GF[6$>3V M#9]H.]9T[>PT&-)NLW,AH%&
L3\L%1*&#/P8YP:P>#T:+? MG@*AQSKG0B!;?];T!5FH#Z^ OD!?H"]W],W6-&2](="6IB'W@3]THQMBB&4V MV:5&RT*BJ")3V_0GT_?]_" @/'A+6<3L/4 8_X")H. \0R]4!>_@"@;;V1

M+*E(4C:[IP$ J@; >L L?P#0ZF69(.!$5D+Q7>D(.(O2MWA4U6!E5!4-5$'X MJ<[Q<B2YO'EC+W.T7<%%-5*H07.B "VYQD3)850@NC$9+0Z)Z3 # M8%%I"*L06)A$71A(-
W)H&@\55RD,C"O?H[WF*";\H7#K^]Z-_0,+5V,[#(4K MH1>01[&#MWFS.<'U(G_^9GO]38B%U3GVG?'D4/+8-R5%T_QN&,Y6#Z;'\/E M8F\8_QZY3V/0>4#Y*ZYH-
'>GB9@IILY.&IV&%I8&X,48-G @R02 M/&QV:JT>"J"'CO"#MRBB]3;_N\;CE*:1)&F[1H+,;=71D^,@<[A:DA/5$N"! MRW/0.:$@H]Y0&BU9,8B[;'&X?
9TH6*"PCA]AW(AL5RF,K'N@D5!Z U#AX<1B MBO:2I4%%HWK;1*92[I.U@-1*X^_E8E;?CEFP2;D\C5T 3H;N*W:,_\:!GP01 MX]TZ K5V> %LAGD[O.00DB'\U1[;W@
+=@2'LS.E$H\:9E8G7;8E2+=[8M^5 M/YGX'E-J<3RN-XO"R/8H63+O:K3YCH4D345R00"M3EH+YO#!'+YJS(\|\EK) M'#Y9HB.QD275V\,J1ZAAGZMFG[L]OS+/?
4ZF.4X%:;J.+!&F4L(^[O< ?L< MA_-F99GFCI&BU7L@" @U"'5%0ITBGUN^4-/1/LNWH_)HFW/$0),2QJQ\$(02YZ>'F!_ M(+\&[B BM_[FQ_>#P^EI2F?388N_!'T!9W=2BUG1Y,WP*;?
&3SQ_>S>YB5=;5D9&6Vf&E#)B2K!E(32BP!6!P!"X0= M> (\R3G;LMX4!'P%,.U2P'6*K "JN4%UBH:,8:S*X3& Y -DZD&IR&*(D26SMS(W E'8I$%#59%I
MJ<=Z_M"JNY#PT.$]ZI9@LX)'GH%H*BCB ?)]^:!OWN'Q_?HOX[:H M-E]J)B'95)$D'=V/$X !@@?T/2WZEA-VSEVQ:0O%IB'1.HD>28#*O:A\[^,'
MS#T]YN8=/\U=Y>B@-1@'&PH1\$5T!?H"_3ECKZ9NN&H*;OAW ?^T(WHM-;, M=KO1:$DBDA0+R<9F"!3&!("$\4O?'/I-;83G\IG4I,'VK/(E40 M@*IS=!P2GF=-7Y"%^O *Z OT!?H"?
<^,OME\CY1S0YDQ>[5LRW8]8MIBZHW< MX:@W?+1?,WLE$FVZ:R)+/&8* "CTKA4(<"0 1C\ B-EN*H08-#V]S)M?P^X MX X7*:-8A>""%M(K$M(2#LN6#HRS*+OZF %-
CYS>^KYW8_ \[.I5^MG4P77 MB_QM!UYHX M?]5A-5H;,D0+:=:FWUS]'G:B<($]_XI$,<7,N;+$41-IK)9L@RRR.7AQ/%8FI:DU!FK19ME6G(XV U4]#>6B5MZ%6C!-:WLX.R-
2ANXK=IK_QH&? M!!)EJ6$ *+9#*V)K-\>5/)K[' M]%D[CADUN>OIZRJL M238'CR-D-8V;JI2+QMAHMRT*&I1*\'YB<",@6R%;I&V;*$7^E2Y0N-EJ* MAB1Y<[8,
]\4@SR#/.^0Y10:X?'F6&BW5I%ND@42QWC,/0:A!J$L7ZA1'8LH7 M:C;W3Y%D9&FP3X-(@TAG$NGUYKMCXWKP RY@NL-L!?1%HG3,5EHIW]_ MC\C/'OEI>PZM!9,_3IEW)Y.9Y],^
O84S\CCAD(L $+W_3;WY#90/98+S/A+ ML!=PXB:]R!5=@ Q<*9TK(>GSF'@"G"%!ZYDLO]3G%K\+;#)1S:/:C#+BQE> M5TMV5V9C7VVT)"0K)I+4HV>X [1
X($KP)7:A6'6>WN4KX:U76[X3A$7P#5' MN$YQ**-@7.L$UZ:!-/$D#K<#JCE M92BNK-@5-.)=DB5-:1K] 7V!OD!?[NB;Z?2'OGX&,_<1 MFKI)2]E464=B0L< F#X! L8O??,X7I6RP?$1
F:|@/$,@/5H8>X ,$0ZI5JR M%*2(FU%N $#% -@(K.4/ *G1DB2D2Q:=5%T] LYBD$_2E&J7#62" %1Z-O,G M\="4_*SI"[*P=_=[ISY;NX0,"&)!!'H" _0%^G)'WTS!Q=TE!44,-#5DZ@N;
MBH8,:[/=,*""@T*3/66!A:!"V84*,&3,'I*[*_H*@:3;:.FJB'3-!$ "(+,.5 MXQ4"2*W14I!JZ$A5 9+G4F(X\BAUN@0:$^Y];I^T BX@B;_&GJC9*A-(-S:U M&:3&>? ."YT7N D'@\"!0R2
%CJBHFF+&CINN%]1^LCO_",5"'@3_Y2!9$_L?O[=^$3W=^A 5)VM 8W ?Q MH?83RJN 0B +=>,5T!?H6W2$?",FNN:P3+SQC\ODZ0E=;Q!@.\3?B-4PMR6Z
M"U.BZ_5G3Z'KN';PEME=T1HM742B+B%#WXR.IO=8 #(@DGS0-X? :!6"2-L1 M(DG9'&H"0.$BV+2G!T$5D#'FNEM$NKPYBAUT-Y<%T54 A<[W-I BB4B23J(K M)$
U7^VVK[|"%:"UZ'D30Q.1)FUNBJ4KMT,KF>?]2Y_\+//(G&RU,4T__XB6Z MF8RUK_;8]@98L"/H)9HZYZ('0N]BE+(6(>X>%GSE3R:^Q(V<:UA;Q:%D>U1 MLF15-
Q:M$5*01AQAU:SWV8U\-4^!PT3SASQ_JO'04;/'T::N:B#)1>=Q8+@E M$6V!%&W3ZP)%P76]!/;N>ZY:V MY>Y6 7EMN9OZ0"'ZP-PL# 9-)H -$$EFD#GT?A6J:LN(=F0D)70JQ74!:@+
M4!>5Y!'T/14N%2L..LI2M) LBTBQCLF8@MARA% 0VV-W^11GOLH75IWUFS,T M)%D0CP=E * M0%MPHBU2G- N7UM8Q+@P+:2K,JB+0JLH^:K=@ZO@JO17 M ;3AJA.]"J
-5YWH50!MN.I$KP)HPU4G>A5 &ZXZT:L VG#5B5[%H/V9A6) MOX[!TOJ5_%A*%)*\F"5;N MM?C0X-CHK+&(S;(;7M)#[*[9Q[36%/^KT7H<8<$>'T'GWMO?F>L\";?,8"G9
M7O;H8"C\'-AC86H'$1TE%8UPB(7OGCUSW @[PI7O.=@+X]]85-:F+W]S/=L; MN.2#_8B\,"%/"%X<2;#X%9=^7T0N4O1IE"<_X/8UO/TF/ MRP"/[6"$'WKPZ^R42E#
MGVV08R.5QU9YV^O=W;3_UA&ZM[??[WJ/OW<>VO>=[X_=]WY=,5\V":]Z=]>= MNW[G6B"_]7LWW>OV(_FC_TC^N>W8YA?L5*![&7V+R?#9N%DGN33
MN_WQ2Y(RS.G)F%7XL6&P_#-YPK$]#?'EXI^K'XMS9JOI9_9 M%\9OSW6N1;8P0Z)J=^YIS;]XKI$OR'-_3GA=OE E)?$M\K#_Q;/IG?-5JN@,W.H^'[44C' A7_F0:
MX!'V0O<%"UUOX$_PZ3[_HT_'R3 QGA?$_D6(2V*%TWWHNY5Z7F%1T'O">BQF MAS)CP_LJJV>>4\O8YF78< MTD0-J<8IG?
*%;0ZVN=*VN=WB6E3K8$54B.QJ]9YM!5(+4EN1U'(X8T,15>IV M6LC2+20KL"&#:(-H']"2UUAOYL]32UY%I"UY)1WIFD&L;CFWEKP@8B!BI>V> M'#;)5T36/E :(-H'R#:
M'+:\5T23&,,&,B4-*>#P@F2#9!\@V>7,KLLHV%:CI4D*4BT)B=(I#;@K1+(S MUX4-V?]XK?U*)CM+5S:?;-K.@7:$P%YHS\%-"$M[/PB=_OV]8'O.HOZ70!5[M]*B]
<#^V/2@02X\&_I+CVV31E"7Y2T:13(;_444.0-]BZ0NR4!]> 7V!O@?0 M-Y,IFF*HTF^!33[B7,\":JR21?G./^SQ#@*@MD15TME1+8351*)IXET2T&2 MN!D0U!" $)]SYJ^QWOF9HI14
4K.6F7DJN3%PX(+:18PER?/[2K6*)@K,H$ MJQHRK$'GJ4M%8APSL<"6,_M#"E86(P&@48"Q/RP5$H8,_!CG!K!X/1XA"I"C"'].SG3U/E:=(FX[VPG0#H M6Y\8(? *9 'H"_0]0?
IF<_[6SZYM(W4[^TS8+ M?#(7NP,"0,)]%5Y9CP#F+V$:2!C7"$@98#L" 7JCI8@2,G4-V,\=^]J%W.&H-WRT7S-[(R9M2V4@2|T\] .8 MX*&48W=-6B&8L+9CX@PK-P"0NP-DQ0-
2%ALM#6F:"G $.&8K=2L$CA+1C[]" M-+'>S2V@LBT]::]\CZPGI&CTA*M[WLW]@\L;!E;1B>E^T(Q\]W2?57MN4]CW,<#&'EW"G@LHD(6KQ]0$,
(%8=\511MT47KS0%WG2@I3RFINY02 ML,FKKD0[#C2':R8M63,!(/@_'GXX##*J#IU@1$2:HB/+%#GE[5$#U*.'; ME"^YT;)$D"T^PP0H331]2!\>7JI"RA@.&OZ@BP<$?
Y)_L_#V:XDL;WZW>1$>< -;@WT!?H>$$EX/[I8GS 1,!>8"\S- M_:QT"F,CI:%H53V-0|%0XIB>M/2L/0TQTMCBEB:I2/!P1-^/ O)-<]P._# *
M(61X&NF*RANIDB6SM[*'2+1&RY)49,J;%?"0Q^+ H2*#;YKE.^<\AR MT"M02P7T/6GZEM2,_]T6BT-!E]HAS"TK70.Z OD#?HL]AEZ'7S'>])EF; M1R#K%*$
4)YP,!28RUGCR,,UC@4:)Y^:RR<_<'#0C/SII4@?4 C]L>L(E$Z\ MQDN3(?O5'K-PJ1T)MW8P& F*A 19E%6@.:#@-KKKBW146.G^HI[CS(E%D=$ M>
],HC&R/DB6KUM+$1DN7D6FH2%P\\?,C=ZZWF \HZ2X]P-Z]W84!>[3++*?QOC13SZH MD5FR)2+92#9![#F,R,,^Q^3&+&^?HXWZ+ W).L@#;'*PR1VPR>T6UKPVN4W)
MI9T4Q7H[U"'U(+4526V*G&+YJE*3%-#1)*I(<6H]XEV$&T0[8I,_5LI^QM7 M).1TY*LB(D61D)10<9?YF!J(&(A8R;NGM;M-*|@1$L3E"S:MQ5-EI&D*.I3-@F40;1!M$.VlHJWP*-
IFHV4A4R'[M@8! M:!!L$.P#!#NYE6O%@DVKOC09*:9,_CN)63]%BO:AQV27UB35HB LF2$LC=E\ MLD-,'W\RQ5YHSW%/'D^(1ECH], O!=MSA!C# @$Q|B+W!OOW8|N#PK$\<,)?
M,KV 0PRI1:;H8F/@2XES_;X%-/K)Y'H.93,QB MNEHRF+*:Z3KK1FU*"I+%3?\;@,41L$#8@2? DYQ#)RD:T!:L@*5="KA.41) M-3>H3G'LHF!4RP35&A*5>@?^ -+
<0#I%D77!D%:8HI9-)*L:H/KL9\K 7T M!?H"?;FC;[8C'"EGQ=P'_M"-;H@=EMF>5QLM6:7GGI$HP; @D+ ZT3>/0U+K MH<_)4P#">,: >MAPOP1H#=:JB4A0P7V\\?^]9!:_NPWF (P-
)/\IU:/@+.8 M1=*+1CA@190!'F$OI!62KD?^QA" 2L]F_B0>VCF?-7U!%NK#*Z OT!?H"_0] M_!F<3XD&C_9K9':&C#W0%F1*/,Z[]#XK" MJ_$*P82U'1,UK.D 0@95%<$(
U:D"\A\S2*00&/95;!%8)'B2A(0T.Z=!*E MG 6'$/F*><%5<%7ZJW*82E./%@1[9]) V>9AK?I/N28|N5&_).YNA)AGIWY# M/N&)-/F?JR@0M_PIKV/Z).UZ^KI*:V+$B<>>I89RFL-
H3J"+!^QO5&AV|P/- M=7]33W42#6QNL+D5O;F5T[=W4VBU4QQ" P(+ ENTP/+8C=?0Z?P9"5F6B313 M :D&J3Y[J*-"+?DKJY:Q\S>@:D"Z2KZ#TS1;N\
M\F7*;+04)&LZLFJ>LP>9!IDN7Z93=& K7Z9I59@L(EVG V= JD&J0:JS276* M#G2E2[4ITEDSBFX@0X>(%<@TR'0VF2YGSGE&F:,EB8J(1$5"J@4[=2'GGY=6 MI)"O=?
P9X2#7)5XP9::24Z,I@<)?LKS8[MY[A*;$KK' E7*X G)WZAP&K@!7 M>.!*-A-^O:M>Z5VT3GNHFT@SN)^>9R6VO"L\Q"|[- 8/+%R-[3 4KH1>0![%#MZ$N">RX'J1/W^SO?XF1,3J' '/
M>"9K2Y-M:;UI8$*!:3<,9ZOUI3%^/J#8&\;_1^[3&/?Q@%P:N3ASO-QB!=0* M[0%Z[/DLR)D4"DD M?;M,@A1NY6&4XS!SN&(R$A43 *(&I\P/AT%&S6'2DS.*HB/1 'N&\S@WT+<8
M>S'%[('2Y-&B/1AE3099Y*/H8YJSCB5AA2"Z6Y5(_K|/IU Q=&K"L:7"UMI M%VS!.N7_,'<^2!FZK|AL'?A)(Y'G M3@$@((! W].B;[6AVGP4G#Y7<"?1:1'0N1>=[_$J8.
[I,;>D&&H^FL< S7-F M%=<$>>0):+5U&-F3J>#,HC=AB"< 7-*\|4(WOJ1O98<+U_X1C$P\"??)1G M1_['[^W?(+AZ&BDA*$ Y;_]"+-2'5T!?H&|%8;^)-_YQV7;^-0NC"?:B\-%O
M$T+0V]GC>]MUNMY5;#WTJ7EQ3:R+;_B T@^ST3(M9$D:E+>!] %]@;[EQ/Q* MTF[65NU6)[<;H%GFZ)]RH"FQ4F'3W.SO",@\>V16GJ3.)5-!0I6'5>VQ/Q66> M\W%!3WX4^9.-
B4%+PX3HHD)_[#I<3Z=/QO17>VQ[RS8$8SNR9QRR0,AM5=^ MVPI'9WIFBM_,O$|EIB)2T5[LRB,;(_2);.ZDQLM74&BJB-1KK>9F* J.603
MKPSS_.G&_ZR";:G9Q9L>2#3/=RL!)OXC?TS($L9G$;K>8#RCM+CW WK[=A0% M[M,LL@D5'_T[WZ-?$/ACLJ[G+ODJHCBBS.I"(>H"*2)HBIIE0V#7W;_K&N7M
MNFJC9:H2DO5Z>QG5"Q)LN;#EYK?E[M8 >6VYF^I H^H - %H M $G&@"DT?C M6R?&MZ$A1560JBJ@+T!?@+XHC"@9&YNL5['L:FQ2ON:@C?=H)M@TD6H<,U4/ MY)8CB(+
<'KO/RRD.1I0OK6:C)2-349!EU+N-%F@+C@0#M,71VB*Y8J9B;6$U M6BK9UR6+> :0P@-] ?]"&WTA5TH: N.! .TQ9':D4C ML/)U!9UL1^P*3920KH(OPFUVB2-CU.,*"/: 3
MYFWOC5!2H*>Y0\$.R,L>G;B%GP-[+$SM(**GQJ,1#K'PW;,)QB/L"%> ^YV O MC'|C?+'IR]]7 MZYZ3C>;K7?[M?K_K/?[>>6C?=
[X_=J_Z*453O$@6SO@5ET([(AM^$JW;_=^';3>^_^\+*&67#8*A0X1 M6N>P0S$ID;&U0/;<:*JLT#2GUE+"G$A:55&'O>2)30T|' G#L?\S[AOE3W% M['CB6E#W](5->#@(<7.B+#F#
(O5)D|S!S&A<(_BAG\^TMIR&-0@?HL,'*I+C M G-F*\A)5XYS'_A#-Z*SW#.' MQN1&RU"1J9I(3S@KG*9'7::M#M!]3NA=3QSE#U^ET5)T)-&C[O*^@K"$\ZY-
!20/[5[M*;ITSWS,EKNJJI:IEUE9T>-RM.9] M>P:[>\;)871WMIQ2]"LEZ-42/3.#56^TZ&D;$XGZY@ M'G;RD^/JGH*I?-AJ M4+9JHHC4'4V>TNBAZIONG)<%1B,
[4S::P!T(E/\43T_8P\0)$CX]VZ[W"Z%" M&++$6\W1(YQ\SLNBA2_3]XFI"O;,QW@H)F,1T[,0[TP.F\W7M<6\X?X&6'1$? M*+-(LA,/NK$Y'B+W.
HP.TM\H1AN6T0!B\A(,.>+BSOPK]UZ1&,%]%&DX41 MW A/CDI?U F]!6@]1LXY0KL>L:OQ'+59X:]P5]7T^*2H;8X&!#.P!#.P8/>%5D[EMPPE][NHCSVUTVTE]9Z Q&N]QO&_78\1
M^.&#OIGUE4RW)(484;*XSXBJXC8E=6:UH-)(9E(K*["]O5A>@X[P/%,'[JOV&G^&P=*$K^UI9F^9>7/ M^-=AIP&>VJZS2)>]M9JSM3JG[Z&^M4|/FVNR@A0YKS]Y\
[95BPBEY,YUH|$R M=0M)YF9Q66$A%?Y5U6-@.YB%2GSF8T_MM\,=[#/:;C-JK/9@P [PW M.A42F8:,+&E/AAA,JY)K /)GMM5H*4A2+63L"^^?EUFU[AHN!7?!PLHE1;7/
M4[B94_PM*Z95D2@PHKXD60*+J_+H8.G""O<:1OBL8$PHS[&C[*FO?-ECWK 3W"ZS?&;'=!_,7A[W8Z?-=)[X*.H N MKKT[81!U9 JJ4C4FF1/[;/ 5:6-*B#@IR
MR12_'MA<1L'<6=,X*:DTDH%859&E0 MH,N;DCN0Z3O+P6*#>+EPW#&<$ M<5(5G%GT)E*]OQCBP/T+QWQDF^]M[WLW]@],6V& _][^]5P:6.5U M8GP1F.@-
&=6O9]G+OS6=-@=1#5J3L]=!#2L*OPX^%Z.IHXI&47%E.IM4JVF M#?TI)4@HX%<<#%P:82(/BN,>H/&T7*'KT4E=[@L6[L^H!6@Q1A7;87LQS3L+ MDF=64V:C99$-
U]J3[@&#JFR#*@5[=^LL*Q^=Q;V?"@N$!5:]P%-S-K[.WN@C MT5#(C 6X_6<W/B2I(W_%44?F9GNB-D!@3BTKWK"-IVG^,] M;MMOVSWS//O/AD"%T;20&%WLYGSZ-S.K=$,2(!
@;&WL|+$QDDI9F5EY_>7J M\V'/K- N'FS?K0K@L$4D%1P*74X5P(F<+-FFU/5DPL:48YW9+XQ/\S1PR-J8 M4.TE1_.P[<#BQ\^4F?H^3I<3M$'W483&-P,GR7#J?P?BWUNH; !_&+-]
:4! M6_0=7$#'&(,;B'\86GKR@]@W;ZRQZ2-1K\" LEW-_ WV90Y7P.^X1L/RF2X: M?FVKN-+JG%TH U7N=]5J5?.^6T|;L)SM!%E-Q3*YIMSLO+O)S.M] ZZL#:&F ML1&"?
F#1[ARJC+@RPG2XVN&=I.:!1O>E88"$+,7ED\ML8;E!J&%55EMM$)V* MI;[?$&.5Z&-4G)]Z<.3W^G*WVY1;_34^:UVM_(:JE8]I!%WFG6NR-&+/AF5A M" R; 8G]WTLBHXC24?
>G%6-2'_)U0_*3L=L@A+M M1B_H=VM61 GL;GA62 ?TL _)*NVI65#/B?LH-'M834$K'!A/169P(/*R(M M$)%&'\PD5>XWU\S3X!"MA3CH.<&=;Y\1U|OH9G9(| M\C2X@Y[(: *?
BDOL$;P.3T9L;$]G$*]B%D$VW:;S"%:P2E6,_'VW>"P-IKP7 M+'5C!9'4K[93THB2'A8#J1VYK^X_)%(S^#MB\-7IAM(X?&5M;*]=I#;V[X1] M"?_5C9>+_X1_ O+.-.?9L,XY<$9@WO*K1\
[?HSOM[[HX6V#W''/*YH!>:<4NM MV<0YBE,X^<9C>P:+6>#)>&=C\8[FX'!%. ,_]]NQHIC37' ZJ,&5P"/ZP-%\W ML*'@TK9T' %$/Y'/I^''HK0-+GSTX ,J$6IL2*]F(YMB_!,#G^?!E]K=
[;:C MOGWB]H(9NIT&ZI"Y[1IDCCO,U+#'\ .KH7M3P2OQZX+U1=H(]A_W\N_9.\R MT&JN4X.TIFZ2&/%_<;6H>PRES3KJ0%+3=;I*&I_T!JKK-_MJX.1WM5'VO\]
M_;/@HFGH0,^U9W8^\B\1G?4=C.<$%(]3R"};>^?0@U MDB)A*CI"]_QV?W]W. SC6KKY]NW'W?W3[]??AP_7/YYN+A^K(2=5(A;0Y_I1
M>KJ7+N_OKJIO'J^O*?'^]N;J^$3_/+UYFYX=WDSO)4>G^"#;I=W3X_2";[G MX_4#K/[+]7>IW90EI:ET]L8+AU89'X(WV=/#"QI:PQG-;447]_B@.1N*10>\]A?_T^KV_S!'
MTAN\=YXUR_B3PF*1'P"_#"W]P0&/P?+HU_M)Z!A$?L%5&!U^@D=\,:E],G M.]POI3+@H2<^PP4P8TE"X&_B MWK2XZ)EX_XRG*JNLLV69^I?
O>L9DL;MS56,V9M\;3MS&QLSI)LHZIZK,=(O M4HFS6"';,VA3OYG-?(NFS@(G^)XQA@,1/%=I#-=@Q 46!O:X-#* O\=3"Y;W MO)"$IRMI^HOH@>0WP$$9G@T?
Z\"O+E7M6A.XB^5)OC5CGF012 [A+4],;08$ MM)V%Y/Z$3_"<^9<-OC)F.C#6X3:D-:L48W)-6 @\RWHV1?PY7-_$'A/ ,_ E M,K3.7IAI$XXV\OBC;<&O/XV9-
I(^H,PJS<^/MW_03ZW/'V6XJV7#%9+G&.?N MG(WQ7:2;V_-6:TC+I1^_PKM,C9%!$?$[S;)'MKZ QVF>--5<>NX<: >"H)FR M--+$>H! I"OOGZ]OE$Q]TSZ\@)&J^&&9 M*
*X_4+O\]G.KP:F3!BAO,/N"K8+&%WP'NTC7BK^+#1Q\%>'31!-RA9WGXTH MU1(Q?8 Z@7_^XH-DX$HNZ7N<:!^ ,74V'3(T>'9)RKZ-T)6:-0Q0'L6TI^54
MQPBGY61NW/#9873@2Z^&-Y5^9Z;QBYCE.O- B,* B,SDE*0?@[8KQ!8$U* : M>^AJOX*)]W4:I[_L='-9>EU:HRGTBO(V,0P MX2NT57A9-
)"&%AY^0EQG!=DLS@'+]^#,XA6@(;.3Y6 2@#'A20/L340V+% MP64?4>^X/IZQ_,09SAW#E%2Z7L%SY9G1L'E:G@'$=/V1:^B&YL "&VG&V=[S M.NJ!L>K^&WH>G$V'(\Q3
+'R0,X)&-@ MC0P'0\TX>M6T@T$/0\LK_C@2A=@#I>B)4O#([5P0-=,%44 ;!A1E@ M:9L7 -^,K>XN;^IJC^=(UE>'R;9QF&P;QY-MF<>+,"= >=M\XE7,+2:^ M75:;\]D]79?@;^A2/8
+"58AP!$O@#B6I_N%/M-6?85M-TX6C8>)|!%/OV7]M.-IBQPB\QU0&&&MP9_#M8$ P:W@M__QGV5\E/ M:;<;S4&[H::[X=$30S"+7*%5KW7KZ0U\,3A?7M W-HV9H#0G%%
Q\)OIQ,4U M_+#H*W_ WNCV3"9B?KN[_2/C_C)^>0Z6D TO?*MKTHA$RU<#/&Z$G M.,H8DF;0 MPAW_T7AL2+\-AP^AR:&A0^JAO0//&RWH-E$Z.J:AX::6KCG@U^QX3_A+;\.
M'[!$=[-H+4 0#)H@_&W(RX;E@&AKA=$6/)K"U_C]NU?K@TL-OS18N^SM[]DV^ M7X_G_Y>,_=HP8Q8CKT-&$"RM0 MV+;'MT;X:H3Y%!**'H[[:S+@O*S-A<<##Y&GQG#G^%Z
%A'F]BU\SGH6)HA M^NP;?']!M<\8'H+P]X27I_F@@\!VI'QR;!UH9&)93;#7F5MS&8&8!#LT?+Q, M;%#FE3_F.C%-=-&/R"SEE,.=;JRVWRIS+-QP(MESPQ)2#[?4GFG9&(']8Q
M\")LBZ5RZD%-K[KHOF-VZY)$\UP4$(C&T;0(F*$&#\%#H'&*WAQ!(S.FY!

**9,;X!4N+[ID5S;(<1#>)TW!8>1 M*OJ@AC0#$DU=X;H\HI; HX#'K8-\(RT4Q21X;=@'>+Y.#/02'H..>&[P)(QP M.4@"+$#B'A(2"%2 M+E8.=>=!=1E7#!W>BGX-OE^&3I6A ==,
(PP0(?Q3ZZ< MW:GMFR#Y^+9:H,/^Y5N\\HN4V,'|59+RN,.W34G0SD[8P^TMDV?@\4!<%YP2K,\&K-.\Y\,K)=)N +3".1^]" M*-WO7S,C="8#]T,$]\<+BCQ'=IDLG?
WVY>&,7^'F7Y)G-(EGPW_:W<[G^*K. MKGVL!URSE, JR@@0QQVNHHQPT$Q'01?]![?EKV&AJ.[=';RG'PA9&MXH\]DZ M&8YG+^T05YNL:STLKD##$S#'A4K9?
9'U$L3!WX5L.H,/8U_^?KS3'3@!A0F MQM9:HKZ60K\!2OPP$F?WTLZ.^_6 M[-<<3R_A$L3S71NMWF$F>Q'F7IP$5#B(LVL^K9;*E6F<=UB4V,LO2JSK"^OZ
MPKJ^L*XOK.L+CT^9NK[PI*1MJ_K"_*1,5IV&2G4:>=>@Y9Q%*VPD1]TJFLC. ML3/N$Y)DG>5\WNH?S7 F%ZU[Q$']+)+E:G09APNF,CR/!6-3KE&>&>>#I?([#
MF%RT5EVF.6,.DQ.OI2(K&%@!>],##_OFX?M?M=G\\U48+YQ24$723'B0Q4-) M$Y^N\5WV>9UK8^0'XYN>]HL[P108]O?I:/Q(P<4DQB/
M'5\S@_B(Q6(A99'CQ=R2B*PDBT(E6#S2MC\81@JB)[@ M3G(I)1\&7^BHBN(O0,T7S3%LWP6E-O9LQQ6YR52R9J8M@JB[+(U\+TR*!%EF MSY;C(9LP_]W8F/-
%8\6!]S4@WIE";35LF<\NJ@;7/?BM^T14.&%,H*P M#3^9)1lL//F,[("O:+]:7!6[],:)]' MP<::XU F.]3S>5$SGK5")_,2)B(R EJ8=H$TT?:'#,M\.I\/BI9%Z[M.V,* MG?'@%[4?
H,2(W2#,!>G&Q.11G6E$?-:>,7F3I?MDH(T$;NSYE!0FXN3L&-\C M)R./1?F3MJZBK($A%FQT"1$3ZX3H*T/R44D3%XOH"4&P9X3XO**]_ M'-
B/JR5,;!HZ)GJ,$=.$RC)X58[.*.">NWN\JS H8E)Q>Q7C:/ MYK/G$O>"%'.=#89*0FEAMO.% MEUJ!'4JY6N%08VFF;7*3,O8XRE3S^S:P%R?YI&7%18L#16GP(Q9L9]!/?U(4
M!0];7G"&A4.X8> >AMX?(C*.]L)+@N3[G.'S0Q_EE@,>8\^WBLJ^F5DP@;O M!\:N)\V M[BZQ&9*_;$I8<8;]+^*(CO!7>A8*"!,_G(DX)'!UUL#>E;OAI'
M[V#-5J5W,X/N3\29.:]I(%R@BR-0X5\"_PFDWCC63.$1S\8!0:.0T'9Z;@T% 49C@\')9V8M*9@-!.4F&&])^AQ^'1U,BG(L] M,#Q31@P198E4Y,8;V";*9N%>PX=P#S;#JGIG$;K.6*..D["
<9_(]ES%@UD. M;W?&!EZZ;"CACL-^K UR6+BJ5&L(J9]0;E>]0]&AVN$ZN',%CHO@F%)P^,: M5G,79_=(KYW=TROR>Y[%ULI(Y]L9Q+AX%!HN3LAQ*1XZS^:A4V,A#A:0K\;3
M.IH91,>@)C+/Y0Q4A!U^]7$]NA>;@\]KG("PS#&H\!<%5(:3X3UK28M+&\,B M>&&$3>,34@$DH M5;$0JRY1JTO4ZA*U=(E:.[-$K5/UAHW":&86[EC4P"I,*"6]-UP?^X0%D[<
M%N_%;XL_17%AY53CPE]CG8G8NLSM>/*60Y@OE)BC2WC99*/.3G.M)XN&&Y_.2 ,K3R>3HX*O*E+9&#<:X#WOY^U<) M)$(&RH19D+F#@&ZT#*IIP(].HJ(L6@!'Y"1Z
MM?!T[6H'$ \P#+OVI*'.2T^079/9!X;;A[E>W^&=N]%[:^0:)Y<]PME$L TN M""5ZR%B=0L_%D#F/ XT=&(]55'S#>$);W"'^#C*O_8#[86WBS@SB*F$@A4X
MN2)NI>GX6'"57[@S;44X@+'[-F"3Z442;_DW-Y8%0RH#+S[S!F]:_ <^N89: M0R=AY$P+^&7&-)?ZU<5:.;?Q9\67G04\N$M?:64.SZ\81:5\M_2- MTV+7="K>D6X8N]|]J)Y^AIW2;Y?
09E]!G"M',>2IN0@>(Q:O'3Y>2GVE62'' M805?'!/7$/1?%/$W(N#'(.\)K,FX ?,:H1V,F?$B3BN&S?660%8%29]K!OV! MJA*QMUP+"P07I&,PA0CF BBR6.%B6+C'E2'-0@'5
3PPD*F640P*FK:../2 MJ1@7BP)&7K0E %ZQ;M.:^QXITE@.)O;2]J<'[UN79^]>GGV+6R.UZ#BS FO# MY _9MM!|)/'A*BI|^XR73GTY52JOSSG;7-D+4F[B'350VW$07#$M$ EFY
MA:CF5NU_GV"&R2JH,7-T4K"^!%95"85YB#62/!;6/R]49>&8*)^S40E,E$[MDXE*U:8SW5X0[I?KM6GN""">K]1%4JHL'KA9(S@K4!\R>2\>!+F0%2B?\L/
M/BQ115YOD\N1+D*8&LS!ML+%/W$H/>3^9PICBS YQ+H M-^&-8UAN/*Z!F'Q ,MMB2U4R<|_!T)(K0"SM,5\)2 1OL E09YA+12I1: F>
M0"P#GM7)^B*PO'@(!T]#M:*)>OSN#>VA7P$-WPP$1O9TL-[YHJ(>]HBD] = M"]Y3EBQ&04VJ8HDUB^#'O+$Q+!#4V1S4N:'Q*-Q5[#>:WA$6J4;%4Z"[<07G M5*_&2Z:BD1ET&
(@6+[R*37P37,\7SOH)&L$[C\^-7^=30P>+YQ/N0_?L@OPQ ML?GHA:W>>J6[\>;_H+7<&A.6F,N*J_BD^\XK^,,NLR*>Z)U=3% 3(.A?"MRZ ML:Z19KYB8SAR%_6Q9
3H]DM,MP:U4_\0JITPMDB5.1LS"@4F#5N]"VCPGV/ MHQM1?E]H"]LRGW-@XJ$G\Q T;E8"K"+\%-;I8^>O3YBK M8[ZAGN<8(Y_'YPEW-V?1Q J@6&!=+P8&Z:+-

'(Z.6J;4:3,2-.FF$I1_FMWA*#534B&\8.=JQ M""3V&A1\"U09VT> /"/N5676:S MF?U!6(&8<8')?._NUK$;X^W9(E\(Z6^O(M MS5S\R'9$;1@/7 $[,W(G@KFMW%\-2]@(F"4:&A-T<+UPB'##>K')@@^] MC[C;*GK$X2WB<]+R0*XX=)+.^&S8".DO_H8CS=0(3BF98^'T3>98<(Y.'$0)
MEH)5(AR3*6I.R\5BRHZ;OSISQ4;&WH!&=&#B5,Q!X3!0YB($@O*BYP]$)TZ? M=?!,Q5(A>*A\P>!CO/ST?BYFY-U0)2_L%48#4[@7@PI'?8LFF CPD0B1*,3= MW[C&8^K8,/_H)M M \441:.CE1/E,KDR0I@G&N\FX-N$%I2T5YJI1+*);=) M# -#&$%$"PNW*> ;JI6,*DS> *TS1%R-:WBJT R*#G"Q8XY2)V&YZ(I"JA+' M=%9]BX7R%V!#-' /GO.R9KXSR9[N)72M9X?
&F(>YBB^F!CO\.)[:.'U-W BK M1? +,UMGHB9_?=6C\&([32C'10^\$I',+WBVQ6DBQ[@'2!'[]<7&V\411E/9T,1]L/[W?((E<&"/N99^7$5 MW#2$#ED85):>VBB\#JC%&Z=QSZ+-$]5S8=%R^L56+3"<"A\; $*;7 14LSH< M3K+Y-:Y^!+,Y *V8O@02)OA#](@D-CVL#>6Q5](K<=Q?L07+JF;$R([$3#4- MX'N*)>P"C,AE3H)M#%4]F:
<.AX8.356Q=_%K8G4D\6I^';;$6?#'1KQ'+!=_ M"EY&S!;5Y^#'R2F)3P[QUD+ZDSGX.9@\)*L=C22N2@0A9L^D :R/6;/-T=$CH!A<<-LW
M,C*P*R9J%2%O+AHN*7@P#S0V&O']R'!*K304;21@-,A"UD&4<6*Y94MS?P2$ M#*K:@KQ.G UJ@N1 M<$H[YEF6,T?0L4YYI:5/C%?HT) MA4GB19BHG/@\/^&
B5@5&*",5UFS8(ZJ=5[P@7#'6. I^6#$"GMAP$&A?V*Y MF7?@/@.BFB=N$.CC6"5R;% WM3,=3OU4I32*+-C &/]4+7>651:>>>:3I.:5^8)TLWP:+]9=G1V4;5\D3,EXPB1?
BD0V.&1.IQF2=;=Y4EXPAS-%XFL3$ M&3#EQ BSO$DU'!,TWAP&JZ(Y00UI&(LS8]_*X<8<",_V4L,IN&%IS/05O^8 MGXC307"XF*?DB1>3&D,UPN40P>MDB#(]D OS\G
9SW7&0)$W)7\8(1*FM,6S MQ7@5MZ;C'K8VGYN45X _BUY&VG)X1*&0AQ!'AWU".PWOET9@5\Q@HP7I<)Z M/3-(W MKGO"!UK\5X0$+LQH7%KZ)V)@(E3IF]"5+A3ET,;
<>79'>![KI$L)U M86R1LJ96LZZ,K2MCZ\K8NC*V"O6?=65L71E;5\:F*V/5S,K8;M5=GH*>(TY' MP8@ \?8ESAT _X>1P"@B4I9N5T\RFN1%7M@#MTKU['L9B0
MV%)LKJ8WM7)'M221]^F]VN$%RQYJWBI$N1&G']//-0%R:OD4+T(DW9PK M8^4Q$7Z#*+-%7TDW3&J)WY3NX=R;O%>*MF.+U1(.K#'AJP+O1HXA<6[RACIO
MLXV]Y#O,@*!:N+BQ! 66@%JC1 ,P:A9/#C,3)V* OZD-S-D#.YB%A%6QW MSR"#ZX&H;8=*J+;E,.LU Y>.6?! MK7< HHSX7N,V@ZCP3F[G+%?!
(0NL/Y(S+)9KIX?]%8=I)4IFHM'9$5G"?)H MC$Q+<[3%W&N!')?(NF-XCB!ZPI&/<#KPT&(2T2H:^Y@L+R+LHA">>!P1EV*2 M/!
=4E1V@ZJ6^AI!KEC2<.X8I*0/RL5NR],VVK5NLDA[^ MENR,TK#__SP"(PA[EZ0/WI1%0PS/;^DK<(/@"V*VU$=>-/>-.>.?TN],.[WI
M&-7/'[]I0UFZTIP9$$GW9.DWAA!*"^F#N.>WW_^X^BV\"2Z%TX4(IFA;S+1_ M&C-MQ'N(M%EB08^W?T@/_//P%KQ%*BQ+Y\6XN^Y1T*$%Z[MY^/Y7;3;_?$6@ M,
[=_D"7B,$QP8L4PZOYX*:'F9G">E6:Q.C^VH1]Z.\@0[TM'1%HQB+0#1H MY.A42PX5$#QIAM.Z=R71\PLL#MW!3/(%= 5PF^]Z GX#;+%Z'+;(YOBN]
M_9(,1FT%B04:;H1@0473B7EKPS@D"-<3P:1JG+&*ST=>RGP^GNU9X!]Q:E V M!;\;L] ^Q B/4=PE^.4I?P2=1IZ/)L4%?C$=26OH"1D8ZI!<[L786%BZ@-6
M&FD<^7_!/*]>Q=2)SLL'&+RW/8.S")F%UWR MUZ-F C<0,U=H*"T"]J7/[PA1(L==3CF84ZV M[Y]9W]0"N28(8%OW0:H%L=UXYW-?X'T$* ICENE"D/>"\$%DS8@4#VZ*,A^ MQI
$SO+@\Q<06GB$DR;?$(K45ZZ""L!VFF1E [80_0B<:ZOR(2/EOD]F+_* MX8]H]"K1.+HN*2/O"+'N 6U;(.$P+.38!=B2WVQHZ30']\'&P3.>&'""6YSY M-
U+.6@8XW>!M@=/EEM[,Q0[DU#)D#%S!J16]EEJAW)$X[&(-&]2VU?HL?0_W M7_K"[13W2$DD6F-@X2;Z93..BXE/]7MHW/GD@0>I-$UX[Q&]#?]F47=3(Q@4)@ ="><8?'9/$7LC1
M2T66%)XBW)H"#1E\/: 6Q[7-*D6'2US; E<^ZA,0I @0O0]>#8KG".<_V5;% MK&?M:.B1XGX%6@=@08KZ-EQ;?"GE%\6[C-IMI90MQ--P8Z2,%D1FGHA1I,KH
M&\$X;CPF0EV80'SQ1%0V\C^6'86Z"FM-%5:KKL*JJ[#]*JRZ"JL*M49U%59= MA5578:6KL"I?;[5=#4, JXL3+%T^4 1-1S2Q,<;N:88I+-"@#2 /$"&>]8 ?
M%CQ$VI"&X&5SNSSF7*.+0$-WH[:,3%=$."#+ 78WAO4B+@\<^@#FV^;P+0Y# M_]&-#&)Z,PKTBGX'<$'\<=AW(!Y(,%SHOP39W.!2 9I'SA,-S^51@@P2YO7# M"
(0[TZ*/Y)/LAZLN0-W1J:=L3%4)04%$7%M, U1^?&N*:N1EXF'_M+' 2EOU<$P19BR@(=U8 M24@9T=9$[Y-U1S$^FX(IIFN'^*"$]! !GQJ3U2_$H0;I,S'_CN>3\!'E(*,5
MQOTY$C>'Q26ZS?@^B3SK0O0H,LZV[MJ)/3^'V $&=.4'?B/3Q." M_<%$*ZCC!9;[8'R4KFQG@K]P#M4M--M-X$F_^,_R]+CJ^']R1P3C[4/=" 9 M!&HT64.
<_PT4Q#*5.IM0B8@3#/0I3*0P@KQ7.TTC3IF/,KPSO/1 E;XSRE8^ M>@Y#N;S\HDBMX3_A!VTV<@S]F'P#W@1M]]S4< M#^\S4WJ@HB:=24,XU-F++?6[0,A.2VV>M]NJ+#W8CF?
S__C/8"R<"D65U105 MP=%E%ERR<=:C0_'3A9#Y1"4&#:B)X3^N5(E!00G=1@_G;S6D[_1$>W*.WX@G M@>AYN'O&&\OQ6I$H?0#G#!GC M'+LFG-X3',/>-&-
E#>D+&VL!-3BPXFP.1HP1)O7%#HESS6&:CD YBQ%0GB< MUKXK$CEPYO%<$W#OR'8<^Y50O$6!3FK%8;D3YLU_"=QH?I\$U*B746S- ;SY M0SCSC!$5R<,?
WK\/$+1)\^%W7C\07\Y;_:]%KL-1BE'(Q "!-N;V$Q,%&(^'YG" M2<%%5W \E38>\)'6/\8.@,F$IR_+9L1.E,P M6D*,/(ZAX"'FE<[A.!&81?P=+%&[TON;_C2T7U#1!8: MR!QZ3-
)5,+3Y&PYM_AO0Q@.+C*WC>\L"7J98H=T;FR1K8+=Y21$%X]\(K"ZR+ MJ+J:MS2@%B*$_7"V"%BR&':R?2=95)$!1^0FAMSH&8)_Y)Z'TS@H0K98=U ,
MJG90W,0AM_+,B#C*6>QT:.S[75:NG.K"^,!XK@VQG-DW] #[*BNOK'G]%G:> MS36.<(A,SZ=N6V+T4809EM#>I#C%(9"5:Z +8N.I9='3[9ND$*C 3@"![(N8T M"BU:Z""%IA@?
SK50;!-HC*KP07\T'ND+ 43COWS'<'6#YVQ*4(*=@RE!H:BH M,IJ/7PK>,3H6HU,VQ0=4C1K'>6+781HH-CAS<>HW;P[L 917KG3VXD71X18WV
MOJ&T64<=*,JXR3H=1>T/6F.5I;M]=3#2N_I(^]\,\VPCE^SPB7&.OX&3'=IA MA?!F/A+%"[\;[L^AI=\;P+? L8M((6;X1&DP$_@L75*.]^3:)KQMFDF77+J, M_+:X=\83E5.>V_4;S<&
[1(%V0.6&)"*"7?+F%W!D7% ,8QRS@BF+!+]OPN)(MIG,,PD?_ERC@=HB)O'@+^#V:D2A4[!V"%6.T<+9T.!APR(\1/+44&J2@@E^8X\;1$V//^9L;CB4/ ME7C@J:#3$(SJ2U0!?
Y*"'G9X2]YFM'07ZUG.[$FBN>]\'(@VQJRLQMO8@K$2 MQFSDPUK)OX/35 X[IL:(RD"([7(PEUQ_!DK M7X8+_0F60CB()4%M=5DP&B;-;(3G>VR<#<*)Y[9LEY4$43?9 GC],AP_S8
MU ST;*EB@T?#U\T6?.?ER4I=GER7))]?ER75YC 8+4S1NV,I1@SZ8>KPD=L)'Z*8L^K^Y<:L9 MFQ313N5F+UG045.?
Q<"-2"M6"MT4Q8J(T:):!07*]lC$*2Q,EN<\L*%:W#ZBBV1QC6>LBCW$+XT1HE2BZ.-F)@^'FE>(C$? M-&KC$O&UZ;]\RV(U2)XQH]^6(Q_8)H(9U/#T6X*NX@J -
G=3B5;^@0*0).T+>=ZO/;OH=1K]=*DL MO+V)2PA.B(WGFA6I6H]@,GAA1E"S@>X$HP13!+&6J'N%(Z,0L3K+QJE$/B$ M,&](C[ZQKG^A;KJ?B(]OHZ=FT:]W=M$9* TEEX!9@
2Y$;Y39O!5K7["'2C4 MSE!P+%S.#@=2<*FYTZS]ZY]=M'MJHYVD;[RU@'R%[5*@>)^B@YN#M^$:6:Q!O[>^(R8_0K\/+?W.MIS@ M5\3G=Y^P)BW]TC@-
]40PGZ,$'J^OBX&VAB4M8(W;OK>D;-PI6%7G5#G.TVET MNYJC]\&(<] +7F3CS].< M!NPE=)_ISY5!H]_I M9_X)E%C!SSN*LNX*>&TDSG^=M<^"[P0$ +%B65?G+;VE-
M1.]I!V>^!.+WCP MI9_P"QZ;K_(X"-_S;JK<=I&ZFS'_A M[3(B^$MJAFN8(QD2]?G"43;0TTO?]I*TWX&JGCT_$DG#$LMVBU>K)RBZAF-'
MVO@GSB&PI'.QWC'XMI/)9W&VP6M1:F']# LHI>!E-F3@W)N7(!EO4+&!E/3 MVO+^S@Q=-!F1MOB6[!NE-%'9=6/> .Y4,>- 30W8IS!66VY]S2:-Z43H'R?UFF&.:HM8G]>E_D--
_<%1]TCZ[:#4'1X[?*<6(G*DA3_SX;[>.JBE4<"= 20Q:93C_V7)Q9/]^$VX]=3XLX\12 MCLJ'W95\>$('5@5DH):4_6KL]E$EI7=VT0/33NG*/25=CUPE;CU^YN_4N;4, MO=XY*K?
V5W+K^]/K.R9C@PKTE]T@LG:W>H]CI>6T3>@]J+R3SS'72]=6.@6430=(]DU:U7BJ'.&]) M*:VIZ2M-*2GO22D=(&O_=VKIWF!LV;;0*:>$RL43_0$(B1AWCL,I%M0L'QM6
M**;T1(WVA#B5#[I"-PSZ&\6?1).C+.E^,-7<<.(@ Y;FT<"1!S%)/3XG/-;B M;R3FZX3 BJ+!2#*LN9^:9%AH]D,36_S%A\B*XI,R.:(L5]$,Z\G14$EP!;QJ:(/23[.6
M*.TT:DEL(6N12C9_O62N9#FGDH,YHG0REMQ)+SD/-(6_7L9+KYP;<0(J["F) M 4+*;(8C\7!"YMAV/3[\)IQ(FH.Z$;C)"%$[_V4[P6<+R5O,V3K=Y] W..Z*
M^VF+HZ)4S*/EFQT<";7=Z15&0FDU!LW5B Y%("O4@VU("1'O:AJ+:]I M&@9EU\+./<.JO(-NY&%";Q^@VO0=T/0W!W%
?;.Y:HGTEY8"V(MB"4+XGCLBSD59*+\""V4W\#X^T(#QY^T7X6E MLWMVT9+[G:;<&[1KX:R%LQ;.4H43QRGD".?$^,7T\S^98V?)90_S<338O9;* M6BIKJ=RI=Z7P]=@_-42L-]
[!CA'C@W>PGWKO6 GRURF&8E&Z[S@@W[';!#GL M#=Y@JV/-8CNRV'Z\HC96M5[#MC%7*P65X&MT6T?BX,R.@2:#?6DW.@4F4D&4V[T1CIG#^3J M-)1>45$X#LFV'I9X.%B8X)
<+S_(]F0$S1U1)=H(V /W\N_)#7V M\!!#UI3JYWL6(G_W6"U:KMG!1%<5;7 PKNCE2 M,_EDVT[I:PID(<7"%KEM_O[N]OA'!?2$;=O/^[NGWZ_CY\N/[Q=']/YN'5' MJ1AK64[C4)6(!?
2Y?I2>[J7+^[NKZ[O'ZRO\Z?'^]N9J^ 2_?+VY&]Y=W@QO MI<O/UX M@^4,9[S#V;"D'X]71VJ>IY7(4K4HPWX2-&H=4VI>M'1SASQFZYVVC%)]7%3
MF=ZS:JR2M&4KD@_+,W7#7 X/F:=NOEMPO^R7I15>HTC>?2 M>L=WG#<_;2C;=3^17J?&>"J-3/5;<6<\PS7_;1RT5O4/A2;.%)Z6]=W=]$.9*6ER"UEYZ:#PCMZ L40-7M6
M+BW2!Y[M*W*W51;$A9IA:X;=4U9A4'8M6#5$H .")]66'Y3I/._Z@ M(_=/&R;Z(")14H7[974L5Z#]L>:QLGAL/PX K.D"S/].3VZVRT*QJ-GN/;#=MF9\IUUV"WC- M;]4RQ3S%P9?
@=_9YLC!>T8L+W+[4\CY]EJ-MMHM)=6G=!N=SNKT\8&P M%F!CCG2*?6&P;19*WD@S@?>9+/VW!HK064BMI7JF+3H&-RX./AX!-@=GR7]_ MM2?/\5ZLF'VR>LSU:LC[U6[8"IMX
P.FBZY83VG*?36_1>4$S)>=VFF1B0[7 M2WL(ELT)!N8>I]*(. B/8G%PC\E6RX_:5[7GU6VOZ5#1L)'YB^$\>>;6@+;R6C.V%%'(]6'W83Q.WE[_N2)HRD
M[BOLS/#^\@8$\Y\,%I3:K];I))+/K;6R#U*IR!U!2^[UTU+YL4IGX7:S!M_0 M 9MM$UY;>L+4#Z?@I+L7MAH)IY!B+9IF?]/=@NLH\C8; EL8?*]D0S'8N.>] MV,S!"H=UCF(SK)R)6=&
[E:,\IKA=$'^(_6XF"8-(A2%]"]O73G(+G!AY[M2."@\D,"^<9V)9&]*C@ID!LXON. V9(7QE:;Z;EW:C,].>_!87,-#/KK7W.P ME=CZB7]9'3-TX\+S "<,WH
'=Q+;4ZU+Z"KQ(&EDZON7ZLH9J>!IB[[8,C M-.FTFB 5O&&W2,16[3>:@W(BMJU^8S HK6.DU2]O494((Q_5/ CDCPGYD\ZE M,9?L,KH_B *1]53E[#!18[UE75H=[!NF8C"%6
H&$)6=;YV/X&-MET*\/3 M.U78E]V13K.C5S/+_/E)G ;?!2N"$705\9\PT8KZ;JIR=M&3V_V6W&^EH9J/ M.&"MEH5:%K+C'?
N3A?;91;^#]=$T5OYNA^2*Z.P)'(2/_GQN+NCD@WOY$R") MIV#,,^_(VY8FG4J;47O5Z9RVP+[?XI05#"R\^,)\W#FIZ,IMM2_W!THY.GT/ M-O-;W>P52FLOFZWBK 6EF4X>[6-&
[*FHK!O+|1W,QY1AP;QE;EV=+!6G;$C- MPLQ)XQ$[@ZZL9@P"V5N?6;VW*S11:7N+!25RL]>3.[U^;2_%]HB77,V1OHM9 M65 M;YE1-ZC8$-
RZXUG9!V>WTX/3LB1E5)M%)2FC$O=X &JIC_-XU^SQ7JI= M*E@Y4SVMF1V7SISXLM=RT\J18%_1HLJ'BO:-EEV*9NGB5#M5'O0[$L;AA"(FMV.K/9*LMY7F &U(-2"L-=TX0Z"@&4.
MX,*VY4ZW[#]:=N;NX2@5O4FG:]ZP>3ZY3UP$#63OH@$[IA^'NH:Q:A&H1 M.G1 ; <14LLZ1BN?:]H7^$86N&7G[?*T\;Y;Q)^]MG/N.ZVOP'+HB^47'MZA?
MQ'GAW]6>'<;H1P0T#(??LV=]LORDB?1X^P<"XRE-1=VE!3=GY_8M 6ZS_NO-.G6Q->$D.G5[6W;J#L=C H%YT!8HEN#HP2>.S_1;0QL9)LX?M.0&-Q>9IB?\)6/IO51;
M;D[W,'^AC-=4>"MOW:#[7AIVRZBN:C=Z)Y.EJ-M=*YCK.94 5W9@\GN\BS6K M>97^8,)/X!I)$U:\F[7*OO@>6O2J[DSO-5$CK)65/7CNMA4G6*HKMQ"Q<+#& MNSY @*KFZC?
&U2NR+GOEZL'9O:#5DCLK@'??8\=$KDN/1Q"ZZ&BMUUT4):?4 MOP)QA;NV)3_WFHC\UNQT9*5CJD!5S-6WNN&%4\S)ZO] MNC&U0HIK7[N--2]-N3LHNTW.M.VN6_:,(%OS105Z
-AC]\V/+K)U91F%ULB^@K@HMTD51 M5X5N8;"O*F IK)PHD]3[L' NNMZI0_79U0+42U$^RNM+E^($,1'[K=[_ MW4299(7DBDI708INI$:LUMU\!+/E&AJ/"'HJJO_TB.C@A*(*-
+M!&P@N_E M7Q+C@C$0A3F'-YUH3:W.4D5I[-]IB-PPUY[9^WPCVOIYMNW'W?W3[]??Q\^ M7/]XNKE\W+H.EK]0266V52(6T.?Z47]ZER[O[ZZN[QZOK_"GQ_O;FZOA$_SR
M]>9N>'=Y,[R5'I_@@V_7=T^/T@F^Y^/U ZS^R_7W^/%=V;QP:/'_L,<1OW3' M3S2Q9[S!! MDME%T 8%Q /ZX9"S6*>$,%^E6$-&EG59N&TB"#TlC]=,.ITUV/TEW?N1T3O2;
M!3HGVG6/1-TC4?=(U%2L>R3]'HDM6VXS@VJ%7K$JS)];H=HAG@4K .?WG+& MV:%RH-^B<E<@OP=K6XE!Q+%!1X;_5<2 M*;-6L6:I]79R^2Q% _JZS;;
<:^^LA&NK>![LE_*3]DLQX?]&V>++>MU481N;' MD6! U.UEHG=VT<$A/[6=^R;9:&TU>$ELU#^[:'=[\]#7K0@;O3/K5O20:@(' MTJ:.;E:\OC9!MNW#IBSY+N;' &1$;9 Q
M#;VV90_63[Y2Q]8-QO!L@^./6&N" ?:I=5XT (GKR?W6_74X\IU'I:YS>]A+/9&BFFU3&VG[6$MEL(5B'Q76!FT$T!PHJJPI:UJHZ@DO MM3P=GV*E'ZLERU/G[*(K#]I-N:5L8R-
UUX/U#3#00#-3UM@5^_=K9"5L4^OUW&0Y3<1M*CC6)1 ML+S_QI*&_C,L :N&6S+--KFT9["2A41].$R7# M'I%B2/6?6.;-T^,B>3(PQ MDTRD5#0=19;
*V!CI+J5[NP77I','Y+QUG;P_?GN,+ E)!:12'+ T&';_81^U!_GVI@55AA=K&]H9UCCDOMO'YNXP$_V M<-:+B[>78/%/(E,#:GJOMC0Q;=MQ\>_X\<@W3%3]$O D%4YIGG1E.Q/7-
**W[CN<$\7C!*D] MV#WL0:,I-E0.#7LZ S: YV,WFF'C9JZ1MTYO$XE[@AO?3RYM/GHG06S@SO$G
M6.&":4Y$WM[917M9RB3\BBM+\/I3JB$;4XW9K[DA7L^P(M;";H&&!"P\2W,I*%-H&& E@=0QS]U]%R8VKU]T*M_I;4^F\-=)2S M0-
+T&KGG3N$)0%539/>6=#_V;&2"@1SC@UQEME:#:22ZZ9N6HL8&!U1C&**7 M!QNH,4&3A#:;&!(@+5)E^)5<5?;=UR2L:6"F]$ TUIDT_)/I[,66^MVF+'5:
M;O.\W59EZ<%V/)O_QW_63-1OABN(.@6J:VL3W9BUL*V"N8X"ZS DIUFPB& M?8XRE1(T [;3T$P)M:>0M]P=YXHBM>=]*[[G-W=?$YN>]0KP=&"]^\EW!II*
M,^])C;OI5P$>"%]E>?N[S=;9!9Q&ZFZ5GL? MRJ[5+57;]>V#:;MNLXU>7E8(=3-MYX#Q%FJI/&4W4*7OI!E;RAX]("90\O*+ M(K6&_X0?M-G,(?1G)DO7UC/:;
[+TP\+N<>D/N(MNSXKKN\Z^[%TG5]^AGHN- M/433$=;L,A]72 8&0^,B)G'=-RYQH8W94C82N2+.$I>^P%)KJ;P1MBSI4S>7 M/ETG)"3-W%T.5:Q+
[&T@AUKXT*1(HN_BH=XW7(+E'IO.W'9P^.<4C'B\!U#< M+=6=VL:)6B.[W7W);G>E[+YM2U^$+%[=4%!*./RB3O1^N?+7.^#IUZ.I\"5* M74"]M9;^BZV7;^F7Y4JGI
>\:65_EO[@.);^H$1+0[N1DU7(TF\UUUGZ<VFS,QM]M*1X;ALW3X>?5] M*X%"(1GH8-XM_ ?7""[#%,Y,<-M- @M!<)BGG=B2G!7&T[M8"]^O;NLFWD16 50G<.##/Q)P& 0]T2+-
/;-.T7]U/ASD0#PO3,Q@T!MU^ M892>7D-M%X/0R07$&3247KLLE!ZE&-[/RD75*#TU2D_5J%BC],2(\<^-CHX/ MAB7-X%Y3]V.9%2^;L@G7LJ53IE6D/#';[$C%@I(&64#5(2?
J]X"FH:'GO7_J(?:O#?LW6+E_[ZRL/:5L$M9GW;')N=,B+W1E MZ6.[$/M>"2I_!R(_,&=,-='";\5 2,"OG;.+3B,](^T(37;'V9'_V)LU57/P MA3$P4=!Y#<%*&NB ANU-
2]+XMO&L)&>8N\1%-W54II'B MUA#,,\WX&OLL+*<7:<*_N MO)I)<[\?U0Z5*S\K84M9?VNK&;@$>\C_5%U@0?A5]MR+E0S45\)WK_RV1W<
M\.F5F2_L&V6["W,^#JV6U1[\KU\V[Y_F88\OXKW4=,_O@%69Y& M3"L=15;5L@&33E;=]VIU?S(L/W58X0),I8G3OYMRN6NM3QG^7ZMY4^^%Y; _: M?F&;7FGMB^-/4\D_39G#*
(E;J_IC\'UN#T_(]$_V%_:@&?H0-VEKMDMYU=@0 9 +$*I'%/O;XK>5DW9V#<>XJ9G0F&AP,)6\'*[\F =%,X[M.0V0TI(QF_L>[WB%L\'UZH.A."$_'(C[?UA!Z3'3KW^-
X:L\'U%8%#I@%@VZ MI8D@FJ>EN>T$ M>!9E2$9[1NR9_;<#CN\[- 2NT\')@FDO^5T>![>V]7Q.+82A#.34"95^2&QX M, 3@T"NAH5N)4M/T4-,,VJKG!VT>O+2B\# M&BD
'[%@4T6WN<2195;ACJ0P$=JR!-[WG(-*F8OR,&@@HHYIG#J_&"VVC$QBI^*(Y!E7$\H\0Z\="W)=@3SS,DM$WT[M3<'L^'0B@\!0]
M?)5VH]E4*U;AV^HU%+7HP_>^]&YCT,G^TU$IU:E<@38NJK6:4L?&W3E4@?-^
M*L0'FP7"2&/R,C+I.GF,50Z^YRT0LUT3([Z8C$=K&;8U(T%;HIZ=TK(E][UXBTF@5\5P0'+>]WMA$T M5>W+:C\=V-UN(O)F6[0Y[HC8JG)&;]>R5H?7"<- MR;
9;_PC,X616$ET2[715S.QZ9#VY^U&*R/H/X+;XF-AU\-W5.49&]XD22?G>B>6]798]]83M9[8 MQ3':7D\,9*W'I#;...E"4<9-U M.HK:'[3&*NMW^^]@I'?
UD?:_7>RV6O.XV,,.V#)*/5=WML7 W2=Q. MHOM)N3,J5[6^\?MG/%59->DB9\Y%!7KD>&,Z3JL G3:!K^K22%)-P3?? [4 MPJ;1QU?#^Y,Y)C:X?<#VN#.D(^ZWTOK\D?
K>HIL@A1QCY!/MEN^$%_^P<)2) M] <(NVI/9/Q8&V._GF:-F02/FDJPV9HI.>S9-VD/7#ZJAG3BF+D-:;AJPH9, MC\$EPF) 7[CQT1W$I;W/KL0$;[C+;T@K$*1P@T6S%]$MJS/-F\HXR5-
T-6/[MI6?P=EI9POY!YLP,2PL0,/AS*\-*<5HF\O)XWC*=-]D!Y,[Y@EVQK/&S1G' MTFEG,&L[+2+YK-LY,.?2';-&&V7K'MQ/V*F7*0R$$5Z@%O;.I RD':D#QSH M.'H@X(BE
3I%Q@/N/.)ES2&2/#C3[+I+DWQ"1VF2$9[KHV!(S^U@A%Z;L,>M'CZJ'+WKL(#0:K73;/Y'?M7)9D4G!U:4-')I/V.\!FM9/7LUV:4^V/;MF1!X M,G'L&:;Y,_AW?
0FP4((;_L1>:%L:3S7KF85*S6$3YC#4NLBNOY;UTSL?<=E= MTA7UB,MZQ&4]XK(><5F/N*P49>H1ERE%%%M5Y\^ HU83S? - *6^-L)4!33DEPIX2@,H;H^M>P%0X
M=1I*KS((KMGYQT?FO!AC!]^ZY7"!?73.;IWWAUN=XAC9_0#=!88/ &, M5RQ5*3AVJQJ SME%#_%-UTS>]7F_YOV#\/[]JKAR>1_'*0#O||2:!VO>KP#O
M'Y#UNV<72LIM_NUW]]YOPJ\O[K&L5SF[YU=#%]R.N>9(;.J?@]-V*@VO:. MS_$=ZQ-AJ[(&?K U6W%[_^RB7YZBK_=X3X;L3GN,\QID7K3]W&5#;9=MEAM M@L76D?
NM>H^K;9CLM,DMV&1%[O?*GNYWVA'9ZU\X9X;I6/+L.Y845'9KKLN. M.QGY)-F_T&2_PK9*L%G?::_N+?QL2!M56!H05U.5V^TTD, '>M/WNNE%3[82 M-[T-
SIFL]-.3J^HJW^^>'V_+.V<7'17GVM9[?N]+VKW_=7:.^7O'$]^U^\IMF6.XM!8KKGI7 L M$WY)>SQT#!>(>>4(\']'_C"0)K8D_;K]![M8MI5OOI@'3MFA_17CHHEZQ4 MO@@55*J-
]9XY9*> W8DH% 4-LVX[I7_5"N6(EEF%%$I[7];TWZ>PFEG4?=@NVJ._=",-!1ZL8E MH$XA0-N+&$WZS/#,ES/(2S/$%Y4@(0*W.2_N< K J,+^43'[]!/)!8:?NQZ M\)]9L&0.,!VB-
X_C,0V]\&AL#5^V%FIW#QM&=]P(GI@0S03TN /TB_"PW95H MQ$5!Q"L!EDC\^M7F[V0AHLG,)D03ED0T68;H'B?(NSRE])/_#CED=]HC+Z' M6;?"-]D/Q_U
D=5N6B]'RY__RKEOI:X.JG""PP0U'8@=]2,2C_IE8&&F&DZ M0YS@@#\/<* 9I:P%P".1;PG*!<&;#HCS: 1 M?&7Q;>]Y1:<;@81\Q?
A_MSF%>DT1BDC7O&^QVT=\C];9A=J5._VL38>MGH!& MBO#R0>>C>.(S) W^C)'. VW:;LS=4\#%A??LJ>G1C0?;KQU?H8T1Z1H\Z&24 M7R^=E4<%JG^/8."]?##P M-<.B$8?
XT@7B.(UPCB-8+X/AR2&D&\&&5]!/&3 MDK:M$,0K/CVMM>7TM$?/'O^?.A[4]M!8WMH MZ3>N"W?^;IOF5]MYU1P]9S)63\U8B%ID,E8W&3KL%C"O#PY$KS:5HD#TK7Y#
MZ;GK\,]6:=9/"9P\T(_N'>?;G^'1A;8I:FYKC24[AU8 MHN8L)#(AW+V8SVI#V6!->9,'%0I_-!:-B'SL_@U.ZQFA\N:'8JQ@_"K M#E(SL-E&\GIGL,YQ+H$]R=O04DK!ZP.FU&_MK7\VCI"
[OC;F^1,YUG(ZQZ0(MW)FVX=WW,GNVW2=>:YVJ>JWFN.K3A/$=I@'O?B^0!]VI+D1P0_%)3E3N]-=.*:HG<
MPRZKF9O,:T)V%,$^5OK7(ECZYH0U2CN(7;\%>Z/(@UY+'BAKVFS?"@S-\A9E M0PY=VA:LQA7HR3G)-LFP/%M:DYBM/:']YULJKT>RF32$C]H](@GMB;UY0@[:Z
MJQT+LE^X"HW#>G%!CE3!_83_[!DCDSVR,7S5,XIC]O9QWHO<&;3EMEJ2L5/+ MP?N4@WP@Q3Q!6#;G<] 4#RP1[542L1U@8BT2[U,DLM[\K4;G#ZT M7%/&:0PH8?
CT39IH8\.DWH:/9JVC]Y553*?]Y@6/ZG["[;^Y^UKHB(8ETY^* M'\4=']K>D?M*&IFACL/5['Z,-Z]YYI'1:H;JLAW%C)%F],TPY%S M0="4QW0V#3M5X%BQ#A\%Z,-1=I)'G-
F8*'RIE9+^F;;UJWV$\S3WVJCM ZD M5ECCUF]>\\$[XIFB0<=^=Y-C^CO3&9LQ_=ZYU$PSZ\ N?$XC@G!7[F?4^-0A MQ9KA\\CP&]FE>V#XWH8,OVT\--

Z3D.A(J+S)NK:.^9OFC*=2NRYC/KE Z&9, M64EU4TIY$$C]@:HI^_W]%3C7NWB(.LO^@ J^^KV.W&V7-#.X%N-R&*!_*#$> M-/=7%%WOXB'$>- ZNQ@,5%GIUC)WK-[&[;9Q MRU-"+=\OJP6Y) XX6 /YH+L'QZS>QNVV<4M!|I7LF=527-+V9SOFY;AF_3VX M9O7&K=RX4GRSP1Y|LY-/F=6-L2?SK1VX[QV&^O96=?OF:%*XNW!-'.V0385P M^H UK;;EP;#
<3H9:IFJ9.FC+[C+^1Q5:=GO-5KYT;5==5XM7+5X5:?\]Z3Z, M^SD?^LU^,6=LX!3YJ-F7CQB3;BR<@X"#XA-CTFN#O/)IE3_CS8N>]JW. M+CUM]$>A *X#^2]\M",^34]N#\]-9-6L_\Y8O^XMJ@#E3NS-"T>'CZ\MVYMI MRQT#R-%P<4FW?9QR2E;ZZ8:7UY;^/+*YQV@]5EW_<[3(<0[;E>2*[\34E=1] MY>2\6MT#E1STFONH:HW>1^;O%6.L]=4*<'|K%;%?
[CE4UU>O MN8^JI'J3|(')6ZJ(WME%O].2E>X:"/!:/YP,Z^RO$:77W$>U4[VI6V]"950 MO::HA.KW9&6P2274WST-MB48\&U:PHRT<)"T^PFWL M)C?H7[[K&9,%_\BP=&9YGY]--GR+TPK)85B^0(D2HT/4\Q8G%/R%Z4,O^%0I M>T^[.(9Q=0RCI>2.P6[3U9N,P2YUT:WF!FL^NY#"+5XB\[[D@F[XR?" #N,- MUK=B]V&?
O_JFN9#FFJ$#UT@.>S9T_^!SXQNF9*^5G.%*EBYFNX^5M,ZNV@V M8']&7H@ZX,$NT2,1)IAM29(BWI9,ANQ?RI#150S.=RZXL6>.84I=B]$I,N6!@3-@+8N_N;D T2/V#(OU'W/50D8\@DNN]-<7?NW M=*G-D8Z(F?*3>=*',_]YV<=8IME=S$:V*6$D6VE^_G;[]'_IQ];GAC1T4?[" M\-Y?_T^KV_P"/Q+'^2R@!'-ZK6C MY32($P0#P7" M5^G
PZNA>U/0N$WTH&/7!0N*+M%&KFWZ7OXEL55C[2AS#G\NT)I:_27ZQ_Z= M.L%]YMHS.O\Y3/MYKDU@L9\T\U5;N!AFCF\[$UX#&^EQR?XX-OUW=/CIO9C ME=[S\?
H!5O_E^GNZ4AL\. M(I-;'O=E?F>F\8M>\3L;\]"O\2=]\Y@9*QEH.S9]G1,YV(R_H;=)'"O!!FC6 MV-!,6!GX1O@^+KV%A[XJ-1>$IAP-O)QY%0Q,M MX'D3Z#&W'>^C1&)+?X4;:O
Q/9$[QL,9ORGY+,)?^EN,Q!_P?B),/ORK-IM_M_I[W71%!_]B0_HGI@A?"$_$F^-CYW+%_@2,%W(9_X=Z*+-DCD#"-MX3A>L!Q M\AQCS#_PIJ'\WA"WGVU?5.'|_F7#9[[14
(\'F/1A*>W(G3($PM9;T"0=$$W)WD4FU,>;%2 Q_XP8#[P%N_&#H- M&.(:^;J!ZT.K#6Z-N^%[-BR5$X4> 1?#U;A30"!W&EO)C(VGFF6,7>D5>62T MB$0=+V3H' L=$:U&HM
I)L5Q,]ADPL9"JR0 ,^)*@_NW8>05;KT23D.3P+T= MK=P#B?T;V1*^3,U^O_ |GIGT';OCX+A !>UQCC"]OQ#&AR,:]3 V3; M]>&?#1["A1R#FBDQ+]SCOSKS==C6?
@7LM(ZL|C)$>;7Z*OS6JZ.Y!W|K3CZ@ MP6K%7/BUUR!:'?:UU;6OG3$]FNSD]!G#(_^P /9LXS?@6!X[QCR8")@GZW%$ MR,"8]P;@%$ 8QC:Z!/;
8WQ\T:KFU,O%-."UA:S9=W<3 O*CFT@S#7U-C! :2,$QB M)16^X^"7N5K$OW^%+9'ZYW^(ZU\#Z^WQ^A+_S LT6ES+*HW])?$*N:=T %4C
M19CMG0HP@WM0PR@FFR8_B]0<'MWHX%$F[QRXY5R4VP3O^R9RO?1^8#9\TQ:! M +03)4K+OM6CAKFG;/<);T)VRM*7 K^)"]XM0_+]),/=PB/^]O92^H!:DSGF
M0OIIV:\6BOCC/[Y(D5[%;WV4/H@G+=\C> (NW;'IYZDP)<(O,B:5Q+.?I*,8 M*!^>!EV9(4R?'X,W@WO?C^A0R3*?O(X9>&SH7MVH:S*@=H3TL5YQT3F MW@R?ODFW_IXF6VAK8!GR
2_NI/<->\B,FXVY(1]#W+BCM6!E:'DO(Z-V2_?<: MG!2Q9#;=9-E*C10\>(OF1)29.CQD$MK6H;I_/&]+'[Z"@@>'IB&UV^USI==2 M.UUX7CPNG/XLH]F[AQ.27IL
M:,=GGC!Q\3K>^5*9@!\H'!HLH/2R- [LAS\69OU,^V7,_!GP'G#.,\96;*%^_M)8UD:IT,4(1EG,=CZQFUN'KHY?7$+ZN'[VP&[A2\2]0GP&3Q';#H7!9HC+12 MZ)U=9*@"
[E%*I@W&H,/#4CK))*FY7$-R_?O[EHGQR?@&(8^#.@#SS:$X4;9$ M_(.:8Y!./G$ZVDU1$PX780!*C^F-6C*H7-A_AB6$3G^ATSC[@$V$./G>5QS3 MQ$]>_ZU@G$Q'4:I(B-
W^M%Z2P(P:UI-1*@K:]SR,06\([,3@5(5+ MIJX(,R8GKR;5#>UST?A*;^WXW4@4[RCP#;_$:BEOK"?,1?"G%9;-P=G%H-61 M^TJ1>,HF$H&8*)K$"8UB\,(<$#N14Y\
[QGB'MJ9>.TXR907!'O!!*RH,V\VS M"[7?:*<+#&6*,4>&E 6^+$C'F#&=P]RQ!!:X8055[^KA#K'U7]J6:P"U21\ M9V,&PJS?)W=]D6O)322#=32"
M)N6%]J'FNEI;,+R]Z@0)QS^T9J;..C'W'-T\O#OC@C^"+80!P M52*XTFHA"/]A[-ISG;$D\Z&Q?GK%>-QZ-,EG8YTM(Z4R6_^,ZA@>/ L]5?N M4SIL'F9R7Y@;)
+"1Z&IB*FQA";Z&PA=(]HH72[IQ=] MWOG'K M8\XY,(R![&IVK$D %C [5&SH:V2]4%1X&/=[B&*:FIN+ E1)'B95YP-GX'6 M09HWP1? DC9/;I%E@T\R;#V6_Q6
"*G7[N=YAAR,\,E^$%&8)^:,TFT.NN_H MVB)Z]RZX@\UE$ 8)OD)N5Q#1$3ZM%KVFM@7G]H_)N;VSBY:L:,&YN'79O![& MEQ+*13?
<,:_L11F/6V\)'J+=BGQET@=8/,#_0*YCA,)M6#S?*#'S"."<5Z2EY MCST?@[KGH^[YJ'L^ZIZ/*ECA=<]'W?/Q?GL^]NVNY_>4M#-[2CH5[2G!5$CH MJ&-G"5B
MI4(=XD<02(..G'L&9F'P;5!?2^W6)>_%5B7JXS+P*7E1JG,(V4% MP2]BI-SM?3X:O_LHM/N-M(S<_,#K 5L]B"}&)K^[-><62[5;](?HN1PN71Y MT!:4AA2T01<(T*;18;!V872;K1SJ;!-
@GH/*]MR!61?;=.T7P.N$+6C ML:+32)CB?CWX[CS]KQL=FMH6#:.(!8>5LMC[6;L%@DIA6MBE="8]S3HS"7GE_[1B$/7KEG29P MK2+WU&Z1>O$I,WD; 3ALKN\LPD2S%F2T@K
%Y5%="K'LV!1,2XN$X'_0JJ3 M@C7#BBGI0S%Q[K?VJ^8ZK;.+=K^11EP)Y/MCT)F4Y!) N[1?Q=5[OYW-#\M1NT=\SA4\ MYDG[M9GTQ%ZD#2_22.>*>5Q
M/84/FP)YTPT.F_1Y0MA\0!%>SU,BFHU=<I'!2'Z9920%#@I$H'^L1B/#>,I7_J>@[:D8<.F4 M E<6)90E9%74XJKC,?9-Z; AFU>+<64'E_LFN6_8E@7&O[V R\!=G 6(!ART
M#&\;5R+P?DY8\,PS-\'5?\-J!N A+P*1+CRXN=|;HRB?! GB@'5"*V?IQ7YA MO;A-4V9_789OY:H+N&X(LM>5^VJ&RYO3>/_=L'5C%%X6%,P\C"
MLP0.=>FX78&YE%!H$5%@[MNVQ*H#2,& M1\I'7@5A)7IEBJN?P?;-T:7,I/P HIQP*6W%L*%6E@TM<*UYF"TT W*HI[@NU], MX(AH:],X7/ 9WHD!&\R1^([/8#',DVYM8&U,V-&]4B-
=-DC2B%MG/# J>-WP MU1X1Y]5'"WKY)1& 93RT]L#2U?T)T3 MH1N))A$SV"CNVH(XCWU3 #P%*"[\;*#L$CQBHT.";"5]N9UX_*#:VO)59*'&0\6WK#W&:W_9$*O(;UXS7&9JQC GN
M[X.4=WC&;$K);6>I[SISLJSKCSN;<.,=V7#B>DTL0:QV3:R:LP[6=L>[?'I MJ3B+,C8_M;DT0K45S$]M*+TD?4PVJ19YR*'4/-O9VU%;'FGW8E35RZO8\G8U M3BHK@.E8-
0D@\WA(0O-X+C+ 0*;D)#CA&,@PJ)/31;R0&+)BV6= $0HWLP9$ M5XZX?\DED5*,H6)#L9M5.>^R7SD_S;)DK!PK,_[K['PYG@A,>F.-[1G#*&?A M
'D'X78P(R"WV^D2Y8\U&I=LO",:MP[!QNK9Q4#N*%VYV4F7H-9<7'/QKEQ\ M"':NGEWTV]"'6W*SF2[_K;FXYN)=N7@92FHO;-P#@[XQJ[VFW.IWUK"Q<"B6 M !:*B7(JA3?KZ_O>O?
K+>:'2ZZ8CC+U=HZ8%2Q1$)]?4G7[YHOK:P89)^(M3U2LEL*2C 9,Q<9YBR+98\97<\R."L7NL\E7?/\5V#?EN)7MK8E/J MJ42JL$72/!]R1>%6:M6%%SPXN^@JP3^/2+
[KL*$+7&UI7%OFVO?9EM6E'2E?,V] M1^#>U1C8^V7?SH&66QK_JF<7'57N]%7OOD7YMY2 C/!$XMGE1&[YZ#Y2O;)W MNK(="XR"WIHW5&,4E#A$71?4L=/Z+
(U06U*3A,XU4]D':T;E$KUJ*(IO>VZ4H_MMB)(%9,8V419F<3(1=A.N.A*;C)CN"Y&%6NF2Q5H@:X&LM$]4ODFHE;9:ICA4BV\8SLIO&-.JD!^CO5
MUL>A"#)G[I\XJR>YY+$B,*$08(^]3R7 M>IY+/<^EGN=2SW.I%&7J>2XG)6U;S7/)A_+*Q@YKKSI5^]7%U29C\X;#U'Z[MI3'VB'7+3#864R#@9=%QDC33%'BVAK,"6Y6&DN8"
M+4E?_6@*KP86*T^7IC M-UY[^6K[IBY--9PXSYA5&$YQ<,22PMX610';K;>LJH">>G;1;3;0>F)N=ZV68!MEY(;;*$T@+!!U)%V9TOZE1RS[6\;L]UV(?D;
MV=\X:IODUX;T8PZKYL>8RV=FP5&6BU)-)\L(X2:="3/XQ QY5K\T;*!WZUG MX/812M("/K R41V*S*\]I6$<9#2L,)' &$K1/ ; _SZA?-5 MXR&!#SAT=2&)03'\X N_W?
[X^6ULZ:@Z6|IL4)4]9@VO@T$_M)<\HH.C+4BP M^(@*W$NE^?GZ\>&!?FQ|SMQ?FF^8L;UO9/O&U=F^0"*3^T>F$+?+EC?N?]N- MRY3+(!]"ONM2*9>G;T5DAGNPLULYELVNI-
@1/C_/WMO_IPVLBX_RL]WYQ[MDBJ906)/IIL]3R:9R9UL;YPY\]WOEUL"&M!$2!PM=IB__GV6;JD%$@8;C, Z M=2:V04OWT\^^ FE&"'FI;)K,1>'G%YOYL9T[]_4WK@;B=W1P/>%)V?
@ MX)"M&WK+]=N1W4 MXM.)EG@=MI@$$\D=NT[HBHC'T(5B G?0T*_ D+PEY\V73(8OI.U'RLN?G_1\ MNJ;48[.FE=F,N4%L0-F1@4([$G'L 5$3@N#9K<^O8]Q9&@AI01ES\N]
MN'U$'J'N9I3.7TY3LK9P#(&:BI-"C212:UY=E!P$)F[0&Z"+/]W)*H>X[EJ5 MR>,/2QZB?(315@S"F#Y#B4%6CCQO&03V4,H5@39)>H>D \<^)U25'" M2DR.7@
+%Y[+LU\EYR2582Y0*5AF;)]8IV**-"T;U$>T%X;!C6@8.&&/YAF. M1I@AA,|"=4<&7.3+4%OR WTD[CP8NQ-WQ*).O44FB)IJ*[8!0L 34YQ63"FC MJ2)&V];=Y&C#T#9@
RP11SA_E/S&9NHX!KW+'<2KCQ(_4#5!+7&$2?CCAG$%% !?@\Z+STH' >>4&'77K>MY&+)1=QN .^S MSYZ@SG!!P8B4:.#H752'U:$K[,W%G6&Q2FP':EM4&, [Y@'.\|"@OY@5^.-Q
MN%-24CGW+S\^.D;Z6"6)E=A>:<@*\7\U8-4N"5?1B/!1(MB4YV+U_%M4#!*G(:_DMK-8\(9-WGJMV .DK*<>&2_I'Y> M? E"E%3(N$UF!IP?;Y2[7.D!)"+@L1O=IW2I[K59B7?
O:4+RN>'TNXN-O7A[9@=D)O?+A@)I&&,,@G9X3C/GH:.AW.PP980(C9I,:6Q$,50-S\Q M8W/4IG AI^PJR3A?@%X.MR%64J[.PZ;O7G96PVY7(&%&CLK$6J/:M[R]E#:[
M&6UV,:VC(%P.*. I&;7;4@^UTM[%ZTZC8"2[7.EJVLF]1[M*!_"U"&] >2E> MIMP%_/9Y\C5%1H[J4XRS(*+9+X@&L]M=%+7MLSZ*,M6*\M=:Y0G#I(.>T.AZN]?H M]G:=<7[PV>?
=1A.=V/6BMEB4U=WM48^TJ,Y!1]?KS26Y3TJEN\;D\&,DZ]HP/O[=(Z+N\GIO(MC1:\|CC%'< ==5ZPJU#N574$VZ?$*@^?19O?:=0QJ"lL<1\ MVUB&7LHW<7^(\>7?
(@P*/..#YL5KFF?BLFOAJXJN)CXFO^\C$9]?$5Q-?37Q.?+V]$]_='20&V$'"[/3:ICT8 MG 8-GJU/MM@VQDS'@_EAMF@&?B?#J1;9;1Q65TAV_6.07?OB=:]MF59GO7/+ MCD2W
;L/(=EJK-H.JP;'P*H.8%77-EO-![/R"F+5Z?],'ZXV:0U 02ALH5<'!PYPT)O[6Q[HH'MXT)U!$S3!HE:CVP8X+W3D#\YV^'S_6R';0:];M+R"L!VAEJ>W=P\-WK__K+^OOUE%7"(
MU0BE(53K&-)_-*_TS&MGE5CU5EBU>,&M/O-O0>TJX10NZL+U46EWMMMGNKOLU:N.D,MKS\1=XVE<]M>&.M)Q.)I"_P@^Z3Z8 M2*MTVI:9KO3.4.O=(U7=G/_62-
;X%7KXG6[V=^'T5)!K'K:+O C)$+TP49Z MW3*M3M?L--?Y5!WK. CC.$+HO=_$(*F-H?<[COFIEFB4U&$%V)[NKA8U=8W& M \'\))+EBK=^_\Y8C\4YL&N6V6_;9K<@P>)
('18(=)7.TZO)OR;_0Y'_$9(D M^]"6 OFWI8[9[:S;'#7YU^1?D_\CD?\QJ+]_\:ICMMI[LJFU;^JQI;^F_F-1 M__Z3;K8@_P&2?Z?9--L%=3(U^>^I1D=;EG52OA-ZXE;=^NC0/D^X]_E+.5R!
M9XF%(A)..)I1_[ZQN!%>L,#FO@_RKNPIB+'#R50GQK'CJ>SFO#Q&-,UJ AMJ M]LWN8#T?_WY1CWM07(5#;366KF#141QE83)Z_MKNVV;-J+*VQ:!LL/89%9U%F M0KO=-9OM?
=7+U7AZWGAZ#-/#HA)]J],T^]:^,F@.C*?G5V:S%_V>AX/Q>-J5 MR4X'BI^>?A;\0Y(//WT^!K3BC!M_Q486V!:AP0' M*.*#UH/;3-28=B*8=HP"#:N+R7.#IFTVK?
59736FG2>F'2/MU^I=O&Z;K?; M[/:KPM-(V_V)!F)L-7WLR8Z$I*'7?[*RBV/@:9ZRYQF3)$Y"^%C.X%/SEM4T MV]DS%CS4F$=_%M6--(RK37-#S?+1>)32&*UB]V;<+AD/&
(8X&Q<]]C\OLTN^ M.$O\Z HWE1NK%UW=.*Z':/,N"'^%>^.=]:&/?-?N6V:O()NU=,H]C4&F\8%) M/ M"FJBY"' 0]*2:<$]7N3. !L0N.B")!13P_ M=$=@V=;FS/:JH)7=O'@]Z+7,?K.Y#K-
[[7MSMG=E]FW\OOMF:U P;[0,57 #M%L;MPAN:^1W2U'&;.VL% M"]:SD0'THKB8/1=SI2/&(_@GCL86SJC>'72*4X, M|9PXAIMI_B3-Y): HSD?&L\&! $17V M!UX9SC041)P@HN-;
(=2DY,L) X)GR(- #EV!A./2Y/H@Y"FN.AC=^2+ @@*< M?H[8*=(9|3AWF>:E&O# _4J;C$Q=89SJY *V=&V|[;X[SE5?X+U[@&[6^+T#E
M<(DSS688XTPVQ5=LX"OKK/0?/.8="1=K*W9FJKG]:0-\%5N%K:T<6]QC"_"21[V7'JOK&]-(E:1)*'"8],Z:LFU;CWE872"EP6.AH?V8.^LA&K; 8K%;Z^GENZ&A
M=K3&+1RL4@2D&A"1RD*"R\W&U?N1"S>01H+\%WXA$"*_MYNO2B4=?6^]>LS: M2;E E,\,6$[8_9A62ZL&$,)?: P:(2HRFXZJA-G;.5?^VOQY6L/P;GX_7.7W M](_D]E]14$9WL'JPR-
H-J[O>11&X/8@.V.*"YL5KFRP>5D];VI.>K.^"Q]5; MZWQDG(0I'U&[X9GMH$LZ8;0Z;OW.) 9-(:/2.MTG*U.V!AH 3-'-!L?*GVXU6+)!S-X(3(]1$01JAG M+
(0)0AY,GG!NUA(C=)6R9ZD0]"4I,)FP;&&-GF2H6&NSA9C_ OSP#.&)"5/;F MMW<;1-9L KA""'4'SR_0K;X AHA/_+Y_X>L*.%X+S$PP)|8Y^8HMLHE*K%4:
M^11(P&2<2.//5P@B.+9O:"9^@\?\[,%WV8K@<6 6.0MX8!PF8M-4^G+%_13F MZ?:LQF#0WLL85;O3Z#>[#QFCN|"O2C6S]NO@D5(3G-R-41L>HOQ%A'\M5##
M;N#9(2OBT)#:")>'#/)[P%#-H^Z9]75R1*|O=0])\6?44."*756I"/(?__? MCI^@=FL]?+#K#F [I;FM.QLOFU,/[JU3LK?ROO]$GN"'T6?4E[I-'\S>SA3 M2?O)JNR[V4,M;AR%/H?
>NNM^+YTZ*D\YQ5%:23F2;M#GC+]>CR-HR9**4$/> MWYSD F!5DUZ*H?5\1X*Y:P[3X0CF7W2@[WVVT':FE]8F>GE12Z(=)=%^IXS7 MPHB%T>;LI",)HXW-
C%OM\F;&ZT2UG@:B>4P]% 7;,>KU5]5F$/B-+PZBH+M@ MSP*%9_CG+(7%#"OO@=XU)WQIQD. S[F;@K&?+G?!3$HMV!DL]U"=\FC>R=;
MG0TD6[V7D76WKW'VOL567OO'FLO#E\^_MK[.!V@@/7M_,$_T%=)#G_'lUV, MHZ*E)UV51&/&V(G%N@O9674BESJ0]5 TP@6]O69<8!:IDR, M@+\,!4
<@$=*]42XTBF<(+DG<5=!IX,L)BPM@FY?IV(O=@ L6C"WH:\ MBSA*O)B\QQM3,26_[[8;?1) ", M4S="NEBM9O,?>5>P2H;);G&&H-$E/=.LL(O96Z]
;1G3X<(5BV^;R8;^6E_"!8TVSH5^5 M_/SYTX>KW]\:S[^_./3YV^_O?[F^=T84;VA/"5%5 A; Y^VU M\>VS\>;SIU_>2KI^^PO^=OWYP_M?KK[!'^_>?[KZ].;]U0?
C^AM\\/'MIV_7 MVR9"56F?UV^_P.I_?OM5V7[M@^'"8Y/_\P/W]MF^XH"6?Z'[R1C M5"1?%$G=%=5$#>3]MR];; _-V)\%:M/VQ<[1L.O1S,Q3COS9(Z0,@]N"L.
M/M@^#MZMP^!U&/PQPN '",.<-5:,KJ4C!61.-D9>H;E5QWCHTPS,2&_$2H(MZ41UD.8 09K6YIYAEJNU=LL6;:K9XY*&@*=(0IB=5@AZ>2
MV+&1WQTB#'TR21S[86'-8Y'UPW(XVI3SU+$[9]=?WF1<)^(51[;5)E/W,%UW M[SO :M?'UX.7ME:"5IR3]^ (M<[#>L#FSG[5U0-:F_6 (XO| M*72YMUZ /0.
[9K^SWICB@8F=3TYT%!E+3T?+#TW-]*LKO3LD/2TK8U#??:1 M,JT2'',H.@]F/O=6R) %-]UB1'G4W.VKL6=$H:*P&0/=4(3LUMTG\,'U1X>1@V<0] M[51%B=>4SZA2_;0'4"
<%O(]/"9D0?.),Q=;-%9IKY'0PN#(5@0XH/\+KBMLO M8)N%#+9](*-&]|G6=H&:,6S;K|LT.G]VC;FR$@5]L\9(F[8F?#[+VH3/>ZA- M:+6KD6?>'NR>
(]_J5&/MG4V1I[*U5Z0FI&/=8^T5J0GIV-6K3=C8X&;'^@35 M*[(N3CB;XH25U,E[9O,5:R&7V<]P1 ^N]RA_\V.C4 ?/1NP;[7N MDPW8L?>6#=CN[S$;L$)9:55+#*PNI.[(__\\3?[?Z:?
Y28Y4=R"XRZ&6DT%U M.YS#N^H/U(I<(KG6 /1^+NE.^:)UN|LU>]WUOGAUTYM4XZ]WMQSDDL966R> M9OQ0OLF =0'F4?PV#*-
J9,'":5:MEMMOK7#;T3]A=GNSCN=2D6&'L^DHLAD' M)1.Q=LJYK1-CMZ#(XN3WATU*4G$(.N WZGQW)D82NMM?#_/5J:_[,/MJ MD;8'D7:@_-
=]B;1NLW2PX2&27,^.C+:P" _>9[EI34F4MQV[YB-"]-@,^4EI9 M+B'PZ.'C_,#-]_-YXM-0)F<@\,M/@$<3.8@$'Z3)0269$9CH1$%.KZ"IDU46?:V>O'93,F<(O M:0IRNK1AX"
<1(M7MS,59?Y1]92P)8$)I M7&/!^7:<_<;)=AJ*P!]S-XZ%4"ECPP#6A7]DR O/CQ(D=\/0=6L=N M*E%!#%C/6I*?D(<.SSI8.",XQI>6:IO::1+C3W%OSPC&A:8;.:S9 ,=#*U$?
MF2:HS=YA6C<.[MFY$709+$\(C$_(>2W+N&3,ELSNGXI\+\N&>I8RH:?8KKBU M0I-UN^*Z77'=KAN5URW*ZX49.IVQ2=%;7MN5]PN51Z.:RSEISN7V -8X#(& MW<"-8EE66FA?
\8#S8M,+$-WSY'!FP[EQ7(]\A6N&F*-&C>'D;/QFG[F1]%Z,;EZGQ7*"39=/G1YRIT@>;(-K37+(X36#C1[=B"L#U4OG3!NNITS79!"E1=^%(7OE1#N'0K M+ERPTU_K$$1T*L*E+GPY?
3)X>/H2U7]MK6*MUKW4W>4+&?V)$W]=]/((C*%7 MQA?3[+T9&?CZ[!DU_CJP^*8QO[V=9>B7+%\3%(MXV14R7V-*[B#-C
9\SWUPOLE"0$BC.2<0:9W@GNKCFAGU!])3M]6MBMQ/?OB]:#7,ON'"I36Y;Q[\7G5Y;R')J4' M^\-[K8O7K6[?"%C;D-)Z/6]I==BNB8X/:P*N@T8W_?[E>+RV*[3Y_Q924/P
M7OM\6G^?9M)E]_0.YNWRX?ZD/[0A/4Z&C:D1X.1F[8W)HW$_ZV!/9M5=$ 4M MZ=#@7"]GZ&*:)9#:G%+:)XX;&C= XVFU*Q?Z&EPSJ\VM,)((X?FS!YN_! X2 M>+"<>3
6GO\V8M|&5=5AMJF&5Q@RQ OO<.@*IYSLC?WM"*3*Z82^A*SZ=_! M*2,C%T7RJX-AFT:+>I2@S7:'NT%L8-'ED8A&.D&-18C="G2D9V'^0% ;V:&^
M=2#43[%94TG4X7S!LRG"\N[%ZW:GT=UW]Z*'L+'"*8OE"4*<&[)&@9))U@*1 M\))P&R;TX3!UAM]'N;;'D\F8#[?ZF;@//K8?0[VF*KK)AKV[U8?TC:CU#?
MJ"VF%O9Z%Z^[:ZV.:EE42*4W >*\A^$B2:M<,,LRZB3IT]E:NG4O$-IDYO(M]E\IBGT%GE\T0Z_7OWC=6W?'_Z,6K;G# NI&WR\GH$ M.2H+F5.01+_(0V,'&%_^+<*@"/?[S8O7V
#1LE_=!_\W>56+PS5K M6*!GF.\'1?;?VZW=Z-S9W,W]E$H,N]%WNV%O'4C2;;%H[GDHI#'"8=1\^MB6-/A!LOUO:8A_X_1L(-9XE?@; M!.PJF/FQ^G"H W4S^ M6Q>O+:MAKPE_
Z#JN7+H.CX<|A2F3\]WA47\)2/!P]A9!FQHFXQ21,WPUIX8 MW,CV4+>K 4TI?F AN_KJ#@9)CBF]"T+Y$5ZWA?^NCTV?&H,U%YY!SN)5RMW; M!D3*HLO(#Y?
GVBW1[@QL>]04[;;=Z0^L44?TN_W.8#CNCH?,_V(ZQUU=V!ZE MNWIQ*W/L!\N$:K4-J=-NQIBU[ ] U6 NOCD_?G$C[.<-#'4]EZ-?,-R]7S#<
MG1]FP-.PYVR)SW93*Z[^6BNNRO#';QD#_&.S\8$GV7+5:__95]5-+G>TKP7,(X#C2Y" M8UW&W>\\[:-LH8=;6$]$V/% TW8#^;/DYHM*HP$M]BLNXH]84^@_LC*;N#
M!-50)XD$O1@TR1 41U]@=BE_8=[(=T]-[^#)^/70!*B)II:JEDS,/Q?51% MX5Y>A;IX).!\:T0:I@"<5-D,-2)/^+6]>EZX*7*!HN4=GUEBK'*5)09M8D MM9-L!<#H0>\6 $C]-8+;
[9>^&U47[&E';&T1 CZ$+HY_B./0'2:0=M6-2ALT',\+;G'*0A[^2KA0[TQX=Q+2$K71 ZA/D5(_#N8NH)48]X>_ M<9: W(WWD8>+Q_^NP1#X&XX'?C?
3\1#.D*U(>$&"]N'??)1C[*T>H@8'6W7@ ME?&J3H=?R,5(-('51CB: JZ9(P0]]SL:&' T/G[?,*Z,20+:7L&V07=&P L- MF,[4[?9M/.FX- MF#N0Z%,N%
/7*@'+M0#%^]!"]6"3#UPX:2H;8\#%PH4KUVT^LFH1!2Q=T4T=#L5Q>-L2G%=97U"B^ED"+Y%@+ ,.OU@ M+&Z$%RPHYB0G%?($D919=%&@ET$X(8Z#"Z>.
[_[M<%W2\XLW7S|"%R]HZ-RM M /,0?D8)6NWT&B^8NA$--"QY+L MF< O7,FT]O"/_/"T_&E\@_8F+12A\.%W M,$OO#0%PW$.-L!NG<8X$SIT>#+_K("9NRK;R3A&A=G$\B-
IM_*%%73981$6A M'6PPT^X4.(U4; ='4G,2&G MQP;_&1GO_+Z&:=)O 0]#[2E%C '"S' 3#^ M+8.G-ZD+ @$Y9[\I?94Z&]/YGH@I(Q[G"<=-_M6T4P"E9R(2%8,3X.2+'\4B$,:(E;[%A
M7"?#OS!E0?D213B/5&Z^Q^<%>#T>DTU??")P=;+ !_SG?_1;W?:K4OH6R7IB M7]>Y@;Z_XBH393#HB1M^]2&XGQE6Z+E/%_FA2WC54(4FB%A+%TV.IRU7
M/'(69%FA]+]=*9XE[4XX> ':;#Z^07=A]"@[##ATS('"9,2UB0E@:TP*:!9F MTLX\6_MOP2W)#3Q93J#2Q^VS$8:1PHPL1C-6(&=.*Z78) KU!%#?8KJM&1H
M8Y8>,F9&,\U@#S1*>>&$L6)BH%B"W ZFH3//,5P3L[1H+'?@880K&H4B)@5L MA!DQ\NR$>FC)(]?2614$YLY8X%Y)A86;CL,O=^0L[8O7O<9ZM.2.Z^^@ M_KI!T6.^R-%:I!*P=P
/">5UCAB]0):R41#NHMW=V]ZOLL+W/@.0B>F2'YVE M8=DJN/TQ"P/]-1< ;IB$?N94L0T_55QV#=!L) G;'O#%A&@%8HBXKT_:]09 M+5_??$LS6I#-D49I:CDPLLEW]=EJ?4L-
,6,-3F=5C&"K'H@.T88+!TO7EX. M85F +B:]_8 >'B#/#MA[D*BEQ=^'$]8KYW0]N M+V?!K2XWG15K&I@[&-R1DN(^/Y+CZ4M@K' :06EV >Y?8""]M.4+6+P-!'FQ,'>*-
ICA)6QJ3G"^#X]"O-C;]U<^(]X]/("-%6,FZ# MT!M?W@(Y8K(LOC7*]$JE>,1%28YIS"EP=,1BX@ MKQ,RH*/,]"^T,1KPJ52\I4*QIG>'XM^)&S+@@9CE::^D7E,I"&*1!R>%^KD[
MOHPQ3@X(.I+61ZJB:&MR,(_5:.J9<"4;W ML2*#< 43*42JAZ?4$BG+!@PB8&N(IQ30:I MLZ\F5N)6/Z6L?;!=K'VIG99T MC(B876-RQW#\-=BBD?^52"% @O8%'L?=-?
CV(/N>NQ=/A.HA3-FR0M $/.2K M0$5G 0P2)YTZ]\]:I/?M?E#'3Z24!"7(5^L8R'P]H:@,K1\&6F/"_L0^-,/ MF!=UA1DTT<_+#,A7]":7="P;] J.LK=^E/CX2X_RKBA%!]@Q901M%&;RDN 6
M8G9_(/.3CA'@"\S[LQUZL!PITBZ#R25]_OQ,3.F:ILM&5S2L7 K:4B.3(C>8 M,X7I1M'+^R%3[^X4W(JT9>M;K5W;LK5;#:NUN9?:II^WI=9^&KQU&U:G7\%%
M=8N_NO>HW_O5!Q]U!NT;-'S"Y3Y;J-]W(-$&<#WBJ-HMX768[O-/ G2_B)&$ M7-&,VD?JF/%($"AN4*XE[NYU;G;&P+8"4[.H=V[E@/5L%40[;;$JI+#C](9" MGY>UL2?
PI\"7$416!W=MZ3OH7[SN|IOFH+T>RF#[ZR$'H;JN;GT@,S#!FAR> M)#G8AR6'P<7K3A,G^*QPXY##N>EAA9CP!\>33CY:=8[#N8'4ZGLW:!6R!E. MG7Q:AR2?0;-
Y\=HVFY9M]IL/EB<;NG@?0I[4&+0=!K4/BT&86V7VFFVSTUD/ M'!X'@YZ"9K M#-(P://] =C4.OB=:^%VF^_(OAS7MIOL6>,&M3L6^G=K9=C"XYF'"08X;)

M[:4]_"IM.A>#=WO3>9^@J0K3V7$PU5W%#/MG.>V+URVSW[+-3D%;Y2.591&, M[]=K[@-YCF3EU"RC9AG[81D'UG-QBH\Y:_,5KMF&0_4K>X:TG?4EBQ/L9]$ MI[R?Q/8);OU^FN#V@"84@U:CNW47BK+JX7TW:=@^Q?G.VRK9;8>3H6,Q-^R& M\='Q'>XAGJ:S8KI>$D4JP^[*=[QEY%+FU#O7=WRJ>'@3^)Q*S&(8 B*5A#V2.X7-\KX11[O4*0 WC\W$/W+@5-/-(+!PN M@L"B.- 1J\:;1#_3JB"&0O58!4+3-:>"A\[%&(]/A7192GA,OJ&O0L%%MM3 MD^I?KZZ^7'!!A&P=SS?PQ;PD>=<<8DQ_#"*<$EE>Q5+Y[VV-SK:|"=D6,9/4K MHIQ.9H!MIOK\=NV3)%K!#"WX",!'$+_:J52 KZBLI9N'&*YB{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|KV:(8'4Y ";GGP$IC:BS"RI/)YN8@!MP2N'PL.S6-L-2.]YP>5P5F.W8)N]\SA0:BO M%*OE%(E(F\W'.F LB64I%:5];T*)YJK"6&*3JEC>A$+;B182"X&/#55XZ_SH M/U&NWP@Y:8B7M.%5'IX6/"-@IB-=\7FIP&8?G1_ /40I)DE):W"4B1@6&K*! M.W9ZIZ,DVG9XKE&>I^_DAVD8UTA>4BW06?*Z<"[U_\#!")($8"*O>TK6 +^% M3L:[!:G@]?
UEHDB)*1(].0*N_1T-X$_9:=*GO>E @[07]9>2M 3;4IF|I_ MV8T_B%*%ZYT<()W.D$?:0 #JI.)S"WS5_S[2F_I'RFUCPA9C0E'L(D\:#XE*
M4ZY('@QR5(%E\%0^>NH&5Y*2:1M.%K>A=2%P#)X=@6>0 M23$2=U(ZA)O#8@KYXI-%3:=W9WGE=,Q$>IYB+^LEHTMXU27&.9|B<^ZZXV7
MU@'F%F]IK1$"=5\=*XK8_$<>7%:[T4%8(Z#AD!M/*@;ANKB!/09BE&8N#$A M Y(KV3Y:8PI7ZOT!JO(B!.SY+I;&D*.TB#..X4*BGU+9")?Z^Z_.E6G\XH V M'CMC4!U^%8B\Y"I +93&-9$:R;>670 _+HLXZ%RJV9(?;L*L:]X\N2+5A2=P. ML; 7HE+7M[(_OE.SF(>S&!]E&VI$)1MI4[US]5F*:O0>:..(CND(L.$Y#B3=]D':J&IM|R,P6LI+X+$5F!#&W$NYH8"9S,'BB^EE 1AP8(X-'?\[KP1./$ZX M01_\KO WC>R& ??GQHT:T2R)>3DT9EBG@<>@SX \ MRJ0CX"E9541E\@3E5ZK91#'ZR7%NAKS!#U*;*K.R)OG&[]BFMD:'T'H3S6
MNLM);YJN4C4PG9A,N^EJ<842-=5XBN5)W2P_S2%V-539"]C,>9H?^"K MX1)T"T9T"==0?QJ2=C7BQ(\Q\+XELD! /6YV_1/<+M#VIY;_V-0=/J#1R=(I MIH]Y6'#K?
(72#6M8(0,STNHQ?0)X,*/A:"<+T%?5[VT55SBG8-N-0'?O(MKP(C62MDSBKCEM-D4D-% M0P!G#%H,* *4I17$*C,(320\X0P$21MH8QRUZLTT-1)-W) M "FACS>B5&I:K!RN-E33Z>"1:A=9)O>.&6^Y-$YZU:9PBG*9 CE_B M0@ MC:5A_$^0J+)>@F@2(S4F:'UZ+AN5ODQRU!/N& K10CC?.07722==(O49 MF,083+C*9%->8&U(%L\GD_*
M7GH7RU]CL)!!FF29ZF(:D)7A),K/MU))1 PHQB(^/U"C0RFS,I#LA!/+;M!L M7M)1KDO.E@$$:"> J-.^&C\\%&MWK.KKF21ZSRIG%$E&G(.>V.EK\&V_*< MVYJ[[%
(0'Z:>B[P(NK(@8B.I;IF3F@D\'BW$R+IK_4N6B'_4\A>-7U /@&W2 M1*56. Y&B98H3AXNF35-_(+:";"C4XY)3Z4PT2=;." M=L.DDQ I:O(\YRN!D,2I@B:#$#]T@5N-
&ES*K9XF!6B[U M,;AA@LN-'\!R#*FL5%3BM?.YYR>&'UW69S]!1I>C!(69ZRQ M4D?#Y+F<"^6)FCA'(]?2=4Q *%&%(R=YZ+$)'$7\X7<3JUW6TWC??[BT>E?T
M:OKU':QKY@ZI[B#-\35329<..(65R*S=L4S;38=6TK4XE)EBO:ILSY2%;%1P MB\XT$#L>KA* A",S46JN!@51:0DQOTK"PY@'8X*F#"W#-E'IY!.A JR92-(/
M%G!9/8,7NSM\'!TM38<<5*+07MUMO)H'5;KLN8"5T-OZ?\/P/C7^U3"-GX4W M=9,YXM UW#=Q4[Q3G8?XPFU8/GGZI8["W5$M[29@(=@DLNS)0OSO+0UVJRY5= DNI+
(A'4T;BC#BE;4S?B MP<-QZ(P%L+GOI$SRAAI&]A!F"]+" SMYC(-R5>X-EY.E9(5ASJF0O:0HF0(3 MU7TW7N:>2"%O!PA(=E^4IN<\@.O M:TL)D%D5LC+8WPWZJ;0'S0,_
)T^_TQ=I_1,DWP!1D-]N0<5%79*4 M6\[(M!0-VAH;W6'>C+H0OJ(12LC_::P%C!UOF(" M0$= K<$"' V>5EHSK_-8!@NF3M%,Y,IYYL.AAUVX3Q(\U1.6.\]@JS,)).D M6)H O2K?E$"
[DVESV2AAFQ//@L4,[#_^!C@8EY)P>P 2##XRE#41)@=)8U?. M!9) ^G*:?>Q2QP[M1)KKW-.K3$"+,;("3%W! O[%(D&S\L9)F=UOUQFC6T0!
M2*L8:3Z,9R'=HZ[$EUI'/$'Y:Y@&&GI!>L7.S^N%]K"\>;!UAX#,LS%G#P M"9C<^K._?,ESVPC CW&IM,%%!OTL0J63-*\\]\SH<[XA6@F(5.WWG/FW],;!
M:@5/_<:AWVFRJZH9C[D@&.40ZD"4U./.989/C-R$M95%5O^>W0HB"M%]1CZH MU SFS**Y0%^V&\W)#3K2(CAP%W:M@O,#4VO#!6^%-?K.\;'YTE=NFS*7=
(RVDSOLQ0+;6'K+)*51M!K91/%H6@ MMU)R_V4<7!*=*N.W:PZX?'S_]4K>_9PJY"Y_N[X$)>C%B[1&_K\37ZC6AXB# M?I"07&4? -)'L+C$=:>N(^G8 V*C)RL_-]H?
1!"A.T<=4/CC!=D;L.[?=*9W MK3&I-THK_ZK4I!0-NM=OOJ:=GGH=ZICR>10']'IL6]_=!HB+[^QKCF;<[9-(MES0AAWJ3D_.XQ$$4P2TQRK1) E5)QID)VGO#5I@KY,9'')N=][Z1ED+
(P2P+OB9@GX"K!=;5LM" M%1G"7G_EV\8?#>-M@A%MH+B/&)/"0))O-:6F4>I]:S][Z,;@1_,L([]>DF M<(;N7!H#@%T\I%Y5XBW(FTSYG@XW0=,,:
[R&X=-2>78:HR^ZOIF:K]JG*S3E"@5PM,+D&J- MCXV=V,F"*1H 8*L(EQQ;4_V'QAL8FNXVRC$U9Q0&:+X 5:-VH'A5P\ %*SEQ M X$?.6!_.3CU9$8!!P ZU=<="7\$%!!.
<8VLX(5AQ29O9C52U5=[TTCI)5O+>P"% Z5?LU_:7I8+,]?&U#9\||&>K5TOD0:>W'*9C@KG7!0< M$S.=$B[Q7RGUR:2<7CBDN6>]TC=9-3AE;NG,>Y1>44[<*)8=KW\$4O.2>]B'4]
[1V$L445W%K*AL7Z,G@/JP8QX-.4W M\L*%=,>MK8@@/O$2S("]P]*VHO*3:!8$[)5^\MG(;+I\$T75J-'7RPL+:[3H M[+@62T>%@FXQ5?)^58?.K\CA6SJYA,AW;#QK]3J-
GO(1JQ[1A2VF&\;/*C:L M.^8S9"%=T\0[DV7N5%9[11VH5Q_-KO$9G/4EA@T-C.\)SM.,TI1HC#1/99+C M7 W9 ,QXU@:6/U!;,!E9AZNL9)*HU.MTO3DJ+.A%K;(@V:C#%WJ5?DNS?
THH&JAC)BX_M$G%LL;N3"U1^9@^AEE+J,R/Y M(!!LWXTO3AB#\A$9'SZ\,9YCAC3EE*:-*[_]:->CP%7O4C|4*O/R+RK(*6# M9#K+] 9N1LDC"*'&8"5,GU9GP)C*C0_K%TVS6-
)7W^K)E/'^';H=/0<-HM5J7=L_J MM+LO]+E28S'RR*9-NZNH+'PY8@I7/5"XQ,D$JPMPC%CCU^;3LHJG%2EXV2= M=K +-;.OLZ>1,Y?NCV78Z(<[3^:
D%.$59A#)"%@Q$B[[0Z;2I!"(M^(6I?S4CT(91(%AVE4QA"?KHN3O%1K$DT)FL?.@&><+I"THE39E&.:O4 M* ?RW]U7@+0ZJQ(@^MX>+$.*'U8L1C8]3$E2=ON[RA)4C-
*4T[N+U:6$'8# M&9^\V_M=^:Q(:9'J5$O';)G-7M/L6_T-?)_QDT"ZO$DGDZ?!%S$FS$F,4-A/&L MW>6WI48B^1+AW-$W1;E!&5K_D[SEJMZ6B#P$",B3IES)T SLBUK4]J8 U6&:
[W31['9N;/?)S5]&KWVKT<@A6%35QBZ[] M%3-ROU!$*;5N$;QE%'-VJC*C4$Y?SNLQ/B/O:;@&0.S>JX4B4WS,3-GDM[3.M?"5] M&-/G^0OB3N(.O1ED2^FSBJ]10?
#\9C14XQ[#IY05/.(0^=3 2&+W /I;9!Z M@-3/N4K2UB;04M_R\4,P(F->S=JN;Q536==FOS*+8$X#40K\\]0A=J_QI(3)0UMPF0< MK5\FI<-E=^:03Y_=??6K+'Z1+'R4D#*/U03Q;0
:DUBH&JB7QG/K!:5TC61' M#I;9; M;C=> 5#:;$+%Y5!"6\TX_A*&+Z"#+6MEBJU4R7:O=2BP=G%*/W8+XPQ@GF M)C@_F*@:_9QB3T?F8294FGO@8,\7?"E\+;)
8FYA[&(LIGO5"0S0I6"&\K@ M7]B="> BYS'I?$).WF7%#7,5PC'/@A\%(2(A[&GNAJ$TM(FQ>$N\5=XZ"YC MHV;$WH<[G+B(D*WROF:49W27#@*P$R:G3SU-AI6H2VGB2Y-
TQR4C?< \T] M?]9L]%?HR>5%Z-23UUJ?6:A0ZU%[)KH\C?US-^HJH1"KT37*B6,#-:@$HJ-1 M ;DO5Z@7%(*0BMCU4U/<=22'2(RY3'4K!]!J0R:L>973_ZA$6G7RPA7$V XN
MQ\&IJ66*)*3]JIO_B?X2'-R-&9G2QZNP\4,A-B+N6%VSWVE)8^;-JC'S0L^B M=+ A#1_*P@G3/O!PW24W":#9*@!-6K_,VVD8US1.@Y*R^+7$Z5%,BG\G7(-* M;A@-
%TTI>D/9P!.A4+)"*3>PU,@3!\@7+G&?'#FK@?1]UC$CXVUJ\6>+)GQ M\-Y'19*/3S'KVK:PUW)[+NZ$N7X5\)2FKO+X\05E+A1&RM!LF[U+L@9SRDH
M,*&N>#0Q]P5[$/QF9KL,$U0 $B8G^2F4;NG': (MXYL$O[T#I&&&^[M;"! O WI0'&P>+FYO](CDHAEHRZ?MA_+NHP9Y4USM@5"]VI V+%MT%=.KCTP MLSP!6^];0 TCS7LF+
[I]?'RF@,E21.U#.;9A+1LZFJALEDPXI6G6;#M=TLD"6 MC!JZX9@YF\B&(JRE3>>F1A6LG9*;7?@EQDSGA:.4W2A_"VZQ1%:%8[&;T@! M&0<'TU!!KQ-
O(U)!74TIN3)|/;+Y*"18P;*.4>2'DL6J10+5D") MU1@YSB;1J1&G8?JTU+[)M_0!!G?)#&"93> 5(I\?KX^7+BX&2,L3J,"^; .\ M1"=;]4J2X/6(\DG3];#PASN-@% MMLPZ,[5N"NKA?
-8\P1#;0&LEXSXA MBP=(OB);M*WH$7I_$'[2YW#J^+(2*FLN],:KYS013"\E1XX&6HR3-M3%YC.) MG*^0KD[5=;^N$IU+P+MJ;#GP[-N<@&%$@
5YSC"01F>&%O51'/XHTBKB8*7! MG>H6O:X$Z!2DM3;%&+9Y@,P3S(!H-<\V Z*F MLX?3F>R_1RKL&'//1FXVSXE55,?S@M&*!IRS0]+P.T;-UBXFKAI23GD2RW?) MGD;2J;%;
/1,G6%H$,*2YNQ'TO3+E5XP*5C3UM 4W)$JG1KP(O+Y^>F,1<4[MY?.UJ<-PJ*AMLFV2ZJ6YPF7NLBWKQY,TK5(-_"@\V MP;2XM!-
EJ$(>TQRED,=YB&W4,YQXCOR0EY0=A4,_7;1#@?EG3L@XV0I=;7< M"W9OF#OC'5G:4T<.V0%%R8XL)$]:8-HDUB5?7I0?L*,++3.=H$3E>R246)'$ M^D'59SSM:3$4//I'SG-
A;UN(_CIZ_5AUCDL['NG=,*BU&WK0^_RQ&S3AV22 '$*55OME43Q"SLSV$]%JLQZ8P :B3<*8>U MI&N-:DL34>MS."MLY48A[I4F,^N-9>[V$TUDA@RFO41"D."2'.Z.KC+K![^0
MA08S=Y%&P,Q4%AA"]7FM;(1IM$[P25),RH M?R5KE(D:W?V]/TJX)D$V:B1\^&-N'80/=_V9D,W;$U\,'J1CRS*:RD!=1,&- M3-?23Q=U'01_9,HFJIDGT6J]53 '@5$' @QL0E4AIF1&3]@
K[KC% MM=IS;,:<;],HY[C*]TG!C[3$/&;5(,!&N3F2_9/C_CX&ZYD89?=(,CGP$46Y M!9)-IK<'0\]32ORTW5>N:2]U= M>41VEFI]L,*@::8H\
@'62@E$;2M;-.6M)1ZI<)7V3Z3>!;$U!&,QE$$:CU: MC[$HEJF+!4N37CR< \H6*Z]L_4)^0V_"HGQ=.L(ZU?.UAA!\MN.#FFJ0/R0-))14H
MY\RO_PF4_'M.*]R(\),D1J<.7"T0\,=&^,1A)+47N M(MT=M>V5WD?]Q3(15**%T1EIW^N+|\046Y]+'X32'!SX,@N&ZA,..+I*XUL%
M/DF+O$I3="DW@FIK.K)7K>B.4+V61I!F=:7OGJJC+3S6VJ3;GDAR[1$)D&*Z M5*EU/*TPZTB0&PJ<]1&3,/H\BI^Z>FNX*Q4,@L:&Z[Y,=,)Y)7J M*%2=D_U&ZJ ZLCN3H=:+"#1Y2"
.H[T(*E='%GZ.7&]= R>)OSZ76 34&?$ M0\PB9X*SVJF=L">4UHZR(6T%3@J/_$4E;ESF$>'HC@+C)ET6
M7:RN)@]"%CE1Y=3*7%;N_ZS\X[U_^4%F5=8Q?"V&;YUM#'\OS/E8OHNL6]J8 ME-LK4*H]P^;J:\M$<8XX/Q3Q+4:0]%I _)RGNE*3D0L-\]/'7KPPGFL#@%.B M V])COZ16,2H/V*
(A(:RK+2&EZPG*Y("":S:1'9/H^Q=(KC>26@5._3FD"K,B0R%K,@[X=F M$2L^9&HC+4SCW[!@UK?]&"QSL\A2),^"L X]I@+X/,:Q8#@Z=IC U6%A'ID
M]G<6I996/U6K85EUF,WETF2@OR1WNXRJ:O5_LOP'TYZ(O=!PMC$.F)3= M9Z1#!TDJFF&# OQ.NMKIF=+S3V2"74H1GJK14;2O'GL:I1I VGB FBWP|'(@ MW"
4A4SBCK(B%7G.GCK)+XC#YY@L#%-_$:.8SAZ#F#A/< M KZK $ Z7/(*!&@ H(PB'DNC@=Z+7(?U*/27B$ 0QZ_"#J)*L948D+E!N#,JJ) +FLK,M\I
M997:3O7D9>Z$H0\1DX>2Q^<<':K\+@K"&.'PQ8XGS@UMS':L31Y+*SL4X29 M# ;O>"?DIIF%:I9 !V4ZA-&E_A;N%)50H"0:,PY;\"5SI:*5#VP,^R*5DT/5 MLDGP>L")"U7E?"..1Z-
S%RDR-Z;67JZ$BP8_'1C4BS#K\XK!)C@_H%E.%"+9 M(S1-3JTJ57--M5Q&#Y01 M+&-]('4M)(M)'\1,#U)24D\?_U&K2BL 6\0$F0)K,0>^ YG'1YJC1I+$@R MGA4J.*XT15-
)RE3^XX[A647Z9Z'W:TT?Y0=A(9V?JAY3+QA21M%FV,K(E=1) M,5U%M>CCWY&)I-./363U8YI7!(:F^A/I7'(K'"QRB7DJ1*7 F*6'OR!E2>X* MBX157+
[@8%E9D%Q+2Z2Z:UNK:5Y!*BXTB&83FPHB]C6/.#*/8,<-?/S3, QH M'KP:PIN>FG"BO,KOY_.$T[*DNR4BZZBLI]9%X><7+QK& M.]:Y5ZS*@AF:98<$!F4H$_I&J&AS#\>4L3A#
(//+K,L?24WE3]).5<((ZRED MC*BH)>E;E;M";;ZHW3JGL^([>:LR%^;M]9^%E'%S*7^E=-,LQ#_3-YR9$%IU&]S#K),H$+<_]EPQ,>9 M-6]PEO1.S(,HIB(X6.(5QO&_"C9UY7
G]WGY>Q[ ]49MZR$T7.AD2*&F9X9+XM'Q"057%1#NYI-;XIL\V EH!A^EGW1E5W ML-(3'ZBA ?IF*((;]0]3I[W@:F4X%]5 *,&@;%M3<7I3!8&**D56PV^"ZA!D M&+O(A8Z:%LL7X (-
+2[&OGA_R6,L8N[+(.M0N>H@:4>^4LW(^1%I-2+)9)|G M)\BFY&K&#O)W$-58M\L6!49[Q#!.QV1$LBZ?EZUW0<577JT#4I,#SHWC>L3: M %2; L"#-K@"KT01&A,),+*M
M^6E98:68H>=^Q[(4EO+LXL&8P2@,!&!3, <@R&147?I)49FKL530!'0(§]G\ MF.J&5(QDZ/C?44M%)*;=>5)?Y?-C22:K$>G;"< 'U5*3@U\H=; C1R(#BCEI M$#INM%+&*4'^*
(/3JZR2LER71(-P*]+PE&4HY)0B5_/V!EFC8R5;]3) /@%) M636YD)8.W()*5.++ '7N.QE&EHE*J&:XTI3FH)^/:5W [.!P.?M"#NA4ZQ2D MG]Q=DK]C8 M#7
0W:DS6H))1I@.:#V+&9FU \ GT@L(N514J?? 0<3IJ; M$QI!%;W$>0,Y37(>,QL$+@>6](M\&Z7U MQQ)W=URJG]6>JKQFLO0:M6Q]2]NIBH%:I7'\5]!^6<-
CQV27QIVRAIX']JKE3/5T,C?W4]#D+IL> MH$C.I+<)UT>V >B6 ;@1?].0IN*52D3 6WA>5]?LM;OTT&>6W3$[?2M-/.,9
M(H3ZV/)CN^$B&>9Y2RY5W_I1VBS"VWMMIM/IF5:;YRL_LWM=LSVP5E94C_9\ M1-]+]]SWLH/Z8-D79^*Q.::*<\? D]23F V"V:I90<4U-YH>&+I1-F1R^T%) MQ$:0'3U"
(!+NXQY%*=5C!O$EN6(6D7BI?GD%MMX";,.7KD^;I9M>Y9&W [!" M70EU#OD6>B%_+2E@,&AT.STD@CB$_\;JQ9(^&@"\G]8,;S4;-MY5\!60S(Z? MM^WV77? MA&$_^>B=:&N40
;4P<[:JM@&5U&N8]_& 52]J_XL:;'S43T0[M81GBH.-F&@:)/[Z4'!#[$$TFKR1U(P-%@EK$!NE]AN*0,O/F9=.P0,"4(F;I M\]>\OQ*D= BXV8L?
N/,"^;W"%YDE[EM:#>Z4N1WJD8""Z",+HK?%FG [%2'Q M^%!84$,[M3M]:.\)VF_((U&#Z.QYXX@M'>R8U.%*M]]P['<$^' MAJNE:]?
K]\KZ=N8A*\Q(YQ%V=7C$>@RCLV'TYKTXQ0E*^UT.M6D4*(.5.]%G MJT>WTQ:UK5'"0J7V]KS5,7OP7\=JOWC(-A5Y;KW=_;@V-;*=%++US$Z_8UJM
M;HUK53B/L\8UNV]:G:,9ZO5/$=G2^^W=U*1"Q*O>Z;1Z5L/BV-^C'LYQ=EOH M1;JWVGY2VGJY5J_8G9SEOHN2"(SX12@:9WJ*TG\IV;'8#0A^"S6Z#-&=Z.!VS M-;#,;K-
7'T[U#L_OH*#4A_-8"DJWT=]1/]G'V9RD?K)!,:N\1_]; M@,5UP7[\^B?HK=O%SM#\OE;.Z5MM B\^^.?MEFE9MMEL#G:V#[<#Q E8CN=U MHG":@QXFU[?
J$SV/$VTU3:O5,>WN[@[#^D2K>*)VRVZD[2&.H>K6TOR]_ J;: [4QMG_ZW.9>.MY.@#@!X_N\3O0^.EY]HE4^T?OH
M>/6)5OA$3TW'.RPR54C'6\E;MSIUXG]=N'ZV]]]AV%05P>]K'G95?>Q/\]] MNC'ZC9Y=&4]&L8[S>;?-3>W,.(NX<\[L]@=F=[!K4 =L]=L8=IO?4#5/*"V937:=6[-^>?6?,
F<4,:QBHU%2-V?M29-2>6 MP5_FM^V:,&:V9=7U%14\'_Z1:8[Q/C0"59U\; R_>$^/ID#GXRW99I]>N3J=I)V%:_T3E#)?RQFQ-4WD'Y
M28Y2KF.G9YZ2B,Y*RVJ;;7N'+E=UDFF53]2RS*XU,%N=.A'\3$X4G:*#CMGL M6?6)GL6)GIHCM4X$/X#[Y;S<-UOL2T.?%N#(.$APR% .?XZ5(UTO[=!+>U*] MW=!\2OQ0.!Z-
#)SBY/;G:$^]P)F8/%:<)VR)41+*:9T^,.!9$,8TQ]=P_1L1 M\03OV@@[B^RNYRT<:6GMD'90)]X]TM&TS':K9]IU;G%5#^AYR^QU;]!2--P'W-T" MJ@_GX(=C-0>-1YXR>9(>X5..4%^-
XL0)7<=;U6;$?.$%2R&,H?#%Q(T-$.M^ MW27N/ (^SRVK8W;MW1O!U;&X@^LL]/J](X0C*M/9RO"Z;3-7K]. *C@T;0& MG<8C9Q>!?-%*&;"C]R;M-*&59?:J7+F,9;G|9E6IVZO]EY
M'&?+;,,PA78=-JL1:D^9+^; PK%;NT^ J ^TD@=J67:C,H=9H:#V7AQ4E=?X MWN1TO7LG+YZ@#VK+,"T/C5^+U#Z !U0.!W8>V[<7T%2;)6"&9Z?3,3O=>S?_ M?Q!XCN3$](FB)HH-
1-$WK;9M#IH[A*U]FJAIXJQIPNZ;;R^<,%'L MXNT^&(%4#QM:[?YC<$*^EF,B8F5LO9\HJQ!^CMV;U_%_Z@US9UPZQ]\94& MGG\E4>Q.EH?:!#WQI1O#ZT9WG'1350551,(01S-
*B/Q%W @O6& :9+K;U;V5 M[N7U?PU#$#S=];['Q/2U'8^S':>&6^^?HY,?+27((VF.QD%_C@9Q?BN M+S-\:2M[EKP?WOK;-<%\$0J BQ,'X=)P1K%[PQFYZ;-6;H1G7G_X77\K7K7A M-
5^B*U-^;Z]\CU\[/ZX75[20\FN^?/EBK@%QT+!3&&JPCI+%]"/# _2"]0NH M/3(-6_%=]KV-@BCF1&DXWBCQ:+Y!+O4? M62QMO97\ #32H$5<03AW?_1N $_B8
M'1@&M_&L890>N81SM]W $U\$D8MWOJ3G WQ?W;KC> ;GA,>@WR=5NF9VBS,$ M!2Z)RV_1T&D$5"G"Q\&_N\LK3E;.%-Q.82C^'[I3&"Q+QWOUEE& M:*;H%
/D(A\^:#6Z\/ZRW4O:4G!KK"I^#!+^Q 64\F.XJ-6EBK$_B3/6*=2X!NW3H2\RMJ?_FCMD4WIBNU6;*JC;3XNBFI9:>4B2HLH MQL3DD1/-C)GP\%-CZ/C?67/
3[7B*OR2R[XNJ>Q*]\T:BV&L%6B5B_(3H@'9 M9^R;\\-XN|)G[%1$\WJK-$9N;K3U<+SFME#W06FU'#?*ZXXAR$GX2^OTC#@< M)*'Q1^/W!BO^@(#)%,1GE PC=^P"
0A"35P@79'=D5VSE%>TS@(WF6GEP[CR ML)]_R*7LG2F_'JU%L!FSFSMRVDWH'93G12)?;34Z#V']8R%Y-.#EG6\:W,'R M\=!\N&8K]"#F@B=8 MLKF-.R_]4E8W*\V=O*X
'L]91.*E^N65RF5P?=H2W?0JK]9V%FM.5SHD_EKJ MOH-!H]OIH?HKDUWDBZ5FW 0_;3^>:O9L/&N@]} 6=[Q\];=ONN.B]>/; 86 M^NM:W<<+#5KVH_2]JL/%1]RT/T&
(J2%"YL(H>6:D;3M\;@710FFYK_!%9HGI MUF &V_4+1"SD<7-VV(5H7VO=+P]=9=^:L!NU<#>$[#?S!Q_>K]NW4XR\!I M;--\]UOWWMI?
[ZUCMXJJ[!]3/ZP=N<%IY.Y_7@B,KFG1W"=7GOG HS_Z_(YZ M<8^SN"?5=*8L,ZJN[-FR^T+E3G3GQ.M*)E"7-);HV6;;LLQ>\R3[Y=3(=E+(M9K< T=IF(;+N4>%2Z5*-
D*D^S4T_EV4-3 MH\JKP^59]4_.7#[33]JV938' [-9||FMXNE8';,U:)6M7N7D?IT#GXZ'5!1 M^F;_O_L@_IP#GTXK5[C&+W53U)#V:":5=Z1_RV(03\)N!/.T&'W2Z6QEF5 MBS\?
M'"VA=G;9;[%3H X =OQO$ZT!7KHH&W:S1T$:GVB53[13MML6UVS/2OZ*318O8^.5[?,K?*)WD?'JT^T
MRB=Z'QVO/M$*G^BIZ7A/IJWV2KIZ/2NZSE<_X_OO,&RJBF#U50^[JC[V)WG5 M7MT8_4;/KHPGHUC'66N85#LSSB+N;/7-0;-E-GO->K)W-4_(-@<=+V^SL/,FT
M/J#'(J$.G%#3[%BM^H2J>4*==K-AU]DUYX]=@UW0C*&8!*'>3*[.K3FQ+X2 MSVVO;7:QQJ*]>P;-B<7@3_%/T6EW3:EMP.B=9;G7VI],WVUU05 ://>]/IUM M(AC-;J-]0A&,?
2#&V<0I]M3DU"05C>K I;Y_V_N?5'^,]5[8M3%P8B*SK! 0 M=,UFYR3[2)S[T72:9K-?VV@5!EKT#0'O9IHJG0EHCNRGZ[;W8'_#;.M&TRB>*+LZ!9?;LW=L;U"=:S1,%^NQT
M02?:H6U3?:(5/E%TI?9/R)5:)X,?P %S7@Z<+?:EH<_J1/=CYTG72SOTTIY4 MA[=/!6/. E^?;:::-<,V<#0 S: !:-I0RKZ.H_$+NQGU:U35RMZ/"VSV>Z:
MG5:_/I']M:S&TZG9W9[_;HE7/4.I]!]]"M\T025]LE5NNKCE90=C M.'%"U_%XB#$HL&*^\(*E$,90^&+BQ@+8 QZ^[IY'<,.7Y937-_BY"MHZ](EY(
MW&S9=5)L!4]F8)F=3]<^F8]\%WZ-@O@C%3/B1>Z/* MJFK_V9G'T5]#GCGUHVV5ZK#L?M#);-H]T[8Z-4+5 "+67S W;[-H#TV[M[B&K M#[22!]KO-
BJ3*%>AO(F|..0JKVF^R>F8]\Z//4'7UPZ9 +L2>>5,>><)D%MN MOMIDC8G [0YVA=Z],O[XLFH#2=6H>_:HVVJ95K=M=JS=QYK6J%N10WRBJ-NV M3+O?-
>WF[B[D2J/N+L[EL[(0++O=."7_P6&1J4(FRBZIW5NJYJ>DP1<1](,S MB[=-('[2+R+\^XG2?N'GV+UY_5_PSPHZ=MN-/N#V(HC :
(WP2\UN\;[G$X!*[V&.)IKJ[_27$1E>>_U<2Q>YD>3B8TO-?NC&\ M;G2'G$#8?!61<,+1C/+/?Q$WP@L6F'6>WV$Q^N3W4@29;>Y[3,FXMN-QMN-T MO*EQ*T)A/.O9C;8![_>
JHQ)$!KQ3!@^/,Z8PSMFD2$ /<;&M5C$8CX4(4O< M5M,T[*;=-BD4Z81P11P8S^Q6H[?+PPSYG%;#^#:C0":00"2,8&(\:_>U9RU" M%[-H&00K^#7 5!S=|CZ':Z?
[70!XMIQ81U3O&TP+AG8-*C*E? !,WGAEO MOGZ.3'RTER!S2S,V7Z,J4W]LKW^/7SH_KQ14MI/R:+U^^F&M MM-J-9@I$#=A1LE@ ^/&)7C!U ;5'!J#FC3N2NXH20+8-L%W=VR(!
]1O=20: M(;B,<9@PS+<"P>KZ=0S$Q3ZS&@,=*0 7HL#WA7>I-C<'%HI@+4^" H\3+#0$V M 0;10N !"FI!*DA0 0NL+BRELQ&[(#;I\S40%T,8])?+=)?E#Y8+RU,.I&8 M80S0@7,*)I-
(Q,803@QNER^'[3|K-KHZ. +*)[C|:8_'*"O$8'<4,K*7X1P M=@C>$JS$(:Z"2D!2;TMUH(K3_R!)TZZTXN:VLR@_;4E/2]R5K,YNFF3$.GL M+$,:G6VXA<8&@G#J^.[?#JJE

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|"'H!TDH\AZ/ M!,C$(T01'!H 2';O01:/C=[W<%H=S_D$!T6$942P*E3%'#U;+Q_?1[)3 ?B8 MPO&Q#,[_P%|"(8PEF+WH!XRB9(ZWY)Q/>@:::;&O1*$Z;Y2(COND+/[DFX&-YH M$BHI[R"LD4%H//;ACO8PQ5\6[1VIXY\?J6 M"(,G7H)*#CQ4@X6W9-K'C2&PZ.>87&FTH=BE?0)V%FX-%CP-G3F A'.SR(_G MC&9$@05;E8! YZ>4U4AP1#M\? \/X4_I0):U0H"R&E9)XSQ1M)#^9>S@,:8F% M\(.O94($O5AE>R /X7.C6U/&US#^(*HD9@I[%PQ0/&8X@]2MJR-3N7L7G<+L M+Y'>=Q-]Q'!Y2(PJPU#67X3.39) \H%R71&YX /Q%- H,1+D^,F4N_QI_#D M]%V*[Z3O9+$Q=Y9*=*C@[JT82(\YQ"#?"48+VB=B"H(:'7NPWVCF+OCYZ6'! MZ|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}&0UR," ^7F1?_ M@&KD R!;;<0"E+*Z@%9-NP;9MF,M.M@QKF,V!P\T]DY9)KZ=3 1W'9D'-R*M M(14_1C.,5AD8O8IRl:FV6SW]B,9I>XLO?6K MS<5V:l-GM2K>]!,EZG-5??@BJR^7Z499L;B6]7,D'\V##N3<6K#N$S35;B7Y MO-6A'2U;@&?76[(G\(8 TKHE>=4)RV[VDPRN.03TC+O0(-2N/0$ M$BUl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{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l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|$2?56):!*Q3YBRA-EX M!-L)@M!;\AMF//>VRI6ID,^XY:>"|&PW8["6D&?>*F2X^U"24P(ED6C9EQ+5 M,OK%KQ7C:BD0Y'7 %0HB:YXV&>XDI<^N\.5I]_+E%SMV\)D]<(X71K MY @Z=_M OPJ5#H3NAT%M>A_3E!O$3I07^;Z%)'10[) *J_W%4[C";T_B491/+ MJD6?+258RK,&S*RR^>@-P5[L4-__#[*X[3Y;(.5N'"- MHO_W_2&K%;3)%L\QGZ\/YU\#),:7P@ 9ZZEL1) (];\/Y*N<+ON5BZZ'04RU9$\^U7$R_P7Y!$S,:CI9UZ.*PNMI?$Q55<3N9 M& XW=|%TDETT8|9_W6#"Z1;-.+Q*9U4"P]=2B%@.']_8=5;U+O_N+3_93A%K MO- =HB0.'WB)OQK\SFX8BJG84"4,EN_/]PL9\[S.8!CRN@SGZUUQ42&L/R; M.Q-?8>/H A$#3T2%^%J8UU[MR&9Q@[G<3MR(.Y!HJ=;W>\\6'ECJY'V.H\ S M PW;3UQM-- O=*,3/**=!3CN/;!7#:\FZD ET4<>R0H^O-)#-3 ;!5Y]-)US> MX7QF.<_WE63ZFZ*F^]8F=I3[_+DIFTEJS$>BHZ%CMG*#Q+IG_D0N7O)B M\>/XX@F*EG!%,V42+I?N"ZOS+? 3#.7,NY"&+;ZU:U.D)_XB>\[7(:YS/RE?4 M__C(9FG;*I?U9DJJNLS/AY*OPN-9Z78-(4]!54,0 \G&\2!T^;2$.=.Q'YT M$T%';":"6K[B 1B@!70-');+5]S!_*8ZX9_ 9=,*LUB,%6*BL>IN(6 MK1D4#045#\%:6Q9K)&T[EFXJY/GASZ)R(N?T?"G"T[4?EZM;!X%5:F(TPH MUO$BIV 5ZM^%WHPX]@+I^%!0N I^K*_T.VPA%"^:[%;IJH^.X!/^ MXV6*KO!_?M694T1^8S. &QP2(YA5]JHZ2K#![1&1@.D_M152E]+% \3)4 M*K@;,C80=C1]?HNQ/X /]/.YO%G(Y2K1"+[Z-B)/G.%DT]@%0>)VN2>E(E68 MC73"11C0P];A$>=I TVW5%)5\.P6OIBZ52I2(9\XF; (5;OKR5? V9_=\N7LE M I7H0#K3VZA/5K2NS6)5 "/ID_N>%_J8K^#ACKEL(9M5P5O,O.6+YARMH# MI9 _AI_B"(GBAX-*P>_])2W;WDK@<=?XE8\HT/%/IU>OKTMJ/T3(D MUCU?9&G[KJ7F!PA'M&">XE%<=?XV/QW_\^5V-/l-A.Q<6VT"F\)G'9?6RU<5 MNTRODBX1QSP\.AV1)+*;+H@U!*0SBL>O?.ID^!.[*;%%Q6BN%JS$]JZ>\HKW M)G8(X6#Y$S^G[! <;#CA_H:".S914PO&$ELL_YB;>[*7<+E0J^]V!SMS*99"Y M>I%QXR3!&/$&B+ZA@"_\6'N,:+T1(GQ["A?%?. N3;YU.#,YLXS,&"1-%[-\ MYJMC=8YDBU8B)4;$L= =]AP?NN)-_^5PYA3? +13"ZB[S.V;@Q>\@&FZHBHAZ M2SN[HN!TB:P)&\I=_.!X<#8B_,20-QG* ZEZ.%;FOBAP[BSX%4[M9.)09, FXQ[\].Z_4$L#!!0 (+ X9UF=W^+Q51T #(6 0 5 ;6YL M:RTR,# (T,#DS,%]C86PNx=8LW5U9>ZRK9< MEG+OG2<6EH;%"47]DI27^?73H!93M!8N.-)Q*BBMU/'!! 2'7H!&XV___>5D M].033F?#R?C7I_QG]O0)CM,D#\??OK;?P#\Z_F'-T]> M3M+9"8[G3UY,.3T MZW3X\7C^1#"A+^[_.OT%Y5TCDQ49(4&@\N% XV,*LT(&CYOJ_/OZ2<[09 M/:HHP7O3"}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|_8Y ;Q@/=:KEV9.E66WCQM4M[ZOM;IFM%$%H"-XBJ.(L!%O(#Z7?E=&E MGJQK'S?>!]? #GF[G'8MH#3GI$&2LHQ,U>'0:DBZ"A>B!:B% R$E3R'E2UYF%#I MRR?#\7 VK^__A!?O'T25--JL@%GO*38QY/EI&O3@G;[Q+< ZE/RGLW M3JQ.BY:R:)B%-T-

Z33VH\1(_X6BR.%!Y"8ECH{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|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`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|FW9],.HV12L@PS M:%MO<9DC9.@+!"8C,N,=SP\YP9MR_2"(HZ&^G:CO:X+IKPD?P^^O,LU\7,87 M-]>7ZX\-)2M>++#@:/TI4D-,A29=./.2ZQA5B_=]S?!'PWX+\=IGW?;G_23G M&<[GE_^IT^6TYT2)D7R H$6]UF*':#EM/!JY5X5S@M1;KBY*37 =EM3!?6Q"@HCBEI#<7QJG:!0_"!0225"R%9HWJ>G*P:]>@(MWD*8*]CM=3!6E>QDAF&YF"'"R"(9!DEEK-OKN\W1RY= ;5TPR!FG;KU>GJ"WXX|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|'1]D|LZVHF XAQ\$]MZO97Z7?CTKD&FF6D&0M.Z68 M!B<9!VF%C#;RD%7K2_V'$3UYC1A \,L_2^-5(\IQ=SJP: MD[)66*'YAQ1(=[.-NDAF>>LXGXV '8V2M*=A ,/^_MQ'OF#A5BI(.I::H$#: MJP)I;PF,9IVTLZV7C?LHCD8+>@IX / ,!J(5KHQ.BMO:3RDK2UL:K60T5U>K M=PBE7"HQ- P\6>!#0,=F'/<4]@"ZLV*-.62\XV339UL0T=)&\6F8@V."S ML2GE!RMW-S0B|NGY-R1Q,U-B2P8&,#*?5_%B_@4G],WBW44L;3VF7"F34>%1 M(08'6M1.$]+F>C\M:\ODPE+ (Y!6WSA_HAO"8E&= ;H8|DK@!*A47K&6"W"=+ MH'*^;!KE20!1>1?B@|6DFVTXQZ07_24|K*DY"DF]&&I*C3"U]9^(X!5*<)@2 MYU):*5]? +N[5Q1C.IN@DR@%"!VH@|'AQMHQZG.1GTTG=RW"2*C1OE$S(.3 C M+2AM$D3AZ8MV-$6C+;-M1\#9PGSWHK43?L_'(%K5Y7+K[=6+MJ_UY> MUR["H 2C14:R&J_(;FK>95VABX!FEZ+C M.15@T=#4,!IP-CGP27AMK&"TEPR21'*-8?<4]^%D9?K(E@(=(D(\YZ7PPNF| M,,ZO)L_"E_$BG(ZX9:H4,AF<)>U5L7!PG@M)FGNA7M7FM\"KH;RLEN=X! M#/+WN C5?W@19A/;2N8G*9V?G9_20I:K9Y'&BQ&:[/"|)\)00ECO,P.A!HDB M6^.T5LWO"AI'1:1UH;'0APCVN$:T/*ZNA01G^+EZEU^Q-J [P|?3>0U*?UL^ MAM|'5@:GEQ&PPA)<9B*X&!48&E;WR?>Q?"D*>XET %M!$+BE)CY[XZ?LL.&.2O%$/'JMA M&VKG868"A"AX\,I9:]H73FJ!_$DKTQ[(&\#MO'UUOFH-5*$8YA@4FSB0F,B2 M=O3&)$:;7!#"Q_>+4?8\1ER)ZWA|A!X;L'YC1<%3P=++HD#6"2M"1I+\'EH" 7RVE)DKGHUHF^@U?!BZAY M8LF2_C*:DY6DSE+2DA? 0BA*35_QHJ^!UX?.1*GA=Q'CX5?"4X3D;QL85Y6GO MY9H$(R(@^58EQA3,@QV!CK$*7B>"-ZZ"UT70NZE_M@FB'[8*7B>Z'B^$MHVL M=Z,%/&6K!7<02[UA)=L*4XJKXLC:-Z0^_505XI#9G_K*GB-R>\BXMU4P3-) ML\(R Q]3!,6T($_':,AI%H'>\U!0R&$N, ^N"EXCJK<1[&!O]7)^Y"&]G2U7L[R\8WV' MLV53G)%U@H5$/K'169#5ZRQXI0UD$:RS2I'SW'QM? QS601P<|'$(6HM^C[(7@ M1G^DD_/%Y^EL_#^81TE+VL*R!1>-),5%1FN4+2"$1\N,1UY:5TI\ ,XQ:4,O M40^[1EQ >S6?GQ.L3':,$\J0?5-SD]TWX$*A+]X7FJQ%^C*T!EQ .3[VMQ#Q M $/#_9'*R49IG.DG4_(&HR!M!&&!,E*JY4QWKG6U]B'T91N5SJPK;#7AC@, M?8C\X2-]_=N+-Q_O'WY]MV+]RN5 M+62|HZL'9;0I(4.P]>S$Y 0^.P<\F"X$,W]0'.Y[W2]F_"^8@O,P^%F$;,0__WN< M(SVP=H=XCE_Q=+HLYWF)|B_!6OX"7K.:O35473BI5BO91Q MBC 2:.|$)H.WL5(\ NE8U**EY(?HK7%WTJ- @#0|2"I!1\5H;2H!WPD+@DON0 MDRJFM2K< W$LY/>3[@ Q$/L*Q?Z^!6V1ZR+-2H7JD7##5S"&O"AB /.S #4I&A(U!C M:%[0<0V4(U&0?B(>(.? VW6Q**);;74DF>.\R&"$]N3BVQE9P#2PDB<7PB*;U MS=+UZ$^>WRT%,4!^[1M1Q MZ$9S.H9JP:FF_,/Z;[(G^;_/YXO+7D(7)2)4M.[Q&H7-L):(T 6\-PQ0&%Y0 M<,Y]ZT#W5MB? _!:S%Q(']_^P;AYW:I*>ADDM3?+K))Q52_I_/^5A+Z<[&P\ MIY?K.IF|K%U.G4):J&MU+.:,*=YS;%Y?;,CY'*W2 M[ISL :H,;%14QV@;0\ (*:A0*^L$H&\49*:YRX)YE9L? SQUD8:,=KH9;"7]M MQ8%>E_9WX5U!V^]8P-HDE7>"O,-4>_FF %%9#5R%)*20!IO7RVH\A2>O=OND M]+Z&^@$U=&3(MY'6*! >]\]TJR.=!9:%84WL7N1!7.TZ M\31,9- (Z:!N)Q<0HI0SFK+6E<+%47AJZ?$D]'&>FQ|6-T3\A^]N"N^!W"% M_Q-KRV3,)U]Q%C[AF_]^;?E7]+)+V$^3]_DLLB2+$S'5:ZW/PYB2-5O1ZU* MD5XTU;;">"3WT^'HV/%4M<[-&L-VN?CTW/Z[?UD)9F\+5I*,$8R\K110TRN M !8L(6E=&+8VV#I"/%8%:D+)"A7JO5U>5>^]RFR^!#K*G-8^GU.MC<.K:B-I M-? =@2VW6$[U@S9.5UD!Y\BK10L0KJ.^]I=S%=;&FD4.:9"08PC%-J.@[+VT! MIAF/B)B3;EV*<"60HZ.1NWA7D+Z'A-%G_W'RY]O/KQZ\^)__KJXW_=!MLU>>Z++F@7"(9*'% (/F*3R|PH.U&&?FB0'F M6N5=52N(>07>M+WPBU^E,;X$/&':H"INFB.Y($[H(>P -N*CO?)G*]*(-40E:-3U*LGYKO@(&!)V-PZ08 MY[RU5WES_'V5PN|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|BOB'5+\AV!R@ALE#+_CX&5D)H9(3@-SM=RS$."5B<"R+O0_GIW?Y>+W MAR;NB,LAR@-\K/(YGWU;SF*)^221>&;UK*/&#"T^3_.(EU0+AA:R!Z2Y2$@- M.3,0HC94Y^32\M:Y&)O@.FZ|:LY,R|(RI./U4>P5S)Z2=*[/)Y-?EO3) 49 MDM=YG(_S.,R^C5 *Y9"$XX0BU;>V0*CG(=]BML(JFMBC6<,-K1<74B|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|&];*\DO& ML(Y[15I+?P"+Y^5TAN-/DV? GLQE.TK>/LS"9AV5$VU53WO<83FN3WI$.EJO$ M#=A(R95CE)LU:6=+K68B16I!:Y\-?85I" M>5:OTDGCYJ/:)"NGA(6GUBK022(14;(,3CI'>,D>YVXO/W\HZ&RA]B&]!=[M5\$^7-PYSD>")R&"(S/$D*&]?#+@HBK@R%*611M?;.M#M;5@GC+Y;26]-F^] M8>C*RS">+4W1ORVS(I:7T7V"4QY\7N_PD\W1-@HPN3M@?CMY7Y.,9I=]2.=7 M6^]%'!+F5Y.K:N(G<;Y\ [4F1G).L(!ANZUN?$)Q"#25QIE2|) .M,QP:P.YM M.6X/X?(<.YH4JVND8KV2H;:RI]I8(&&Z4FA3S+EUV=*^F'<5!K-KK;QGB>Z2 MVWU'UMR!_ ?OG_!V-:WV?!\[? 7^!5/E^>4%7]FLH!TQH$B XVL-1D@E."T MS|'ST#JG;S-D^[JKV]VRK-/4=]0-X66OVM;NX[VL3,*DW9J\F9'6>5QDLWY B:F'MH E6I#=$BP*>&P.9 M>K M_W3Y1FTREX&,I);SV),-U4)![I7=V#.[VR 3>?D2U0EEPPZDR^N"'+PY*.# MB+D4Z6P)K'5\T.%KZF,6V:$K:A=2!VH,3G#?Y[7@(7ERJR=5MF3I^.% M((BY* @8E^Z.8-X&EG"PRY#UL'Y,-Z Q70/TPEWE17\'>/DR;0)QA\>A=^#M M_1"T#;4;'%.UX&5'YYYWH3(F;:KQ=:S0H]PBE^"4EA S?1]NB]P%;-|/>FIL M?L:Y- \WI0L>N3LJ_+\M7K9]#\2(Z!F24U7HU6D"P#J'(9)P.+CK;NL;$)K@. MXZ"S%Z&;G(CW86, P_GD:QB?UOWXY73V(=RL0_LUNUK#R+]7DZ|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sVVZ M9*E-RD+Z@3XJWWI*:./^!-7$ 9G>__*V=1 W4N)X$%E4?:J&,^GGP/'9J6%=%!-R?9-IYJ M:P##1%"UD<=>8J;06D9^B8*0K*M*K2!R7RMS<=,Y+YUCO2P<5,H47&2!W M"69K+<,(4:=:QCJC,HY$(5J?:CW9F<DN^K)- S%07+@XF9FJS>CI::#)AL18Q MJ9T?@M'@/"8HQ8FD!?>BM$Z,/^R*:LWU8;NB:5UXV7M!JTW _E$TK27CO2I; M;4/7WG5,*L>C) |&.+9,QA40@B*OQG%O%2W_K@Q=Z/7)%DW;G6IU86G'1=/(MV[5:,4=& I,$B&5R8HP"JU$4K@KWH;51^82+IG4BLD/1M"XL-#S071:.?WAK M?_C,;]D!8GIZ2A_^+2X,$*R2!BO:(*K':F,MPFH+TX)VCO0:S=UD8&]4#_ Y<1# M\WB/]78MN8B=K1"_VO2?=^P53?_:.6:8I[]-WI;K>7Z?'7,A^6,L8(ZR M)A6BO4YE XF)(*(K6OC6*8 #SN@/==^WF@Q0 JKAAH2RQA.;,(*^*+0(P2>$ MC);%7*6L6R_DC:V1AO=3%[W%3G)>/]>&]=-(9Q>!6-M?.FWPU-XW25V1-[H> M>HWS.>)R\,N: ,9/L&!TSGHQ(SGO'4:TB.0

M^KYYJQ|_<;R<98E>D357TC*:4AIP/'E:(Y@0M#$:Z5KO'0_ V=653TL=N+N* MMY+VOB]WYK/%J/:A?#%?T,)V,LDW5KGG2'M4&E^^J]\G^;9<=4)='@4*FU(0 MEM$Z72OK%,\A!.9 DRR-*:B*VB@JEI#H/ MIL#?A#.\1GP58[P!YBZ700TT;17.W=X%[5@5.BI@,QX/10=]JJU;ZPV'C*SV MH2>+7TD)7J',,11+5NK1Z=Z:NZ(G]'I=Z&NH"0[1%@A:Y*!6\UCYNQ/*]1Q\ [O_UDV?HM?A;.XFR< M/^$M1";62J96T_(5JQ%G"%%@"9!Y%S!A=#YOQ.[*QQ\[P_UE.L Q[M7DWM'" MLB!)U-S$+]7%^N5;+:ZPW+^8DYII6EVLLPE4KEFPUF7@GLL@43 =6L>X;0#K M6+R .% LVP;P]A/!UIS:356G)R\#'WQN!+4P*X5%P&(" MJ-HN)**.P)GA6>N<:2\Y%M5Y}$=M(#2G QU#5*XX'Y_FZVKJ7.>4DV8@A*K7 MGAJ|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`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

\@("%6VU"4)L)'F"4IRD4B$>. M@S?>GG>O':+?X]$/#Y]HA?+.Y.5OO)UHWE8V3POGM=*Y\[?*9F9]U MC7B9%W.\^KP0%[:'&U4EQ,?M-J;)T;XO""V61?W*ZGU&OI\E.&G84*#3"=+MTX B+,.7?D^0&^MM@HV?08 M95+508]8-#,WWHX=KSMTV7%TX]5KCVHUZLSHEK^)SV.L->3LK ;.P1Z: MN*63F2=V-ATMKR5FYEE.I1_/&%G+!//,"AN* \D5G6;?*%QW.-%N^Z*P _7S1 M^0$PDWA8+?^V^/R-E.(797;\U?!!'^LU|UYNRU*'#7KM^N5Y/Z1;SF[_(*4* M2?3-)/&[BDP4(Z_6*U[H)U5 PM00O/ZYCW6MXU[O-
]LUU['L[_IMMY0_U$GEW\Z^9\9_A91XP_, S4HU7H9E4 MW:YIFEBS;/EYY#=+U]3D9UD(9]+A=EF=BYQE0EFQ4XIOBJ/B2;2GQ3d\$_5%^
M(=]WN_V[==EP6]=E03=U$S:O/R@EKU>U4OBR.7=42YCB<9&S6*8DCA#Q>:HV MY3Y&F<\%RC*?X#0F$4LX*&/LEK^)4\('W#:W-H#97\=OPS"]^W(ZAIX"]]7; MWUV=<[_X/6?>VO#O,SDZC5%?I5\?#S)9[*WLYG&DVPS@K0-\"S@^PV_)OCY@_ MRC>D7*E54Q_];U,1!;M=\=?%9 MD(F?)"GD\-V2CQD/X$'7'E\ZT>Y7F[,:CFK>F6HBWW,&V^[;*-]O6SZ!28.Z\
MI\TM23BVH95[QJ?=MKL&O1/Y*]3C:B-MR,>N&^TI5'6^LKYW.TM/9IF"; M/[H$;%L7%2RH3(6N@$5^E&0(BS1'),Q3_QI?^"H MJ $=GLMW8.@%7TBSLQ\K-O_;G3_=#;\=N+><0(VN7*A+UN;UJQ,H|<393D$# MOJWZI/Q]X-,X4)1O^?I1>?>W2W)ONL&Z\/C4-18Z6-%D47!@B!T'YCNP2]*/ M[\4<" [S1",R>U\U>4=;M1'AK#9ME^:<;?
LV(E1_(SCI+5<"JX,8%'*QB&WA\OBJT<1D.JL@,AE\!R*)G+^KFN/1] ML1+O:O%0+51\$H>Y3%""4XQP&OHHHS%%.*$\2IF,P]C(18U2FMA)M3 E/<+>
M5TW::V@;XF"/:\LL)>%$!S#G9"F^'53+D&@NP5K.TID?KF5(W+. +8,/6)=Q M*L_P:DFJZK8[YQ,L"H*84^23(%+!!?91C@E&^GY2%F&69S$H17E*8IZXHJ'H
MW48(+*8_U86:;UTEI%3%'T DZ R"9&'=EA,<YJXU"@=F6*^2R,M8OH/&SW# M11EA2:X;>)U$41YRN,X0GXB0H3UI222* L4(4NS,B[% M'FIH@<,H8T)(A(-,-TY+ I3AE*,(!G'& Y;E& 2D>!T[D\<)N_VEKAU0^E]5 MLG5B;=[!HZ+^0XB5Q[3[5_\&IR0"Y^JU,*%>B_1])-(4\R0) M61++A7J.KG^\%|-GR^;5J+?
1!CJOO(\E+U:D[$XS*Z]8U>M=%'3\RY=Z5V;A MXGSZAZUL#5]>RYC70V(G MBCLY%G8S*_R$ZHX_Z[K?72[4-T>]|"U<]5D<8V1I2.T%R:-(
M$!5PX8"I((PQAR*$I4A(]6>"L6YV"P3S-Z4]<;#5<=)N##M6O$'P/AL? #3T@>C9;I"?2'LQI;!77YT+W35]=G$<1'.R$8H/"#U6!.\]!8\IS
M8^M#57(&1A\\A<6**43YUW*]>6Q:HC8K]+?U4CW[J5[=/M2FA1TCTTSL-S1U MKR'O-?2]'@/>)U%ORI5W^[#>K R]A8EB#,((=SH!AA#7]P,60I@):A<^C,P] M7^A@)N1!V%W(<-C_Z]6F+'5QY19<7_@)B9.(HERR!&$>2MVP+T,Z=T-Q MEA$1@? K!ZE-;=Y'+7P\Y+&6 =CB/ZPQL^7>F1Z)GW8C$^MX"UEIUT+0#(Z M6L&':NR?$@R6, 1F$H X1I'"/B$X)R
M'\M0Y!A'<0RQ\1%Z4Y\.B;KIA-M<@;N0L(/9^YC^S>H59@-G_N%EM+W/O: M_7^2NVN& CMR &/49G4!AJ(?.P'3QRSKI\[LBK^T9R_J=U I2;G[3V+E>ZI
M56W/YC[*M\I65]QO0L8;Z28M-<:XGG<^4;H3 *(FY\AMY&"+]2X*P"'FB_I:G MDH'*KAPS.'6UUI,HGPKQATY,U|]$YN*CJMFZA>P
MPA<^3T4>L!CAE*L_2(Y1%L3:+X=92F).^\CHMVA%_D M]N;KUMS?DJ+\G2PWO=/?:A^^RSP.1$)"M(,(QQ&,2)9EB*UUPIE)I,H34&0 M18/4)K9<3=MKB'N_*D>F2%OT
QI6E[ER[4P),-OMR7]X+W:*'8B1C(Y6XF%: MLZZ^1F(?K[AF#]D>IZQ$+QZ]UAMZI<^/NH]0_7FNRA940F^2)*$Q8G,4)9+ M#?F^Y+;=&:OA0/>C]YL(2]=UT^
M."B9/;3#R8SSHCI<$N@$T.'B0/BWU=S>U$6&7,L$6+2[KYYJ4]:R*/"8,5F<+%T3%?;'2M1H> M)>=,M^L^$NHE%=A:?@CDM;TXVB/M&JMD6$"GJ"472+T ?LFPT.>13$:>L>W87-
UNZF_K MLOB'X(M4IA$+T@@%"=;G)9PCD@B"6!R':A:P"F]J9.+1^5CW;T? M8('NJ6+.@]'KQ 4F%@_3&*XOYEX6Q55]ZBF!>2M,+PIX4B-Z>:1%.',NT;&%
M:OHD5N/([LNQ.G1:Y"%D2$(HDHSG"DDI$U5!1G@H@8EBA]@V<[J3)Q[; M/-SZT%1OO-5NCU.V_&P/E@'+T"[!FO^-#ISDK:\)?8P:1TKV9/E:=0%B",F M49M=A.%0?; (!*Z$P=@$,-
U\40M-F]\;\H6V-'G5608^S@1 M'!@#-3+WB-[H3KB[&\Z.X;,'A7.)'WV>T/P TH,"GT60'GYBYOYX6Ü?2;9N> M2+'4G+U=EW]5S]8+S*F4,N(H\@.*,*,A(@GV-1AEH*R?
QIS#P"@G8G3.0R.O MJ*I-T]O2'M]PJO=EYH=^A+=@D>^YKL?>_GB@0Z?_)M09T(2Z]X=0J?NG^ M>V-L_G/TXC-4MK_^?*;T7"2K=O>C/B@E;B.YGJ5.Q F2"><("Y^BW,\P"M3N
M.16"R="''17)C%*?>)Z|7]T@]|^]KLOM5>>C3;/]]M#.-=RJ761=l;Y<*43$$\E1@$-= MT9/%*,,]NL-I2((@I9QAOJ@UL):9)S@F #+\'1GC[[H%7ENM5ZBCYY&& 9B!
MGVC%$)ZOD15FOBVE:4SUDA2.+/-D^ED-\9)PQW9W<=P5C46."O06F. @B ,) M?!&I/1266.VA(H+2..%A@EDJN'F*^@*1B>?9?>Q\M+C:<=-LXUH]!DMF!U##
MVV<^CTMA'0ALT5_D"L&O;3!BK "[#B,7)#-J,7+\[/P]1BYP?[;)R*6QEBD? M<:_?ZB?11+ZK^Q84ZQB##69%.%SOZ\V#8@:1VE:HPHCEOW@&B MAI,D NAA2R=!EN*C;.H-
[\]"B2V"WB+-U;X_D!21*%4Q"?4%(D$>(!G'+(V4 MRV 8A*=PB=#$KD WP6AJW!XUT0;:LLG'>C_]]OGU_I_0[.PEK1FZ! >Z 'H! M1;%);+:UO@W5/:RE0[.?DQ.OU RE6
MBRS*E"%&'.49\97AYA*'TB1 4>GG]A<-3%/4 ,^MO2 S7N/ M=&%FCO82PHP0(!P&X*Q@)Y@#YT==U0OF%[%2?ZGUU)\U M8"EKBQCS5$DAPAB1.,MU7BQ'A
<)"OPHHB0/0A506W1_4]M\D"YH63?Q^6" MCLSLSIGD,#/<|FKIZ'9M6K;]F*0SR["(;GNQ7*#U$MU7AL6^T&]EY"&827-1 M+-ZLZJ)^_D*^O^,;/4<6K-D1MION!>,ISU.AC-A/?-W5-
U6&S0/$&Q,)7OP)AD0S0FMC];REOKX=OT0M(1]Z^$FU(?V8&Z4@K,.O<*>3H>O.6 MLCMC-1#/D>4.49K5C U$/K9IDT?L#%S7R)+]VUVY?BJXBA^??ZL$[V%!W[*Z
M>&K;/H=A&@:)#%!$M;WG/$99E#'$_,#G.,)\2&DIL6<],35#KIW#U.<>'*Y M_L;Z.)&9>_[HUBR8P1F_ #=FOF':30& MCFL-[*W"@'G#D/ "$9_4E<(4$I3P-"6"QA%.(\L3E''J4Y=[*!-
Z/(!CU3"U M=%.I'7Q5>6S]0(N5S<$K2,/@TQ:W>KOJ".: %6_+BZ?^WN-FDH,9(%LC[@Z?/O^'BGF?I%#G?Z0ETZVCD8 MX[!C[R+#-
(T)35#&N$9"RHGZ6XH1YS&/&>=1&@=7=^]=VIRF[-"[P&&4Q;X? MHC#G#&&9I0Y;UX"Z48>ANKA41Z'>N">Q M:T=TEL;+]R"^Z)H&!UON,;:-
\=]>#_KZV'JEN[\T:UTF4^629(2X\".$N<\0 MH42B,/:C.-"PRB%HQ1^D-O6)5=O48D_3*A08UI?A#L&5%H G5E %P*-^$\%< M1?F#M.:-ZDW$/HGBC1ZR;UGQJZB_K?
F^>MBPM<"%QR>VS8,&%BUI\X8"ER0> M-D9'PL),\(R%5&">F\Y9:-W:\T([Y/KTK!B_KRX:B#V]A'4Q6!G:! M[M7A TK8[PX;.1Y.Y_R251"/?3M=L5?
BR>Q7#\V$4$;X+7T#FA.O]EL.FK[P/1YTDKHIP6A,I&I^?\>J1';/>4\>MVE#T M3ZL)H,.@ZY\)5 (XGV;>R8/.ANN&?3V_/I;1D]JAV]'MT_38 0!4O M\U;LL"WF>SLP2 SW.AQ$T7!
(;C[@#?Z5[T:%%: M;H!]*8SU9K8?G4(;T$P7K;T]HGL|;"E27R;23#G$! .*ZPHKS)3LO?AB0&6< M8(M!G[U$[6^UU5KQM!KNNZE+41=EL?G0JK>I&5%TF)LED+$,2(A'P &%,
M.,JXA@CR\S2) AS@!%81 V1@ZF*9EIA.96D_/-3HSHT^S3S)E%["9>92M@G26 MJVNI? MN_[CFL[;4OQ](U;LN:GA2(C,-.H0DBR)$*;J;\3' 0I#(23!H0@#$"2Q
C:U7]8](_,^_C6"LPAV.E$+ # 8CHR&>84)S530!4<.P9((;@C0, MMM(E7%DZ(Q2E0M^GR6B(;,@B1"(%ROQKA8/8_&PX2S3??(= M<6]
[4+TEW^S&-0^";_2:^%7SXC7,.#]I!HAM=7!M,O|LY[@ 8?O'VI#'[!;& MWRKQ4;ZIZN*!U$+M?O,H\E5PB[*$IP@SM?&EE.=(1;MYZJL-<&R&3W9^^HF7
M.$5,7WG>D8.M9T>.;%NT[.6#F>FQ://DP,Y+YVCA.9I\UM7EO&#'2\B%41:7 M,OA_?UGK*QZW#[7Q38S>,Q/;C2*UJ>HF'5*0#]K9W8". ^T]$'5_[;*6$6<]E M
9T=F%\2QNZV17^B^;Y8G&'_X%[%N=];GA&1YZ;AZ.V*;RM\@;N%@1DF/*GH MB!Z4)D^R&S 0S]5!PP"E>\<4QD4^.3XP> 3NK7M9AT^"K9]$^0STW9=GF']3
M#W!M$+G'';D;D6'FV*/I;8E.Y]W');3R]0/3SN;YQT7KKP,&HRU"I/O[^M4W MM<=95:O?R?+=ZO/FX;&=N*I77^CR[;]\?5S2Y7^5OXH&&M@TCH)./'6P=7]?
MBGL54'JOONF2<(V<=Z?&Z^"D.?#0<;[R9IN'S5*-VE\ITTV!;Y?+[3%X>RK> M-=II ?BT9.38!)I2:$#\|GX/!D'>E*\ & F^A/:]KZU8KN[WVJK3+A8%4YLO M8+55Q$%4:SV)
[;'CYP>R7/[2@=#C?S = 9X4Y M/>D[/\RR,KFM]ZNZS3;[?-C_ GK]+'HE]=UVR9@);.EGI.(M4VY82;*4%[:N&1++:.IV=<+;=T9 X_0W0X#B8'55EO0UOK,!MN"#[=P^6\5:[^2
MNKO:U4"(/C?E>V +|/(JC0""U&U)[),X9RM7V" 4,\R"6 MZM<)J&.1$ZXF-O&[@T8##SLN=6:P^K96'YR:5/^B_)NHF_B4ZRN1U8X_*.RO
MBQ=E%NK/KGZ8PSG4_)Y!W4%ZQV*S&VB8U']DUMNH3M7G#,38!$@QX[5.,1 M2++R2T0F0C=+$GYQJC])O5L/9NN7Y_V0 MN|;V&V#8]
[O*;)&'22[B$$6I\!$.PQP1$4@D@B3($XH%(1D(W?QJEB8V\88Z M:L@?E4GL>=389/UQ'9]>"UUL5 4^U?LRBW'F?0LPOS/3"X #MSO3F2MT]^1Ø MFA<"WID"3W#BW

*V,MVK;QAML^<[4,N[M)E 7=KK5= M8'8PM,?G86I=*P: N=;07,X;EO.Y^ M\9DNH$>78:,4^WZHW&,42X(P9QHI35 4IQGGDOC*98)N6!E3GOI ZO!^\?7-
M@,U5:A883](HX#'6_G(QN;:_L]PO-A;?\?WB<;HO;3P!/)KWY M>_U\^T?)*W?Et(_HZZ8V97B_E4%L[7W6O^U@5G<%>)V+:O;K4|fU.N^XAFB MY/%LUD3ZA?F9:57KN)S90F-6F3,
(G=ER:1,"]|-K-H_;!3BM3WLOU#;SM:A8 M63SJ#V*?G.$QS4(<,41U1@U':8QR$<AU;JOVA|^$\=Q/T@PE/B,(YU0%)2S(5(R"_21+8B9\T D?A/C$ M+FA++V^MW'(1F6'''Z-
$RR3*0A8)ZEOV?1B?OtVIKHUH"-#EPE6R"D\[VW6"CE M).5B,X?%[=?<]>,^MNZ+/XAN"+ZKJHV@GI;+_4&]VDT>UCO0EE(!9<<<M)3RDNF^2H"S(E0<*0N9G5.
(P.7(YUS(R=2E!QUE3%*EY\|B.N<;BBH8]P-'/_M-4HW."J;294P/[73XD?90M!Z>[Z:0Z*6,T^SYG6\0>J5W&H9<.XVD[.MCN-L MM.IH:,Z!7@9/[*Z9?[Z#/_=:.#C?
L*]N5*^TK5&Z\CA]/,>2D:NRL?@TW MPM-H#>CW 0I5F&V_0@?3UG6=I?PC%'-J<2P4FMP"HO@M#VX>:>D6M7%D)!1 M;V<
.&6ASP13OB52#B;3#&4'1RC!+$DX%FD@C5+PPV2FWM>VYU(PLU.#1#@ M7%,/09#H1&B8*$@K[fC-0P0'Q&U.%& 7E<%>/"SL&A5K,*BZ_/1\(=.H! @1-HQ_HP3I-=
(24X&=83<()PXK(P[K):QP3FSEU=$/!,ANK2 M2/NZ0OV?MN@GLM07V#Z)]BX++75]?_T)M<0Y_T!NYX!0'B5K\$,, ME*W&/*,A#N*,8K%X%&6QYI]K4M:&)GH-
3Y#O_)@S6)U=4[^M_R+VU&||*NZ+ M5=-C>2V]E@"\+-'^C<0^]7!V1!"@DL0K4N$\0T>!O02@$S0@E&>?=&WFSXC_D
M^]CRY>)M"/73%WD/AFYZ+LT";/HB=.,U:GW3U^:>%\:=HI5^|/^$VZ+2Z)6 ME.,"4WM>9B!"O5IMYPI3KY_4%G6BJ;3O:NH_*"VTV&>[4NTP2D/,9(Q$Q!.= M!,L1";
(013PF29*G/A8@,+@Q@A,'C|N,'6*+ ^H:\E;X]U#(!!8(8T9V9SW*I M$9A;VBJC(WWCI8E(@Y%O**DSI(41]7.I6_("01-)0IBHG4M[49 M131@(?
*QC,-8\IP&H'LSDW$ZLXZ8)HH8&%^&G+IAXBIV$Y M=A,?I203B#+EKCG#.0DC$/+O.2I3IP>[(8T MM(&XO6>U8N87KY85YM-
:#MF2R>9%&/\L*WM?.2K'#ICZ'3F%>8#)U@BX$7[,3[YN!5@4IGNR)X MC3KZ=P6OF@>. WQ7KOF&-7A[7;12O5X_D&*U\/T@H5&6H\BG@>ZP'],,)Q)1 MF3*1)6G_$FR*
WR1RN2)GX9NDV'M"'M?6\H 0.#+.AKV',XDAR9X+(0&(0./M'G4%.O#EN6=#!AX5KX\,/#[XRA2-KI7\V-P0[ZNTRQ-1)A&B,>4(9P%)$T M#*U
NA92^'P8Q!UW9NTAIZAJBSQ_O+:,@)SH!9C&ND=1Q%N)C=5?7^7G_J+'"N MDP0G=%YFDW])W(N;|(L/\!FNOCRYOU!W?-6NJ6M>:1)AR071X&L1PC)3RRH6
M#/DD)DD6B810"C%A YH3&[/1E=&&$> U6Q-UFEF_8R7!_(+_8!= $:B1\[MA.*L;@&@@F,'7G4SE5HK)<&ZF7?(P?:8'MHB@EWH'N0FA[=2=)1)@(Z^G@'-M2B_B>_WE#
[%)$K^N5_6W:B&$]*7(,T2E4,%A MYON(A)P@&4>1P#SW*0'=0+-E9&)C5%)&(;,9^%1,X.=0T\PX]YB.>U1*#M4 MIQU;-SKO2X7:6A,\QOLO0UR+/B75B9F<'V0'2G"#\[Q-
JW=W2M^K5 M=E^6'[X85&(B)]E"$LF42X(0RQ.1(2%8%%]5&, +)SVQU1E?F]8<04 Q0.H= M-MQIE>8X1=S7E\V=4YCB(//@A4RG0C'R8<'A JQ4<$P. AHQAGA0&PD/00
ML9KA:A3,55WP8KG15VSWZ;PWW]ERPP77#>ATU=VfID[6WY!2WSNK[D39\-MF MF&/J^[J7)L))ZB.EN&V
MK4"/Y0,%NF;4URW79/&LS(5AYE_09)+M2,EF"_2\4P%SB%E)/2#&*>+6I=3F_GB 5H@QJC:&RW!Y2I MY;JJ/%+794$W;NVI3Z16TRJU\]=8*>,^-V(C0P,FE);HVZ(;JX>#P6L.8
M9*ZN-ERD,^_UAC%Q3ZXXC#Y@@X)V6F.E48YTY5^7;0B#5*WB:AT))AZ35@M& $)PS)/*0(!PSIG X*SACKD"CN,>P),PG|\%L=BFX=Y\ M9]|TIOL#>1"+.%;;E%Q0Y*=IBC"7;.
(D|%&2L"QCE$]2&!5_7R(P=3:X(^EM M:7]:J)F97|3)L%&[D!1X)@<<3TMA@QR09N!BI'FTM4_UE;Y 7)YS% _.;$V1K; MZ#C+9$"#VJR>O?U>5 L<,JEV$13A+_ 45B+"B
JULG*9QQ'KF8/;) MC:IM\F)>5\U.>#!R*$B#+?ZMN(!M.?&DL&W].%7M0!N2L$_KCYI8RV+U?TOI"]9ZI7.M:JULC@#>%,8Y_JUM!9P+
MJ93(E;6IE0V+F"CC2S!*\B#,DHRS.)5A3O@:6*3W=^!N/&V3'IJ]I9CTVOX MO/$TIUVNVMMRJ^/!W:FH?0I"%V_.S%O,_#Y@/F;F5V%_A^5ZY;F^ZG(%1RI$ M(^9Z%5Z\,,-
@:EL\SO6C*,MGG8NH=2P*Z4\X=U9&OY]YYB+Z$Y%.2^A/A{@95*_%:ETV75':6I<%Y4G TC1" MN6
)PKY,4!Y&$8H#&?.:RBR/0%#4QP0F7O(T=,.^%AZ8!9UHQ,N+.W2R(Z,KJ36>UO$O"'9O?Q7%V-MB#FVYP#Q)I%DC"!8VC &*#QP0FML'WZ]4]6A9/NN>M!3[HB3K,C.\;
M(8$++F9;O?2/?[;!\8/.Z)(0C\SJ9?E;SNB3Z[F"/].E!_+S[4^ M:VUVH-L2V@47>1)2&:.49K[&^,H0(9E$44@RG$G,.1?P?EV#-"BT''7+-[C**ZQYK1A(;,HV3/$%NK
9J>\!6S:S1Z_&7'[S_5%]+]T5AGE=*BZ0/1@-FHL_BJF_KLD9JS@?O M@91_$YTN@6O\Q&K'O',,25,O-;4N80[*"%72<^J8KM'"?$B3,SNG;Y1B@3WI
MRB5]$!50#^E^@Z_%DUBNFZ/KO/8@D8)B7B*49[&&J4D8C$48!2EN9Q$LL@-M8+E%N?(@42-[N;I2>!PKH$=YV\G3G)HP$ M=.07AFG-Z@B,Q#ZV?+.'K@7%.-^2JH?'4?WR?
K7T=2<-=)&=-H&%PB(4FF M03BE#.$B8)Q M[5LT2Y%&W90Q8/VNM7S/7.8O6P#FM X5Y?:::4+#/EM?R MY7WM_C_)+O)+;DJBK7F8IY2V&O5=5(
>_6$\&S\EY(K)ZK"V]LIGZM=G&F MR?9SST[L9O;$/$W-/%-^5L[Q1/BU(L)\@GK%7)?G])8USU1B4#)[2"RK7/79 M"6=+10^)T\\T#XZSW.J-
Q267PI((ZU5[\;TMV7]W]NJR02ZH/F[]JE8+@/H2 M/JV72^45]/@%#R3C4FC%,Q5),!5)$.:'*(Q)$+"0T116_#,;YU-O!0WV&8/-MC*8#.>HP'UJ9O)Y0-UY/+.^K%LSK)(-N&&?
!5@PWE#_B%P#<I]$QDRM1%E(;)X>@Z+(>S,/51>7.2NVZ) M>F)+U;XPOD+)C#$1'-%&NEN;KB!&=@WKM*U@HZN7IJ D M/Y/E]2'=W5,?:7XIC[
XDFTV8[70A8KP7\1*_676C>#^2#]:!5+^5F43P43 MK]95_:H4O*AORZ)2G/;Y_:5)BGTAWQ=Q&N=)EBL7&-$,898QE(G$1Z'$//(Q M35D$PD::F-_)RR040U!51:D!%ZWF?A5FGG8
M^^@%P=QQVY'Z@'/OIY;W/WLZ^?7C=3)XG1!-VZH;KWVIG12>%L/[J17DS].D MAV=2L:OK1A-S.^]H7E4?W+A:2:R\|2U;ES,U6+$-K7BZJ.4BFA961R:W2I>.SSY:.-A:TGXXV M?
V@"W-NN_M!/4,E[7ZA82]UQ=Y[3 N';6,EJH_22>5QZ X3S;XI<(NMRC.I MG ..D9_Q"G&>*$T*RGG*<1NJ6E6LX_REC$-E=,4LFH0XV.-;S1!P3E(<(1
MQ\IKQC$BN:1(<#\D,8O25(#*+82P"?MG,8_RF^<V^UX+=/HB3WXL-& MIQ_^RM?%J0=KN4BBV"=8 ;W]T7'FGNE_WX(%?[#V8.?T)=0OS_EM&O(X3[\. MG5W\UV/CQNL8=+
<(6"K"T6H I3[KLF"IFN/UP78.MX5$.FURW+*QU\QQ=V7W M@Z@_2EUFPEA*0X)C)(BN&!+*J65APE&29P&6Q*=)PEU4#$$9F_K\6=3>9E4* MLFR2(?=-9G+99";5SJS7_'?2]
[4YH6DZQ'H-)"Q=ZR;RB'PNXO5$I[(*), M(@QAZ6-$61HA$824^[ZCXI#:('3/^0JO+H-M'XG802%1=TFWJP8J!5N2JBID MP=I6,B_TNLR6K)
[=YXFK5:MC:YYU!QXRO8.]JN;@Q;S6]HAE0S[+X?:@+DCB"*<7NDUD-.[M>FIHWMGJ[@R$ZU=,F0QW''E<]:,1A1AOA,4)80CGV>4"!')E!$(H.!U{(#L
M'8Y!J-GRJ)#K4GA%VRJL)M_!W46NT;?9EG\^+<(=*7;;S?8M M?!E0OTT'$P=:<]?=V!IFYNY\XD!Q9[JBN)@5'HN\6U6%&OFEY$VM>2&]NW+-_M;OGZL1;\[9+?+;(%K0?
XY@_9'D:3[HOBX"%/.1!A)! M=&<T>S1'%@40BBB.:AA'6> (P,#8U+>15M4); ^VW5.W)@BB+PA%&+;A8^0,6! M6=^K(=;A9X0]7ET=".HIYSW]ZPEQ-
P]#M5U..$$TQ

*[Y2L", MW+7^'/EO9VS-ZK9=*_/86SN?WS)B)TO190UU>]"/\HM:+BK"--77ZP=2K!9I MC*4OTD1M@XHS&S+Z48-P*TF"%?%^79T7.X)L55>8OLY+K-)OLI5V\T+X&SM-MAD9?)G]?$%HL6{AK)=7V1DN&N9_&%/%8XU-'68I(3'T4AR'/]:]*%1Y;H$$8-MD[l]{OL: /!JH&J-/,)TRD(YB>VY)YU+Z8C@,9,;2U:Q)Z9R7_9#94P#33C-M&/&71&3)[X0H_UJN-X]O5WML8\/_?F""B;U;#]1G3-MI+V&]HW;3Z[KU;H&=#P;4L%X,.|(>ICI#PGN?77:1-101]L_?VC>V>)[_^'Z-MX;W))9C#FB-15A[]>AU-7BYMTH3(B"K|C>-MGV*@?V/;D--=&ZG=&G.BMD6ISU",$]§"Y60L$x@+F7#.5>0DC9H&3*9&IVTP-M)U.C6<#D6CDP7WFN.]*[3B]=8\]YNOJ|0&^B'Z_#T#5]@EQU^[$#L+]6MQ6MU>:AO8CXYONC8+7@KXNG@HL5_Z1V\0L:BR3@288BY9L13DF$"N)]VGH#<]7@@O5^DN7Y!KS^\]1H@M5OJ.273!A^]/]+-K1!6$QJ27-!4,S# M0+E\%632/.*(<8QEFD4T2(WR<<<3SW4FK6G!#Z$;T8?]YC4"P=R;F2Q69\M] MQ]Z3FXFFOT$N<_^N4/C@]_;PB<\/(A2'UGD218",<294&6()Q0 MC1(>Y<@7<48PPWF:L\63*.G:'"WA#!W{-]6G9A[;.HUVU"V&M+)D'G%82E M]&GB$\2Y\!$.6(:dAR'TRK;U1+$H(;ERM'IOH;BKEF 5D5XL,3.(=23H|-M\N"@1,Z 'L[1IF!G584#,4PB'H<%V%*9S_K&1=W?+_MLA^7WA\IG.Q{H"@ZM<[MVN3 +REA//_M0'Z8V9F)/D$6?$12ZRK/?04+CI-9V)/^\; M$W^J5[!7N\PZV!0-IY0-M>MVRSTVO$^BW10K[_>J=UYC;IJF2AHWU0GT S-= M,]5,8+IR:U,V93&;*8-%+IOZM!'9TZ_MOVEWZV]NFQV+563*_[RC:PZ4+C? M1:5V|UM0N_56FX^ I#%2.Y &54FHV#K'2- \3F*)$Q;8=#.=BW\C@[R^%6H+ MN?G4D'X!M -/H2V4B$H&?4A0G(D:8^^$B*>&(1%BR-)EKXEM,83*98:+O_MNM0W15|+6N\OD7=MC[4,5:TX+:H%(5+X41ZA M+'"49PH+EB(B(ZW+Z((HYBX,L@E380!F8N-IF1]!CQG= K75IYMRGU!#PX$!1MIH%5W'@[U!C E+V]Q@2=C.\T-4E.B\ M9R7NRH^)A8B%VM0$/@K35#ZC5%*L0E\F0P*"BIV.UUM*<2[E;(#M0EMDD%]E@BI@2@%"R*$T_;0(&A\D:>Q MC'(A/JC;lN0<3YSOFB22BJ97=$1?NH;W[&M{@3CKV!?QPX1;6A!/2^)M1?F1 MBWB'U/XCAE|G^:?WGC<*&U#]L,#9(&-ZTX%?RO7C8/'0!2,AX[F,L$<%-%I 2 ME*H-/&\=KP6D/=&=_K0DIE=(I3BY(YV*Q39X_:0[4= M-[V5T-OS8U-3!U3>L,E-JS>8;4)5-D%!CYT]K.IZ@*1F*^^Q4T&_RL=R!LMS M.,;6FU5=K.[OULN"Z60|K>]2,%/8EE[VEZ6Z+>URU9EW#DH[*Y.N2Y M3&C>XYQ1@4\,;L.?L,P@L&^";QH(X;.A9P,LO+R/K65ZH^3=]!\3"LBSR M4Q2GA""<8HQHEJ9(4IXF+&(88Q 0FUOV)EY,/V\>'DCYK"_3 R&*^V^Z#H4\ MB9+<"X_L>=)-M;8MG@OUXX$6+7.\,L-4P8N]"&!>H.-SUPKG_-Z_!;3+%PV=-M67NIO!XGP,MW MYFHT"Y[]7X*4;U;\M3Y/2$F9O)3((&&!,)BN0@(N3S@88,"96 M'SQ@=*S=HOY>5)40'Q_5]D%O^]XKHQ<[S-/?5ER1TSM"P=]\9VKH[8/^UR+E M$?6YQ$AP"*K]5R01"<(4T4!{!7.6_S^RN.BV\WUO1W-FE7#I=EA-U7[[M@);^.U4;18$3*0UW!TX_7@==/M<>2U;7LN7N^#@*K4X"A3L M>)@U:+A*3$ <=ZU-;8+|"7@6F'L-"+3?;&S>;0'_"=_.S'0[M[\RF=R3.J3D=#[\&E!66??@K'<'-RG%>1#1".5^EB$<(QOE+(E1GOL$"\;Q MS$'HB9<(31QW*X*HHZBSH_*Z+;^H\:#$P=2 X]-&HI]X/EI3DU&!'-U9G*)MS+PG)B/"GIR7C(V'5\A\TE4ZM]^+:H&Y"_,P98BP2!EF2"G* J&S:#Q.I! ! M,8-//IAUZK,)W1^VJ@N]#^PE$-27]6@;]I4YU,*P^5G+!DSWVXD%*ILY$>.* MDIG]7+.5RYRPWR^5.?VE!8246.O.H\:04>WPB;_WNS M5\V%HU*K42FMS.GRK+,9V*A@?9,;'VQEA-J2Q?KVZ;[99.NBZ-N\&F"#9Y^? MP00;_ZS^N^V*.]H*

$UA.&$F;DVC SQ:D7 [?\Z'4#M<%!(6S,\/^F<5C@H MUI$1#H^URS]HO)%B==_$]'X69U(WE>91$" <)&J/$_D!HD&:<9KCA 2@BYB] MN2

H8]X+C38[_EAW&]0 M,OC:XC6TX/N&CYNZJLF**V?^2,"U"C^?WZTX) -U>8:]PZ@A-2 H.., C.I&0=VUQ&G_1.0' MA",2V-B]C,C3^A4]['$=?A[YC?NXI-@L?F.$YZW#&!MFF4@9:&O, ^P+7;(X M%(D, A3+A"E?00DB6>8CI£&K:8)3GR>@-,(QA:F3"1V]:\[^3K5BF%JX1E9@ M@F$KYB3U0!<%<95L.)E_WI3#))?%.$@\7:!\)CWR;CQVH52RV?[TC!?Z]>K3^+M9=/-KSO^AC>P!\PY\=T=9+|5/1+[FC;GOB#VAV#!^>}] MEX>]@9FRIM00PE"6ST816G@PC%-KG;B-^/Y:V>O^+.&K4.]@9ZWS8+DTSMBLC$M,|+SN5(H8'C>.S)SA^HS(,)U!V)S8OH,"'"V^,L)8"&-"<&TK&7 UG M4&4 #ULZ6LX+'9G[AJ4%?[=Z11X+92K=*NVG(18TRU'{J8]P1G-$>$A01F4> M8$*B/*$@!SM$;6K'NJ/=!-_HW:'-QM7RPLTQHNB,JV0'93*;A=R?L,9]B*# O5W),,#+8[=U$2/ MRCS?=)'Y_OK2=K6,92!#GZ $LQ#A,/15X"PRY/M9+JG/DY29G\&-$)O8#COJ MWI9_[H)'.O*5]8^*>U.>-/F!GP'?EF@G!J*>Q5?K55T6=-,. %^H?M$UL%CQ(M8A('##$6-;110(0HQCZ*A/OQOH*EX(%)RX&GWXS'^CRT#WVIDYC$* M1)5F=NY80="*(I:^;5Z>ZN1O6#;Q'E+FTKEI'&5"I2!$VS 1%ND(*_;KI>0QBXL()7D9FQ7RTXS+QM9 :,|*!,CHSX/(U9S790 MS&-#'1YL9YH?O!\|T/ARO5)_96VY_GE06S]+E+/@(0]Q7LK]0'#*T@!Q&08'' M"S^*L1&JB2T#$QOT)\$4Z>6S]ZZ!7/?ZS0T.F/-6Z]H[%K5WR]>/QK?IK=5NMY@#FF5",,22A.+NMN'F1A6V4X\BY@\|K,Z'EOE'/LDZWG@R$[?E662LEB_79>" MD6]:KQ)16GE*92X1IG"*<9 $B64 0)D$4)\17<851FN RB8E=SI:8.;K2!4T, M^P@W\L&\P):.XPYEPV)<@;MT8>+90)B&!>LC,HV,M L&WI:RI+D+RFDF&.4HS@E3:SZ+4>Z1N|SQ-D7N],G?SZ^52+UR[|FU5KW>S]|-OGU_O)_@S;.V_I&4> M$9ZI$$IG.;ER7T+MA]16"$4D3Z0?TB3*R>))E'0]HYI[| "+_XF.D<=;XMY/ MQ5;@0 ,K4AF-(E5&)7!U17*0S[Q"%F+@G1Q2C#UC@L8I']_*_D4K< MWI>BG;W!+R\?25D_][%5XI#'41 B&9!<[28T"#0.)$I2&8]$2>5(1E$.B.K4 M9MPCVMRK!YX[PC0XO@=$1"| &X>K!(8#"Q7O&K8QMP$:\WAITA^%QAFVK.[7%@6!K]8/#^M5LUK^O]Y%=5O71'<>_ +)N8MY]D>4BH2Q.$$TE1CB,U-8R M80*E49K++#$M?,], UQ;TO=^)NMYH09(]1=0 * UVJQ.XR\$KUP&H$3<4=+!(0[*!(T?@CDXW3OMS;HNZN=W.@X@K"Z>Q&M2DZZAVB+D&$=" ^$CF(44X23@B M$6,HR'F<8C\1 37N.3A$;&*WUI+Y>K1U_SWBO8(4.X\]:]BEN50!,$MF*3VH M"Z&);%:= ' T:/MF.\X>7' CA&/*TZ;&H"RY64'96<>O@,T-[[=3Z,DF!7W!..9\)07WJQ5$I_R4.!!2$9J$_Y)%Q.I).V\-^/.X6:,.C. MWXQAAO^E!0US;PTO](&O>]@T&LP0I^]_KB.:Z_A^*;]G[=]9RWK-]!=^+NS MPU>>2$S.B{D17_),JB|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|[,Y0C"P.1,99@X7-E?U@D<)8RB0F769XG-MRA(3H_Q|"!JSG.T&#C@=/T@QY&2R\4E|+SG\78R:XQ-A#[ )&HA;8##M .*3ME'^" ^0@)(;C@@>7+Z,Z]1YR3_I @;=E=!#IK.#@ ^EA276;Y)@3G-% X*15 M_DW,2!C+R.)\>8;(;F49.G$5Q4TT"+WIB)X_ MXX(-P(A8CI3')59%7M%$U,E'GO<3F'?J34*P;O%|$3PC1O7#,C49RXQ#=5Y MA'D^)K[T,B=*5>[?]M4K/AQP 3).>.;]S)O 1G/&(X3X10N[7(PQAT#@#2G_PL MH,ZQ6(=LT1.M_A+M.98K3E"|904X%P@(L)F=F!VJ.%0V.SH7;$M9UB6%=:\ M7;DK&[!0?%=CA8#4YQTT9 ?-T>@ARV5LIPX/R^;TR-=OJ7U|P_+\N^;0OV MGNA>?@31X88X3C$A<8Q)E 8X3Z,,>UF2156G0(GL!D$1G2GMCH[+J@7O+=I M5?KZ]:E.E8IMM-CO[1_0*05FZ!K&:(QC!HP_]:A F@.D64 \']:)08')6R\ M=@1G5F8<=@*.X'GT >]vR>V)W%?M-5*X=U1+)DX'.+Z4Q8MRI$2;DE|W\T#!?Z\] MK"_EZ@^QTB58C\7B?P1O;[:47>S^DW[.?PARGT=9[F&1*G>(!"G%.<[C=0S* M8IZ'F4PRD&F:E_V)++=Q_"UWEH,X7[$54]%'HI\BC%A#9PU8X+8.//:>;^OF7'\ M>;^:XQCO5H9-*95FNBDPU4VX=WQ?=3?X2*DW^FKPK>'-%G\(Y*YZ.,[+_+RM M(7_(ASGJ./ECN+!M_[_2&^)=5;XLN#KRO_ZF&+U1Y_V7MECL6C<&:"=,>R1+ M2<#5+],GG9.0IS@C),-^$*8T3V-_B2"F%,>H4VB9W7NJ86:*%3ISH^$-TR M-WMX:R?[<Q&8G=9@-2]PA@M=\/KFMQ:T7{%W0ICH%1W]H_YZ^1L3MGKF+/Q20X_[]X!7L+,VV=*Vl,VAR33(1199F#,LX5*?K,)#*^A>4!YC)-/!)1 M27Q0=M4)&A/;CEU1)#SIYA0B9H;@0CEA&K\3<2\9QYU6#TCC2'U/49A53P=$ M/%3(H4?M-._3@N;+9:/#UP5O,BB|/O;O_[U>K%X?U-$QIZ&78,ET]E^8!)@R M*C 3>>")5$_F_JGA&,&)=;)QIM!RQP2B!4>B(0W3T%'DS-35)1XPW?UT ,+[M81#]FLJF2,]'B4WJU*;"G<;O623>6B^%/^1GKX[.]153L6IGSIOVV3KY M|L21&DT4:.K8W^NCF42.2.DP+'9,.2IE.+#>;(IT7:L;$ T]==EGR52RU MN>OMB9N\!$)HZG$NL)ZGHCLS9)AZ/L5Q(/*8LBA+(F)SOW&6XL2Z^&M9K.O. M#ZM:'K;5>_.7)(E_@>?(<4MB5@A.@8%]\(8TW /6(3Y#582RIX^#[>7H_)%X^_M*OZY$/?XBW;&X0-=5$TAWZ^OVS_^YT*=BROV_?63>%&HZ#%"69H$<29#[&5. MG5L3RG#&.(0%ZA$_#TD4): &8V9D)S83FG);?{fVM!N.\>7Z=ZLQ3(9@FMD& MJQ#!#,0EZ(#-TQ81S;"D.BLA@(&Q*&U +YM9S(^;[.G=ZEB[>A9W4.)EX@ M<.03B4DFS (_Q.;$U17*_'1$;GL<|+)2K?.TS5,.-ROX6 M]2C_>N3Q"SWYZ[H6JJ;=\5OBZ_:(.BV'=<%_U(G>9?]9#F^EZ;C-WP_^E3 M/Z!IXAG0';TBJA4Z\S$)TRB-$AG$"6BF[@NF)C8!W_3D'!TD+N5A-8A.N%A/ MKPG|O5A[%2^Q0U'[Q2^,??]^X5U;'A&N^%/0,1/^MD>,*|0RB#8/2]2PB?YL&)W&YW"}G.OSRB4L_9C3C ,0SYYU7*QMW=/Y;=$> !2M MMV6ADPE$P70ES05=GVPTVK?'"_IQ,E659S@&[MH] VC/W? 9#LN) MEL\6B\'R7T2CW39SKU]@EXY%41$PL-_^$NB>S|S'>4A#G.99ZH=9DH:!42GY MB;4G=A .;J@;FP8)"YZ"8=@(7"@<3,4AV^%.LXUX.R-$?ZK; MN49%&:DP|+DGG*)T\2G&>!C[D4S_!\P M(8,.-E8L/4$,/-01U@5\K_G#C76-Q .;G27Q.D!:CFODACE+JTR ,4Q^$D(#E!.Q,.K*W-3.]4.C M+35]5&F6<2GQ6OT+;<-H9<>WSM+CO.F3+=]H1!0G(7*FR%I%JGC5>+A6(8TMXE)R[E.+9KD0'HQ^\1=WT-W01U7#@+[R>U8/=#[,1!TZ!Q V\T2<^:P> ^<6 MNI;5KE!8(ZC_OKM,G;*KYS@4D_7X'"#](@SM^CH,RWQ_38 V8#;JKU<,WM7G0M:E'^5M1J]85<"/ZN?%+NRD-$8B_/4@[|:.);C00QIC[A.(Z#((S30'@L,W$] M!JE,GL'1TD5_MN0,0ZK#P S;"&?B],XQI(:J[B1)$.ZK!;HZ;'ZMYT.#Z\] MB{:,B;?12K.'X3|]3<$7+PN^IFW^OZ&/OO_6Q#]T(V;8@/*$?. -^MKU(,#W9 MT7VL7F>?2M'<'$^IV1SCTR+T'>$S3UAF#S.V?EHW14NW]^-BTD6-E?@NBGKQ M(M]JV&YLA-+ED>=4[4%A@$D6*_\W26/L:2DE,0FIB"DHG]B4\L2*U>,#-8R@ M/4ZZ3B_;&-C5.T\W4FP@FGL]>W;FZ,)4W>T.KHIA>_&4H M'$<9S> %X#[L5T&7[VLIZ_BZX#V"[X0BQ19MKS_Z)&[E7:5#Y*O7SL,+U1$Z M2X,0DSA),"$RPC3+0NQ17Z.1YQ$1J]0NKBT34[\-*)(Z?WE#U,(3MH9WW%&> M S20M0'C|?*G+Q7XG?;FO1LWOBEX/2=]8O7L@WG]=OD'[;3[`QL2KK^K>B M4FSJM[(?%6D=]/E5R+++2LWP>>"*)X%&$HRC1]19!CE/& IR&/-$EDY&D_*%M MJ/QM1:N5::C/$7\0@=3SDTE@9&R;0>LL%>E1LH#?+=@YE+AX71:$CY#E=ZOG- MT+B@]T^EO%&/Y(`$89Y]!U6WR_EP4%(LT@&P@N2O/M4[PO^TW^H#8^./L,H M^$_PC4P#NS\ =6C4UV#T2O]HT7Z=',_H8_-U/FV42'.LA[>YC D[1M%9P-@5 M7S-`DQW#>1OJ=DW@@LFT^=$TREUKME!?=XJT_>F;UMW]@L_UTW.3O,*)ENMN M;OY#$*N]4R8>JC.A/"T_E&HW31D6,N:>D)'GYZ#V l.Q.O%9#]LIU/0I4(ZN M-ERDFC.+;?3?"LS4_US?_%@=D+XW7V&O.5[_6#^BDf.86@'+O1ZK_3X[UW]M.1$8LH)QYOX8>C'L6"4 1+\SM&9)XFO(8>XHJ>5S[KF26A1 M_$MY"-KIU9\"?2[+XA/[]G4V_[Y^B.@]L@4CL-J>A$L=CMB1PS=2M3"HNE=M*"2@N.I"8>TIJX!"PZ[!B0:+*DZ]=Y\]50#7.\54PT]!T\R>E\UUZ[7!5V^ MZD8GVTY!ANE&Y]Z?.E11564ARG5]<%;NV#/!1CHK_["9<"4ZS%2,2{W^=-K3MR$1&JRRFLXO.EL\T)E8_LVGTV0O';;WO>HEO._ZDA&=)1HD"37G5).3*M99^ MCG.?4N;[>9!'-N)?GZ4TL8[N2MKLVJ6?1\C,TW8B-TO!=R)O:$[2G6A4,M=C MN8[H_)CA7.?$/3NBZ^P+\(VRL0%LM;+Y:MNP/AI.Q.T"7^UTX&^K@KP]@E; M=6*%W=]4.J[.5!\O]?]|=BN'FM=&$G9+O@s<'P+G@X^F-Y;(C?!AFV'B-4V M#B0UV^9N!T%_R1=M96!*XR3?Q.Q;^5%(PPR=)?^GY0TT,M04AH M\ @%D^CG),(!8Y]L6Q>YWXRH# YR5R6H8]33XC.-AY3HKA4.?16S,&.L!Q MO!_F//N4G9OU>SLNO=N3/1|2U(IR',<1QT3$F?,]W''"2)KZ5(C(\R!^TM[J M$]N"CI:E:[./@YEO8BT=S!H8"P9V)TX*X,@?V%][U@W]I%B':_+IARRS ;JI M!|?RBUAUf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|++PWA+3][AW]Z=%+:|? M_F]?;N[?OT/_=?/EX|O;SY?_Q(IY'OB!=+P^W/_+N7W8_]-Y2L_S;CUG?_,A/ M_,V\A0'\(<^#<2$/*4EC/\=ISF(=8B)(JOX4JE]_P$3B\2>)VE5'"'*L2* ML-$'][P]",KFL(3M+Z,74$0V*?MK248?,FZ\.ZK8.6+J%Y!?MRI=R?6UG8VIV?*U;3=SV^9FPPRX]&X?@%/!U+A M87H++=;#W!(R$MJ[O87G+O>[J0X)VKM3C[W0>.P?\=,V/QZV,+FMNU:<[M>MU2O:!"G\LFYNO@A/$C[.!4X]1C!),@_3-&%8^B(E42CS@%ATWW3.)T0GK+MP M-AS4J-P1/|%[$U9%.V4U-IP3.IT'R_**?&S,.7$HQR30'@XR\,(Y])/0LG" M+-E^/.-^G#_!PJ^WY3SUX?:[!VV_^&+>.. MFIQ.@:G+WFY.^9N_I=L4)\)LY#8)(8M2VN_%XTWOQ3>(NZYOY>_U[GA\M]+= MM|L_JO?_7KU>_ZULD_K/_*9X^U+O/ZHN\'2T]-9R_8E=Z'8JHY[\VFO42)M< MTDWFLXX&OQWF%V6%_A"T0N__O=;S'3M[K1]LI\>^U1Z2^J.-^"%"!;PO]N%\^ M!^HP(SL=X Z3C5Q 9U>^:1TWDTD+>"V'9*^F]=*V[T\=[*75'|\TXDWOZSU?U MBJ|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|"KUU74QDOZ[R>%G\^/=:.+?3^ M1?U%P=O%(5QEGK8)UZ@W$^>*37V!!8TH;F(I/3-)D-@-4IE8;7##MA.FE'MZ4]=KP=46 MK=R=NR:CJ,FM;?[N=C,^KCV^\P<,Y$%&8P[NNZ#1)3BG%",/9+XD0A#D?NP M[E)0#J;>?%MR2&SH]3I*=;?3-X6^@M%W.G?J5?3F2[D2R/>AB5I@Z V-P92 M @V%)H=:7E#++#&[YN6H3JY0^\|@&]"U/+L=D6<+A;(H6E/[.0[8LX3F>P66[M$+I"T%=!E^^;'@[7!>^-07XGGBO!VENQ=Z)FU:*AJ1,-RF=1K5Z;J8RC[!B)W1?V=M>:'\|ED'E#8C4C8G]'1B4282'V'W5'\2/"$I3*,><(2'K=*DN(§C(IH+M(5.\8%ZC&R' M'(W'2"Z$#"!/Q5T=O?U#B&$?>/;P#!XI0]:<+[K?1LY]Z[ZK1:P. ^ENFD<<2D2@7E8TS2.%4'VES@3/HI"V.:\.@HA6F.T.0F=IH5:HNC/[^3W'N.2>CH\B6S*P'PC%A#\]HI\]:]-41 MHOI8E>OGYCA9U1_@HTfEEIA8#S5EU)!&'>TK]*$L5T4):5 U!.&P6CJ4']:5 M0X)/.&O-0$;[SCT#Z\[7S&=Q%QC$$$XJ37ZMJ%H P5.?B6WL '#N-0+0($3@&A;@M4J+B#[- M[M'?=6&%1P2,D ^$ EPC9]YZ7"HB,&*Y+YWC,NTA6>Q2 M_D\M.%_B_X X>^G_0_91<)^I?6BUA<N?O1EX8,2_+_W##),@H#A-?!^+- G\(&591HTN3UTP,[&V-JRU%X$[MYAH_I,<>VO&'-@S"PF\7?0ZS5>U<(,/LA36^$Y4WN$#)42CP(E9F#1>Z .TPMI.AD34O;N%XL]3FYVV)[ZD62!GFA#)E[2*.L\3+L(BI3*,&DI/AJEQ MB&* <;H">07S"+28P'1V'PZ;3@,FORCPZ MX18?N]C$!3]\;6%*"7-C!D(3!,O,%),QEV@M'%ZSN;8L81&{|0M37TF^OX7<-M/);&\04K 6#61/^N.)!PQ+3E-6$Y=\C@B/'I*\##O|PP368W7@4X!WA@A3E2 M0O,FPDPP]A /-?Y(^\;<<;-K;4D,%TZ<55\U0OLHD$A+0K@#P2ZH/Y]L]+,Y>\'AQ7OQ\-8%NK MUPTMO95-0KMNB-*'1-EIKPAO,I8!%DA<^C(:U>S"@:?'>\;DL'0&GQ80<R9-1,3V;S9<8HSCYXUAN!X"]WYJY:M7U[H8JE[47PHJVIT M*=Z)?/5-L'6U6"U$W:OH^EB5=?U;40FZ7/R/^E>Z"X5LJRT-_H0TBR-"]#8X3 MGN9MF.,2QJ/6.DX7M[B@T><[707;-/7I&OSL*E"E1Z)<1-B/=$-GJQD+O6U MIPA#(@GU_="HW_TH8F-7D.Z228H+,HC>-$PS00;2IQ$A&*B9>&F#(:XC0. M X5:3%,_>%B5*[]<$ZE]"?&L3X$!/ME_JBK[KT>QVEDZCY_V-2'UO6]R_EZ@^QTM,$'@N|Q>G6:E]+|__3H6N=\L# MI1Y->)9BP3V[S|H!IH$7*|/G24(8R:((IU/SIATDR\>ZC=^T-*^T8/YPW8^18M?]R3<$J/4K\@T++]+7U>*"9OBG_I$3ME M<5/H#HL+OJ#5ZX'4^(*68S5_Z]=3L0>SK.XQ4P$>23"V$\]:7P.NHR7J=/7 M6M)HL:&-]$\]2;8>=K.K=GZ_0KI=NO@6!L>*^1"&[1/!?*$-8_H^M64-;=[0 MYAMLN5-_0CO^YIL,:'Z9#W*[$\[$T,..06[&CPH74ABOJ,4&RSV#EN.EK38 M9KXNZK_4*>_.3XM]KM=CJ=9?OLBO2"4E$2)A0'/M9@DD4QCCU4XG3-._R1 @6M^9GQ7F) <.(-0W/0-FS;,@$P4": &1A\QS# K+HFWL1.MN3WLLY,J[/L@ &8 M9\< V=G@0: '8>[W&SN, M/&LYF[%^]XR5N"_%\|+;;KN==@>=,&DF[-'8 M2P^9S+L'-_![,$VQ9B&QON=4*.C0_4[7S5XWW2;/,ZKWVIMY_^.5Z_7?ROI]K(O5QEGK8)UZ@W$^>*37V!!8TH;F(I/3-)D-@-4IE8;7##MA.FE'MZ4]=KP=46 MK=R=NR:CJ,FM;?[N=C,^KCV^\P<,Y$%&8P[NNZ#1)3BG%",/9+XD0A#D?NP M[E)0#J;>?%MR2&SH]3I*=;?3-X6^@M%W.G?J5?3F2[D2R/>AB5I@Z V-P92 M @V%)H=:7E#++#&[YN6H3JY0^\|@&]"U/+L=D6<+A;(H6E/[.0[8LX3F>P66[M$+I"T%=!E^^;'@[7!>^-07XGGBO!VENQ=Z)FU:*AJ1,-RF=1K5Z;J8RC[!B)W1?V=M>:'\|ED'E#8C4C8G]'1B4282'V'W5'\2/"$I3*,><(2'K=*DN(§C(IH+M(5.\8%ZC&R' M'(W'2"Z$#"!/Q5T=O?U#B&$?>/;P#!XI0]:<+[K?1LY]Z[ZK1:P. ^ENFD<<2D2@7E8TS2.%4'VES@3/HI"V.:\.@HA6F.T.0F=IH5:HNC/[^3W'N.2>CH\B6S*P'PC%A#\]HI\]:]-41 MHOI8E>OGYCA9U1_@HTfEEIA8#S5EU)!&'>TK]*$L5T4):5 U!.&P6CJ4']:5 M0X)/.&O-0$;[SCT#Z\[7S&=Q%QC$$$XJ37ZMJ%H P5.?B6WL '#N-0+0($3@&A;@M4J+B#[- M[M'?=6&%1P2,D ^$ EPC9]YZ7"HB,&*Y+YWC,NTA6>Q2 M_D\M.%_B_X X>^G_0_91<)^I?6BUA<N?O1EX8,2_+_W##),@H#A-?!^+- G\(&591HTN3UTP,[&V-JRU%X$[MYAH_I,<>VO&'-@S"PF\7?0ZS5>U<(,/LA36^$Y4WN$#)42CP(E9F#1>Z .TPMI.AD34O;N%XL]3FYVV)[ZD62!GFA#)E[2*.L\3+L(BI3*,&DI/AJEQ MB&* <;H">07S"+28P'1V'PZ;3@,FORCPZ MX18?N]C$!3]\;6%*"7-C!D(3!,O,%),QEV@M'%ZSN;8L81&{|0M37TF^OX7<-M/);&\04K 6#61/^N.)!PQ+3E-6$Y=\C@B/'I*\##O|PP368W7@4X!WA@A3E2 M0O,FPDPP]A /-?Y(^\;<<;-K;4D,%TZ<55\U0OLHD$A+0K@#P2ZH/Y]L]+,Y>\'AQ7OQ\-8%NK MUPTMO95-0KMNB-*'1-EIKPAO,I8!%DA<^C(:U>S"@:?'>\;DL'0&GQ80<R9-1,3V;S9<8HSCYXUAN!X"]WYJY:M7U[H8JE[47PHJVIT M*=Z)?/5-L'6U6"U$W:OH^EB5=?U;40FZ7/R/^E>Z"X5LJRT-_H0TBR-"]#8X3 MGN9MF.,2QJ/6.DX7M[B@T><[707;-/7I&OSL*E"E1Z)<1-B/=$-GJQD+O6U MIPA#(@GU_="HW_TH8F-7D.Z228H+,HC>-$PS00;2IQ$A&*B9>&F#(:XC0. M X5:3%,_>%B5*[]<$ZE]"?&L3X$!/ME_JBK[KT>QVEDZCY_V-2'UO6]R_EZ@^QTM,$'@N|Q>G6:E]+|__3H6N=\L# MI1Y->)9BP3V[S|H!IH$7*|/G24(8R:((IU/SIATDR\>ZC=^T-*^T8/YPW8^18M?]R3<$J/4K\@T++]+7U>*"9OBG_I$3ME M<5/H#HL+OJ#5ZX'4^(*68S5_Z]=3L0>SK.XQ4P$>23"V$\]:7P.NHR7J=/7 M6M)HL:&-]$\]2;8>=K.K=GZ_0KI=NO@6!L>*^1"&[1/!?*$-8_H^M64-;=[0 MYAMLN5-_0CO^YIL,:'Z9#W*[$\[$T,..06[&CPH74ABOJ,4&RSV#EN.EK38 M9KXNZK_4*>_.3XM]KM=CJ=9?OLBO2"4E$2)A0'/M9@DD4QCCU4XG3-._R1 @6M^9GQ7F) <.(-0W/0-FS;,@$P4": &1A\QS# K+HFWL1.MN3WLLY,J[/L@ &8 M9\< V=G@0: '8>[W&SN, M/&LYF[%^]XR5N"_%\|+;;KN==@>=,&DF[-'8 M2P^9S+L'-_![,$VQ9B&QON=4*.C0_4[7S5XWW2;/,ZKWVIMY_^.5Z_7?ROI]K(O5QEGK8)UZ@W$^>*37V!!8TH;F(I/3-)D-@-4IE8;7##MA.FE'MZ4]=KP=46 MK=R=NR:CJ,FM;?[N=C,^KCV^\P<,Y$%&8P[NNZ#1)3BG%",/9+XD0A#D?NP M[E)0#J;>?%MR2&SH]3I*=;?3-X6^@M%W.G?J5?3F2[D2R/>AB5I@Z V-P92 M @V%)H=:7E#++#&[YN6H3JY0^\|@&]"U/+L=D6<+A;(H6E/[.0[8LX3F>P66[M$+I"T%=!E^^;'@[7!>^-07XGGBO!VENQ=Z)FU:*AJ1,-RF=1K5Z;J8RC[!B)W1?V=M>:'\|ED'E#8C4C8G]'1B4282'V'W5'\2/"$I3*,><(2'K=*DN(§C(IH+M(5.\8%ZC&R' M'(W'2"Z$#"!/Q5T=O?U#B&$?>/;P#!XI0]:<+[K?1LY]Z[ZK1:P. ^ENFD<<2D2@7E8TS2.%4'VES@3/HI"V.:\.@HA6F.T.0F=IH5:HNC/[^3W'N.2>CH\B6S*P'PC%A#\]HI\]:]-41 MHOI8E>OGYCA9U1_@HTfEEIA8#S5EU)!&'>TK]*$L5T4):5 U!.&P6CJ4']:5 M0X)/.&O-0$;[SCT#Z\[7S&=Q%QC$$$XJ37ZMJ%H P5.?B6WL '#N-0+0($3@&A;@M4J+B#[- M[M'?=6&%1P2,D ^$ EPC9]YZ7"HB,&*Y+YWC,NTA6>Q2 M_D\M.%_B_X X>^G_0_91

~~MSAD[N=@L2CDDQD;'\|I^YZ.C25C*]$VVT3H=MH2E*!FO]Z&..KDU4G*$=:U9`-MGO-8@0Y"3F!R?#PZ1FB"H7H0#"X]39TG\"/.6*/BGCEYC;|G%U"\?6YVW^TMJ_HA3Q*/Y7FJ#E548!(0AM6Q*\2$>LP7"N0D(MO{)?.8XA$AFYLDV!:BN2&^_M*5_'1A2/43*++)MH);.786U+;$?#N@HAGQ7-40#Q>?l;@X5GQ#@.'YQ^T5#Y=_M'-PUT&A;./;&(*6)E!XE7!<=<*5\/,0Y%P)3/\M2'=+WF5'Y@0&MR9-OQ#-=_M\/"?)1@C0R5T(SE0'9L6-!W5MK_C5$,>#.1SI:<#E.;5V'&1CW37X!6G6;^[_MM.U?7W>/=%F=3<;2SF5]4ID4/^NGMC^5A*FMKK?2WV;OERL7K^JG>\AS%). M69#@U \\M2D+AFF2<"QRM2<'(CW4O6ZHZ,T%)Y3:A_#U7-MQO5.@KDI\V;=LKQSY!M/<4G.,S1GH2T\323I@/.]'^\Z;8>J5=0X!MW_Q< M9+$GTQB+Q%8P&D$W#G(34Z6C?]>>H=3+9[F1'6Q]+_M%T#V,D?^_[8# - U,^338 :SQ]ON(&\V7/RBH=N=&#<-0R8:+@,$P-VL&5/" M 0)R8A(-=6+R_IKQJUX*?'G7\0NP:AH<]0)@(?YS[SE9E1QJ7,#U,< M4Y:D@L,LC(UN64!4}[8P+?W&F#SU.4!UVS ,TG37&,AABS(9/, !#95OJZ(;_++# MC-VM$\&]T](D&//(PDFL?1P'H41CGWJO7XLLH" SO6#U":VF5\FRIT%^ES. M0(!9QC.YO>\F8QUN3G>^V-\)R.QC=)!'8SNNO/EMB4H(,_WX+6I@^_O:U%[_M!W91NN^AK.*>*&8,+6SOD_Z7_64+++935O?6FG/6ZBDA#B:NGGS$IJL678IN MGEK;^?:^O%,?!+LZKMR+ZNG!RZ00+&4X)$&L,WDSG(=_8'!8>0 (,_'1K?6C1. MXDI'T=T6C7NW:$#:<[E#Q,)-UX7H 'MWF8D[W,-K9(T9>WF92,/?T\OP'<=3 M'?6 N'>ESH!]X"LT2", <1+(",6ZL%#+,2,DDRW^,$R(§ZF.NYH3FSO!@88 MMO1=S77LH6CF^#O&!NC^V\B;K+CL.:33W;L4?PY)CL>0V \V?'$]Y8I >R[MX&MM>KHH0^\,5 ^\3>BPQ\8D?03MY7=UD6U. M>-[[:# @1}?*\6L;X?+)[&=:*TK!9H++,#T;V92"3W@88AJD&291ZN,LS!GF M7B)$P!*:!]#6) .T)C8M+66T&[F^H6TU5W%]H(GH&YSO$-E0OD*_ MTF53ßN=ZIK2!J.IN.\2FOO"=DSD$S>THZ]87B9LF.0Q5]K/8VP$#Sc)BPTK8OTN.NQ6L;-$M;VG]71V>]#_T >]%+I6EJ^_*Y8*!IC2$X=3S8QRENßQB M+^.<^A #9$1UZO0S1;PYP31_Z+$!LS5F)J9&.>PP"S+642N4,L#^K/[YR1F M!22](VMB1G-6(P*"X=!VP%ZVC)>V"; U%Y&]J>NU=E+U',7Z@80)RZB4.*&1 M;F+&(IQ',L'4CV(1Y8F@,;C@:8C8U)>N'>GMK1!:=-01T^2!\=$AU P#HXZP M@%F%/@QM@\,-X690K,,"11/Y7 5"ATC-&PU/HH|&GRCL5U[UOZE%<+_BCV M!NDR0FW^D]FO#Q2;<1&597 M-W)"M^Y]$6T&)YV6%7 O>[',=K>QQ[\7=NTZ*,W@>9>OI-^>[8AWD?.]B=?A) MRQ-%^?2T6#7V27LB9:$SVD7!%J(^-3DP]W/AIS[!:2;4PY E'LX#+\8R2GWF MASGA80/Z6H#(3VUYMLRT?G62&^_Q X;]X7EC,]R UFO'QS%.X F6\(.'%0RN M3B PXO,>1:R.3J3V*UB;WW*HG&+N@TL]*0G$NGC(-%7LXD> M+\F%)Q}>1)67$!.S1P.B&7U*(4IB],]AMN-?3S,38.UC'#MWP@WP3"DLY(X M5.#]H6?7T9/BG5+#TP_"DZ8_"Z]5MKE<,TR8[KTR\.;;;43*L&3T49U@]++I $ MIA0=$6;[2<^G_MKB!/Q;40E6/A.+_VEJQ_M6P|! M'B=YG/DX\ZFOSL0DPWGL"YS{ON!)EOJ2FE=+&A*=6&W.[']O6<\6*~~

~~00KM-MN .<)BV1-#A+3X /3!G[#*"^LWIMY\]2# (~~

~~+!5TYW$OHY MCC,98A*S!.>12'$4Q$)XC"=)8M3+ D9V8L.YZ\"P%$WN/]VR@]CB10?.F[_A M]-;L &R$.;(&9G02O&"&= ?5IQ;]'1=-WH*&JF4$?9L,*H!!G00R.Y/]##]8M804C,&A:S5>;S[B"}=PSK_"W+4;!*KG*0GQ5=OQ%5*_QUN*^[-]HPWLKWA2S5 M+Z9I861>O@I8(>"_TG_TP@UF11U# M!IMX"@? .;PI@,Y\1TOAPN\-*+5X_8(II/I:^-3PNB_B[^:OZH1T7CK,S0[{MT[VRA[L)KHNU*^UZ>-Y??\92,!GP7(^:Y;G_/=NT9&GF0_3 730,30ZFV4V!>XA@N^$N)^G)SCJRU1B(DQ-7S=^&SQ-Z7ZR4Y7G_)*I'M?K'JOQ[M]5VWQJ#%ZT.:Y10(D>$@T V9E8G :>XEV)>I2)4USK+4J)AJA,[$!]&EC#:D M44L;=<3-)PX-(35L"QS*#U-^2!%!,XD,!+,.3S2T[FR3B@R%ZP\M,GGB,/$2S'Q),.T$GV,AHSF8LHX$9U M"!"BDZ<(;<@WJ2^T8^""%I6C*!K$"B? !J;8FW+I'CSZ[F##PZ7]*4G M=(G59=TI+\/,JCFEJ? FO2E'UY]]-.6I=*/GR,SK@(\(>^1RCSUOZV2.5;M6='FCSO[_M_)=X?0@$CGRW8ASR2&*2$H+3).=8T)!G&8|RH\9^E,(CW1%%#56DR8(=_MZD-<3)WI"Z2U5S#UX0V_U8T6*U?V)N MYE8TQ.'+.1:ASP2KQHZNA%MU,WN5$JU52G[N&@&UGPHV_7:\(1%U WXX0 AN.D^!W"#;V.4'3M7[?R?]]-C M@G836:X0E>JS*X K*1:K=>5R&) }/"[#=D .YH_AV4%T.]!GN13,(M;5ZF';MG>6;TF2]Z#1)O(1Z>93{3!FX*, DD#]N%Q/L!XSR-(@BX1E= YRE,+4UZTB! M.B&=AV/8BC@1$F@C#.4S5O51&8846;W<4V+U;SL%/K_N+.HY*M9&^<8?M',V M/HI"*>E.,H^+8VM2/V/ PY#3*,*5*YPCQ!N{'KW8 M1485PB"[U#9]N @QT/C$^QSLR^%A6[XJL^@MO*\X-$T_'5YHZF:8L M\,)KZS"/+WD>.QQ]+8AWD?.]B=?A) MRQ-%^?2T6#7V27LB9:$SVD7!%J(^-3DP]W/AIS[!:2;4PY E'LX#+\8R2GWF MASGA80/Z6H#(3VUYMLRT?G62&^_Q X;]X7EC,]R UFO'QS%.X F6\(.'%0RN M3B PXO,>1:R&JP\MGGB,/$2S'Q),.T$GV,AHSF8LHX$9U M"!"BDZ<(;<@WJ2^T8^""%I6C*!K$"B? !J;8FW+I'CSZ[F##PZ7]*4G M=(G59=TI+\/,JCFEJ? FO2E'UY]]-.6I=*/GR,SK@(\(>^1RCSUOZV2.5;M6='FCSO[_M_)=X?0@$CGRW8AS R

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|TU.O4* !#UF'X.59GN0L"5#.68QP M% N49\QOIEF_4K]4*C-Z(LH:6'J6JWA:TLQ!O#SV\ &6&KL?TX6/1D5&@>\U MTY?8.+926)L'6Q!.+/.NCS[X/7';?:#3,$=^_W#L2=U[IUG'7KS[(9LTX"KI M5*WO7+X)MRHIM#LC(;C[@>#^S ME@Z:HI/NFS]N7]V\[@.0K\/M=^2] 8(G=>>UP0(]]OL4(EF%4'5>X7:TV@K?Y M,;I6(N*I46Y]JK:ZS^OYV]-W-U7VFTRT@CW*44]D1#@-,2)4;?O#-" QYS]) MPO040;U$FY'7I[U\'3[]5!3+C^1WT71&>W>3V'$507.+D*GEZDR{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`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|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{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|&_8.]5>WO?_E_M4$L#!\0 (+ X9UE.4B&#Z\($CP!@ 5 ,6YL:RTR,# (T,#DS,%]P M&ULY+U9=UQ)CB;XWK\B)N=U4&'[4J>K^C"T9.F.0E)+RJZN>?%C"TSR M3LI=[>Y4A.K7#\R=.YVD+W9YC=DG,RBN]V+Y# ; 8,!__6]_?CO]Y047G*5YGLZ^_,M?_O,Y: ;B__+=__2_Y;_^7P#_\[>/;W]Y.4]G MWW"V^N7% L,*\R]_3%=?:PUE]O5_^:?A+ ^N_^S%_/O/ MQ? 3+U]4O@@EU\6L7/UW\LTHZ1\XR)"LD*#\0>7"@<;&%6Z,!1<_W_?/GGG*/- MZ#G]1DB@8O00=;3@G4DE,::R=>N'GDYG?__G^B&&)?Y"[,V6ZR__Y2]?5ZOO M__SKKW_|| <<__1D7I_\T7WSY53 F?[WX[;^<__]?=W[_#[G^;>Z]_W7]T\M? M74ZW_2(]EO_Z/W]_^RE]Q6\!IK/E*LQ2?<%R^L_+]3??SE-8K;7^^%V_W/L; MJ2NX^#6HW@(N0/)_^G.9__*O_^677S;B6,Q/\2.67^]_? OXYO*5W^,SV6GX M.ZI^.*KG]_Q7_ZRG'[[?HH7W_NZP/(O?_DV,_TI M5\TR+UE!W?^]^<-?K\[Z?8%+@LJ:RI? TC?,_KV_9EP+\|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{BH98FN?]O+MXX"DN:?25,B=@.4S_> [$\A"%H^4BE:65DHP' M+S0+88S0*3#Q^'<Y EV1T<]6U=.N:T'ZFX+(/#69"<_\]G84%///WY$;,/%ZM) M-CFE%,@'TYJ,.&;$0K$2I+'2%NZ33FVP<.0%7=F(=K X1KR=(.0#+]:S_&]6 M7Y(/U&Z*,<$V-PT7:"C<^+ M,%M.IU_N\!V$LX6<::.)?%6A'44V@$)'I=^(83+\E1DH(@'+"0%ZX5A$@6+S*CDB[D.\F'-M\[F[N+F6W<"A7EFH#A"L%T\%TLS1=DX-9"6> <*7|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`K'A!$.O.DKS4.WHX> 8UX(,XA/O)5G82R,9IH+@2P1=BATEGI"A>Q=3:9MQ/S;C6HS%4 M&@E]Q(VF%@&OFQPA.5KKM.2\'.=DJQ((=B@9"%6R)K6%{2(M;# Y5]$4>A< MK,7T:&'QHV\9-R)]I<;Y$#+MP NY&=Q=2.NBLIBB<6.BQF@:0 D=0.HDI<49O?5*5A=KY=]W)1+G]!FU5&7 MM=\.R2ND0.LDZH+9):WKA_=E.8;!Q_9V' >9)>1W@[>F\Z\KY@X58]2#]6>C6, M5HHP*M%)*%*8"2EI)UM;:]N4C&N&S00@HX4=E]>|)804R?%;1T G)6E;9LL;KT3 M4OMQ";5<*C$W+_9YD*!QSZZ&\Z6/%'T'9N>>S?I.AL$IZP4GGR_;>HT9702G MF8%@@_&IH0?G#33T&G:,[/S%% [XL0#8S74Z4\L=P.LE%EIS^3>K#SA; MDHYJNGRK#"">%1X48'&A1[!)FVM-B22$L,)2R)UZWM,^U'9C&'@#ZJD# M%&YG(A47K&6"PEI+3.1\/KC6D\"B\B[$!P>8-- LDN_'1<V/J>*GWY6=-0I{J MAGHM01A7FP-%\ HE,$R)>35?UE7= ML_QB/JOI-$X%6#0D"HPG&G$T.?I)>&RL8I9<63K-(P: M:!VCSZVW1I94;@?@..,EYW?HCG'X(T_QF[B)>GI*N-N&6J5+(I7*65HJ*A8/S M7 R2;(JH+O2_#1],RGCAD<-H=)"U!T@VB.N0IWK7H7%C+;,+Y4E*9]_.3LG@ MYAKQI>Ej@B;fG#"!9(IXJG4$@3@$B2);Xf16S<_<'Z=]W)"H(8X:*Z #2%WC M8'WD4ELP+_!KS1C\P#I\^QN^G2_K1:'WY7/X)(Y]PM'2: VHF@Z0M]ZXO\]Y/21_+C=0F23*ML=X@\|&DI;_.MJ9$,..$$+ED]_K;.3=^E8MS#C8;X.5+_'<'3FOT[G\]%7?!U'I6F[]_J .O2"&K MU6(:SU:U!.KSO"8MY[.544%(_'+)-2?2M$D>/-:@(4@'CID (0H>O'+6FO;M 6E10/FXZ:% [-;@B.[!M-\M=MME]%8IACD&QB0.)E:(41ZL5,=K(@Q F/MC3 M^\CT]%::=H) <\R:]P>>LCU=_,T]<;?>#VO)\?75-%&X?X.95]U[;[B2?KX M/L#54S;U#=$C*]7 VGUM2)7A.1O&P1CER67@&EP6 M$9#"V!>C"N;!^9W_N$U!H]Q%W\[C9TFF2IVRUX YB";96FM.VSTDX MNCABP1N*4%],T^?3U"U' EKO]9DW2K+#,P,<403$M\(P&C*7 M05BC=11#G-UWWM1W+[T^WM1W'R'W!9.+?K/11I=R)=F{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

*{SCY\175[_O)L]?,UXG*2"T\FE_1;!EJ*%+?1AD,Q%WW0VA:% MRMW^?]RMVCWLU>,>[3P%ZIY)1UXF=?:) 67K(WHP++JO0@C:\=9#AHE(U<\ MI-"\5>N>G>D&:U[XE%;L0(EW@)6=>EJ4*$NMS #+ZV3S(#U$D2-8"O0.)N%\ M\YZLS9J+#-,Y\"GQU5Q+'2!O+:W-V-?K&_\F EO_\/WWJLOEJSlQD:,;D!$RL M="CKGA]E=55+O8Y="U\3UT4SXW1I7MNY/Y7C-AY[4MEA*"ASQO1$$+V?R'$[A76 T$;ZZQ>@FR7X8C[!06\B M!M^7S>>K;,S>(¦'23/98-$F4A5AK4DC*B@>X7B_@<M=D(I&U"2O_N4\O51BL?M)8! M=(?0;+\X'B_4QYF5D9D8(@5DS-4Q"4* 5R8"R[K0_WEV_BF-;AL4#]=BK ,8 M#Z#8#E#\N8KS;/%SS?2:Q9-$TES4_%6M UQ]G><)+ZEVJR[D\TBSN7<>Z1NYX\Y28,*ZF\8<2K!-,VW/[%Y)}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{LN#0IL.:]=P;F M:>1;RD^"Z;YPT8$]?8GTYC3=7)C@T?.0,$/,%*HIZW.MOXN *BKG$$W0K4.7 MZ^\?UZ;VA8QY(S5U +&+7OJW;^<8Y:UTY-Y80UR(.BM9&0DI83!_5GY8#"XEI,%$[?E_-OG(M]HK6TUB0%1C/R M<9*D;2591B++EA/+(N?6UF\WRL:]Y= 75_CN!#V6K+G_$QB4D+X M$.L>56'O07RPY&\4$#(9%S!,LB@J6W$'C\L+M8ME%@/T?0=W.SEY(I+5Z\9^NOQ^HVU"2H)<8X*8I 4MLJ.I"B%L[K. M.;'C]$=-U'\G)FM:3AS7.]JK9^+K;>|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|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`2 Z#L T8/=- .*7+O-@'U'5DRT4 MO ?-#?A8- KB1JKF)5[==KYMI?.=FOH=H(.P'33Z>-A!XCA9X!Z"Y.L!Z_\'>V\NV0.G8)1GD&1M M!9.$ .I"@F2$R\0F.9*M3=)>:(X\G=@UVDX774 Q-LLW1+F!7.<]1GCA):M M8%(X<-%)DJ(H\(F^9,+ZE))!W;SX95\:>QEGU!PNC!0$--5=LW/;P."9TMFW ML_4,V+\NYLOEWV:+_;9]1S\-RSS!2W^/R<**&M)$<7,P7>Y.'2JF>T/>0@ M?4&?%&]M/)L0WLOXC9%1/("6^S>[]S)=RSNNF;.BBN,Y@ZWUP_6:+?B:B\PB M\>RBR(ZW;H36A/!>FM_W"NW#M;P_M/T&VC^4@GY_.0%B)-Z:I2B-B"](@'S M',#%P(*+%*.++M'_1]H\'+=D=CR<-M%5GYU$M9&NO?A:9Y(MI[/+&]9YV5*F M=%TL;4N[#B9@J&*N-A)Y^O(M':0,WBI K,-+=+U&F+@$[53QB D-.^WL]56^.MA189RUC "69KK]\(4:)3D$@O'UM>"\(2@R$UVG)8Q"*5H>]B/?^.8'LAY*B.8/NH]RW0$VTDI_?(? 89$GUMKDC:Q=_@KQ'82G?407L#SH8H7S-MV*ONYIL=^0J.=T&+07 M;N8=*+$#*WHLZU=YUB1XL$(RB%AK$C19BG4+(I*#M<9(U+EUT^-FQ(^#\G&Q MMU? X/100#EX!WW$QG>=/]I!8-5D'IU=?4AI_@TK,_?; MGI/\OXVI9%WN'I?UL<-%$E5@>H&D[<2P?>,7+1, \N7A:$]LW6GVU:TC^.# M=+4*1H%/Z=.#[`_$5,=NK8IJ:^8N&3Z->GRY/V+-R27?R>!8)[_,7M?KL1S M*13F0E+&6, <91W'2!NTR@82$T%$5[3PK2_'#LO1,">QSV;%/#%D^EE'#3=3 ME+6NW(1]$%1$;!)X2,EL527.UD/#D8LG;R#Y:E&)'IUO>_CB3Y^#F6UY5S M,4WO1Y4G6H4+))02]V[B'4Z;.OCVP<)&OL [>G0=7<>9BL] MC9WA. ^?D(^FN9N%):B]KUGS^O?HQY_Q-O"TN2"N "4<:1<$UQ0(.FZ,=HR; M1RW:SF\;%U4--3L?4LQCX^;)VH?OI^>C]_#[*R0;.YJH[&;8IMH%30/.=&& M[C)]* (VM-Y"/=-> MLW.RP/"^K#_-G/Z'A!.MHW%1"W"EFFOE)2T1X] RLMJ^(/+,=W*^'WE1CPG*-M S4Z'TB\W5B@FTS5T8OORXOY;`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`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`,<4+'*4-JD$1OKU.!,+SCL! M$,H[23LG6K MR,>IZM'S/@Y=-VED;',TC9UW9W6S?E\^X@S_"*?OU!);3JP2&- >)C5S375:P MVJ1% RL&%<,0E0H[6:;=W]GC=M; 2-TD]$[MU3E'=9%,)).9A53;T2&#>BD' M'/,>W6(_W3_*\L*\\D/8O,+_7%-GUSW$<,LUPYX]7+SQ[#"H^OD#GUALQ*2)AP/4UW'$$V(MS@+!B7 ;% 5Z,CF(V2@GM9*AM$[LM:VNN]E8'14TGV P3M1[$\+4T%.30?,;! M46@;2S$V%)EXZWK"? 6D<. ^EP,$(>MF2-E=/=:'GF+O^LK^@.NTJ9RGO.DM8+L M48/*WI%8=002(YJBDF[?%V-?&L?.23P-^(Y53L\;[.NSU=D";S@/1^^A#SRS MV3:Y*!T#U9E'*((-CZLR ;!5$8V/M8JJL$C:QVXW3.ML)MP6R%Y1A 81WLDSMQ^O(,W]'2_OP'GO[W^>SU=?EQ"G+E4,',==K/Q@\ M>"P!4%F*HXICQ,9?E(?1VM6^.3@LCU76,P)E77"?_YA/8C$A>30@N"!?)/ MS@3Z4*L5497,2NOA:WN2,/8YP)-#\!&O=%^H$,5/&\[F0ZPLMV"O[WLTRXH M1\U[&X/G9+&K449;I=KJ8>Q7>[WM-Y"/=-> MLW.RP/"^K#_-G[Z'A!.MHW%1"W"EFFOE)2T1X] RLMJ^(/+,=W*^'WE1CPG*-M S4Z'TB\W5B@FTS5T8OORXOY;`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`,<4+'*4-JD$1OKU.!,+SCL! M$,H[23LG6K MR,>IZM'S/@Y=-VED;',TC9UW9W6S?E\^X@S_"*?OU!);3JP2&- >)C5S375:P MVJ1% RL&%<,0E0H[6:;=W]GC=M; 2-TD]$[MU3E'=9%,)).9A53;T2&#>BD' M'/,>W6(_W3_*\L*\\D/8O,+_7%-GUSW$<,LUPYX]7+SQ[#"H^OD#GUALQ*2)AP/4UW'$$V(MS@+!B7 ;% 5Z,CF(V2@GM9*AM$[LM:VNN]E8'14TGV P3M1[$\+4T%.30?,;! M46@;2S$V%)EXZWK"? 6D<.

*MV]$=OH__7O]H>4F8LBH0B&"I!TX,'Y''1X.9&K"0PDEB62I_W2BKTU6B"MY. MD\: EBD%S^5/,<1X'<.'Q2L{G>[,W25S.%HO**+"X\R\B(QF"E$GO.%)*R-+ M5R-U)*U. XA1,598'@T8Lj/!D,?4@2E&F.46I+D>7@/.$;8*2^.:!?^VL2"T M^/"">*D%H#[X/C"~>S*X(:A/N6.:SXUV N(L&.2PU_EMCC=*.VS8Z'F,'B%H M\>$[+QZ"]N!W9>BL6;-NWJ_9P4/6* <*X%U GJH$&D PLESE2%KPP+"EG.Y< M%1{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|%!(&@"A(02N)*PX#Y[CSTK!.N=P4/E0C YA"JM-@W&ID.ED$# M@-K?P(IZ1!SS"IRR/ TWY,>PA&HD"$M!A$B3+=W8Z^SZP? 42=*=^<'VXW@!T MGG8J8TH0YUQ"25-PLCP84\\]FJ)UN2>'P3I*"-*T25O/*5* ME3ZUGJ>]\A%16OR[H"HKB]]!U-]G((I_Y_>#LZN+]T5=@'- DACB#F(ML9@FTLU=HID#L141SY2&2*%A3D?@;,-V)\/<"}>3*?S5=[" MYJW?=B-@AK50,:& KO9ZM\NQ,R.D<;@@=6RW)K]^D(^"Y$)(0 MIP(41-L 4L61D,B<8]6'8CVFH& [$>KHD#T#B!+96/QGLCX,N+K,Z"$X9 AL' M+*9]"6PI)A3@[D 1Y?[;H?$X8^T@8!3!#UP2(FW <:SWZQ;D*B,$[*\KSN,& +)^ MKO*+7>8AP-??XFRY%/'E;YM'F%LC MGG2BRIM^:]MPU'I#%.:,!2QI'"6(*LQ!(%PVETC%G&.X7F\($'!@S^=&_+ M#6GVI3C>YL8I-(ARNC)!A=O-PG\%/]+W:WM-4?$;55A ;D4[;,.-&'#*5(-MI&2"21)^U&F0U#.PZ4Q0'1- 51N;SL050^YRZS76_O;Z^F2M?EU"[#+ZGQ/-OI&(0-U4@=O=U^^/G-+<;A+]6 RDF3W72D487,#-M/GSGV5G*F.0B'.%2H1R\@%S\4204P85D LYDN=NJL$ 9;\&I=L5;7HX=&HXB MF181]T M8VYG%/+D4)I?WU@ND Z6(8(]Q3Q2I4CYV>'G/M6NE_O[3+7K(XS: MIU^'H6O.@VF7$/8&##M:>)V:0<3P@):D)7)/@:.+?|Y3E/M>LETYY3[?HPN 4[MM+? %#N964*TY,L8(Q$,>$2D$AM34"4Z$YZ'X,/K3H]V1S03O;O.\]> 1KY'#[07'H+72\@=A#WX7B+P/EP MLU]N["Q,9E>7G$6(8*U!8U$H1I+'4WL/>@A^]@_P#>MIYTS\2A$[E M?8LX>M_]DA"O$U$6.4QA*T)'9+T4* IFG=-->V_&-4,|^G2_<1*\HBD[D?%L@.M.M@/4.9K(T9PIH2\.B(1EKX/*0A4"SF"%2/N8OTYEQM-KT44%51!+U8[&[M_?P^7X&.K%8V^Y-? YMN>QEQ[B$.B0=2*[#?"B>T4! HX2N!H M_2X.#_4X/_R1NI>XA>U8*68V!(I/,2?7\G/FNPT|N(K:,$UQV)KB'$5B8&L* M-JF5]B@OHRV03G>K6ZDWW? KWHV.]W2+&_A0'SP_O4F9U3A#P^R'6]G#]|# M7BHM4LR-R1B3 7&J)-(I1.1.4DKJ]'SY7K0IZ^N,OASAL!M+-FWA|N-BXN^ M#L5"HDIQ)(3COY8R@E]AY*B(@\? B426SB4PX=FN&MQJ !P#$B87/!)F0"S;,,!4E"$NULZ21G+P*[P>R, M,N?CB:/+_,/V^\2%]>705(B4@B()>L0%XDB&[U'1AO&H]/$.=G7 MW]KWH6Z0.8-,>7&N-F"=MH7*MP5*A[6=^?AJOEPM+X,-+N!HD34XY]3 YAH- M?Q1:6,;B%=Z7;DQXC)YN0#]C9'DQYK< I,7E4+B\MBH8.LL\K M>_WMUYO5CR_VCTL9; <+>,T2BS^VK*#B"*A_+PGCX.YT(II8E/_"];L XE^QX M"2XV8&>^+*)=WBQ^/+QB|/^ZF2QRM8-33C) ,<0 NO,YI;W M8#1D3-99+[T@L'YGUIK(:YLX@$? Y"@JI]M#VXLKR_$/J4!78I/<4FWV4[Q13H M46Z9+EU"GM(DB8FPBVX=#0]_HQM:SB7W78B7Q2!1=&CC^[AZ-U\NOVV38*_L MU-],UVO.T\ [/!@QQ/.$K|88Z#MU;J2&/=I&O2Y.WB<;IL7_.14I&6&2"6]*OW@_A M0\\]8.?;&3 ^9J9>? =>YHKE+_,'NK.=KOGK M9'JSBN&>"0%3C<&6&BT@8)#Y56&>/R9\="9HEF\?"S/A9& (K#S,R@=:=<_!E M!-> 9_9HHV?18:NIPBBHW':_LLPI$B@$3AA67HDX"_"ZB+IA1#^&]] M)-#$V(S_&R=77S,08%%[%1]?1CZH:;C%&>$X2DB1 {(T7 M-.FH2V+74[\I<#,;QT9:!D'IU60\ZGI3*.YX031O' M$4LIQ,2|(:+T"=R3Q+K&L05L%A%>$^C"H]T_CG(,#V=XD[C9:L2ER#TDE0U(A@CFF;B 3'(:&4>= MYE;21$HG;0^04O=- SHM@YO2F%T3/F/FV]W:1RX*^%TRN/5FR?"M.-5C!\V8 MB9X%;Y!V#")'DG(BET?$C< T>2;L&5OW2]7-JE_[7\Q6DY!Q#ER]?ZOQ^@_ MO0%6;F[T2M&D0X'"*H 0]P(L?L D2> (#KG$NF@HA96:.U*OQHL MNX-&$VQ\$/?DHJF>B!N(5N]F[CZ\D]D,"F">X> =L7>f]\G'F5U.YIL&BP^>P=8B >LUD"PAU7IK#E6'R M<3%_,U]?X=?I[9-;**45TGGQ]8) <9YQ_<.I!*C:1-RM!L9 J+&>]VPE0Y"I+CSWG-F&5<$3AA67HPX,PU$5V5 N$/5#F|[-T!;&WMOK14^@'+EWC.Y9L.Q9"(W@W[T;68<$,3BGYTNG&4K2W,O>[-M^EE:!0P-*$&_R]& %27@MR(E*$;<>HZTAQT]K8G#@3H12N@B,(P_,'5&:5GZ.KW!\K F\#=<0$V7DU')$Y9$ M(^K638:!-=I2AJ(ED5]CRK3S&)&4>Q93 MXI&#OT,8)Z>XLM*9<2XX!TP]&*TE1A.X*R;N)L!WR@-[+E@(C"$1&,2&6D>D M.+F-N2WW_|4YSFF0OKUF1K\MR#,=?+NPI,PYP*N=F&<{G[G0UP M]AHO453<4Q<'X;ETAZ|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|CGGJ;|\ !H=FMOYC>+]U:K?L='@IKWMVI1.M!?AH\?YB@ZFN<*TC;CRA65?VV ^ZG=#T9-LY8,.\9,H:ISQ&-C"#>*XPZU=YZ MQ"\9\1N',>\VM@O#QQO52@L_/F(DFC CEY,U_]FVZ;GR9Y>_Y%_&R^=C 8; M\&0CSGGBJ"P")FKX15N?O&3)L<*VLAMEC9*=@&WJ_FLS!9>W1QD:_,[56\3*QAAE!(I&0+UH3 MTA8B+S-F*LO? >=':SQ:*Q\Y5C1+V]$[@V<$\?;A 6?']<i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|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eVZ2:[*ABT4BK5/)4-7,,_70%)&>E M1$/1T] (}E"OQWRZ7-S'\>K, WF[VLM[V\D&9_NTE4 R76A&(]UT"0Q$]>)> M(&UL0)%#F!8ID[+\N_[>5)Y!&O'QFEA(8(2QW1#EF3$B@XYWET M>$)4)DIX\ISN-@- LJ"]O7*0%T%\=2"T8.D';G_;]/ &@'77G"G1*%UP&$G+ M2'X(I&--#_>LMR;Q,"5,*8I^N%M=-(<\>?4G%;04_\P&2_R4@38$(E"F@J0 M"R42&>89"M2I$"28$MI,I^=!,;O\2X?](>>GK4\,%@LIF$>*\|S&D"6D!<;(M'"(U6!(K6#-W*8/]$]5?ZE,/.>=4QOA_X^3]*QQZ%^"IVJMX 2'>]88'Q6L6 MG__4: 6*/7?91C6BHB0Q!R;:2: (13]2"SR,U2IH3)P.QI'@+KY^F&!$RNV4D MR#%"\MN5A,!O3(@K+P+3Q*18_)GX7]6/(;3$[8C5B#_$W$&X_JIGB@>.0L$(N M3X?G"2(=%S!!4A#%&5=;V-)/*[*:L0^$#A6C=A"@UA:5N!%;EC 5Q\Y),! MU\E&A8QD'%$=-",*/^?]G5$U8B^A=:M&[,/!!HQ#@=]>P)2W6&(DB+&YQSY'3GF_M+$W>QHB|H@GN6ZT? S\!EI0&K<(>>50"P93DSD4=-FFKX]NYLS+;:JK$-E M0=**NKCG.>&Z<>),|)N;RVMR&0,5(3"!,'PV^]D!&08>+|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{!\\E!W&;WSG M0/+0=^81(11":6X8,(%HI+W&00>AE&:E.3&(XLK/TTL@ZG!/K-%%6/GN,!)>$ MK\]T[HV#G6[Z(CAPCV7$B+G$%! EIHB34^ M N:EQ5$;4QN5?&>G,)1B'^DHDBH0P701EJ=EL?G8:I0P34 MNT0L)- AY:2Y7A(K/GN;BQ^6K_[DTP3&EP=V$D:P<70>QC['$(6&CED)(X]V MJ5]&_U]7\^__O5UQ XWM'^Z1O'DWE/#C9PA=+3>7KW8)@E,QQ'C[":* M>E/N8O*X+F 0<\3(Z'SI- R>GTM*FIL7K2 8#,Y=&NI&1R\(C^7E\,9QMDO*\7>3,I/)@EY?'>C)QV==%8'C2 \XA+[9!Q/!SYO@O9ZI7G1#7@@3+W#S/XO1+0^)O,_MT,+ IRXW7|E>]^<+>)SR5'8=7/-% /%SP;I- OD[SH%]CV+_##?Q8A\^Fj5;3\ M65G<:FXGCE1T.Q_1%U=?YZ&PO';6K!*^G":M_=OH1%8?X;.KQ?4LO)G:JR*2 M>KQBE63&27+:RXE&I)0U_M5L&1;EQ+2S9)5ZS).MWU->- '"*H_YG_^YZ^LA;P MP-)5F@V>)+CCO*DLP+LS=7(=PYMY+FWZ|KN=#E:W8^M6Z7'72W0=N-*^XBU? M@9L7O<DA0#% p-1U_Y2=8.RXSR?/\> VJHTG=[3M=P^WQJD1/L6K":A SR? =V- S8>$I_1@D5LU|[P=#WVD\ M-R33 /|>7W^;SG_$^'D%3MIF/-2SIORD9K4'O|/V{*\ATMUM2_I,_ID_LISP9;?K[X]'D46#$_O;9G5!6$1V?6UW[C=O'E;^L|[_7Y#KQ& MV_UOVAZE5$"JQSAUL@"G9_XVVQ_\45.6C+*XK_4>'-MT/@G?0_)UQM9,l89WX+<#X9)$+KF[91/>]TNW$7FIK3,AR>^=OA2.\F22?S[M+'"RF/ZX^1W^SF*PF<7EQO1HNM[VE=G+&<7VI'6-)"RJ[_+YM2QU_U4CAQF1V5A/=;L'W_[VH-I5=?9U&7Z?N7;#,35 ?^3Q4UF-L]6QD-5G]@'FR<#6C=JIGT(5- M4W>U=5]NZG!V:;'2U4K MV3]56OM945D^MP3-[/3'^#[*DLO<^K?WY<^_^++|O% MZ^5]LGD(7/)=4Z]7787DG 7)C8H]M\G\^F:-MS1_2_\ROXZM-3[\W]M\CR/]HQ^I=G)=$0!=^- @@#V/&_;NQTDB9^2_T7^\[QF4Y";BKUU9^'K58!??P^5@70XY6+5/\<(;9 MY<]'^^/WY8,Y1*4+?[]L/T"O@3G#:WWN%]EVX=I#"@\U[Y$WVOYWK7T1R>.%ZU5='13'O MQY? *HOL8Y?T2D=+|*S9]2YWD/|+|+Q^D4^0-+[(N+87:M>]%XJ>0<6A+|]%5_R MI/FK/O&O^L1^L@G_[\M\'8/58_'U4KHSJF'7LW6UL T^D=6885WW>Y>1Z? M7G;/N^R|ME"NKE;K5TNSY>QW"\K[^>;Z>I.W6[VF7!STS7OQ\6WJIO|8E)!9 M[Z_5]-0.26Q>@'T-B#W3#%M$?$M$^:9^.#/-K8ZS_\| H[]$_?%JOP= NE M-,3;Y^H[TNP!\XS*;W. ;B0!K;Q&^+62;\U?=%^,_KO;B'?8!/[Z#?0&8]/!-:->P##Q.9F\[5N1B^2%M MM_$AK1%MXW"Z#CYH]6>>1:W(2FYN3%;Z9AO;=?\UE8 M_K] WY1"3B$2]CTL+8.CLH*HC*I? OX>P_+#XL/[Z> T4+C^&#[.IW;0?Y;__M|-3]2QI^K2^C:690'L54"E(EOE_M<6L9/44064P_2W:7[_?]M\CK*E]KE94!*N*O%^1#2Q,.Z;V9E=.WYU>N9P--DV9E?M6UFC(O?%O.;;V^7 MRYN"$VCV;C7?]U0[^CR/:EO4K[E1?[@CM)04CZU;S>,\U;H^SZ/]NCC_,E_9 M:8GG>[MK5>N25%?0E=^-6-G4Y_?+234$A0^Y:LU@_E='D=X4SMF]H\ MY0X4K]/&0[.QT]K5VIR<*+AG>%/;L:PMZ+_X?E7,-AY7*^\;OXZ24!,A-V6DFI/3!7K$W*BN$!C9>VP<.^[OY M\EB]UBE3WA^OW4F(K22PCK*GNK>SXWD/5;^]"W825TL]J&-LJ=VA- CM4>4>%/M!+9OO4[R:BEA=(0I+.3XBTPU>[A0)P&UE.79QX;]3LA|<*GD[1]Y-%2#F9G M\VV4>0)1HZ5=I2[F]3!.M7Y[#=P7+;$_1J?2C%97\;4JE-]?QE.0FPI =*= M9=7/I3#)=- DIQ_3[_>Y*73_MWHGR;:4" ^G,L-K'VFPY^V665OD)4;'ZXP-K M=GH3T%)6Y!GF5*\@N'_]5:Y48/^;G4374AKD&>;T.GW@[6PY 69^6=CUY,G% M(M=-YZD*.QF @:;, (CGRFR%R"KMLH,*3@R:>>P.+$9K\'EQV2@;Y;[I<\R6;X M>(*]"U;LA/N<+:|[EG(\PH_9-P1UI@]^2[BQ5339'N;U7*@V]+KV83O?8DC+M-M M<@\OW("LCG3.?98A?W5>KZ5#? W5A_ZL+>[^,UFHQ_1(7U\L/Z/-'-ME]VF0_U\A.<94]U3R%25F-SX>*5]["^?[^G!]MM^*2+Y,5H/=ZT=+57L(?Z)0 M'C&@LE0^W4PCP4Z0[-6$^;=5#&^F]FJ0> ZM6>V1>S\]Y<,2^NG\,61V9-EJ MK]K[B>UYQC1A- <HJ^U1>6$A@AU>M]HQ]D!UL3FRW K{?E (SNZN6_.E^BG6\ _MFI#5ZS^-^318E1;6S8+UWZ:= (;C\WFA#4KS<;P@[/Z&Z]>]_,3O'.+@>:,$,OG MZ&\6D]4D+B^NKBZ^V\ETV/N&(^O6>R=^BL'\N8\KH,_S]<3#QOXN)C[$:.^# M'WUFA.O@PILH?AW\\%- /,%+@7GC_^H,N3;;+AX=+EX]]GU^]D:OCHW)[?-/2 MD5_5+\/VT?E^OMJ26B;?W_TKC:3_!\KY"/_&M^C;'^1?G%W&__V__C]02P$"-M% ,4 "_"P.&=9X^ 2-(H' #%)P ' -@ $;6QT M>%\R,#(T<3-X97@S,3%D87-I;'9A+FAT;5!+ 0(4 Q0 (+ X9UD_Q)-+ M@0< &^HG ? " <0' !M;'1X7S(P,C1Q,WAE>#,Q.FD)CO M9&5N32"/! WA(!P M (!@@\ &UL=`A?,C R-'$S>&5X.S(Q9&%S:6QV82YH=&U02P$"-M% ,4 "_"P.&=9GP&0^1_$ "<$@ 'P @ %+%;6QT M>%\R,#(T<3-X97@S,C)B;V1E;G-T961T+FAT;5!+ 0(4 Q0 (+ X9UG%-MIJ2L'U8! #6I$@ 1 " 1L9 !M;FQK+3(P,C0P,3,P+FAT M;5!+ 0(4 Q0 (+ X9UD@A\9Z+Q $FR 1 " 6EO M 0!M;FQK+3(P,C0P.3,P+GAS9%!+ 0(4 Q0 (+ X9UF=W^+Q51T #(6 M 0 5 " <=_ 0!M;FQK+3(P,C0P.3,P7V-A;"YX;6QO2P$"-M% ,4 "_"P.&=93F3 #M(+0 %0 @ %G0$;6YL M;RTR,#(T,#DS,%]D968N>&UL4$L! A0#% @ I+AG63+=;2H=Y $N<(M !4 (!"?P! &UN;&LM,C R-# Y,S!?;&%B+GAM;%!+ 0(4 M Q0 (+ X9UF,4B&#ZI($CP!@ 5 " 5G@ @!M;FQK G+3(P,C0P.3,P7W!R92YX;6QO2P4& H "@"X @ =G,# end XML 86 mnlk-20240930_htm.xml IDEA: XBRL DOCUMENT 0001821586 2024-01-01-012024-09-30 0001821586 us-gaap:CommonClassAMember 2024-11-01 0001821586 us-gaap:CommonClassCMember 2024-11-01 0001821586 2024-09-30 0001821586 2023-12-31 0001821586 us-gaap:CommonClassAMember 2024-09-30 0001821586 us-gaap:CommonClassAMember 2023-12-31 0001821586 us-gaap:CommonClassCMember 2024-09-30 0001821586 2023-12-31 0001821586 2024-07-012024-09-30 0001821586 2023-07-012023-09-30 0001821586 2023-01-012023-09-30 0001821586 us-gaap:CommonClassAMember 2024-07-012024-09-30 0001821586 us-gaap:CommonClassAMember 2023-07-012023-09-30 0001821586 us-gaap:CommonClassAMember 2024-01-012024-09-30 0001821586 us-gaap:CommonClassAMember 2023-01-012023-09-30 0001821586 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-12-31 0001821586 us-gaap:CommonClassCMember us-gaap:CommonStockMember 2022-12-31 0001821586 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001821586 us-gaap:RetainedEarningsMember 2022-12-31 0001821586 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001821586 us-gaap:ParentMember 2022-12-31 0001821586 us-gaap:NoncontrollingInterestMember 2022-12-31 0001821586 us-gaap:AdditionalPaidInCapitalMember 2023-01-012023-03-31 0001821586 us-gaap:ParentMember 2023-01-012023-03-31 0001821586 us-gaap:NoncontrollingInterestMember 2023-01-012023-03-31 0001821586 2023-01-012023-03-31 0001821586 us-gaap:RetainedEarningsMember 2023-01-012023-03-31 0001821586 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-012023-03-31 0001821586 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2023-01-012023-03-31 0001821586 us-gaap:CommonClassCMember us-gaap:CommonStockMember 2023-01-012023-03-31 0001821586 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2023-03-31 0001821586 us-*

gaap:CommonClassCMemberus-gaap:CommonStockMember 2023-03-31 0001821586 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001821586 us-gaap:RetainedEarningsMember 2023-03-31 0001821586 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001821586 us-gaap:ParentMember 2023-03-31 0001821586 us-gaap:NoncontrollingInterestMember 2023-03-31 0001821586 2023-03-31 0001821586 us-gaap:AdditionalPaidInCapitalMember 2023-04-012023-06-30 0001821586 us-gaap:ParentMember 2023-04-012023-06-30 0001821586 us-gaap:NoncontrollingInterestMember 2023-04-012023-06-30 0001821586 2023-04-012023-06-30 0001821586 us-gaap:CommonClassAMemberus-gaap:CommonStockMember 2023-04-012023-06-30 0001821586 us-gaap:RetainedEarningsMember 2023-04-012023-06-30 0001821586 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-012023-06-30 0001821586 us-gaap:CommonClassCMemberus-gaap:CommonStockMember 2023-04-012023-06-30 0001821586 us-gaap:CommonClassAMemberus-gaap:CommonStockMember 2023-06-30 0001821586 us-gaap:CommonClassCMemberus-gaap:CommonStockMember 2023-06-30 0001821586 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001821586 us-gaap:RetainedEarningsMember 2023-06-30 0001821586 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001821586 us-gaap:ParentMember 2023-06-30 0001821586 us-gaap:NoncontrollingInterestMember 2023-06-30 0001821586 2023-06-30 0001821586 us-gaap:AdditionalPaidInCapitalMember 2023-07-012023-09-30 0001821586 us-gaap:ParentMember 2023-07-012023-09-30 0001821586 us-gaap:NoncontrollingInterestMember 2023-07-012023-09-30 0001821586 us-gaap:RetainedEarningsMember 2023-07-012023-09-30 0001821586 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-012023-09-30 0001821586 us-gaap:CommonClassAMemberus-gaap:CommonStockMember 2023-07-012023-09-30 0001821586 us-gaap:CommonClassCMemberus-gaap:CommonStockMember 2023-07-012023-09-30 0001821586 us-gaap:CommonClassAMemberus-gaap:CommonStockMember 2023-09-30 0001821586 us-gaap:CommonClassCMemberus-gaap:CommonStockMember 2023-09-30 0001821586 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001821586 us-gaap:RetainedEarningsMember 2023-09-30 0001821586 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0001821586 us-gaap:ParentMember 2023-09-30 0001821586 us-gaap:NoncontrollingInterestMember 2023-09-30 0001821586 2023-09-30 0001821586 us-gaap:CommonClassAMemberus-gaap:CommonStockMember 2023-12-31 0001821586 us-gaap:CommonClassCMemberus-gaap:CommonStockMember 2023-12-31 0001821586 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001821586 us-gaap:RetainedEarningsMember 2023-12-31 0001821586 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001821586 us-gaap:ParentMember 2023-12-31 0001821586 us-gaap:NoncontrollingInterestMember 2023-12-31 0001821586 us-gaap:AdditionalPaidInCapitalMember 2024-01-012024-03-31 0001821586 us-gaap:ParentMember 2024-01-012024-03-31 0001821586 us-gaap:NoncontrollingInterestMember 2024-01-012024-03-31 0001821586 2024-01-012024-03-31 0001821586 us-gaap:RetainedEarningsMember 2024-01-012024-03-31 0001821586 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-012024-03-31 0001821586 us-gaap:CommonClassAMemberus-gaap:CommonStockMember 2024-01-012024-03-31 0001821586 us-gaap:CommonClassCMemberus-gaap:CommonStockMember 2024-01-012024-03-31 0001821586 us-gaap:CommonClassAMemberus-gaap:CommonStockMember 2024-03-31 0001821586 us-gaap:CommonClassCMemberus-gaap:CommonStockMember 2024-03-31 0001821586 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001821586 us-gaap:RetainedEarningsMember 2024-03-31 0001821586 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001821586 us-gaap:ParentMember 2024-03-31 0001821586 us-gaap:NoncontrollingInterestMember 2024-03-31 0001821586 2024-03-31 0001821586 us-gaap:AdditionalPaidInCapitalMember 2024-04-012024-06-30 0001821586 us-gaap:ParentMember 2024-04-012024-06-30 0001821586 us-gaap:NoncontrollingInterestMember 2024-04-012024-06-30 0001821586 2024-04-012024-06-30 0001821586 us-gaap:RetainedEarningsMember 2024-04-012024-06-30 0001821586 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-012024-06-30 0001821586 us-gaap:CommonClassAMemberus-gaap:CommonStockMember 2024-06-30 0001821586 us-gaap:CommonClassCMemberus-gaap:CommonStockMember 2024-06-30 0001821586 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001821586 us-gaap:RetainedEarningsMember 2024-06-30 0001821586 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001821586 us-gaap:ParentMember 2024-06-30 0001821586 us-gaap:NoncontrollingInterestMember 2024-06-30 0001821586 2024-06-30 0001821586 us-gaap:AdditionalPaidInCapitalMember 2024-07-012024-09-30 0001821586 us-gaap:ParentMember 2024-07-012024-09-30 0001821586 us-gaap:NoncontrollingInterestMember 2024-07-012024-09-30 0001821586 us-gaap:RetainedEarningsMember 2024-07-012024-09-30 0001821586 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-012024-09-30 0001821586 us-gaap:CommonClassAMemberus-gaap:CommonStockMember 2024-07-012024-09-30 0001821586 us-gaap:CommonClassCMemberus-gaap:CommonStockMember 2024-07-012024-09-30 0001821586 us-gaap:CommonClassAMemberus-gaap:CommonStockMember 2024-09-30 0001821586 us-gaap:CommonClassCMemberus-gaap:CommonStockMember 2024-09-30 0001821586 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001821586 us-gaap:RetainedEarningsMember 2024-09-30 0001821586 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0001821586 us-gaap:ParentMember 2024-09-30 0001821586 us-gaap:NoncontrollingInterestMember 2024-09-30 0001821586 mnlk:CommercialPaperAndCertificatesOfDepositMember 2024-09-30 0001821586 mnlk:CommercialPaperAndCertificatesOfDepositMember 2023-12-31 0001821586 srt:MinimumMember 2024-09-30 0001821586 srt:MaximumMember 2024-09-30 0001821586 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember 2024-09-30 0001821586 us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember 2024-09-30 0001821586 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember 2023-12-31 0001821586 us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember 2023-12-31 0001821586 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CertificatesOfDepositMember 2024-09-30 0001821586 us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CertificatesOfDepositMember 2024-09-30 0001821586 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CertificatesOfDepositMember 2023-12-31 0001821586 us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CertificatesOfDepositMember 2023-12-31 0001821586 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001821586 us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001821586 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001821586 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001821586 us-gaap:CommercialPaperMember 2024-09-30 0001821586 us-gaap:CertificatesOfDepositMember 2024-09-30 0001821586 us-gaap:CashAndCashEquivalentsMember 2024-09-30 0001821586 us-gaap:DebtSecuritiesMember 2024-09-30 0001821586 us-gaap:FairValueInputsLevel2Member 2023-12-31 0001821586 us-gaap:FairValueInputsLevel2Member 2024-01-012024-09-30 0001821586 us-gaap:FairValueInputsLevel2Member 2024-09-30 0001821586 mnlk:SwitzerlandOfficeMember 2021-08-012021-08-31 0001821586 mnlk:SwitzerlandOfficeMember 2021-08-31 0001821586 mnlk:SwitzerlandOfficeMember 2023-12-31 0001821586 mnlk:PortoOfficeMember 2023-10-092023-10-09 0001821586 mnlk:PortoOfficeMemberus-gaap:BuildingMember 2023-10-09 0001821586 2023-10-092023-10-09 0001821586 mnlk:PortoOfficeMember 2023-10-09 0001821586 mnlk:CambridgeOfficeMember 2023-10-132023-10-13 0001821586 mnlk:CambridgeOfficeMemberus-gaap:BuildingMember 2023-10-13 0001821586 mnlk:SwitzerlandOfficeMember 2023-12-122023-12-12 0001821586 mnlk:SwitzerlandOfficeMember 2023-12-12 0001821586 mnlk:PortoOfficeMember 2024-08-142024-08-14 0001821586 mnlk:PortoOfficeMemberus-gaap:BuildingMember 2024-08-14 0001821586 2024-08-142024-08-14 0001821586 mnlk:PortoOfficeMember 2024-08-14 0001821586 srt:ScenarioForecastMember 2024-10-012024-12-31 0001821586 mnlk:ConversionOfClassCIntoClassAMemberus-gaap:CommonClassCMemberus-gaap:CommonClassAMemberus-gaap:CommonStockMember 2024-01-012024-03-31 0001821586 mnlk:ConversionOfClassCIntoClassAMemberus-gaap:CommonClassCMemberus-gaap:CommonStockMember 2024-01-012024-03-31 0001821586 mnlk:ConversionOfClassCIntoClassAMemberus-gaap:CommonClassAMemberus-gaap:CommonStockMember 2024-07-012024-09-30 0001821586 mnlk:ConversionOfClassCIntoClassAMemberus-gaap:CommonClassCMemberus-gaap:CommonStockMember 2024-07-012024-09-30 0001821586 mnlk:MoonLakeAGMemberus-gaap:CommonStockMember 2024-09-092024-09-25 0001821586 us-gaap:CommonClassCMemberus-gaap:CommonStockMember 2024-09-092024-09-25 0001821586 us-gaap:CommonClassAMemberus-gaap:CommonStockMember 2024-09-092024-09-25 0001821586 mnlk:ATMSharesMembermnlk:May2023SalesAgreementMember 2023-05-11 0001821586 mnlk:ATMSharesMembermnlk:May2023SalesAgreementMember 2023-06-27 0001821586 mnlk:ATMSharesMembermnlk:May2023AndAugust2023SalesAgreementMember 2023-08-31 0001821586 mnlk:August2023SalesAgreementMember 2024-01-012024-03-31 0001821586 mnlk:August2023SalesAgreementMember 2024-03-31 0001821586 mnlk:August2023SalesAgreementMember 2024-07-012024-09-30 0001821586 mnlk:August2023SalesAgreementMember 2024-04-012024-06-30 0001821586 mnlk:UnderwritingAgreementMember 2023-06-272023-06-27 0001821586 mnlk:UnderwritingAgreementMember 2023-06-27 0001821586 us-gaap:OverAllotmentOptionMember 2023-06-272023-06-27 0001821586 mnlk:UnderwritingAgreementMember 2023-06-302023-06-30 0001821586 mnlk:MoonLakeImmunotherapeuticsMembermnlk:UnderwritingAgreementMembermnlk:MoonLakeAGMember 2023-07-092023-07-09 0001821586 mnlk:MoonLakeImmunotherapeuticsMembermnlk:MoonLakeAGMember 2023-07-092023-07-09 0001821586 mnlk:MoonLakeImmunotherapeuticsMembermnlk:MoonLakeAGMember 2023-07-102023-07-10 0001821586 2023-07-10 0001821586 mnlk:MoonLakeImmunotherapeuticsMembermnlk:UnderwritingAgreementMembermnlk:MoonLakeAGMember 2024-03-082024-03-08 0001821586 mnlk:MoonLakeImmunotherapeuticsMembermnlk:MoonLakeAGMember 2024-03-082024-03-08 0001821586 2024-03-08 0001821586 us-gaap:CommonStockMembermnlk:MoonLakeAGMember 2024-03-082024-03-08 0001821586 us-gaap:CommonClassCMemberus-gaap:CommonStockMembermnlk:MoonLakeAGMember 2024-03-082024-03-08 0001821586 mnlk:EquityIncentivePlanMember 2024-07-012024-09-30 0001821586 srt:ProFormaMember 2024-07-012024-09-30 0001821586 srt:ProFormaMember 2024-01-012024-09-30 0001821586 srt:ProFormaMemberus-gaap:CommonClassAMemberus-gaap:SubsequentEventMember 2024-11-01 0001821586 srt:ProFormaMemberus-gaap:CommonClassAMemberus-gaap:SubsequentEventMember 2024-11-012024-11-01 0001821586 us-gaap:RestrictedStockMember 2024-07-012024-09-30 0001821586 us-gaap:RestrictedStockMember 2023-07-012023-09-30 0001821586 us-gaap:RestrictedStockMember 2024-01-012024-09-30 0001821586 us-gaap:RestrictedStockMember 2023-01-012023-09-30 0001821586 us-gaap:EmployeeStockMember 2024-07-012024-09-30 0001821586 us-gaap:EmployeeStockMember 2023-07-012023-09-30 0001821586 us-gaap:EmployeeStockMember 2024-01-012024-09-30 0001821586 us-gaap:EmployeeStockMember 2023-01-012023-09-30 0001821586 us-gaap:EmployeeStockOptionMember 2024-07-012024-09-30 0001821586 us-gaap:EmployeeStockOptionMember 2023-07-012023-09-30 0001821586 us-gaap:EmployeeStockOptionMember 2024-01-012024-09-30 0001821586 us-gaap:EmployeeStockOptionMember 2023-01-012023-09-30 0001821586 mnlk:EquityIncentivePlanMember 2023-07-012023-09-30 0001821586 mnlk:EquityIncentivePlanMember 2024-01-012024-09-30 0001821586 mnlk:EquityIncentivePlanMember 2023-01-012023-09-30 0001821586 us-gaap:ResearchAndDevelopmentExpenseMember 2024-07-012024-09-30 0001821586 us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-012023-09-30 0001821586 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-012024-09-30 0001821586 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-012023-09-30 0001821586 us-gaap:GeneralAndAdministrativeExpenseMember 2024-07-012024-09-30 0001821586 us-gaap:GeneralAndAdministrativeExpenseMember 2023-07-012023-09-30 0001821586 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-012024-09-30 0001821586 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-012023-09-30 0001821586 mnlk:EquityIncentivePlanMember 2024-09-30 0001821586 mnlk:EmployeeStockOptionPlanESOPMember 2024-09-30 0001821586 mnlk:MoonLakeAGMember 2021-04-28 0001821586 us-gaap:CommonClassCMembermnlk:MoonLakeAGMember 2021-04-28 0001821586 us-gaap:RestrictedStockMembermnlk:MoonLakeAGMember 2021-04-28 0001821586 us-gaap:RestrictedStockMemberus-gaap:CommonClassCMembermnlk:MoonLakeAGMember 2021-04-28 0001821586 us-gaap:RestrictedStockMembermnlk:MoonLakeAGMember 2021-04-282021-04-28 0001821586 us-gaap:RestrictedStockMember 2022-12-31 0001821586 us-gaap:RestrictedStockMember 2023-09-30 0001821586 us-gaap:EmployeeStockMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember 2024-01-012024-09-30 0001821586 us-gaap:EmployeeStockMembermnlk:ShareBasedPaymentArrangementTrancheFourMember 2024-01-012024-09-30 0001821586 us-gaap:EmployeeStockMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember 2024-01-012024-09-30 0001821586 us-gaap:EmployeeStockMemberus-gaap:ShareBasedCompensationAwardTrancheThreeMember 2024-01-012024-09-30 0001821586 us-gaap:EmployeeStockMember 2022-12-31 0001821586 us-gaap:EmployeeStockMember 2023-09-30 0001821586 us-gaap:EmployeeStockMember 2023-12-31 0001821586 us-gaap:EmployeeStockMember 2024-09-30 0001821586 us-gaap:EmployeeStockOptionMembermnlk:EmployeeStockOptionPlanESOPMembermnlk:ShareBasedPaymentArrangementTrancheFourMember 2024-01-012024-09-30 0001821586 us-gaap:EmployeeStockOptionMembermnlk:EmployeeStockOptionPlanESOPMemberus-gaap:ShareBasedCompensationAwardTrancheThreeMember 2024-01-012024-09-30 0001821586 us-gaap:EmployeeStockOptionMembermnlk:EmployeeStockOptionPlanESOPMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember 2024-01-012024-09-30 0001821586 us-gaap:EmployeeStockOptionMembermnlk:EmployeeStockOptionPlanESOPMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember 2024-01-012024-09-30 0001821586 us-gaap:EmployeeStockOptionMembermnlk:EmployeeStockOptionPlanESOPMember 2022-12-31 0001821586 us-gaap:EmployeeStockOptionMembermnlk:EmployeeStockOptionPlanESOPMember 2023-01-012023-09-30 0001821586 us-gaap:EmployeeStockOptionMembermnlk:EmployeeStockOptionPlanESOPMember 2023-09-30 0001821586 us-gaap:EmployeeStockOptionMembermnlk:EmployeeStockOptionPlanESOPMember 2023-12-31 0001821586 us-gaap:EmployeeStockOptionMembermnlk:EmployeeStockOptionPlanESOPMember 2024-01-012024-09-30 0001821586 us-gaap:EmployeeStockOptionMembermnlk:EmployeeStockOptionPlanESOPMember 2024-09-30 0001821586 mnlk:EquityIncentivePlanMember 2022-04-052022-04-05 0001821586 mnlk:EquityIncentivePlanMember 2022-12-31 0001821586 mnlk:EquityIncentivePlanMember 2023-09-30 0001821586 mnlk:EquityIncentivePlanMember 2023-12-31 0001821586 mnlk:PrepaidExpensesCurrentMember 2024-09-30 0001821586 mnlk:PrepaidExpensesNoncurrentMember 2024-09-30 0001821586 mnlk:SonelokimabProgramSLKProgramMemberus-gaap:LicenseMember 2024-09-30 0001821586 country:CH 2024-09-30 0001821586 country:CH 2023-12-31 0001821586 country:GB 2024-09-30 0001821586 country:GB 2023-12-31 0001821586 country:PT 2024-09-30 0001821586 country:PT 2023-12-31 shares iso4217:USD iso4217:USD shares

mnlk:lease mnlk:lease_contract mnlk:segment utr:sqft mnlk:period pure iso4217:CHF mnlk:vote mnlk:plan mnlk:co-founder iso4217:CHF shares iso4217:EURfalse2024Q3-12-310001821586P3Y1110-Qtrue2024-09-30false001-39630MOONLAKE IMMUNOTHERAPEUTICSE998-1711963Dorfstrasse 296300ZugCH41415108022Class A ordinary share, par value $0.0001 per shareMLTXNASDAQYesYesLarge Accelerated Filerfalsefalsefalse630639298412693756562914511693371182684005983890024070621056862159844252102203512316178514167302325119736284805813783208652064550.00010.000150000000050000000063046025630460256046645360466453630560470.00010.000110000000010000000084126984126925054762505476842516753434436099601899884771166574722833970235762148819532549567568373063151781533649550164051349101951821332852654011535735514758513672411709237040877376495539160721099643112009-12976743-93510710-39094204708969113863131890307029525573602231831590430-74607640-36141647921062892324105950080-36114424-11619353-74848699-36191727-35390337-9426049-73331005-28570184-724087-2193304-1517694-7621543-3255103437291508860304653811562939157-110878-19323-44113934764483979823027215-36555563-8142905-74450717-33164512-35822526-6590259-72941435-26095926-733037-1552646-1509282-706858662896782628967825351765553517655628032206280322045485650454856505-0.56-0.56-0.18-0.18-1.17-1.17-0.63-0.6338977600389813723511137312919229 1-80650212350946488982961986840268766698187599218759927011952771873517351714064923-9004856-9004856-3214131-12218987-12625-12625-5047-1767217660318-176603-18237049178723883 6-2388360391542033916135469081355131308849-896550683401084199916017112989591124912474161247416250451497661974489497445128411945128509345128509 3-10139279-10139279-2214108-12353387-348906-348906-82655-4315614587713459-4587713-4595709595439225753517-5753517053486810534989591958965895499 79-997943473512448979700193129544991099551238144123814418750714256519-9426049-9426049-2193304-1161935328357902835790640658347644874678 7-74678-754559131495487 40-5487400-6006176111 35-6006062657310111-2750515535614885356888451788953127195 3-109220396287519842493300064709186489642186604664536047250547625160996923 6-116657472235762149567568317815336513491019169310116931 01-158931677208-13673656-13673656-301865-139755212579492579495554263503149335614 9-1493356-149105369807660310613583-106135830-113154-904-1140581141085 0-466719619-466717730572 16-160996116853 2-209148289152540095254019052540190628746376287995267100670185376-1303311282693096542553731983265755238638818132071813207150381828245-24267012-24267012-491742-2475875456381156381111807575618628746376287995267100671998583-1545981403256907520663737936776053003149718275711827571150381842609-35390337-35390337-724087-36114424-432189-432189-8950-441139153998 16-153998-161336078925213453 30-134533001739029129691298912988991589915188491799630460256305841269846754343443-1899884772833970488195325730631549550164 0-74848699-361917278344086953480625500499-2678-50740-1189056-96364135020050362654430752332 9-869187887291931497 56-872121-117832995404-3195591-68113589-304338412033346911757327111454140503368168883439530-58264594-142051023525401904512850931470436091298050051161002451285093-295865-140047-755130462786601824511693373950562737565629131816580955485700verview of the Company<div style="margin-bottom:12pt;text-align:justify">Corporate Information</div><div style="text-align:justify;text-indent:0.36pt">MoonLake Immunotherapeutics is a clinical stage biotechnology company advancing therapies to address significant unmet needs in inflammatory skin and joint diseases. MoonLake Immunotherapeutics is currently a single asset company focused on the development of Sonelokimab (“SLK”), a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.</div>Unless the context otherwise requires, “MoonLake” and the “Company” refer to the combined company following the Business Combination (as defined in Note 2 —) Business Combination Agreement with Helix and Recapitalization included in MoonLake’s audited financial statements and notes thereto for the year ended December 31, 2023 included in MoonLake’s Annual Report on Form 10-K for the year ended December 31, 2023, which was filed with the Securities and Exchange Commission (“SEC”) on February 29, 2024 (the “Annual Report”)) consummated on April 5, 2022, together with its subsidiaries.Basis of Presentation and Significant Accounting Policies<div style="margin-bottom:12pt;text-align:justify">Basis of Presentation</div><div style="text-align:justify">The accompanying unaudited condensed consolidated financial statements include those of the Company and its subsidiaries, MoonLake Immunotherapeutics AG, a Swiss stock corporation (Aktiengesellschaft) registered with the commercial register of the Canton of Zug, Switzerland under the number CHE-433.093.536 (“MoonLake AG”), MoonLake Immunotherapeutics Ltd., a private limited company incorporated in the United Kingdom, and MNLK Immunotherapeutics, Unipessoal Lda ("MNLK PT"), a private limited company incorporated in Portugal, after elimination of all intercompany accounts and transactions. The accompanying unaudited condensed consolidated financial statements and notes hereto have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) as set forth by the Financial Accounting Standards Board (“FASB”) and in conformity with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X for interim financial reporting. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) of the FASB.
</div><div style="text-align:justify">In the opinion of management, all material adjustments necessary for a fair presentation of the financial information, which are of a normal and recurring nature, have been made for the interim periods reported. Results of operations for the three and nine months ended September 30, 2024 are not necessarily indicative of the results for the entire fiscal year or any other period. The unaudited condensed consolidated financial information for the three and nine months ended September 30, 2024 and 2023 have been prepared on the same basis as and should be read in conjunction with MoonLake’s audited financial statements and notes thereto for the year ended December 31, 2023 included in the Annual Report.</div><div style="margin-bottom:0.12pt;text-indent:0.36pt">
</div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">All amounts are presented in U.S. Dollar (“$”), unless otherwise indicated. The term “Swiss franc” and “CHF” refer to the legal currency of Switzerland, "GBP" refers to the legal currency of the United Kingdom, and “€” and "Euro" refer to the legal currency of Portugal. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires the Company to make judgments, estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses. The significant judgments, estimates and assumptions relevant to the Company relate to: •determining whether the in-process research and development expenditure (“IPR&D”) has an alternative future use; •determining assumptions used in estimating the fair value of share-based compensation; •estimating the recoverability of the deferred tax asset; and •estimating the amount of accruals in connection with the completion of clinical trial milestones.
 The Company bases its judgments and estimates on various factors and information, which may include, but are not limited to, the Company’s forecasts and future plans, current economic conditions and observable market-based transactions of its own shares, the results of which form the basis for making judgments about the carrying value of assets and liabilities and recorded amounts of expenses that are not readily apparent from other sources. To the extent there are material differences between the Company’s estimates and the actual results, the Company’s future results of operation may be affected. Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash and cash equivalents are recorded at cost, which approximates fair value. As of September 30, 2024, the Company considers $59.8 million of short-term marketable debt securities in the form of eurocommercial papers and certificates of deposit to be cash equivalents. As of December 31, 2023, the Company considered $129.4 million of short-term marketable debt securities in the form of eurocommercial papers and certificates of deposit to be cash equivalents. Marketable securities and short-term investments The Company invests in short-term marketable securities in the form of debt securities. At the time of purchase, the Company assesses whether such debt security should be classified as held-to-maturity or available-for-sale debt securities. Debt securities are classified as held-to-maturity when the Company has the positive intent and ability to hold the securities to maturity. Held-to-maturity debt securities are carried at amortized cost, adjusted for accretion of discounts or amortization of premiums to maturity computed under the effective interest method. Such accretion or amortization is included in “Interest and dividend income”. Marketable debt securities not classified as held-to-maturity are classified as available-for-sale and reported at fair value. Net unrealized gains and losses on available-for-sale debt securities are excluded from the determination of earnings and are instead recognized in the “Accumulated other comprehensive income” component of equity until realized. Realized gains and losses on available-for-sale debt securities are computed based upon the historical cost of these securities, using the specific identification method. A decline in the fair value of any security below cost that is deemed other than temporary results in a charge to earnings and the corresponding establishment of a new cost basis for the security. Dividend and interest income are recognized when earned. Realized gains and losses are included in "Other income" and the cost of securities sold is determined using the specific-identification method. Marketable debt securities are classified as either “Cash and cash equivalents” or “Short-term marketable debt securities” according to their original maturity at the time of acquisition. Changes in unrealized gains and losses pertaining to cash equivalent securities are added back into the consolidated statements of cash flows as those are excluded from the determination of earnings but impact the cash and cash equivalents position. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentration of credit risk consist of cash accounts in large financial institutions which, at times, may exceed the CHF 100,000 deposit protection limit in Switzerland, the $250,000 Federal Deposit Insurance Corporation deposit insurance coverage limit in the United States, the GBP 85,000 Financial Services Compensation Scheme deposit protection limit in the United Kingdom, or the €100,000 Fundo de Garantia de Depósitos deposit protection limit in Portugal. The Company believes it is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash and cash equivalents are held. Additionally, the Company ensures further protection against credit risk by diversifying its cash holdings across a variety of credit institutions, thereby minimizing the potential impact of any adverse events on a single institution. Further, the Company’s investment strategy for cash (in excess of current business requirements) is set to invest in short-term marketable debt securities. Management actively monitors credit risk in the investment portfolio. Credit risk exposures are controlled in accordance with policies approved by the board of directors to identify, measure, monitor and

control credit risks. Fair Value Measurements The Company follows the guidance included in ASC 820, Fair Value Measurement. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. There are three levels of inputs to fair value measurements: •Level 1, meaning the use of quoted prices for identical instruments in active markets; •Level 2, meaning the use of quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active or are directly or indirectly observable; and •Level 3, meaning the use of unobservable inputs. Observable market data is used when available. Transfers between Levels 1, 2 or 3 within the fair value hierarchy are recognized at the end of the reporting period when the respective transaction occurred. Segment Information The Company operates as a single operating segment. The Company's chief operating decision maker, its Chief Executive Officer, manages the Company's operations on a stand-alone basis for the purposes of allocating resources and assessing financial performance. Property and Equipment Property and equipment, net is stated at cost, net of accumulated depreciation. Depreciation is computed using the straight-line method based on the estimated useful lives of three to five years. As of September 30, 2024, property and equipment, net relates to information technology, office equipment, and leasehold improvements. Research and Development Contract Costs and Accruals Research and development expenses include employee payroll, consulting, contract research and contract manufacturing costs attributable to research and development activities and are expensed as incurred. Upfront payments and milestone payments made for the licensing of technology are expensed as research and development expenses in the period in which it is probable that a liability has been incurred. Advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed. The Company has entered into various research and development contracts with companies both inside and outside of the United States. These agreements are generally cancellable, and related payments are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies or trials, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company's estimates. The Company's historical accrual estimates have not been materially different from the actual costs. Share-Based Compensation The Company recognizes compensation expense based on estimated fair values for all stock-based payment awards made to eligible employees, members of the board of directors and independent contractors that are expected to vest.
 The valuation of stock option awards is determined at the date of grant using the Black-Scholes option pricing model. The Black-Scholes option pricing model requires the Company to make assumptions and judgements about the inputs used in the calculations, such as the fair value of the common stock, expected term, expected volatility of the Company's common stock, risk-free interest rate and expected dividend yield. The valuation of restricted stock awards is measured by the fair value of the Company's common stock on the date of the grant.
For all stock options granted, the Company calculated the expected term as the period that share-based awards are expected to be outstanding. The estimate of expected volatility is based on comparative companies' volatility within the Company's industry. The risk-free rate is based on the yield available on United States Treasury zero-coupon issues corresponding to the expected term of the award.
The fair value of the common stock granted under the ESPP (as defined in Note 13 — Share-based compensation) has historically been estimated by management with reference to the market-based transaction with its Series A investors, as there was no public market for the common stock.
 Share-based payment arrangements are accounted for under the fair value method. Total compensation is measured at grant date, based on the fair value of the award at that date, and recorded in earnings over the period the employees are required to render service. The Company recognizes compensation cost only for those awards expected to meet the service conditions on a straight-line basis over the requisite service period of the award.
 Foreign Currency The functional currency of the Company and its subsidiaries is the U.S. dollar. Balances and transactions denominated in foreign currencies are converted as follows: monetary assets and liabilities are translated using exchange rates in effect at the balance sheet dates and non-monetary assets and liabilities are translated at historical exchange rates. Revenue and expenses are translated at the daily exchange rate on the respective accounting date. Gains or losses from foreign currency translation are included in the consolidated statements of operations and comprehensive loss in "other income, net". The Company recognized foreign currency transaction loss of $26,746 and $125,581 for the three and nine months ended September 30, 2024, respectively, and a foreign currency transaction loss of $557,144 and $276,491 for three and nine months ended September 30, 2023, respectively.
 Income Taxes The Company accounts for income taxes by using the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. A valuation allowance is recorded to the extent it is more likely than not that all or a portion of the Company's deferred tax assets will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. Net Loss per Class A Ordinary Shares Basic net loss per Class A Ordinary Share is calculated using the two-class method under which earnings are allocated to both Class A Ordinary Shares and participating securities. Basic net loss per share is calculated by dividing the net loss attributable to Class A Ordinary Shares by the weighted-average number of Class A Ordinary Shares outstanding for the period. The diluted net loss per Class A Ordinary Share is computed by dividing the net loss using the weighted-average number of Class A Ordinary Shares and, if dilutive, potential Class A Ordinary Shares outstanding during the period. In periods in which the Company reports a net loss attributable to shareholders of Class A Ordinary Shares, diluted net loss per share attributable to shareholders of Class A Ordinary Shares is the same as basic net loss per share attributable to shareholders of Class A Ordinary Shares, since dilutive Class A Ordinary Shares are not assumed to be outstanding if their effect is anti-dilutive.
 Acquisitions The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first assessing whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. On April 29, 2021, MoonLake AG entered into an in-licensing agreement (the "In-License Agreement") with Merck Healthcare KGaA, Darmstadt, Germany ("MHKDG") to acquire the Sonelokimab program (the "SLK Program") and determined that substantially all of the fair value of the gross assets acquired related to IPR&D of SLK. Therefore, this transaction was accounted for as an asset acquisition.
 IPR&D represents incomplete technologies that the Company acquires, which at the time of acquisition, are still under development and have no alternative future use. The fair value of such technologies is expensed upon acquisition. A technology is considered to have an alternative future use if it is probable that the Company will use the asset in its current, incomplete state as it existed at the acquisition date, in another research and development project that has not yet commenced, and economic benefit is anticipated from that use. If a technology is determined to have an alternative future use, then the fair value of the program would be recorded as an asset on the balance sheet rather than expensed. Contingent consideration payments (for example milestone payments due upon the occurrence of a specific event) in asset acquisitions are recognized in the period in which it is probable that a liability has been incurred (unless the contingent consideration meets the definition of a derivative, in which case the amount becomes part of the cost in the asset acquired). Upon recognition of the contingent consideration payment, the amount is expensed if it relates to IPR&D or capitalized if it relates to a developed product which is generally considered to be when clinical trials have been completed and regulatory approval obtained. Future royalty payments due on net sales will be recognized in cost of goods sold when net sales are recognized. Pension Accounting The Company accounts for pension assets and liabilities in accordance with ASC 715, <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-

height:112%">Compensation – Retirement Benefits, which requires the recognition of the funded status of pension plans in the Company's consolidated balance sheet. The liability in respect to defined benefit pension plans is the projected benefit obligation calculated annually by independent actuaries using the projected unit credit method. The projected benefit obligation as of September 30, 2024 represents the actuarial present value of the estimated future payments required to settle the obligation that is attributable to employee services rendered before that date. Service costs for such pension plans, represented in the net periodic pension benefit cost, are included in the personnel expenses of the various functions where the employees are engaged. The other components of net benefit cost are included in the consolidated statements of operations and comprehensive loss separately from the service cost component, in "other income, net." Plan assets are recorded at their fair value. Gains or losses arising from plan curtailments or settlements are accounted for at the time they occur. Any net pension asset is limited to the present value of the future economic benefits available to the Company in the form of refunds from the plan or expected reductions in future contributions to the plan. Actuarial gains and losses arising from differences between the actual and the expected return on plan assets are recognized in accumulated other comprehensive income. Leases
 The Company determines if an arrangement is or contains a lease at contract inception. For these arrangements, it is evaluated if the arrangement involves an identified asset that is physically distinct or whether the Company has the right to substantially all of the capacity of an identified asset that is not physically distinct. In arrangements that involve an identified asset, there is also judgment in evaluating if the Company has the right to direct the use of that asset.
 MoonLake does not have any finance leases. As of September 30, 2024, the Company has five operating leases related to the office spaces located in (i) Dorfstrasse 29, 6300, Zug, Switzerland (comprised of two leases), (ii) 95 Regent Street, CB2 1AW, Cambridge, England, United Kingdom, and (iii) Rua Manuel Pinto de Azedevo 860, 4150-335, Porto, Portugal (comprised of two leases). The operating leases are recognized on a straight-line basis over the lease term commencing on the date the Company has the right to use the leased property. Right-of-use assets and lease liabilities are measured at the lease commencement date based on the present value of the remaining lease payments over the lease term, determined using the discount rate for the lease at the commencement date. Because the rate implicit in the leases is not readily determinable, the Company uses the incremental borrowing rate as the discount rate, which approximates the interest rate at which the Company could borrow on a collateralized basis with similar terms and payments and in similar economic environments.
 Leases with an initial term of 12 months or less that do not have the option to purchase the underlying asset are not recorded on the balance sheet, with lease expense for these leases recognized on a straight-line basis over the lease term commencing on the date the Company has the right to use the leased property.
 Recently Issued Accounting Pronouncements not yet Adopted In November 2023, the FASB issued ASU 2023-07, Segment reporting — Improvements to Reportable Segment Disclosures. This new standard requires public entities to disclose significant segment expenses and additional segment items annually and to provide all reported segment profit or loss and assets disclosures currently required annually on an interim basis. The standard also requires disclosure of the Chief Operating Decision Maker's title and position. The standard does not change the manner in which public entities identify their operating segments, aggregate them, or apply the quantitative thresholds for determining their reportable segments. It is effective for fiscal years beginning after December 15, 2023 and interim periods in fiscal years beginning after December 15, 2024, with early adoption permitted. The Company has determined it operates as a single segment, therefore, we do not anticipate this ASU to materially impact our consolidated financial statements and related disclosures.
 In December 2023, the FASB issued ASU 2023-09, Income taxes — Improvements to Income Taxes Disclosure. The purpose of this guidance is to enhance the transparency and usefulness of income tax disclosures and provide comprehensive income tax information, particularly in relation to rate reconciliation and income taxes paid in the U.S and foreign jurisdictions. It is effective for fiscal years beginning after December 15, 2024 and interim periods in fiscal years beginning after December 15, 2024, with early adoption permitted. This ASU will result in the required additional disclosures being included in our consolidated financial statements, once adopted. The accompanying unaudited condensed consolidated financial statements include those of the Company and its subsidiaries, MoonLake Immunotherapeutics AG, a Swiss stock corporation (Aktiengesellschaft) registered with the commercial register of the Canton of Zug, Switzerland under the number CHE-433.093.536 ("MoonLake AG"), MoonLake Immunotherapeutics Ltd., a private limited company incorporated in the United Kingdom, and MNLK Immunotherapeutics, Unipessoal Lda ("MNLK PT"), a private limited company incorporated in Portugal, after elimination of all intercompany accounts and transactions. The accompanying unaudited condensed consolidated financial statements and notes hereto have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") as set forth by the Financial Accounting Standards Board ("FASB") and in conformity with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X for interim financial reporting. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification ("ASC") and Accounting Standards Updates ("ASU") of the FASB.
 In the opinion of management, all material adjustments necessary for a fair presentation of the financial information, which are of a normal and recurring nature, have been made for the interim periods reported. Results of operations for the three and nine months ended September 30, 2024 are not necessarily indicative of the results for the entire fiscal year or any other period. The unaudited condensed consolidated financial information for the three and nine months ended September 30, 2024 and 2023 have been prepared on the same basis as and should be read in conjunction with MoonLake's audited financial statements and notes thereto for the year ended December 31, 2023 included in the Annual Report.
 All amounts are presented in U.S. Dollar ("$"), unless otherwise indicated. The term "Swiss franc" and "CHF" refer to the legal currency of Switzerland, "GBP" refers to the legal currency of the United Kingdom, and "€" and "Euro" refer to the legal currency of Portugal. The preparation of financial statements in conformity with U.S. GAAP requires the Company to make judgments, estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses. The significant judgments, estimates and assumptions relevant to the Company relate to: •determining whether the in-process research and development expenditure ("IPR&D") has an alternative future use; •determining assumptions used in estimating the fair value of share-based compensation; •estimating the recoverability of the deferred tax asset; and •estimating the amount of accruals in connection with the completion of clinical trial milestones.
 The Company bases its judgments and estimates on various factors and information, which may include, but are not limited to, the Company's forecasts and future plans, current economic conditions and observable market-based transactions of its own shares, the results of which form the basis for making judgments about the carrying value of assets and liabilities and recorded amounts of expenses that are not readily apparent from other sources. To the extent there are material differences between the Company's estimates and the actual results, the Company's future results of operation may be affected. The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash and cash equivalents are recorded at cost, which approximates fair value.59800000129400000 The Company invests in short-term marketable securities in the form of debt securities. At the time of purchase, the Company assesses whether such debt security should be classified as held-to-maturity or available-for-sale debt securities. Debt securities are classified as held-to-maturity when the Company has the positive intent and ability to hold the securities to maturity. Held-to-maturity debt securities are carried at amortized cost, adjusted for accretion of discounts or amortization of premiums to maturity computed under the effective interest method. Such accretion or amortization is included in "Interest and dividend income". Marketable debt securities not classified as held-to-maturity are classified as available-for-sale and reported at fair value. Net unrealized gains and losses on available-for-sale debt securities are excluded from the determination of earnings and are instead recognized in the "Accumulated other comprehensive income" component of equity until realized. Realized gains and losses on available-for-sale debt securities are computed based upon the historical cost of these securities, using the specific identification method. A decline in the fair value of any security below cost that is deemed other than temporary results in a charge to earnings and the corresponding establishment of a new cost basis for the security. Dividend and interest income are recognized when earned. Realized gains and losses are included in "Other income" and the cost of securities sold is determined using the specific-identification method. Marketable debt securities are classified as either "Cash and cash equivalents" or "Short-term marketable debt securities" according to their original maturity at the time of acquisition. Changes in unrealized gains and losses pertaining to cash equivalent securities are added back into the consolidated statements of cash flows as those are excluded from the determination of earnings but impact the cash and cash equivalents position. Financial instruments that potentially subject the Company to concentration of credit risk consist of cash accounts in large financial institutions which, at times, may exceed the CHF 100,000 deposit protection limit in Switzerland, the $250,000 Federal Deposit Insurance Corporation deposit insurance coverage limit in the United States, the GBP 85,000 Financial Services Compensation Scheme deposit protection limit in the United Kingdom, or the €100,000 Fundo de Garantia de Depósitos deposit protection limit in Portugal. The Company believes it is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash and cash equivalents are held. Additionally, the Company ensures further protection against credit risk by diversifying its cash holdings across a variety of credit institutions, thereby minimizing the potential impact of any adverse events on a single institution. Further, the Company's investment strategy for cash (in excess of current business requirements) is set to invest in short-term marketable debt securities. Management actively monitors credit risk in the investment portfolio. Credit risk exposures are controlled in accordance with policies approved by the board of directors to identify, measure, monitor and control credit risks. The Company follows the guidance included in ASC 820, Fair Value Measurement. Fair

value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. There are three levels of inputs to fair value measurements: •Level 1, meaning the use of quoted prices for identical instruments in active markets; •Level 2, meaning the use of quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active or are directly or indirectly observable; and •Level 3, meaning the use of unobservable inputs. Observable market data is used when available. Transfers between Levels 1, 2 or 3 within the fair value hierarchy are recognized at the end of the reporting period when the respective transaction occurred. The Company operates as a single operating segment. The Company's chief operating decision maker, its Chief Executive Officer, manages the Company's operations on a stand-alone basis for the purposes of allocating resources and assessing financial performance. Property and equipment, net is stated at cost, net of accumulated depreciation. Depreciation is computed using the straight-line method based on the estimated useful lives of three to five years. As of September 30, 2024, property and equipment, net relates to information technology, office equipment, and leasehold improvements. P5Y Research and development expenses include employee payroll, consulting, contract research and contract manufacturing costs attributable to research and development activities and are expensed as incurred. Upfront payments and milestone payments made for the licensing of technology are expensed as research and development expenses in the period in which it is probable that a liability has been incurred. Advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed. The Company has entered into various research and development contracts with companies both inside and outside of the United States. These agreements are generally cancellable, and related payments are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies or trials, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company's estimates. The Company's historical accrual estimates have not been materially different from the actual costs. Share-Based Compensation The Company recognizes compensation expense based on estimated fair values for all stock-based payment awards made to eligible employees, members of the board of directors and independent contractors that are expected to vest.
 The valuation of stock option awards is determined at the date of grant using the Black-Scholes option pricing model. The Black-Scholes option pricing model requires the Company to make assumptions and judgements about the inputs used in the calculations, such as the fair value of the common stock, expected term, expected volatility of the Company's common stock, risk-free interest rate and expected dividend yield. The valuation of restricted stock awards is measured by the fair value of the Company's common stock on the date of the grant.
For all stock options granted, the Company calculated the expected term as the period that share-based awards are expected to be outstanding. The estimate of expected volatility is based on comparative companies' volatility within the Company's industry. The risk-free rate is based on the yield available on United States Treasury zero-coupon issues corresponding to the expected term of the award.
The fair value of the common stock granted under the ESPP (as defined in Note 13 — Share-based compensation) has historically been estimated by management with reference to the market-based transaction with its Series A investors, as there was no public market for the common stock.
 Share-based payment arrangements are accounted for under the fair value method. Total compensation is measured at grant date, based on the fair value of the award at that date, and recorded in earnings over the period the employees are required to render service. The Company recognizes compensation cost only for those awards expected to meet the service conditions on a straight-line basis over the requisite service period of the award. The functional currency of the Company and its subsidiaries is the U.S. dollar. Balances and transactions denominated in foreign currencies are converted as follows: monetary assets and liabilities are translated using exchange rates in effect at the balance sheet dates and non-monetary assets and liabilities are translated at historical exchange rates. Revenue and expenses are translated at the daily exchange rate on the respective accounting date. Gains or losses from foreign currency translation are included in the consolidated statements of operations and comprehensive loss in "other income, net".-26746-125581-557144-276491 The Company accounts for income taxes by using the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. A valuation allowance is recorded to the extent it is more likely than not that all or a portion of the Company's deferred tax assets will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. Basic net loss per Class A Ordinary Share is calculated using the two-class method under which earnings are allocated to both Class A Ordinary Shares and participating securities. Basic net loss per share is calculated by dividing the net loss attributable to Class A Ordinary Shares by the weighted-average number of Class A Ordinary Shares outstanding for the period. The diluted net loss per Class A Ordinary Share is computed by dividing the net loss using the weighted-average number of Class A Ordinary Shares and, if dilutive, potential Class A Ordinary Shares outstanding during the period. In periods in which the Company reports a net loss attributable to shareholders of Class A Ordinary Shares, diluted net loss per share attributable to shareholders of Class A Ordinary Shares is the same as basic net loss per share attributable to shareholders of Class A Ordinary Shares, since dilutive Class A Ordinary Shares are not assumed to be outstanding if their effect is anti-dilutive. The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first assessing whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. On April 29, 2021, MoonLake AG entered into an in-licensing agreement (the "In-License Agreement") with Merck Healthcare KGaA, Darmstadt, Germany ("MHKDG") to acquire the Sonelokimab program (the "SLK Program") and determined that substantially all of the fair value of the gross assets acquired related to IPR&D of SLK. Therefore, this transaction was accounted for as an asset acquisition.
 IPR&D represents incomplete technologies that the Company acquires, which at the time of acquisition, are still under development and have no alternative future use. The fair value of such technologies is expensed upon acquisition. A technology is considered to have an alternative future use if it is probable that the Company will use the asset in its current, incomplete state as it existed at the acquisition date, in another research and development project that has not yet commenced, and economic benefit is anticipated from that use. If a technology is determined to have an alternative future use, then the fair value of the program would be recorded as an asset on the balance sheet rather than expensed. Contingent consideration payments (for example milestone payments due upon the occurrence of a specific event) in asset acquisitions are recognized in the period in which it is probable that a liability has been incurred (unless the contingent consideration meets the definition of a derivative, in which case the amount becomes part of the cost in the asset acquired). Upon recognition of the contingent consideration payment, the amount is expensed if it relates to IPR&D or capitalized if it relates to a developed product which is generally considered to be when clinical trials have been completed and regulatory approval obtained. Future royalty payments due on net sales will be recognized in cost of goods sold when net sales are recognized. The Company accounts for pension assets and liabilities in accordance with ASC 715, Compensation – Retirement Benefits, which requires the recognition of the funded status of pension plans in the Company's consolidated balance sheet. The liability in respect to defined benefit pension plans is the projected benefit obligation calculated annually by independent actuaries using the projected unit credit method. The projected benefit obligation as of September 30, 2024 represents the actuarial present value of the estimated future payments required to settle the obligation that is attributable to employee services rendered before that date. Service costs for such pension plans, represented in the net periodic pension benefit cost, are included in the personnel expenses of the various functions where the employees are engaged. The other components of net benefit cost are included in the consolidated statements of operations and comprehensive loss separately from the service cost component, in "other income, net." Plan assets are recorded at their fair value. Gains or losses arising from plan curtailments or settlements are accounted for at the time they occur. Any net pension asset is limited to the present value of the future economic benefits available to the Company in the form of refunds from the plan or expected reductions in future contributions to the plan. Actuarial gains and losses arising from differences between the actual and the expected return on plan assets are recognized in accumulated other comprehensive income. The Company determines if an arrangement is or contains a lease at contract inception. For these arrangements, it is evaluated if the arrangement involves an identified asset that is physically distinct or whether the Company has the right to substantially all of the capacity of an identified asset that is not physically distinct. In arrangements that involve an identified asset, there is also judgment in evaluating if the Company has the right to direct the use of that asset.
 MoonLake does not have any finance leases. As of September 30, 2024, the Company has five operating leases related to the office spaces located in (i) Dorfstrasse 29, 6300, Zug, Switzerland (comprised of two leases), (ii) 95 Regent Street, CB2 1AW, Cambridge, England, United Kingdom, and (iii) Rua Manuel Pinto de Azedevo 860, 4150-335, Porto, Portugal (comprised of two leases). The operating leases are recognized on a straight-line basis over the lease term commencing on the date the Company has the right to use the leased property. Right-of-use assets and lease liabilities are measured at the lease commencement date based on the present value of the remaining lease payments over the lease term, determined using the discount rate for the lease at the commencement date. Because the rate implicit in the leases is not readily determinable, the Company uses the incremental borrowing rate as the discount rate, which approximates the interest rate at which the Company could borrow on a collateralized basis with similar terms and payments and in similar economic environments.
 Leases with an initial term of 12 months or less that do not have the option to purchase the underlying asset are not recorded on the balance sheet, with lease expense for these

leases recognized on a straight-line basis over the lease term commencing on the date the Company has the right to use the leased property. 522 In November 2023, the FASB issued ASU 2023-07, Segment reporting — Improvements to Reportable Segment Disclosures. This new standard requires public entities to disclose significant segment expenses and additional segment items annually and to provide all reported segment profit or loss and assets disclosures currently required annually on an interim basis. The standard also requires disclosure of the Chief Operating Decision Maker's title and position. The standard does not change the manner in which public entities identify their operating segments, aggregate them, or apply the quantitative thresholds for determining their reportable segments. It is effective for fiscal years beginning after December 15, 2023 and interim periods in fiscal years beginning after December 15, 2024, with early adoption permitted. The Company has determined it operates as a single segment, therefore, we do not anticipate this ASU to materially impact our consolidated financial statements and related disclosures.
 In December 2023, the FASB issued ASU 2023-09, Income taxes — Improvements to Income Taxes Disclosure. The purpose of this guidance is to enhance the transparency and usefulness of income tax disclosures and provide comprehensive income tax information, particularly in relation to rate reconciliation and income taxes paid in the U.S and foreign jurisdictions. It is effective for fiscal years beginning after December 15, 2024 and interim periods in fiscal years beginning after December 15, 2024, with early adoption permitted. This ASU will result in the required additional disclosures being included in our consolidated financial statements, once adopted. Risks and Liquidity Going Concern, Liquidity and Capital Resources MoonLake is subject to risks common to companies in the biopharmaceutical industry, and the Company believes that changes in any of the following areas could have a material adverse effect on the Company's future financial position or results of operations: ability to obtain future financing, regulatory approval and market acceptance of, and reimbursement for, product candidates, performance of third-party contract research organizations and manufacturers upon which the Company relies, protection of the Company's intellectual property, litigation or claims against the Company based on intellectual property, patent, product, regulatory, clinical or other factors, and the Company's ability to attract and retain employees necessary to support its growth.
 The Company is dependent on third-party manufacturers to supply products for research and development activities in its programs. In particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply the Company with its requirements for the active pharmaceutical ingredients and formulated drugs related to these programs. These programs could be adversely affected by a significant interruption in the supply of active pharmaceutical ingredients and formulated drugs.
 The Company's ability to generate revenue sufficient to achieve profitability will depend on the successful development and eventual commercialization of SLK in one or more indications, which is expected to take a number of years. The Company expects to continue to incur significant expenses and operating losses for at least the next three years as the Company continues the development of SLK and prepares for commercial launches. It is expected that operating losses will fluctuate significantly from year to year depending on the timing of the Company's planned clinical development programs and efforts to achieve regulatory approval.
 The Company incurred a loss of $74.8 million for the nine months ended September 30, 2024. As of September 30, 2024, the Company's current assets exceeded its current liabilities by $492.2 million. As of September 30, 2024, the Company had $375.7 million of cash and cash equivalents. Based on the Company's current operating plan, management believes that the Company has sufficient capital to fund its operations and capital expenditures until the end of 2026.-748000004922000003757000000Fair Value Measurements<div style="text-align:justify">The following table presents information about the Company's short-term marketable debt securities measured at fair value on a recurring basis and indicate the level in the fair value hierarchy in which the Company classifies the fair value measurement:
<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"></td><td style="width:29.848%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:15.540%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.544%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2024</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top">December 31, 2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle">Level 2</td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle">Total</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle">Level 2</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle">Total</td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">Eurocommercial Papers</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">89,072,100 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">89,072,100 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">109,608,915 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">109,608,915 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle">Certificates of Deposit</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">88,991,100 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">88,991,100 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">79,626,727 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">79,626,727 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">Total</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">178,063,200 </td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#ffffff;border-

bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">178,063,200 </td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">189,235,642 </td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">$</td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">189,235,642 </td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table>
 Cash and accounts payable approximate their fair values as of September 30, 2024 and December 31, 2023, due to their short-term nature. Pension plan assets fair value is determined based on Level 2 inputs. The following table presents information about the Company's short-term marketable debt securities measured at fair value on a recurring basis and indicate the level in the fair value hierarchy in which the Company classifies the fair value measurement:
<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"></td><td style="width:29.848%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:15.540%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.540%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.540%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle">Level 2</td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle">Total</td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle">Level 2</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle">Total</td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">Eurocommercial Papers</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">89,072,100 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">89,072,100 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">109,608,915 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">109,608,915 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle">Certificates of Deposit</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">88,991,100 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">88,991,100 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">79,626,727 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">79,626,727 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">Total</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">178,063,200 </td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">$</td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">189,235,642 </td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">189,235,642 </td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table>
 The fair value and amortized cost of investments in short-term marketable debt securities by major security type as of September 30, 2024 are as follows:
 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.347%"><tr><td style="width:1.0%"></td><td

style="width:21.904%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.522%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.522%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.522%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.530%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle">Amortized cost</td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle">Gross unrealized gains</td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle">Gross unrealized losses</td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle">Fair value</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle">Eurocommercial Papers</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">87,231,307 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">1,840,793 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">— </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">89,072,100 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ceeeff;padding:2px 1pt;text-align:left;vertical-align:middle">Certificates of Deposit</td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ceeeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">87,602,179 </td><td style="background-color:#ceeeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ceeeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">1,388,921 </td><td style="background-color:#ceeeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ceeeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="background-color:#ceeeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ceeeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">88,991,100 </td><td style="background-color:#ceeeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle">Total</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle">174,833,486</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle">3,229,714</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle">— </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle">178,063,200</td></tr></table> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.347%"><tr><td style="width:1.0%"></td><td style="width:21.904%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.522%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.522%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.522%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.530%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ceeeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle">Of which classified within cash and cash equivalents</td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ceeeff;border-top:2pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">59,212,123 </td><td style="background-color:#ceeeff;border-top:2pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ceeeff;border-top:2pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">582,677 </td><td style="background-color:#ceeeff;border-top:2pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ceeeff;border-top:2pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="background-color:#ceeeff;border-top:2pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ceeeff;border-top:2pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">59,794,800 </td><td style="background-color:#ceeeff;border-top:2pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle">Of which classified within short-term marketable debt securities</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">115,621,363 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">2,647,037 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">118,268,400 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table>
 The following table presents the changes in fair values of the Company's short-term marketable debt securities, classified as Level 2 financial assets, and recognized in accumulated other comprehensive income:
 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.347%"><tr><td style="width:1.0%"></td><td style="width:71.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.444%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ceeeff;padding:2px 1pt;text-align:left;vertical-align:top">Beginning balance, January 1, 2024</td><td style="background-color:#ceeeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#ceeeff;padding:2px 0;text-align:right;vertical-align:top">2,720,854 </td><td style="background-color:#ceeeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Other comprehensive income before reclassifications</td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">13,000,645 </td><td

style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Amounts reclassified from accumulated other comprehensive income</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(12,491,785) </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Ending balance, September 30, 2024</td><td style="background-color:#ffffff;border-bottom:2.5pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td colspan="2" style="background-color:#ffffff;border-bottom:2.5pt double #000000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle">3,229,714</td></tr></table></div><div style="margin-bottom:0.05pt;margin-top:0.05pt;text-align:justify">
</div><div style="margin-bottom:0.05pt;margin-top:0.05pt;text-align:justify">As of September 30, 2024, the Company's marketable debt securities maturities are all due within one year.</div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt">The fair value and amortized cost of investments in short-term marketable debt securities by major security type as of September 30, 2024 are as follows: </div><div style="margin-bottom:0.12pt;text-indent:0.36pt">
</div><div style="margin-bottom:0.12pt;text-indent:0.36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.347%"><tr><td style="width:1.0%"></td><td style="width:21.904%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.522%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.522%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.522%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.530%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle">Amortized cost</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle">Gross unrealized gains</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle">Gross unrealized losses</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle">Fair value</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle">Eurocommercial Papers</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">87,231,307 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">1,840,793 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">— </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">89,072,100 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle">Certificates of Deposit</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">87,602,179 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">1,388,921 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">88,991,100 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle">Total</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle">174,833,486</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle">3,229,714</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman';sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle">— </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle">178,063,200</td></tr></table> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.347%"><tr><td style="width:1.0%"></td><td style="width:21.904%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.522%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.522%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.530%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle">Of which classified within cash and cash equivalents</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:2pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">59,212,123 </td><td style="background-color:#cceeff;border-top:2pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:2pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">582,677 </td><td style="background-color:#cceeff;border-top:2pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:2pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="background-color:#cceeff;border-top:2pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:2pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">59,794,800 </td><td style="background-color:#cceeff;border-top:2pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle">Of which classified within short-term marketable debt securities</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">115,621,363 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">2,647,037 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman';sans-serif;font-size:10pt;font-weight:700;line-

height:112%">118,268,400 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table> 872313071840793089072100876021791388921088991100174833486322971401780632005921212358267705979480011562136326470370118268400 The following table presents the changes in fair values of the Company's short-term marketable debt securities, classified as Level 2 financial assets, and recognized in accumulated other comprehensive income:
 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.347%"><tr><td style="width:1.0%"></td><td style="width:71.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.444%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Beginning balance, January 1, 2024</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top">2,720,854 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Other comprehensive income before reclassifications</td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">13,000,645 </td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Amounts reclassified from accumulated other comprehensive income</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top">(12,491,785)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Ending balance, September 30, 2024</td><td style="background-color:#ffffff;border-bottom:2.5pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td colspan="2" style="background-color:#ffffff;border-bottom:2.5pt double #000000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle">3,229,714</td></tr></table> 2720854-1300064512491785322971 4Prepaid Expenses <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.096%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.992%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.418%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle">Prepaid expenses - current</td><td colspan="3" style="background-color:#cceeff;padding:2px 1.27pt 2px 1pt;text-align:right;vertical-align:middle">September 30, 2024</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.27pt 2px 1pt;text-align:right;vertical-align:middle">December 31, 2023</td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle">Non-clinical research and clinical development services</td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle">7,381,811</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman';sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle">842,729</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle">Supply and manufacturing services</td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle">6,358,892</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle">1,205</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle">Insurance</td><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle">1,496,521</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle">1,077,478</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle">Other prepayments</td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle">747,201</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle">180,791</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle">Total</td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle">15,984,425</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle">2,102,203</td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2.5pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2.5pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle">Prepaid expenses - non-current</td><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle">September 30, 2024</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle">December 31, 2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle">Supply and manufacturing services</td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle">2,064,575</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle">8,423,468</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle">Total</td><td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td colspan="2" style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle">2,064,575</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman';sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</td><td colspan="2" style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle">8,423,468</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> Supply and manufacturing services, current and non-current, relate to advance payments made to a contract manufacturing organization pursuant to a manufacturing run reservation agreement for the commercial-scale manufacturing of SLK in 2025. <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.096%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.992%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.418%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle">Prepaid expenses - current</td><td colspan="3" style="background-color:#cceeff;padding:2px 1.27pt 2px 1pt;text-align:right;vertical-align:middle">September 30, 2024</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.27pt 2px 1pt;text-align:right;vertical-align:middle">December 31, 2023</td></tr><tr><td

colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle">Non-clinical research and clinical development services</td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle">7,381,811</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle">842,729</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle">Supply and manufacturing services</td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle">6,358,892</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle">1,205</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle">Insurance</td><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle">1,496,521</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle">1,077,478</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle">Other prepayments</td><td colspan="3" style="background-color:#cceeff;padding:2px 4,27pt 2px 1pt;text-align:right;vertical-align:middle">747,201</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle">180,791</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle">Total</td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle">15,984,425</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle">2,102,203</td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2.5pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2.5pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle">Prepaid expenses - non-current</td><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle">September 30, 2024</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle">December 31, 2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle">Supply and manufacturing services</td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle">2,064,575</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle">8,423,468</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle">Total</td><td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td colspan="2" style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle">2,064,575</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</td><td colspan="2" style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle">8,423,468</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table>
738181184272963588921205149652110774787472011807911598442521022032064575842346820645758423468Trade and Other Payables <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.096%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.992%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.418%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">September 30, 2024</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.27pt 2px 1pt;text-align:right;vertical-align:middle">December 31, 2023</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle">Research and development services and license fees</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td colspan="2" style="background-color:#ffffff;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle">7,113,098</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman';sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</td><td colspan="2" style="background-color:#ffffff;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle">911,454</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle">Supply and manufacturing fees payable</td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle">3,044,237</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle">553,459</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle">Consulting and advisory services</td><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle">307,581</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle">80,695</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle">Legal advisory fees payable</td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle">104,317</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle">47,095</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle">Other payables</td><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle">141,370</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle">244,981</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle">Total</td><td style="background-color:#cceeff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td colspan="2" style="background-color:#cceeff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle">10,710,603</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td colspan="2" style="background-color:#cceeff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 4.27pt 2px

0;text-align:right;vertical-align:middle">1,837,684</td></tr></table> Accrued Expenses and Other Current Liabilities <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.096%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">September 30, 2024</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">December 31, 2023</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle">Research and development services and license fees</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle">3,253,581 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle">1,226,281 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle">Bonuses and related employees compensation expenses</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">2,922,982 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">2,780,219 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle">Supply and manufacturing services</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">894,894 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">1,603,739 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle">Tax liabilities</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">484,482 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">367,976 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle">Consultant and other fees</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">351,774 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">853,905 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle">Legal fees</td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle">17,811</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle">98,000</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle">Total</td><td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td colspan="2" style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle">7,925,524</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td colspan="2" style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle">6,930,120</td></tr></table> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.096%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:0.418%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">September 30, 2024</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.27pt 2px 1pt;text-align:right;vertical-align:middle">December 31, 2023</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle">Research and development services and license fees</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td colspan="2" style="background-color:#ffffff;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle">7,113,098</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</td><td colspan="2" style="background-color:#ffffff;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle">911,454</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle">Supply and manufacturing fees payable</td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle">3,044,237</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle">553,459</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle">Consulting and advisory services</td><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle">307,581</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle">80,695</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle">Legal advisory fees payable</td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle">104,317</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle">47,095</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle">Other payables</td><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle">141,370</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle">244,981</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle">Total</td><td style="background-color:#cceeff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td colspan="2" style="background-color:#cceeff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle">10,710,603</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td colspan="2" style="background-color:#cceeff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle">1,837,684</td></tr></table> 711309891145430442375534593075818069510431747095141370244981107106031837684 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.096%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:0.418%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">September 30, 2024</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:

color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">December 31, 2023</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle">Research and development services and license fees</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle">3,253,581 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle">1,226,281 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle">Bonuses and related employees compensation expenses</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">2,922,982 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">2,700,219 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle">Supply and manufacturing services</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">894,894 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">1,603,739 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle">Tax liabilities</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">484,482 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">367,976 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle">Consultant and other fees</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">351,774 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">853,905 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle">Legal fees</td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle">17,811</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4.27pt 2px 1pt;text-align:right;vertical-align:middle">98,000</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle">Total</td><td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td colspan="2" style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle">7,925,524</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</td><td colspan="2" style="background-color:#ffffff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000;padding:2px 4.27pt 2px 0;text-align:right;vertical-align:middle">6,930,120</td></tr></table>
3253581122628129229822780219894894160373948448236797635177485390517811980007925524693012 0Leases In August 2021, the Company entered into an open-ended office lease agreement, effective November 1, 2021, to lease approximately 2,300 square feet of space on the last two floors of the building located at Dorfstrasse 29, 6300 Zug, Switzerland. The Company estimated the effective duration of the lease at inception and determined a period of 3 years, with expected expiration in November 2024. In December 2023, the contract was extended, leading to a new estimated effective duration of the lease period of 3 years, with expected expiration in January 2027.
 On October 9, 2023, the Company entered into an office lease agreement, effective as of October 9, 2023, to lease approximately 3,900 square feet of office space on the fifth floor of the building located at Rua Manuel Pinto de Azedevo 860, 4150-335, Porto, Portugal. This lease has a 3-year initial term, with two extendable periods of 3 years each. It is expected to be extended once until October 2029.
 On October 13, 2023, the Company entered into an office lease agreement, effective as of October 16, 2023, to lease approximately 6,000 square feet of office space on the first floor of the building located at 95 Regent Street, CB2 1AW, Cambridge, England, United Kingdom. This lease has a 3-year term agreement and is set to expire in October 2026.
 On December 12, 2023, the Company entered into an open-ended office lease agreement, effective as of January 15, 2024, to lease approximately 1,700 square feet of additional office space at its existing corporate headquarters located at Dorfstrasse 29, 6300 Zug, Switzerland. The Company estimated the duration of the lease at inception and determined a 3-year term.
 On August 14, 2024, the Company entered into an office lease agreement, effective as of September 8, 2024, to lease approximately 2,000 square feet of additional office space at its existing office located at Rua Manuel Pinto de Azevodo 860, 4150-335, Porto, Portugal. This lease has a 2-year initial term, with two extendable periods of 3 years each. The Company currently expects that it will be extended until October 2029.
 The weighted average remaining lease term and weighted average discount rate for the operating leases as of September 30, 2024 and December 31, 2023 were as follows:
 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"></td><td style="width:57.531%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.273%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.274%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">September 30, 2024</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">December 31, 2023</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle">Weighted average remaining lease term (in months)</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">32</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">39</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle">Weighted average discount rate</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">4.7 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">4.9 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td></tr></table> The maturities of the Company's operating lease liabilities as of September 30, 2024 are as follows:
 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"></td><td style="width:70.906%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.272%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Year ending December 31,</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle">Amount</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle">Remainder of fiscal 2024</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td colspan="2" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle">386,519</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle">2025</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">1,571,589</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle">2026</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle">1,571,589</td></tr></table>
 The Company leases office space in Switzerland, Portugal, and the United Kingdom under operating lease agreements. The Company's lease expense for the three months ended September 30, 2024 and 2023 was $1.6 million and $1.5 million, respectively. The Company's lease expense for the nine months ended September 30, 2024 and 2023 was $4.7 million and $4.5 million, respectively.
 The Company's lease expense for short-term leases was $0.1 million and $0.2 million for the three months ended September 30, 2024 and 2023, respectively. The Company's lease expense for short-term leases was $0.3 million and $0.5 million for the nine months ended September 30, 2024 and 2023, respectively.
 The Company's lease expense for variable lease payments was $0.1 million and $0.1 million for the three months ended September 30, 2024 and 2023, respectively. The Company's lease expense for variable lease payments was $0.3 million and $0.3 million for the nine months ended September 30, 2024 and 2023, respectively.
 The Company's lease expense for sublease income was $0.1 million and $0.1 million for the three months ended September 30, 2024 and 2023, respectively. The Company's lease expense for sublease income was $0.3 million and $0.3 million for the nine months ended September 30, 2024 and 2023, respectively.</div><div style="text-align:justify">
</div><div style="text-align:justify">Supplemental cash flow information related to leases was as follows:</div><div style="text-align:justify">
</div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"></td><td style="width:70.906%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.272%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Year ending December 31,</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle">Amount</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle">Remainder of fiscal 2024</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</td><td colspan="2" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle">386,519</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle">2025</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">1,571,589</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle">2026</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle">1,571,589</td></tr></table>
 Other

color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">1,242,550</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle">2027</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">140,313</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle">2028</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">140,313</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle">Thereafter</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">95,627</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle">Total lease payments</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">3,576,911</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle">Less imputed interest</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">(196,309)</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle">Total lease liability</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">3,380,602</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle">Less current portion of lease liability</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">(1,444,893)</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle">Long-term portion operating lease liability</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:1pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle">1,935,709</td></tr></table>
 Operating cash outflows for amounts included in the measurement of lease liabilities was $1,101,661 and $78,270 for the nine months ended September 30, 2024 and September 30, 2023, respectively.</div><div style="text-align:justify">
</div><div style="text-align:justify">The Company recorded the following lease and variable lease expenses for the three and nine months ended September 30, 2024 and September 30, 2023: </div><div style="text-align:justify">
</div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"></td><td style="width:23.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.251%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.406%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.410%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">Three Months Ended September 30, 2024</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">Three Months Ended September 30, 2023</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">Nine Months Ended September 30, 2024</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">Nine Months Ended September 30, 2023</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Operating lease expense</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">358,583 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">39,562 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,061,029 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">117,832 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Variable lease expense1</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,398 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,398 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total lease expense</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">363,981 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">39,562 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,066,427 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">117,832 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> <2300P3YP3Y3900P3Y2P3Y6000P3Y1700P3Y2000P2Y2P3Y The weighted average remaining lease term and weighted average discount rate for the operating leases as of September 30, 2024 and December 31, 2023 were as follows:
 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"></td><td style="width:57.531%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.273%"></td><td style="width:0.1%"></td><td

style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.274%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">September 30, 2024</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">December 31, 2023</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle">Weighted average remaining lease term (in months)</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">32</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">39</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle">Weighted average discount rate</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">4.7 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">4.9 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle">%</td></tr></table> The Company recorded the following lease and variable lease expenses for the three and nine months ended September 30, 2024 and September 30, 2023:
 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"></td><td style="width:23.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.251%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.406%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.410%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">Three Months Ended September 30, 2024</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">Three Months Ended September 30, 2023</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">Nine Months Ended September 30, 2024</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">Nine Months Ended September 30, 2023</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Operating lease expense</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">358,583 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">39,562 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,061,029 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">117,832 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Variable lease expense1</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,398 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,398 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total lease expense</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">363,981 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">39,562 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,066,427 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:125%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">117,832 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> P32MP39M0.0470.049 The maturities of the Company's operating lease liabilities as of September 30, 2024 are as follows:
 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"></td><td style="width:70.906%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.272%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Year ending December 31,</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle">Amount</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle">Remainder of fiscal 2024</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td colspan="2" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle">386,519</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle">2025</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">1,571,589</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle">2026</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">1,242,550</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle">2027</td><td colspan="3"

style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">140,313</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle">2028</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">140,313</td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:justify;vertical-align:middle">Thereafter</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">95,627</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle">Total lease payments</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">3,576,911</td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:justify;vertical-align:middle">Less imputed interest</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">(196,309)</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle">Total lease liability</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">3,380,602</td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt;text-align:justify;vertical-align:middle">Less current portion of lease liability</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">(1,444,893)</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle">Long-term portion operating lease liability</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt double #000000;border-top:1pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle">1,935,709</td></tr></table>
3865191571589124255014031314031395627357691119630933806021444893193570911016617827035853395621061029117832539805398036398139562106642711
Benefit Plans The Company operates a defined benefit pension plan in Switzerland (the "Plan") and a defined contribution pension plan in the United Kingdom, in accordance with local regulations and practices. As of September 30, 2024, the Plan covers the Company's employees in Switzerland with benefits in the event of death, disability, retirement, or termination of employment. Components of Net Periodic Benefit Cost under the Plan <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"></td><td style="width:29.848%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.540%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.540%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.540%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.544%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">Three Months Ended September 30, 2024</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">Three Months Ended September 30, 2023</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">Nine Months Ended September 30, 2024</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">Nine Months Ended September 30, 2023</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle">Service cost</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top">71,107</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top">31,175</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top">210,387</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top">91,596</td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle">Interest cost</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top">8,387</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top">7,784</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top">24,814</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top">22,872</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle">Expected return on plan assets</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top">(15,330)</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top">(9,280)</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top">(45,380)</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top">(27,265)</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle">Amortization of unrecognized loss</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top">2,609</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top">—</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top">7,717</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td colspan="3" style="background-color:#ccceff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top">—</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle">Prior service credit recognized in current year</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top">(2,582)</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top">—</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top">(7,639)</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top">—</td></tr><tr><td colspan="3" style="background-color:#ccceff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle">Total net periodic benefit cost</td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td colspan="2" style="background-color:#ccceff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000000;padding:2px 3.75pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-

weight:700;line-height:125%">64,183</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td colspan="2" style="background-color:#cceeff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000000;padding:2px 3.75pt 2px 0;text-align:right;vertical-align:middle">29,679</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td colspan="2" style="background-color:#cceeff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000000;padding:2px 3.75pt 2px 0;text-align:right;vertical-align:middle">189,899</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td colspan="2" style="background-color:#cceeff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000000;padding:2px 3.75pt 2px 0;text-align:right;vertical-align:middle">87,203</td></tr></table> The components of net periodic benefit cost other than the service cost component are included in general and administrative expense in the Company's unaudited condensed consolidated statements of operations and comprehensive loss. Employer Contributions under the Plan For the nine months ended September 30, 2024, contributions of $192,563 (CHF 169,455) were made to the Plan. The Company presently anticipates contributing an additional estimated amount of $64,188 (CHF 56,485) to fund the Plan in 2024 for a total of $256,751 (CHF 225,940).</div><div style="margin-bottom:4pt;text-align:justify">Components of Net Periodic Benefit Cost under the Plan</div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"></td><td style="width:29.848%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.540%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.540%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.540%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.544%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">Three Months Ended September 30, 2024</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">Three Months Ended September 30, 2023</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">Nine Months Ended September 30, 2024</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">Nine Months Ended September 30, 2023</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle">Service cost</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top">71,107</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top">31,175</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top">210,387</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top">$</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:top">91,596</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle">Interest cost</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top">8,387</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top">7,784</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top">24,814</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top">22,872</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle">Expected return on plan assets</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top">(15,338)</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top">(9,280)</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top">(45,380)</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top">(27,265)</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle">Amortization of unrecognized loss</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top">2,609</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top">—</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top">7,717</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top">—</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle">Prior service credit recognized in current year</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top">(2,582)</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top">—</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top">(7,639)</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top">—</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle">Total net periodic benefit cost</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td colspan="2" style="background-color:#cceeff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000000;padding:2px 3.75pt 2px 0;text-align:right;vertical-align:middle">64,183</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td colspan="2" style="background-color:#cceeff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000000;padding:2px 3.75pt 2px 0;text-align:right;vertical-align:middle">29,679</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</td><td colspan="2" style="background-color:#cceeff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000000;padding:2px 3.75pt 2px 0;text-align:right;vertical-align:middle">189,899</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td colspan="2" style="background-color:#cceeff;border-bottom:2.5pt double #000000;border-top:0.5pt solid #000000;padding:2px 3.75pt 2px 0;text-align:right;vertical-align:middle">87,203</td></tr></table> 711073117521038791596838777842481422872153389280453802726 5-26090-77170-25820-

7639064183296791898998720319256316945564188564852567512259405hareholders' Equity <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.502%"><tr><td style="width:1.0%"></td><td style="width:18.275%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none

colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle">Balance at June 30, 2024</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">500,000,000</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">62,874,637</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">100,000,000</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">995,267</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">600,000,000</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">63,869,904</td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle">Conversion of Class C Ordinary Shares into Class A Ordinary Shares</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">—</td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">153,998</td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">—</td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">(153,998)</td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">—</td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">—</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle">Options exercised under the Equity Incentive Plan</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">—</td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">17,390</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">—</td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">—</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">—</td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">17,390</td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle">Balance at September 30, 2024</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">500,000,000</td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">63,046,025</td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">100,000,000</td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">841,269</td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">600,000,000</td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">63,887,294</td></tr></table> (1)   Fully paid-in registered shares with a par value of $0.0001 Class A Ordinary Shares On April 6, 2022, the Company's Class A Ordinary Shares began trading on The Nasdaq Capital Market ("Nasdaq") under the symbol "MLTX". As of September 30, 2024, there were 63,046,025 Class A Ordinary Shares issued and outstanding. The Company is authorized to issue up to 500,000,000 Class A Ordinary Shares, par value $0.0001 per share. Holders of Class A Ordinary Shares are entitled to one vote per share. Class C Ordinary Shares As of September 30, 2024, there were 841,269 Class C Ordinary Shares issued and outstanding. The Company is authorized to issue up to 100,000,000 Class C Ordinary Shares, with a par value $0.0001 per share. Each Class C Ordinary Share entitles the holders thereof to one vote per share, but carries no economic rights. At the closing of the Business Combination, MoonLake, MoonLake AG and ML Party (as defined in Note 2 — Business Combination Agreement with Helix and Recapitalization, included in MoonLake's audited financial statements and notes thereto for the year ended December 31, 2023 included in the Annual Report) entered into a Restated and Amended Shareholders' Agreement (the "A&R Shareholders' Agreement"). With the intent to approximate the rights, obligations and restrictions that an ML Party would enjoy if it were a holder of Class A Ordinary Shares, the A&R Shareholders' Agreement (i) imposes certain transfer and other restrictions on the ML Parties, (ii) provides for the waiver of certain statutory rights and (iii) establishes certain mechanics whereby MoonLake and each of the ML Parties are able to effect the conversion of MoonLake AG Common Shares and Class C Ordinary Shares into a number of Class A Ordinary Shares equal to the Exchange Ratio of 33.638698 (as defined in Note 3 — Basis of Presentation, included in MoonLake's audited financial statements and notes thereto for the year ended December 31, 2023 included in the Annual Report). On September 9 and September 25, 2024, pursuant to the A&R Shareholders' Agreement, certain holders of Class C Ordinary Shares submitted exchange notices to the Company, pursuant to which such holders of Class C Ordinary Shares effected the conversion of 4,578 MoonLake AG Common Shares and 153,998 Class C Ordinary Shares into 153,998 Class A Ordinary Shares using the Exchange Ratio. The foregoing description of the A&R Shareholders' Agreement is not complete and is qualified in its entirety by reference to, and should be read in connection with, the full text of the A&R Shareholders' Agreement filed as an exhibit on the Company's Current Report on Form 8-K filed with the SEC on April 11, 2022.
 Equity Offerings At-the-Market Offering On May 11, 2023, the Company entered into a Sales Agreement (the "May 2023 Sales Agreement") with Leerink Partners LLC (formerly known as SVB Securities LLC) ("Leerink Partners"), through which the Company could issue and sell up to $200,000,000 of its Class A Ordinary Shares (the "May 2023 ATM Shares"), through Leerink Partners as its sales agent. The May 2023 ATM Shares to be sold under the May 2023 Sales Agreement, if any, would be issued and sold pursuant to the Company's shelf registration statement on Form S-3 (File No. 333-271546), which was declared effective by the SEC on May 9, 2023, and a prospectus supplement thereto filed with the SEC on May 11, 2023.
 On June 27, 2023, the Company reduced the maximum aggregate offering amount of its Class A Ordinary Shares that could be issued and sold under the May 2023 Sales Agreement to $0 and no longer intends to sell Class A Ordinary Shares under the May 2023 Sales Agreement unless the Company files a further prospectus supplement indicating an amount of shares proposed to be sold.
 On August 31, 2023, the Company entered into a Sales Agreement with Leerink Partners (the "August 2023 Sales Agreement" and together with the May 2023 Sales Agreement, the "Sales Agreements"), through which the Company could issue and sell up to $350,000,000 of its Class A Ordinary Shares (the "August 2023 ATM Shares"), through Leerink Partners as its sales agent. The August 2023 ATM Shares to be sold under the August 2023 Sales Agreement, if any, would be issued and sold pursuant to the Company's shelf registration statement on Form S-3 (File No. 333-274286), which was declared effective by the SEC on September 11, 2023, and a prospectus supplement thereto filed with the SEC on August 31, 2023.
 During the three months ended March 31, 2024, the Company sold 914,828 Class A Ordinary Shares under the August 2023 Sales Agreement at a weighted average share price of $58.31, for aggregate net proceeds of approximately $52.5 million, after deducting sales agent's commissions and transaction costs.

During the three months ended June 30, 2024 and the three months ended September 30, 2024, there were no sales under the August 2023 Sales Agreement.
 Public Offering of Class A Ordinary Shares On June 27, 2023, the Company entered into an underwriting agreement with SVB Securities LLC and Guggenheim Securities LLC as the representatives of the underwriters named therein, to issue and sell 8,000,000 Class A Ordinary Shares at a public offering price of $50.00 per share (the "Offering"). In addition, the Company granted the underwriters an option for a period of 30 days to purchase up to an additional 1,200,000 Class A Ordinary Shares at the public offering price less the underwriting discounts and commissions (the "Option"), and such Option was exercised in full by the underwriters. The Offering closed on June 30, 2023, and net proceeds from the Offering, including proceeds from the exercise in full by the underwriters of the Option, were $436.7 million, after deducting the underwriting discounts and commissions and the offering expenses in the amount of $23.3 million.
 Following the completion of the Offering, the Company opted to direct a substantial portion of the net proceeds to MoonLake AG. This was executed as a two-step process: (i) the Company acquired the remaining 22,756 MoonLake AG Common Shares held in treasury through a share purchase and assignment agreement formally executed on July 9, 2023 ($38.9 million) and (ii) the Company contributed additional funds to MoonLake AG's capital reserves through a cash contribution agreement formally executed on July 10, 2023 ($275 million). A stamp duty tax of $2.8 million was levied on the aforementioned capital contribution which the Company has classified as cash flows from financing activities in order to correctly mirror the underlying nature of the transaction.
 On March 8, 2024, the Company executed a similar transaction as a two-step process: (i) the Company acquired 501 MoonLake AG Common Shares held in treasury through a share purchase and assignment agreement ($0.8 million) and (ii) the Company contributed an additional $150.0 million of funds to MoonLake AG's capital reserves through a cash contribution. A stamp duty tax of $1.6 million was levied on the capital contribution which the Company has classified as cash flows from financing activities in order to correctly mirror the underlying nature of the transaction. The aforementioned increase in treasury shares occurred during the three months ended March 31, 2024 as a result of an employee termination entitling MoonLake AG to repurchase such employee's unvested shares (501 MoonLake AG Common Shares and 16,853 Class C Ordinary Shares) previously awarded as part of a share-based compensation program. Since the shares were subsequently sold to MoonLake, the corresponding Class C Ordinary Shares were canceled.
 Options Exercised under the Equity Incentive Plan In the three months ended September 30, 2024, certain participants exercised their stock options under the Equity Incentive Plan (as defined below) for an aggregate of 17,390 Class A Ordinary Shares and total cash consideration of $91,298. <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.502%"><tr><td style="width:1.0%"></td><td style="width:18.275%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.025%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.025%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.025%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.025%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.025%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"> Class A Ordinary Shares(1) </td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"> Class C Ordinary Shares(1) </td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle">Total Number of Ordinary Shares</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">Authorized</td><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">Issued</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">Authorized</td><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">Issued</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">Authorized</td><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">Issued and Outstanding</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none">

colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">—</td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">—</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">—</td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">(16,853)</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">—</td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">(16,853)</td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle">Balance at March 31, 2024</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">500,000,000</td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">62,874,637</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">100,000,000</td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">995,267</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">600,000,000</td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">63,869,904</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle">Balance at June 30, 2024</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">500,000,000</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">62,874,637</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">100,000,000</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">995,267</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">600,000,000</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">63,869,904</td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle">Conversion of Class C Ordinary Shares into Class A Ordinary Shares</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">—</td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">—</td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">153,998</td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">—</td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">(153,998)</td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">—</td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">—</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle">Options exercised under the Equity Incentive Plan</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">—</td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">17,390</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">—</td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">—</td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">—</td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">17,390</td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle">Balance at September 30, 2024</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">500,000,000</td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">63,046,025</td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">100,000,000</td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">841,269</td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">600,000,000</td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">63,887,294</td></tr></table> (1) Fully paid-in registered shares with a par value of $0.0001500000000604664531000000002505476600000000629719291493356-1493356914828914828168531685350000000062874637100000000995267600000000638699045000000006287463710000000099526760000000063869904153998-153998173901739050000000063046025100000000841269600000000638872940.00010.000163046025630460255000000000.000118412698412691000000000.0001133.63869Loss per Share The following table sets forth the loss per share calculations for the three and nine months ended September 30, 2024 compared to the three and nine months ended September 30, 2023:
 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"></td><td style="width:38.557%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.363%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.363%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.363%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.366%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle">Three Months Ended September 30, </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle">Nine Months Ended September 30, </td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle">2024</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span

style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">2023</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle">2024</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle">Numerator</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle">Net loss attributable to controlling interests shareholders</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td colspan="2" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle">(35,390,337)</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td colspan="2" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle">(9,426,049)</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td colspan="2" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle">(73,331,005)</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</td><td colspan="2" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle">(28,570,184)</td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle">Denominator</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle">Total weighted average number of outstanding shares</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">62,896,782</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">53,517,655</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">62,803,220</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">45,485,650</td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000000;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle">Net loss per share – basic and diluted</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle">(0.56)</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle">(0.18)</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle">(1.17)</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle">(0.63)</td></tr></table> The weighted average number of shares used to calculate the net loss per share – basic for the nine months ended September 30, 2024 excludes Class C Ordinary Shares as they do not carry economic rights. If the ML Parties elected to convert all of their MoonLake AG Common Shares into Class A Ordinary Shares as of January 1, 2024, the weighted average number of shares outstanding would have been 63,881,246 and 63,809,450 for the three and nine months ended September 30, 2024, respectively, resulting in a net loss per share of $0.57 and $1.17, respectively. Upon conversion, all Class C Ordinary Shares would be forfeited and there would no longer be any noncontrolling interests.</div>Upon conversion, the Company's number of Class A Ordinary Shares outstanding would be 63,905,198 as of November 1, 2024, including the 17,904 Class A Ordinary Shares issued pursuant to stock options exercised under the Equity Incentive plan subsequent to September 30, 2024.<div style="margin-bottom:6pt;text-align:justify">The following table sets forth the loss per share calculations for the three and nine months ended September 30, 2024 compared to the three and nine months ended September 30, 2023:</div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt">
</div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"></td><td style="width:38.557%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.363%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.363%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.363%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.366%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle">Three Months Ended September 30, </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle">Nine Months Ended September 30, </td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle">2024</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle">2023</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle">2024</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle">Numerator</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle">Net loss attributable to controlling interests shareholders</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td colspan="2" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle">(35,390,337)</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td colspan="2" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle">(9,426,049)</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td colspan="2" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle">(73,331,005)</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td colspan="2" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle">(28,570,184)</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle">Denominator</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle">Total weighted average number of outstanding shares</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">62,896,782</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">53,517,655</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">62,803,220</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">45,485,650</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle">Numerator</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle">Net loss attributable to controlling interests shareholders</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td colspan="2" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle">(35,390,337)</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td colspan="2" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle">(9,426,049)</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td colspan="2" style="background-color:#

color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle">(73,331,005)</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td colspan="2" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle">(28,570,184)</td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle">Denominator</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle">Total weighted average number of outstanding shares</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">62,896,782</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">53,517,655</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">62,803,220</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">45,485,650</td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000000;padding:2px 1pt 2px 1.27pt;text-align:left;vertical-align:middle">Net loss per share – basic and diluted</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle">(0.56)</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle">(0.18)</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</td><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle">(1.17)</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle">(0.63)</td></tr></table> -35390337-9426049-73331005-285701846289678262896782535176555351765562803220628032204548565045485650-0.56-0.56-0.18-0.18-1.17-1.17-0.63-0.6363881246638812466380945063809450-0.57-0.57-1.17-1.1763905198179045hare-Based Compensation As of September 30, 2024, the Company had the following share-based compensation arrangements: a. Restricted Founder Shares (as defined below) - created in April 2021 by MoonLake AG (fully vested as of April 2023); b. The Employee Share Participation Plan ("ESPP") - created in July 2021 by MoonLake AG; c. The Employee Stock Option Plan ("ESOP") - created in July 2021 by MoonLake AG (fully vested as of January 2024); d. MoonLake Immunotherapeutics 2022 Equity Incentive Plan ("Equity Incentive Plan") - created in April 2022 by MoonLake Immunotherapeutics.
 The purpose of the arrangements is to attract and retain the best available personnel and to provide participants with additional incentive to increase their efforts on behalf and in the best interest of the Company and its subsidiaries. The reference to "Common Shares" refers to shares in MoonLake AG.
 MoonLake AG's compensation plans are settled with its Common Shares and with a number of Class C Ordinary Shares of the Company, determined by multiplying the number of Common Shares by the Exchange Ratio. The owners of Common Shares have the right to exchange their Common Shares for a number of Class A Ordinary Shares derived using the Exchange Ratio. In the event MoonLake AG shareholders elect to exchange their Common Shares, such MoonLake AG shareholder forfeits a number of Class C Ordinary Shares equal to the number of Class A Ordinary Shares issued (refer to Note 11— Shareholders' Equity- Class C Ordinary Shares).
 As of January 1, 2024, the Company executed the conversion of the majority of the outstanding ESOP awards into an equivalent number of Equity Incentive Plan option awards that are settled with Class A Ordinary Shares, thereby eliminating the intermediary right to the exchange step noted above. From an accounting perspective, there is no underlying modification to the economic, control or legal rights of the awards, including vesting terms and conditions, exercise price and accounting classification. This is purely an administrative change as opposed to an accounting modification whereby the plan issuer is amended from MoonLake AG to MoonLake Immunotherapeutics. Consequently, there is no incremental fair value generated following the conversion and therefore no incremental expense recorded. Any remaining unvested compensation expense will be recorded over the remaining vesting period of the original awards, thereby resulting in no change to the consolidated financial statements.
 As a result of this administrative conversion, the two main plans which remain active as of September 30, 2024 are the ESPP and Equity Incentive Plan, whereas the Restricted Founder Shares and ESOP are fully vested as of April 2023 and January 2024, respectively.
 For the three and nine months ended September 30, 2024, the Company has recognized an increase in equity in the condensed consolidated balance sheet, and share-based compensation expense in the condensed consolidated statements of operations and comprehensive loss of $1.8 million and $5.3 million, respectively. The share-based compensation expense was driven by the aforementioned two main active share-based compensation plans and programs:</div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"></td><td style="width:27.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.007%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.007%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.162%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.165%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle">Compensation Plan</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">Three Months Ended September 30, 2024</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle">Three Months Ended September 30, 2023</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">Nine Months Ended September 30, 2024</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle">Nine Months Ended September 30, 2023</td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle">MoonLake AG Restricted Founder Shares</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">— </td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">— </td><td style="background-color:#ffffff;border-

top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">— </td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:123%">$</td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">1,574,299 </td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle">ESPP</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">741,154 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">762,309 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle">2,191,557</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle">2,590,576</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle">ESOP</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">255,171 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle">614,469</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle">Equity Incentive Plan</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">1,101,455 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">408,171 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle">3,156,505</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle">721,155</td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle">Total share-based compensation expense</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">1,842,609 </td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">1,425,651 </td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">5,348,062 </td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">5,500,499 </td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle">Of which: included in research and development expense</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">508,697 </td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">262,717 </td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">1,446,049 </td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">1,150,815 </td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle">Of which: included in general and administrative expense</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">1,333,912 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">1,162,934 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">3,902,013 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">4,349,684 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table>
 We expect that all future employee awards will be made under the Equity Incentive Plan. As of September 30, 2024, 3,281,755 Class A Ordinary Shares from the authorized pool of 4,353,948 Class A Ordinary Shares remain available for future grants, and 973,800 and 98,393 Class A Ordinary Shares are reserved for issuance upon exercise of stock options granted under the Equity Incentive Plan and ESOP, respectively. The latter relate to awards not yet subjected to the conversion described above.
 MoonLake AG - Restricted Founder Shares On April 28, 2021, the shareholders' agreement between the co-founders, the Series A investors and MoonLake AG imposed a reverse vesting condition on 90% of the total 110,000 Common Shares (the equivalent of 3,700,257 Class C Ordinary Shares) held by each of the three co-founders. Therefore, 99,000 Common Shares (the equivalent of 3,330,231 Class C Ordinary Shares) held by each of the co-founders were subject to these restrictions and considered unvested (the "Restricted Founder Shares"). The Restricted Founder Shares vested on the 28th of each month at a rate of 4.166% over a period of two years until April 28, 2023. In the event of termination of the contractual relationship of the relevant co-founder before the end of the vesting period, MoonLake AG in first

*priority, or any third party designated by it, and the other shareholders in second priority pro rata to their shareholdings, had an option to purchase all or a pro rata portion of the leaver shares that remained unvested on the effective day of the termination at nominal value of CHF 0.10. <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"></td><td style="width:71.994%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Grants awarded</td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom">Restricted Founder Shares</td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom">Number of Shares</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle">Awards unvested as of January 1, 2023</td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">1,110,078</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle">Awards vested for the nine months ended September 30, 2023</td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">(1,110,078)</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle">Awards unvested as of September 30, 2023</td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">—</td></tr></table> Employee Share Participation Plan (ESPP) 2021-2025 - MoonLake AG The ESPP grants will vest 25% on each anniversary of the grant date. In the event of a termination of contractual relationship between the Company and the entitled employee, the awards can be deemed forfeited by MoonLake AG if certain conditions are met. Awards feature an accelerated vesting condition linked to a "Change of Control", defined as any transfer of shares that results in the proposed acquirer holding more than 50% of the then issued share capital of MoonLake AG or the Company, as the case may be, where all the outstanding awards (whether currently outstanding or granted in the future) will be deemed fully vested. <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"></td><td style="width:71.994%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Grants awarded</td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom">ESPP</td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom">Number of Shares</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle">Awards issued as of January 1 and September 30, 2023</td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">2,237,915</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle">Awards vested as of September 30, 2023</td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">1,525,582</td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle">Awards issued as of January 1, 2024</td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">2,237,915</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle">Awards forfeited for the nine months ended September 30, 20242</td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">(16,853)</td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle">Awards issued as of September 30, 2024</td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">2,221,062</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle">Awards vested as of September 30, 2024</td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">1,827,826</td></tr></table> As of September 30, 2024, MoonLake AG had $3.8 million of total unrecognized compensation expense related to the ESPP that will be recognized over the weighted average period of 1.30 years.
 Employee Stock Option Plan (ESOP) 2021-2025 - MoonLake AG The ESOP grants will vest 25% on each anniversary of the grant date. In the event of a termination of the contractual relationship between the Company and the entitled employee, options can be deemed forfeited by MoonLake AG if certain conditions are met. Awards feature an accelerated vesting condition linked to a "Change of Control", defined as any transfer of shares that results in the proposed acquirer holding more than 50% of the then issued share capital of MoonLake AG or the Company, as the case may be, where all the outstanding awards (whether currently outstanding or granted in the future) will be deemed fully vested. <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.813%"><tr><td style="width:1.0%"></td><td style="width:71.952%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.848%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom">Grants awarded</td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom">ESOP</td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom">Number of Options</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle">Awards outstanding as of January 1, 2023</td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">466,770</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle">Awards granted for the nine months ended September 30, 2023</td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">133,444</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle">Awards outstanding as of September 30, 2023</td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">600,214</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle">Awards exercisable as of September 30, 2023</td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">186,593</td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle">Awards outstanding as of January 1, 2024</td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">585,078</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle">Awards converted from ESOP to Equity Incentive Plan for the nine months ended September 30, 2024</td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">(486,685)</td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle">Awards outstanding as of September 30, 2024</td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">98,393</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle">Awards exercisable as of September 30, 2024</td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">98,393</td></tr></table>
MoonLake Immunotherapeutics 2022 Equity Incentive Plan On April 5, 2022 (the "Effective Date"), the Company created the Equity Incentive Plan to promote and closely align the interests of employees, officers, non-employee directors and other service providers of MoonLake Immunotherapeutics and its shareholders by providing share-based compensation and other performance-based compensation. *

 The Equity Incentive Plan provides for the grant of options, stock appreciation rights, restricted stock units, restricted stock and other share-based awards and for incentive bonuses, which may be paid in cash, Common Shares or a combination thereof, as determined by the compensation committee of the board of directors or such other committee as designated by the board of directors to administer the Equity Incentive Plan. The Equity Incentive Plan shall remain available for the grant of awards until the 10th anniversary of the Effective Date.
 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"></td><td style="width:71.994%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom">Grants awarded</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom">Equity Incentive Plan</td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom">Number of Options</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle">Awards outstanding as of January 1, 2023</td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">180,000</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle">Awards granted for the nine months ended September 30, 2023</td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">56,485</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle">Awards outstanding as of September 30, 2023</td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">236,485</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle">Awards exercisable as of September 30, 2023</td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">60,000</td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle">Awards outstanding as of January 1, 2024</td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">312,400</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle">Awards granted for the nine months ended September 30, 2024</td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">241,820</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle">Awards exercised for the nine months ended September 30, 2024</td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">(17,390)</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle">Awards converted from ESOP to Equity Incentive Plan for the nine months ended September 30, 2024</td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">486,685</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle">Awards forfeited for the nine months ended September 30, 2024</td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">(49,715)</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle">Awards outstanding as of September 30, 2024</td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">973,800</td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle">Awards exercisable as of September 30, 2024</td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">368,910</td></tr></table>
 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"></td><td style="width:71.994%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle">Weighted average assumptions for the awards issued during the nine months ended September 30, 2024</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Estimated fair value of the option on the grant date using Black-Scholes model ($)</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">31.31</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Exercise price ($) </td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">45.63</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"> Expected term of the award on the grant date (years) (1) </td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">6</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"> Expected volatility of the share price (2) </td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">75%</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"> Risk-free interest rate (3) </td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">4.3%</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Expected dividend rate</td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top">—%</td></tr><tr><td colspan="6" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"> (1) The expected term represents the period that share-based awards are expected to be outstanding. (2) The expected volatility was derived from the historical stock volatilities of comparable peer public companies within the Company's industry. (3) The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the measurement date with maturities approximately equal to the expected term. </td></tr></table>
 As of September 30, 2024, the Company had $11.2 million of total unrecognized compensation expense related to the Equity Incentive Plan that will be recognized over the weighted average period of 1.96 years. 2180000005300000The share-based compensation expense was driven by the aforementioned two main active share-based compensation plans and programs: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"></td><td style="width:27.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.007%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.007%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.162%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.165%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle">Compensation Plan</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">Three Months Ended September 30, 2024</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle">Three Months Ended September 30, 2023</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">Nine Months Ended September 30, 2024</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle">Nine Months Ended September 30, 2023</td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle">

style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">MoonLake AG Restricted Founder Shares</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">— </td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">— </td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">— </td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle">ESPP</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">741,154 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">762,309 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle">2,191,557</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle">2,590,576</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle">ESOP</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">255,171 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle">614,469</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle">Equity Incentive Plan</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">1,101,455 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">408,171 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle">3,156,505</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle">721,155</td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle">Total share-based compensation expense</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">1,842,609 </td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">1,425,651 </td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">5,348,062 </td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle">5,500,499 </td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle">Of which: included in research and development expense</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">508,697 </td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">262,717 </td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">1,446,049 </td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">1,150,815 </td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle">Of which: included in general and administrative expense</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">1,333,912 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">1,162,934 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">3,902,013 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">4,349,684 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table>
2000157429974115476230921915572590576025517106144691101455408171315650572115518426091425651534806255004995086972627171446049115081513339121" style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"></td><td style="width:71.994%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.806%"></td><td

style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Grants awarded</td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom">Restricted Founder Shares</td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom">Number of Shares</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle">Awards unvested as of January 1, 2023</td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">1,110,078</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle">Awards vested for the nine months ended September 30, 2023</td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">(1,110,078)</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle">Awards unvested as of September 30, 2023</td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">—</td></tr></table> 1110078111007800.250.250.250.25 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"></td><td style="width:71.994%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Grants awarded</td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom">ESPP</td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom">Number of Shares</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle">Awards issued as of January 1 and September 30, 2023</td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">2,237,915</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle">Awards vested as of September 30, 2023</td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">1,525,582</td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle">Awards issued as of January 1, 2024</td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">2,237,915</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle">Awards forfeited for the nine months ended September 30, 20242</td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">(16,853)</td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle">Awards issued as of September 30, 2024</td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">2,221,062</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle">Awards vested as of September 30, 2024</td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">1,827,826</td></tr></table> 22379152237915152558222379151685322210621827826380000O P1Y3M18D0.250.250.250.25 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.813%"><tr><td style="width:1.0%"></td><td style="width:71.952%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.848%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom">Grants awarded</td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom">ESOP</td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom">Number of Options</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle">Awards outstanding as of January 1, 2023</td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">466,770</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle">Awards granted for the nine months ended September 30, 2023</td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">133,444</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle">Awards outstanding as of September 30, 2023</td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">600,214</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle">Awards exercisable as of September 30, 2023</td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">186,593</td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle">Awards outstanding as of January 1, 2024</td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">585,078</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle">Awards converted from ESOP to Equity Incentive Plan for the nine months ended September 30, 2024</td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">(486,685)</td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle">Awards outstanding as of September 30, 2024</td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">98,393</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle">Awards exercisable as of September 30, 2024</td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">98,393</td></tr></table> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"></td><td style="width:71.994%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom">Grants awarded</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom">Equity Incentive Plan</td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom">Number of Options</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle">Awards outstanding as of January 1, 2023</td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">180,000</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle">Awards granted for the nine months ended September 30, 2023</td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">56,485</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle">Awards outstanding as of September 30, 2023</td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">236,485</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle">Awards exercisable as of September 30, 2023</td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">60,000</td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid

#000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle">Awards outstanding as of January 1, 2024</td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">312,400</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle">Awards granted for the nine months ended September 30, 2024</td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">241,820</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle">Awards exercised for the nine months ended September 30, 2024</td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">(17,390)</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle">Awards converted from ESOP to Equity Incentive Plan for the nine months ended September 30, 2024</td><td colspan="3" style="background-color:#cceeff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">486,685</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle">Awards forfeited for the nine months ended September 30, 2024</td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">(49,715)</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle">Awards outstanding as of September 30, 2024</td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">973,800</td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle">Awards exercisable as of September 30, 2024</td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle">368,910</td></tr></table>
4667701334446002141865935850784866859839398393P10Y1800005648523648560000312400241820173904866854971597 3800368910 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.968%"><tr><td style="width:1.0%"></td><td style="width:71.994%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle">Weighted average assumptions for the awards issued during the nine months ended September 30, 2024</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Estimated fair value of the option on the grant date using Black-Scholes model ($)</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">31.31</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:106%">Exercise price ($) </td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">45.63</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"> Expected term of the award on the grant date (years) (1) </td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">6</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"> Expected volatility of the share price (2) </td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">75%</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"> Risk-free interest rate (3) </td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">4.3%</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Expected dividend rate</td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top">—%</td></tr><tr><td colspan="6" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"> (1) The expected term represents the period that share-based awards are expected to be outstanding. (2) The expected volatility was derived from the historical stock volatilities of comparable peer public companies within the Company's industry. (3) The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the measurement date with maturities approximately equal to the expected term. </td></tr></table>
31.3145.63P6Y0.750.043011200000P1Y11M15DIncome Taxes The Company's effective tax rate ("ETR") was 0.3% and 0.3% for the three and nine months ended September 30, 2024, respectively, and 0.2% and 0.1% for the three and nine months ended September 30, 2023, respectively. The Company is not aware of any items that would cause the quarterly ETR to be significantly different from the Company's annual ETR. The difference between the income tax provision that would be derived by applying the statutory rate to the Company's loss before income taxes and the income tax provision recorded was primarily attributable to the change in the valuation allowance. The Company continues to incur losses for the entities domiciled in the Cayman Island and Switzerland, and its ability to utilize the deferred tax asset related to the tax losses is not considered more likely than not. A full valuation allowance has been recorded against the deferred tax asset. 0.0030.0030.0020.001Commitments and Contingencies Commitments The Company has entered into agreements as of September 30, 2024 primarily in regards to the clinical and non-clinical development services with contract research organizations ("CROs"), as well as supply and logistics services with contract manufacturing organizations ("CMOs"), for the advancement of SLK. As of September 30, 2024, the total committed expense under these agreements amounted to $145.1 million, of which $8.0 million are recognized under Prepaid expenses - current, $2.1 million are recognized under Prepaid expenses - non-current, and the rest remain unrecognized.
 The Company's In-License Agreement with MHKDG includes contractual milestone payments related to the achievement of pre-specified research, development, regulatory and commercialization events and indemnification provisions, which are common in such agreements. Pursuant to the agreements, the Company is obligated to make research and development and regulatory milestone payments upon the occurrence of certain events. Subject to the terms of the license, additional milestone payments of up to €299.6 million ($335.2 million using a September 30, 2024 exchange rate) are potentially payable upon satisfying specific milestones related to regulatory filing acceptance, first commercial sales, and aggregate annual net sales. The milestone payments are payable in cash. Milestone payments due prior to obtaining regulatory approval will be recorded as research and development expense upon determination that a milestone payment is probable to occur. Milestone payments due after obtaining regulatory approval will be capitalized when and if incurred. The Company will use commercially reasonable efforts to cause the milestones to occur. However, if the Company reasonably determines that a technical failure or commercial failure has occurred with respect to all or a part of the SLK Program, the Company, at its sole discretion, can terminate all or part of the SLK Program. As of September 30, 2024, the Company made a total of €7.5 million ($8.1 million using the then applicable exchange rates) in additional milestone payments.
 In addition, on May 12, 2023, MoonLake AG entered into an agreement with Research Cooperation Technologies, Inc. ("RCT") and MHKDG, effective as of June 1, 2023, pursuant to which the Company was granted a royalty-bearing, nonexclusive, sublicensable right and license under RCT's patents and know-how related to a manufacturing process using an underlying yeast strain, Pichia pastoris, to develop, manufacture, use, sell, offer for sale, and import and otherwise commercialize SLK on a world-wide basis, subject to certain restrictions. This agreement replaces the Company's sublicense for similar rights under the In-License Agreement. In the aggregate, the Company is required to pay royalties within the range of low to mid-teen percent of net sales under the aforementioned agreements with MHKDG and RCT. Royalties will be recognized in the consolidated statements of operations and comprehensive loss when net sales are recognized.
1451000008000000.021000002996000003352000007500000810000 0Segment Information and Geographic Data The Company operates as a single operating segment. Long-lived assets, consisting of property and equipment, net, and operating lease right-of-use assets by geographical area as of September 30, 2024 are as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.813%"><tr><td style="width:1.0%"></td><td style="width:43.136%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.158%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.160%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Country</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">September 30, 2024</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">December 31, 2023</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Switzerland</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">680,946 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span

style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">507,392 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">United Kingdom</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,012,806 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,704,555 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Portugal</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,138,823 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">737,398 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">3,832,575 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">3,949,345 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>Long-lived assets, consisting of property and equipment, net, and operating lease right-of-use assets by geographical area as of September 30, 2024 are as follows:<div style="text-align:justify;text-indent:0.36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.813%"><tr><td style="width:1.0%"></td><td style="width:43.136%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.158%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.160%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Country</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">September 30, 2024</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">December 31, 2023</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Switzerland</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">680,946 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">507,392 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">United Kingdom</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,012,806 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,704,555 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Portugal</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,138,823 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">737,398 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">3,832,575 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">3,949,345 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 6809465073922012806270455511388237373983832575394934 5falsefalsefalsefalse